/*
 Navicat Premium Data Transfer

 Source Server         : mysql
 Source Server Type    : MySQL
 Source Server Version : 80018
 Source Host           : localhost:3306
 Source Schema         : huisuan

 Target Server Type    : MySQL
 Target Server Version : 80018
 File Encoding         : 65001

 Date: 03/04/2020 17:32:40
*/

SET NAMES utf8mb4;
SET FOREIGN_KEY_CHECKS = 0;

-- ----------------------------
-- Table structure for main_ori
-- ----------------------------
DROP TABLE IF EXISTS `main_ori`;
CREATE TABLE `main_ori`  (
  `Reference` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Reference_ID_S` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Evidence_level` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `level_1` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Drug_ref` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Drug_temp` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Drug_en` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Drug_ch` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Drug` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `MAX phase` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Disease_Ref` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Disease_en` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `RelatedDisease` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `site_cosmic` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `DrugEfficacy` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `clinical_type` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Biomarker` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `ApprovedSymbol` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Mutation_type` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Mutation_class` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Mutation_exon` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `AAMutation` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `MutationEffect_rule` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `Interpretation_1` longtext CHARACTER SET utf8 COLLATE utf8_general_ci NULL,
  `Summary` longtext CHARACTER SET utf8 COLLATE utf8_general_ci NULL,
  `Germline_somatic` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `pro_DrugEfficacy` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL,
  `update` varchar(255) CHARACTER SET utf8 COLLATE utf8_general_ci NULL DEFAULT NULL
) ENGINE = InnoDB CHARACTER SET = utf8 COLLATE = utf8_general_ci ROW_FORMAT = Compact;

-- ----------------------------
-- Records of main_ori
-- ----------------------------
INSERT INTO `main_ori` VALUES ('PMID:21606412', 'NCT00215605', 'clinical trial - phase1', '4', 'cabozantinib', 'cabozantinib', 'cabozantinib', '卡博替尼', 'cabozantinib|卡博替尼', '4', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', 'na', 'sensitivity', 'EVI_000002', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', '携带MET扩增的甲状腺肿瘤患者可能对卡博替尼治疗敏感。卡博替尼(cabozantinib, XL184)是一种有效的MET、VEGFR2、RET抑制剂，同时还有强大的抗血管生成，抗肿瘤及抗侵袭效果的能力。本文的目的在于对甲状腺髓样瘤(MTC)患者的卡博替尼I期临床实验收益的早期观察。病人及方法: 口服卡博替尼的剂量递增I期实验由罹患肿瘤的病人来进行，其主要的观察对象为药物的安全性，药代动力学以及确定最大可耐受的药物剂量(MTD)。另外，实验中也记录病例的实体瘤疗效评价标准(RECIST)数值，药效学，RET突变情况以及生物标记的分析。结果: 共有85例患者参与，其中包括37名甲状腺髓样瘤患者，髓样瘤患者每日服用卡博替尼175毫克。影响患者用药剂量的原因有3级掌跖痛性红斑(PPE)，2级黏膜炎，谷草转氨酶(AST)，谷丙转氨酶(ALT)，脂肪酶升高等，这些因素均会导致用药阻碍及剂量和药效下降。在35例甲状腺髓样瘤患者中，有10例(29%)确认对用药有部分缓解。总的来说，共有18例患者的肿瘤缩小了30%甚至更多。另外，有15例(41%)甲状腺髓样瘤患者疾病稳定至少6个月，病情稳定在6个月及更长，加上部分缓解的甲状腺髓样瘤，有效果的病例占到总患病人数的68%。结论: 卡博替尼对甲状腺髓样瘤有效，且安全性在可接受范围，同时卡博替尼作为MET, VEGFR2, RET等在甲状腺髓样瘤发病中起重要作用的信号通路基因抑制剂，在临床实验中能带来不错的收效。一项全球性的III期多中心临床实验正在进行中。(ClinicalTrials.gov number NCT00215605)', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21468130', '.', 'case report', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'endometrial carcinoma', 'Uterine Neoplasm', '子宫肿瘤', 'na', 'sensitivity', 'EVI_000004', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '携带PTEN基因失活突变的子宫肿瘤患者可能对奥拉帕利治疗敏感。一位58岁的患有子宫内膜腺癌的女性患者接受了手术以及辅助放疗来治疗早期子宫内膜癌。在过去9年时间，该患者已经因为病情复发而多次更换了化疗疗法，并且表现出对含铂类药物的治疗方案非常敏感的状况。调查研究: CT扫描显示在肝，肺及腹膜处均有转移，另外核磁共振发现多处脑内转移。诊断: 子宫内膜腺癌二级伴脑转移。治疗方案: 根据患者对铂类治疗方案较敏感的情况，该患者在铂类药物治疗的同时口服PARP抑制剂奥拉帕利(olaparib)作为I期治疗的一部分。在10周治疗后用核磁共振复查发现脑内转移灶显著变小，且没有经过类固醇或放疗类似的治疗。另外病人也表现出因肿瘤带来的症状有主观上的明显改善。在8个月的奥拉帕利治疗后，患者出现客观疾病进展。通过对患者先前的肿瘤样本活检发现患者BRCA1和BRCA2突变检测为阴性，但是提示有PTEN缺失，这也是对PARP抑制剂敏感的另一个预测结果。患者在完成奥拉帕利疗程后仍存活了10个月，已经继续开始铂类药物治疗以获得进一步的疗效收益。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23582881', 'NCT00976755', 'clinical trial - phase2', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_000006', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', 'The phosphatase and tensin homolog (PTEN) tumor suppressor gene is deregulated in many advanced prostate cancers, leading to activation of the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway and thus increased cell survival. Everolimus activity in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) is moderate, but PTEN deletion could be predictive for response. ', 'PTEN肿瘤抑制基因在许多恶性前列腺癌中都存在表达缺失，从而导致mTOR信号通路的异常活化。依维莫司是mTOR通路抑制剂，可能对携带PTEN缺失的肿瘤患者有效。 在前列腺癌中，PTEN肿瘤抑制基因出现失调，导致PI3K(磷脂酰肌醇3激酶)-AKT-mTOR(哺乳动物雷帕霉素靶蛋白)通路被激活并增加了肿瘤细胞的存活率。本文的目的为评估mTOR(哺乳动物雷帕霉素靶蛋白)抑制剂依维莫司(everolimus)在转移性去势抵抗性前列腺癌(mCRPC)患者中的疗效，利用蛋白质组学探索潜在的血清标志物，PTEN表达水平在肿瘤组织中的意义以及依维莫司对免疫细胞亚群的功能及其影响。实验的设计及参与者: 总共37位化疗初治且有疾病进展的mCRPC患者参与本次II期的单组临床实验(NCT00976755)。 药物的干预: 持续每日给予患者10毫克依维莫司。结果测量及统计分析: 临床实验的主要终点为12周的无进展生存期(PFS)。结果及其局限性: 共有13例患者达到实验的主要终点(primary end point)(占总数35%，95%置信区间CI为20-53)，确认2例患者(5%)前列腺特异性抗原(PSA)反应大于等于50%，4例患者(11%)PSA下降大于等于30%，同时羧肽酶M和载脂蛋白B的血清水平增高也在预计结果之中。另外，PTEN的缺失与药物反应及更长的无进展生存期相关，治疗效果也与CD3，CD4，CD8 T淋巴细胞的剂量依赖性相关，也和CD8的增殖及调节性T细胞的增加相关。本实验最主要的局限性为样本过小。结论: 依维莫司对随机选择的转移性去势抵抗性前列腺癌(mCRPC)患者疗效适中，PTEN的缺失与否可以预估药物疗效。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28645941', '.', 'clinical study', '4', 'GSK2636771', 'GSK2636771', 'GSK2636771', 'GSK2636771', 'GSK2636771|GSK2636771', '2', 'prostate cancer', 'prostate cancer', '前列腺癌', '前列腺癌', 'sensitivity', 'EVI_000008', 'PIK3CB:CNV:.:.:gain', 'PIK3CB', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项临床试验评估了GSK2636771的安全性、药代动力学、药效学和抗肿瘤活性，以确定II期的推荐剂量(RP2D)。共招募65名患者，剂量限制性毒性是低磷血症和低钙血症。不良事件包括腹泻(48%)，恶心(40%)和呕吐(31%)。一名携带PIK3CB扩增的去势抵抗性前列腺癌(CRPC)患者治疗的部分响应，时间超过一年; 另外10名患者获得持久的临床获益(≥24周)，其中包括两名患有CRPC且携带PIK3CB突变的患者(≥34周)。 ', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28645941', '.', 'clinical study', '4', 'GSK2636771', 'GSK2636771', 'GSK2636771', 'GSK2636771', 'GSK2636771|GSK2636771', '2', 'prostate cancer', 'prostate cancer', '前列腺癌', '前列腺癌', 'sensitivity', 'EVI_000009', 'PIK3CB:nonsynonymous SNV:exon22:p.L1049R:', 'PIK3CB', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.L1049R', '.', '.', '一项临床试验评估了GSK2636771的安全性、药代动力学、药效学和抗肿瘤活性，以确定II期的推荐剂量(RP2D)。共招募65名患者，剂量限制性毒性是低磷血症和低钙血症。不良事件包括腹泻(48%)，恶心(40%)和呕吐(31%)。一名携带PIK3CB扩增的去势抵抗性前列腺癌(CRPC)患者治疗的部分响应，时间超过一年; 另外10名患者获得持久的临床获益(≥24周)，其中包括两名患有CRPC且携带PIK3CB突变的患者(≥34周)。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000018', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'The following targeted agents are recommended (category 2A) for patients with specific genetic alterations: crizotinib (for ROS1 rearrangements and for high-level MET amplification or MET exon 14 skipping mutation), dabrafenib (with or without trametinib) and vemurafenib (for BRAF V600E mutations), and cabozantinib (for RET rearrangements). ', 'NCCN以2A类证据推荐携带BRAF V600E的病人可以使用达拉非尼、达拉非尼与曲美替尼联合或者维莫非尼，尤其是对达拉非尼和曲美替尼联用不耐受的患者，可以采用达拉非尼或的维莫非尼单药治疗。一项研究对欧洲晚期BRAF突变型肺癌患者进行了一项回顾性多中心队列研究。数据匿名化，集中评估年龄，性别，吸烟，组织学，分期，局部分子诊断结果，全身治疗和生存。采用RECIST1.1评估最佳反应。35名患者在17个中心使用vemurafenib，达拉非尼或索拉非尼治疗。中位年龄63岁（范围42-85）;性别平衡;14（40%）从不吸烟;全部（100%）有腺癌;29（83%）有V600E突变;6（17%）有其他突变;其中一个具有伴随的KRAS突变。三十（86%）位患者首次化疗。一线治疗的总生存期，携带V600E突变患者为25.3个月，非V600E为11.8个月。三十一名患者接受一种BRAF抑制剂，另外四名接受了二种抑制剂。BRAF治疗的总体反应率为53%，疾病控制率为85%。BRAF抑制剂治疗中位无进展生存期为5.0个月，总生存期为10.8个月。该研究以Vemurafenib，达拉非尼为主（PMID:26200454）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000019', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'Evidence increasingly suggests that BRAF V600E mutation makes response to panitumumab or  cetuximab highly unlikely, as a single agent, or in combination with cytotoxic chemotherapy.', '虽然KRAS/NRAS基因突变的患者对EGFR抑制剂无效，但是一些含有野生型KRAS/NRAS基因的肿瘤也对这些治疗无效。大约5%-9%结肠直肠癌患者携带BRAF基因（V600E）的突变。BRAF基因突变仅出现在没有KRAS exon2 突变的患者肿瘤中。BRAF基因的V600E突变导致其编码蛋白的组成性激活，而且BRAF基因处于EGFR信号通路的下游，从而绕过EGFR抗体（西妥昔单抗或帕尼单抗）对EGFR信号通路的抑制。根据多项临床研究报道，NCCN认为具有BRAF V600E突变的结肠癌患者不能从西妥昔单抗、帕尼单抗治疗中获益。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000020', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'Evidence increasingly suggests that BRAF V600E mutation makes response to panitumumab or  cetuximab highly unlikely, as a single agent, or in combination with cytotoxic chemotherapy.', '虽然KRAS/NRAS基因突变的患者对EGFR抑制剂无效，但是一些含有野生型KRAS/NRAS基因的肿瘤也对这些治疗无效。大约5%-9%结肠直肠癌患者携带BRAF基因（V600E）的突变。BRAF基因突变仅出现在没有KRAS exon2 突变的患者肿瘤中。BRAF基因的V600E突变导致其编码蛋白的组成性激活，而且BRAF基因处于EGFR信号通路的下游，从而绕过EGFR抗体（西妥昔单抗或帕尼单抗）对EGFR信号通路的抑制。 根据多项临床研究报道，NCCN认为具有BRAF V600E突变的结肠癌患者不能从西妥昔单抗、帕尼单抗治疗中获益。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000021', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'Presence of EGFR-activating mutations represents a critical biological determinant for proper  therapy selection in patients with lung cancer.  The exon 20 insertion mutation may predict  resistance to clinically achievable levels of EGFR TKIs.', 'EGFR基因20号外显子的插入突变与酪氨酸激酶的活性相关。携带该类突变的肺癌患者可能对酪氨酸激酶抑制剂耐药。肺癌中，EGFR 20 Exon插入突变的发生频率仅次于19 Exon del和21 Exon L858R突变，是EGFR突变的第三大类型。常见于不吸烟者，与年龄、性别、种族或肿瘤分期没有关联。肿瘤形态与常见EGFR突变相似，但固相结缔组织更多些。目前的研究结果不仅解释了不同的EGFR 20 Exon插入突变及其对EGFR-TKIs的应答效果，也提供给EGFR 20 Exon插入突变的NSCLC患者不同的靶向治疗策略和选择:如果采用测序方法检测到A763_Y764insFQEA的患者可以考虑使用EGFR-TKI治疗，20号外显子的其他插入变异则不适合EGFR-TKI治疗。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000022', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'Presence of EGFR-activating mutations represents a critical biological determinant for proper  therapy selection in patients with lung cancer.  The exon 20 insertion mutation may predict  resistance to clinically achievable levels of EGFR TKIs.', 'EGFR基因20号外显子的插入突变与酪氨酸激酶的活性相关。携带该类突变的肺癌患者可能对酪氨酸激酶抑制剂耐药。肺癌中，EGFR 20 Exon插入突变的发生频率仅次于19 Exon del和21 Exon L858R突变，是EGFR突变的第三大类型。常见于不吸烟者，与年龄、性别、种族或肿瘤分期没有关联。肿瘤形态与常见EGFR突变相似，但固相结缔组织更多些。目前的研究结果不仅解释了不同的EGFR 20 Exon插入突变及其对EGFR-TKIs的应答效果，也提供给EGFR 20 Exon插入突变的NSCLC患者不同的靶向治疗策略和选择:如果采用测序方法检测到A763_Y764insFQEA的患者可以考虑使用EGFR-TKI治疗，20号外显子的其他插入变异则不适合EGFR-TKI治疗。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000023', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'Presence of EGFR-activating mutations represents a critical biological determinant for proper therapy selection in patients with lung cancer.  The exon 20 insertion mutation may predict  resistance to clinically achievable levels of EGFR TKIs.', 'EGFR基因20号外显子的插入突变与酪氨酸激酶的活性相关。携带该类突变的肺癌患者可能对酪氨酸激酶抑制剂耐药。肺癌中，EGFR 20 Exon插入突变的发生频率仅次于19 Exon del和21 Exon L858R突变，是EGFR突变的第三大类型。常见于不吸烟者，与年龄、性别、种族或肿瘤分期没有关联。肿瘤形态与常见EGFR突变相似，但固相结缔组织更多些。目前的研究结果不仅解释了不同的EGFR 20 Exon插入突变及其对EGFR-TKIs的应答效果，也提供给EGFR 20 Exon插入突变的NSCLC患者不同的靶向治疗策略和选择:如果采用测序方法检测到A763_Y764insFQEA的患者可以考虑使用EGFR-TKI治疗，20号外显子的其他插入变异则不适合EGFR-TKI治疗。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27528220', '.', 'clinical study', '4', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000024', 'SOX2:CNV:.:.:gain', 'SOX2', 'CNV', 'CNV', '.', '.', 'gain', '.', '患者对EGFR TKI治疗的获得性耐药可能是由于EGFR基因的二次突变（如发生在激酶结构域，T790M）、MET基因扩增、组织学变化（非小细胞肺癌变成小细胞肺癌）或者上皮细胞一间充质细胞转换。晚期非小细胞肺癌(NSCLC)患者常伴有敏感的表皮生长因子受体(EGFR)突变，往往会形成获得性EGFR酪氨酸激酶受体抑制剂(TKIs)耐药。鉴定引起耐药的突变，有助于指导后续的治疗决策。其中，一个主要的耐药机制是患者发生二次突变，EGFR-T790M。其他的耐药机制包括HER2和MET扩增，PIK3CA突变也有报道。然而，除了这些已知的突变，其余的患者中的耐药机制尚不清楚。在本次研究中，我们用二代测序技术(NGS)对83例首次诊断时对TKIs敏感，但后来获得了对第一代TKIs耐药的非小细胞肺癌患者进行416个与肿瘤相关的基因测序。我们总共发现了322个变异基因，每个病人平均有三个突变。有61%的患者仍表现出TKIs敏感性的EGFR突变，36%的患者则出现EGFR-T790M。除了其他已知的耐药机制，我们还发现12%的患者有TET2突变。有趣的是，在EGFR-T790M阴性患者中，我们还发现了SOX2扩增，该扩增对埃克替尼的耐药有一定关系，而埃克替尼是中国非小细胞肺癌患者广泛使用的药物。我们的研究为非小细胞肺癌患者对第一代TKIs的耐药情况提供了信息，具有潜在的治疗参考意义。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27528220', '.', 'clinical study', '4', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000025', 'EGFR:nonsynonymous SNV:exon20:p.T790M:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', '.', '患者对EGFR TKI治疗的获得性耐药可能是由于EGFR基因的二次突变（如发生在激酶结构域，T790M）、MET基因扩增、组织学变化（非小细胞肺癌变成小细胞肺癌）或者上皮细胞一间充质细胞转换。晚期非小细胞肺癌(NSCLC)患者常伴有敏感的表皮生长因子受体(EGFR)突变，往往会形成获得性EGFR酪氨酸激酶受体抑制剂(TKIs)耐药。鉴定引起耐药的突变，有助于指导后续的治疗决策。其中，一个主要的耐药机制是患者发生二次突变，EGFR-T790M。其他的耐药机制包括HER2和MET扩增，PIK3CA突变也有报道。然而，除了这些已知的突变，其余的患者中的耐药机制尚不清楚。在本次研究中，我们用二代测序技术(NGS)对83例首次诊断时对TKIs敏感，但后来获得了对第一代TKIs耐药的非小细胞肺癌患者进行416个与肿瘤相关的基因测序。我们总共发现了322个变异基因，每个病人平均有三个突变。有61%的患者仍表现出TKIs敏感性的EGFR突变，36%的患者则出现EGFR-T790M。除了其他已知的耐药机制，我们还发现12%的患者有TET2突变。有趣的是，在EGFR-T790M阴性患者中，我们还发现了SOX2扩增，该扩增对埃克替尼的耐药有一定关系，而埃克替尼是中国非小细胞肺癌患者广泛使用的药物。我们的研究为非小细胞肺癌患者对第一代TKIs的耐药情况提供了信息，具有潜在的治疗参考意义。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000026', 'EGFR:nonsynonymous SNV:exon20:p.T790M:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'Acquired resistance (to EGFR TKI therapy) is associated with second site mutations within the  EGFR kinase domain, amplification of alternative kinases (such as MET), histologic transformation  from NSCLC to SCLC, and epithelial to mesenchymal transition (EMT).', '患者对EGFR TKI治疗的获得性耐药可能是由于EGFR基因的二次突变(如发生在激酶结构域的T790M)、MET基因扩增、组织学变化(非小细胞肺癌变成小细胞肺癌)或者上皮细胞向间充质细胞转换(EMT)等情况引起。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000027', 'EGFR:nonsynonymous SNV:exon20:p.T790M:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'Acquired resistance (to EGFR TKI therapy) is associated with second site mutations within the  EGFR kinase domain, amplification of alternative kinases (such as MET), histologic transformation  from NSCLC to SCLC, and epithelial to mesenchymal transition (EMT).', '患者对EGFR TKI治疗的获得性耐药可能是由于EGFR基因的二次突变(如发生在激酶结构域的T790M)、MET基因扩增、组织学变化(非小细胞肺癌变成小细胞肺癌)或者上皮细胞向间充质细胞转换(EMT)等情况引起。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000028', 'EGFR:nonsynonymous SNV:exon20:p.T790M:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'Acquired resistance (to EGFR TKI therapy) is associated with second site mutations within the  EGFR kinase domain, amplification of alternative kinases (such as MET), histologic transformation  from NSCLC to SCLC, and epithelial to mesenchymal transition (EMT).', '患者对EGFR TKI治疗的获得性耐药可能是由于EGFR基因的二次突变(如发生在激酶结构域的T790M)、MET基因扩增、组织学变化(非小细胞肺癌变成小细胞肺癌)或者上皮细胞向间充质细胞转换(EMT)等情况引起。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000035', 'EGFR:nonsynonymous SNV:exon21:p.L861Q:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L861Q', '.', 'Presence of EGFR-activating mutations represents a critical biological determinant for proper  therapy selection in patients with lung cancer.  There is a significant association between EGFR  mutations--especially exon 19 deletion and exon 21 (L858R, L861) and exon 18 (G719X, G719)  and exon 20 (S768I) mutations--and sensitivity to EGFR TKIs.', 'EGFR 19号外显子缺失、p.L858R、p.L861Q、p.G719、p.S768I这些突变与酪氨酸激酶抑制剂的敏感性有显著关联，携带这些突变之一的患者对酪氨酸激酶抑制剂(如厄洛替尼、吉非替尼和阿法替尼)敏感。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Soft Tissue Sarcoma <4.2019>', '.', 'guideline:NCCN', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'Gastrointestinal Stromal Tumors', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_000041', 'KIT:nonsynonymous SNV:exon9:.:exon9act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon9', '.', 'exon9act', 'In patients with advanced GISTs, approximately 90% of patients benefit from imatinib when their  tumors have a KIT exon 11 mutation; approximately 50% of patients benefit from imatinib when  their tumors harbor a KIT exon 9 mutation, and the likelihood of response improves with the use of  800 mg imatinib rather than the standard 400 mg dose. Most mutations in the PDGFRA gene are  associated with a response to imatinib, with the notable exception of D842V. In the absence of KIT  and PDGFRA mutations, only a subset of patients with advanced GISTs benefit from imatinib.  Metastatic disease with acquired drug resistance is usually the result of secondary, imatinib  resistant mutations in KIT or PDGFRA.', '在GIST患者中，90%携带KIT基因11号外显子突变的患者可以从伊马替尼治疗中获益；50%携带KIT基因9号外显子突变的患者可以从伊马替尼治疗中获益，并且需要使用高剂量伊马替尼（800 mg）。除了PDGFRA D842V突变外，大部分PDGFRA基因突变都对伊马替尼敏感。在没有KIT或PDGFRA基因突变时，只有少部分患者可以从伊马替尼治疗中获益。其它发生在KIT基因上的激活突变也可能提示患者对伊马替尼敏感。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Soft Tissue Sarcoma <4.2019>', '.', 'guideline:NCCN', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'Gastrointestinal Stromal Tumors', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_000042', 'KIT:nonsynonymous SNV:exon11:.:exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', 'In patients with advanced GISTs, approximately 90% of patients benefit from imatinib when their  tumors have a KIT exon 11 mutation; approximately 50% of patients benefit from imatinib when  their tumors harbor a KIT exon 9 mutation, and the likelihood of response improves with the use of  800 mg imatinib rather than the standard 400 mg dose. Most mutations in the PDGFRA gene are  associated with a response to imatinib, with the notable exception of D842V. In the absence of KIT  and PDGFRA mutations, only a subset of patients with advanced GISTs benefit from imatinib.  Metastatic disease with acquired drug resistance is usually the result of secondary, imatinib  resistant mutations in KIT or PDGFRA.', '在GIST患者中，90%携带KIT基因11号外显子突变的患者可以从伊马替尼治疗中获益；50%携带KIT基因9号外显子突变的患者可以从伊马替尼治疗中获益，并且需要使用高剂量伊马替尼（800 mg）。除了PDGFRA D842V突变外，大部分PDGFRA基因突变都对伊马替尼敏感。在没有KIT或PDGFRA基因突变时，只有少部分患者可以从伊马替尼治疗中获益。其它发生在KIT基因上的激活突变也可能提示患者对伊马替尼敏感。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('中国胃肠道间质瘤诊断治疗专家共识(2017年版)|CSCO胃肠间质瘤专家委员会.临床肿瘤学杂志.2013,18(11)', '.', 'guideline:CSCO', '1', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_000046', 'KIT:nonsynonymous SNV:exon9:.:exon9act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon9', '.', 'exon9act', '.', '舒尼替尼(sunitinib)二线治疗的患者中，KIT基因野生型胃肠间质瘤患者和原发KIT基因9号外显子突变的患者生存获益优于KIT基因11号外显子突变的患者；而治疗后KIT基因13、14号外显子继发性突变患者的疗效优于KIT基因17、18号外显子继发性突变。其它发生在KIT基因上的激活突变也可能提示患者对舒尼替尼敏感。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Soft Tissue Sarcoma <4.2019>', '.', 'guideline:NCCN', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'Soft Tissue Sarcoma;GIST;Gastrointestinal Stromal Tumors', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'resistance', 'EVI_000047', 'PDGFRA:nonsynonymous SNV:exon18:p.D842V:.', 'PDGFRA', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.D842V', '.', 'In patients with advanced GISTs, approximately 90% of patients benefit from imatinib when their  tumors have a KIT exon 11 mutation; approximately 50% of patients benefit from imatinib when  their tumors harbor a KIT exon 9 mutation, and the likelihood of response improves with the use of  800 mg imatinib rather than the standard 400 mg dose. Most mutations in the PDGFRA gene are  associated with a response to imatinib, with the notable exception of D842V. In the absence of KIT  and PDGFRA mutations, only a subset of patients with advanced GISTs benefit from imatinib.  Metastatic disease with acquired drug resistance is usually the result of secondary, imatinib  resistant mutations in KIT or PDGFRA.', '伊马替尼作用于PDGFR下游的酪氨酸激酶，PDGFRA Exon18及Exon12发生突变的多数GIST患者对格列卫敏感，但PDGFRA Exon18的D842V突变会导致GIST患者对伊马替尼原发耐药。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:imatinib_Revised:01/2015', '.', 'guideline:FDA', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'Dermatofibrosarcoma Protuberans', 'dermatofibrosarcoma protuberans', '皮肤纤维肉瘤', 'na', 'sensitivity', 'EVI_000048', 'PDGFB:FUS:.:COL1A1-PDGFB:.', 'PDGFB', 'FUS', 'FUS', '.', 'COL1A1-PDGFB', '.', 'translocation of collagen type I alpha 1 (COL1A1; on 17q22) with platelet-derived growth factor Beta (PDGFB; on 22q13) to form the oncogenic chimeric fusion gene t(17;22)(q22;q13).', '携带COL1A1与PDGFB形成融合基因肿瘤的患者对伊马替尼治疗敏感。隆突性皮肤纤维肉瘤(DFSP)是一种皮肤性软组织肉瘤，其特点是携带17号染色体和22号染色体易位引起的COL1A1-PDGFB基因融合。在一项开放性、多中心、Ⅱ期临床试验中探究了伊马替尼对Abl, Kit或PDGFR蛋白激酶相关的生命威胁性疾病的作用。在这项研究中有12名DFSP患者，接受每日剂量800 mg伊马替尼。这些患者在参组治疗时患有初始手术切除后转移性、局部复发的DFSP，且不适宜进一步手术治疗。另有5篇文献中报道的6名DFSP患者也接受了伊马替尼治疗。因此，总共有18名DFSP患者，其中8名患者患有转移性疾病，文献中报道的成人患者为每日剂量400 mg或800 mg。一位儿童患者每日剂量为400 mg/m2，随后增加至520 mg/m2。18名患者中有10名患者携带PDGFB基因重排，5名患者没有有效细胞遗传学信息，3名患者携带有复杂的细胞遗传学异常。在18名患者中，有12名患者获得完全缓解（N=7）或部分缓解后通过手术使疾病消除（N=5，包括一名儿童），总的完全缓解率67%。另有3名患者获得了部分缓解，因此总缓解为83%。在8名转移性疾病患者中，5位获得部分缓解，3为获得完全缓解。在10名携带PDGFB基因重排的患者中，4名获得完全缓解，6名获得部分缓解。在临床试验中患者的中位持续缓解时间为6.2个月，最长持续时间为24.3个月，而文献中报道的中位持续缓解时间为4周~20+个月。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000049', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NCCN以2A类证据推荐使用靶向药物：携带MET基因高度扩增的病人可以使用克唑替尼。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000050', 'MET:skipping_mut:.:.:skipping_mut', 'MET', 'skipping_mut', 'None_pos', '.', '.', 'skipping_mut', '.', 'NCCN以2A类证据推荐MET exon 14 skipping mutation(14号外显子跳读突变) 的病人可以使用克唑替尼。美国癌症基因研究组(The Cancer Genome Atlas，TCGA) 通过对mRNA和DNA高通量测序结果及序列比对分析，发现约4%(10/230) 肺腺癌存在MET14外显子剪接位点突变，导致MET第14号外显子在mRNA水平出现部分或完全跳跃缺失(exon14-skipping) (PMID:25079552)。在同一期杂志中发表了两篇报道:(1)Paik等在178例VI期肺腺癌中发现8例MET exon14缺失(发生率约4%)，4例患者接受克唑替尼或卡博替尼，1例获得CR，3例获得PR(PMID:25971939)。 (2)Frampton等在38028例肿瘤中发现了224例(发生率约0.6%)，其中发生率较高的癌症依次为肺腺癌(3%)，其他肺肿瘤(2.3%)，脑胶质瘤(0.4%)及原发灶不明癌(0.4%)(PMID:25971938)。另外，刘学文等通过高通量测序及针对MET基因进行双向测序，在36例肺肉瘤样癌中发现了8例(发生率约22%) MET exon14缺失，同时报道了1例肺肉瘤样癌接受克唑替尼治疗后肿瘤退缩约80%。这8例MET exon14突变患者的特征：不存在EGFR、KRAS、BRAF、ALK突变(互斥)，其中1例合并有PIK3CA突变。8例MET突变中7例的肿瘤组织存在腺泡样腺癌成分(PMID:26215952)。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24366379', '.', 'preclinical', '4', 'lapatinib', 'lapatinib', 'lapatinib', '拉帕替尼', 'lapatinib|拉帕替尼', '4', 'breast cancer', 'cancer cell lines_', '肿瘤细胞', 'na', 'resistance', 'EVI_000057', 'PIK3CA:CNV:.:.:gain', 'PIK3CA', 'CNV', 'CNV', '.', '.', 'gain', 'In preclinical models, activating PIK3CA mutations mediate cellular resistance to lapatinib treatment in a breast cancer cell line.', '临床前研究表明，PIK3CA的激活突变（包括基因扩增）可能导致乳腺癌肿瘤细胞株对拉帕替尼耐药。针对PI3K/Akt信号通路的药物在早期临床试验中显示出了希望，目前针对多种适应症的的后期临床研究正在进行中。而其他靶向药物的研究经验表明，药物的临床有效反应可能因为获得性耐药而变得较为短暂。本次试验中，我们在HER2阳性，PIK3CA突变的耐药乳腺癌细胞株中建立了临床前模型KPL-4，并确定了一个迄今未报告的耐药机制。特别是PIK3CA等位基因突变具有较高水平的扩增，导致PI3K信号明显上调，使耐药细胞在临床相关浓度的PI3K抑制剂中恢复了其增殖能力。我们还通过小干扰RNA技术敲除了实验细胞扩增的PIK3CA突变的等位基因，在与亲本细胞相当的水平下恢复了对PI3K抑制的途径信号传导和敏感性。这些新的临床前研究结果表明，除了要评估先前报道的其他耐药机制外，还应将活检样本中的PI3K拷贝数变异的评估纳入到疾病进展的分析中。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21163703', '.', 'clinical study', '4', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000058', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', '.', 'PTEN基因缺失可能使得结直肠癌患者对帕尼单抗耐药。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21468130', '.', 'clinical study', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'endometrial carcinoma', 'Uterine Neoplasm', '子宫肿瘤', 'na', 'sensitivity', 'EVI_000059', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', '.', 'PTEN基因缺失的子宫肿瘤患者可能对奥拉帕利敏感。一位58岁的患有子宫内膜腺癌的女性患者接受了手术以及辅助放疗来治疗早期子宫内膜癌。在过去9年时间，该患者已经因为病情复发而多次更换了化疗疗法，并且表现出对含铂类药物的治疗方案非常敏感的状况。调查研究: CT扫描显示在肝，肺及腹膜处均有转移，另外核磁共振发现多处脑内转移。诊断: 子宫内膜腺癌二级伴脑转移。治疗方案: 根据患者对铂类治疗方案较敏感的情况，该患者在铂类药物治疗的同时口服PARP抑制剂奥拉帕利(olaparib)作为I期治疗的一部分。在10周治疗后用核磁共振复查发现脑内转移灶显著变小，且没有经过类固醇或放疗类似的治疗。在8个月的奥拉帕利治疗后，患者出现客观疾病进展。通过对患者肿瘤样本的活检发现患者BRCA1和BRCA2突变检测为阴性，但是提示有PTEN缺失，这也是对PARP抑制剂敏感的另一个预测标志物。患者在完成奥拉帕利疗程后仍存活了10个月，已经继续开始铂类药物治疗以获得进一步的疗效收益。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18483379', '.', 'preclinical', '4', '[HDAC inhibitor]', 'vorinostat', 'vorinostat', '伏立诺他', 'vorinostat|伏立诺他', '4', 'retinoblastoma', 'eye cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000060', 'RB1:CNV:.:.:loss', 'RB1', 'CNV', 'CNV', '.', '.', 'loss', '.', 'RB1基因缺失的视网膜母细胞瘤患者可能对HDAC类抑制剂敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24691995', '.', 'preclinical', '4', '[SRC inhibitor]', 'dasatinib', 'dasatinib', '达沙替尼', 'dasatinib|达沙替尼', '4', 'solid tumor', 'solid tumor', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000062', 'TSC2:CNV:.:.:loss', 'TSC2', 'CNV', 'CNV', '.', '.', 'loss', '.', 'TSC2基因缺失突变的肿瘤患者可能对SRC抑制剂敏感。淋巴管肌瘤病(LAM)是一种渐进性囊性肺肿瘤，会影响一些结节性硬化症(TSC)的女性。因为TSC2基因的体细胞突变，散发性LAM亦可在没有TSC的女性患者中出现。越来越多的证据支持LAM是一个低级的、破坏性的、转移性肿瘤，但LAM细胞的转移机制目前仍知之甚少。从观察LAM细胞的行为模式上得知，该细胞的浸润性生长模式、转移潜力和细胞分化改变等特征与上皮间质转化细胞相似。在该研究中，我们发现LAM患者肺部细胞和TSC2(-/-) 细胞中因为自噬的减少导致Src激酶水平升高。同时因为上调转录因子Snail，Src激酶活性的增加促进了TSC2(-/-)细胞的迁移和侵袭能力并抑制E钙粘蛋白的表达。值得注意的是，Src激酶抑制剂降低了TSC2(-/-)细胞的迁移和侵袭能力且相对于TSC2(+/+)对照组，TSC2(-/-)细胞的肺定植水平在体内注射之后有更大程度上的减弱。我们的研究结果揭示了LAM细胞的致病机制，并且为Src激酶作为治疗LAM和TSC的新的治疗靶点提供了依据。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27252416', '.', 'clinical study', '4', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib|rociletinib', '3', 'lung cancer', 'lung cancer', '肺癌', 'na', 'resistance', 'EVI_000063', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', 'Amplification of either MET or ERBB2 in tumors that were resistant or developed resistance to third-generation EGFR inhibitors and show that ERBB2 and MET activation can confer resistance to these compounds.  KRAS G12S mutation in a patient was resistant to AZD9291 as a potential driver of acquired resistance. ', 'MET或ERBB2基因扩增，KRAS基因突变与肿瘤患者对第三代EGFR抑制剂的耐药有关。我们分析了7例奥西替尼(AZD9291)或rociletinib(CO-1686)治疗前后的患者的组织活检样本，并在体外模型中对候选基因的相关性进行功能评估。发现MET或ERBB2在肿瘤中的复发性扩增导致第三代酪氨酸激酶抑制耐药或耐药进展，表明ERBB2及MET的激活赋予了患者耐药的能力。此外，我们还发现一例患者中的KRAS G12S突变可能是患者对AZD9291耐药的潜在驱动力。最后，我们还证明EGFR/MEK的双重抑制对克服携带KRAS突变的EGFR突变细胞的耐药可能是一个可行的策略。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21289267', '.', 'preclinical', '4', 'MK2206', 'MK-2206', 'MK-2206', 'MK-2206', 'MK-2206|MK-2206', '2', 'thyroid cancer', 'thyroid cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000066', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', '.', 'PTEN基因缺失突变的肿瘤患者可能对MK2206（AKT抑制剂）敏感。磷酸肌醇3-激酶(PI3K)/Akt通路被广泛认为是甲状腺癌的一个有效的治疗靶点。本研究的目的是测试甲状腺癌中新的Akt抑制剂MK2206的治疗潜力。我们研究了MK2206对甲状腺癌细胞PI3K/Akt通路中的基因的影响。结果显示，携带PIK3CA、PTEN、RAS或RET/PTC基因突变的甲状腺癌细胞ocut1，K1，FTC133，C643，hth7，和TPC1的增殖可激活PI3K/Akt通路，也明显的被MK2206所抑制(半抑制浓度值(IC(50))小于或近于0.5μM)。与此相反的是，MK2206对大部分没有携带PI3K/Akt通路基因突变的Hth74，KAT18，sw1736，WRO和TAD2细胞则没有明显的抑制作用。同时，抑制作用也有基因选择性，携带突变与未携带突变细胞的MK2206平均抑制效果对比为: 1 μm MK2206 59.2 ± 11.3 vs. 36.4 ± 8.8% (P = 0.005)和3 μm MK2206 64.4 ± 11.5 vs. 38.5 ± 18.9% (P = 0.02)。在不携带PI3K/Akt通路基因突变的SW1736细胞中，MK2206的抑制效果最低，但在转染外源PIK3CA突变，PIK3CA H1047R突变和E545K突变之后，SW1736细胞对MK2206的敏感度有了明显的提升。MK2206也完全克服了西罗莫司诱导的哺乳动物雷帕霉素靶蛋白的抑制带来的AKT激活反馈，两种药物可协同抑制甲状腺癌细胞的生长。我们的研究表明，MK2206在甲状腺癌中选择性的抑制PI3K/Akt通路的基因突变，可以在甲状腺癌临床试验中继续研究。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23553849', 'NCT01031225', 'clinical trial - phase2', '4', 'ganetespib', 'ganetespib', 'ganetespib', 'ganetespib', 'ganetespib|ganetespib', '3', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000068', 'ALK:FUS:.:EML4-ALK:.', 'ALK', 'FUS', 'FUS', '.', 'EML4-ALK', '.', '.', '一项II期临床试验中，使用Ganetespib作为单一疗法来治疗NSCLC患者，在无EGFR及KRAS突变的患者中，Ganetespib表现出良好的活性，这些患者中存在ALK重排，主要类型为EML4-ALK,特别是对未经crizotinib治疗且存在ALK重排的8名患者中4名患者获得部分缓解，治疗持续时间从7.4到21个月；3名患者在121-218天内病情稳定；只有1名患者发生了病情恶化同时治疗所伴随的不良反应可控。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22025146', 'NCT00410761', 'clinical trial - phase3', '4', 'vandetanib', 'vandetanib', 'vandetanib', '凡德他尼', 'vandetanib|凡德他尼', '4', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', 'na', 'sensitivity', 'EVI_000070', 'RET:nonsynonymous SNV:exon16:p.M918T:.', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon16', 'p.M918T', '.', '.', '一项关于凡德他尼对晚期或转移型髓性甲状腺癌患者疗效的临床III期实验中，共有331名患者参与，其中90%为偶发性，95%治疗前发生转移，且50%患者发生RET阳性突变。经双盲实验结果表明，接受凡德他尼治疗的患者相比服用安慰剂的患者中位无进展期明显增加(hazard ratio [HR], 0.46; 95% CI, 0.31 to 0.69; P＜001)。偶发性或遗传性RET突变的髓性甲状腺癌患者相比无RET突变的患者，能够从凡德他尼治疗中获益,延长中位无进展生存期。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:alectinib_Revised:12/2015', '.', 'guideline:FDA', '1', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000071', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '阿来替尼（Alectinib）适用于克唑替尼治疗后疾病进展或不耐受的、ALK阳性的转移性非小细胞肺癌患者。FDA批准阿来替尼治疗ALK阳性的非小细胞肺癌，此项适应症是基于两项多中心、单臂、开放性临床试验结果获批。参与两项试验的患者确诊为ALK重排阳性的非小细胞肺癌，患者对克唑替尼不耐受或发生疾病进展，且大多数的患者先期接受了系统性化疗。试验主要的疗效指标为由独立评审委员会（IRC）根据RECIST v1.1评估的客观缓解率（ORR），其他的指标包括根据RECIST v1.1评估的反应持续时间（DOR），中枢神经系统客观缓解率（CNS ORR）。在第一项研究（N=87）中独立评审委员会（IRC）评估的ORR为38%(95% CI: 28%, 49%)，研究者评估的ORR为46% (95% CI: 35%, 57%)。在第二项研究中（N=138）IRC评估的ORR为44% (95% CI:36%, 53%),研究者评估的ORR为48% (95% CI: 39%, 57%)。在第一项研究患者的中位DOR为7.5个月，第二项研究中为11.2个月。对两项研究的综合分析显示，患者的CNS ORR为61% (95% CI: 46%, 74%)，中位DOR为9.1个月(NCT01871805;NCT01801111)。J-ALEX研究是一项开放标签、随机、III期研究，招募了207例ALK+、晚期或复发性NSCLC患者，比较了alectinib和克唑替尼作为一线疗法的疗效和安全性。主要数据如下：与克唑替尼相比，alectinib使疾病进展和死亡风险降低了66%（HR=0.34，99% CI：0.17-0.70）;克唑替尼组中位PFS为10.2个月（95%CI: 8.2~12.0个月），alectinib组中位PFS数据尚未获得（95% CI：20.3 ~not estimated）;Alectinib组3~4级不良事件发生率低于克唑替尼组（27% vs 51%）;在最常见不良反应（>30%）方面，alectinib组主要为便秘（36%）。克唑替尼组包括恶心（74%），腹泻（73%），呕吐（59%），视觉障碍（55%），味觉改变（52%），便秘（46%），ALT升高（32%），AST升高（31%）。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:crizotinib_Revised:04/2016', '.', 'guideline:FDA', '1', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000072', 'ROS1:FUS:.:.-ROS1:.', 'ROS1', 'FUS', 'FUS', '.', '.-ROS1', '.', '.', '克唑替尼(crizotinib)适用于ALK阳性或ROS1阳性的转移性非小细胞肺癌患者。FDA批准克唑替尼治疗ROS1阳性的转移性非小细胞肺癌，此项适应症获批基于一项多中心、单臂试临床试验结果。试验的主要疗效指标为由独立影像评审委员会(IRR)和研究者根据RECIST v1.0评估的客观缓解率(ORR)，其他的测量指标为持续反应时间(DoR)。在这项单臂试验中纳入了50名患者，通过FISH或RT-PCR临床实验检测确定为ROS1阳性。其中IRR评估的ORR为66% (95% CI：51%，79%)，中位DoR为18个月。研究者评估的ORR为72% (95% CI：58%，84%)。(NCT00585195)', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:crizotinib_Revised:04/2016', '.', 'guideline:FDA', '1', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000073', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '克唑替尼(crizotinib)适用于ALK阳性或ROS1阳性的转移性非小细胞肺癌患者。FDA批准克唑替尼治疗转移性ALK阳性的转移性非小细胞肺癌，此项适应症获批基于一项多国家、开放性、活性药物对照的、随机临床试验结果。在这项试验中纳入了347位转移性非小细胞肺癌患者，这些患者对基于铂类为基础的化疗有疾病进展且经中心实验室通过FISH检测患者肿瘤样本为ALK阳性。将这些患者按1：1随机分配到克唑替尼治疗组(N=173)或化疗治疗组(N=174)，化疗组中的患者接受培美曲塞(58%)，如果先期接受过培美曲塞治疗则给予多西他赛治疗。化疗治疗组中64%的患者随后接受了克唑替尼治疗。与化疗组相比，克唑替尼显著延长了患者的无进展生存期(PFS)[HR=0.49，(95% CI：0.37，0.64)，p<0.0001]，克唑替尼治疗组和化疗治疗组的中位PFS分别为7.7个月和3.0个月。克唑替尼治疗组的客观缓解率(ORR)显著较高(65% vs. 20%)，克唑替尼治疗组和化疗治疗组的中位反应持续时间分别为7.4个月和5.6个月。但是两组的总生存期(OS)没有显著性差异[HR=1.02 (95% CI：0.68，1.54)]。(NCT00932893)', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:trametinib_Revised:11/2015', '.', 'guideline:FDA', '1', 'trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000075', 'BRAF:nonsynonymous SNV:exon15:p.V600E:.', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.V600E', '.', '.', 'FDA于2013年5月批准曲美替尼(trametinib)治疗伴有BRAF V600E或V600K突变的不可切除或转移性黑色素瘤。该批准基于一项入组322例接受过≤1种化疗方案的患者的多中心、国际化、开放性、随机双盲研究，Trametinib组相较于化疗组PFS分别为4.8个月：1.5个月（P<0.0001），客观有效率为22%：8%。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:trametinib_Revised:11/2015', '.', 'guideline:FDA', '1', 'trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000076', 'BRAF:nonsynonymous SNV:exon15:p.V600K:.', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.V600K', '.', '.', 'FDA于2013年5月批准曲美替尼(trametinib)治疗伴有BRAF V600E或V600K突变的不可切除或转移性黑色素瘤。该批准基于一项入组322例接受过≤1种化疗方案的患者的多中心、国际化、开放性、随机双盲研究，Trametinib组相较于化疗组PFS分别为4.8个月：1.5个月（P<0.0001），客观有效率为22%：8%。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:dabrafenib_Revised:10/2019', '.', 'guideline:FDA', '1', 'dabrafenib,trametinib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000079', 'BRAF:nonsynonymous SNV:exon15:p.V600E:.', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.V600E', '.', '.', 'FDA批准dabrafenib单药治疗BRAF V600E突变型黑色素瘤，此项适应症基于一项多中心、国际性、开放性、随机活性药物对照试验中无进展生存期(PFS)提高而获批。试验中有250名患者参与，这些患者先期未经治疗，组织学确定为不可切除的Ⅲ期或Ⅳ期黑色素瘤且均经中心实验室检测确定为携带BRAF V600E阳性突变。将患者随机分配至达拉非尼(dabrafenib)治疗组(N=187)或达卡巴嗪治疗组(N=63)，28位达卡巴嗪治疗组的患者在出现疾病进展时转至达拉非尼治疗组。研究者评估达拉非尼治疗组的PFS得到显著延长[HR 0.33 (95% CI：0.20，0.54)；p < 0.0001，stratified log-rank test]，达拉非尼治疗组和达卡巴嗪治疗组的中位PFS分别为5.1和2.7个月，独立审查委员会(IRC) 评估的PFS结果与研究者的分析结果一致。研究者评估达拉非尼治疗组的客观缓解率为52% (95% CI：45，59)，其中完全缓解率为3%；达卡巴嗪治疗组的客观缓解率为17% (95% CI：9，29)。两个治疗组的中位反应持续时间大约均为5个月，总生存期没有统计学显示性差异(NCT01227889)。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:dabrafenib_Revised:10/2019|Druglabel:trametinib_Revised:10/2019', '.', 'guideline:FDA', '1', '.', '.', 'trametinib + dabrafenib', '曲美替尼 + 达拉非尼', 'trametinib + dabrafenib|曲美替尼 + 达拉非尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000080', 'BRAF:nonsynonymous SNV:exon15:p.V600E:.', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.V600E', '.', '.', 'FDA批准trametinib + dabrafenib(曲美替尼 + 达拉非尼)联合治疗BRAF V600E或V600K突变型黑色素瘤，此适应症是基于两项国际性、随机、活性药物对照临床试验结果获批：一项为双盲试验，另一项为开放性试验。在两项试验中，与曲美替尼或达拉非尼单药使用相比，联合使用会提高患者的持续客观缓解率。在双盲试验中纳入了420多名患者，将其按1：1随机分配至曲美替尼+达拉非尼治疗组(N=211)或达拉非尼+安慰剂治疗组(N=212)。患者经中心实验室检测确定为BRAF V600E(85%) 或V600K(15%)。这项试验达到了主要临床终点，据研究者评估其无进展生存期(PFS)显著提高[HR 0.75 (95% CI：0.57，0.99)；p=0.035]，曲美替尼+达拉非尼治疗组和达拉非尼+安慰剂治疗组的中位PFS分别为9.3个月和8.8个月。另外，总生存期(OS) 也有了显著的增加[HR=0.71 (95% CI：0.55，0.92)；p=0.01]，曲美替尼+达拉非尼治疗组和达拉非尼+安慰剂治疗组的中位OS分别为25.1个月和18.7个月，总响应率分别为66%和 51%，中位反应持续时间分别为9.2和10.2个月(NCT01584648)。第二项开放性试验纳入了704位患者，将其按1：1分配至曲美替尼+达拉非尼治疗组(N=352)或维莫非尼治疗组(N=352)。这项试验达到了主要临床终点，试验显示OS得到了显著提高[HR 0.69 (95% CI：0.53，0.89)；p=0.005]，曲美替尼+达拉非尼治疗组中位OS尚未达到，维莫非尼治疗组中位OS为17.2个月。另外，曲美替尼+达拉非尼治疗组PFS有了显著改善[HR 0.56 (95% CI：0.46，0.69)；p <0.001]，曲美替尼+达拉非尼治疗组和维莫非尼治疗组的中位PFS分别为11.4个月和7.3个月，总响应率分别为64%和51%，中位反应持续时间分别为13.8和7.5个月(NCT01597908)。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:dabrafenib_Revised:10/2019|Druglabel:trametinib_Revised:10/2019', '.', 'guideline:FDA', '1', '.', '.', 'trametinib + dabrafenib', '曲美替尼 + 达拉非尼', 'trametinib + dabrafenib|曲美替尼 + 达拉非尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000081', 'BRAF:nonsynonymous SNV:exon15:p.V600K:.', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.V600K', '.', '.', 'FDA批准trametinib + dabrafenib(曲美替尼 + 达拉非尼)联合治疗BRAF V600E或V600K突变型黑色素瘤，此适应症是基于两项国际性、随机、活性药物对照临床试验结果获批：一项为双盲试验，另一项为开放性试验。在两项试验中，与曲美替尼或达拉非尼单药使用相比，联合使用会提高患者的持续客观缓解率。在双盲试验中纳入了420多名患者，将其按1：1随机分配至曲美替尼+达拉非尼治疗组(N=211)或达拉非尼+安慰剂治疗组(N=212)。患者经中心实验室检测确定为BRAF V600E(85%) 或V600K(15%)。这项试验达到了主要临床终点，据研究者评估其无进展生存期(PFS)显著提高[HR 0.75 (95% CI：0.57，0.99)；p=0.035]，曲美替尼+达拉非尼治疗组和达拉非尼+安慰剂治疗组的中位PFS分别为9.3个月和8.8个月。另外，总生存期(OS) 也有了显著的增加[HR=0.71 (95% CI：0.55，0.92)；p=0.01]，曲美替尼+达拉非尼治疗组和达拉非尼+安慰剂治疗组的中位OS分别为25.1个月和18.7个月，总响应率分别为66%和 51%，中位反应持续时间分别为9.2和10.2个月(NCT01584648)。第二项开放性试验纳入了704位患者，将其按1：1分配至曲美替尼+达拉非尼治疗组(N=352)或维莫非尼治疗组(N=352)。这项试验达到了主要临床终点，试验显示OS得到了显著提高[HR 0.69 (95% CI：0.53，0.89)；p=0.005]，曲美替尼+达拉非尼治疗组中位OS尚未达到，维莫非尼治疗组中位OS为17.2个月。另外，曲美替尼+达拉非尼治疗组PFS有了显著改善[HR 0.56 (95% CI：0.46，0.69)；p <0.001]，曲美替尼+达拉非尼治疗组和维莫非尼治疗组的中位PFS分别为11.4个月和7.3个月，总响应率分别为64%和51%，中位反应持续时间分别为13.8和7.5个月(NCT01597908)。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:dabrafenib_Revised:10/2019', '.', 'guideline:FDA', '1', 'dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', '.', '.', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000082', 'BRAF:nonsynonymous SNV:exon15:p.V600.:wildtype', 'BRAF', 'nonsynonymous SNV', 'wildtype', 'exon15', 'p.V600.', 'wildtype', '.', 'FDA批准达拉非尼(Dabrafenib)与曲美替尼(Trametinib)联用治疗BRAF V600E突变的转移性非小细胞肺癌。FDA暂未批准拉非尼(Dabrafenib)用于BRAF野生型的非小细胞肺癌患者(Limitations of Use)。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:dabrafenib_Revised:10/2019', '.', 'guideline:FDA', '1', 'dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', '.', '.', '甲状腺癌', '甲状腺癌', 'resistance', 'EVI_000083', 'BRAF:nonsynonymous SNV:exon15:p.V600.:wildtype', 'BRAF', 'nonsynonymous SNV', 'wildtype', 'exon15', 'p.V600.', 'wildtype', '.', 'FDA批准在没有令人满意的局部治疗选择时，达拉非尼(Dabrafenib)与曲美替尼(Trametinib)联用治疗BRAF V600E突变的局部晚期或转移性变性甲状腺癌。FDA暂未批准拉非尼(Dabrafenib)用于BRAF野生型的甲状腺癌患者(Limitations of Use)。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:dabrafenib_Revised:10/2019', '.', 'guideline:FDA', '1', 'dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'resistance', 'EVI_000084', 'BRAF:nonsynonymous SNV:exon15:p.V600.:wildtype', 'BRAF', 'nonsynonymous SNV', 'wildtype', 'exon15', 'p.V600.', 'wildtype', 'TAFINLAR is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF.', 'FDA批准达拉非尼(Dabrafenib)用于BRAF V600E突变的不能切除或转移性黑色素瘤患者；达拉非尼(Dabrafenib)与曲美替尼(Trametinib)联用治疗BRAF V600E/K突变的不能切除或转移性黑色素瘤患者；达拉非尼(Dabrafenib)与曲美替尼(Trametinib)联用治疗BRAF V600E/K突变和淋巴结受累的黑色素瘤(完全切除后)的辅助治疗。FDA暂未批准达拉非尼(Dabrafenib)用于BRAF 野生型的黑色素瘤患者(Limitations of Use)。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:vemurafenib_Revised:11/2017', '.', 'guideline:FDA', '1', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'resistance', 'EVI_000085', 'BRAF:nonsynonymous SNV:exon15:p.V600.:wildtype', 'BRAF', 'nonsynonymous SNV', 'wildtype', 'exon15', 'p.V600.', 'wildtype', '.', 'FDA批准维莫非尼(Vemurafenib)用于BRAF V600E突变的不能切除或转移性黑色素瘤患者。FDA暂未批准维莫非尼(Vemurafenib)用于BRAF 野生型的黑色素瘤患者(Limitations of Use)。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:olaparib_Revised: 12/2018 ', '.', 'guideline:FDA', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_000086', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2014年美国FDA批准抗癌新药奥拉帕利 olaparib (Lynparza)，作为单药治疗之前至少经过3次化疗的晚期卵巢癌患者，或者生殖系的BRCA突变的晚期卵巢癌。欧盟药监局（EMA）也批准了Olaparib用于铂敏感复发性卵巢癌患者，对携带BRCA体细胞突变的肿瘤患者也有一定作用。FDA批准olaparib治疗携带生殖细胞BRCA有害突变(gBRCAm) 或疑似有害突变的晚期卵巢癌，患者曾接受过三线或更多线的化疗，此适应症是基于一项国际性、单臂临床试验结果。试验中纳入了137名gBRCAm相关且可测量的接受过三线或更多线化疗的卵巢癌患者，这些患者接受olaparib单药治疗直到出现疾病进展或不可接受的毒性。主要疗效指标包括研究者根据RECIST v1.1 评价的客观缓解率（ORR）和反应持续时间（DOR）。对BRAC Analysis CDxTM 伴随诊断有效的血样中，97% (59/61)的患者被证实了有害或疑似有害的gBRCAm状态。临床试验结果表明研究者评估的olaparib ORR为34% (95% CI: 26, 42)，中位反应持续时间为7.9个月 (95% CI: 5.6, 9.6)。(NCT01078662)', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:erlotinib_Revised:06/2016', '.', 'guideline:FDA', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000087', 'EGFR:nonsynonymous SNV:exon21:p.L858R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', '厄洛替尼（Erlotinib）：（1）适用于EGFR 19号外显子缺失或21号外显子 L858R突变的转移性非小细胞肺癌的的一线治疗；适用于以铂类为基础的一线化疗4个疗程后没有进展的局部晚期或转移性非小细胞肺癌患者；适用于既往至少接受1种化疗方案失败的局部晚期或转移性非小细胞肺癌的治疗。局限性：不推荐厄洛替尼与铂类为基础的化疗联合使用；厄洛替尼一线治疗EGFR其他突变的转移性非小细胞肺癌的安全性和有效性尚未建立；（2）厄洛替尼联合吉西他滨适用于局部晚期、不可切除的或转移性胰腺癌的一线治疗。FDA批准厄洛替尼治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌，此项适应症是基于一项随机的、多中心的、开放性临床试验结果获批。试验中纳入了134名患者，按1：1随机分配至厄洛替尼治疗组或铂类为基础的两药化疗治疗组。患者均经临床实验检测确定为携带EGFR 19号外显子缺失或21号外显子L858R突变。试验的主要临床终点为研究者评估的无进展生存期（PFS），次要终点包括总生存期（OS）和客观缓解率（ORR）。厄洛替尼治疗组和化疗治疗组的中位PFS分别为10.4个月和5.2个月[HR 0.34 (95% CI: 0.23, 0.49), p <0.001]，中位OS分别为22.9个月和19.5个月 [HR 0.93 (95% CI: 0.64, 1.35), p=0.6482]， ORR分别为65%和16%。(NCT00446225)', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:erlotinib_Revised:06/2016|PMID:26046796', '.', 'guideline:FDA', '1', 'erlotinib', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic Cancer', 'pancreatic Cancer', '胰腺癌', '胰腺癌', 'sensitivity', 'EVI_000088', 'EGFR:nonsynonymous SNV:exon21:p.L861Q:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L861Q', '.', '.', '厄洛替尼(Erlotinib)：(1) 适用于EGFR 18号外显子G719X、19号外显子缺失、21号外显子 L858R、L861Q突变的转移性非小细胞肺癌的的一线治疗；适用于以铂类为基础的一线化疗4个疗程后没有进展的局部晚期或转移性非小细胞肺癌患者；适用于既往至少接受1种化疗方案失败的局部晚期或转移性非小细胞肺癌的治疗。局限性：不推荐厄洛替尼与铂类为基础的化疗联合使用；厄洛替尼一线治疗EGFR其他突变的转移性非小细胞肺癌的安全性和有效性尚未建立；(2) 厄洛替尼联合吉西他滨适用于局部晚期、不可切除的或转移性胰腺癌的一线治疗。临床研究涉及569名患者，其中盐酸厄洛替尼100 mg组患者521例，盐酸厄洛替尼150 mg组48例。结果主要为100 mg队列中的患者。试验的主要终点指标是总体生存。盐酸厄洛替尼组的生存期显著延长，盐酸厄洛替尼/吉西他滨和安慰剂/吉西他滨组的中位总生存期分别为6.4个月和6.0个月。厄洛替尼盐酸组相对于安慰剂组的死亡调整危险比(HR) 为0.81，p = 0.028。次要终点是无进展生存期(PFS)，肿瘤反应率，反应持续时间，EGFR状态和生活质量。盐酸厄洛替尼/吉西他滨的组合在100mg队列中具有较长的中值PFS(EG 3.8个月和PG 3.5个月)，HR为0.76，p = 0.006。相比之下，肿瘤反应(EG 8.6%和PG 7.9%)或反应持续时间(EG 24周和PG 23周)无统计学差异。在这项试验中，肿瘤的EGFR表达与生存率无关，但可用的EGFR样本数量较少(少于三分之一的患者可以获得EGFR表达情况数据)。一项单中心前瞻性临床试验中(NCT01608841；PMID：26046796)，88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变，主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率(64%对25%；P <0.001)，无进展生存期(中位数3.8对2.4个月；P <0.001)和总生存期(中位数7.2对4.4个月；P <0.001)。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，表现在其疾病控制率(85%对33%；P = 0.001)，无进展生存期(中位数5.9对2.4个月；P = 0.004)和总生存期上(中位数 8.7对6.0个月；P = 0.044)。 KRAS突变与治疗反应或生存无关。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:erlotinib_Revised:06/2016|PMID:26046796', '.', 'guideline:FDA', '1', 'erlotinib', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic Cancer', 'pancreatic Cancer', '胰腺癌', '胰腺癌', 'sensitivity', 'EVI_000089', 'EGFR:nonsynonymous SNV:exon18:p.G719.:', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon18', 'p.G719.', '.', '.', '厄洛替尼(Erlotinib)：(1) 适用于EGFR 18号外显子G719X、19号外显子缺失、21号外显子 L858R、L861Q突变的转移性非小细胞肺癌的的一线治疗；适用于以铂类为基础的一线化疗4个疗程后没有进展的局部晚期或转移性非小细胞肺癌患者；适用于既往至少接受1种化疗方案失败的局部晚期或转移性非小细胞肺癌的治疗。局限性：不推荐厄洛替尼与铂类为基础的化疗联合使用；厄洛替尼一线治疗EGFR其他突变的转移性非小细胞肺癌的安全性和有效性尚未建立；(2) 厄洛替尼联合吉西他滨适用于局部晚期、不可切除的或转移性胰腺癌的一线治疗。临床研究涉及569名患者，其中盐酸厄洛替尼100 mg组患者521例，盐酸厄洛替尼150 mg组48例。结果主要为100 mg队列中的患者。试验的主要终点指标是总体生存。盐酸厄洛替尼组的生存期显著延长，盐酸厄洛替尼/吉西他滨和安慰剂/吉西他滨组的中位总生存期分别为6.4个月和6.0个月。厄洛替尼盐酸组相对于安慰剂组的死亡调整危险比(HR) 为0.81，p = 0.028。次要终点是无进展生存期(PFS)，肿瘤反应率，反应持续时间，EGFR状态和生活质量。盐酸厄洛替尼/吉西他滨的组合在100mg队列中具有较长的中值PFS(EG 3.8个月和PG 3.5个月)，HR为0.76，p = 0.006。相比之下，肿瘤反应(EG 8.6%和PG 7.9%)或反应持续时间(EG 24周和PG 23周)无统计学差异。在这项试验中，肿瘤的EGFR表达与生存率无关，但可用的EGFR样本数量较少(少于三分之一的患者可以获得EGFR表达情况数据)。一项单中心前瞻性临床试验中(NCT01608841；PMID：26046796)，88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变，主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率(64%对25%；P <0.001)，无进展生存期(中位数3.8对2.4个月；P <0.001)和总生存期(中位数7.2对4.4个月；P <0.001)。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，表现在其疾病控制率(85%对33%；P = 0.001)，无进展生存期(中位数5.9对2.4个月；P = 0.004)和总生存期上(中位数 8.7对6.0个月；P = 0.044)。 KRAS突变与治疗反应或生存无关。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:erlotinib_Revised:06/2016|PMID:26046796', '.', 'guideline:FDA', '1', 'erlotinib', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic Cancer', 'pancreatic Cancer', '胰腺癌', '胰腺癌', 'sensitivity', 'EVI_000090', 'EGFR:nonsynonymous SNV:exon21:p.L858R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', '厄洛替尼(Erlotinib)：(1) 适用于EGFR 18号外显子G719X、19号外显子缺失、21号外显子 L858R、L861Q突变的转移性非小细胞肺癌的的一线治疗；适用于以铂类为基础的一线化疗4个疗程后没有进展的局部晚期或转移性非小细胞肺癌患者；适用于既往至少接受1种化疗方案失败的局部晚期或转移性非小细胞肺癌的治疗。局限性：不推荐厄洛替尼与铂类为基础的化疗联合使用；厄洛替尼一线治疗EGFR其他突变的转移性非小细胞肺癌的安全性和有效性尚未建立；(2) 厄洛替尼联合吉西他滨适用于局部晚期、不可切除的或转移性胰腺癌的一线治疗。临床研究涉及569名患者，其中盐酸厄洛替尼100 mg组患者521例，盐酸厄洛替尼150 mg组48例。结果主要为100 mg队列中的患者。试验的主要终点指标是总体生存。盐酸厄洛替尼组的生存期显著延长，盐酸厄洛替尼/吉西他滨和安慰剂/吉西他滨组的中位总生存期分别为6.4个月和6.0个月。厄洛替尼盐酸组相对于安慰剂组的死亡调整危险比(HR) 为0.81，p = 0.028。次要终点是无进展生存期(PFS)，肿瘤反应率，反应持续时间，EGFR状态和生活质量。盐酸厄洛替尼/吉西他滨的组合在100mg队列中具有较长的中值PFS(EG 3.8个月和PG 3.5个月)，HR为0.76，p = 0.006。相比之下，肿瘤反应(EG 8.6%和PG 7.9%)或反应持续时间(EG 24周和PG 23周)无统计学差异。在这项试验中，肿瘤的EGFR表达与生存率无关，但可用的EGFR样本数量较少(少于三分之一的患者可以获得EGFR表达情况数据)。一项单中心前瞻性临床试验中(NCT01608841；PMID：26046796)，88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变，主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率(64%对25%；P <0.001)，无进展生存期(中位数3.8对2.4个月；P <0.001)和总生存期(中位数7.2对4.4个月；P <0.001)。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，表现在其疾病控制率(85%对33%；P = 0.001)，无进展生存期(中位数5.9对2.4个月；P = 0.004)和总生存期上(中位数 8.7对6.0个月；P = 0.044)。 KRAS突变与治疗反应或生存无关。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:erlotinib_Revised:06/2016', '.', 'guideline:FDA', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000091', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', '厄洛替尼（Erlotinib）：（1）适用于EGFR 19号外显子缺失或21号外显子 L858R突变的转移性非小细胞肺癌的的一线治疗；适用于以铂类为基础的一线化疗4个疗程后没有进展的局部晚期或转移性非小细胞肺癌患者；适用于既往至少接受1种化疗方案失败的局部晚期或转移性非小细胞肺癌的治疗。局限性：不推荐厄洛替尼与铂类为基础的化疗联合使用；厄洛替尼一线治疗EGFR其他突变的转移性非小细胞肺癌的安全性和有效性尚未建立；（2）厄洛替尼联合吉西他滨适用于局部晚期、不可切除的或转移性胰腺癌的一线治疗。FDA批准厄洛替尼治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌，此项适应症是基于一项随机的、多中心的、开放性临床试验结果获批。试验中纳入了134名患者，按1：1随机分配至厄洛替尼治疗组或铂类为基础的两药化疗治疗组。患者均经临床实验检测确定为携带EGFR 19号外显子缺失或21号外显子L858R突变。试验的主要临床终点为研究者评估的无进展生存期（PFS），次要终点包括总生存期（OS）和客观缓解率（ORR）。厄洛替尼治疗组和化疗治疗组的中位PFS分别为10.4个月和5.2个月[HR 0.34 (95% CI: 0.23, 0.49), p <0.001]，中位OS分别为22.9个月和19.5个月 [HR 0.93 (95% CI: 0.64, 1.35), p=0.6482]， ORR分别为65%和16%(NCT00446225)。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:erlotinib_Revised:06/2016|PMID:26046796', '.', 'guideline:FDA', '1', 'erlotinib', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic Cancer', 'pancreatic Cancer', '胰腺癌', '胰腺癌', 'sensitivity', 'EVI_000092', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', '厄洛替尼(Erlotinib)：(1) 适用于EGFR 18号外显子G719X、19号外显子缺失、21号外显子 L858R、L861Q突变的转移性非小细胞肺癌的的一线治疗；适用于以铂类为基础的一线化疗4个疗程后没有进展的局部晚期或转移性非小细胞肺癌患者；适用于既往至少接受1种化疗方案失败的局部晚期或转移性非小细胞肺癌的治疗。局限性：不推荐厄洛替尼与铂类为基础的化疗联合使用；厄洛替尼一线治疗EGFR其他突变的转移性非小细胞肺癌的安全性和有效性尚未建立；(2) 厄洛替尼联合吉西他滨适用于局部晚期、不可切除的或转移性胰腺癌的一线治疗。临床研究涉及569名患者，其中盐酸厄洛替尼100 mg组患者521例，盐酸厄洛替尼150 mg组48例。结果主要为100 mg队列中的患者。试验的主要终点指标是总体生存。盐酸厄洛替尼组的生存期显著延长，盐酸厄洛替尼/吉西他滨和安慰剂/吉西他滨组的中位总生存期分别为6.4个月和6.0个月。厄洛替尼盐酸组相对于安慰剂组的死亡调整危险比(HR) 为0.81，p = 0.028。次要终点是无进展生存期(PFS)，肿瘤反应率，反应持续时间，EGFR状态和生活质量。盐酸厄洛替尼/吉西他滨的组合在100mg队列中具有较长的中值PFS(EG 3.8个月和PG 3.5个月)，HR为0.76，p = 0.006。相比之下，肿瘤反应(EG 8.6%和PG 7.9%)或反应持续时间(EG 24周和PG 23周)无统计学差异。在这项试验中，肿瘤的EGFR表达与生存率无关，但可用的EGFR样本数量较少(少于三分之一的患者可以获得EGFR表达情况数据)。一项单中心前瞻性临床试验中(NCT01608841；PMID：26046796)，88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变，主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率(64%对25%；P <0.001)，无进展生存期(中位数3.8对2.4个月；P <0.001)和总生存期(中位数7.2对4.4个月；P <0.001)。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，表现在其疾病控制率(85%对33%；P = 0.001)，无进展生存期(中位数5.9对2.4个月；P = 0.004)和总生存期上(中位数 8.7对6.0个月；P = 0.044)。 KRAS突变与治疗反应或生存无关。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:gefitinib_Revised:07/2015', '.', 'guideline:FDA', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000093', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', '吉非替尼（Gefitinib）适用于EGFR 19号外显子缺失或21号外显子L858R突变型转移性非小细胞肺癌患者的一线治疗。局限性：吉非替尼治疗非EGFFR 19号外显子缺失或21号外显子L858R突变型转移性非小细胞肺癌的安全性和有效性尚未建立。FDA批准吉非替尼治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌，此项适应症是基于一项多中心、单臂开放性临床研究结果获批。试验中纳入了106名EGFR原发性突变的转移性非小细胞肺癌患者，这些患者接受吉非替尼治疗直到出现疾病进展或不能忍受的毒性。试验中主要的疗效指标为独立审查委员会（BIRC）和研究者根据RECIST v1.1评估客观缓解率（ORR）。BIRC评估的ORR 为50% (95% CI: 41, 59)，中位反应持续时间（DoR）为6.0个月。研究者分析评估的ORR 为70% (95% CI: 61, 78) ，中位反应持续时间（DoR）为8.3个月。在另一项关于吉非替尼一线治疗非小细胞肺癌（组织学为腺癌）的随机性、多中心、开放性临床试验中，对其中一个亚组的探索性分析支持吉非替尼治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌。这项试验纳入了1217名患者，按1：1随机分配至吉非替尼治疗组或6疗程的卡铂/紫杉醇治疗组，疗效指标包括BIRC评估的PFS和ORR。探索性分析的研究对象为186名确定为EGFR阳性的患者。在此亚组中有88名患者在吉非替尼治疗组， 98名患者在卡铂/紫杉醇治疗组，BICR评估分析显示吉非替尼治疗组和卡铂/紫杉醇治疗组的中位PFS分别为10.9个月和7.4个，HR 0.54 (95% CI: 0.38, 0.79)。另外，BICR评估分析显示吉非替尼治疗组和卡铂/紫杉醇治疗组的DoR分别为 9.6个月和5.5个月，ORR分别为 67% (95% CI: 56, 77) 和41% (95% CI: 31, 51) 。(NCT01203917;NCT00322452)', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:afatinib_Revised:04/2016', '.', 'guideline:FDA', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000094', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', '阿法替尼（Afatinib）适用于一线治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌患者。局限性：阿法替尼治疗EGFR其它突变类型患者的安全性和有效性尚未建立。阿法替尼也适用于铂类为基础的化疗后出现疾病进展的转移性鳞状非小细胞肺癌患者。FDA批准阿法替尼一线治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌，此项适应症是基于在一项多中心、国际化、开放性、随机试验中患者无进展生存期提高而获批。在这项试验中345位转移性非小细胞肺癌患者按2：1随机分配至阿法替尼（n=230）治疗组和培美曲塞/顺铂化疗治疗组（n=115），主要疗效指标为由独立评审委员会（IRC）评估的无进展生存期（PFS）。试验中纳入的患者经检测确定为EGFR突变阳性，突变状态分为EGFR 19号外显子缺失（49%）、21号外显子L858R突变（40%）和其他（11%）。在阿法替尼治疗组中患者PFS显著延长[HR 0.58 (95% CI: 0.43,0.78); p < 0.001, stratified log-rank test]，阿法替尼治疗组和培美曲塞/顺铂化疗组的中位PFS分别为11.1和6.9个月，客观缓解率分别为50.4%和19.1%。两个治疗组的总生存期（OS）无显著性差异。携带EGFR 19号外显子缺失或21号外显子L858R突变的患者在阿法替尼治疗组和化疗治疗组中的中位PFS分别为13.6和6.9个月(NCT00949650)。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ibrutinib_Revised:06/2016', '.', 'guideline:FDA', '1', 'ibrutinib', 'ibrutinib', 'ibrutinib', '伊布替尼', 'ibrutinib|伊布替尼', '4', 'mantle cell lymphoma;chronic lymphocytic leukemia;waldenstrom\'s Macroglobulinemia', 'leukemia', '白血病', 'na', 'sensitivity', 'EVI_000099', 'TP53:nonsynonymous SNV:.:.:inact', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '伊布替尼(Ibrutinib)适用于（1）曾接受至少1次既往治疗的套细胞淋巴瘤患者（2）慢性淋巴细胞性白血病患者（3）17p缺失的慢性淋巴细胞性白血病患者（4）华氏巨球蛋白血症患者。其中，17p缺失与TP53的失活突变存在一定的相关性。 FDA批准伊布替尼治疗慢性淋巴细胞性白血病（CLL）/小淋巴细胞性淋巴瘤（SLL）包括17p缺失型CLL/SLL，此适应症是基于一项随机的、国际性、多中心、开放性Ⅲ期PCYC-1112临床试验（RESONATE）结果获批。试验中纳入了391名至少接受过一次治疗的CLL或SLL患者，按1：1分配至伊布替尼治疗组（N=195）接受治疗直到出现疾病进展或不可接受的毒性，或在奥法木单抗治疗组（N=196）接受24周的治疗。试验的主要终点是独立审查委员会根据修正的慢性淋巴细胞白血病国际研讨标准评估的无进展生存期（PFS），次要终点是总生存期（OS）、总响应率（ORR）。临床试验数据显示对于先期治疗的CLL/SLL患者，与奥法木单抗治疗组相比，伊布替尼单药治疗显著延长了PFS(中位PFS尚未达到 vs. 8.1 months; HR 0.22, 95% CI, 0.15 to 0.32; P<0.0001) )和OS(HR 0.43; 95% CI, 0.24 to 0.79; P=0.05）。伊布替尼治疗组和奥法木单抗治疗组的总响应率分别为42.6%和4.1%。试验中有32%的患者携带17p缺失变异（N=127），63名患者分配至伊布替尼治疗组，64名患者分配至奥法木单抗治疗组。17p缺失变异型患者在伊布替尼治疗组和奥法木单抗治疗组中的总响应率分别为42.6%和4.1%。与奥法木单抗相比，伊布替尼单药治疗显著延长了PFS(中位PFS尚未达到 vs. 5.8 months; HR 0.25, 95% CI, 0.14 to 0.45)。(NCT01578707)', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18955458', '.', 'clinical study', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000100', 'KIT:nonsynonymous SNV:exon13:p.K642E:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.K642E', '.', 'Progression-free survival (PFS) and overall survival (OS) were longer for patients with secondary KIT exon 13 or 14 mutationsthan for those with exon 17 or 18 mutations when treated with sunitinib. (PMID:18955458) ', '大部分胃肠间质瘤患者中表达组成性激活的KIT或PDGFRA。携带KIT基因K642E突变的胃肠间质瘤患者可能对舒尼替尼敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000105', 'FLT3:nonsynonymous SNV:exon20:p.I836H:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.I836H', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.I836H突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000106', 'FLT3:nonsynonymous SNV:exon20:p.I836D:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.I836D', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.I836D突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000107', 'FLT3:nonsynonymous SNV:exon20:p.I836M:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.I836M', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.I836M突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000108', 'FLT3:nonsynonymous SNV:exon20:p.I836V:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.I836V', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.I836V突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000109', 'FLT3:nonsynonymous SNV:exon20:p.I836L:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.I836L', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.I836L突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000110', 'FLT3:nonsynonymous SNV:exon20:p.I836F:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.I836F', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.I836F突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000111', 'FLT3:nonsynonymous SNV:exon20:p.D835E:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835E', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.D835E突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000112', 'FLT3:nonsynonymous SNV:exon20:p.D835V:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835V', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.D835V突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000113', 'FLT3:nonsynonymous SNV:exon20:p.D835A:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835A', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.D835A突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000114', 'FLT3:nonsynonymous SNV:exon20:p.D835Y:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835Y', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.D835Y突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000115', 'FLT3:nonsynonymous SNV:exon20:p.D835N:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835N', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.D835N突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22504184', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'resistance', 'EVI_000116', 'FLT3:nonsynonymous SNV:exon20:p.D835H:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835H', '.', 'Data suggest that sorafenib (FLT3 inhibitors) are not efficacious in FLT3 tyrosine kinase domain–mutated AML (PMID:22368270;PMID:23714533;https://ash.confex.com/ash/2012/webprogram/Paper54311.html;PMID:22504184).', '在发生FLT3-ITD的AML患者中，携带FLT3基因p.D835H突变的患者可能对索拉非尼（Sorafenib）不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26287849', 'NCT01524978', 'clinical trial - phase2', '4', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000121', 'BRAF:nonframeshift deletion:exon15:p.V600_K601delinsE:.', 'BRAF', 'nonframeshift deletion', 'Exact_pos', 'exon15', 'p.V600_K601delinsE', '.', 'BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans\'-cell histiocytosis (PMID: 26287849).', 'p.V600_K601delinsE是BRAF基因上的罕见突变，cosmic数据库中该突变出现仅出现28次（COSMIC，2017）。多篇文献报告该突变可能导致BRAF基因的过度活化（PMID:22563563;PMID:24255689;PMID:23833300）。临床研究表明，大多数BRAF V600位点突变阳性的晚期肿瘤患者可能对BRAF抑制剂(维莫非尼，达拉非尼等)敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21594665|PMID:19633047', '.', 'clinical study', '4', 'trastuzumab', 'trastuzumab', 'trastuzumab', '曲妥珠单抗', 'trastuzumab|曲妥珠单抗', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'resistance', 'EVI_000122', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Higher risk of progression was associated with HER2-positive status and the presence of PIK3CA mutations (P??.014). ', '针对ERBB2（HER2）的靶向治疗药物如Trastuzumab对PIK3CA基因发生激活突变的人群疗效欠佳。曲妥珠单抗(T)在携带HER2过表达和/或扩增的转移性乳腺癌(MBC)中是有效的，但是在相当数量的HER2阳性患者中出现对曲妥珠单抗的耐药性。了解耐药机制对于这些患者的保护及生命至关重要。我们从256名接受曲妥珠单抗治疗的MBC患者中收集其福尔马林固定石蜡包埋的肿瘤组织样品，而临床资料是从患者病历中回顾性收集的。通过荧光原位杂交(FISH)和/或免疫组织化学(IHC)对HER2状态进行的中心评估显示，在227名符合检查要求的的患者中，只有139名(61%)是真正的HER2阳性。同时患者的PTEN，ER，PgR和Ki67通过IHC进行评估，而PTEN状态通过FISH评估，并且用单核苷酸多态性(SNP)基因分型鉴定PIK3CA突变。HER2阳性患者的中位疾病进展时间(TTP)为14.4个月，HER2阴性患者为10.3个月(log-rank，P=0.22)。从曲妥珠单抗(survivalT)开始的生存期为HER2阳性患者50.4个月，HER2阴性亚组为35.3个月(P=0.006)。更高的进展风险与HER2阳性状态和PIK3CA突变的存在相关(P=0.014)。由IHC确定，PTEN的缺失与整个人群(P=0.029)和HER2阳性人群(P=0.017)中的较低的存活率相关。若PIK3CA突变和/或PTEN缺失状态一起作为单一参数进行评估，并用以估计PI3K/AKT分子途径激活的影响，可以发现其与TTP的降低显著相关(总人群中P=0.003，在HER2阳性患者中P=0.004)和存活(存活T，总共P=0.011，在HER2阳性中P=0.006)。在接受曲妥珠单抗治疗的乳腺癌人群中，PIK3CA激活突变与更短的TTP相关联，PTEN的缺失与存活率降低相关联。PI3K/AKT途径的激活中出现的任意缺陷均与TTP和存活率相关，表明该途径的状态对曲妥珠单抗的药效的有不利的影响(PMID:21594665)。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21594665', '.', 'clinical study', '4', 'trastuzumab', 'trastuzumab', 'trastuzumab', '曲妥珠单抗', 'trastuzumab|曲妥珠单抗', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'resistance', 'EVI_000123', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'PTEN loss, as determined by IHC, was associated with lower survivalT in the whole population (P??.029) and in the HER2-positive population (P??.017). ', '针对ERBB2（HER2）的靶向治疗药物如Trastuzumab对PIK3CA基因发生激活突变的人群疗效欠佳。曲妥珠单抗(T)在携带HER2过表达和/或扩增的转移性乳腺癌(MBC)中是有效的，但是在相当数量的HER2阳性患者中出现对曲妥珠单抗的耐药性。了解耐药机制对于这些患者的保护及生命至关重要。我们从256名接受曲妥珠单抗治疗的MBC患者中收集其福尔马林固定石蜡包埋的肿瘤组织样品，而临床资料是从患者病历中回顾性收集的。通过荧光原位杂交(FISH)和/或免疫组织化学(IHC)对HER2状态进行的中心评估显示，在227名符合检查要求的的患者中，只有139名(61%)是真正的HER2阳性。同时患者的PTEN，ER，PgR和Ki67通过IHC进行评估，而PTEN状态通过FISH评估，并且用单核苷酸多态性(SNP)基因分型鉴定PIK3CA突变。HER2阳性患者的中位疾病进展时间(TTP)为14.4个月，HER2阴性患者为10.3个月(log-rank，P=0.22)。从曲妥珠单抗(survivalT)开始的生存期为HER2阳性患者50.4个月，HER2阴性亚组为35.3个月(P=0.006)。更高的进展风险与HER2阳性状态和PIK3CA突变的存在相关(P=0.014)。由IHC确定，PTEN的缺失与整个人群(P=0.029)和HER2阳性人群(P=0.017)中的较低的存活率相关。若PIK3CA突变和/或PTEN缺失状态一起作为单一参数进行评估，并用以估计PI3K/AKT分子途径激活的影响，可以发现其与TTP的降低显著相关(总人群中P=0.003，在HER2阳性患者中P=0.004)和存活(存活T，总共P=0.011，在HER2阳性中P=0.006)。在接受曲妥珠单抗治疗的乳腺癌人群中，PIK3CA激活突变与更短的TTP相关联，PTEN的缺失与存活率降低相关联。PI3K/AKT途径的激活中出现的任意缺陷均与TTP和存活率相关，表明该途径的状态对曲妥珠单抗的药效的有不利的影响(PMID:21594665)。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:15928335', '.', 'preclinical', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '肿瘤细胞', 'na', 'resistance', 'EVI_000124', 'PDGFRA:nonsynonymous SNV:exon15:p.T674I:.', 'PDGFRA', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.T674I', '.', 'The substitution T674I is another potential cause of imatinib resistance in PDGFRA-mutant GISTs.', 'PDGFRA基因的T674I突变可能导致患者对伊马替尼（Imatinib）耐药。临床上FIP1L1-PDGFRA阳性患者出现伊马替尼耐药较BCR-ABL1阳性患者少见。迄今只报道过1例对伊马替尼原发耐药的FIP1L1-PDGFRA阳性患者，在疾病慢性期检测出PDGFRA-S601P和L629P突变，体外试验证实只有S601P突变具有耐药性。PDGFRA突变的获得性耐药发生率也很低，仅报道PDGFRA-T674I和D816V两种，这些突变位于PDGFRA的ATP结合结构域。PDGFRA突变阳性患者获得性耐药通常发生在用药后1年内，发生耐药突变的患者几乎均处于疾病的急变期。（《中华血液学杂志》 , 2013 , 34 (2) :159-161）', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23444215', '.', 'clinical trial - phase2', '4', 'selumetinib', 'selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_000125', 'MAP2K1:nonsynonymous SNV:exon2:p.K57N:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57N', '.', 'This study showed that selumetinib, a selective inhibitor of MEK, induced tumor regression in 3 of 5 patients with BRAF mutant melanomas that had low expression of phosphorylated AKT. No responses were seen in the high phosphorylated AKT group. One of these patients had a mutation in the MAP2K1 gene that encodes for a K57N mutation in helix A of MEK1, a primary downstream effector of BRAF.', '一项临床研究表明，司美替尼（MEK抑制剂）对3名携带BRAF基因突变的黑色素瘤患者有效，这些患者具有较低的AKT磷酸化水平，其中一名患者的MAP2K1基因具有K57N突变，该基因是BRAF的下游调控分子。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24622468', '.', 'clinical study', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'renal cancer', 'kidney cancer', '肾癌', 'na', 'sensitivity', 'EVI_000126', 'MTOR:nonsynonymous SNV:exon48:p.Q2223K:.', 'MTOR', 'nonsynonymous SNV', 'Exact_pos', 'exon48', 'p.Q2223K', '.', '.', '携带mTOR基因Q2223K突变的肾癌患者可能对依维莫司敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25295501', '.', 'preclinical', '4', 'rapamycin', 'rapamycin', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'resistance', 'EVI_000127', 'MTOR:nonsynonymous SNV:exon45:p.F2108L:.', 'MTOR', 'nonsynonymous SNV', 'Exact_pos', 'exon45', 'p.F2108L', '.', '.', '携带mTOR基因F2108L突变的肿瘤细胞可能对西罗莫司耐药,该突变可能阻止药物与蛋白的相互作用。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21189378', '.', 'case report', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000128', 'STK11:nonsynonymous SNV:exon4:p.D194E:inact', 'STK11', 'nonsynonymous SNV', 'None_pos', 'exon4', 'p.D194E', 'inact', 'A patient with advanced pancreatic cancer that was induced by Peutz-Jeghers syndrome (PJS) was achieve a partial remission treaed by everolimus.', 'STK11（编码 LKB1的基因）是一种丝氨酸/苏氨酸激酶，它与能量稳态和细胞极性的调节有关。STK11功能缺失突变与mTOR信号通路的异常活化有关，可能导致Peutz—Jeghers综合征（PJS），这是发展成为胃肠道肿瘤及胰腺癌的高危因素。一名携带STK11基因失活突变的胰腺癌患者使用依维莫司后取得部分疗效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23470635', '.', 'case report', '4', 'dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_000129', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'Dabrafenib is a potent ATP-competitive inhibitor of BRAF kinase and is highly selective for mutant BRAF in kinase panel screening, cell lines, and xenografts. It was report prolonged antitumor activity in the first patient with V600E BRAF-mutated GIST who was treated with a BRAF inhibitor. Whole exome sequencing performed in tumor tissue obtained at the time of progressive disease demonstrated a somatic gain-of-function PIK3CA mutation (H1047R) as well as a CDKN2A aberration, which may have contributed to eventual resistance to treatment.', '达拉非尼是一种BRAF抑制剂，可能对携带BRAF基因V600E的胃肠道间质瘤患者有一定疗效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23200175', 'NCT00890825', 'clinical trial - phase2', '4', 'selumetinib,docetaxel', 'selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000132', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项临床试验表明，司美替尼联合多西紫杉醇可以延长KRAS突变的非小细胞肺癌患者无进展生存期。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22761467', 'NCT00773526', 'clinical trial - phase1', '4', 'RO5126766', 'RO5126766', 'RO5126766', 'RO5126766', 'RO5126766|RO5126766', '1', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_000133', 'NRAS:nonsynonymous SNV:exon3:p.Q61.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon3', 'p.Q61.', '.', 'This phase I study assessed the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics, pharmacodynamics, and clinical activity of the first-in-class dual MEK/RAF inhibitor, RO5126766. Three partial responses were seen: two in BRAF-mutant melanoma tumors and one in an NRAS-mutant melanoma. ', 'I期临床试验表明，3名患者使用MEK/RAF抑制剂（RO5126766）取得了部分缓解，其中一名携带NRAS突变，2名携带BRAF突变。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22761467', 'NCT00773526', 'clinical trial - phase1', '4', 'RO5126766', 'RO5126766', 'RO5126766', 'RO5126766', 'RO5126766|RO5126766', '1', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_000134', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'This phase I study assessed the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), safety, pharmacokinetics, pharmacodynamics, and clinical activity of the first-in-class dual MEK/RAF inhibitor, RO5126766. Three partial responses were seen: two in BRAF-mutant melanoma tumors and one in an NRAS-mutant melanoma.', 'I期临床试验表明，3名患者使用MEK/RAF抑制剂（RO5126766）取得了部分缓解，其中一名携带NRAS突变，2名携带BRAF突变。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23497317', '.', 'preclinical', '4', 'quizartinib', 'quizartinib', 'quizartinib', '奎扎替尼', 'quizartinib|奎扎替尼', '3', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'resistance', 'EVI_000140', 'KIT:nonsynonymous SNV:exon17:p.N822.:.', 'KIT', 'nonsynonymous SNV', 'Partial_pos', 'exon17', 'p.N822.', '.', 'Cells expressing exon 17 mutations at codons N822 and D816 show resistance to quizartinib treatment (PMID:23497317).', '携带KIT基因N822或D816突变的肿瘤细胞株可能对quizartinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23497317', '.', 'preclinical', '4', 'quizartinib', 'quizartinib', 'quizartinib', '奎扎替尼', 'quizartinib|奎扎替尼', '3', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'resistance', 'EVI_000141', 'KIT:nonsynonymous SNV:exon17:p.D816.:.', 'KIT', 'nonsynonymous SNV', 'Partial_pos', 'exon17', 'p.D816.', '.', 'Cells expressing exon 17 mutations at codons N822 and D816 show resistance to quizartinib treatment (PMID:23497317).', '携带KIT基因N822或D816突变的肿瘤细胞株可能对quizartinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26577299', 'NCT01353781', 'clinical trial - phase1', '4', 'AZD5363', 'AZD5363', 'AZD-5363', 'AZD-5363', 'AZD-5363|AZD-5363', '2', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000142', 'AKT1:nonsynonymous SNV:exon3:p.E17K:.', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'In a phase I trial AZD5363 showed clinical activity in a variety of Akt1 E17K mutant solid tumors. PRs were reported in 6 patients with ER+ breast cancer (n=2), lung adenocarcinoma (n=1), cervical squamous cancer (n=1), endometrioid ovarian cancer (n=1), and TNBC (n=1) with a median duration of 8.3 months.|https://www.escholar.manchester.ac.uk/uk-ac-man-scw:291375', 'I期临床试验表明，携带AKT1基因E17K突变的实体瘤患者可能对AZD5363有部分响应。6名患者（ER+乳腺癌2名，肺腺癌1名，宫颈鳞癌1名，卵巢癌1名和3阴性乳腺癌1名）的平均持续时间为8.3个月。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24968756', '.', 'case report', '4', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000143', 'AKT1:nonsynonymous SNV:exon3:p.E17K:.', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'A colorectal cancer patient harboring the E17K mutation did not respond to cetuximab therapy.', '一名携带AKT1基因E17K突变的结直肠癌患者对西妥昔单抗耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20440266', '.', 'preclinical', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'B-cell lymphoma', 'lymphoma', '肿瘤细胞', 'na', 'resistance', 'EVI_000146', 'AKT1:nonsynonymous SNV:exon3:p.E17K:.', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'AKT1 E17K expressing v-Abl transformed cells are less sensitive to imatinib treatment than non-mutated v-Abl transformed cells. Further, E17K confers resistance to apoptosis after imatinib treatment.', '体外试验表明，AKT1基因的E17K突变与伊马替尼的耐药相关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20101210', '.', 'preclinical', '4', 'LY294002', 'LY294002', 'LY294002', 'LY294002', 'LY294002|LY294002', '1', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'resistance', 'EVI_000147', 'AKT1:nonsynonymous SNV:exon3:p.E17K:.', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'The PI3K inhibitor does not inhibit cell growth of MCF10A cells harboring the E17K mutations. Mutant cells treated with LY294002 do not display increased sensitivity compared to wild type cells and do not predict response to LY294002 in this cell line model.', '肿瘤细胞对LY294002（PI3K抑制剂）的耐药可能与AKT1基因E17K突变相关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24265155', '.', 'preclinical', '4', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'melanoma', 'melanoma', '肿瘤细胞', 'na', 'resistance', 'EVI_000148', 'AKT1:nonsynonymous SNV:exon4:p.Q79K:.', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.Q79K', '.', 'The presence of AKT1 activating mutations alters BRAF inhibitor sensitivity. Compared to AKT1 wild type melanoma cells, AKT1 Q79K or E17K conferred vemurafenib resistance. The combination of vemurafenib and MK2206 was more effective than either agent alone in reducing melanoma cell growth expressing AKT1 Q79K.', 'AKT1基因的Q79K或E17K突变可能与肿瘤对维莫非尼的耐药相关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24265155', '.', 'preclinical', '4', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'melanoma', 'melanoma', '肿瘤细胞', 'na', 'resistance', 'EVI_000149', 'AKT1:nonsynonymous SNV:exon3:p.E17K:.', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'The presence of AKT1 activating mutations alters BRAF inhibitor sensitivity. Compared to AKT1 wild type melanoma cells, AKT1 Q79K or E17K conferred vemurafenib resistance. The combination of vemurafenib and MK2206 was more effective than either agent alone in reducing melanoma cell growth expressing AKT1 Q79K.', 'AKT1基因的Q79K或E17K突变可能与肿瘤对维莫非尼的耐药相关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24879796', '.', 'preclinical', '4', 'NVP-BEZ235', 'NVP-BEZ235', 'dactolisib', 'dactolisib', 'dactolisib|dactolisib', '2', 'breast cancer', 'breast cancer', '肿瘤细胞', '[ER(+);PR(+);HER2(+)]', 'sensitivity', 'EVI_000156', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'These preclinical data support the findings of the BOLERO 3 trial that shows that targeting of the PI3K/mTOR pathway in combination with trastuzumab is beneficial in trastuzumab-resistant breast cancer.', '临床前研究表明，携带PIK3CA激活突变的乳腺癌肿瘤细胞可能对NVP-BKM120(buparlisib)敏感。PI3K/mTOR信号传导的改变涉及许多乳腺癌的发病机制，包括那些对激素和HER2靶向治疗有抗性的乳腺癌。将四种PI3K/mTOR抑制分子包括pan-PI3K抑制剂(NVP-BKM120)，p110α异构体特异性PI3K抑制剂(NVP-BYL719)，mTORC1特异性抑制剂(NVP-RAD001)和双重PI3K/mTORC1/2抑制剂(NVP-BEZ235)，在体外和体内试验中对48个人乳房细胞系进行效果评估。每种药物在体外试验中显示出显著的抗增殖活性，特别是在携带PI3K突变的鲁米那(luminal)雌激素受体阳性和/或HER2(+)细胞系中。另外，四种抑制剂中每一种的单一疗法都可以显著抑制HER2(+)乳腺癌模型中的体内生长。PI3K/mTOR途径的抑制剂在体外和体内也能有效克服细胞原发和获得的曲妥珠单抗抗性。此外，HER2和PI3K/mTOR的组合靶向增加了体外试验中细胞的凋亡并且在抗曲妥珠单抗的异种移植模型中诱导肿瘤消退。最后，如之前所示，单独用RAD001靶向mTORC1导致AKT在体外和体内模型中出现一致的反馈激活，而双重mTOR1-2/PI3K抑制剂BEZ235阻断了这种反馈循环。尽管有这些明显的信号传导差异，两种分子在抑制体外和体内模型的肿瘤细胞增殖方面依然同样有效。结论: 这些临床前数据支持了BOLERO 3试验的结果，显示靶向PI3K/mTOR途径与曲妥珠单抗联合治疗在曲妥珠单抗耐药性乳腺癌中是有效的。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24879796', '.', 'preclinical', '4', 'NVP-BKM120', 'NVP-BKM120', 'buparlisib', 'buparlisib', 'buparlisib|buparlisib', '2', 'breast cancer', 'breast cancer', '肿瘤细胞', '[ER(+);PR(+);HER2(+)]', 'sensitivity', 'EVI_000157', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'These preclinical data support the findings of the BOLERO 3 trial that shows that targeting of the PI3K/mTOR pathway in combination with trastuzumab is beneficial in trastuzumab-resistant breast cancer.', '临床前研究表明，携带PIK3CA激活突变的乳腺癌肿瘤细胞可能对NVP-BKM120(buparlisib)敏感。PI3K/mTOR信号传导的改变涉及许多乳腺癌的发病机制，包括那些对激素和HER2靶向治疗有抗性的乳腺癌。将四种PI3K/mTOR抑制分子包括pan-PI3K抑制剂(NVP-BKM120)，p110α异构体特异性PI3K抑制剂(NVP-BYL719)，mTORC1特异性抑制剂(NVP-RAD001)和双重PI3K/mTORC1/2抑制剂(NVP-BEZ235)，在体外和体内试验中对48个人乳房细胞系进行效果评估。每种药物在体外试验中显示出显著的抗增殖活性，特别是在携带PI3K突变的鲁米那(luminal)雌激素受体阳性和/或HER2(+)细胞系中。另外，四种抑制剂中每一种的单一疗法都可以显著抑制HER2(+)乳腺癌模型中的体内生长。PI3K/mTOR途径的抑制剂在体外和体内也能有效克服细胞原发和获得的曲妥珠单抗抗性。此外，HER2和PI3K/mTOR的组合靶向增加了体外试验中细胞的凋亡并且在抗曲妥珠单抗的异种移植模型中诱导肿瘤消退。最后，如之前所示，单独用RAD001靶向mTORC1导致AKT在体外和体内模型中出现一致的反馈激活，而双重mTOR1-2/PI3K抑制剂BEZ235阻断了这种反馈循环。尽管有这些明显的信号传导差异，两种分子在抑制体外和体内模型的肿瘤细胞增殖方面依然同样有效。结论: 这些临床前数据支持了BOLERO 3试验的结果，显示靶向PI3K/mTOR途径与曲妥珠单抗联合治疗在曲妥珠单抗耐药性乳腺癌中是有效的。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20713702', '.', 'preclinical', '4', 'NVP-BEZ-235', 'NVP-BEZ235', 'dactolisib', 'dactolisib', 'dactolisib|dactolisib', '2', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', '急性髓性白血病', 'sensitivity', 'EVI_000161', 'PIK3R1:nonframeshift deletion:exon11:p.K459_S460delinsN:.', 'PIK3R1', 'nonframeshift deletion', 'Exact_pos', 'exon11', 'p.K459_S460delinsN', '.', 'NVP-BEZ-235 (100nM), PIK90 (500 nM) and A66 (700 nM) induced 70-80% reduction in focus formation by highly transfroming iSH2 domain mutants (KS459delN, DKRMNS560del and K379E) of p85a (PMID:20713702). Furthermore, these inhibitors show reduction in AKT phosphorylation.', '临床前研究表明，具有PIK3R1基因突变的肿瘤细胞可能对NVP-BEZ-235(dactolisib)敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20713702', '.', 'preclinical', '4', 'NVP-BEZ-235', 'NVP-BEZ235', 'dactolisib', 'dactolisib', 'dactolisib|dactolisib', '2', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', '急性髓性白血病', 'sensitivity', 'EVI_000162', 'PIK3R1:nonframeshift deletion:exon13:p.D560_S565del:.', 'PIK3R1', 'nonframeshift deletion', 'Exact_pos', 'exon13', 'p.D560_S565del', '.', 'NVP-BEZ-235 (100nM), PIK90 (500 nM) and A66 (700 nM) induced 70-80% reduction in focus formation by highly transfroming iSH2 domain mutants (KS459delN, DKRMNS560del and K379E) of p85a (PMID:20713702). Furthermore, these inhibitors show reduction in AKT phosphorylation.', '临床前研究表明，具有PIK3R1基因突变的肿瘤细胞可能对NVP-BEZ-235(dactolisib)敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20713702', '.', 'preclinical', '4', 'NVP-BEZ-235', 'NVP-BEZ235', 'dactolisib', 'dactolisib', 'dactolisib|dactolisib', '2', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', '急性髓性白血病', 'sensitivity', 'EVI_000163', 'PIK3R1:nonsynonymous SNV:exon10:p.K379E:.', 'PIK3R1', 'nonsynonymous SNV', 'Exact_pos', 'exon10', 'p.K379E', '.', 'NVP-BEZ-235 (100nM), PIK90 (500 nM) and A66 (700 nM) induced 70-80% reduction in focus formation by highly transfroming iSH2 domain mutants (KS459delN, DKRMNS560del and K379E) of p85a (PMID:20713702). Furthermore, these inhibitors show reduction in AKT phosphorylation.', '临床前研究表明，具有PIK3R1基因突变的肿瘤细胞可能对NVP-BEZ-235(dactolisib)敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25284480', '.', 'preclinical', '4', '[MEK inhibitors]', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901|PD-0325901', '2', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000164', 'PIK3R1:stopgain:exon9:p.R348*:.', 'PIK3R1', 'stopgain', 'Exact_pos', 'exon9', 'p.R348*', '.', 'BaF3 cells in an in vitro assay expressing PIK3R1 mutations (E160* and R348*) are sensitive to several PI3K pathway inhibitors (PMID:25284480). However, these cells did not show any sensitivity to the selective p110 inhibitor GDC0941. (PMID:25284480)', '细胞学研究表明，携带PIK3R1基因失活突变的肿瘤可能对PI3K信号通路抑制剂敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23166678', '.', 'preclinical', '4', 'MK2206', 'MK-2206', 'MK-2206', 'MK-2206', 'MK-2206|MK-2206', '2', 'glioma', 'brain cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000165', 'PIK3R1:nonframeshift deletion:exon13:p.D560_S565del:.', 'PIK3R1', 'nonframeshift deletion', 'Exact_pos', 'exon13', 'p.D560_S565del', '.', 'BaF3 cells in an in vitro assay expressing PIK3R1 mutations (E160* and R348*) are sensitive to several PI3K pathway inhibitors (PMID:25284480). However, these cells did not show any sensitivity to the selective p110 inhibitor GDC0941. (PMID:25284480)', '细胞学研究表明，携带PIK3R1基因失活突变的肿瘤可能对PI3K信号通路抑制剂敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23166678', '.', 'preclinical', '4', 'MK2206', 'MK-2206', 'MK-2206', 'MK-2206', 'MK-2206|MK-2206', '2', 'glioma', 'brain cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000166', 'PIK3R1:nonframeshift deletion:exon13:p.T576del:.', 'PIK3R1', 'nonframeshift deletion', 'Exact_pos', 'exon13', 'p.T576del', '.', 'BaF3 cells in an in vitro assay expressing PIK3R1 mutations (E160* and R348*) are sensitive to several PI3K pathway inhibitors (PMID:25284480). However, these cells did not show any sensitivity to the selective p110 inhibitor GDC0941. (PMID:25284480)', '细胞学研究表明，携带PIK3R1基因失活突变的肿瘤可能对PI3K信号通路抑制剂敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24291104', '.', 'preclinical', '4', 'TAK441', 'TAK-441', 'TAK-441', 'TAK-441', 'TAK-441|TAK-441', '1', 'medulloblastoma', 'brain cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000167', 'SMO:nonsynonymous SNV:exon8:p.D473H:.', 'SMO', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.D473H', '.', 'Preclinical studies suggest that the 2nd generation SMO inhibitor TAK-441 is capable of inhibiting cells expressing the vismodegib/cyclopamine-resistant SMO D473H mutant at clinically relevant concentrations (IC50 = 79 nM;PMID:24291104). Although, this inhibition was nearly 30-fold less than seen for wild-type SMO cells (IC50 = 3.2 nM). ', '细胞学试验表明，第二代SMO抑制剂对携带SMO基因D473H突变的肿瘤细胞有抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23786770', '.', 'case report', '4', 'pazopanib', 'pazopanib', 'pazopanib', '培唑帕尼', 'pazopanib|培唑帕尼', '4', 'head and neck cancer', 'head and neck cancer', '头颈部肿瘤', 'na', 'sensitivity', 'EVI_000168', 'FGFR2:nonsynonymous SNV:exon7:p.P253R:.', 'FGFR2', 'nonsynonymous SNV', 'Exact_pos', 'exon7', 'p.P253R', '.', 'A single, head and neck squamous cell carcinoma patient with a P253R mutation in FGFR2 had marked reduction in tumor size with pazopanib treatment.', '一名携带FGFR2基因P253R突变的口腔鳞癌患者对培唑帕尼（pazopanib）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19844230', '.', 'preclinical', '4', 'pazopanib', 'pazopanib', 'pazopanib', '培唑帕尼', 'pazopanib|培唑帕尼', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'resistance', 'EVI_000169', 'FGFR1:nonsynonymous SNV:exon13:p.V561M:.', 'FGFR1', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.V561M', '.', 'In an in vitro kinase assay, cell expressing the FGFR1 V561M variant are resistant to pazopanib-mediated inhibition, while wild-type cells are sensitive (PMID:19844230).', '细胞试验表明，FGFR1基因V651M突变可能导致肿瘤细胞对pazopanib（培唑帕尼）产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19844230', '.', 'preclinical', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'resistance', 'EVI_000170', 'FGFR1:nonsynonymous SNV:exon13:p.V561M:.', 'FGFR1', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.V561M', '.', 'In an in vitro kinase assay, cells expressing the FGFR1 V561M variant are resistant to sorafenib-mediated inhibition, while wild-type cells are sensitive (PMID:19844230).', '细胞试验表明，FGFR1基因V651M突变可能导致肿瘤细胞对索拉非尼产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:16857985', '.', 'clinical trial - phase2', '4', 'lestaurtinib', 'lestaurtinib', 'lestaurtinib', '来妥替尼', 'lestaurtinib|来妥替尼', '2', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000171', 'FLT3:nonsynonymous SNV:exon20:p.D835Y:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835Y', '.', 'A phase II trial demonstrated that out of a subgroup of 5 AML patients with FLT3 mutations, 3 (ITD, D835Y, and I836del) demonstrated transient hematological responses to listaurtinib therapy.', '在一项II期临床试验中，5名携带FLT3突变（IDT，D835Y或I836del）的AML病人对lestaurtinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:16857985', '.', 'clinical trial - phase2', '4', 'lestaurtinib', 'lestaurtinib', 'lestaurtinib', '来妥替尼', 'lestaurtinib|来妥替尼', '2', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000172', 'FLT3:nonframeshift deletion:exon20:p.I836del:.', 'FLT3', 'nonframeshift deletion', 'Exact_pos', 'exon20', 'p.I836del', '.', 'A phase II trial demonstrated that out of a subgroup of 5 AML patients with FLT3 mutations, 3 (ITD, D835Y, and I836del) demonstrated transient hematological responses to listaurtinib therapy.', '在一项II期临床试验中，5名携带FLT3突变（IDT，D835Y或I836del）的AML病人对lestaurtinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:16150941', '.', 'preclinical', '4', 'PKC412', 'PKC412', 'midostaurin', '米哚妥林', 'midostaurin|米哚妥林', '4', 'acute myeloid leukemia', 'leukemia', '肿瘤细胞', '急性髓性白血病', 'resistance', 'EVI_000174', 'FLT3:nonsynonymous SNV:exon16:p.N676K:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon16', 'p.N676K', '.', '.', '携带FLT3基因N676K突变的肿瘤细胞可能对PKC412(midostaurin)耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23934192', '.', 'preclinical', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'lung cancer', 'lung cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000182', 'ERCC1:nonsynonymous SNV:.:.:inact', 'ERCC1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'ERCC1编码蛋白在DNA重组修复中起重要作用，细胞研究提示ERCC1功能低下的肿瘤细胞对于PARP抑制剂相对敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23934192', '.', 'preclinical', '4', 'niraparib', 'niraparib', 'niraparib', '尼拉帕利', 'niraparib|尼拉帕利', '3', 'lung cancer', 'lung cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000183', 'ERCC1:nonsynonymous SNV:.:.:inact', 'ERCC1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'ERCC1编码蛋白在DNA重组修复中起重要作用，细胞研究提示ERCC1功能低下的肿瘤细胞对于PARP抑制剂相对敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23934192', '.', 'preclinical', '4', 'BMN 673', 'BMN 673', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '2', 'lung cancer', 'lung cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000184', 'ERCC1:nonsynonymous SNV:.:.:inact', 'ERCC1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'ERCC1编码蛋白在DNA重组修复中起重要作用，细胞研究提示ERCC1功能低下的肿瘤细胞对于PARP抑制剂相对敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25294897', '.', 'clinical study', '4', 'sorafenib,refametinib', 'refametinib + sorafenib', 'refametinib + sorafenib', 'refametinib + 索拉非尼', 'refametinib + sorafenib|refametinib + 索拉非尼', '2', 'hepatocellular carcinoma', 'liver cancer', '肝癌', 'na', 'sensitivity', 'EVI_000186', 'KRAS:nonsynonymous SNV:exon3:p.Q61.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon3', 'p.Q61.', '.', 'Refametinib plus sorafenib showed antitumor activity in patients with HCC and was tolerated at reduced doses by most patients. Frequent dose modifications due to grade 3 adverse events may have contributed to limited treatment effect. Patients with RAS mutations appear to benefit from refametinib/sorafenib combination. ', '临床研究表明，refametinib与sorafenib联用在大部分肝癌患者中都显示出一定的抗肿瘤活性，而且对KRAS基因有突变的患者也有一定疗效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25500057', 'NCT01155453', 'clinical trial - phase1', '4', 'buparlisib,trametinib', 'trametinib', 'trametinib + buparlisib', '曲美替尼 + buparlisib', 'trametinib + buparlisib|曲美替尼 + buparlisib', '4', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_000187', 'KRAS:nonsynonymous SNV:exon2:p.G12.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'MAPK and PI3K/AKT/mTOR pathways play important roles in many tumors. In this study, safety, antitumor activity, and pharmacokinetics of buparlisib (pan class PI3K inhibitor) and trametinib (MEK inhibitor) were evaluated. At RP2D, buparlisib 60 mg + trametinib 1.5 mg daily shows promising antitumor activity for patients with KRAS-mutant ovarian cancer. Long-term tolerability of the combination at RP2D is challenging, due to frequent dose interruptions and reductions for toxicity.', '临床研究表明，携带KRAS基因突变的卵巢癌患者可能对buparlisib（PI3K抑制剂）与trametinib（MEK抑制剂）联合治疗有响应。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19573811|PMID:20505189', '.', 'preclinical', '4', 'rapamycin', 'rapamycin', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'glioma', 'brain cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000188', 'NF1:nonsynonymous SNV:.:.:inact', 'NF1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Loss-of-function mutations in the NF1 tumor suppressor result in deregulated Ras signaling and drive tumorigenesis in the familial cancer syndrome neurofibromatosis type I. It was reported that NF1 is inactivated in sporadic gliomas via two mechanisms: excessive proteasomal degradation and genetic loss. NF1 protein destabilization is triggered by the hyperactivation of protein kinase C (PKC) and confers sensitivity to PKC inhibitors.', 'NF1基因是最早被发现的肿瘤抑制基因之一，它是一个GAP蛋白(GTPase-activating protein)。NF1基因缺失突变会提高RAS蛋白的活性，后者通过RAS介导的信号转导途径导致细胞的过度生长、增殖和癌变。有大约一半的神经纤维瘤病人的NF1基因具有缺失突变。携带NF1基因缺失突变的肿瘤患者可能对PI3K、mTOR(如sirolimus、everolimus等)或MEK信号通路抑制剂(如PD-0325901)敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24509877', '.', 'preclinical', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'malignant peripheral nerve sheat tumor', 'nervous cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000190', 'NF1:nonsynonymous SNV:.:.:inact', 'NF1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Mutations in the neurofibromatosis type 1 (NF1) tumor suppressor gene are common in cancer and can cause resistance to therapy. MAF is an NF1- regulated transcription factor and regulats  RAS/MAPK/AP-1 signaling in malignant peripheral nerve sheath tumor (MPNST) cell lines. MAF was also downregulated in human MPNST. Acute re-expression of MAF promoted expression of glial differentiation markers in MPNST cells in vitro, decreased self-renewal of embryonic precursors and transiently affected tumor cell phenotypes in vitro by increasing MPNST cell death and reducing metabolic activity and anchorage-independent growth. Paradoxically, chronic MAF overexpression enhanced MPNST cell tumor growth in vivo, correlating with elevated pS6 in vitro and in vivo. RAD001 blocked MAF-mediated tumor growth, and MAF regulated the mTOR pathway through DEPTOR. MAPK inhibition with NF1 loss of function is predicted to show limited efficacy due to reactivation of mTOR signaling via MAF.(PMID:24509877)', 'NF1基因是最早被发现的肿瘤抑制基因之一，它是一个GAP蛋白(GTPase-activating protein)。NF1基因缺失突变会提高RAS蛋白的活性，后者通过RAS介导的信号转导途径导致细胞的过度生长、增殖和癌变。有大约一半的神经纤维瘤病人的NF1基因具有缺失突变。携带NF1基因缺失突变的肿瘤患者可能对PI3K、mTOR(如sirolimus、everolimus等)或MEK信号通路抑制剂(如PD-0325901)敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25878190', '.', 'case report', '4', 'temsirolimus', 'temsirolimus', 'temsirolimus', '替西罗莫司', 'temsirolimus|替西罗莫司', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000192', 'NF2:frameshift insertion:exon5:p.K159fs*16:.', 'NF2', 'frameshift insertion', 'Exact_pos', 'exon5', 'p.K159fs*16', '.', 'A point mutation in the NF2 gene (K159fs*16; NF2 alterations can activate mTor) was found in one patient who attained CR (3+ years).', '一名携带NF2失活突变的病人，使用含西罗莫司的药物治疗在3年内都能取得完全反应（complete response ）。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25294897', '.', 'clinical study', '4', 'sorafenib,refametinib', 'refametinib + sorafenib', 'refametinib + sorafenib', 'refametinib + 索拉非尼', 'refametinib + sorafenib|refametinib + 索拉非尼', '2', 'hepatocellular carcinoma', 'liver cancer', '肝癌', 'na', 'sensitivity', 'EVI_000193', 'KRAS:nonsynonymous SNV:exon4:p.A146.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon4', 'p.A146.', '.', 'Refametinib plus sorafenib showed antitumor activity in patients with HCC and was tolerated at reduced doses by most patients. Frequent dose modifications due to grade 3 adverse events may have contributed to limited treatment effect. Patients with RAS mutations appear to benefit from refametinib/sorafenib combination.', '临床研究表明，refametinib与sorafenib联用在大部分肝癌患者中都显示出一定的抗肿瘤活性，而且对KRAS基因有突变的患者也有一定疗效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19671762', '.', 'preclinical', '4', 'NVP-BEZ235', 'NVP-BEZ235', 'dactolisib', 'dactolisib', 'dactolisib|dactolisib', '2', 'glioma', 'brain cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000194', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'NVP-BEZ235（dactolisib）是一种PI3K及mTOR信号通路抑制剂，可能对具有PIK3CA基因激活突变的肿瘤患者有效。人类胶质瘤的异常基因变异，如表皮生长因子受体的扩增，肿瘤抑制基因PTEN的突变和/或缺失，以及PIK3CA的突变，有助于磷脂酰肌醇3-激酶(PI3K)途径的构成型激活。我们研究了NVP-BEZ235的潜在抗肿瘤活性，其是在神经胶质瘤中新的PI3K/mTOR双重抑制剂。该化合物通过在PI3K/Akt/mTOR信号通路中特异性抑制包括Akt，S6K1，S6和4EBP1在内的靶蛋白的活性，以低纳摩尔范围的IC(50)值抑制神经胶质瘤细胞增殖。NVP-BEZ235在神经胶质瘤细胞系的治疗导致细胞G(1)细胞周期停滞和诱导自噬。此外，在神经胶质瘤细胞中作为重要血管生成调节剂的血管内皮生长因子(VEGF)的表达显著降低，表明NVP-BEZ235也可以发挥抗血管生成作用。NVP-BEZ235治疗效果的临床前试验表明，它显著延长了带瘤动物的存活，而没有引起任何明显的毒性。而该药处理后从动物获取的肿瘤提取物显示该化合物抑制了PI3K/Akt/mTOR级联中的靶蛋白的活性。与对照组相比，免疫组织化学分析还显示NVP-BEZ235处理的肿瘤切片中VEGF血管性血友病因子(因子VIII)的染色显著减少，进一步证实NVP-BEZ235在体内具有抗血管生成作用。我们从这些发现得出结论，NVP-BEZ235拮抗PI3K和mTOR信号传导并诱导细胞周期停滞，下调VEGF并引起自噬作用。这些结果证明NVP-BEZ235值得进一步开发用于人脑胶质瘤或具有PI3K/Akt/mTOR信号传导途径异常的其他晚期癌症的临床试验。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19223544', '.', 'clinical study', '4', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000195', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'PIK3CA基因的激活突变可能导致结直肠癌患者对EGFR抗体类药物产生耐药。单克隆抗体(moAb)帕尼单抗和西妥昔单抗靶向表皮生长因子受体(EGFR)，且已被证明对转移性结直肠癌(mCRC)有治疗价值。EGFR介导的信号传导涉及两个主要的细胞内级联反应：一方面KRAS激活BRAF，其反过来触发丝裂原活化的蛋白激酶。另一方面，脂质激酶PIK3CA的膜定位抵消PTEN并促进AKT1磷酸化，从而激活平行的细胞内轴。KRAS的构成型激活绕过了相应的信号级联反应，因此携带KRAS突变的mCRC患者在临床上对帕尼单抗或西妥昔单抗治疗具有抗性。我们假设激活PIK3CA的突变还可以通过类似的机制阻止细胞对EGFR靶向的moAb的响应。在这里，我们进行了PIK3CA和KRAS的突变分析并评估了110例用抗EGFR moAbs治疗的mCRC患者中的PTEN蛋白状态。我们观察到有15例(13.6%)患者携带PIK3CA突变，32例患者(29.0%)携带KRAS突变。PIK3CA突变与帕尼单抗或西妥昔单抗的临床耐药显著相关，且没有一个突变患者达到客观反应(P=0.038)，当仅分析KRAS野生型肿瘤时，统计学相关性更强(P=0.016)。而PIK3CA突变患者的无进展生存期也显示出更差的临床结果(P=0.035)。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19223544', '.', 'clinical study', '4', 'cetuximab  ', 'cetuximab  ', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000196', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'PIK3CA基因的激活突变可能导致结直肠癌患者对EGFR抗体类药物产生耐药。单克隆抗体(moAb)帕尼单抗和西妥昔单抗靶向表皮生长因子受体(EGFR)，且已被证明对转移性结直肠癌(mCRC)有治疗价值。EGFR介导的信号传导涉及两个主要的细胞内级联反应：一方面KRAS激活BRAF，其反过来触发丝裂原活化的蛋白激酶。另一方面，脂质激酶PIK3CA的膜定位抵消PTEN并促进AKT1磷酸化，从而激活平行的细胞内轴。KRAS的构成型激活绕过了相应的信号级联反应，因此携带KRAS突变的mCRC患者在临床上对帕尼单抗或西妥昔单抗治疗具有抗性。我们假设激活PIK3CA的突变还可以通过类似的机制阻止细胞对EGFR靶向的moAb的响应。在这里，我们进行了PIK3CA和KRAS的突变分析并评估了110例用抗EGFR moAbs治疗的mCRC患者中的PTEN蛋白状态。我们观察到有15例(13.6%)患者携带PIK3CA突变，32例患者(29.0%)携带KRAS突变。PIK3CA突变与帕尼单抗或西妥昔单抗的临床耐药显著相关，且没有一个突变患者达到客观反应(P=0.038)，当仅分析KRAS野生型肿瘤时，统计学相关性更强(P=0.016)。而PIK3CA突变患者的无进展生存期也显示出更差的临床结果(P=0.035)。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726761', '.', 'case report', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'medulloblastoma', 'brain cancer', '脑部肿瘤', 'na', 'sensitivity', 'EVI_000198', 'PTCH1:nonsynonymous SNV:exon15:p.W844C:.', 'PTCH1', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.W844C', '.', 'A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies was treated with a novel hedgehog pathway inhibitor, GDC-0449; treatment resulted in rapid (although transient) regression of the tumor and reduction of symptoms. ', '一名26岁的成神经管细胞瘤使用GDC-0499（vismodegib）治疗后肿瘤缩小,该患者携带PTCH1基因突变。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21325073', '.', 'preclinical', '4', 'PKI-587', 'PKI-587', 'gedatolisib', 'gedatolisib', 'gedatolisib|gedatolisib', '2', 'glioma', 'brain cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000199', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'U87MG多形性胶质母细胞瘤携带PTEN基因缺失，Gedatolisib可以导致携带该异种移植肿瘤的小鼠肿瘤消退。 Gedatolisib在1.56至12.5mg/kg（d×5，剂量 - 反应方案）下可以明显抑制荷瘤小鼠的肿瘤生长。与对照组相比，在第10天，12.5和6.25mg/kg的Gedatolisib分别导致肿瘤生长减少78%和86%。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22932669', '.', 'preclinical', '4', 'MK-2206', 'MK-2206', 'MK-2206', 'MK-2206', 'MK-2206|MK-2206', '2', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000200', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在乳腺癌细胞系中，MK-2206可以剂量依赖的方式抑Akt信号传导和细胞周期进程，增加细胞凋亡。大部分具有PTEN/PIK3CA突变的细胞系对MK-2206显著敏感，虽然该类细胞系中仍有部分具有MK-2206抗性。在乳腺癌细胞中，PTEN的siRNA敲除可增加Akt磷酸化，同时增加MK-2206敏感性。将PIK3CA E545K/H1047R突变的质粒稳定转染到正常乳腺细胞MCF10A中，可增强其对MK-2206的敏感性。研究发现，对MK-2206较不敏感的细胞系中Akt1/Akt2比率较低，Akt siRNA敲除导致的生长抑制也较少。在含PTEN突变体的乳腺癌异种移植物ZR75-1中，MK-2206可抑制Akt信号传导，进而抑制细胞增殖和肿瘤生长。在MK-2206敏感细胞系与体内实验中，MK-2206可与紫杉醇协同作用，该组合比单独用药具有显著增强的抗肿瘤效力。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23085766', '.', 'preclinical', '4', 'MLN0128', 'MLN0128', 'sapanisertib', 'sapanisertib', 'sapanisertib|sapanisertib', '2', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000201', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '研究人员在一组乳腺癌细胞系中评估了Sapanisertib的体外抗增殖活，并使用具有PIK3CA突变的非VEGF（ML20）和VEGF驱动（MV165）的MCF-7亚系乳腺癌异种移植模型评估Sapanisertib对肿瘤生长，血管生成和转移的影响。研究发现，Sapanisertib可有效抑制携带PIK3CA，PTEN，KRAS和/或BRAF突变的乳腺癌细胞系的细胞增殖。体内实验中，Sapanisertib在非VEGF和VEGF驱动的MCF-7异种移植模型中可显著降低原发性肿瘤生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23039341', '.', 'preclinical', '4', 'E6201', 'E6201', 'E6201', 'E6201', 'E6201|E6201', '2', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'resistance', 'EVI_000202', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '携带PTEN基因缺失的黑色素瘤患者可能对E6201治疗不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21163703', '.', 'clinical study', '4', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000203', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'PTEN基因缺失可能使得结直肠癌患者对cetuximab耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21289267', '.', 'preclinical', '4', 'MK2206', 'MK-2206', 'MK-2206', 'MK-2206', 'MK-2206|MK-2206', '2', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', 'na', 'sensitivity', 'EVI_000204', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在具有PI3K/Akt途径相关基因（PIK3CA，PTEN，Ras/RET/PTC）激活突变的甲状腺癌细胞中，MK2206可有效抑制肿瘤细胞增殖。相反，在没有PI3K/Akt途径相关基因激活突变的甲状腺癌细胞中，没有观察到MK2206的有效抑制。同时，MK2206抑制功效是具有遗传选择性的。具体而言，对于具有突变的细胞，使用1μm MK2206时，平均抑制效率为59.2±11.3；使用3μm MK2206时，平均抑制效率为64.4±11.9%。缺乏PI3K/Akt途径突变的SW1736细胞对MK2206的反应最小，用外源性PIK3CA突变体PIK3CA H1047R/E545K转染可显著增加细胞对MK2206的敏感性。MK2206还完全克服了由替西罗莫司诱导的mTOR的反馈激活，这两种抑制剂可协同抑制甲状腺癌细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25409150', '.', 'clinical study', '4', 'BYL719', 'BYL719', 'alpelisib', 'alpelisib', 'alpelisib|alpelisib', '1', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'resistance', 'EVI_000205', 'PTEN:nonsynonymous SNV:exon8:p.K342.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', 'exon8', 'p.K342.', 'inact', '.', 'PTEN基因失活突变的乳腺癌患者对alpelisib(BYL719)的治疗不敏感。研究人员们调查了一名转移性乳腺癌患者的肿瘤基因组进化，其具有活化的PIK3CA突变。患者接受PI3Kα抑制剂BYL719治疗，获得了持久的临床反应，但患者最终对该药物产生了耐药性（出现肺转移），并在此后不久死亡。快速尸检收集14个转移部位的材料并测序。与治疗前肿瘤相比，所有转移性病变都具有PTEN的拷贝丢失，BYL719难以控制的病变部位皆具有不同的PTEN遗传改变，导致PTEN表达的缺失。研究人员调查了另外6名接受BYL719治疗的乳腺癌患者。其中一名患者存在获得性PTEN双等位基因丢失，另有两名患者在疾病发生进展后就难以检测到原发性肿瘤中存在的PIK3CA突变。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25409150', '.', 'clinical study', '4', 'BYL719', 'BYL719', 'alpelisib', 'alpelisib', 'alpelisib|alpelisib', '1', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'resistance', 'EVI_000206', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', '.', 'PTEN基因失活突变的乳腺癌患者对BYL719(alpelisib)的治疗不敏感。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19541609', '.', 'preclinical', '4', 'rapamycin', 'rapamycin', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'Peutz-Jeghers syndrome', 'Peutz-Jeghers syndrome', '非特定癌症', 'na', 'sensitivity', 'EVI_000208', 'STK11:nonsynonymous SNV:.:.:inact', 'STK11', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Among mitogenic signaling pathways, the mammalian-target of rapamycin complex 1 (mTORC1) pathway is hyperactivated in tissues and tumors derived from LKB1 (STK11)-deficient mice. Rapamycin, a mTOR inhibtor, has been shown to suppress tumor growth and induce apoptosis. Consistent with a central role for mTORC1 in these tumors, rapamycin as a single agent results in a dramatic suppression of preexisting GI polyps in LKB1+/− mice.(PMID:19541609) ', 'STK11基因的失活突变可能导致mTOR信号通路的异常活化。西罗莫司是一种mTOR信号通路抑制剂，可以抑制肿瘤生长，诱导肿瘤凋亡。动物模型表明，具有STK11基因失活突变的小鼠对西罗莫司的抗肿瘤作用敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19165201', '.', 'preclinical', '4', 'rapamycin', 'rapamycin', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'lung cancer', 'lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000210', 'STK11:nonsynonymous SNV:.:.:inact', 'STK11', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'STK11 is  somatically inactivated in approximately 30% of non-small-cell lung cancer (NSCLC). LKB1/KRAS mutant NSCLC cell lines are sensitive to the MEK inhibitor CI-1040 shown by a dose-dependent reduction in proliferation rate, whereas LKB1 and KRAS mutations alone do not confer similar sensitivity. This subset of NSCLC is also sensitised to the mTOR inhibitor rapamycin. (PMID:19165201)', 'STK11与KRAS基因双突变的非小细胞肺癌肿瘤细胞可能对MEK抑制剂CI-1040敏感，对mTOR抑制剂西罗莫司也敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22923433', 'NCT00805129', 'clinical trial - phase2', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'bladder cancer', 'bladder cancer', '膀胱癌', '膀胱癌', 'sensitivity', 'EVI_000211', 'TSC1:nonsynonymous SNV:.:.:inact', 'TSC1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Targeted sequencing revealed TSC1 mutations in about 8% of 109 additional bladder cancers examined, and TSC1 mutation correlated with everolimus sensitivity (PMID: 22923433).', '临床试验分析了13例接受everolimus治疗的膀胱癌患者TSC1突变，结果显示：携带TSC1突变的患者接受依维莫司治疗的缓解时间长于野生型患者(7.7 vs. 2.0个月, P=0.004)，复发时间得到显著改善(4.1 vs. 1.8个月; hazard ratio=18.5, 95% CI：2.1 to 162, P=0.001)。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23221341', '.', 'preclinical', '4', 'PD0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901|PD-0325901', '2', 'neurofibromatosis tumors', 'nervous cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000212', 'NF1:nonsynonymous SNV:.:.:inact', 'NF1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'NF1基因是最早被发现的肿瘤抑制基因之一，它是一个GAP蛋白(GTPase-activating protein)。NF1基因缺失突变会提高RAS蛋白的活性，后者通过RAS介导的信号转导途径导致细胞的过度生长、增殖和癌变。有大约一半的神经纤维瘤病人的NF1基因具有缺失突变。携带NF1基因缺失突变的肿瘤患者可能对PI3K、mTOR(如sirolimus、everolimus等)或MEK信号通路抑制剂(如PD-0325901)敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24947927', '.', 'clinical trial - phase1', '4', 'RO4987655', 'RO4987655', 'RO4987655', 'RO4987655', 'RO4987655|RO4987655', '1', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_000213', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'This multicenter phase I expansion (part 2) study has demonstrated that the MEK inhibitor RO4987655 has clinical activity in patients with BRAF V600-mutated melanoma, BRAF wild-type melanoma, and KRAS mutated non–small cell lung cancer (NSCLC), but not in KRAS-mutated colorectal cancer. The safety profile of RO4987655 was at the level predicted from the dose escalation in phase I, with no new safety signals being identified. Evidence of target modulation and early biologic activity was shown among all indications independent of mutational status. Further development of RO4987655 based on its toxicity/efficacy profile and early clinical results in this expansion phase may potentially be pursued in BRAF wild-type melanoma in combination with other emerging signal transduction inhibitors after immunotherapy failure. Initial observations of clinical activity in NRAS-mutated melanoma need further confirmation. In KRAS-mutated NSCLC, combinations with taxanes, other cytostatics or PI3K inhibitors and/or mTOR inhibitors may be rational approaches for the future.', '临床试验表明，MEK抑制剂RO4987655对BRAF基因野生型或V600突变的患者均有一定抗肿瘤作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24947927', '.', 'clinical trial - phase1', '4', 'RO4987655', 'RO4987655', 'RO4987655', 'RO4987655', 'RO4987655|RO4987655', '1', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000214', 'KRAS:nonsynonymous SNV:exon2:p.G12.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'This multicenter phase I expansion (part 2) study has demonstrated that the MEK inhibitor RO4987655 has clinical activity in patients with BRAF V600-mutated melanoma, BRAF wild-type melanoma, and KRAS mutated non–small cell lung cancer (NSCLC), but not in KRAS-mutated colorectal cancer. The safety profile of RO4987655 was at the level predicted from the dose escalation in phase I, with no new safety signals being identified. Evidence of target modulation and early biologic activity was shown among all indications independent of mutational status. Further development of RO4987655 based on its toxicity/efficacy profile and early clinical results in this expansion phase may potentially be pursued in BRAF wild-type melanoma in combination with other emerging signal transduction inhibitors after immunotherapy failure. Initial observations of clinical activity in NRAS-mutated melanoma need further confirmation. In KRAS-mutated NSCLC, combinations with taxanes, other cytostatics or PI3K inhibitors and/or mTOR inhibitors may be rational approaches for the future. ', '一项临床试验表明，MEK抑制剂RO4987655虽然在黑色素瘤和KRAS基因突变的非小细胞肺癌中有效，但对KRAS基因突变的结直肠癌患者无效。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24947927', '.', 'clinical trial - phase1', '4', 'RO4987655', 'RO4987655', 'RO4987655', 'RO4987655', 'RO4987655|RO4987655', '1', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000215', 'KRAS:nonsynonymous SNV:exon2:p.G13.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G13.', '.', 'This multicenter phase I expansion (part 2) study has demonstrated that the MEK inhibitor RO4987655 has clinical activity in patients with BRAF V600-mutated melanoma, BRAF wild-type melanoma, and KRASmutated non–small cell lung cancer (NSCLC), but not in KRAS-mutated colorectal cancer. The safety profile of RO4987655 was at the level predicted from the dose escalation in phase I, with no new safety signals being identified. Evidence of target modulation and early biologic activity was shown among all indications independent of mutational status. Further development of RO4987655 based on its toxicity/efficacy profile and early clinical results in this expansion phase may potentially be pursued in BRAF wild-type melanoma in combination with other emerging signal transduction inhibitors after immunotherapy failure. Initial observations of clinical activity in NRAS-mutated melanoma need further confirmation. In KRAS-mutated NSCLC, combinations with taxanes, other cytostatics or PI3K inhibitors and/or mTOR inhibitors may be rational approaches for the future.', '一项临床试验表明，MEK抑制剂RO4987655虽然在黑色素瘤和KRAS基因突变的非小细胞肺癌中有效，但对KRAS基因突变的结直肠癌患者无效。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24947927', '.', 'clinical trial - phase1', '4', 'RO4987655', 'RO4987655', 'RO4987655', 'RO4987655', 'RO4987655|RO4987655', '1', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000216', 'KRAS:nonsynonymous SNV:exon3:p.Q61.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon3', 'p.Q61.', '.', 'This multicenter phase I expansion (part 2) study has demonstrated that the MEK inhibitor RO4987655 has clinical activity in patients with BRAF V600-mutated melanoma, BRAF wild-type melanoma, and KRASmutated non–small cell lung cancer (NSCLC), but not in KRAS-mutated colorectal cancer. The safety profile of RO4987655 was at the level predicted from the dose escalation in phase I, with no new safety signals being identified. Evidence of target modulation and early biologic activity was shown among all indications independent of mutational status. Further development of RO4987655 based on its toxicity/efficacy profile and early clinical results in this expansion phase may potentially be pursued in BRAF wild-type melanoma in combination with other emerging signal transduction inhibitors after immunotherapy failure. Initial observations of clinical activity in NRAS-mutated melanoma need further confirmation. In KRAS-mutated NSCLC, combinations with taxanes, other cytostatics or PI3K inhibitors and/or mTOR inhibitors may be rational approaches for the future.', '一项临床试验表明，MEK抑制剂RO4987655虽然在黑色素瘤和KRAS基因突变的非小细胞肺癌中有效，但对KRAS基因突变的结直肠癌患者无效。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23224737', 'NTR2530', 'clinical trial - phase2', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'lung cancer', 'lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000221', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'KRAS mutation is the most common oncogenic mutation in non–small cell lung cancer (NSCLC). Patients with this mutation are believed to be refractory to treatment with an EGF receptor (EGFR)-tyrosine kinase inhibitor (TKI) and may derive less benefit from cytotoxic chemotherapy. Inhibition of the RAF/MEK/ERK axis, which stimulates cell growth and proliferation, could be promising because this pathway is overactive in patients with a KRAS mutation. A Phase 2 clinical trial evaluating the response to sorafenib treatment in 57 NSCLC patients with KRAS mutations reported 52.6% of patients with partial response or stable disease at six weeks.', '一项临床试验表明，57名携带KRAS基因突变的非小细胞肺癌患者使用sorafenib治疗，52.6%的病人在6周的治疗期间取得部分响应或者疾病稳定，中位持续反应时间为9周，中位无进展生存期为2.3个月。sorafenib对KRAS突变的非小细胞肺癌患者具有临床活性，可以抑制KRAS突变引起的过度活跃的Ras/Raf通路。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma;basal cell skin cancer', 'basal cell carcinoma', '基底细胞癌', 'na', 'sensitivity', 'EVI_000227', 'PTCH1:nonsynonymous SNV:exon19:p.G1093R:.', 'PTCH1', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.G1093R', '.', 'In a phase 1 study, 18/33 (55%) of patients with locally advanced or metastatic BCC showed response (2 CR and 16 PR) to GDC-0449. Retrospective analysis revealed 7 out of 10 patients with PTCH1 mutant BCC responded to GDC-0449. One of these patients with complete response carried two germline PTCH1 variations (G1093R and T1195T).  Five patients with partial response carried different somatic PTCH1 mutations - Patient 1: G238E, P644S, S683F and P1198S; Patient 2: intronic splice site; Patient 17: W236*; Patient 23: W863*; Patient 27: Q838*. ', '一项I期临床试验表明，33名基底细胞肿瘤患者使用GDC-0449（vismodegib）治疗后，18名患者获益。回顾性分析发现，10名具有PTCH1基因突变的患者中，7名患者对GDC-449敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma;basal cell skin cancer', 'basal cell carcinoma', '基底细胞癌', 'na', 'sensitivity', 'EVI_000228', 'PTCH1:nonsynonymous SNV:exon22:p.T1195T:.', 'PTCH1', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.T1195T', '.', 'In a phase 1 study, 18/33 (55%) of patients with locally advanced or metastatic BCC showed response (2 CR and 16 PR) to GDC-0449. Retrospective analysis revealed 7 out of 10 patients with PTCH1 mutant BCC responded to GDC-0449. One of these patients with complete response carried two germline PTCH1 variations (G1093R and T1195T).  Five patients with partial response carried different somatic PTCH1 mutations - Patient 1: G238E, P644S, S683F and P1198S; Patient 2: intronic splice site; Patient 17: W236*; Patient 23: W863*; Patient 27: Q838*.', '一项I期临床试验表明，33名基底细胞肿瘤患者使用GDC-0449（vismodegib）治疗后，18名患者获益。回顾性分析发现，10名具有PTCH1基因突变的患者中，7名患者对GDC-449敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma;basal cell skin cancer', 'basal cell carcinoma', '基底细胞癌', 'na', 'sensitivity', 'EVI_000229', 'PTCH1:nonsynonymous SNV:exon5:p.G238E:.', 'PTCH1', 'nonsynonymous SNV', 'Exact_pos', 'exon5', 'p.G238E', '.', 'In a phase 1 study, 18/33 (55%) of patients with locally advanced or metastatic BCC showed response (2 CR and 16 PR) to GDC-0449. Retrospective analysis revealed 7 out of 10 patients with PTCH1 mutant BCC responded to GDC-0449. One of these patients with complete response carried two germline PTCH1 variations (G1093R and T1195T).  Five patients with partial response carried different somatic PTCH1 mutations - Patient 1: G238E, P644S, S683F and P1198S; Patient 2: intronic splice site; Patient 17: W236*; Patient 23: W863*; Patient 27: Q838*.', '一项I期临床试验表明，33名基底细胞肿瘤患者使用GDC-0449（vismodegib）治疗后，18名患者获益。回顾性分析发现，10名具有PTCH1基因突变的患者中，7名患者对GDC-449敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma;basal cell skin cancer', 'basal cell carcinoma', '基底细胞癌', 'na', 'sensitivity', 'EVI_000230', 'PTCH1:nonsynonymous SNV:exon14:p.P644S:.', 'PTCH1', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.P644S', '.', 'In a phase 1 study, 18/33 (55%) of patients with locally advanced or metastatic BCC showed response (2 CR and 16 PR) to GDC-0449. Retrospective analysis revealed 7 out of 10 patients with PTCH1 mutant BCC responded to GDC-0449. One of these patients with complete response carried two germline PTCH1 variations (G1093R and T1195T).  Five patients with partial response carried different somatic PTCH1 mutations - Patient 1: G238E, P644S, S683F and P1198S; Patient 2: intronic splice site; Patient 17: W236*; Patient 23: W863*; Patient 27: Q838*.', '一项I期临床试验表明，33名基底细胞肿瘤患者使用GDC-0449（vismodegib）治疗后，18名患者获益。回顾性分析发现，10名具有PTCH1基因突变的患者中，7名患者对GDC-449敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma;basal cell skin cancer', 'basal cell carcinoma', '基底细胞癌', 'na', 'sensitivity', 'EVI_000231', 'PTCH1:nonsynonymous SNV:exon14:p.S683F:.', 'PTCH1', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.S683F', '.', 'In a phase 1 study, 18/33 (55%) of patients with locally advanced or metastatic BCC showed response (2 CR and 16 PR) to GDC-0449. Retrospective analysis revealed 7 out of 10 patients with PTCH1 mutant BCC responded to GDC-0449. One of these patients with complete response carried two germline PTCH1 variations (G1093R and T1195T).  Five patients with partial response carried different somatic PTCH1 mutations - Patient 1: G238E, P644S, S683F and P1198S; Patient 2: intronic splice site; Patient 17: W236*; Patient 23: W863*; Patient 27: Q838*.', '一项I期临床试验表明，33名基底细胞肿瘤患者使用GDC-0449（vismodegib）治疗后，18名患者获益。回顾性分析发现，10名具有PTCH1基因突变的患者中，7名患者对GDC-449敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma;basal cell skin cancer', 'basal cell carcinoma', '基底细胞癌', 'na', 'sensitivity', 'EVI_000232', 'PTCH1:nonsynonymous SNV:exon22:p.P1198S:.', 'PTCH1', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.P1198S', '.', 'In a phase 1 study, 18/33 (55%) of patients with locally advanced or metastatic BCC showed response (2 CR and 16 PR) to GDC-0449. Retrospective analysis revealed 7 out of 10 patients with PTCH1 mutant BCC responded to GDC-0449. One of these patients with complete response carried two germline PTCH1 variations (G1093R and T1195T).  Five patients with partial response carried different somatic PTCH1 mutations - Patient 1: G238E, P644S, S683F and P1198S; Patient 2: intronic splice site; Patient 17: W236*; Patient 23: W863*; Patient 27: Q838*.', '一项I期临床试验表明，33名基底细胞肿瘤患者使用GDC-0449（vismodegib）治疗后，18名患者获益。回顾性分析发现，10名具有PTCH1基因突变的患者中，7名患者对GDC-449敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma;basal cell skin cancer', 'basal cell carcinoma', '基底细胞癌', 'na', 'sensitivity', 'EVI_000233', 'PTCH1:stopgain:exon16:p.W863*:.', 'PTCH1', 'stopgain', 'Exact_pos', 'exon16', 'p.W863*', '.', 'In a phase 1 study, 18/33 (55%) of patients with locally advanced or metastatic BCC showed response (2 CR and 16 PR) to GDC-0449. Retrospective analysis revealed 7 out of 10 patients with PTCH1 mutant BCC responded to GDC-0449. One of these patients with complete response carried two germline PTCH1 variations (G1093R and T1195T).  Five patients with partial response carried different somatic PTCH1 mutations - Patient 1: G238E, P644S, S683F and P1198S; Patient 2: intronic splice site; Patient 17: W236*; Patient 23: W863*; Patient 27: Q838*.', '一项I期临床试验表明，33名基底细胞肿瘤患者使用GDC-0449（vismodegib）治疗后，18名患者获益。回顾性分析发现，10名具有PTCH1基因突变的患者中，7名患者对GDC-449敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma;basal cell skin cancer', 'basal cell carcinoma', '基底细胞癌', 'na', 'sensitivity', 'EVI_000234', 'PTCH1:stopgain:exon5:p.W236*:.', 'PTCH1', 'stopgain', 'Exact_pos', 'exon5', 'p.W236*', '.', 'In a phase 1 study, 18/33 (55%) of patients with locally advanced or metastatic BCC showed response (2 CR and 16 PR) to GDC-0449. Retrospective analysis revealed 7 out of 10 patients with PTCH1 mutant BCC responded to GDC-0449. One of these patients with complete response carried two germline PTCH1 variations (G1093R and T1195T).  Five patients with partial response carried different somatic PTCH1 mutations - Patient 1: G238E, P644S, S683F and P1198S; Patient 2: intronic splice site; Patient 17: W236*; Patient 23: W863*; Patient 27: Q838*.', '一项I期临床试验表明，33名基底细胞肿瘤患者使用GDC-0449（vismodegib）治疗后，18名患者获益。回顾性分析发现，10名具有PTCH1基因突变的患者中，7名患者对GDC-449敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma;basal cell skin cancer', 'basal cell carcinoma', '基底细胞癌', 'na', 'sensitivity', 'EVI_000235', 'PTCH1:stopgain:exon15:p.Q838*:.', 'PTCH1', 'stopgain', 'Exact_pos', 'exon15', 'p.Q838*', '.', 'In a phase 1 study, 18/33 (55%) of patients with locally advanced or metastatic BCC showed response (2 CR and 16 PR) to GDC-0449. Retrospective analysis revealed 7 out of 10 patients with PTCH1 mutant BCC responded to GDC-0449. One of these patients with complete response carried two germline PTCH1 variations (G1093R and T1195T).  Five patients with partial response carried different somatic PTCH1 mutations - Patient 1: G238E, P644S, S683F and P1198S; Patient 2: intronic splice site; Patient 17: W236*; Patient 23: W863*; Patient 27: Q838*.', '一项I期临床试验表明，33名基底细胞肿瘤患者使用GDC-0449（vismodegib）治疗后，18名患者获益。回顾性分析发现，10名具有PTCH1基因突变的患者中，7名患者对GDC-449敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000236', 'EGFR:nonsynonymous SNV:exon19:p.K728R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.K728R', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796) ', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000237', 'EGFR:nonsynonymous SNV:exon19:p.I740T:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.I740T', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000238', 'EGFR:nonsynonymous SNV:exon19:p.K757R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.K757R', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000239', 'EGFR:nonsynonymous SNV:exon20:p.A767D:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.A767D', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000240', 'EGFR:nonsynonymous SNV:exon20:p.V774A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.V774A', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000241', 'EGFR:nonsynonymous SNV:exon20:p.L778P:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.L778P', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000242', 'EGFR:nonsynonymous SNV:exon20:p.Q787R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.Q787R', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000243', 'EGFR:nonsynonymous SNV:exon20:p.D800G:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D800G', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000244', 'EGFR:nonsynonymous SNV:exon20:p.V802A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.V802A', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000245', 'EGFR:nonsynonymous SNV:exon20:p.L814P:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.L814P', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000246', 'EGFR:nonsynonymous SNV:exon20:p.I821T:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.I821T', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000247', 'EGFR:nonsynonymous SNV:exon21:p.A839V:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.A839V', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000248', 'EGFR:nonsynonymous SNV:exon21:p.N842I:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.N842I', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26046796', 'NCT01608841', 'clinical trial - phase2', '4', 'gemcitabine,erlotinib|gemcitabine', 'erlotinib', 'erlotinib + Gemcitabine', '厄洛替尼 + 吉西他滨', 'erlotinib + Gemcitabine|厄洛替尼 + 吉西他滨', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_000251', 'EGFR:nonsynonymous SNV:exon21:p.E865K:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.E865K', '.', 'Disease control rate (64% vs. 25%; P < 0.001), progression-free survival (median 3.8 vs. 2.4 months; P < 0.001), and overall survival (median 7.2 vs. 4.4 months; P < 0.001) were better in the gemcitabine plus erlotinib group than in the gemcitabine alone group. In the gemcitabine plus erlotinib group, disease control (85% vs. 33%; P = 0.001), progression-free survival (median 5.9 vs. 2.4 months; P = 0.004), and overall survival (median 8.7 vs. 6.0 months; P = 0.044) were better in patients with EGFR mutations than in those without EGFR mutations. KRAS mutation was not associated with treatment response or survival. Gemcitabine plus erlotinib is more effective than gemcitabine alone for treating metastatic pancreatic cancer patients, especially those with EGFR mutations. (PMID: 26046796)', '一项单中心前瞻性临床试验中（NCT01608841；PMID:26046796）， 88例未接受化疗的转移性胰腺癌患者随机接受吉西他滨或吉西他滨加厄洛替尼治疗。分别分析EGFR和KRAS突变。主要终点是疾病控制率。结果显示，吉西他滨加厄洛替尼组比单独使用吉西他滨组疗效更佳，其疾病控制率（64%对25%;P <0.001），无进展生存期（中位数3.8对2.4个月;P<0.001）和总生存期（中位数7.2对4.4个月; P<0.001）。在吉西他滨加厄洛替尼组中，携带EGFR突变患者的疗效更好，其疾病控制（85%对33%;P = 0.001），无进展生存期（中位数 5.9对2.4个月;P = 0.004）和总生存期（中位数 8.7对6.0个月;P = 0.044）。KRAS突变与治疗反应或生存无关。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26698910 ', 'NCT01970865', 'clinical trial - phase2', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'lung cancer', 'lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000252', 'ALK:nonsynonymous SNV:exon22:p.C1156Y:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.C1156Y', '.', 'In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y). Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor. When her tumor relapsed, sequencing of the resistant tumor revealed an ALK L1198F mutation in addition to the C1156Y mutation. The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding. However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib. The patient received crizotinib again, and her cancer-related symptoms and liver failure resolved. ', '在ALK融合基因阳性的肺癌患者中，ALK基因的C1156Y和L1198F突变可能导致患者对crizotinib耐药；但是携带C1156Y突变的患者可能对lorlatinib敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21163703', '.', 'clinical study', '4', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000254', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'PTEN基因缺失可能使得结直肠癌患者可能对panitumumab耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25923550 ', 'NCT01526928', 'clinical trial - phase2', '4', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib|rociletinib', '3', 'non-small cell lung cancer;lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000255', 'EGFR:nonsynonymous SNV:exon20:p.T790M:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'Rociletinib was active in patients with EGFR-mutated NSCLC associated with the T790M resistance mutation.', '一项临床试验入组130例患者，其中46例T790M阳性的NSCLC接受rociletinib治疗，缓解率为59%，疾病控制率(完全缓解或部分缓解或疾病稳定比例)为93%(43/46)，中位无进展生存期为13.1个月。而17例T790M阴性的NSCLC患者，缓解率仅为29%(95% CI：8-51)，疾病控制率为59%(17/10)，中位无进展生存期为5.6个月。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25294897', '.', 'clinical study', '4', 'sorafenib,refametinib', 'refametinib + sorafenib', 'refametinib + sorafenib', 'refametinib + 索拉非尼', 'refametinib + sorafenib|refametinib + 索拉非尼', '2', 'hepatocellular carcinoma', 'liver cancer', '肝癌', 'na', 'sensitivity', 'EVI_000256', 'KRAS:nonsynonymous SNV:exon2:p.G12.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'Refametinib plus sorafenib showed antitumor activity in patients with HCC and was tolerated at reduced doses by most patients. Frequent dose modifications due to grade 3 adverse events may have contributed to limited treatment effect. Patients with RAS mutations appear to benefit from refametinib/sorafenib combination.', '临床研究表明，refametinib与sorafenib联用在大部分肝癌患者中都显示出一定的抗肿瘤活性，而且对KRAS基因有突变的患者也有一定疗效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25294897', '.', 'clinical study', '4', 'sorafenib,refametinib', 'refametinib + sorafenib', 'refametinib + sorafenib', 'refametinib + 索拉非尼', 'refametinib + sorafenib|refametinib + 索拉非尼', '2', 'hepatocellular carcinoma', 'liver cancer', '肝癌', 'na', 'sensitivity', 'EVI_000257', 'KRAS:nonsynonymous SNV:exon2:p.G13.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G13.', '.', 'Refametinib plus sorafenib showed antitumor activity in patients with HCC and was tolerated at reduced doses by most patients. Frequent dose modifications due to grade 3 adverse events may have contributed to limited treatment effect. Patients with RAS mutations appear to benefit from refametinib/sorafenib combination.', '临床研究表明，refametinib与sorafenib联用在大部分肝癌患者中都显示出一定的抗肿瘤活性，而且对KRAS基因有突变的患者也有一定疗效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23444215', '.', 'clinical trial - phase2', '4', 'selumetinib', 'selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000258', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'This study showed that selumetinib, a selective inhibitor of MEK, induced tumor regression in 3 of 5 patients with BRAF mutant melanomas that had low expression of phosphorylated AKT. ', '司美替尼（selumetinib，MEK抑制剂）可能对携带BRAF基因突变的黑色素瘤患者有效，并且能降低肿瘤细胞内AKT的磷酸化水平。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:olaparib_Revised: 12/2018 ', '.', 'guideline:FDA', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_000259', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2014年美国FDA批准抗癌新药奥拉帕利 olaparib (Lynparza)，作为单药治疗之前至少经过3次化疗的晚期卵巢癌患者，或者生殖系的BRCA突变的晚期卵巢癌。欧盟药监局（EMA）也批准了Olaparib用于铂敏感复发性卵巢癌患者，对携带BRCA体细胞突变的肿瘤患者也有一定作用。FDA批准olaparib治疗携带生殖细胞BRCA有害突变(gBRCAm) 或疑似有害突变的晚期卵巢癌，患者曾接受过三线或更多线的化疗，此适应症是基于一项国际性、单臂临床试验结果。试验中纳入了137名gBRCAm相关且可测量的接受过三线或更多线化疗的卵巢癌患者，这些患者接受olaparib单药治疗直到出现疾病进展或不可接受的毒性。主要疗效指标包括研究者根据RECIST v1.1 评价的客观缓解率（ORR）和反应持续时间（DOR）。对BRAC Analysis CDxTM 伴随诊断有效的血样中，97% (59/61)的患者被证实了有害或疑似有害的gBRCAm状态。临床试验结果表明研究者评估的olaparib ORR为34% (95% CI: 26, 42)，中位反应持续时间为7.9个月 (95% CI: 5.6, 9.6)。(NCT01078662)', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:gefitinib_Revised:07/2015', '.', 'guideline:FDA', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer;lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000260', 'EGFR:nonsynonymous SNV:exon21:p.L858R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', '吉非替尼（Gefitinib）适用于EGFR 19号外显子缺失或21号外显子L858R突变型转移性非小细胞肺癌患者的一线治疗。局限性：吉非替尼治疗非EGFFR 19号外显子缺失或21号外显子L858R突变型转移性非小细胞肺癌的安全性和有效性尚未建立。FDA批准吉非替尼治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌，此项适应症是基于一项多中心、单臂开放性临床研究结果获批。试验中纳入了106名EGFR原发性突变的转移性非小细胞肺癌患者，这些患者接受吉非替尼治疗直到出现疾病进展或不能忍受的毒性。试验中主要的疗效指标为独立审查委员会（BIRC）和研究者根据RECIST v1.1评估客观缓解率（ORR）。BIRC评估的ORR 为50% (95% CI: 41, 59)，中位反应持续时间（DoR）为6.0个月。研究者分析评估的ORR 为70% (95% CI: 61, 78) ，中位反应持续时间（DoR）为8.3个月。在另一项关于吉非替尼一线治疗非小细胞肺癌（组织学为腺癌）的随机性、多中心、开放性临床试验中，对其中一个亚组的探索性分析支持吉非替尼治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌。这项试验纳入了1217名患者，按1：1随机分配至吉非替尼治疗组或6疗程的卡铂/紫杉醇治疗组，疗效指标包括BIRC评估的PFS和ORR。探索性分析的研究对象为186名确定为EGFR阳性的患者。在此亚组中有88名患者在吉非替尼治疗组， 98名患者在卡铂/紫杉醇治疗组，BICR评估分析显示吉非替尼治疗组和卡铂/紫杉醇治疗组的中位PFS分别为10.9个月和7.4个，HR 0.54 (95% CI: 0.38, 0.79)。另外，BICR评估分析显示吉非替尼治疗组和卡铂/紫杉醇治疗组的DoR分别为 9.6个月和5.5个月，ORR分别为 67% (95% CI: 56, 77) 和41% (95% CI: 31, 51) (NCT01203917;NCT00322452)。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:afatinib_Revised:04/2016', '.', 'guideline:FDA', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer;lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000261', 'EGFR:nonsynonymous SNV:exon21:p.L858R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', '阿法替尼（Afatinib）适用于一线治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌患者。局限性：阿法替尼治疗EGFR其它突变类型患者的安全性和有效性尚未建立。阿法替尼也适用于铂类为基础的化疗后出现疾病进展的转移性鳞状非小细胞肺癌患者。FDA批准阿法替尼一线治疗EGFR 19号外显子缺失或21号外显子L858R突变的转移性非小细胞肺癌，此项适应症是基于在一项多中心、国际化、开放性、随机试验中患者无进展生存期提高而获批。在这项试验中345位转移性非小细胞肺癌患者按2：1随机分配至阿法替尼（n=230）治疗组和培美曲塞/顺铂化疗治疗组（n=115），主要疗效指标为由独立评审委员会（IRC）评估的无进展生存期（PFS）。试验中纳入的患者经检测确定为EGFR突变阳性，突变状态分为EGFR 19号外显子缺失（49%）、21号外显子L858R突变（40%）和其他（11%）。在阿法替尼治疗组中患者PFS显著延长[HR 0.58 (95% CI: 0.43,0.78); p < 0.001, stratified log-rank test]，阿法替尼治疗组和培美曲塞/顺铂化疗组的中位PFS分别为11.1和6.9个月，客观缓解率分别为50.4%和19.1%。两个治疗组的总生存期（OS）无显著性差异。携带EGFR 19号外显子缺失或21号外显子L858R突变的患者在阿法替尼治疗组和化疗治疗组中的中位PFS分别为13.6和6.9个月(NCT00949650)。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:16618717|PMID: 23404247', '.', 'preclinical', '4', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000263', 'KRAS:CNV:.:.:gain', 'KRAS', 'CNV', 'CNV', '.', '.', 'gain', 'Patients with tumors harboring mutations in KRAS did not benefit from anti-EGFR antibody therapy. Patients with KRAS mutated tumors appeared to do worse when treated with EGFR antibody therapy combined with an oxaliplatin based chemotherapy compared to the patients treated with an oxaliplatin based treatment alone. ', 'KRAS基因突变与大肠癌等肿瘤患者酪氨酸激酶抑制剂等靶向药物的原发性耐药有关。KRAS基因野生型的患者能从爱必妥 (Erbitux，又称西妥昔单抗/Cetuximab)或维克替比(Vectibix，又称帕尼单抗/Panitumumab) 治疗中获益，而KRAS基因突变的大肠癌患者治疗效果较差。欧洲药监局和美国FDA明确规定了在使用靶向药物爱必妥和维克替比治疗转移性大肠癌前必须检测KRAS基因。临床研究表明，携带KRAS基因扩增的肿瘤患者可能对EGFR抗体类药物耐药。细胞学试验表明，携带KRAS基因扩增的肿瘤细胞对anti-EGFR抗体药物可能耐药。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:16618717|PMID: 23404247', '.', 'preclinical', '4', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000264', 'KRAS:CNV:.:.:gain', 'KRAS', 'CNV', 'CNV', '.', '.', 'gain', 'Patients with tumors harboring mutations in KRAS did not benefit from anti-EGFR antibody therapy. Patients with KRAS mutated tumors appeared to do worse when treated with EGFR antibody therapy combined with an oxaliplatin based chemotherapy compared to the patients treated with an oxaliplatin based treatment alone. ', 'KRAS基因突变与大肠癌等肿瘤患者酪氨酸激酶抑制剂等靶向药物的原发性耐药有关。KRAS基因野生型的患者能从爱必妥 (Erbitux，又称西妥昔单抗/Cetuximab)或维克替比(Vectibix，又称帕尼单抗/Panitumumab) 治疗中获益，而KRAS基因突变的大肠癌患者治疗效果较差。欧洲药监局和美国FDA明确规定了在使用靶向药物爱必妥和维克替比治疗转移性大肠癌前必须检测KRAS基因。临床研究表明，携带KRAS基因扩增的肿瘤患者可能对EGFR抗体类药物耐药。细胞学试验表明，携带KRAS基因扩增的肿瘤细胞对anti-EGFR抗体药物可能耐药。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18676761', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000265', 'EGFR:nonsynonymous SNV:exon20:p.K806E:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.K806E', '.', '.', '一项回顾性研究分析了23例携带EGFR 20号外显子突变的非小细胞肺癌(NSCLC)患者，其中9例(39%)患者除20号外显子突变外还同时存在其他EGFR突变，16例患者接受gefitinib治疗，其中4例出现临床反应，临床应答率为25%，远低于EGFR 19号外显子缺失和L858R突变的NSCLC。其中一名携带K806E使用gefitinib治疗后疾病发生进展(PD)。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:imatinib_Revised:01/2015', '.', 'guideline:FDA', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'systemic mastocytosis', 'systemic mastocytosis', '胃肠间质瘤', 'na', 'resistance', 'EVI_000268', 'KIT:nonsynonymous SNV:exon17:p.D816V:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D816V', '.', '.', 'FDA药品使用说明书中表明，伊马替尼(Imatinib  mesylate)仅适用于非KIT D816V突变或KIT突变型未知的侵袭性系统性肥大细胞增生症成人患者。因此，携带此突变的肿瘤患者可能对伊马替尼耐药。在一项开放性、多中心、Ⅱ期临床试验中探究了伊马替尼对Abl, Kit或PDGFR蛋白激酶相关的生命威胁性疾病的作用。这项研究中有5位侵袭性系统性肥大细胞增生症（ASM）患者，接受每日剂量100 mg -400mg伊马替尼治疗，患者年龄49-74岁。除5位患者外，10篇文献报道中和案例系统中描述的23位年龄在26-85岁ASM患者也接受每日100 mg -400mg剂量伊马替尼治疗。在28名ASM患者中评价了20名患者的细胞遗传学异常状态，其中有7名患者携带FIP1L1-PDGFRα融合（或CHIC2缺失）。携带细胞遗传学异常的患者主要是男性，患有与系统性肥大细胞病相关的嗜酸性粒细胞增多症；两名患者在KIT膜旁区域存在突变（Phe522Cys；K509I）；4名患者携带KIT D816V突变，其中一个伴有CML。在这28名ASM患者中，有8名患者（29%）获得了完全血液学缓解，9名（32%）获得了部分血液学缓解，总缓解率为61%。Ⅱ期临床试验中和文献报道中的患者中位持续治疗时间分别为13个月（范围：1.4–22.3个月）和1-30+个月。携带FIP1L1-PDGFRα融合（或CHIC2缺失）的7位患者均获得了完全血液学缓解，携带KIT膜旁区域突变的患者均获得了部分血液学缓解。在4位携带KIT D816V突变的患者中，仅有1位患者获得血液学缓解。在细胞遗传学异常未知或不存在的患者（N=15）中，有7名患者获得了部分血液学缓解。未证实伊马替尼在非侵袭性系统性肥大细胞增生症有效，因此不推荐伊马替尼用于治疗皮肤肥大细胞增生症、静止性系统性肥大细胞增多症、克隆性血液非肥大细胞系疾病相关的系统性肥大细胞增生症、肥大细胞白血病、肥大细胞肉瘤或外肥大细胞瘤。携带KIT D816V突变的患者对伊马替尼不敏感，不应接受伊马替尼治疗。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:imatinib_Revised:01/2015', '.', 'guideline:FDA', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'hypereosinophilic syndrome;chronic eosinophilic leukemia;', 'leukemia', '白血病', 'na', 'sensitivity', 'EVI_000269', 'PDGFRA:FUS:.:FIP1L1-PDGFRA:.', 'PDGFRA', 'FUS', 'FUS', '.', 'FIP1L1-PDGFRA', '.', '.', '伊马替尼(Imatinib  mesylate)：适用于有FIP1L1-PDGFRA融合激酶表达(突变性分析或萤光原位免疫组化证实CHIC2等位基因缺失)的嗜酸性粒细胞增多综合征和/或慢性嗜酸性粒细胞白血病成年患者，和FIP1L1-PDGFRA融合激酶阴性或未知的嗜酸性粒细胞增多综合征和/或慢性嗜酸性粒细胞白血病患者. 在一项开放性、多中心、Ⅱ期临床试验中探究了伊马替尼对Abl, Kit或PDGFR蛋白激酶相关的生命威胁性疾病的作用。这项研究中有14名嗜酸性粒细胞增多症/慢性嗜酸细胞白血病(HES/CEL)患者，HES患者每日接受100 mg-1000 mg伊马替尼治疗，年龄为16-64岁。后续搜集了35篇文献报道中和案例系统中的162名年龄11-78岁的HES/CEL患者，这些患者接受日剂量为75 mg- 800 mg。在FIP1L1-PDGFRα阳性的HES/CEL患者(N=61)中,完全血液学缓解为100%，在FIP1L1-PDGFRα阴性的HES/CEL患者（N=56）中，完全血液学缓解为21%，部分血液学缓解为16%。在细胞遗传学异常状态未知的患者（N=59）中，完全血液学缓解为58%，部分血液学缓解为12%。总的来说，在这些患者（N=176）中，完全血液学缓解为61%，部分血液学缓解为13%。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24396447|PMID:28424065', '.', 'case report', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000277', 'EGFR:nonsynonymous SNV:exon19:p.L747S:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747S', '.', '.', 'EGFR基因上的L747S（外显子19），D761Y（外显子19）,T854A（外显子21）突变以及MET的扩增与EGFR-TKI获得性耐药有关。3例临床案例报道携带L747S可能对EGFR-TKI抑制剂耐药。细胞学试验表明，gefitinib对携带L858R突变的肿瘤细胞的IC50为3.38 nM，对携带L858R/L747S突变的肿瘤细胞的IC50为15.1 nM。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24396447|PMID:28424065', '.', 'case report', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000278', 'EGFR:nonsynonymous SNV:exon19:p.L747S:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747S', '.', '.', 'EGFR基因上的L747S（外显子19），D761Y（外显子19）,T854A（外显子21）突变以及MET的扩增与EGFR-TKI获得性耐药有关。3例临床案例报道携带L747S可能对EGFR-TKI抑制剂耐药。细胞学试验表明，erlotinib对携带L858R突变的肿瘤细胞的IC50为1.82 nM，对携带L858R/L747S突变的肿瘤细胞的IC50为8.68 nM。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25939061', '.', 'clinical study', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000282', 'EGFR:nonsynonymous SNV:exon20:p.C797S<顺式>:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<顺式>', '.', '.', 'EGFR基因上的C797S突变可能与肺癌病人对osimertinib(AZD9291)的耐药相关。一项研究具有对EGFR-TKI抑制剂osimertinib耐药的晚期肺癌受试者，收集血浆中的DNA(cfDNA)。先对7名受试者的cfDNA进行二代测序，检测到获得性EGFR C797S突变；后在细胞系中发现这种突变型的EGFR表达对osimertinib具有抗性。对15名接受osimertinib治疗后耐药患者的cfDNA标本进行数字PCR检测。治疗前T790M突变均为阳性，但osimertinib耐药后，出现三种分子亚型：6例获得C797S突变；5例维持T790M突变，但未获得C797S突变；4例失去T790M突变。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21764376|PMID:24353160', '.', 'clinical study', '4', 'neratinib', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '肺癌', 'resistance', 'EVI_000285', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'EGFR exon 20 insertion mutations affecting aminoacids Ala767, Ser768, Asp770, Pro772, and His773 are resistant to clinically achievable doses of EGFR inhibitors that have gained regulatory approval or entered late-stage clinical trials, such as gefitinib,erlotinib, neratinib, afatinib, and PF00299804.', '在EGFR20号外显子处的插入突变，尤其是在Ala767, Ser768, Asp770, Pro772, 及His773附近，可能会导致肿瘤患者对EGFR抑制剂耐药。EGFR 20外显子插入突变仅次于EGFR 19和21 L858R，是EGFR突变的第三大类型。常见于不吸烟者，与年龄、性别、种族或肿瘤分期没有关联。肿瘤形态与常见EGFR突变相似，但固相结缔组织更多些。目前的研究结果不仅解释了不同的EGFR20插入突变及其对EGFR-TKIs的应答效果，也提供给EGFR20插入突变的NSCLC患者不同的靶向治疗策略和选择：如果采用测序方法检测到A763_Y764insFQEA的患者可以考虑使用TKI治疗，20外显子的其他点位则不适合TKI治疗。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21764376|PMID:24353160', '.', 'clinical study', '4', 'PF00299804', 'PF00299804', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '3', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '肺癌', 'resistance', 'EVI_000286', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'EGFR exon 20 insertion mutations affecting aminoacids Ala767, Ser768, Asp770, Pro772, and His773 are resistant to clinically achievable doses of EGFR inhibitors that have gained regulatory approval or entered late-stage clinical trials, such as gefitinib,erlotinib, neratinib, afatinib, and PF00299804.', '在EGFR20号外显子处的插入突变，尤其是在Ala767, Ser768, Asp770, Pro772, 及His773附近，可能会导致肿瘤患者对EGFR抑制剂耐药。EGFR 20外显子插入突变仅次于EGFR 19和21 L858R，是EGFR突变的第三大类型。常见于不吸烟者，与年龄、性别、种族或肿瘤分期没有关联。肿瘤形态与常见EGFR突变相似，但固相结缔组织更多些。目前的研究结果不仅解释了不同的EGFR20插入突变及其对EGFR-TKIs的应答效果，也提供给EGFR20插入突变的NSCLC患者不同的靶向治疗策略和选择：如果采用测序方法检测到A763_Y764insFQEA的患者可以考虑使用TKI治疗，20外显子的其他点位则不适合TKI治疗。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('CSCO胃肠间质瘤专家委员会.临床肿瘤学杂志.2013,18(11)|PMID:18955458', '.', 'guideline:CSCO', '1', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'resistance', 'EVI_000287', 'PDGFRA:nonsynonymous SNV:exon18:p.D842V:.', 'PDGFRA', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.D842V', '.', '.', '一般认为KIT、PDGFRA的突变类型可以预测伊马替尼的疗效，其中KIT外显子11突变的疗效最佳；而PDGFRA D842V和D846V突变可能对伊马替尼和舒尼替尼治疗原发性耐药。舒尼替尼二线治疗原发KIT外显子9突变和野生型GIST患者的生存获益优于KIT外显子11突变患者；而治疗继发性KIT外显子13、14突变患者的疗效优于继发KIT外显子17、18突变。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000289', 'EGFR:nonsynonymous SNV:exon18:p.V689M:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.V689M', '.', '.', 'V689M突变发生在EGFR基因的18号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000290', 'EGFR:nonsynonymous SNV:exon18:p.V689M:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.V689M', '.', '.', 'V689M突变发生在EGFR基因的18号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000291', 'EGFR:nonsynonymous SNV:exon18:p.N700D:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.N700D', '.', '.', 'N700D突变发生在EGFR基因的18号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000292', 'EGFR:nonsynonymous SNV:exon18:p.N700D:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.N700D', '.', '.', 'N700D突变发生在EGFR基因的18号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000297', 'EGFR:nonsynonymous SNV:exon18:p.S720P:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.S720P', '.', '.', 'S720P突变发生在EGFR基因的18号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000298', 'EGFR:nonsynonymous SNV:exon18:p.S720P:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.S720P', '.', '.', 'S720P突变发生在EGFR基因的18号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000299', 'EGFR:nonsynonymous SNV:exon20:p.V765A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.V765A', '.', '.', 'V765A突变发生在EGFR基因的20号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000300', 'EGFR:nonsynonymous SNV:exon20:p.V765A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.V765A', '.', '.', 'V765A突变发生在EGFR基因的20号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000301', 'EGFR:nonsynonymous SNV:exon20:p.T783A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T783A', '.', '.', 'T783A突变发生在EGFR基因的20号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000302', 'EGFR:nonsynonymous SNV:exon20:p.T783A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T783A', '.', '.', 'T783A突变发生在EGFR基因的20号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000303', 'EGFR:nonsynonymous SNV:exon21:p.N826S:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.N826S', '.', '.', 'N826S突变发生在EGFR基因的21号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000304', 'EGFR:nonsynonymous SNV:exon21:p.N826S:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.N826S', '.', '.', 'N826S突变发生在EGFR基因的21号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000305', 'EGFR:nonsynonymous SNV:exon21:p.A839T:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.A839T', '.', '.', 'A839T突变发生在EGFR基因的21号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000306', 'EGFR:nonsynonymous SNV:exon21:p.A839T:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.A839T', '.', '.', 'A839T突变发生在EGFR基因的21号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000307', 'EGFR:nonsynonymous SNV:exon21:p.K846R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.K846R', '.', '.', 'K846R突变发生在EGFR基因的21号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000308', 'EGFR:nonsynonymous SNV:exon21:p.K846R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.K846R', '.', '.', 'K846R突变发生在EGFR基因的21号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000309', 'EGFR:nonsynonymous SNV:exon21:p.G863D:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.G863D', '.', '.', 'G863D突变发生在EGFR基因的21号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000310', 'EGFR:nonsynonymous SNV:exon21:p.G863D:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.G863D', '.', '.', 'G863D突变发生在EGFR基因的21号外显子区域，携带该突变的肿瘤患者可能对酪氨酸激酶抑制（如吉非替尼、厄洛替尼）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000315', 'EGFR:nonsynonymous SNV:exon20:p.N771T:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.N771T', '.', '.', 'EGFR基因20号外显子的突变与酪氨酸激酶的活性相关。携带该类突变的肺癌患者可能对酪氨酸激酶抑制剂耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000316', 'EGFR:nonsynonymous SNV:exon20:p.N771T:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.N771T', '.', '.', 'EGFR基因20号外显子的突变与酪氨酸激酶的活性相关。携带该类突变的肺癌患者可能对酪氨酸激酶抑制剂耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210|PMID:17045698', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000317', 'EGFR:nonsynonymous SNV:exon20:p.V769L:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.V769L', '.', '.', 'EGFR基因20号外显子的突变与酪氨酸激酶的活性相关。携带该类突变的肺癌患者可能对酪氨酸激酶抑制剂耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17318210|PMID:17045698', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000318', 'EGFR:nonsynonymous SNV:exon20:p.V769L:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.V769L', '.', '.', 'EGFR基因20号外显子的突变与酪氨酸激酶的活性相关。携带该类突变的肺癌患者可能对酪氨酸激酶抑制剂耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24162815', '.', 'preclinical', '4', 'CEP-701', 'CEP-701', 'lestaurtinib', '来妥替尼', 'lestaurtinib|来妥替尼', '2', 'lung cancer', 'lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000320', 'NTRK1:FUS:.:MPRIP-NTRK1:.', 'NTRK1', 'FUS', 'FUS', '.', 'MPRIP-NTRK1', '.', '.', 'NTRK基因编码TRKA受体蛋白，在3.3%肺癌患者中发生NTRK基因的融合，已知的融合基因有MPRIP-NTRK1，CD74-NTRK1，TPM3-NTRK1。融合导致TRKA磷酸激酶组成型激活，TRKA的自磷酸化激活下游信号通路导致肿瘤生长。ARRY-470是一种TRK A/B/C的专一性抑制剂，CEP-701和crizotinib除了TRKA还能抑制其他磷酸激酶。体外研究表明，使用上述三种抑制剂分别处理携带三种不同的融合基因的肺癌细胞，NTRK融合的肿瘤细胞能对上述三种药物产生反应，对crizotinib的响应较弱，但是肿瘤细胞集落大小均受到抑制，细胞周期停止发生细胞凋亡。MPRIP-NTRK1的肺癌患者使用crizotinib治疗后血清CA125水平下降，但3个月后疾病发生进展，治疗效果不佳。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041|PMID:26698910', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000327', 'ALK:nonsynonymous SNV:exon22:p.C1156Y:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.C1156Y', '.', 'C1156Y, G1202R, 1151T-ins, L1152R and F1174C mutations also conferred resistance to ceritinib, although ceritinib was still more potent than crizotinib against these mutations. (PMID:24675041)', 'ALK+肺癌患者ALK基因p.C1156Y发生点突变的非小细胞肺癌患者可能对塞瑞替尼（ceritinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21791641', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000328', 'ALK:nonsynonymous SNV:exon23:p.F1174L:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', 'Somatic kinase domain mutation in ALK might cause crizotinib resistance in ALK(+) NSCLC (PMID:21791641).', 'ALK+肺癌患者ALK基因p.F1174L发生点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 32:5s, 2014 (suppl; abstr 8031)', '.', 'clinical study', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000329', 'ALK:nonsynonymous SNV:exon23:p.F1174L:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', 'http://meetinglibrary.asco.org/content/134805-144', 'ALK+肺癌患者ALK基因p.F1174L发生点突变的非小细胞肺癌患者可能对塞瑞替尼（ceritinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000330', 'ALK:nonsynonymous SNV:exon23:p.G1202R:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.G1202R', '.', 'Somatic kinase domain mutation in ALK might cause crizotinib resistance in ALK(+) NSCLC (PMID:22277784). 2.To date, seven different acquired resistance mutations have been identified among crizotinib-resistant patients. The most frequently identified secondary mutations are L1196M and G1269A. In addition to these mutations, the 1151Tins, L1152R, C1156Y, G1202R, and S1206Y mutations have also been detected in crizotinib-resistant cancers. (PMID:22235099;PMID:22277784;PMID:24675041)', 'ALK+肺癌患者ALK基因p.G1202R发生点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_000331', 'ALK:nonsynonymous SNV:exon23:p.S1206Y:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.S1206Y', '.', 'Ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T and S1206Y mutations, not G1202R and F1174C (PMID:24675041).', 'ALK+肺癌患者ALK基因p.S1206Y发生点突变的非小细胞肺癌患者可能对塞瑞替尼（ceritinib）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20979473', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000332', 'ALK:nonsynonymous SNV:exon23:p.L1196M:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1196M', '.', 'Somatic kinase domain mutation in ALK might cause crizotinib resistance in ALK(+) NSCLC (PMID:20979473;PMID:22235099;PMID:22277784;PMID:23344087) 2.To date, seven different acquired resistance mutations have been identified among crizotinib-resistant patients. The most frequently identified secondary mutations are L1196M and G1269A. In addition to these mutations, the 1151Tins, L1152R, C1156Y, G1202R, and S1206Y mutations have also been detected in crizotinib-resistant cancers. (PMID:22235099;PMID:22277784;PMID:24675041)', 'ALK+肺癌患者ALK基因p.L1196M发生点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_000333', 'ALK:nonsynonymous SNV:exon23:p.L1196M:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1196M', '.', 'Ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T and S1206Y mutations, not G1202R and F1174C (PMID:24675041).', 'ALK+肺癌患者ALK基因p.L1196M发生点突变的非小细胞肺癌患者可能对塞瑞替尼（ceritinib）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22235099', '.', 'clinical study', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000334', 'ALK:nonsynonymous SNV:exon25:p.G1269A:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.G1269A', '.', 'Somatic kinase domain mutation in ALK might cause crizotinib resistance in ALK(+) NSCLC (PMID:22235099;PMID:23344087) 2. To date, seven different acquired resistance mutations have been identified among crizotinib-resistant patients. The most frequently identified secondary mutations are L1196M and G1269A. In addition to these mutations, the 1151Tins, L1152R, C1156Y, G1202R, and S1206Y mutations have also been detected in crizotinib-resistant cancers. (PMID:22235099;PMID:22277784;PMID:24675041)', 'ALK+肺癌患者ALK基因p.G1269A发生点突变的非小细胞肺癌患者对克唑替尼（crizotinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_000335', 'ALK:nonsynonymous SNV:exon25:p.G1269A:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.G1269A', '.', 'Ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T and S1206Y mutations, not G1202R and F1174C (PMID:24675041).', 'ALK+肺癌患者ALK基因p.G1269A发生点突变的非小细胞肺癌患者对塞瑞替尼（ceritinib）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'case report', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000336', 'ALK:nonsynonymous SNV:exon22:p.I1171T:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171T', '.', 'Somatic kinase domain mutation in ALK might cause crizotinib resistance in ALK(+) NSCLC (PMID:22235099;PMID:23344087). 2.Researcher found that a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib. Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response. Thermodynamics simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib (PMID:25228534).', 'ALK+肺癌患者ALK基因V1180L或I1171T发生点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）及alectinib耐药，但对塞瑞替尼（ceritinib）敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_000337', 'ALK:nonsynonymous SNV:exon22:p.I1171T:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171T', '.', 'Ceritinib effectively inhibits ALK harboring L1196M, G1269A, I1171T and S1206Y mutations, not G1202R and F1174C (PMID:24675041). 2. Researcher found that a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib. Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response. Thermodynamics simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib (PMID:25228534).', 'ALK+肺癌患者ALK基因V1180L或I1171T发生点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）及alectinib耐药，但对塞瑞替尼（ceritinib）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'case report', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000338', 'ALK:nonsynonymous SNV:exon23:p.V1180L:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.V1180L', '.', 'This mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response (PMID:25228534). 2. Researcher found that a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib. Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response. Thermodynamics simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib.(PMID:25228534)', 'ALK+肺癌患者ALK基因V1180L或I1171T点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）及alectinib耐药，但对塞瑞替尼（ceritinib）敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26032424', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'leukemia', 'leukemia', '白血病', '[ALK:FUS]', 'sensitivity', 'EVI_000339', 'ALK:nonsynonymous SNV:exon4:p.A348D:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.A348D', '.', 'These mutations are oncogenic, and cells transformed by these mutant versions of ALK are sensitive to crizotinib and other ALK inhibitors (PMID:26032424).', 'ALK抑制剂治疗用于肺癌ALK重排的患者。一项研究分析了ALK抑制剂克唑替尼对携带ALK突变的Ba/F3细胞的抑制作用。表达两种突变体的Ba/F3细胞对克唑替尼高度敏感，ALK A348D细胞的IC50为33 nM，ALK F856S细胞的IC50为6 nM。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26032424', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'leukemia', 'leukemia', '白血病', '[ALK:FUS]', 'sensitivity', 'EVI_000340', 'ALK:nonsynonymous SNV:exon15:p.F856S:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.F856S', '.', 'These mutations are oncogenic, and cells transformed by these mutant versions of ALK are sensitive to crizotinib and other ALK inhibitors (PMID:26032424).', 'ALK抑制剂治疗用于肺癌ALK重排的患者。一项研究分析了ALK抑制剂克唑替尼对携带ALK突变的Ba/F3细胞的抑制作用。表达两种突变体的Ba/F3细胞对克唑替尼高度敏感，ALK A348D细胞的IC50为33 nM，ALK F856S细胞的IC50为6 nM。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000341', 'ALK:nonframeshift insertion:exon22:p.T1151_L1152insT:.', 'ALK', 'nonframeshift insertion', 'Exact_pos', 'exon22', 'p.T1151_L1152insT', '.', 'To date, seven different acquired resistance mutations have been identified among crizotinib-resistant patients. The most frequently identified secondary mutations are L1196M and G1269A. In addition to these mutations, the 1151Tins, L1152R, C1156Y, G1202R, and S1206Y mutations have also been detected in crizotinib-resistant cancers (PMID:22235099;PMID:22277784;PMID:24675041).', '肿瘤细胞ALK基因p.T1151_L1152insT插入突变的可能对克唑替尼（crizotinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000342', 'ALK:nonframeshift insertion:exon22:p.T1151_L1152insT:.', 'ALK', 'nonframeshift insertion', 'Exact_pos', 'exon22', 'p.T1151_L1152insT', '.', 'C1156Y, G1202R, 1151T-ins, L1152R and F1174C mutations also conferred resistance to ceritinib, although ceritinib was still more potent than crizotinib against these mutations. (PMID:24675041)', '肿瘤细胞ALK基因p.T1151_L1152insT插入突变的可能对塞瑞替尼耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000343', 'ALK:nonsynonymous SNV:exon22:p.L1152R:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.L1152R', '.', 'C1156Y, G1202R, 1151T-ins, L1152R and F1174C mutations also conferred resistance to ceritinib, although ceritinib was still more potent than crizotinib against these mutations (PMID:24675041). 2. Somatic kinase domain mutation in ALK might cause crizotinib resistance in ALK(+) NSCLC. (PMID:21791641)', 'ALK+肺癌患者ALK基因p.L1152R点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000344', 'ALK:nonsynonymous SNV:exon22:p.L1152R:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.L1152R', '.', 'C1156Y, G1202R, 1151T-ins, L1152R and F1174C mutations also conferred resistance to ceritinib, although ceritinib was still more potent than crizotinib against these mutations (PMID:24675041).', 'ALK+肺癌患者ALK基因p.L1152R点突变的非小细胞肺癌患者可能对塞瑞替尼（ceritinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22072639', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'neuroblastoma', 'neuroblastoma', '脑部肿瘤', '[ALK:FUS]', 'sensitivity', 'EVI_000345', 'ALK:nonsynonymous SNV:exon25:p.R1275Q:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.R1275Q', '.', 'Crizotinib inhibited proliferation of cell lines expressing R1275Q-mutated ALK and a cell line with amplified and overexpressed wild-type ALK (PMID: 22072639).', '细胞学实验表明ALK的R1275Q突变可能对小分子抑制剂克唑替尼（Crizotinib）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'case report', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_000346', 'ALK:nonsynonymous SNV:exon23:p.V1180L:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.V1180L', '.', 'This mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response (PMID:25228534). 2.Researcher found that a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib. Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response. Thermodynamics simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib (PMID:25228534).', 'ALK+肺癌患者ALK基因V1180L和I1171T点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）及alectinib耐药，但对塞瑞替尼（ceritinib）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22072639', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'glioma', 'brain cancer', '脑部肿瘤', '[ALK:FUS]', 'resistance', 'EVI_000347', 'ALK:nonsynonymous SNV:exon23:p.F1174L:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', 'Cell lines harboring F1174L-mutated ALK were relatively resistant to crizotinib. Biochemical analyses revealed that this reduced susceptibility of F1174L-mutated ALK to crizotinib inhibition resulted from an increased adenosine triphosphate-binding affinity (as also seen in acquired resistance to epidermal growth factor receptor inhibitors). Thus, this effect should be surmountable with higher doses of crizotinib and/or with higher-affinity inhibitors.(PMID:22072639)', '细胞系研究发现携带ALK基因p.F1174L突变的肿瘤细胞需要更高剂量的克唑替尼才能产生抑制作用。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'case report', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000348', 'ALK:nonsynonymous SNV:exon22:p.I1171T:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171T', '.', 'Researcher found that a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib. Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response. Thermodynamics simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib.(PMID:25228534)', 'ALK+肺癌患者ALK基因V1180L或I1171T发生点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）及alectinib耐药，但对塞瑞替尼（ceritinib）敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'case report', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000349', 'ALK:nonsynonymous SNV:exon23:p.V1180L:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.V1180L', '.', 'Researcher found that a novel V1180L gatekeeper mutation from the cell line model and a second novel I1171T mutation from the patient who developed resistance to alectinib. Both ALK mutations conferred resistance to alectinib as well as to crizotinib, but were sensitive to ceritinib and other next-generation ALK-TKIs. Treatment of the patient with ceritinib led to a marked response. Thermodynamics simulation suggests that both mutations lead to distinct structural alterations that decrease the binding affinity with alectinib.(PMID:25228534)', 'ALK+肺癌患者ALK基因V1180L和I1171T点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）及alectinib耐药，但对塞瑞替尼（ceritinib）敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21030459', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'neuroblastoma', 'eye cancer', '炎性肌纤维母细胞瘤', '[ALK:FUS]', 'resistance', 'EVI_000350', 'ALK:nonsynonymous SNV:exon23:p.F1174L:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', 'The F1174L mutation, while activating, reduces ALK sensitivity to crizotinib in xenograft, cell-line and enzymatic assays (PMID:21030459). 2.Compared with the R1275Q activating mutation, the F1174L substitution increases ATP binding affinity, leading to crizotinib resistance that should be surmountable with higher doses of crizotinib and/or new higher-affinity inhibitors (PMID: 22072639).', '虽然ALK基因的p.F1174L突变导致蛋白激活，但其体外实验（动物模型、细胞、酶活）表明该突变对克唑替尼（Crizotinib）的抑制作用不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22277784', '.', 'clinical study', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000351', 'ALK:nonsynonymous SNV:exon23:p.S1206Y:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.S1206Y', '.', 'Somatic kinase domain mutation in ALK might cause crizotinib resistance in ALK(+) NSCLC. (PMID:22277784) 2.To date, seven different acquired resistance mutations have been identified among crizotinib-resistant patients. The most frequently identified secondary mutations are L1196M and G1269A. In addition to these mutations, the 1151Tins, L1152R, C1156Y, G1202R, and S1206Y mutations have also been detected in crizotinib-resistant cancers. (PMID:22277784;PMID:22235099;PMID:24675041)', 'ALK+肺癌患者ALK基因p.S1206Y点突变的非小细胞肺癌患者可能对克唑替尼（crizotinib）耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24185512', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000361', 'ESR1:nonsynonymous SNV:exon8:p.S463P:.', 'ESR1', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.S463P', '.', '.', 'ESR1基因的配体结合结构域（ligand-binding domain）的点突变可能导致肿瘤病人对抗雌激素治疗产生获得性耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24185512', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000362', 'ESR1:nonsynonymous SNV:exon8:p.V534E:.', 'ESR1', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.V534E', '.', '.', 'ESR1基因的配体结合结构域（ligand-binding domain）的点突变可能导致肿瘤病人对抗雌激素治疗产生获得性耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24185512', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000363', 'ESR1:nonsynonymous SNV:exon8:p.P535H:.', 'ESR1', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.P535H', '.', '.', 'ESR1基因的配体结合结构域（ligand-binding domain）的点突变可能导致肿瘤病人对抗雌激素治疗产生获得性耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24185510', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000364', 'ESR1:nonsynonymous SNV:exon8:p.L536Q:.', 'ESR1', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.L536Q', '.', '.', 'ESR1基因的配体结合结构域（ligand-binding domain）的点突变可能导致肿瘤病人对抗雌激素治疗产生获得性耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24185512', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000365', 'ESR1:nonsynonymous SNV:exon8:p.L536R:.', 'ESR1', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.L536R', '.', '.', 'ESR1基因的配体结合结构域（ligand-binding domain）的点突变可能导致肿瘤病人对抗雌激素治疗产生获得性耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24398047', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000366', 'ESR1:nonsynonymous SNV:exon8:p.Y537C:.', 'ESR1', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.Y537C', '.', '.', 'ESR1基因的配体结合结构域（ligand-binding domain）的点突变可能导致肿瘤病人对抗雌激素治疗产生获得性耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24398047', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000367', 'ESR1:nonsynonymous SNV:exon8:p.Y537S:.', 'ESR1', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.Y537S', '.', '.', 'ESR1基因的配体结合结构域（ligand-binding domain）的点突变可能导致肿瘤病人对抗雌激素治疗产生获得性耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24398047', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000368', 'ESR1:nonsynonymous SNV:exon8:p.Y537N:.', 'ESR1', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.Y537N', '.', '.', 'ESR1基因的配体结合结构域（ligand-binding domain）的点突变可能导致肿瘤病人对抗雌激素治疗产生获得性耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24398047', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000369', 'ESR1:nonsynonymous SNV:exon8:p.D538G:.', 'ESR1', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.D538G', '.', '.', 'ESR1基因的配体结合结构域（ligand-binding domain）的点突变可能导致肿瘤病人对抗雌激素治疗产生获得性耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22649091', '.', 'case report', '4', 'dasatinib', 'dasatinib', 'dasatinib', '达沙替尼', 'dasatinib|达沙替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000371', 'BRAF:nonsynonymous SNV:exon11:p.Y472C:.', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.Y472C', '.', 'A patient with a BRAF Y472C mutation, no common mutations in BRAF, EGFR or KRAS, and no ALK rearrangement responded to dasatinib, and the patient’s cancer has been inactive with no additional treatment for four years.', '一名携带BRAF基因Y472C突变的肺癌患者，使用达沙替尼后疾病在4年内保持稳定。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:9000575', '.', 'clinical study', '4', '[androgen deprivation therapy]', '[androgen deprivation therapy]', '[androgen deprivation therapy]', '【雄激素阻断治疗】', '[androgen deprivation therapy]|【雄激素阻断治疗】', '5', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'resistance', 'EVI_000372', 'AR:CNV:.:.:gain', 'AR', 'CNV', 'CNV', '.', '.', 'gain', 'AR amplification is significantly enriched in metastatic castration resistant prostate cancer (mCRPC) compared to primary untreated prostate cancer and is one mechanism of treatment resistance to androgen deprivation therapy (Koivisto et al. 1997; Kahn et al. 2014; Linja et al. 2001; TCGA 2015).', 'AR基因扩增可能是前列腺癌患者对雄激素阻断治疗产生耐药的原因之一。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27148695', '.', 'clinical study', '4', 'enzalutamide', 'enzalutamide', 'enzalutamide', '恩扎卢胺', 'enzalutamide|恩扎卢胺', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'resistance', 'EVI_000373', 'AR:CNV:.:.:gain', 'AR', 'CNV', 'CNV', '.', '.', 'gain', 'Amplification of the AR gene is associated with decreased response to enzalutamide (Wyatt et al. 2016) and is more common in patients progressing on enzalutamide than on other therapies (Azad et al. 2015).', '携带AR基因扩增的前列腺癌患者可能对enzalutamide的反应较弱。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25848357', '.', 'case report', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000374', 'FLT3:CNV:.:.:gain', 'FLT3', 'CNV', 'CNV', '.', '.', 'gain', 'The patient with metastatic colorectal cancer, aged 51 years and FoundationOne identified 6 genomic alterations (KRAS G12D, FLT3 amplification, BRCA1 Q1756fs*74, TP53 splice site 920-1G>T, APC E1379* and CDK8 amplification), showed significant symptomatic and laboratory improvement with sorafenib treatment (400 mg twice daily).', '一例具有FLT3扩增、KRAS激活突变以及CDK8扩增的直肠癌患者在使用索拉非尼后颅内病变迅速改善。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726788', '.', 'preclinical', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'medulloblastoma', 'brain cancer', '脑部肿瘤', 'na', 'resistance', 'EVI_000375', 'SMO:nonsynonymous SNV:exon8:p.D473H:.', 'SMO', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.D473H', '.', 'This alteration has been identified as an acquired mutation that confers resistance to Hedgehog (Hh) pathway inhibitor, vismodegib, in medulloblastoma (PMID:19726788).', '实验表明，该突变可能导致肿瘤对vismodegib产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ruxolitinib_Revised:03/2016', '.', 'guideline:FDA', '1', 'ruxolitinib', 'ruxolitinib', 'ruxolitinib', '芦可替尼', 'ruxolitinib|芦可替尼', '4', 'myelofibrosis', 'myelofibrosis', '骨癌', 'na', 'sensitivity', 'EVI_000376', 'JAK2:nonsynonymous SNV:exon14:p.V617F:.', 'JAK2', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.V617F', '.', '.', 'Ruxolitinib是一种激酶抑制剂,抑制Janus相关激酶(JAKs)JAK1和JAK2，介导对造血和免疫功能重要的若干细胞因子和生长因子信号。JAK信号涉及细胞因子受体对STATs的激活和随后STATs定位至细胞核，导致基因表达的调控。骨髓纤维化(MF)是一种骨髓增生性肿瘤(MPN)，已知与JAK1和JAK2信号失调有关联。在一个的JAK2 V617F-阳性MPN小鼠模型中，口服给予ruxolitinib可以预防脾肿大，脾中JAK2 V617F突变细胞优先减少和减低循环炎症细胞因子(如，TNF-α，IL-6)。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 33, 2015 (suppl; abstr TPS5608)', 'NCT02272790', 'clinical trial - phase2', '4', 'MK-1775', 'MK-1775', 'MK-1775', 'MK-1775', 'MK-1775|MK-1775', '2', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_000377', 'TP53:nonsynonymous SNV:.:.:inact', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '|http://meetinglibrary.asco.org/content/149027-156', '当肿瘤细胞DNA发生损伤时，可以通过相关蛋白信号通路的激活和磷酸化激活WEE1，随后WEE1通过磷酸化CDK1以抑制其活性而阻止与cyclin B的结合，导致G2/M检查点发挥作用阻滞细胞进入有丝分裂，直到DNA损伤修复完成。抑制Wee1则促进细胞提前进入M期，发生DNA修复异常，DNA损伤増加，染色体分散存在、组蛋白沮装异常，称为有丝分裂灾难，结果导致肿瘤细胞发生调亡。AZD1775（MK-1775）是首个Wee1抑制剂，临床前研究模型显示AZD1775单药就有抗肿瘤活性，与P53野生型细胞系比较，可以增加对P53缺失细胞的细胞毒性。ASCO2015年会报道的一项国际性II期临床试验共纳入了121例TP53突变的铂类敏感的卵巢癌患者，随机分为[AZD1775+紫杉醇和卡铂(P/C)组]和[P/C]组，两组分别有59例和62例。[AZD1775+P/C]组和[P/C]组患者的客观缓解率(ORR)分别为81.4%和75.8%、两组患者的最佳缓解率分别为81.35%和74.19%。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27410477 ', '.', 'clinical study', '4', 'GDC-0810', 'GDC-0810', 'GDC-0810', 'GDC-0810', 'GDC-0810|GDC-0810', '2', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);NA;NA]', 'sensitivity', 'EVI_000378', 'ESR1:nonsynonymous SNV:.:.:act', 'ESR1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'GDC-0810 has robust in vitro and in vivo activity against a variety of human breast cancer cell lines and patient derived xenografts, including a tamoxifen-resistant model and those that harbor ERα mutations. GDC-0810 is currently being evaluated in Phase II clinical studies in women with ER+ breast cancer.', 'GDC-0810对多种乳腺癌肿瘤细胞都具有抑制作用，包括对他莫昔芬已经耐受的、携带ESR1基因激活突变的肿瘤细胞。II期临床试验正在评估GDC-0801对携带ER+的乳腺癌患者的疗效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22238366', '.', 'preclinical', '4', 'ponatinib', 'ponatinib', 'ponatinib', '帕纳替尼', 'ponatinib|帕纳替尼', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000379', 'FGFR1:CNV:.:.:gain', 'FGFR1', 'CNV', 'CNV', '.', '.', 'gain', 'Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examined.', 'FGFR1-4属于受体酪氨酸激酶家族，其拷贝数增加可见于多种恶性肿瘤，通过激活下游MAPK，PI3K/AKT等通路，促进细胞增殖、侵袭等，与肿瘤发生发展密切相关。帕纳替尼是一种多靶点蛋白激酶抑制剂，包括FGFR。动物试验表明，帕纳替尼可以对荷瘤小鼠有较好的肿瘤抑制作用。相关临床试验正在进行中。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22238366', '.', 'preclinical', '4', 'ponatinib', 'ponatinib', 'ponatinib', '帕纳替尼', 'ponatinib|帕纳替尼', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000380', 'FGFR2:CNV:.:.:gain', 'FGFR2', 'CNV', 'CNV', '.', '.', 'gain', 'Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examined.', 'FGFR1-4属于受体酪氨酸激酶家族，其拷贝数增加可见于多种恶性肿瘤，通过激活下游MAPK，PI3K/AKT等通路，促进细胞增殖、侵袭等，与肿瘤发生发展密切相关。帕纳替尼是一种多靶点蛋白激酶抑制剂，包括FGFR。动物试验表明，帕纳替尼可以对荷瘤小鼠有较好的肿瘤抑制作用。相关临床试验正在进行中。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22238366', '.', 'preclinical', '4', 'ponatinib', 'ponatinib', 'ponatinib', '帕纳替尼', 'ponatinib|帕纳替尼', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000381', 'FGFR3:CNV:.:.:gain', 'FGFR3', 'CNV', 'CNV', '.', '.', 'gain', 'Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examined.', 'FGFR1-4属于受体酪氨酸激酶家族，其拷贝数增加可见于多种恶性肿瘤，通过激活下游MAPK，PI3K/AKT等通路，促进细胞增殖、侵袭等，与肿瘤发生发展密切相关。帕纳替尼是一种多靶点蛋白激酶抑制剂，包括FGFR。动物试验表明，帕纳替尼可以对荷瘤小鼠有较好的肿瘤抑制作用。相关临床试验正在进行中。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22238366', '.', 'preclinical', '4', 'ponatinib', 'ponatinib', 'ponatinib', '帕纳替尼', 'ponatinib|帕纳替尼', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000382', 'FGFR4:CNV:.:.:gain', 'FGFR4', 'CNV', 'CNV', '.', '.', 'gain', 'Daily oral dosing of ponatinib (10-30 mg/kg) to mice reduced tumor growth and inhibited signaling in all three tumor models examined.', 'FGFR1-4属于受体酪氨酸激酶家族，其拷贝数增加可见于多种恶性肿瘤，通过激活下游MAPK，PI3K/AKT等通路，促进细胞增殖、侵袭等，与肿瘤发生发展密切相关。帕纳替尼是一种多靶点蛋白激酶抑制剂，包括FGFR。动物试验表明，帕纳替尼可以对荷瘤小鼠有较好的肿瘤抑制作用。相关临床试验正在进行中。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20179196', '.', 'preclinical', '4', '[endocrine therapy]', '[endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'resistance', 'EVI_000383', 'FGFR1:CNV:.:.:gain', 'FGFR1', 'CNV', 'CNV', '.', '.', 'gain', 'amplification and overexpression of FGFR1 may be a major contributor to poor prognosis in luminal-type breast cancers, driving anchorage-independent proliferation and endocrine therapy resistance. ', 'FGFR1基因的扩增或者过表达与luminal型乳腺癌预后不良有关，可能导致肿瘤非依赖性生长和对内分泌治疗的耐药。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23238879', 'NCT00870337', 'clinical trial - phase2', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'endometrial cancer', 'Uterine Neoplasm', '子宫肿瘤', 'na', 'sensitivity', 'EVI_000384', 'PIK3CA:stopgain:exon21:p.W1051*:.', 'PIK3CA', 'stopgain', 'Exact_pos', 'exon21', 'p.W1051*', '.', '.', '一项临床Ⅱ期试验中，2名患者使用everolimus治疗后获得部分响应，测序发现这些患者PIK3CA基因发生截短突变（PIK3CA基因3\'末端的截断突变可能导致其编码蛋白的持续性活化）。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24569458', '.', 'case report', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'lung adenocarcinoma', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000387', 'ARAF:nonsynonymous SNV:exon7:p.S214C:.', 'ARAF', 'nonsynonymous SNV', 'Exact_pos', 'exon7', 'p.S214C', '.', 'One patient with advanced-stage lung adenocarcinoma, who was treated with oral sorafenib, demonstrated a near-complete clinical and radiographic remission for 5 years. Whole-genome sequencing and RNA sequencing of primary tumor and normal samples from this patient identified a somatic mutation, ARAF S214C, present in the cancer genome and expressed at high levels. ', '一名携带ARAF基因p.S214C突变的肺腺癌肿瘤患者对索拉非尼的治疗敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27761963', '.', 'preclinical', '4', 'celecoxib', 'celecoxib', 'celecoxib', '塞来昔布', 'celecoxib|塞来昔布', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000389', 'CTNNB1:nonsynonymous SNV:.:.:act', 'CTNNB1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'celecoxib suppressed cell proliferation and inhibited TCF7L2 expression with almost same strength as celecoxib. DM-celecoxib also inhibited the TCF-dependent transcription activity and suppressed the expression of Wnt/β-catenin target gene products cyclin D1 and survivin. ', 'CTNNB1是WNT信号通路中的重要成员，塞来昔布可以通过抑制WNT信号通路的异常活化抑制肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26244327 ', '.', 'clinical study', '4', 'Ibrutinib', 'Ibrutinib', 'ibrutinib', '伊布替尼', 'ibrutinib|伊布替尼', '4', 'Waldenström\'s Macroglobulinemia', 'lymphoma', '淋巴癌', 'na', 'sensitivity', 'EVI_000391', 'MYD88:nonsynonymous SNV:exon5:p.L265P:.', 'MYD88', 'nonsynonymous SNV', 'Exact_pos', 'exon5', 'p.L265P', '.', 'Whole-genome sequencing identified the MYD88 L265P variant as the most prevalent mutation in patients with Waldenström\'s macroglobulinemia (WM), a type of non-Hodgkin\'s lymphoma.1 In 93 to 97% of patients with this disorder, allele-specific polymerase-chain-reaction (AS-PCR) assays identified MYD88 L265P, which results from a T→C transversion at position 38182641 on chromosome 3p22.2. Signaling studies showed that the mutant protein that is encoded by MYD88 L265P triggers tumor growth through the activation of nuclear factor kappa light-chain enhancer of activated B cells (NF-κB) by Bruton\'s tyrosine kinase. This kinase is targeted by ibrutinib, a drug that is widely used in the treatment of B-cell cancers. In addition, CXCR4 WHIM mutations (associated with a syndrome called WHIM [warts, hypogammaglobulinemia, infections, and myelokathexis]) that were found almost exclusively in patients with WM who have the MYD88 L265P variant were found to convey resistance to ibrutinib.', '髓样分化因子88(myeloid differentiation factor，MyD88)是一种介导多数Toll样受体( Toll-like receptors，TLR) 、白介素-1受体( interleukin-1 receptor，IL-1R) 、白介素-18受体( interleukin-1 8 receptor，IL-18R) 细胞信号传导的重要衔接蛋白，在固有免疫中起着重要的作用。近年来有研究发现，在约90%的淋巴浆细胞淋巴瘤/华氏巨球蛋白血症和约29%的激活型弥漫大B细胞淋巴瘤等B细胞肿瘤中有功能活化的MYD88 L265P突变。突变的MYD88可以进一步使得布鲁顿氏酪氨酸激酶(Bruton\'s tyrosine kinase)磷酸化，从而激活下游信号通路。携带MYD88突变的肿瘤患者可能对BTK抑制剂敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26546295', '.', 'case report', '4', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '2', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000392', 'NTRK1:nonsynonymous SNV:exon14:p.G595R:.', 'NTRK1', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.G595R', '.', '.', 'Entrectinib是一种新型的泛-磷酸激酶抑制剂。一例携带LMNA-NTRK1融合基因的结直肠癌患者服用Entrectinib治疗后，患者获得部分缓解，肝部转移肿瘤缩小30%；临床效应持续4个月后但随后出现耐药性。体外肿瘤模型试验表明NTRK1发生了p.G595R和p.G667C突变而导致耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26546295', '.', 'case report', '4', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '2', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000393', 'NTRK1:nonsynonymous SNV:exon15:p.G667C:.', 'NTRK1', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.G667C', '.', '.', 'Entrectinib是一种新型的泛-磷酸激酶抑制剂。一例携带LMNA-NTRK1融合基因的结直肠癌患者服用Entrectinib治疗后，患者获得部分缓解，肝部转移肿瘤缩小30%；临床效应持续4个月后但随后出现耐药性。体外肿瘤模型试验表明NTRK1发生了p.G595R和p.G667C突变而导致耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2016) 27 (6): 416-454. 10.1093/annonc/mdw383', 'NCT01877083', 'clinical trial - phase2', '4', 'lenvatinib', 'lenvatinib', 'lenvatinib', '仑伐替尼', 'lenvatinib|仑伐替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000394', 'RET:FUS:.:.-RET:.', 'RET', 'FUS', 'FUS', '.', '.-RET', '.', 'LN showed promising clinical activity in pts with RET-positive NSCLC. For most pts, toxicities were manageable with dose modification. These results provide support for LN as a potential treatment for RET-positive NSCLC.', '一项临床试验表明，携带RET阳性的肿瘤患者可能对lenvatinib敏感。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23856031', '.', 'preclinical', '4', 'lenvatinib', 'lenvatinib', 'lenvatinib', '仑伐替尼', 'lenvatinib|仑伐替尼', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000395', 'RET:FUS:.:KIF5B-RET:.', 'RET', 'FUS', 'FUS', '.', 'KIF5B-RET', '.', 'Lenvatinib suppressed the growth of CCDC6-RET human thyroid and lung cancer cell lines, and as well, suppressed anchorage-independent growth and tumorigenicity of RET gene fusion-transformed NIH3T3 cells. These results demonstrate that lenvatinib can exert antitumor activity against RET gene fusion-driven tumor models by inhibiting oncogenic RET gene fusion signaling.', 'Lenvatinib对携带RET融合基因的肿瘤细胞有抑制作用。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('ASCO 2015 (abstr e15516)', 'NCT02122172', 'clinical trial - phase2', '4', 'afatinib   ', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'urothelial carcinoma', 'bladder cancer', '膀胱癌', 'na', 'sensitivity', 'EVI_000396', 'ERBB3:nonsynonymous SNV:exon7:p.G284R:.', 'ERBB3', 'nonsynonymous SNV', 'Exact_pos', 'exon7', 'p.G284R', '.', '.', '铂类药物耐药的泌尿道上皮癌患者常发生EGFR (ErbB1), HER2 (ErbB2), 和 ErbB3 拷贝数的变化。阿法替尼是一种Erbb蛋白家族抑制剂。一项临床Ⅱ期实验中对铂类耐药的泌尿道上皮癌患者采用阿法替尼治疗。14名患者中3名获得缓解，其中1名患者携带4个拷贝的HER2，获得部分缓解，且缓解时间为6.9个月；一名患者ErbB3 G284R突变，缓解时间为7个月；1名患者HER2扩拷贝数扩增至73个，且ErbB3 R103G突变，无进展生存期长达10.3个月。所以HER2拷贝数增加或携带ERBB3突变的上皮癌患者可以从阿法替尼治疗中获益。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('ASCO 2015 (abstr e15516)', 'NCT02122172', 'clinical trial - phase2', '4', 'afatinib   ', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'urothelial carcinoma', 'bladder cancer', '膀胱癌', 'na', 'sensitivity', 'EVI_000397', 'ERBB3:nonsynonymous SNV:exon3:p.R103G:.', 'ERBB3', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.R103G', '.', '.', '铂类药物耐药的泌尿道上皮癌患者常发生EGFR (ErbB1), HER2 (ErbB2), 和 ErbB3 拷贝数的变化。阿法替尼是一种Erbb蛋白家族抑制剂。一项临床Ⅱ期实验中对铂类耐药的泌尿道上皮癌患者采用阿法替尼治疗。14名患者中3名获得缓解，其中1名患者携带4个拷贝的HER2，获得部分缓解，且缓解时间为6.9个月；一名患者ErbB3 G284R突变，缓解时间为7个月；1名患者HER2扩拷贝数扩增至73个，且ErbB3 R103G突变，无进展生存期长达10.3个月。所以HER2拷贝数增加或携带ERBB3突变的上皮癌患者可以从阿法替尼治疗中获益。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18635227', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'Renal Cell Carcinoma', 'kidney cancer', '肾癌', 'na', 'sensitivity', 'EVI_000398', 'VHL:nonsynonymous SNV:.:.:inact', 'VHL', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'VHL基因失活突变大约见于75%的散发性肾癌，VHL基因失活突变对于抗血管形成治疗有一定的预测价值。回顾性分析发现，携带VHL基因失活突变(无义突变；移码突变等)的肾癌患者可能对VEGFR类抑制剂敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18635227', '.', 'clinical study', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'Renal Cell Carcinoma', 'kidney cancer', '肾癌', 'na', 'sensitivity', 'EVI_000399', 'VHL:nonsynonymous SNV:.:.:inact', 'VHL', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'VHL基因失活突变大约见于75%的散发性肾癌，VHL基因失活突变对于抗血管形成治疗有一定的预测价值。回顾性分析发现，携带VHL基因失活突变(无义突变；移码突变等)的肾癌患者可能对VEGFR类抑制剂敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18635227', '.', 'clinical study', '4', 'bevacizumab', 'bevacizumab', 'bevacizumab', '贝伐珠单抗', 'bevacizumab|贝伐珠单抗', '4', 'Renal Cell Carcinoma', 'kidney cancer', '肾癌', 'na', 'sensitivity', 'EVI_000400', 'VHL:nonsynonymous SNV:.:.:inact', 'VHL', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'VHL基因失活突变大约见于75%的散发性肾癌，VHL基因失活突变对于抗血管形成治疗有一定的预测价值。回顾性分析发现，携带VHL基因失活突变(无义突变；移码突变等)的肾癌患者可能对VEGFR类抑制剂敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18635227', '.', 'clinical study', '4', 'axitinib', 'axitinib', 'axitinib', '阿昔替尼', 'axitinib|阿昔替尼', '4', 'Renal Cell Carcinoma', 'kidney cancer', '肾癌', 'na', 'sensitivity', 'EVI_000401', 'VHL:nonsynonymous SNV:.:.:inact', 'VHL', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'VHL基因失活突变大约见于75%的散发性肾癌，VHL基因失活突变对于抗血管形成治疗有一定的预测价值。回顾性分析发现，携带VHL基因失活突变(无义突变；移码突变等)的肾癌患者可能对VEGFR类抑制剂敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24360397', '.', 'case report', '4', 'temsirolimus', 'temsirolimus', 'temsirolimus', '替西罗莫司', 'temsirolimus|替西罗莫司', '4', 'lung adenocarcinoma', 'lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000402', 'FBXW7:nonsynonymous SNV:exon9:p.R465H:.', 'FBXW7', 'nonsynonymous SNV', 'Exact_pos', 'exon9', 'p.R465H', '.', 'In a clinical case report, a patient with lung adenocarcinoma harboring FBXW7 R465H demonstrated tumor shrinkage when treated with Torisel (temsirolimus) (PMID: 24360397).', '一名携带FBXW7基因R465H突变的肺癌患者使用temsirolimus(替西罗莫司)后肿瘤缩小。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24586741', '.', 'clinical trial - phase1', '4', 'sirolimus', 'sirolimus', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'hepatocellular fibrolamellar carcinoma', 'liver cancer', '肝癌', 'na', 'sensitivity', 'EVI_000403', 'FBXW7:nonsynonymous SNV:.:.:inact', 'FBXW7', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a Phase I study, Rapamune (sirolimus) resulted in prolonged stable disease in a patient with hepatocellular fibrolamellar carcinoma harboring a FBXW7 mutation (PMID: 24586741). ', '在一项I期临床试验中，一名携带FBXW7基因失活突变的肝癌患者使用西罗莫司后病情稳定时间延长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23274910', '.', 'preclinical', '4', 'belinostat', 'belinostat', 'belinostat', '贝林司他', 'belinostat|贝林司他', '4', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000404', 'FBXW7:nonsynonymous SNV:.:.:inact', 'FBXW7', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a preclinical study, Beleodaq (belinostat) inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).', '一项临床前研究发现，Beleodaq(贝利司他)可抑制携带FBXW7失活突变的人类肿瘤细胞。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23274910', '.', 'preclinical', '4', 'entinostat', 'entinostat', 'entinostat', '恩替司他', 'entinostat|恩替司他', '2', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000405', 'FBXW7:nonsynonymous SNV:.:.:inact', 'FBXW7', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).', '一项临床前研究发现，恩替诺特(MS-275)可抑制携带FBXW7基因失活突变的晚期实体瘤细胞和血液癌细胞。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23274910', '.', 'preclinical', '4', 'entinostat', 'entinostat', 'entinostat', '恩替司他', 'entinostat|恩替司他', '2', '.', '.', '血液癌症', 'na', 'sensitivity', 'EVI_000406', 'FBXW7:nonsynonymous SNV:.:.:inact', 'FBXW7', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a preclinical study, entinostat (MS-275) inhibited cancer cells from advanced solid tumors and hematological cells harboring FBXW7 inactivating mutations in culture (PMID: 23274910).', '一项临床前研究发现，恩替诺特(MS-275)可抑制携带FBXW7基因失活突变的晚期实体瘤细胞和血液癌细胞。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23274910', '.', 'preclinical', '4', 'AR-42', 'AR-42', 'AR-42', 'AR-42', 'AR-42|AR-42', '2', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000407', 'FBXW7:nonsynonymous SNV:.:.:inact', 'FBXW7', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a preclinical study, AR-42 inhibited human cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).', '一项临床前研究发现，AR-42可抑制携带FBXW7基因失活突变的人类肿瘤细胞。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23274910', '.', 'preclinical', '4', 'AR-42', 'AR-42', 'AR-42', 'AR-42', 'AR-42|AR-42', '2', 'hematologic cancer', 'blood cancer', '血液癌症', 'na', 'sensitivity', 'EVI_000408', 'FBXW7:nonsynonymous SNV:.:.:inact', 'FBXW7', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a preclinical study, AR-42 inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).', '一项临床前研究发现，AR-42可抑制携带FBXW7基因失活突变的人类血液癌细胞。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23274910', '.', 'preclinical', '4', 'belinostat', 'belinostat', 'belinostat', '贝林司他', 'belinostat|贝林司他', '4', 'hematologic cancer', 'blood cancer', '血液癌症', 'na', 'sensitivity', 'EVI_000409', 'FBXW7:nonsynonymous SNV:.:.:inact', 'FBXW7', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a preclinical study, Beleodaq (belinostat) inhibited human hematologic cancer cell lines harboring FBXW7 inactivating mutations in culture (PMID: 23274910).', '一项临床前研究发现，Beleodaq (贝利司他)可抑制携带FBXW7基因失活突变的人类血液癌细胞。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23558291', '.', 'preclinical', '4', 'sirolimus', 'sirolimus', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'colon cancer', 'colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000411', 'FBXW7:nonsynonymous SNV:.:.:inact', 'FBXW7', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a preclinical study, Rapamune (sirolimus) inhibited epithelial-mesenchymal transition, motility, and invasiveness in colon cancer cells lacking FBXW7 in culture (PMID: 23558291)', '一项临床前研究发现，雷帕鸣（西罗莫司）可抑制携带FBXW7基因缺失的人类结肠癌细胞的转移性、运动性和侵袭性。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23274910', '.', 'preclinical', '4', 'vorinostat', 'vorinostat', 'vorinostat', '伏立诺他', 'vorinostat|伏立诺他', '4', 'head and neck squamous cell carcinoma', 'head and neck cancer', '头颈部肿瘤', 'na', 'sensitivity', 'EVI_000412', 'FBXW7:nonsynonymous SNV:exon10:p.R505C:.', 'FBXW7', 'nonsynonymous SNV', 'Exact_pos', 'exon10', 'p.R505C', '.', 'In a preclinical study, Zolinza (vorinostat) inhibited growth of a head and neck squamous cell carcinoma cell line harboring FBXW7 R505C in culture (PMID: 23274910).', '一项临床前研究发现，伏立诺他可抑制携带FBXW7 R505C突变的头颈部鳞癌细胞的生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18787170', '.', 'preclinical', '4', 'sirolimus', 'sirolimus', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000413', 'FBXW7:nonsynonymous SNV:.:.:inact', 'FBXW7', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a preclinical study, breast cancer cells harboring a FBXW7 mutation demonstrated sensitivity to Rapamune (sirolimus) in culture and in cell line xenograft models (PMID: 18787170).', '一项临床前研究发现，细胞培养和异体移植模型中，携带FBXW7基因突变的乳腺癌细胞系表现出对西罗莫司的敏感性。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 33, 2015 (suppl; abstr 2540)', '.', 'clinical trial - phase1', '4', 'CH5183284', 'CH5183284', 'debio1347', 'debio1347', 'debio1347|debio1347', '1', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000414', 'FGFR1:nonsynonymous SNV:.:.:act', 'FGFR1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR1 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540). http://meetinglibrary.asco.org/content/146931-156', 'I期临床试验表明，CH5183284可能对携带FGFR基因发生激活突变的肿瘤患者有效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26324363', 'NCT01703481', 'clinical trial - phase1', '4', 'JNJ-42756493', 'JNJ-42756493', 'erdafitinib', 'erdafitinib', 'erdafitinib|erdafitinib', '2', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000415', 'FGFR1:nonsynonymous SNV:.:.:act', 'FGFR1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a Phase I trial, JNJ-42756493 treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363). ', 'I期临床试验表明，JNJ-42756493可能对携带FGFR1-4基因发生激活突变的肿瘤患者有效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23658459', 'NCT00958971', 'clinical trial - phase2', '4', 'Dovitinib', 'dovitinib', 'dovitinib', '多韦替尼', 'dovitinib|多韦替尼', '2', 'Her2-receptor positive breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000416', 'FGFR1:CNV:.:.:gain', 'FGFR1', 'CNV', 'CNV', '.', '.', 'gain', 'In a Phase I trial, Dovitinib (TKI258) promoted 6-month stable disease in Erbb2 (Her2)-positive breast cancer patients with FGFR1 amplification (PMID: 23658459). ', 'I期临床试验分析表明，携带FGFR1基因扩增的肿瘤患者在使用多韦替尼治疗后疾病稳定。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19755509', '.', 'preclinical', '4', 'Selumetinib', 'Selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'stomach cancer', 'gastric cancer', '胃癌', 'na', 'resistance', 'EVI_000417', 'FGFR2:CNV:.:.:gain', 'FGFR2', 'CNV', 'CNV', '.', '.', 'gain', 'In a preclinical study, Selumetinib (AZD-6244) did not inhibit growth of gastric cancer cells with FGFR2 amplification in culture (PMID: 19755509).', '临床前研究表明，司美替尼无法抑制携带FGFR2基因扩增的胃癌细胞增殖。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22238366', '.', 'preclinical', '4', 'Ponatinib', 'ponatinib', 'ponatinib', '帕纳替尼', 'ponatinib|帕纳替尼', '4', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000418', 'FGFR2:nonsynonymous SNV:.:.:act', 'FGFR2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a preclinical study, Iclusig (ponatinib) inhibited receptor phosphorylation and cell growth in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).', '临床前研究表明，携带FGFR2基因激活突变的肿瘤患者可能对帕纳替尼敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22238366', '.', 'preclinical', '4', 'Dovitinib', 'dovitinib', 'dovitinib', '多韦替尼', 'dovitinib|多韦替尼', '2', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000419', 'FGFR2:nonsynonymous SNV:.:.:act', 'FGFR2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a preclinical study, Dovitinib (TKI258) inhibited receptor phosphorylation and cell proliferation in transformed cells expressing constitutively active FGFR2 in culture (PMID: 22238366).', '临床前研究表明，携带FGFR2基因激活突变的肿瘤患者可能对多韦替尼敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23658459', 'NCT00958971', 'clinical trial - phase2', '4', 'Dovitinib', 'dovitinib', 'dovitinib', '多韦替尼', 'dovitinib|多韦替尼', '2', 'Her2-receptor positive breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000420', 'FGFR2:CNV:.:.:gain', 'FGFR2', 'CNV', 'CNV', '.', '.', 'gain', 'In a Phase I trial, Dovitinib (TKI258) displayed safety and preliminary efficacy resulting in tumor regression of 28.2% and 18.5% in two patients with FGFR2 amplified Erbb2 (Her2)-receptor positive breast cancer (PMID: 23658459).', 'I期临床试验表明，携带FGFR2基因扩增的乳腺癌患者可能对多韦替尼敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24122810', '.', 'preclinical', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '2', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000421', 'FGFR2:FUS:.:FGFR2-AHCYL1:.', 'FGFR2', 'FUS', 'FUS', '.', 'FGFR2-AHCYL1', '.', 'In a preclinical study, treatment with BGJ398 prevented transformation of cells expressing FGFR2-AHCYL1 in culture (PMID: 24122810).', 'BGJ398（infigratinib）对携带FGFR2融合基因突变的肿瘤细胞有抑制作用。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26324363', 'NCT01703481', 'clinical trial - phase1', '4', 'JNJ-42756493', 'JNJ-42756493', 'erdafitinib', 'erdafitinib', 'erdafitinib|erdafitinib', '2', 'Advanced Solid Tumor', 'Solid Tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000422', 'FGFR2:nonsynonymous SNV:.:.:act', 'FGFR2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a Phase I trial, JNJ-42756493 treatment resulted in stable disease in 70% (16/23) and partial response in 22% (5/23) of patients with advanced solid tumors harboring FGFR 1-4 activating mutations (including amplifications, mutations and translocations), while no antitumor activity was observed in patients with unknown or no known changes in FGFR (PMID: 26324363).', 'I期临床试验表明，JNJ-42756493(erdafitinib)可能对携带FGFR1-4基因发生激活突变的肿瘤患者有效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26324363', 'NCT01703481', 'clinical trial - phase1', '4', 'JNJ-42756493', 'JNJ-42756493', 'erdafitinib', 'erdafitinib', 'erdafitinib|erdafitinib', '2', 'endometrial cancer', 'Uterine Neoplasm', '子宫肿瘤', '子宫内膜癌', 'sensitivity', 'EVI_000423', 'FGFR2:FUS:.:FGFR2-.:.', 'FGFR2', 'FUS', 'FUS', '.', 'FGFR2-.', '.', 'In a Phase I trial, JNJ-42756493 treatment resulted in partial response in an endometrial cancer patient harboring FGFR2 - BICC1 and FGFR2 - OFD1 fusions (PMID: 26324363).', '一项I期临床试验表明，携带FGFR2/FGFR3基因改变(包括拷贝数变异、易位和点突变)的肿瘤患者可能对JNJ-42756493(erdafitinib)敏感。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27179038', 'EudraCT No. 2011-003718-18', 'clinical trial - phase2', '4', 'AZD4547', 'AZD4547', 'AZD4547', 'AZD4547', 'AZD4547|AZD4547', '3', 'stomach cancer', 'gastric cancer', '胃癌', '胃癌', 'sensitivity', 'EVI_000424', 'FGFR2:CNV:.:.:gain', 'FGFR2', 'CNV', 'CNV', '.', '.', 'gain', 'In a Phase II clinical trial, treatment with AZD4547 resulted in a 33% (3/9) response rate in patients with FGFR2-amplified gastroesophageal cancer, and high-level amplification was associated with clinical response (PMID: 27179038).', '一项II期、开放性、非随机临床试验表明，携带高水平FGFR2扩增的晚期胃癌患者对AZD4547有较高的应答率，而低水平扩增的患者则无应答。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 33, 2015 (suppl; abstr 2540)', '.', 'clinical trial - phase1', '4', 'CH5183284', 'CH5183284', 'debio1347', 'debio1347', 'debio1347|debio1347', '1', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', '非特定癌症', 'sensitivity', 'EVI_000425', 'FGFR2:nonsynonymous SNV:.:.:act', 'FGFR2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR2 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).http://meetinglibrary.asco.org/content/146931-156', 'I期临床试验表明，CH5183284(debio1347)可能对携带FGFR基因发生激活突变的肿瘤患者有效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 34, 2016 (suppl; abstr 4517)', 'NCT01004224', 'clinical trial - phase1', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '2', 'transitional cell carcinoma', 'bladder cancer', '膀胱癌', '转移性尿路上皮癌患', 'sensitivity', 'EVI_000427', 'FGFR3:FUS:.:FGFR3-TACC3:.', 'FGFR3', 'FUS', 'FUS', '.', 'FGFR3-TACC3', '.', 'In a Phase I trial, BGJ398 treatment resulted in complete response in 4% (1/25) and partial response in 32% (8/25) of urothelial carcinoma patients harboring FGFR3 mutations or fusions (J Clin Oncol 34, 2016 (suppl; abstr 4517)). ', 'I期临床试验结果表明，携带FGFR3基因融合突变的转移性尿路上皮癌患者可能对BGJ398(infigratinib)敏感。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Cancer Res October 1, 2014 74:CT326', '.', 'clinical trial - phase1', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '2', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', '非特定癌症', 'sensitivity', 'EVI_000428', 'FGFR3:CNV:.:.:gain', 'FGFR3', 'CNV', 'CNV', '.', '.', 'gain', 'In a Phase I trial, BGJ398 demonstrated safety and preliminary efficacy in patients with select solid tumors harboring FGFR alterations (Cancer Res October 1, 2014 74:CT326).', 'I期临床试验结果表明，BGJ398(infigratinib)可能对携带FGFR3扩增突变的肿瘤患者敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 33, 2015 (suppl; abstr 2545)', 'NCT01752920', 'clinical trial - phase2', '4', 'ARQ 087', 'ARQ 087', 'ARQ-087', 'ARQ-087', 'ARQ-087|ARQ-087', '2', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', '非特定癌症', 'sensitivity', 'EVI_000429', 'FGFR3:CNV:.:.:gain', 'FGFR3', 'CNV', 'CNV', '.', '.', 'gain', 'In a Phase I trial, ARQ 087 demonstrated safety and preliminary efficacy in patients with advanced solid tumors, including tumors with FGFR pathway alterations (J Clin Oncol 33, 2015 (suppl; abstr 2545)).|http://meetinglibrary.asco.org/content/149025-156', 'I期临床试验结果表明，ARQ-087可能对携带FGFR3扩增突变的肿瘤患者敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26324363', 'NCT01703481', 'clinical trial - phase1', '4', 'JNJ-42756493', 'JNJ-42756493', 'erdafitinib', 'erdafitinib', 'erdafitinib|erdafitinib', '2', 'glioblastoma multiforme', 'brain cancer', '脑部肿瘤', '胶质母细胞瘤', 'sensitivity', 'EVI_000432', 'FGFR3:FUS:.:FGFR3-TACC3:.', 'FGFR3', 'FUS', 'FUS', '.', 'FGFR3-TACC3', '.', 'In a Phase I trial, JNJ-42756493 treatment resulted in partial response in a glioblastoma patient harboring FGFR3 - TACC3 fusion (PMID: 26324363).', 'I期临床试验结果表明，携带FGFR3基因融合突变的患者可能对JNJ-42756493（erdafitinib）敏感。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26324363', 'NCT01703481', 'clinical trial - phase1', '4', 'JNJ-42756493', 'JNJ-42756493', 'erdafitinib', 'erdafitinib', 'erdafitinib|erdafitinib', '2', 'urinary system cancer', 'bladder cancer', '膀胱癌', '尿路上皮癌', 'sensitivity', 'EVI_000433', 'FGFR3:FUS:.:FGFR3-TACC3:.', 'FGFR3', 'FUS', 'FUS', '.', 'FGFR3-TACC3', '.', 'In a Phase I clinical trial, JNJ-42756493 treatment resulted in partial response in 2 urothelial cancer patients harboring FGFR3-TACC3 (PMID: 26324363).', 'I期临床试验结果表明，携带FGFR3基因融合突变的患者可能对JNJ-42756493（erdafitinib）敏感。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26324363', 'NCT01703481', 'clinical trial - phase1', '4', 'JNJ-42756493', 'JNJ-42756493', 'erdafitinib', 'erdafitinib', 'erdafitinib|erdafitinib', '2', 'adrenal carcinoma', 'adrenal carcinoma', '肾癌', '肾上腺肿瘤', 'sensitivity', 'EVI_000434', 'FGFR3:FUS:.:FGFR3-TACC3:.', 'FGFR3', 'FUS', 'FUS', '.', 'FGFR3-TACC3', '.', 'In a Phase I trial, JNJ-42756493 treatment resulted tumor shrinkage and no disease progression for 10 months in an adrenal carcinoma patient harboring FGFR3 - TACC3 and FGFR2 - CCDC6 fusions (PMID: 26324363).', 'I期临床试验结果表明，携带FGFR3基因融合突变的患者可能对JNJ-42756493（erdafitinib）敏感。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540', '.', 'clinical trial - phase1', '4', 'CH5183284', 'CH5183284', 'debio1347', 'debio1347', 'debio1347|debio1347', '1', 'Advanced Solid Tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000435', 'FGFR3:nonsynonymous SNV:.:.:act', 'FGFR3', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a Phase I trial, Debio 1347 (CH5183284) dosing regimen has been determined in solid tumor patients with activating FGFR3 alterations (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2540).', 'I期临床试验结果表明，CH5183284(debio1347)可能对携带FGFR3激活突变的肿瘤患者敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21393331', '.', 'preclinical', '4', 'Ruxolitinib', 'ruxolitinib', 'ruxolitinib', '芦可替尼', 'ruxolitinib|芦可替尼', '4', 'cancer', 'cancer cell lines_', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000436', 'JAK2:nonsynonymous SNV:exon21:p.Y931C:.', 'JAK2', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.Y931C', '.', 'In a preclinical study, cells harboring JAK2 Y931C displayed resistance to ATP-competetive JAK inhibitors, such as Jakafi (Ruxolitinib) (PMID: 21393331).', '在临床前研究中，携带JAK2 Y931C突变的细胞显示对ATP竞争性JAK抑制剂的抗性，例如ruxolitinib。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27433843', '.', 'clinical study', '4', 'pembrolizumab', 'pembrolizumab', 'pembrolizumab', '帕博利珠单抗', 'pembrolizumab|帕博利珠单抗', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'resistance', 'EVI_000437', 'JAK2:nonsynonymous SNV:.:.:inact', 'JAK2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a clinical study, a melanoma patient treated with Keytruda (pembrolizumab) initially demonstrated a partial response, however, post 734 days developed disease progression due to a splice site mutation in JAK2, which resulted in an intron inclusion and an early stop codon (PMID: 27433843). ', '在临床研究中，用Keytruda(pembrolizumab)治疗的黑素瘤患者最初表现出部分应答，然而在734天后由于JAK2中的剪接位点突变而导致疾病进展，该突变导致JAK2蛋白的截断突变。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19661358', '.', 'case report', '4', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000438', 'KRAS:nonsynonymous SNV:exon2:p.Q22*:.', 'KRAS', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.Q22*', '.', 'A never-reported K-ras mutation (CAG>TAG) determining a premature stop signal at codon 22 (Gln22Stop) was found in a patient with metastatic colorectal cancer. BRAF and p53 were not found to be modified and microsatellite instability was not present. The patient, however, was found to be unresponsive to an anti-EGFR MAb treatment.', '在一名转移性结肠直肠癌的患者中发现了未报道的KRAS基因突变(Gln22Stop)。该患者并未发现BRAF和p53基因突变，也不存在微卫星不稳定性。但是，该患者对抗EGFR单抗类药物的治疗无反应。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22711607', '.', 'preclinical', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'glioma', 'brain cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000439', 'CDKN2B:nonsynonymous SNV:.:.:inact', 'CDKN2B', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在多形性胶质母细胞瘤(GBM)异种移植系中，CDK抑制剂Palbociclib能够有效抑制携带CDKN2A/B缺失、CDK4野生型、CDK4的单拷贝缺失或高水平CDK6扩增的肿瘤细胞增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25295501', '.', 'case report', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', '转移性间变性甲状腺癌', 'sensitivity', 'EVI_000440', 'TSC2:nonsynonymous SNV:.:.:inact', 'TSC2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '一名57岁的转移性间变性甲状腺癌女性患者，携带TSC2无义突变，参加了everolimus的II期临床试验，几乎完全缓解，持续18个月，随后疾病进展。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20048174', '.', 'clinical study', '4', 'sirolimus', 'sirolimus', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'Perivascular Epithelioid Cell Tumor;PEComa', 'solid tumor', '血管周上皮样细胞肿瘤', '血管周围上皮样细胞瘤', 'sensitivity', 'EVI_000441', 'TSC1:nonsynonymous SNV:.:.:inact', 'TSC1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Inhibition of mTORC1, pathologically activated by loss of the TSC1/TSC2 tumor suppressor complex, is a rational mechanistic target for therapy in PEComas. The clinical activity of sirolimus in PEComa additionally strengthens the pathobiologic similarities linking PEComas to other neoplasms related to the tuberous sclerosis complex.', '一项研究发现，3例转移性血管周围上皮样细胞瘤患者，进行口服mTOR抑制剂sirolimus治疗，观察到3例接受sirolimus治疗的患者有显著的临床响应，其中第3例患者的响应期持续超过14个月。3例患者均存在mTORC1活化，TSC1基因体细胞缺失被认为可能是患者3 mTOR信号通路的活化机制；患者1和患者2的mTOR激活机制尚不清楚，可能是由于TSC1或TSC2的小缺失或失活突变或错义突变引起的。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20048174', '.', 'clinical study', '4', 'sirolimus', 'sirolimus', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'Perivascular Epithelioid Cell Tumor;PEComa', 'solid tumor', '血管周上皮样细胞肿瘤', '血管周围上皮样细胞瘤', 'sensitivity', 'EVI_000442', 'TSC2:nonsynonymous SNV:.:.:inact', 'TSC2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Inhibition of mTORC1, pathologically activated by loss of the TSC1/TSC2 tumor suppressor complex, is a rational mechanistic target for therapy in PEComas. The clinical activity of sirolimus in PEComa additionally strengthens the pathobiologic similarities linking PEComas to other neoplasms related to the tuberous sclerosis complex.', '一项研究发现，3例转移性血管周围上皮样细胞瘤患者，进行口服mTOR抑制剂sirolimus治疗，观察到3例接受sirolimus治疗的患者有显著的临床响应，其中第3例患者的响应期持续超过14个月。3例患者均存在mTORC1活化，TSC1基因体细胞缺失被认为可能是患者3 mTOR信号通路的活化机制；患者1和患者2的mTOR激活机制尚不清楚，可能是由于TSC1或TSC2的小缺失或失活突变或错义突变引起的。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20442311', '.', 'preclinical', '4', 'niluotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000446', 'KIT:nonsynonymous SNV:exon17:p.D816V:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D816V', '.', 'Nilotinib inhibited the proliferation of imatinib-responsive V560G-KIT FDC-P1 and imatinib-resistant D816VKIT FDC-P1 cells with a GI50 of 4.9 and 630 nmol/L.In vivo activity of nilotinib in the treatment of tumors bearing V560G-KIT but not D816V-KIT and the utility of FDG-PET imaging to assess tumor response to this agent.', '一项临床前实验研究了nilotinib对KIT突变的胃肠道间质瘤细胞的抑制效应。nilotinib体外条件下能有效抑制携带imatinib敏感型KIT V560G突变或imatinib耐药型KIT D816V突变的肿瘤细胞增殖，且诱导V560G细胞的凋亡。但是在体内条件下，nilotinib仅抑制V560G而不抑制D816V。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17699867', '.', 'preclinical', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000447', 'KIT:nonsynonymous SNV:exon14:p.T670I:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.T670I', '.', 'The growth of KIT WK557-8del cells was inhibited by dasatinib with an IC50 of 58 nmol/L, whereas imatinib, nilotinib, and sorafenib had an IC50 of 460, 83, and 211 nmol/L, respectively.Dasatinib inhibited the imatinib less-sensitive Ba/F3 KITAY502-3ins.Imatinib-resistant gatekeeper single KITT670I and double KITWK557-8del/T670I mutants are responsive to sorafenib but resistant to dasatinib and nilotinib.Nilotinib inhibited cell growth and induced apoptosis of imatinib-resistant KIT V560del/V654A mutant cells at lower doses than dasatinib and sorafenib.Imatinib-resistant KITV559D/D820Y was sensitive to nilotinib,dasatinib, and sorafenib inhibition.', '携带KIT基因T670I突变的肿瘤患者可能对imatinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17699867', '.', 'preclinical', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000448', 'KIT:nonsynonymous SNV:exon17:p.D820Y:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D820Y', '.', 'The growth of KIT WK557-8del cells was inhibited by dasatinib with an IC50 of 58 nmol/L, whereas imatinib, nilotinib, and sorafenib had an IC50 of 460, 83, and 211 nmol/L, respectively.Dasatinib inhibited the imatinib less-sensitive Ba/F3 KITAY502-3ins.Imatinib-resistant gatekeeper single KITT670I and double KITWK557-8del/T670I mutants are responsive to sorafenib but resistant to dasatinib and nilotinib.Nilotinib inhibited cell growth and induced apoptosis of imatinib-resistant KIT V560del/V654A mutant cells at lower doses than dasatinib and sorafenib.Imatinib-resistant KITV559D/D820Y was sensitive to nilotinib,dasatinib, and sorafenib inhibition.', 'KIT基因p.D820Y突变可能与肿瘤患者对imatinib的耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17699867', '.', 'preclinical', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000449', 'KIT:nonsynonymous SNV:exon17:p.N822K:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.N822K', '.', 'The growth of KIT WK557-8del cells was inhibited by dasatinib with an IC50 of 58 nmol/L, whereas imatinib, nilotinib, and sorafenib had an IC50 of 460, 83, and 211 nmol/L, respectively.Dasatinib inhibited the imatinib less-sensitive Ba/F3 KITAY502-3ins.Imatinib-resistant gatekeeper single KITT670I and double KITWK557-8del/T670I mutants are responsive to sorafenib but resistant to dasatinib and nilotinib.Nilotinib inhibited cell growth and induced apoptosis of imatinib-resistant KIT V560del/V654A mutant cells at lower doses than dasatinib and sorafenib.Imatinib-resistant KITV559D/D820Y was sensitive to nilotinib,dasatinib, and sorafenib inhibition.', 'KIT基因N822K突变可能与肿瘤患者对imatinib的耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17699867', '.', 'preclinical', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000450', 'KIT:nonsynonymous SNV:exon14:p.T670I:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.T670I', '.', 'The growth of KIT WK557-8del cells was inhibited by dasatinib with an IC50 of 58 nmol/L, whereas imatinib, nilotinib, and sorafenib had an IC50 of 460, 83, and 211 nmol/L, respectively.Dasatinib inhibited the imatinib less-sensitive Ba/F3 KITAY502-3ins.Imatinib-resistant gatekeeper single KITT670I and double KITWK557-8del/T670I mutants are responsive to sorafenib but resistant to dasatinib and nilotinib.Nilotinib inhibited cell growth and induced apoptosis of imatinib-resistant KIT V560del/V654A mutant cells at lower doses than dasatinib and sorafenib.Imatinib-resistant KITV559D/D820Y was sensitive to nilotinib,dasatinib, and sorafenib inhibition.', '携带KIT基因T670I突变的肿瘤患者可能对sorafenib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17699867', '.', 'preclinical', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000451', 'KIT:nonsynonymous SNV:exon17:p.D820Y:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D820Y', '.', 'The growth of KIT WK557-8del cells was inhibited by dasatinib with an IC50 of 58 nmol/L, whereas imatinib, nilotinib, and sorafenib had an IC50 of 460, 83, and 211 nmol/L, respectively.Dasatinib inhibited the imatinib less-sensitive Ba/F3 KITAY502-3ins.Imatinib-resistant gatekeeper single KITT670I and double KITWK557-8del/T670I mutants are responsive to sorafenib but resistant to dasatinib and nilotinib.Nilotinib inhibited cell growth and induced apoptosis of imatinib-resistant KIT V560del/V654A mutant cells at lower doses than dasatinib and sorafenib.Imatinib-resistant KITV559D/D820Y was sensitive to nilotinib,dasatinib, and sorafenib inhibition.', '体外药物筛选结果显示，携带imatinib耐药突变(KIT V559D/D820Y)的胃肠间质瘤细胞系可能对nilotinib、dasatinib和sorafenib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17699867', '.', 'preclinical', '4', 'dasatinib', 'dasatinib', 'dasatinib', '达沙替尼', 'dasatinib|达沙替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000452', 'KIT:nonsynonymous SNV:exon17:p.D820Y:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D820Y', '.', 'The growth of KIT WK557-8del cells was inhibited by dasatinib with an IC50 of 58 nmol/L, whereas imatinib, nilotinib, and sorafenib had an IC50 of 460, 83, and 211 nmol/L, respectively.Dasatinib inhibited the imatinib less-sensitive Ba/F3 KITAY502-3ins.Imatinib-resistant gatekeeper single KITT670I and double KITWK557-8del/T670I mutants are responsive to sorafenib but resistant to dasatinib and nilotinib.Nilotinib inhibited cell growth and induced apoptosis of imatinib-resistant KIT V560del/V654A mutant cells at lower doses than dasatinib and sorafenib.Imatinib-resistant KITV559D/D820Y was sensitive to nilotinib,dasatinib, and sorafenib inhibition.', '体外药物筛选结果显示，携带imatinib耐药突变(KIT V559D/D820Y)的胃肠间质瘤细胞系可能对nilotinib、dasatinib和sorafenib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19461405', '.', 'case report', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'metastatic thymic carcinoma', 'thymic cancer', '胸腺肿瘤', '胸腺肿瘤', 'sensitivity', 'EVI_000455', 'KIT:nonsynonymous SNV:exon17:p.D820E:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D820E', '.', 'Tumor cells immunostained with cytokeratins,CD5, c-kit/CD117.molecular analysis by polymerase chain reactionbased direct sequencing showed a missense mutation in c-kit exon 17 (D820E).After 8 weeks of this treatment, a partial response was\ndetected by CT scan.Skin toxicity was resolved discontinuing sorafenib for 1 week every 4 weeks of treatment.', '一例转移性胸腺癌患者，经免疫沉淀检测到c-kit/CD117表达，随后发现KIT基因exon17 D820E突变。使用sorafenib这一KIT酪氨酸激酶抑制剂治疗该患者，8周后经CT扫描患者获得部分缓解，所有转移部位同样获得临床缓解，且皮肤毒副作用在停药后症状消失。所以患者可耐受sorafenib治疗并获益，同时毒副作用可控。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20633291', '.', 'preclinical', '4', 'motesanib', 'motesanib', 'motesanib', '莫替沙尼', 'motesanib|莫替沙尼', '3', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000458', 'KIT:nonframeshift insertion:exon9:.:exon9act', 'KIT', 'nonframeshift insertion', 'None_pos', 'exon9', '.', 'exon9act', '.', 'KIT和PDGFR激活突变可能是导致胃肠道间质瘤发病的重要机制。Motesanib是一种有效的VEGFR1/2/3、PDGFR和KIT的抑制剂。体内体外实验表明，motesanib可以抑制野生型或突变型KIT(V560D，552_559del，AYins503_504)的自磷酸化，抑制效果优于imatinib；且motesanib有效抑制imatinib耐药性KIT突变(近膜结构域双突变V560D/V654A和V560D/T670I，活化环突变Y823D)。所以motesanib在临床前试验中表现出对KIT的有效抑制活性，可能对胃肠道间质瘤中KIT的原发性或二次突变具有临床抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20633291', '.', 'preclinical', '4', 'motesanib', 'motesanib', 'motesanib', '莫替沙尼', 'motesanib|莫替沙尼', '3', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000460', 'KIT:nonsynonymous SNV:exon17:p.Y823D:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.Y823D', '.', 'Motesanib inhibited Kit autophosphorylation in CHO cell lines expressing primary activating mutations in exon 9 (AYins503-504, IC50 = 18 nM) and exon 11 (V560 D, IC50 = 5 nM; Δ552-559, IC50 = 1 nM). Motesanib also demonstrated activity against kinase domain mutations conferring imatinib resistance (V560D/V654A, IC50 = 77 nM; V560D/T670I, IC50 = 277 nM; Y823 D, IC50 = 64 nM) but failed to inhibit the imatinib-resistant D816V mutant (IC50 > 3000 nM).', 'KIT和PDGFR激活突变可能是导致胃肠道间质瘤发病的重要机制。Motesanib是一种有效的VEGFR1/2/3、PDGFR和KIT的抑制剂。体内体外实验表明，motesanib可以抑制野生型或突变型KIT(V560D，552_559del，AYins503_504)的自磷酸化，抑制效果优于imatinib；且motesanib有效抑制imatinib耐药性KIT突变(近膜结构域双突变V560D/V654A和V560D/T670I，活化环突变Y823D)。所以motesanib在临床前试验中表现出对KIT的有效抑制活性，可能对胃肠道间质瘤中KIT的原发性或二次突变具有临床抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22805292', 'NCT00687622', 'clinical trial - phase1', '4', 'trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000461', 'GNAQ:nonsynonymous SNV:.:.:act', 'GNAQ', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Among the 36 BRAF-mutant patients, 30 were BRAF-inhibitor naïve. Among these 30 patients, 2 complete responses (CRs) and 10 partial responses (PRs) were observed (unconfirmed response rate=40%) including 2 confirmed CRs and 8 confirmed PRs (confirmed response rate=33%); the median progression-free survival was 5·7 months (95% CI, 4·0–7·4). Among the 6 BRAF-mutant patients who received prior BRAF inhibitor therapy, 1 unconfirmed PR was observed. Among 39 patients with BRAF\nwild-type melanoma, 4 PRs (all confirmed) were observed (confirmed response rate=10%).', 'MEK突变会激活MAPK通路引起细胞增殖。Trametinib是一种有效的MEK抑制剂，体外条件下可抑制BRAF V600E突变的黑色素瘤细胞系，其中皮肤黑色素瘤患者主要携带BRAF突变，葡萄膜黑色素瘤患者携带GNAQ和GNA11突变。一项临床I期试验中，使用trametinib治疗黑色素瘤患者。30名携带BRAF突变且未接受BRAF抑制剂治疗的患者中2名获得完全缓解，10名部分缓解，缓解率达到40%；中位无进展生存期达到5.7个月，中位缓解持续时间为5.6个月；19名患者肿瘤缩小，6名携带BRAF V600K突变的患者中4名获得缓解。6名接受过BRAF抑制剂治疗的BRAF突变患者中1人获得缓解，缓解率为16.7%。BRAF野生型患者缓解率仅为10%(4名部分缓解，1名携带NRAS突变)。16名葡萄膜黑色素瘤患者(6名携带GNAQ和GNA11突变)中50%获得缓解(8名获得疾病稳定，获益最多的患者携带GNAQ突变)。所以BRAF突变且未接受BRAF抑制剂治疗的黑色素瘤患者以及携带GNAQ和GNA11突变的葡萄膜黑色素瘤患者可以从trametinib的治疗中获益。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22805292', 'NCT00687622', 'clinical trial - phase1', '4', 'trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000462', 'GNA11:nonsynonymous SNV:.:.:act', 'GNA11', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Among the 36 BRAF-mutant patients, 30 were BRAF-inhibitor naïve. Among these 30 patients, 2 complete responses (CRs) and 10 partial responses (PRs) were observed (unconfirmed response rate=40%) including 2 confirmed CRs and 8 confirmed PRs (confirmed response rate=33%); the median progression-free survival was 5·7 months (95% CI, 4·0–7·4). Among the 6 BRAF-mutant patients who received prior BRAF inhibitor therapy, 1 unconfirmed PR was observed. Among 39 patients with BRAF wild-type melanoma, 4 PRs (all confirmed) were observed (confirmed response rate=10%).', 'MEK突变会激活MAPK通路引起细胞增殖。Trametinib是一种有效的MEK抑制剂，体外条件下可抑制BRAF V600E突变的黑色素瘤细胞系，其中皮肤黑色素瘤患者主要携带BRAF突变，葡萄膜黑色素瘤患者携带GNAQ和GNA11突变。一项临床I期试验中，使用trametinib治疗黑色素瘤患者。30名携带BRAF突变且未接受BRAF抑制剂治疗的患者中2名获得完全缓解，10名部分缓解，缓解率达到40%；中位无进展生存期达到5.7个月，中位缓解持续时间为5.6个月；19名患者肿瘤缩小，6名携带BRAF V600K突变的患者中4名获得缓解。6名接受过BRAF抑制剂治疗的BRAF突变患者中1人获得缓解，缓解率为16.7%。BRAF野生型患者缓解率仅为10%(4名部分缓解，1名携带NRAS突变)。16名葡萄膜黑色素瘤患者(6名携带GNAQ和GNA11突变)中50%获得缓解(8名获得疾病稳定，获益最多的患者携带GNAQ突变)。所以BRAF突变且未接受BRAF抑制剂治疗的黑色素瘤患者以及携带GNAQ和GNA11突变的葡萄膜黑色素瘤患者可以从trametinib的治疗中获益。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:dinutuximab_Revised:03/2015', 'NCT00026312', 'guideline:FDA', '1', 'dinutuximab', 'dinutuximab', 'dinutuximab', 'dinutuximab', 'dinutuximab|dinutuximab', '4', 'neuroblastoma', 'neuroendocrine tumor', '神经母细胞瘤', '神经母细胞瘤', 'sensitivity', 'EVI_000463', 'MYCN:CNV:.:.:gain', 'MYCN', 'CNV', 'CNV', '.', '.', 'gain', '.', '在胚胎发育期，MYCN基因编码的产物在组织和器官的形成中具有重要的作用。MYCN蛋白可通过与DNA的特定区域结合调节其他基因的活性。MYCN基因属于原癌基因，当其发生突变时，原癌基因可引起正常的细胞变为癌细胞。MYCN基因扩增与各种肿瘤发生相关，特别是神经母细胞瘤。Dinutuximab适用于联合GM-CSF(粒细胞巨噬细胞集落刺激因子)、IL-2(白介素-2)和维甲酸，治疗先期接受过一线多药物、多手段治疗获得至少部分响应的高风险神经母细胞瘤儿童患者。25%的神经母细胞瘤患者携带MYCN基因扩增，MYCN基因扩增与严重性神经母细胞瘤具有相关性。在FDA label的临床试验中，46%参与试验的患者MYCN基因未发生扩增，36%的患者发生了MYCN基因扩增，19%的患者MYCN基因扩增状态未知。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:盐酸埃克替尼片_Revised: 08/2017|中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）', '.', 'guideline:NMPA', '1', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000464', 'EGFR:nonsynonymous SNV:exon18:p.G719.:.', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon18', 'p.G719.', '.', '埃克替尼(Icotinib)单药适用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌（NSCLC），既往化疗主要是指以铂类为基础的联合化疗。该适应症主要基于一项随机、对照、双盲研究中显示出盐酸埃克替尼（以下简称埃克替尼）对于这类患者无进展生存期的疗效不劣于吉非替尼，进一步的总生存数据尚在收集中。该研究中获得表皮生长因子受体（EGFR）突变检测结果的亚组人群初步分析结果显示，EGFR突变型患者疗效优于野生型患者，但对于EGFR突变型或野生型亚组人群的作用差别尚需进一步大样本研究证实。对于不同病理类型的亚组人群分析结果初步提示，非鳞癌患者疗效优于鳞癌患者。同样，对于鳞癌和非鳞癌亚组人群的作用差别尚需进一步大样本研究证实。建议医生结合同类药物相关研究结果及患者自身状况综合考虑适宜的治疗选择。', 'icotinib适用于治疗1.表皮生长因子受体(EGFR)基因具有敏感突变(L858R/19del/L861/G719等)的局部晚期或转移性非小细胞肺癌(NSCLC)患者的一线治疗；2.既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌(NSCLC)，既往化疗主要是指以铂类为基础的联合化疗。不推荐本品用于EGFR野生型非小细胞肺癌患者。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:盐酸埃克替尼片_Revised: 08/2017|中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）', '.', 'guideline:NMPA', '1', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000465', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '埃克替尼(Icotinib)单药适用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌（NSCLC），既往化疗主要是指以铂类为基础的联合化疗。该适应症主要基于一项随机、对照、双盲研究中显示出盐酸埃克替尼（以下简称埃克替尼）对于这类患者无进展生存期的疗效不劣于吉非替尼，进一步的总生存数据尚在收集中。该研究中获得表皮生长因子受体（EGFR）突变检测结果的亚组人群初步分析结果显示，EGFR突变型患者疗效优于野生型患者，但对于EGFR突变型或野生型亚组人群的作用差别尚需进一步大样本研究证实。对于不同病理类型的亚组人群分析结果初步提示，非鳞癌患者疗效优于鳞癌患者。同样，对于鳞癌和非鳞癌亚组人群的作用差别尚需进一步大样本研究证实。建议医生结合同类药物相关研究结果及患者自身状况综合考虑适宜的治疗选择。', 'icotinib适用于治疗1.表皮生长因子受体(EGFR)基因具有敏感突变(L858R/19del/L861/G719等)的局部晚期或转移性非小细胞肺癌(NSCLC)患者的一线治疗；2.既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌(NSCLC)，既往化疗主要是指以铂类为基础的联合化疗。不推荐本品用于EGFR野生型非小细胞肺癌患者。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:盐酸埃克替尼片_Revised: 08/2017|中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）', '.', 'guideline:NMPA', '1', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000468', 'EGFR:nonsynonymous SNV:exon21:p.L858R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '埃克替尼(Icotinib)单药适用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌（NSCLC），既往化疗主要是指以铂类为基础的联合化疗。该适应症主要基于一项随机、对照、双盲研究中显示出盐酸埃克替尼（以下简称埃克替尼）对于这类患者无进展生存期的疗效不劣于吉非替尼，进一步的总生存数据尚在收集中。该研究中获得表皮生长因子受体（EGFR）突变检测结果的亚组人群初步分析结果显示，EGFR突变型患者疗效优于野生型患者，但对于EGFR突变型或野生型亚组人群的作用差别尚需进一步大样本研究证实。对于不同病理类型的亚组人群分析结果初步提示，非鳞癌患者疗效优于鳞癌患者。同样，对于鳞癌和非鳞癌亚组人群的作用差别尚需进一步大样本研究证实。建议医生结合同类药物相关研究结果及患者自身状况综合考虑适宜的治疗选择。', 'icotinib适用于治疗1.表皮生长因子受体(EGFR)基因具有敏感突变(L858R/19del/L861/G719等)的局部晚期或转移性非小细胞肺癌(NSCLC)患者的一线治疗；2.既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌(NSCLC)，既往化疗主要是指以铂类为基础的联合化疗。不推荐本品用于EGFR野生型非小细胞肺癌患者。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:盐酸埃克替尼片_Revised: 08/2017|中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）', '.', 'guideline:NMPA', '1', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000469', 'EGFR:nonsynonymous SNV:exon21:p.L861Q:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L861Q', '.', '埃克替尼(Icotinib)单药适用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌（NSCLC），既往化疗主要是指以铂类为基础的联合化疗。该适应症主要基于一项随机、对照、双盲研究中显示出盐酸埃克替尼（以下简称埃克替尼）对于这类患者无进展生存期的疗效不劣于吉非替尼，进一步的总生存数据尚在收集中。该研究中获得表皮生长因子受体（EGFR）突变检测结果的亚组人群初步分析结果显示，EGFR突变型患者疗效优于野生型患者，但对于EGFR突变型或野生型亚组人群的作用差别尚需进一步大样本研究证实。对于不同病理类型的亚组人群分析结果初步提示，非鳞癌患者疗效优于鳞癌患者。同样，对于鳞癌和非鳞癌亚组人群的作用差别尚需进一步大样本研究证实。建议医生结合同类药物相关研究结果及患者自身状况综合考虑适宜的治疗选择。', 'icotinib适用于治疗1.表皮生长因子受体(EGFR)基因具有敏感突变(L858R/19del/L861/G719等)的局部晚期或转移性非小细胞肺癌(NSCLC)患者的一线治疗；2.既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌(NSCLC)，既往化疗主要是指以铂类为基础的联合化疗。不推荐本品用于EGFR野生型非小细胞肺癌患者。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:lumacaftor_Revised:05/2016', '.', 'guideline:FDA', '1', 'lumacaftor', 'lumacaftor', 'lumacaftor', 'lumacaftor', 'lumacaftor|lumacaftor', '4', 'cystic fibrosis', 'cystic fibrosis', '非特定癌症', 'na', 'sensitivity', 'EVI_000470', 'CFTR:nonframeshift deletion:exon11:p.F508del:.', 'CFTR', 'nonframeshift deletion', 'Exact_pos', 'exon11', 'p.F508del', '.', '.', 'Lumacaftor与ivacaftor联合用于治疗12岁以上囊性纤维化，患者为CFTR F508del突变纯合子型。局限性：lumacaftor治疗非CFTR F508del突变纯合子型患者的有效性和安全性尚未建立。Orkambi（lumacaftor 200 mg/ivacaftor 125 mg）现已批准用于治疗12岁及以上患有F508del突变的患者的囊性纤维化（CF），该突变导致产生异常蛋白质，从而破坏水和氯化物的运输方式身体。有两个拷贝的这个突变（一个从每个父母继承的）是CF的主要原因。在2108名具有F508del突变的12岁以上CF患者，研究了Orkambi的安全性和有效性。CF患者服用Orkambi的患者，每12小时服用两片药物，与服用安慰剂的患者相比，肺功能改善。除了具有F508del突变的患者，Orkambi的疗效和安全性尚未确定。如果患者的基因型未知，则应使用FDA批准的CF突变检测来检测CFTR基因的两个等位基因上F508del突变的存在。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19915144', '.', 'preclinical', '4', 'Selumetinib', 'selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'melanoma', 'melanoma', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000473', 'MAP2K1:nonsynonymous SNV:exon3:p.P124L:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.P124L', '.', 'In a preclinical study, transformed human melanoma cells expressing MAP2K1 P124L demonstrated resistance to the MEK inhibitor, Selumetinib (AZD6244) (PMID: 19915144).', '在临床前研究中，携带MAP2K1 P124L突变的黑色素瘤细胞系对MEK抑制剂selumetinib具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26582713', '.', 'preclinical', '4', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901|PD-0325901', '2', 'lung adenocarcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000474', 'MAP2K1:nonsynonymous SNV:exon2:p.Q56P:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.Q56P', '.', 'In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to PD-0325901, resulting in decreased cell viability (PMID: 26582713).', '在临床前研究中，携带MAP2K1 Q56P突变的肺腺癌细胞系显示对PD-0325901敏感，导致细胞活力降低。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26582713', '.', 'preclinical', '4', 'Trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'lung adenocarcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000475', 'MAP2K1:nonsynonymous SNV:exon2:p.Q56P:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.Q56P', '.', 'In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Mekinist (trametinib), resulting in decreased cell viability (PMID: 26582713).', '在临床前研究中，携带MAP2K1 Q56P突变的肺腺癌细胞系显示对Mekinist(trametinib)敏感，导致细胞活力降低。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22327936', '.', 'preclinical', '4', 'Selumetinib', 'selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'stomach cancer', 'cancer cell lines_gastric', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000476', 'MAP2K1:nonsynonymous SNV:exon2:p.Q56P:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.Q56P', '.', 'In a preclinical study, selumetinib (AZD6244) inhibited growth of a gastric cancer cell line that requires MAP2K1 Q56P and inhibited phosphorylation of ERK in these cells (PMID: 22327936).', '在临床前研究中，selumetinib(AZD6244)抑制携带MAP2K1 Q56P突变的胃癌细胞系的生长，并抑制这些细胞中ERK的磷酸化。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26582713', '.', 'preclinical', '4', 'Refametinib', 'refametinib', 'refametinib', 'refametinib', 'refametinib|refametinib', '2', 'lung adenocarcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000477', 'MAP2K1:nonsynonymous SNV:exon2:p.Q56P:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.Q56P', '.', 'In a preclinical study, a lung adenocarcinoma cell line harboring MAP2K1 Q56P demonstrated sensitivity to Refametinib (BAY86-9766), resulting in decreased cell viability (PMID: 26582713).', '在临床前研究中，携带MAP2K1 Q56P突变的肺腺癌细胞系显示对Refametinib(BAY86-9766)敏感，导致细胞存活力降低。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26566875', '.', 'clinical study', '4', 'Cobimetinib', 'cobimetinib', 'cobimetinib', 'cobimetinib', 'cobimetinib|cobimetinib', '4', 'lymphatic system cancer', 'lymphatic system cancer', '淋巴癌', '脂质肉芽肿病', 'sensitivity', 'EVI_000478', 'MAP2K1:nonsynonymous SNV:exon2:p.Q56P:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.Q56P', '.', 'In a clinical study, a patient with refractory Erdheim–Chester disease harboring a MAP2K1 Q56P mutation had a reduction of lymphatic infiltrates to background within a month of receiving Cotellic (cobimetinib) therapy (PMID: 26566875).', '在临床研究中，具有MAP2K1 Q56P突变的难治性Erdheim-Chester病患者在接受Cotellic(cobimetinib)治疗的一个月内淋巴浸润减少到背景SUV值。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24463458', '.', 'preclinical', '4', 'Dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000479', 'MAP2K1:nonsynonymous SNV:exon2:p.K57E:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57E', '.', 'In a preclinical study, MAP2K1 (MEK1) K57E mutations restored extracellular signal–regulated kinase (ERK) activation in the presence of Tafinlar (dabrafenib) in cultured melanoma cell lines (PMID: 24463458).', '在临床前研究中，MAP2K1(MEK1)K57E突变的黑色素瘤细胞系中在Tafinlar(dabrafenib)存在下恢复细胞外信号调节激酶（ERK）活化，提示可能对该药物耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26644315', '.', 'preclinical', '4', 'Panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'cancer cell lines_colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000480', 'MAP2K1:nonsynonymous SNV:exon2:p.K57T:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57T', '.', 'In a preclinical study, a colorectal cancer cell line expressing MAP2K1 K57T was resistant to Vectibix (panitumumab) in culture (PMID: 26644315).', '在临床前研究中，携带MAP2K1 K57T突变的结肠直肠癌细胞系对培养物中的panitumumab具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26644315', '.', 'preclinical', '4', 'Panitumumab,Trametinib', 'trametinib', 'trametinib + panitumumab', '曲美替尼 + 帕尼单抗', 'trametinib + panitumumab|曲美替尼 + 帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000481', 'MAP2K1:nonsynonymous SNV:exon2:p.K57T:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57T', '.', 'In a clinical case study, a combination of Vectibix (panitumumab) and Mekinist (trametinib) caused tumor regression in a patient’s colorectal cancer metastases harboring MAP2K1 K57T after being identified pre-clinically as a combination likely to inhibit MAP2K1 K57T expressing colorectal cancer (PMID: 26644315).', '在临床病例研究中，Vectibix(panitumumab)和Mekinist(trametinib)的组合可以抑制MAP2K1 K57T突变的结肠直肠癌细胞的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26644315', '.', 'preclinical', '4', 'Cetuximab,Trametinib', 'trametinib', 'trametinib + cetuximab', '曲美替尼 + 西妥昔单抗', 'trametinib + cetuximab|曲美替尼 + 西妥昔单抗', '4', 'colorectal cancer', 'cancer cell lines_colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000482', 'MAP2K1:nonsynonymous SNV:exon2:p.K57T:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57T', '.', 'In a preclinical study, Erbitux (cetuximab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57T in culture (PMID: 26644315).', '在临床前研究中，cetuximab和trametinib组合可以抑制MAP2K1 K57T突变的结肠直肠癌细胞增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26644315', '.', 'preclinical', '4', 'Cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000483', 'MAP2K1:nonsynonymous SNV:exon2:p.K57T:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57T', '.', 'In a clinical case study, a patient with colorectal cancer developed liver metastases harboring MAP2K1 K57T that were insensitive to Erbitux (cetuximab) treatment and the mutation was confirmed to cause resistance in human colorectal cancer cell lines in culture (PMID: 26644315).', '在临床病例研究中，携带MAP2K1 K57T突变的结肠直肠癌细胞对cetuximab治疗不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24265153', '.', 'preclinical', '4', 'Dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000484', 'MAP2K1:nonsynonymous SNV:exon2:p.V60E:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.V60E', '.', 'In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Tafinlar (dabrafenib) in culture (PMID: 24265153).', '在临床前研究中，携带MAP2K1 V60E突变的黑素瘤细胞系对培养物中的Tafinlar(dabrafenib)具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24265153', '.', 'preclinical', '4', 'Trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000485', 'MAP2K1:nonsynonymous SNV:exon2:p.V60E:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.V60E', '.', 'In a preclinical study, a melanoma cell line expressing MAP2K1 V60E demonstrated resistance to Mekinist (trametinib) in culture (PMID: 24265153).', '在临床前研究中，携带MAP2K1 V60E突变的黑素瘤细胞系对培养物中的Mekinist(trametinib)具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26582713', '.', 'preclinical', '4', 'Trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'colorectal cancer', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000486', 'MAP2K1:nonsynonymous SNV:exon2:p.F53L:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.F53L', '.', 'In a preclinical study, a colorectal cancer cell line harboring MAP2K1 F53L demonstrated sensitivity to Mekinist (trametinib) in culture, resulting in decreased cell viability (PMID: 26582713).', '在临床前研究中，携带MAP2K1 F53L突变的结肠直肠癌细胞系显示对培养物中的Mekinist(trametinib)敏感，导致细胞存活力降低。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26566875', '.', 'clinical study', '4', 'Trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'lymphatic system cancer', 'lymphatic system cancer', '淋巴癌', '脂质肉芽肿病', 'sensitivity', 'EVI_000487', 'MAP2K1:nonsynonymous SNV:exon2:p.K57N:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57N', '.', 'In a clinical study, a patient with refractory Erdheim–Chester disease harboring a MAP2K1 K57N mutation had a sustained clinical response to Mekinist (trametinib) for over 6 months (PMID: 26566875).', '在临床研究中，携带MAP2K1 K57N突变的难治性Erdheim-Chester病患者使用Mekinist(trametinib)治疗后，获得了超过6个月的临床响应。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26644315', '.', 'preclinical', '4', 'Panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'cancer cell lines_colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000488', 'MAP2K1:nonsynonymous SNV:exon2:p.K57N:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57N', '.', 'In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Vectibix (panitumumab) in culture (PMID: 26644315).', '在临床前研究中，携带MAP2K1 K57N突变的结肠直肠癌细胞系对培养物中的panitumumab具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26644315', '.', 'preclinical', '4', 'Panitumumab,Trametinib', 'trametinib', 'trametinib + panitumumab', '曲美替尼 + 帕尼单抗', 'trametinib + panitumumab|曲美替尼 + 帕尼单抗', '4', 'colorectal cancer', 'cancer cell lines_colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000489', 'MAP2K1:nonsynonymous SNV:exon2:p.K57N:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57N', '.', 'In a preclinical study, Vectibix (panitumumab) and Mekinist (trametinib) inhibited colorectal cancer cell lines expressing MAP2K1 K57N in culture (PMID: 26644315).', '在临床前研究中，Vectibix(panitumumab)和Mekinist(trametinib)组合可以抑制MAP2K1 K57N突变的结肠直肠癌细胞增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18632602', '.', 'preclinical', '4', 'Selumetinib', 'selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'lung adenocarcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000490', 'MAP2K1:nonsynonymous SNV:exon2:p.K57N:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57N', '.', 'In a preclinical study, selumetinib (AZD6244) inhibited phosphorylation of ERK in cells expressing MAP2K1 K57N and inhibited MAP2K1 K57N-dependent growth in cell culture (PMID: 18632602).', '在临床前研究中，selumetinib(AZD6244)能够抑制携带MAP2K1 K57N突变的细胞中的ERK磷酸化，并抑制肿瘤细胞的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26644315', '.', 'preclinical', '4', 'Cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'cancer cell lines_colorectal cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000491', 'MAP2K1:nonsynonymous SNV:exon2:p.K57N:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.K57N', '.', 'In a preclinical study, colorectal cancer cell lines expressing MAP2K1 K57N were insensitive to Erbitux (cetuximab) in culture (PMID: 26644315).', '在临床前研究中，携带MAP2K1 K57N突变的结肠直肠癌细胞系对培养物中的cetuximab具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26545934', '.', 'preclinical', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'cancer cell lines_lung', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000499', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'In HER2‐altered NSCLC cells (H2170, Calu‐3, and H1781), afatinib downregulated the phosphorylation of HER2 and EGFR as well as their downstream signaling, and induced an antiproliferative effect through G1 arrest and apoptotic cell death. ', '细胞学试验表明，在具有ERBB2基因激活突变的肿瘤细胞中，afatinib可以下调EGFR和ERBB2信号通路，产生抗肿瘤作用。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21531761', '.', 'preclinical', '4', 'niclosamide', 'niclosamide', 'niclosamide', 'niclosamide', 'niclosamide|niclosamide', '2', 'colorectal cancer', 'cancer cell lines_colorectal cancer ', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000500', 'APC:nonsynonymous SNV:.:.:inact', 'APC', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在临床前研究中，niclosamide可以抑制携带APC突变的结肠直肠癌细胞的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20811697', '.', 'preclinical', '4', 'Vandetanib', 'Vandetanib', 'vandetanib', '凡德他尼', 'vandetanib|凡德他尼', '4', 'colon cancer', 'cancer cell lines_colorectal cancer ', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000501', 'APC:nonsynonymous SNV:.:.:inact', 'APC', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在临床前研究中，Caprelsa(vandetanib)可以抑制APC缺陷小鼠模型中的葡聚糖硫酸钠诱导的肿瘤的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17909047', '.', 'preclinical', '4', 'Celecoxib + Erlotinib', 'celecoxib', 'celecoxib', '塞来昔布', 'celecoxib|塞来昔布', '4', 'colorectal cancer', 'cancer cell lines_colorectal cancer ', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000502', 'APC:nonsynonymous SNV:.:.:inact', 'APC', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在临床前研究中，celecoxib与Tarceva(erlotinib)的组合可以显著减小携带APC失活突变的结肠直肠癌异种移植模型的肿瘤大小。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20473900', '.', 'preclinical', '4', 'Dasatinib', 'dasatinib', 'dasatinib', '达沙替尼', 'dasatinib|达沙替尼', '4', 'colorectal cancer', 'cancer cell lines_colorectal cancer ', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000503', 'APC:nonsynonymous SNV:.:.:inact', 'APC', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在临床前研究中，Sprycel(dasatinib)和姜黄素的组合可以抑制携带APC突变的结肠直肠癌小鼠模型中肿瘤的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18768809', '.', 'preclinical', '4', 'Sirolimus', 'sirolimus', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', 'colon cancer', 'cancer cell lines_colorectal cancer ', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000507', 'APC:nonsynonymous SNV:.:.:inact', 'APC', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '临床前试验显示，在家族性腺瘤性息肉病和具有APC缺陷型肿瘤的结肠癌的小鼠模型中，sirolimus可以有效减小肿瘤的大小。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23724914', 'NCT00585195', 'clinical trial - phase1', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'lung adenocarcinoma', 'lung cancer', '肺癌', '肺腺癌', 'resistance', 'EVI_000508', 'ROS1:nonsynonymous SNV:exon38:p.G2032R:.', 'ROS1', 'nonsynonymous SNV', 'Exact_pos', 'exon38', 'p.G2032R', '.', 'We performed a biopsy of a resistant tumor and identified an acquired mutation leading to a glycine-to-arginine substitution at codon 2032 in the ROS1 kinase domain. Although this mutation does not lie at the gatekeeper residue, it confers resistance to ROS1 kinase inhibition through steric interference with drug binding. ', '研究发现，一名对crizotinib发生耐药的转移性肺腺癌患者携带ROS1基因p.G2032R突变，该突变可能干扰药物与ROS1蛋白的结合。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25688157', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'cancer cell lines_lung', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000509', 'ROS1:nonsynonymous SNV:exon41:p.L2155S:.', 'ROS1', 'nonsynonymous SNV', 'Exact_pos', 'exon41', 'p.L2155S', '.', 'The ROS1 G2032R mutation was identified in crizotinib-resistant tumors from one patient. Furthermore, HCC78CR1 and CR2 cells harbored a novel ROS1 L2155S mutation (73.3% and 76.2%, respectively). ROS1 G2032R and L2155S mutations conferred resistance to crizotinib in Ba/F3 cells.', '携带ROS1基因融合的肿瘤对crizotinib治疗敏感，但ROS1基因上的点突变L2155S会阻碍抑制剂与融合蛋白的结合，从而导致crizotinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24218589', '.', 'preclinical', '4', 'foretinib', 'foretinib', 'foretinib', 'foretinib', 'foretinib|foretinib', '2', 'cancer cell lines_lung', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000510', 'ROS1:FUS::.-ROS1:', 'ROS1', 'FUS', 'FUS', '.', '.-ROS1', '.', 'this alteration exhibits sensitivity to another ROS1 inhibitor, foretinib, though the potency of foretinib against CD74-ROS1 G2032R is less than CD74-ROS1 wild-type (PMID:24218589). ', 'Foretinib可能对携带ROS1融合基因突变并具有G2032R点突变的肿瘤细胞有抑制作用。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'Brigatinib', 'brigatinib', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'solid tumor', 'solid tumor', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000514', 'ROS1:FUS:.:.-ROS1:.', 'ROS1', 'FUS', 'FUS', '.', '.-ROS1', '.', 'In a preclinical study, Brigatinib (AP26113) inhibited growth of transformed cells expressing ROS1 fusion proteins in culture', '在临床前研究中，brigatinib(AP26113)可以抑制携带ROS1融合基因的肿瘤细胞的增殖。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22990016', '.', 'preclinical', '4', 'Quizartinib', 'quizartinib', 'quizartinib', '奎扎替尼', 'quizartinib|奎扎替尼', '3', 'bone marrow cancer', 'bone cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000516', 'CBL:nonsynonymous SNV:.:.:inact', 'CBL', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a preclinical study, Quizartinib (AC220) reduced white blood cell counts and decreased myeloid cell invasion in a CBL mutant mouse model with myeloproliferative disorder (PMID: 22990016).', '在临床前研究中，在具有骨髓增殖性疾病(MPD)的CBL突变小鼠模型中，quizartinib(AC220)可以减少白细胞计数及骨髓细胞侵袭。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('ASH meeting, Dec 2014, abstract #389', '.', 'clinical trial - phase2', '4', 'Crenolanib', 'crenolanib', 'crenolanib', 'crenolanib', 'crenolanib|crenolanib', '3', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'sensitivity', 'EVI_000517', 'FLT3:nonsynonymous SNV:exon20:p.D835.:.', 'FLT3', 'nonsynonymous SNV', 'Partial_pos', 'exon20', 'p.D835.', '.', 'In a Phase II trial, relapsed or refractory acute myeloid leukemia patients harboring FLT3 activating mutations without a history of FLT3 therapy demonstrated a significantly greater overall survival and event free survival compared to those that had prior FLT3 therapy when treated with Crenolanib (ASH meeting, Dec 2014, abstract #389).http://www.bloodjournal.org/content/124/21/389?sso-checked=true', '在II期试验中，携带FLT3活化突变而未接受FLT3抑制剂治疗的复发性或难治性急性髓性白血病患者，使用crenolanib治疗显示出更高的总体存活和无事件存活。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23691988', '.', 'clinical trial - phase1', '4', 'Ponatinib', 'ponatinib', 'ponatinib', '帕纳替尼', 'ponatinib|帕纳替尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000518', 'FLT3:nonframeshift insertion:exon14:.:ITD', 'FLT3', 'nonframeshift insertion', 'None_pos', 'exon14', '.', 'ITD', 'In a Phase I trial, Iclusig (ponatinib) resulted in a 25% (3/12) overall response rate, indicated as partial remission or better, in acute myeloid leukemia patients harboring FLT3-ITD (PMID: 23691988).', '在I期试验中，Iclusig（ponatinib）在携带FLT3-ITD且未接受FLT3抑制剂（如帕纳替尼）治疗的的急性骨髓性白血病患者中导致47%（3/7）的总缓解率。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24002496', 'NCT00462761', 'clinical trial - phase1', '4', 'Quizartinib', 'quizartinib', 'quizartinib', '奎扎替尼', 'quizartinib|奎扎替尼', '3', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000519', 'FLT3:nonframeshift insertion:exon14:.:ITD', 'FLT3', 'nonframeshift insertion', 'None_pos', 'exon14', '.', 'ITD', 'In a Phase I clinical trial, patients with refractory or relapsed acute myeloid leukemia positive for FLT3-ITD demonstrated a 53% (9/17) response rate compared to a 14% (5/37) response rate in those patients negative for FLT3-ITD when treated with Quizartinib (AC220) (PMID: 24002496).', '在I期临床试验中，用quizartinib(AC220)治疗FLT3-ITD突变阳性、难治性或复发性急性髓性白血病患者，其响应率为53%(9/17)，相比之下，FLT3-ITD突变阴性患者的响应率为14%(5/37)。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25847190', '.', 'case report', '4', 'PLX3397', 'PLX3397', 'pexidartinib', 'pexidartinib', 'pexidartinib|pexidartinib', '1', 'leukemia', 'leukemia', '白血病', '白血病', 'resistance', 'EVI_000521', 'FLT3:nonsynonymous SNV:exon20:p.D835H:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835H', '.', 'In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 D835H mutation on the same allele as the FLT3-ITD mutation (PMID: 25847190).', '在临床研究中，FLT3-ITD突变阳性白血病患者对PLX3397(pexidartinib)治疗最初有响应，但在与FLT3-ITD突变相同的等位基因上出现FLT3 D835H突变后，患者出现复发。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25847190', '.', 'case report', '4', 'PLX3397', 'PLX3397', 'pexidartinib', 'pexidartinib', 'pexidartinib|pexidartinib', '1', 'leukemia', 'leukemia', '白血病', '白血病', 'resistance', 'EVI_000522', 'FLT3:nonsynonymous SNV:exon6:p.S652G:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.S652G', '.', 'In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397, but experienced relapse after emergence of a FLT3 S652G mutation on the same allele as FLT3-ITD (PMID: 25847190).', '在临床研究中，FLT3-ITD突变阳性白血病患者对PLX3397(pexidartinib)治疗最初有响应，但在与FLT3-ITD突变相同的等位基因上出现FLT3 S652G突变后，患者出现复发。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25847190', '.', 'case report', '4', 'PLX3397', 'PLX3397', 'pexidartinib', 'pexidartinib', 'pexidartinib|pexidartinib', '1', 'leukemia', 'leukemia', '白血病', '白血病', 'resistance', 'EVI_000523', 'FLT3:nonsynonymous SNV:exon20:p.D835Y:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835Y', '.', 'In a clinical study, a patient with FLT3-ITD positive leukemia initially responded to PLX3397 therapy, but experienced relapse after emergence of FLT3 D835Y on the same allele as the FLT3-ITD mutation (PMID: 25847190).', '在临床研究中，FLT3-ITD突变阳性白血病患者对PLX3397(pexidartinib)治疗最初有响应，但在FLT3 D835Y突变出现后，患者出现复发。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25870145', '.', 'preclinical', '4', 'Selumetinib', 'selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'non-small cell lung carcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000524', 'NRAS:nonsynonymous SNV:exon3:p.E63K:.', 'NRAS', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E63K', '.', 'In a preclinical study, Selumetinib inhibited proliferation of non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63K in culture (PMID: 25870145).', '在临床前研究中，selumetinib能抑制培养中携带EGFR外显子19缺失和NRAS E63K突变的非小细胞肺癌细胞的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25870145', '.', 'preclinical', '4', 'Gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung carcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000525', 'NRAS:nonsynonymous SNV:exon3:p.E63K:.', 'NRAS', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E63K', '.', 'In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion became resistant to Iressa (gefitinib) after the emergence of NRAS E63K in culture (PMID: 25870145).', '在临床前研究中，携带EGFR外显子19缺失的非小细胞肺癌细胞获得NRAS E63K基因突变出现后对gefitinib具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25870145', '.', 'preclinical', '4', 'AZD9291', 'AZD9291', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung carcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000526', 'NRAS:nonsynonymous SNV:exon3:p.E63.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon3', 'p.E63.', '.', 'In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS E63 were resistant to Tagrisso (osimertinib) AZD9291 treatment in culture (PMID: 25870145).', '在临床前研究中，携带EGFR外显子19缺失和NRAS E63基因突变的非小细胞肺癌细胞对培养物中的osimertinib处理具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25870145', '.', 'preclinical', '4', 'AZD9291', 'AZD9291', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung carcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000527', 'NRAS:nonsynonymous SNV:exon3:p.Q61.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon3', 'p.Q61.', '.', 'In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion, EGFR T790M, and NRAS Q61K were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).', '在临床前研究中，携带NRAS Q61K基因突变的肿瘤细胞对培养物中的osimertinib具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21325073', '.', 'preclinical', '4', 'PF-05212384', 'PF-05212384', 'gedatolisib', 'gedatolisib', 'gedatolisib|gedatolisib', '2', 'non-small cell lung carcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000528', 'NRAS:nonsynonymous SNV:exon3:p.Q61.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon3', 'p.Q61.', '.', 'In a preclinical study, human non-small cell lung cancer cells harboring NRAS Q61K had a decreased response to Gedatolisib (PKI-587) in culture (PMID: 21325073, PMID: 12068308).', '在临床前研究中，携带NRAS基因Q61K突变的人非小细胞肺癌细胞系对培养物中的gedatolisib(PKI-587；PF-05212384)的响应率较低。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23629727', '.', 'preclinical', '4', 'Pimasertib', 'pimasertib', 'pimasertib', 'pimasertib', 'pimasertib|pimasertib', '2', 'non-small cell lung carcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000529', 'NRAS:nonsynonymous SNV:exon3:p.Q61.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon3', 'p.Q61.', '.', 'In a preclinical study, Pimasertib (MSC1936369B) inhibited proliferation of non-small cell lung cancer cells harboring NRAS Q61K in culture (PMID: 23629727).', '在临床前研究中，pimasertib(MSC1936369B)能够抑制携带NRAS Q61K突变的非小细胞肺癌细胞的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21107323', '.', 'preclinical', '4', 'Vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000530', 'NRAS:nonsynonymous SNV:exon3:p.Q61.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon3', 'p.Q61.', '.', 'In a preclinical study, a NRAS Q61K mutation conferred resistance to Zelboraf (vemurafenib) in melanoma cells harboring BRAF V600E in culture (PMID: 21107323).', '在临床前研究中，携带NRAS Q61K突变的黑色素瘤细胞对Zelboraf(vemurafenib)具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26343583', '.', 'preclinical', '4', 'Selumetinib', 'selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000531', 'NRAS:nonsynonymous SNV:exon3:p.Q61.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon3', 'p.Q61.', '.', 'In a preclinical study, Selumetinib (AZD6244) modestly inhibited proliferation of human melanoma cells harboring NRAS Q61L in culture (PMID: 26343583).', '在临床前研究中，Selumetinib(AZD6244)适度抑制携带NRAS Q61L基因突变的人黑色素瘤细胞的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25873592', '.', 'preclinical', '4', 'BI-847325', 'BI-847325', 'BI-847325', 'BI-847325', 'BI-847325|BI-847325', '1', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000532', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a preclinical study, treatment with BI-847325 inhibited growth of a BRAF-mutant melanoma cell line with BRAF-inhibitor resistance due to an NRAS mutation in culture (PMID: 25873592).', '在临床前研究中，BI-847325可以抑制携带NRAS突变的黑色素瘤细胞系的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24569456', '.', 'preclinical', '4', 'MEK162', 'MEK162', 'binimetinib', 'binimetinib', 'binimetinib|binimetinib', '2', 'acute myeloid leukemia', 'cancer cell lines_leukemia', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000533', 'NRAS:nonsynonymous SNV:exon2:p.G12.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'In a preclinical study, Binimetinib (MEK162) inhibited growth of acute myeloid leukemia cells that have been demonstrated to harbor NRAS G12D in culture and decreased disease burden in xenograft models with NRAS G12D (PMID: 24569456, PMID: 11238126).', '在临床前研究中，binimetinib(MEK162)可以抑制携带NRAS G12D突变的急性髓系白血病细胞系的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26267534', '.', 'preclinical', '4', 'Vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000534', 'NRAS:nonsynonymous SNV:exon2:p.G12.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'In a preclinical study, expression of NRAS G12V in melanoma cells harboring BRAF V600E conferred resistance to Zelboraf (vemurafenib) in culture (PMID: 26267534).', '在临床前研究中，在携带BRAF V600E基因突变的黑色素瘤细胞中NRAS G12V的突变可能导致肿瘤细胞对Zelboraf(vemurafenib)产生抗药性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25870145', '.', 'preclinical', '4', 'AZD9291', 'AZD9291', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung carcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000535', 'NRAS:nonsynonymous SNV:exon2:p.G12.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12V were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).', '在临床前研究中，携带EGFR外显子19缺失和NRAS G12V基因突变的非小细胞肺癌细胞对培养物中的osimertinib具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25870145', '.', 'preclinical', '4', 'AZD9291', 'AZD9291', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung carcinoma', 'cancer cell lines_lung', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000536', 'NRAS:nonsynonymous SNV:exon2:p.G13.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G13.', '.', 'In a preclinical study, non-small cell lung cancer cells harboring EGFR exon 19 deletion and NRAS G12R were resistant to Tagrisso (osimertinib) in culture (PMID: 25870145).', '在临床前研究中，携带EGFR外显子19缺失和NRAS G12R基因突变的非小细胞肺癌细胞对培养物中的osimertinib具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27601554', 'NCT00648648', 'clinical trial - phase1', '4', 'MK-1775', 'MK-1775', 'MK-1775', 'MK-1775', 'MK-1775|MK-1775', '2', 'Advanced Solid Tumor', 'Solid Tumor', '非特定癌症', '非特定癌症', 'sensitivity', 'EVI_000539', 'TP53:nonsynonymous SNV:.:.:inact', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a retrospective analysis of a Phase I trial, MK-1775 combined with a chemotherapy resulted in a 21% (4/19) response rate in advanced solid tumor patients harboring a TP53 mutation and in those without a TP53 mutation, a 12% (4/33) response rate was observed (PMID: 27601554). ', '在I期试验的回顾性分析中，MK-1775联合化疗对具有TP53突变的晚期实体肿瘤患者的响应率为21%(4/19)，而在没有TP53突变的患者中的响应率为12%(4/33)。MK-1775是一种口服的小分子WEE1激酶抑制剂，WEE1激酶是一种细胞周期检查点调节蛋白。临床前研究数据显示WEE1的阻断可以增强某些抗癌药物的细胞杀伤效能。MK-1775与TP53失活突变可以对肿瘤细胞产生协同致死效应。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18623623', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000545', 'KIT:nonsynonymous SNV:exon17:p.D816H:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D816H', '.', 'Primary KIT oncogenic mutations were found in 11/14 patients (79%). Of these, 9/11 (83%), had secondary drug-resistant KIT mutations, including six (67%) with two to five different secondary mutations in separate metastases, and three (34%) with two secondary KIT mutations in the same metastasis.Analyses in 10 GISTs lacking demonstrable secondary KIT mutations revealed localized KIT amplicons in both samples analysed from patient 10, whose GIST had a primary KIT exon 13 mutation.', '对14名imatinib或sunitinib耐药的胃肠间质瘤患者进行KIT、PDGFRA的突变分析发现，11名(79%)患者存在KIT原发突变，原发突变患者中9名(83%)患者发生2~5种不同的二次突变，其中三名患者在同一转移部位发生2种突变(p.N822Y/K；p.N820G/Y；p.D816E/H)。二次突变集中在KIT ATP结合口袋和激酶催化区域(exon13和14及exon17)。这些突变与肿瘤患者对imatinib的耐药相关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18623623', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000546', 'KIT:nonsynonymous SNV:exon18:p.A829P:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.A829P', '.', 'Primary KIT oncogenic mutations were found in 11/14 patients (79%). Of these, 9/11 (83%), had secondary drug-resistant KIT mutations, including six (67%) with two to five different secondary mutations in separate metastases, and three (34%) with two secondary KIT mutations in the same metastasis.Analyses in 10 GISTs lacking demonstrable secondary KIT mutations revealed localized KIT amplicons in both samples analysed from patient 10, whose GIST had a primary KIT exon 13 mutation.', '对14名imatinib或sunitinib耐药的胃肠间质瘤患者进行KIT、PDGFRA的突变分析发现，11名(79%)患者存在KIT原发突变，原发突变患者中9名(83%)患者发生2~5种不同的二次突变，其中三名患者在同一转移部位发生2种突变(p.N822Y/K；p.N820G/Y；p.D816E/H)。二次突变集中在KIT ATP结合口袋和激酶催化区域(exon13和14及exon17)。这些突变与肿瘤患者对imatinib的耐药相关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18623623', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000547', 'KIT:nonsynonymous SNV:exon17:p.N822Y:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.N822Y', '.', 'Primary KIT oncogenic mutations were found in 11/14 patients (79%). Of these, 9/11 (83%), had secondary drug-resistant KIT mutations, including six (67%) with two to five different secondary mutations in separate metastases, and three (34%) with two secondary KIT mutations in the same metastasis.Analyses in 10 GISTs lacking demonstrable secondary KIT mutations revealed localized KIT amplicons in both samples analysed from patient 10, whose GIST had a primary KIT exon 13 mutation.', '对14名imatinib或sunitinib耐药的胃肠间质瘤患者进行KIT、PDGFRA的突变分析发现，11名(79%)患者存在KIT原发突变，原发突变患者中9名(83%)患者发生2~5种不同的二次突变，其中三名患者在同一转移部位发生2种突变(p.N822Y/K；p.N820G/Y；p.D816E/H)。二次突变集中在KIT ATP结合口袋和激酶催化区域(exon13和14及exon17)。这些突变与肿瘤患者对imatinib的耐药相关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18361409', '.', 'preclinical', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', '前列腺癌', 'sensitivity', 'EVI_000548', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'All three agents alone decreased tumor volume, and RAD001 and docetaxel also decreased levels of serum PSA by 68% and 65%, respectively (both P < 0.01). Combinations of the agents were more effective in decreasing tumor volume than single agents. Three-drug treatment showed the greatest effect: 64% inhibition versus control）', 'PTEN突变失活会导致mTOR通路调节异常，最终导致肿瘤发生。一项体内试验中使用everolimus，docetaxel和zoledronic acid治疗PTEN失活的前列腺癌。三种药物单独使用均可致肿瘤体积缩小；everolimus和docetaxel联用治疗使得前列腺特异性抗原PSA分别减少68%和65%；三种药物联用获得最好的效果，肿瘤抑制率达到65%。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20664172', '.', 'preclinical', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'solid tumor', 'solid tumor', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000549', 'KRAS:nonsynonymous SNV:exon2:p.G12.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'Eleven of the 12 patients with KRAS mutant tumors had disease progression, while only 16 of 31 of WT cases did not benefit from treatment.cancer patients whose tumors carry PIK3CA kinase domain mutations or  PTEN loss of function can benefit from everolimus treatment, except when BRAF/KRAS mutations occur in concomitance with PI3K pathway alterations', 'everolimus是一种mTOR抑制剂，体外实验表明PIK3CA E545K/H1047R突变增加了肿瘤细胞对everolimus的敏感性，而KRAS和BRAF的突变则导致肿瘤细胞对everolimus产生耐药性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20664172', '.', 'preclinical', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'solid tumor', 'solid tumor', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000550', 'KRAS:nonsynonymous SNV:exon2:p.G13.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G13.', '.', 'Eleven of the 12 patients with KRAS mutant tumors had disease progression, while only 16 of 31 of WT cases did not benefit from treatment.cancer patients whose tumors carry PIK3CA kinase domain mutations or  PTEN loss of function can benefit from everolimus treatment, except when BRAF/KRAS mutations occur in concomitance with PI3K pathway alterations', 'everolimus是一种mTOR抑制剂，体外实验表明PIK3CA E545K/H1047R突变增加了肿瘤细胞对everolimus的敏感性，而KRAS和BRAF的突变则导致肿瘤细胞对everolimus产生耐药性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20664172', '.', 'preclinical', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'solid tumor', 'solid tumor', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000551', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'Eleven of the 12 patients with KRAS mutant tumors had disease progression, while only 16 of 31 of WT cases did not benefit from treatment.cancer patients whose tumors carry PIK3CA kinase domain mutations or  PTEN loss of function can benefit from everolimus treatment, except when BRAF/KRAS mutations occur in concomitance with PI3K pathway alterations', 'everolimus是一种mTOR抑制剂，体外实验表明PIK3CA E545K/H1047R突变增加了肿瘤细胞对everolimus的敏感性，而KRAS和BRAF的突变则导致肿瘤细胞对everolimus产生耐药性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23743569', 'NCT00419159', 'clinical trial - phase2', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'metastatic colorectal adenocarcinoma', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000552', 'KRAS:nonsynonymous SNV:exon2:p.G12.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'KRAS mutational status did not significantly influence PFS in either the weekly or daily  everolimus schedules or OSor DCR in the weekly schedule. However, among patients receiving daily everolimus, those with a KRAS mutation experienced significantly shorter median OSand lower DCRthan those with wild-type KRAS.Patients with BRAF mutation had a greater risk of death or progression than patients with wild-type BRAF.Extensive biomarker analyses show that KRAS-mutated patients receiving daily everolimus experienced significantly poorer outcomes compared with wild-type KRAS patients. We also confirmed that patients with BRAF mutation had worse survival than patients with wild-type BRAF.', '40%-60%转移性结直肠癌患者会发生(PI3K)/Akt/mTOR通路调节异常。一项临床II期试验中，对结直肠癌患者使用mTOR抑制剂everolimus治疗。根据给药剂量分为70 mg/周和10 mg/天两组：疾病控制率分别为25%和26%，中位无进展生存期均为1.8个月，中位总存活期分别为5.9个月和4.9个月。对两组患者突变分析， 70 mg/周：KRAS突变/野生型患者无进展生存期、总存活率及疾病控制率无显著差异；10 mg/天：KRAS突变/野生型患者疾病控制率分别为为17.1%/3.0%。9.5%的患者检测到BRAF突变，死亡和疾病进展风险高于野生型。PTEN表达低/高患者获益无显著差异。所以转移性结直肠癌患者无法从everolimus的单一治疗中获益，10 mg/天治疗时KRAS/BRAF突变患者预后较差。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23743569', 'NCT00419159', 'clinical trial - phase2', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'metastatic colorectal adenocarcinoma', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000553', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'KRAS mutational status did not significantly influence PFS in either the weekly or daily  everolimus schedules or OSor DCR in the weekly schedule. However, among patients receiving daily everolimus, those with a KRAS mutation experienced significantly shorter median OSand lower DCRthan those with wild-type KRAS.Patients with BRAF mutation had a greater risk of death or progression than patients with wild-type BRAF.Extensive biomarker analyses show that KRAS-mutated patients receiving daily everolimus experienced significantly poorer outcomes compared with wild-type KRAS patients. We also confirmed that patients with BRAF mutation had worse survival than patients with wild-type BRAF.', '40%-60%转移性结直肠癌患者会发生(PI3K)/Akt/mTOR通路调节异常。一项临床II期试验中，对结直肠癌患者使用mTOR抑制剂everolimus治疗。根据给药剂量分为70 mg/周和10 mg/天两组：疾病控制率分别为25%和26%，中位无进展生存期均为1.8个月，中位总存活期分别为5.9个月和4.9个月。对两组患者突变分析， 70 mg/周：KRAS突变/野生型患者无进展生存期、总存活率及疾病控制率无显著差异；10 mg/天：KRAS突变/野生型患者疾病控制率分别为为17.1%/3.0%。9.5%的患者检测到BRAF突变，死亡和疾病进展风险高于野生型。PTEN表达低/高患者获益无显著差异。所以转移性结直肠癌患者无法从everolimus的单一治疗中获益，10 mg/天治疗时KRAS/BRAF突变患者预后较差。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20160728', '.', 'clinical study', '4', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000554', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', 'The objective response rate (ORR) of mCRC patients with loss of PTEN expression was 6% (5 of 81), whereas the ORR of mCRC patients with normal PTEN expression was 32% (40 of 124).This meta-analysis suggests that loss of PTEN expression is associated with clinical resistance to EGFR-targeted monoclonal antibodies in patients with mCRC.', '一项回顾性研究中对205份转移性结直肠癌肿瘤样本进行meta分析，以EGFR为靶点，经cetuximab或panitumumab靶向治疗后，发生PTEN缺失的样本客观缓解率为6%(5/81)，而PTEN正常表达的样本客观有效率为32%(40/124)。所以PTEN缺失可能会造成结直肠癌患者对EGFR单抗靶向治疗的耐药。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19499221', '.', 'clinical trial - phase2', '4', 'lapatinib', 'lapatinib', 'lapatinib', '拉帕替尼', 'lapatinib|拉帕替尼', '4', 'glioblastoma', 'brain cancer', '脑部肿瘤', '多形性胶质母细胞瘤', 'resistance', 'EVI_000557', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Of 17 patients, 4 had stable disease and 13 progressed. PTEN loss was seen in 6 and EGFRvIII expression in 4. No correlation was seen with outcome and molecular results.', '一项临床I/II期试验中，使用lapatinib治疗复发的多形性胶质母细胞瘤患者，17名患者中4名疾病稳定，13名发生进展。突变分析发现EGFRvIII表达或PTEN缺失的患者不能从lapatinib治疗中获益。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22011666', '.', 'clinical trial - phase2', '4', 'XL647', 'XL647', 'tesevatinib', 'tesevatinib', 'tesevatinib|tesevatinib', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000558', 'EGFR:nonsynonymous SNV:exon20:p.T790M:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'One partial response was observed.The patient with a partial response was an Asian woman whose tumor harbored an exon 19 deletion without a T790M mutation at the time of diagnosis.T790M mutations were identified in 10 of the 40 plasma specimens (25%).A multivariate Cox regression analysis showed that the presence of T790M was a significant predictor of shorter progression-free survival in patients treated with XL647, with median progression-free survival of 1.8 months (90% CI, 1.8 –2.8) compared with median survival of 5.5 months (90% CI, 3.7–7.5) in those in whom a T790M mutation was not detected.', '携带EGFR突变的非小细胞肺癌患者经erlotinib或gefitinib靶向治疗后，50%获得性耐药患者发生EGFR T790M突变。XL647(tesevatinib)是一种有效的EGFR、VEGFR2、HER2和EphB4抑制剂。一项临床试验共招募了41名患者，符合条件的患者包括复发或复发性晚期NSCLC患者，这些患者包括疾病稳定≥12周后发生进展，或对erlotinib或gefitinib有治疗响应，或携带EGFR T790M突变。每天一次给予XL647 300mg治疗，主要终点是客观反应率。收集预处理血浆样品用于循环肿瘤DNA的突变分析，其中33名患者可评估疗效，仅观察到1名患者有部分响应(响应率3%)，在携带T790M突变的患者中，有67%(8/12)的患者发生疾病进展，而无EGFR T790M突变的患者14%(3/21)发生进展。该试验表明，携带T790M突变的肺癌患者接受XL647治疗相比无突变的患者预后效果更差。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:14645423', 'NCT01172548', 'clinical trial - phase2', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000563', 'KIT:nonsynonymous SNV:exon13:p.K642E:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.K642E', '.', 'Overall, 112 (88.2%) of the 127 GISTs evaluated had activating mutations of KIT exon 9, 11, 13, or 17.The most common type of mutation (71 patients) was in-frame deletion of a portion of the juxtamembrane domain (exon 11).Imatinib was similarly effective against the V561D, del DIMH842–845, and delI843 PDGFRA isoforms(IC50, 100 to 200 nmol/L), whereas inhibition of the D842V mutant required 10- to 20-fold higher drug levels.Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.', '大部分胃肠间质瘤患者存在KIT或PDGFRA激活突变。一项临床Ⅱ期试验表明，携带KIT基因K642E突变的胃肠间质瘤患者可能对imatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:14645423', 'NCT01172548', 'clinical trial - phase2', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000564', 'KIT:nonsynonymous SNV:exon17:p.N822H:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.N822H', '.', 'Overall, 112 (88.2%) of the 127 GISTs evaluated had activating mutations of KIT exon 9, 11, 13, or 17.The most common type of mutation (71 patients) was in-frame deletion of a portion of the juxtamembrane domain (exon 11).Imatinib was similarly effective against the V561D, del DIMH842–845, and delI843 PDGFRA isoforms(IC50, 100 to 200 nmol/L), whereas inhibition of the D842V mutant required 10- to 20-fold higher drug levels.Patients whose tumors contained exon 11 KIT mutations had a longer event-free and overall survival than those whose tumors expressed either exon 9 KIT mutations or had no detectable kinase mutation.', '大部分胃肠间质瘤患者存在KIT或PDGFRA激活突变。一项临床Ⅱ期试验表明，携带KIT基因N822H突变的胃肠间质瘤患者可能对imatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17363509', '.', 'preclinical', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000569', 'KIT:nonsynonymous SNV:exon13:p.V654A:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.V654A', '.', 'PKC412 strongly inhibited imatinib-resistant D816V c-KIT.Alternative c-KIT inhibitors, nilotinib (AMN107) and PKC412, were also less active on V560G/V654A c-KIT than on the V560G single mutant; however, nilotinib, like imatinib, potently inhibited the V560G mutant.', '携带KIT突变的胃肠间质瘤患者经靶向治疗后可能出现二次突变，从而导致患者对KIT抑制剂(imatinib、nilotinib和PKC412)耐药。临床前试验中，将KIT V654A突变与GIST特征突变V560G在体外表达，表达V560G/V654A双突变的细胞相比单一表达V560G的细胞对imatinib的敏感性降低；同时nilotinib(AMN107)和PKC412(midostaurin)对表达V560G/V654A 双突变的细胞敏感性相比表达V560G的细胞要低；但PKC412可抑制携带imatinib耐药性突变D816V细胞的增殖。所以胃肠间质瘤细胞发生V654A二次突变可能导致对KIT抑制剂imatinib、nilotinib和PKC412的耐药性。\n', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17363509', '.', 'preclinical', '4', 'PKC412', 'PKC412', 'midostaurin', '米哚妥林', 'midostaurin|米哚妥林', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000570', 'KIT:nonsynonymous SNV:exon13:p.V654A:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.V654A', '.', 'PKC412 strongly inhibited imatinib-resistant D816V c-KIT.Alternative c-KIT inhibitors, nilotinib (AMN107) and PKC412, were also less active on V560G/V654A c-KIT than on the V560G single mutant; however, nilotinib, like imatinib, potently inhibited the V560G mutant.', '携带KIT突变的胃肠间质瘤患者经靶向治疗后可能出现二次突变，从而导致患者对KIT抑制剂(imatinib、nilotinib和PKC412)耐药。临床前试验中，将KIT V654A突变与GIST特征突变V560G在体外表达，表达V560G/V654A双突变的细胞相比单一表达V560G的细胞对imatinib的敏感性降低；同时nilotinib(AMN107)和PKC412(midostaurin)对表达V560G/V654A 双突变的细胞敏感性相比表达V560G的细胞要低；但PKC412可抑制携带imatinib耐药性突变D816V细胞的增殖。所以胃肠间质瘤细胞发生V654A二次突变可能导致对KIT抑制剂imatinib、nilotinib和PKC412的耐药性。\n', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:15459012', '.', 'clinical trial - phase1', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'sensitivity', 'EVI_000572', 'FLT3:nonsynonymous SNV:exon20:p.D835.:.', 'FLT3', 'nonsynonymous SNV', 'Partial_pos', 'exon20', 'p.D835.', '.', 'All 4 patients with FLT3 mutations achieved morphologic or partial responses compared with 2 partial responses in 7 evaluable patients without FLT3 mutations. Responses, although longer in patients with mutated FLT3, were of short duration.', '一项临床I期试验中，使用sunitinib治疗15名急性髓系白血病患者，其中携带FLT3突变的4名患者(2名为FLT3 D835，2名为FLT3-ITD)和6名野生型患者经治疗后均获得部分缓解或疾病稳定，且携带FLT3突变的患者获得缓解更快，持续时间更长。所以FLT3的激活突变患者相比FLT3野生型可能从sunitinib治疗中获益更多。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20733134', 'NCT00045942', 'clinical trial - phase2', '4', 'midostaurin', 'midostaurin', 'midostaurin', '米哚妥林', 'midostaurin|米哚妥林', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', '急性髓性白血病', 'sensitivity', 'EVI_000573', 'FLT3:nonsynonymous SNV:exon20:p.D835Y:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.D835Y', '.', 'Phase 2 studies show that FLT3-mutant AML patients had a 35 % significant clinical benefit and around 50-70% hematological response.The rate of BR for the population in whom efficacy could be assessed was 71% in patients with FLT3 mutant and 42% in patients with FLT3 wild-type. One PR occurred in a patient with FLT3-mutant receiving the 100-mg dose regimen. These results suggest that midostaurin has hematologic activity in both patients with FLT3-mutant and wild-type.', '一项临床IIB期试验中，使用FLT3抑制剂midostaurin治疗急性髓性白血病(AML)和高风险骨髓增生异常综合症患者。71%FLT3突变(FLT D835Y或FLT3-ITD)患者和42%FLT3野生型患者获得外周或骨髓原始细胞减少50%以上，一名FLT3突变患者获得部分缓解。所以midostaurin对FLT3野生型或突变型AML患者均有临床活性，但FLT3突变患者相比野生型患者从midostaurin中获益更多。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18230792', '.', 'preclinical', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'resistance', 'EVI_000574', 'FLT3:nonsynonymous SNV:exon20:p.D835.:.', 'FLT3', 'nonsynonymous SNV', 'Partial_pos', 'exon20', 'p.D835.', '.', 'Cells with FLT3-ITD or D835G mutations were 1000- to 3000-fold more sensitive to sorafenib than FLT3-D835Y mutant or FLT3 wild-type cells. A clinical response was observed in nine (56%) of 16 patients  (three patients in arm A and six patients in arm B). It is notable that all six patients who carried solely an FLT3-ITD mutation (three patients in each arm) had a clinical response.', '体内体外实验表明，索拉非尼诱导FLT3-ITD（内部串联重复）或D835G突变的急性髓性白血病细胞生长停止和凋亡的效率是FLT D835Y突变或野生型细胞的1000或3000倍。临床I期试验中，使用索拉非尼治疗16名原发急性髓性白血病患者，9名获得临床缓解的患者中6人携带单一FLT-ITD突变。所以单一FLT3-ITD突变的急性髓性白血病患者可能更易从索拉非尼治疗中获益，FLT3 D835突变不一定使患者对索拉非尼敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:14654525', '.', 'clinical trial - phase1', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000575', 'FLT3:nonframeshift insertion:exon14:.:ITD', 'FLT3', 'nonframeshift insertion', 'None_pos', 'exon14', '.', 'ITD', 'Eight of the 16 evaluable WT patients exhibited strong inhibition of FLT3 phosphorylation. All patients who exhibited strong FLT3 inhibition at doses<200 mg were FLT3 mutant. This novel translational study bridges preclinical models to the patient setting and provides the first evidence of anti-FLT3 activity in patients.', '一项临床I期试验中，使用舒尼替尼（SU11248）治疗急性髓性白血病患者，6名患者携带多种FLT3T突变：FLT3-ITD(VDFREYE(592–598), KYFYVDFRE (588–596),和DFREY (593–597))、D835Y和G846Y。50%FLT3野生型患者和100%FLT3突变患者血浆中FLT3磷酸化受到抑制。所以FLT3-ITD突变患者相比野生型患者使用舒尼替尼后的临床获益更高。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:14654525', '.', 'clinical trial - phase1', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000578', 'FLT3:nonsynonymous SNV:exon20:p.G846Y:.', 'FLT3', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.G846Y', '.', 'Eight of the 16 evaluable WT patients exhibited strong inhibition of FLT3 phosphorylation. All patients who exhibited strong FLT3 inhibition at doses<200 mg were FLT3 mutant. This novel translational study bridges preclinical models to the patient setting and provides the first evidence of anti-FLT3 activity in patients.', '一项临床I期试验中，使用舒尼替尼（SU11248）治疗急性髓性白血病患者，6名患者携带多种FLT3T突变：FLT3-ITD(VDFREYE(592–598), KYFYVDFRE (588–596),和DFREY (593–597))、D835Y和G846Y。50%FLT3野生型患者和100%FLT3突变患者血浆中FLT3磷酸化受到抑制。所以FLT3-ITD突变患者相比野生型对舒尼替尼的临床获益更高。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23613521', 'NCT01254890', 'clinical trial - phase2', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000579', 'FLT3:nonframeshift insertion:exon14:.:ITD', 'FLT3', 'nonframeshift insertion', 'None_pos', 'exon14', '.', 'ITD', 'The response rate was 46%, including 10 (27%) complete response with incomplete count recovery (CRi), 6 (16%)\ncomplete responses (CR), and 1 (3%) partial response.Response rate was higher in previously untreated patients (4 of 6 [67%] patients including 1 with CR, 2 with CRi, and 1 with PR) compared with primary refractory patients (7 of 12 [58%] patients including 3 CR and 4 CRi) and compared with relapsed patients (6 of 19 [32%] patients including 2 CR and 4 CRi; P 5 not significant).', '一项临床II期试验中，使用索拉非尼联合阿扎胞苷治疗急性髓性白血病患者，93%患者携带FLT3-ITD突变，总缓解率为46%（完全缓解率43%，部分缓解率3%），未接受过FLT3抑制剂治疗、原发耐药和复发的患者缓解率分别为67%、58%和32%。所以索拉非尼联合阿扎胞苷治疗可使FLT3-ITD突变的急性髓性白血病患者获益，且未经FLT3抑制剂治疗的患者获益更多。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:rucaparib_Revised:12/2016', '.', 'guideline:FDA', '1', 'rucaparib', 'rucaparib', 'rucaparib', '芦卡帕利', 'rucaparib|芦卡帕利', '4', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_000580', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'rucaparib适用于单药治疗BRCA（生殖细胞和/或体细胞）有害突变相关的晚期卵巢癌，患者接受了2种或更多种化疗。FDA批准rucaparib治疗BRCA有害突变（生殖细胞和/或体细胞）相关的晚期卵巢癌，患者接受过2种或2种以上化疗，与此同时还批准了基于二代测序的伴随诊断CDxBRCA检测。此项伴随诊断用于检测卵巢癌患者的肿瘤中BRCA1和BRCA2基因是否存在变异，用以筛选适宜rucaparib治疗的晚期卵巢癌患者。Rucaparib的此项批准是基于两项多中心、单臂、开放性试验结果。两项试验中纳入了106名2种或2种以上化疗后有进展的晚期乳腺癌患者，收集福尔马林固定石蜡包埋的肿瘤样本用于伴随诊断检测，在对CDxBRCA test有效的肿瘤样本中，回顾性地确定了96%的样本BRCA突变状态。研究者根据RECIST 1.1评估客观缓解率（ORR）和持续反应时间（DoR）分别为54% (57/106; 95% CI: 44-64%)和9.2个月 (95% CI: 6.6, 11.6)。在铂类敏感治疗组、铂类耐药性治疗组以及铂类难治型治疗组中的ORR分别为66% (52/79; 95% CI: 54 76%)、 25% (5/20; 95% CI: 9-49%)、 0% (0/7; 95% CI: 0-41%)(NCT01482715;NCT01891344)。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:rucaparib_Revised:12/2016', '.', 'guideline:FDA', '1', 'rucaparib', 'rucaparib', 'rucaparib', '芦卡帕利', 'rucaparib|芦卡帕利', '4', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_000581', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'rucaparib适用于单药治疗BRCA（生殖细胞和/或体细胞）有害突变相关的晚期卵巢癌，患者接受了2种或更多种化疗。FDA批准rucaparib治疗BRCA有害突变（生殖细胞和/或体细胞）相关的晚期卵巢癌，患者接受过2种或2种以上化疗，与此同时还批准了基于二代测序的伴随诊断CDxBRCA检测。此项伴随诊断用于检测卵巢癌患者的肿瘤中BRCA1和BRCA2基因是否存在变异，用以筛选适宜rucaparib治疗的晚期卵巢癌患者。Rucaparib的此项批准是基于两项多中心、单臂、开放性试验结果。两项试验中纳入了106名2种或2种以上化疗后有进展的晚期乳腺癌患者，收集福尔马林固定石蜡包埋的肿瘤样本用于伴随诊断检测，在对CDxBRCA test有效的肿瘤样本中，回顾性地确定了96%的样本BRCA突变状态。研究者根据RECIST 1.1评估客观缓解率（ORR）和持续反应时间（DoR）分别为54% (57/106; 95% CI: 44-64%)和9.2个月 (95% CI: 6.6, 11.6)。在铂类敏感治疗组、铂类耐药性治疗组以及铂类难治型治疗组中的ORR分别为66% (52/79; 95% CI: 54 76%)、 25% (5/20; 95% CI: 9-49%)、 0% (0/7; 95% CI: 0-41%)(NCT01482715;NCT01891344)。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18794099', '.', 'clinical study', '4', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000582', 'EGFR:CNV:.:.:gain', 'EGFR', 'CNV', 'CNV', '.', '.', 'gain', 'One study confirmed the association between increased EGFR GCN and outcome after cetuximab. However, because of reproducibility concerns, any decision making based on published cutoff points is not warranted.(PMID:18794099)', '一项临床试验表明，在结直肠癌患者中EGFR基因扩增可能对西妥昔单抗敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17664472', '.', 'clinical trial - phase3', '4', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000583', 'EGFR:CNV:.:.:gain', 'EGFR', 'CNV', 'CNV', '.', '.', 'gain', 'Present exploratory data suggest that mCRC patients with tumors distinguishable by FISH analysis of EGFR as homogenously disomic or with low chromosome 7 polysomy have a reduced likelihood of response to panitumumab. (PMID:17664472)', '临床试验表明携带EGFR基因扩增的结直肠癌患者可能对帕尼单抗敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20633291', '.', 'preclinical', '4', 'motesanib', 'motesanib', 'motesanib', '莫替沙尼', 'motesanib|莫替沙尼', '3', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000584', 'KIT:nonsynonymous SNV:exon13:p.V654A:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.V654A', '.', 'Motesanib inhibited Kit autophosphorylation in CHO cell lines expressing primary activating mutations in exon 9 (AYins503-504, IC50 = 18 nM) and exon 11 (V560 D, IC50 = 5 nM; Δ552-559, IC50 = 1 nM). Motesanib also demonstrated activity against kinase domain mutations conferring imatinib resistance (V560D/V654A, IC50 = 77 nM; V560D/T670I, IC50 = 277 nM; Y823 D, IC50 = 64 nM) but failed to inhibit the imatinib-resistant D816V mutant (IC50 > 3000 nM).', 'KIT和PDGFR激活突变可能是导致胃肠道间质瘤发病的重要机制。Motesanib是一种有效的VEGFR1/2/3、PDGFR和KIT的抑制剂。体内体外实验表明，motesanib可以抑制野生型或突变型KIT(V560D，552_559del，AYins503_504)的自磷酸化，抑制效果优于imatinib；且motesanib有效抑制imatinib耐药性KIT突变(近膜结构域双突变V560D/V654A和V560D/T670I，活化环突变Y823D)。所以motesanib在临床前试验中表现出对KIT的有效抑制活性，可能对胃肠道间质瘤中KIT的原发性或二次突变具有临床抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20633291', '.', 'preclinical', '4', 'motesanib', 'motesanib', 'motesanib', '莫替沙尼', 'motesanib|莫替沙尼', '3', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_000585', 'KIT:nonsynonymous SNV:exon14:p.T670I:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.T670I', '.', 'Motesanib inhibited Kit autophosphorylation in CHO cell lines expressing primary activating mutations in exon 9 (AYins503-504, IC50 = 18 nM) and exon 11 (V560 D, IC50 = 5 nM; Δ552-559, IC50 = 1 nM). Motesanib also demonstrated activity against kinase domain mutations conferring imatinib resistance (V560D/V654A, IC50 = 77 nM; V560D/T670I, IC50 = 277 nM; Y823 D, IC50 = 64 nM) but failed to inhibit the imatinib-resistant D816V mutant (IC50 > 3000 nM).', 'KIT和PDGFR激活突变可能是导致胃肠道间质瘤发病的重要机制。Motesanib是一种有效的VEGFR1/2/3、PDGFR和KIT的抑制剂。体内体外实验表明，motesanib可以抑制野生型或突变型KIT(V560D，552_559del，AYins503_504)的自磷酸化，抑制效果优于imatinib；且motesanib有效抑制imatinib耐药性KIT突变(近膜结构域双突变V560D/V654A和V560D/T670I，活化环突变Y823D)。所以motesanib在临床前试验中表现出对KIT的有效抑制活性，可能对胃肠道间质瘤中KIT的原发性或二次突变具有临床抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27004155', '.', 'case report', '4', 'regorafenib', 'regorafenib', 'regorafenib', '瑞戈非尼', 'regorafenib|瑞戈非尼', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000586', 'KDR:nonsynonymous SNV:exon21:p.R961W:.', 'KDR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.R961W', '.', 'KDR R961W mutation has been described but no functional data has been reported. This mutation occurs in the tyrosine kinase domain of the VEGFR-2. Regorafenib targets VEGFR-2 (KDR).he patient had mutations in KRAS (Kirsten rat sarcoma viral oncogene homolog) which made her ineligible for epidermal growth factor receptor (EGFR) inhibitors; however, a KDR p.R961W c.2881C>T mutation was noted as a variant of unknown significance (VUS). KDR (kinase insert domain receptor) is the human gene encoding for vascular endothelial growth factor receptor 2 (VEGFR-2). She was then considered a suitable candidate for regorafenib, which she could only tolerate at a low dose of 40 mg daily, with the intent of prolonging her survival and to optimize her quality of life. ', '瑞戈非尼（regorafenib）是KDR的抑制剂。一名携带KDR基因p.R961W突变的结直肠癌患者对瑞戈非尼的治疗有效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17698633', '.', 'Preclinical', '4', 'dovitinib', 'dovitinib', 'dovitinib', '多韦替尼', 'dovitinib|多韦替尼', '2', 'chronic myeloproliferative disease', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000587', 'FGFR1:FUS:.:.-FGFR1:.', 'FGFR1', 'FUS', 'FUS', '.', '.-FGFR1', '.', 'In a preclinical study, primary cells from 8p11 myeloproliferative syndrome patients harboring FGFR1 rearrangement were sensitive to Dovitinib (TKI258)-induced growth inhibition in culture (PMID: 17698633).', '在临床前研究中，Dovitinib（TKI258）可以抑制携带FGFR1重排的骨髓增生综合征患者的原代肿瘤细胞。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27550940', '.', 'Preclinical', '4', 'AZD4547', 'AZD4547', 'AZD4547', 'AZD4547', 'AZD4547|AZD4547', '3', 'lung small cell carcinoma', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000588', 'FGFR1:FUS:.:.-FGFR1:.', 'FGFR1', 'FUS', 'FUS', '.', '.-FGFR1', '.', 'In a preclinical study, AZD4547 inhibited survival of small cell lung cancer cells harboring FGFR1 translocation in culture (PMID: 27550940).', '在临床前研究中，AZD4547抑制培养中携带FGFR1易位的小细胞肺癌细胞的生长。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22837387', '.', 'preclinical', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '2', 'malignant glioma', 'malignant glioma', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000589', 'FGFR1:FUS:.:FGFR1-TACC1:.', 'FGFR1', 'FUS', 'FUS', '.', 'FGFR1-TACC1', '.', 'In a preclinical study, BJG398 inhibited Fgfr1 kinase activity and cell growth in transformed cells expressing the FGFR1-TACC1 fusion in culture (PMID: 22837387).', '在临床前研究中，BJG398(infigratinib)抑制在培养中表达FGFR1-TACC1融合体的转化细胞中的FGFR1激酶活性和细胞生长。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27849562', '.', 'Preclinical', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'liver cancer', 'liver cancer', '肝癌', 'na', 'sensitivity', 'EVI_000590', 'RB1:CNV:.:.:gain', 'RB1', 'CNV', 'CNV', '.', '.', 'gain', 'Palbociclib shows encouraging results in preclinical models of HCC and represents a novel therapeutic strategy for HCC treatment, alone or particularly in combination with sorafenib. Palbociclib could potentially benefit patients with RB1-proficient tumours, which account for 70% of all patients with HCC.', 'RB1基因是细胞周期的负调控因子, RB1基因扩增的肝癌患者可能对CDK抑制剂如哌柏西利敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27849562', '.', 'Preclinical', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'liver cancer', 'liver cancer', '肝癌', 'na', 'resistance', 'EVI_000591', 'RB1:CNV:.:.:loss', 'RB1', 'CNV', 'CNV', '.', '.', 'loss', 'Palbociclib shows encouraging results in preclinical models of HCC and represents a novel therapeutic strategy for HCC treatment, alone or particularly in combination with sorafenib. Palbociclib could potentially benefit patients with RB1-proficient tumours, which account for 70% of all patients with HCC.', 'RB1基因是细胞周期的负调控因子, RB1基因缺失的肝癌患者可能对CDK抑制剂如哌柏西利耐药。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('ESMO 2015 (abstract 302)', '.', 'clinical trial - phase1', '4', 'EPZ-6438', 'EPZ-6438', 'tazemetostat', 'tazemetostat', 'tazemetostat|tazemetostat', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000592', 'SMARCA4:nonsynonymous SNV:.:.:inact', 'SMARCA4', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '携带SMARCA1基因失活突变的肿瘤患者可能对tazemetostat（EPZ-6438）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('ESMO 2015 (abstract 302)', '.', 'clinical trial - phase1', '4', 'EPZ-6438', 'EPZ-6438', 'tazemetostat', 'tazemetostat', 'tazemetostat|tazemetostat', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000593', 'SMARCA4:CNV:.:.:loss', 'SMARCA4', 'CNV', 'CNV', '.', '.', 'loss', '.', '携带SMARCA4基因失活突变的肿瘤患者可能对tazemetostat（EPZ-6438）敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('ESMO 2015 (abstract 302)', '.', 'clinical trial - phase1', '4', 'EPZ-6438', 'EPZ-6438', 'tazemetostat', 'tazemetostat', 'tazemetostat|tazemetostat', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000594', 'SMARCB1:CNV:.:.:loss', 'SMARCB1', 'CNV', 'CNV', '.', '.', 'loss', '.', '携带SMARCB1基因失活突变的肿瘤患者可能对tazemetostat（EPZ-6438）敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('ESMO 2015 (abstract 302)', '.', 'clinical trial - phase1', '4', 'EPZ-6438', 'EPZ-6438', 'tazemetostat', 'tazemetostat', 'tazemetostat|tazemetostat', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000595', 'SMARCB1:nonsynonymous SNV:.:.:inact', 'SMARCB1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '携带SMARCB1基因失活突变的肿瘤患者可能对tazemetostat（EPZ-6438）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23079656', '.', 'preclinical', '4', 'PD-0332991', 'PD-0332991', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'acute lymphoblastic leukemia', 'leukemia', '急性淋巴细胞白血病', 'na', 'sensitivity', 'EVI_000596', 'CCND1:CNV:.:.:gain', 'CCND1', 'CNV', 'CNV', '.', '.', 'gain', '.', 'CCND蛋白是细胞周期蛋白CDK4/6的正向调节蛋白，CCND1基因扩增可能导致CDK4/6异常活化，细胞周期紊乱，导致肿瘤发生发展。CDK4/6抑制剂哌柏西利已被FDA批准用于ER阳性，HER2阴性的转移性乳腺癌的治疗。临床试验表明，CCND1-3基因发生扩增的肿瘤患者可能对哌柏西利敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23079656', '.', 'preclinical', '4', 'PD-0332991', 'PD-0332991', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'acute lymphoblastic leukemia', 'leukemia', '急性淋巴细胞白血病', 'na', 'sensitivity', 'EVI_000597', 'CCND2:CNV:.:.:gain', 'CCND2', 'CNV', 'CNV', '.', '.', 'gain', '.', 'CCND蛋白是细胞周期蛋白CDK4/6的正向调节蛋白，CCND1基因扩增可能导致CDK4/6异常活化，细胞周期紊乱，导致肿瘤发生发展。CDK4/6抑制剂哌柏西利已被FDA批准用于ER阳性，HER2阴性的转移性乳腺癌的治疗。临床试验表明，CCND1-3基因发生扩增的肿瘤患者可能对哌柏西利敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23079656', '.', 'preclinical', '4', 'PD-0332991', 'PD-0332991', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'acute lymphoblastic leukemia', 'leukemia', '急性淋巴细胞白血病', 'na', 'sensitivity', 'EVI_000598', 'CCND3:CNV:.:.:gain', 'CCND3', 'CNV', 'CNV', '.', '.', 'gain', '.', 'CCND蛋白是细胞周期蛋白CDK4/6的正向调节蛋白，CCND1基因扩增可能导致CDK4/6异常活化，细胞周期紊乱，导致肿瘤发生发展。CDK4/6抑制剂哌柏西利已被FDA批准用于ER阳性，HER2阴性的转移性乳腺癌的治疗。临床试验表明，CCND1-3基因发生扩增的肿瘤患者可能对哌柏西利敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27663592', '.', 'preclinical', '4', 'dinaciclib', 'dinaciclib', 'dinaciclib', 'dinaciclib', 'dinaciclib|dinaciclib', '2', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_000599', 'CCNE1:CNV:.:.:gain', 'CCNE1', 'CNV', 'CNV', '.', '.', 'gain', 'These findings suggest a specific dependency of CCNE1-amplified tumors for AKT activity, and point to a novel combination of dinaciclib and AKT inhibitors that may selectively target patients with CCNE1-amplified HGSC', '携带CCNE1基因扩增的卵巢癌患者可能对dinaciclib敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27217383', 'NCT01394016', 'clinical trial - phase1', '4', 'LY2835219', 'LY2835219', 'abemaciclib', 'abemaciclib', 'abemaciclib|abemaciclib', '4', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_000600', 'CDKN2A:CNV:.:.:loss', 'CDKN2A', 'CNV', 'CNV', '.', '.', 'loss', 'In a Phase I study, Abemaciclib (LY2835219) resulted in a partial response in a melanoma patient with CDKN2A loss and NRAS mutation (PMID: 27217383).', '在I期研究中，Abemaciclib（LY2835219）在具有CDKN2A缺失和NRAS突变的黑素瘤患者中可能有一定疗效。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22711607', '.', 'preclinical', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'glioma', 'brain cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000601', 'CDKN2B:CNV:.:.:loss', 'CDKN2B', 'CNV', 'CNV', '.', '.', 'loss', '.', '在多形性胶质母细胞瘤(GBM)异种移植系中，CDK抑制剂Palbociclib能够有效抑制携带CDKN2A/B缺失、CDK4野生型、CDK4的单拷贝缺失或高水平CDK6扩增的肿瘤细胞增殖。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 29: 2011 (suppl; abstr 8061)', '.', 'preclinical', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'B-cell lymphoma', 'lymphoma', '淋巴癌', 'na', 'sensitivity', 'EVI_000602', 'CDK6:CNV:.:.:gain', 'CDK6', 'CNV', 'CNV', '.', '.', 'gain', '.', '携带CDK4/6基因激活突变的肿瘤患者可能对哌柏西利敏感。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26578684', '.', 'preclinical', '4', 'vandetanib', 'vandetanib', 'vandetanib', '凡德他尼', 'vandetanib|凡德他尼', '4', 'non-small cell lung cancer ', 'lung cancer', '肺癌', 'na', 'resistance', 'EVI_000603', 'KDR:CNV:.:.:gain', 'KDR', 'CNV', 'CNV', '.', '.', 'gain', 'Preclinical studies suggestKDRactivates invasion but not survival pathways inKDR-amplified NSCLC models. Patients with NSCLC whose tumor hadKDRamplification were not associated with clinical benefit for vandetanib in combination with docetaxel.', '细胞试验表明KDR扩增可能激活肿瘤细胞侵袭。但携带KDR基因扩增的肿瘤患者可能对凡德他尼耐药。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('ENA 2014 (abstr 373)', '.', 'preclinical', '4', 'TAS-117', 'TAS-117', 'TAS-117', 'TAS-117', 'TAS-117|TAS-117', '2', 'cancer cell lines_', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000604', 'AKT2:CNV:.:.:gain', 'AKT2', 'CNV', 'CNV', '.', '.', 'gain', '.', '与ATP竞争性AKT抑制剂相比，具有AKT2扩增的细胞对变构AKT抑制剂更敏感，并且AKT2基因扩增可以是对变构AKT抑制剂的敏感性的标志物。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('ENA 2014 (abstr 373)', '.', 'preclinical', '4', 'MK-2206', 'MK-2206', 'MK-2206', 'MK-2206', 'MK-2206|MK-2206', '2', 'cancer cell lines_', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000605', 'AKT2:CNV:.:.:gain', 'AKT2', 'CNV', 'CNV', '.', '.', 'gain', '.', '与ATP竞争性AKT抑制剂相比，具有AKT2扩增的细胞对变构AKT抑制剂更敏感，并且AKT2基因扩增可以是对变构AKT抑制剂的敏感性的标志物。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22448344 ', '.', 'clinical study', '4', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000606', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'BRAF valine 600 (V600) mutations occur in 10% to 15% of colorectal cancers, yet these tumors show a surprisingly low clinical response rate (~5%) to selective RAF inhibitors such as vemurafenib, which have produced dramatic response rates (60%–80%) in melanomas harboring the identical BRAF V600 mutation. We found that EGFR-mediated MAPK pathway reactivation leads to resistance to vemurafenib in BRAF-mutant colorectal cancers and that combined RAF and EGFR inhibition can lead to sustained MAPK pathway suppression and improved efficacy in vitro and in tumor xenografts.', 'BRAF V600突变发生在10%至15%的结肠直肠癌中，然而这些肿瘤对选择性RAF抑制剂如vemurafenib显示出惊人的低临床反应率(约5%)，而在具有BRAF V600突变的黑色素瘤中却表现较高的反应率(60%-80%)。研究发现EGFR介导的MAPK通路重新激活可能与vemurafenib在BRAF突变结直肠癌患者中的耐药性相关。RAF和EGFR联合抑制可以导致持续的MAPK通路抑制，在体外试验中表现出明显的肿瘤抑制作用。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27148695', '.', 'clinical study', '4', 'enzalutamide', 'enzalutamide', 'enzalutamide', '恩扎卢胺', 'enzalutamide|恩扎卢胺', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', '前列腺癌', 'resistance', 'EVI_000607', 'AR:nonsynonymous SNV:exon4:p.L702H:.', 'AR', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.L702H', '.', 'The AR L702H mutation persists in the setting of enzalutamide therapy, suggesting continued fitness of cells containing this mutation in this therapeutic setting (Wyatt et al. 2016).', 'AR基因上的p.L702H突变可能与前列腺癌患者对enzalutamide产生耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27148588', '.', 'clinical study', '4', 'abiraterone', 'abiraterone', 'abiraterone', '阿比特龙', 'abiraterone|阿比特龙', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', '前列腺癌', 'resistance', 'EVI_000608', 'AR:nonsynonymous SNV:exon4:p.L702H:.', 'AR', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.L702H', '.', 'The emergence of AR L702H has been detected in patients in the setting of abiraterone treatment and is associated with poor outcomes, suggesting that this mutation confers resistance to this therapy', 'AR基因上的p.L702H突变可能与前列腺癌患者对abiraterone产生耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26530965', '.', 'case report', '4', 'lapatinib', 'lapatinib', 'lapatinib', '拉帕替尼', 'lapatinib|拉帕替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阳性)', '[ER(+);NA;HER2(+)]', 'resistance', 'EVI_000609', 'ERBB4:nonsynonymous SNV:exon20:p.H809G:.', 'ERBB4', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.H809G', '.', 'A patient with metastatic ER-positive and HER2-positive breast cancer receiving two lines of targeted therapy over 3 years. At the time of lapatinib resistance, the most abundant private mutation in plasma was in the tyrosine kinase domain of ERBB4 (p.H809G) (PMID:26530965).', '一名ER+、HER2+的乳腺癌患者接受靶向治疗3年。在发现其对lapatinib耐药后，检测出患者ERBB4基因上存在H809G突变。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20368568', '.', 'clinical trial - phase2', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', '甲状腺髓样癌', 'sensitivity', 'EVI_000612', 'RET:nonsynonymous SNV:exon11:p.C634R:.', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.C634R', '.', 'An FDA-approved TKI, whose targets include Ret. A phase 2 trial assessing the efficacy of sorafenib in metastic MTC reported RET mutations (M918T and C634R) in 10/16 sporadic cancers and in all 5 hereditary cancers (C634Y, C634R, M918T, C634F, and C618R). Of the sporadic cancers, 10/11 had SD and 1 had PR. Of the hereditary cancers, 4/5 had SD and 1 had PR (PMID:20368568). ', 'II期临床试验表明，携带RET C634R突变的晚期甲状腺髓样癌(MTC)患者对sorafenib可能敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20368568', '.', 'clinical trial - phase2', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', '甲状腺髓样癌', 'sensitivity', 'EVI_000613', 'RET:nonsynonymous SNV:exon11:p.C634Y:.', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.C634Y', '.', 'An FDA-approved TKI, whose targets include Ret. A phase 2 trial assessing the efficacy of sorafenib in metastic MTC reported RET mutations (M918T and C634R) in 10/16 sporadic cancers and in all 5 hereditary cancers (C634Y, C634R, M918T, C634F, and C618R). Of the sporadic cancers, 10/11 had SD and 1 had PR. Of the hereditary cancers, 4/5 had SD and 1 had PR (PMID:20368568). ', 'II期临床试验表明，携带RET C634Y突变的晚期甲状腺髓样癌(MTC)患者对sorafenib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20368568', '.', 'clinical trial - phase2', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', '甲状腺髓样癌', 'sensitivity', 'EVI_000614', 'RET:nonsynonymous SNV:exon10:p.C618R:.', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon10', 'p.C618R', '.', 'An FDA-approved TKI, whose targets include Ret. A phase 2 trial assessing the efficacy of sorafenib in metastic MTC reported RET mutations (M918T and C634R) in 10/16 sporadic cancers and in all 5 hereditary cancers (C634Y, C634R, M918T, C634F, and C618R). Of the sporadic cancers, 10/11 had SD and 1 had PR. Of the hereditary cancers, 4/5 had SD and 1 had PR (PMID:20368568). ', 'II期临床试验表明，携带RET C618R突变的晚期甲状腺髓样癌(MTC)患者对sorafenib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20368568', '.', 'clinical trial - phase2', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', '甲状腺髓样癌', 'sensitivity', 'EVI_000615', 'RET:nonsynonymous SNV:exon11:p.C634F:.', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.C634F', '.', 'An FDA-approved TKI, whose targets include Ret. A phase 2 trial assessing the efficacy of sorafenib in metastic MTC reported RET mutations (M918T and C634R) in 10/16 sporadic cancers and in all 5 hereditary cancers (C634Y, C634R, M918T, C634F, and C618R). Of the sporadic cancers, 10/11 had SD and 1 had PR. Of the hereditary cancers, 4/5 had SD and 1 had PR (PMID:20368568). ', 'II期临床试验表明，携带RET C634F突变的晚期甲状腺髓样癌(MTC)患者对sorafenib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19726763', 'NCT00607724', 'clinical trial - phase1', '4', 'vismodegib', 'vismodegib', 'vismodegib', '维莫德吉', 'vismodegib|维莫德吉', '4', 'basal cell carcinoma', 'basal cell carcinoma', '基底细胞癌', '基底细胞癌', 'sensitivity', 'EVI_000617', 'SMO:nonsynonymous SNV:exon9:p.W535L:.', 'SMO', 'nonsynonymous SNV', 'Exact_pos', 'exon9', 'p.W535L', '.', 'One patient with metastatic BCC harboring the SMO mutation, W535L, and two PTCH1 mutations displayed stable disease after treatment with vismodegib (PMID:19726763).', '一名携带SMO W535L突变的转移性基底细胞癌的患者在接受vismodegib治疗后获得部分缓解。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22402123', '.', 'preclinical', '4', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901|PD-0325901', '2', 'cancer cell lines', 'cancer cell lines', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000618', 'MAP2K2:nonsynonymous SNV:exon6:p.V215E:.', 'MAP2K2', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.V215E', '.', '.', '细胞学试验表明，携带该基因突变的肿瘤细胞可能对PD-0325901耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22402123', '.', 'preclinical', '4', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901|PD-0325901', '2', 'cancer cell lines', 'cancer cell lines', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000619', 'MAP2K1:nonsynonymous SNV:exon3:p.L115P:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.L115P', '.', '.', '细胞学试验表明，携带该基因突变的肿瘤细胞可能对PD-0325901耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22402123|PMID:21705440', '.', 'preclinical', '4', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901|PD-0325901', '2', 'cancer cell lines', 'cancer cell lines', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000620', 'MAP2K1:nonsynonymous SNV:exon3:p.F129L:.', 'MAP2K1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.F129L', '.', '.', '细胞学试验表明，携带该基因突变的肿瘤细胞可能对PD-0325901耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:16954519', 'CSTI571 B2222', 'clinical trial - phase2', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000621', 'KIT:nonsynonymous SNV:exon17:p.C809G:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.C809G', '.', 'Different molecular mechanisms are responsible for primary and secondary imatinib resistance in GISTs. These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.', 'KIT基因的C809G突变可能与imatinib的耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:16954519', 'CSTI571 B2222', 'clinical trial - phase2', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000622', 'KIT:nonsynonymous SNV:exon17:p.D820A:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D820A', '.', 'Different molecular mechanisms are responsible for primary and secondary imatinib resistance in GISTs. These findings have implications for future approaches to the growing problem of imatinib resistance in patients with advanced GISTs.', 'KIT基因的D820A突变可能与imatinib的耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:15685537', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000623', 'KIT:nonsynonymous SNV:exon15:p.D716N:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.D716N', '.', 'This study shows the high frequency of KIT/PDGFRA kinase domain mutations in patients with secondary resistance and defines genomic amplification of KIT / PDGFRA as an alternative cause of resistance to the drug. In a subset of patients, cancer cells lost their dependence on the targeted tyrosine kinase. Our findings show the sensitivity of the imatinib-resistant KIT -T670I and KIT -V654A and of PDGFRA -D842V mutants to PKC412.', 'KIT基因的D716N突变可能与imatinib的耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:15685537', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000624', 'KIT:nonsynonymous SNV:exon17:p.D816G:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D816G', '.', 'This study shows the high frequency of KIT/PDGFRA kinase domain mutations in patients with secondary resistance and defines genomic amplification of KIT / PDGFRA as an alternative cause of resistance to the drug. In a subset of patients, cancer cells lost their dependence on the targeted tyrosine kinase. Our findings show the sensitivity of the imatinib-resistant KIT -T670I and KIT -V654A and of PDGFRA -D842V mutants to PKC412.', 'KIT基因的D816G突变可能与imatinib的耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18955458', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000625', 'KIT:nonsynonymous SNV:exon17:p.D816A:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D816A', '.', 'The clinical activity of sunitinib after imatinib failure is significantly influenced by both primary and secondary mutations in the predominant pathogenic kinases, which has implications for optimization of the treatment of patients with GIST.', 'KIT基因D816A突变可能与胃肠间质瘤患者对imatinib治疗的耐药性有关。一项临床研究结果显示，imatinib对V560D突变的细胞系抑制作用较强，而对V560D+D816H突变的细胞系几乎没有抑制作用。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25735500', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000626', 'KIT:nonsynonymous SNV:exon17:p.S821F:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.S821F', '.', 'In subsets of gastrointestinal stromal tumors (GISTs), mutations of the KIT and PDGFRA receptor tyrosine kinases correlate with tumor prognosis and response to tyrosine kinase inhibitors (TKIs). Determining genotypes in TKI-resistant GISTs is challenging due to the potential risks and limitations of repeated biopsies during the course of treatment. We prospectively collected plasma samples from three GIST patients harboring KIT mutations that were detected in tissue DNA. The plasma samples were then analyzed for mutations in KIT, PDGFRA, and BRAF via next-generation sequencing. We were able to identify primary KIT mutations in all plasma samples. Additional mutations, including KIT exon 17 S821F and PDGFRA exon 18 D842V, were detected in the patient-matched plasma samples during follow-up and appeared to result in decreased sensitivity to TKIs. Our results demonstrate an approach by which primary and secondary mutations are readily detected in blood-derived circulating tumor DNA from patients with GIST. These mutations can be used as biomarkers for prediction of treatment response. The identification of a resistance mutation in plasma DNA will allow early change to alternative TKIs or dose escalation of imatinib for optimal patient management.', 'KIT基因的S821F突变可能与imatinib的耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25886408', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000629', 'KIT:nonsynonymous SNV:exon14:p.N680K:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.N680K', '.', '.', '携带KIT基因N680K突变的胃肠间质瘤患者可能对imatinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25886408', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000630', 'KIT:nonframeshift deletion:exon17:p.K818_D820delinsN:.', 'KIT', 'nonframeshift deletion', 'Exact_pos', 'exon17', 'p.K818_D820delinsN', '.', '.', 'KIT基因的K818_D820delinsN突变可能与伊马替尼的耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26648736', '.', 'clinical study', '4', '[Endocrine therapy]', '[Endocrine therapy]', '[Endocrine therapy]', '【激素治疗】', '[Endocrine therapy]|【激素治疗】', '5', 'breast cancer', 'breast cancer', '乳腺癌', '[ER(+);PR(+);NA]', 'resistance', 'EVI_000631', 'ESR1:nonframeshift deletion:exon8:p.L536_D538delinsP:.', 'ESR1', 'nonframeshift deletion', 'Exact_pos', 'exon8', 'p.L536_D538delinsP', '.', 'ESR1 mutation was found in 12.1% of a large cohort of advanced breast cancer patients. Exemestane in combination with everolimus might be a reasonable option. Prospective studies are warranted to validate these findings.', 'ESR1基因的p.L536_D538delinsP突变可能与乳腺癌患者对激素治疗的耐药性相关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26134233', '.', 'case report', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer ', 'non-small cell lung cancer', '肺癌', '肺腺癌', 'resistance', 'EVI_000632', 'ALK:nonsynonymous SNV:exon21:p.G1123S:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.G1123S', '.', '.', '携带ALK融合基因的肿瘤患者对ceritinib敏感，但发生G1123S突变后可能产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26464158', '.', 'clinical study', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'non-small cell lung cancer ', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000633', 'ALK:nonsynonymous SNV:exon22:p.I1171S:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171S', '.', '.', '携带ALK融合基因的肺癌患者对alectinib敏感，但发生I1171S突变后可能产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24736079', '.', 'clinical study', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer ', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000634', 'ALK:nonsynonymous SNV:exon23:p.F1174V:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174V', '.', '.', '携带ALK融合基因的肺癌患者对crizotinib敏感，但发生F1174V突变后可能产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25393796', '.', 'clinical study', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'non-small cell lung cancer ', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000635', 'ALK:nonsynonymous SNV:exon22:p.I1171N:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171N', '.', '.', '携带ALK融合基因的肿瘤患者对Alectinib敏感，但同时发生I1171N突变后可能产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer ', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000636', 'ALK:nonsynonymous SNV:exon23:p.F1174V:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174V', '.', '.', '携带ALK融合基因的肿瘤患者对ceritinib敏感，但同时发生F1174V突变后可能产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer ', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000637', 'ALK:nonsynonymous SNV:exon23:p.F1174C:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174C', '.', '.', '携带ALK融合基因的肿瘤患者对ceritinib敏感，但同时发生F1174C突变后可能产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26698910', 'NCT01970865', 'clinical trial - phase2', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'lung cancer', 'lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000638', 'ALK:nonsynonymous SNV:exon22:p.C1156Y:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.C1156Y', '.', 'In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y). Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor. When her tumor relapsed, sequencing of the resistant tumor revealed an ALK L1198F mutation in addition to the C1156Y mutation. The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding. However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib. The patient received crizotinib again, and her cancer-related symptoms and liver failure resolved.', '在ALK融合基因阳性的肺癌患者中，ALK基因的C1156Y和L1198F突变可能导致患者对crizotinib耐药；但是携带C1156Y突变的患者可能对lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26698910', 'NCT01970865', 'clinical trial - phase2', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'lung cancer', 'lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000639', 'ALK:nonsynonymous SNV:exon23:p.L1198F:.', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1198F', '.', 'In a patient who had metastatic anaplastic lymphoma kinase (ALK)-rearranged lung cancer, resistance to crizotinib developed because of a mutation in the ALK kinase domain. This mutation is predicted to result in a substitution of cysteine by tyrosine at amino acid residue 1156 (C1156Y). Her tumor did not respond to a second-generation ALK inhibitor, but it did respond to lorlatinib (PF-06463922), a third-generation inhibitor. When her tumor relapsed, sequencing of the resistant tumor revealed an ALK L1198F mutation in addition to the C1156Y mutation. The L1198F substitution confers resistance to lorlatinib through steric interference with drug binding. However, L1198F paradoxically enhances binding to crizotinib, negating the effect of C1156Y and resensitizing resistant cancers to crizotinib. The patient received crizotinib again, and her cancer-related symptoms and liver failure resolved.', '在ALK融合基因阳性的肺癌患者中，ALK基因的L1198F突变可能导致患者对lorlatinib耐药.', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23743569', 'NCT00419159', 'clinical trial - phase2', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'metastatic colorectal adenocarcinoma', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000640', 'KRAS:nonsynonymous SNV:exon2:p.G13.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G13.', '.', 'KRAS mutational status did not significantly influence PFS in either the weekly or daily  everolimus schedules or OSor DCR in the weekly schedule. However, among patients receiving daily everolimus, those with a KRAS mutation experienced significantly shorter median OSand lower DCRthan those with wild-type KRAS.Patients with BRAF mutation had a greater risk of death or progression than patients with wild-type BRAF.Extensive biomarker analyses show that KRAS-mutated patients receiving daily everolimus experienced significantly poorer outcomes compared with wild-type KRAS patients. We also confirmed that patients with BRAF mutation had worse survival than patients with wild-type BRAF.', '40%-60%转移性结直肠癌患者会发生(PI3K)/Akt/mTOR通路调节异常。一项临床II期试验中，对结直肠癌患者使用mTOR抑制剂everolimus治疗。根据给药剂量分为70 mg/周和10 mg/天两组：疾病控制率分别为25%和26%，中位无进展生存期均为1.8个月，中位总存活期分别为5.9个月和4.9个月。对两组患者突变分析， 70 mg/周：KRAS突变/野生型患者无进展生存期、总存活率及疾病控制率无显著差异；10 mg/天：KRAS突变/野生型患者疾病控制率分别为为17.1%/3.0%。9.5%的患者检测到BRAF突变，死亡和疾病进展风险高于野生型。PTEN表达低/高患者获益无显著差异。所以转移性结直肠癌患者无法从everolimus的单一治疗中获益，10 mg/天治疗时KRAS/BRAF突变患者预后较差。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24651628', 'NCT00087685', 'clinical trial - phase2', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'endometrial cancer', 'Uterine Neoplasm', '子宫肿瘤', '子宫内膜癌', 'resistance', 'EVI_000641', 'KRAS:nonsynonymous SNV:exon2:p.G12.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'Eighty-three percent (5/6) of the patients with prolonged stable disease on everolimus exhibited intact PTEN expression. Loss of PTEN expression was associated with a PPV of 13% (95% CI: 0.7%–53.3%) and a NPV of 69%.All 28 patients were evaluable for pS6rp status analysis. Fifty percent of patients exhibited positive pS6rp staining, however, responders were twice as likely to lack pS6rp compared to non-responders . Thus, pS6rp positive staining was associated with a PPV 14% (95%CI: 2.5%–43.8%) and a NPV of 71%.There were 7 KRAS mutations found (Table 2). Interestingly, 80% (4/5) of patients with prolonged stable disease were KRAS wildtype (Table 1). KRAS mutations were associated with a PPV of 14% (95% CI: 0.8%–58%) and a NPV of 75% (95% CI: 47%–92%).', '一项关于依维莫司的临床II期试验表明KRAS突变的子宫内膜癌患者对everolimus可能耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18199554|PMID:23328556', '.', 'preclinical', '4', 'lapatinib', 'lapatinib', 'lapatinib', '拉帕替尼', 'lapatinib|拉帕替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000642', 'ERBB2:nonframeshift insertion:exon20:.:exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'The HER2_YVMA and G776V,C insertions found in NSCLC tumors conferred resistance to lapatinib when expressed exogenously in cells.', '细胞学试验结果表明，野生型ERBB2肿瘤细胞系对lapatinib抑制非常敏感，但对gefitinib抑制却不敏感。然而，ERBB2 YVMA和ERBB2 G776VinsC（20外显子插入）突变的肿瘤细胞系对lapatinib或gefitinib都具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26169970', '.', 'preclinical', '4', 'lenvatinib', 'lenvatinib', 'lenvatinib', '仑伐替尼', 'lenvatinib|仑伐替尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000645', 'NRAS:nonsynonymous SNV:exon2:p.G12.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', 'In a Phase I clinical trial, Lenvima (lenvatinib) treatment resulted in stable disease in 50% (1/2) of melanoma patients harboring both BRAF and NRAS mutations (PMID: 26169970).', '在I期临床试验中，携带NRAS基因突变的黑色素瘤患者对Lenvima(lenvatinib)治疗可能有响应。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26343583', '.', 'preclinical', '4', 'LY3009120', 'LY3009120', 'LY3009120', 'LY3009120', 'LY3009120|LY3009120', '1', 'acute myeloid leukemia', 'leukemia', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000646', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a preclinical study, LY3009120 inhibited proliferation of human NRAS mutant acute myeloid leukemia cell lines in culture (PMID: 26343583).', '在临床前研究中，LY3009120可以抑制培养物中人NRAS突变型急性髓性白血病细胞系的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24791855', '.', 'preclinical', '4', 'MK-1775', 'MK-1775', 'MK-1775', 'MK-1775', 'MK-1775|MK-1775', '2', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000647', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a preclinical study, MK-1775 showed efficacy in NRAS mutant melanoma and in mutant KRAS colorectal, pancreatic, and lung cancers (PMID: 24791855).', '在临床前研究中，MK-1775对NRAS突变型的Ba/F3细胞系显示出抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21289267', '.', 'preclinical', '4', 'MK2206', 'MK-2206', 'MK-2206', 'MK-2206', 'MK-2206|MK-2206', '2', 'thyroid cancer', 'cancer cell lines_', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000648', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with  PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring NRAS Q61R (PMID: 21289267).', '在临床前研究中，MK2206可以抑制培养物中携带NRAS基因激活突变(Q61R)的间变甲状腺癌细胞的生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22460902', '.', 'preclinical', '4', 'obatoclax', 'obatoclax', 'obatoclax', '奥巴克拉', 'obatoclax|奥巴克拉', '2', 'Advanced Solid Tumor', 'cancer cell lines_', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000649', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a preclinical study, obatoclax decreased proliferation in human tumor cell lines with NRAS mutation in culture (PMID: 22460902).', '在临床前研究中，obatoclax可以抑制NRAS突变的人肿瘤细胞的增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27488531', '.', 'preclinical', '4', 'Palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000650', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a preclinical study, Ibrance (palbociclib) treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrated a lack of benefit (PMID: 27488531).', '在临床前研究中，Ibrance(palbociclib)不能抑制携带NRAS突变的黑色素瘤细胞的生长。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27488531', '.', 'preclinical', '4', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901|PD-0325901', '2', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000651', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a preclinical study, PD-0325901 treatment resulted in stable tumor growth in melanoma cell line xenograft models harboring an NRAS mutation, however, growth later ensued and thus, demonstrates a lack of benefit (PMID: 27488531).', '在临床前研究中，PD-0325901不能抑制具有NRAS突变的黑色素瘤细胞系异种移的肿瘤生长。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23406027', 'NCT00970359', 'clinical trial - phase1', '4', 'Selumetinib', 'selumetinib', 'selumetinib', '司美替尼', 'selumetinib|司美替尼', '2', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', '滤泡状甲状腺癌', 'sensitivity', 'EVI_000652', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a Phase I study, selumetinib demonstrated an increase in iodine uptake and retention in a subgroup of patients with thyroid cancer that was refractory to radioiodine; including patients with BRAF and NRAS mutations disease (PMID: 23406027).', '一项I期研究，在一个放射性碘难治性的滤泡状甲状腺癌患者的亚组中，selumetinib提高了患者对放射性碘的吸收和保留，且对携带NRAS突变的患者其有效性可能更高。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26343583', '.', 'preclinical', '4', 'Vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000653', 'NRAS:nonsynonymous SNV:exon2:p.G13.:.', 'NRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G13.', '.', 'In a preclinical study, human melanoma cell lines harboring a mutation in NRAS were resistant to Zelboraf (vemurafenib) mediated growth inhibition in culture (PMID: 26343583).', '在临床前研究中，携带NRAS基因突变的人黑色素瘤细胞系对培养物中的Zelboraf(vemurafenib)具有抗性。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:24588695', '.', 'guideline:NCCN', '1', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000656', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。携带这些基因突变的肿瘤患者可能对EGFR信号通路抑制剂类靶向药物耐药。NCCN指南建议KRAS基因突变与肿瘤患者对EGFR抑制剂的原发耐药有关。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000657', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。携带这些基因突变的肿瘤患者可能对EGFR信号通路抑制剂类靶向药物耐药。NCCN指南建议KRAS基因突变与肿瘤患者对EGFR抑制剂的原发耐药有关。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colon cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000658', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。结直肠癌患者需要检测KRAS和NRAS基因的突变状态。携带KRAS或者NRAS激活突变的肿瘤患者不应当使用EGFR抗体药物（如西妥昔单抗或帕尼单抗）。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000659', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。携带这些基因突变的肿瘤患者可能对EGFR信号通路抑制剂类靶向药物耐药。NCCN指南建议KRAS基因突变与肿瘤患者对EGFR抑制剂的原发耐药有关。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000660', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。携带这些基因突变的肿瘤患者可能对EGFR信号通路抑制剂类靶向药物耐药。NCCN指南建议KRAS基因突变与肿瘤患者对EGFR抑制剂的原发耐药有关。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000661', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。携带这些基因突变的肿瘤患者可能对EGFR信号通路抑制剂类靶向药物耐药。NCCN指南建议KRAS基因突变与肿瘤患者对EGFR抑制剂的原发耐药有关。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:27252416', '.', 'guideline:NCCN', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'lung cancer', 'lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000662', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。携带这些基因突变的肿瘤患者可能对EGFR信号通路抑制剂类靶向药物耐药。NCCN指南建议KRAS基因突变与肿瘤患者对EGFR抑制剂的原发耐药有关。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27252416', '.', 'clinical study', '4', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib|rociletinib', '3', 'lung cancer', 'lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000663', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。携带这些基因突变的肿瘤患者可能对EGFR信号通路抑制剂类靶向药物耐药。NCCN指南建议KRAS基因突变与肿瘤患者对EGFR抑制剂的原发耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colon cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000664', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。结直肠癌患者需要检测KRAS和NRAS基因的突变状态。携带KRAS或者NRAS激活突变的肿瘤患者不应当使用EGFR抗体药物（如西妥昔单抗或帕尼单抗）。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colon cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000665', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。结直肠癌患者需要检测KRAS、NRAS和BRAF基因的突变状态。携带这些基因激活突变的肿瘤患者不应当使用EGFR抗体药物（如西妥昔单抗或帕尼单抗）。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colon cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_000666', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'KRAS和NRAS基因exon2(codons 12 and 13),3(codons 59 and 61),以及4(codons 117 and 146)位点的突变会导致RAS信号通路的异常活化(PMID:20570890)。RAS基因是EGFR通路下游的效应因子，突变型RAS基因编码异常的蛋白会促进肿瘤细胞的生长和扩散，且不受上游EGFR信号影响。结直肠癌患者需要检测KRAS、NRAS和BRAF基因的突变状态。携带这些基因激活突变的肿瘤患者不应当使用EGFR抗体药物（如西妥昔单抗或帕尼单抗）。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:15184865', '.', 'preclinical', '4', 'vandetanib', 'vandetanib', 'vandetanib', '凡德他尼', 'vandetanib|凡德他尼', '4', 'thyroid cancer', 'thyroid cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_000667', 'RET:nonsynonymous SNV:exon14:p.V804L:.', 'RET', 'nonsynonymous SNV', 'Partial_pos', 'exon14', 'p.V804L', '.', 'RET mutations in certain inherited forms of medullary thyroid carcinoma, as in codon 804, seem to confer resistance to vandetanib', 'RET基因804密码子的基因突变(V804L、V804M)可能导致vandetanib的耐药，但V804G突变对vandetanib仍然敏感。', 'S', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27042123', '.', 'clinical study', '4', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'resistance', 'EVI_000672', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', 'EGFR 20外显子插入突变仅次于EGFR 19和21 L858R，是EGFR突变的第三大类型。常见于不吸烟者，与年龄、性别、种族或肿瘤分期没有关联。肿瘤形态与常见EGFR突变相似，但固相结缔组织更多些。目前的研究结果不仅解释了不同的EGFR 20外显子插入突变及其对EGFR-TKIs的应答效果，也提供给EGFR 20外显子插入突变的NSCLC患者不同的靶向治疗策略和选择：如果采用测序方法检测到A763_Y764insFQEA的患者可以考虑使用TKI治疗，20外显子的其他点位则不适合EGFR-TKIs治疗。一项临床研究中，对38名携带EGFR突变的患者采用icotinib治疗后，19外显子缺失突变的患者ORR为60%(n=15)，L858R突变的患者ORR为43.8%(n=16)，而在20外显子插入突变的患者(n=15)中未观察到PR。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17363509', '.', 'preclinical', '4', 'niluotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'resistance', 'EVI_000673', 'KIT:nonsynonymous SNV:exon13:p.V654A:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.V654A', '.', 'PKC412 strongly inhibited imatinib-resistant D816V c-KIT.Alternative c-KIT inhibitors, nilotinib (AMN107) and PKC412, were also less active on V560G/V654A c-KIT than on the V560G single mutant; however, nilotinib, like imatinib, potently inhibited the V560G mutant.', '携带KIT突变的胃肠间质瘤患者经靶向治疗后可能出现二次突变，从而导致患者对KIT抑制剂(imatinib、nilotinib和PKC412)耐药。临床前试验中，将KIT V654A突变与GIST特征突变V560G在体外表达，表达V560G/V654A双突变的细胞相比单一表达V560G的细胞对imatinib的敏感性降低；同时nilotinib(AMN107)和PKC412(midostaurin)对表达V560G/V654A 双突变的细胞敏感性相比表达V560G的细胞要低；但PKC412可抑制携带imatinib耐药性突变D816V细胞的增殖。所以胃肠间质瘤细胞发生V654A二次突变可能导致对KIT抑制剂imatinib、nilotinib和PKC412的耐药性。\n', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colon cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'sensitivity', 'EVI_000674', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', '结直肠癌患者需要检测KRAS、NRAS和BRAF基因的突变状态。携带这些基因激活突变的肿瘤患者不应当使用EGFR抗体药物（如西妥昔单抗或帕尼单抗）,反之若患者的这些基因不存在激活突变，则可能从EGFR抗体药物的治疗中获益。NCCN同时指出，原发右侧的结肠癌I线使用帕尼单抗或西妥昔单抗治疗效果欠佳，或没有原发左侧结肠癌效果好。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colon cancer', 'colorectal cancer', '结直肠癌', '结直肠癌', 'sensitivity', 'EVI_000675', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', '结直肠癌患者需要检测KRAS、NRAS和BRAF基因的突变状态。携带这些基因激活突变的肿瘤患者不应当使用EGFR抗体药物（如西妥昔单抗或帕尼单抗）,反之若患者的这些基因不存在激活突变，则可能从EGFR抗体药物的治疗中获益。NCCN同时指出，原发右侧的结肠癌I线使用帕尼单抗或西妥昔单抗治疗效果欠佳，或没有原发左侧结肠癌效果好。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('CSCO黑色素瘤专家委员会,人民卫生出版社2017版|Druglabel:vemurafenib_Revised:11/2017', '.', 'guideline:CSCO', '1', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'melanoma', 'melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_000680', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '全球首个关于BRAF抑制剂应用于BRAF突变型转移性黑色素瘤的3期临床试验(BRIM-3试验)显示，vemurafenib用于具有BRAF V600突变的转移黑色素瘤患者，起效迅速，有效率高达57%，中位总生存时间(OS)为13.6个月，中位无进展生存时间(PFS)达到6.9个月。因此，国内外权威指南中，均列明vemurafenib作为BRAF V600突变阳性的不可切除或转移性黑色素瘤一线标准治疗方案。与治疗BRAF突变黑色素瘤的传统药物dacarbazine相比，dacarbazine的起效时间缩短约一半，客观缓解率(ORR)提升了近7倍，无进展生存时间(PFS)延长近半年，而dacarbazine标准化疗对照组的无进展生存时间仅为1.6个月。此外，vemurafenib作为口服靶向药物，较少出现因不良反应而停止用药的情况。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:brigatinib_Revised: 12/2018', 'NCT02094573', 'guideline:FDA', '1', 'brigatinib', 'brigatinib', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_000681', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', 'FDA批准Alunbrig(brigatinib)用于治疗进展期或crizotinib不耐受的ALK阳性的转移性非小细胞肺癌患者。针对crizotinib耐药的肺癌患者，有效率55%，控制率86%。Brigatinib是一种处于观察期的口服酪氨酸激酶抑制剂(TKI)，对ALK重排和crizotinib耐药突变均具有临床前活性，该临床I/II期试验均显示了brigatinib的良好前景。ALTA临床试验招募222位ALK阳性而且使用crizotinib之后耐药的晚期非小细胞肺癌患者，随机分成两组，A组患者每天口服90mg；B组患者前七天每天口服90mg，接下来每天口服180mg。A组的客观缓解率是45%，1名患者肿瘤消失；B组的客观缓解率是55%，5名患者肿瘤完全消失。AB两组的疾病控制率都超过了80%。尤其值得一提的是，对于脑转移的患者来说，A组42%的患者颅内肿瘤有明显缩小，而B组有67%的患者颅内肿瘤缩小。最常见的3级以上的不良反应(A/B)为：肌酸磷酸激酶升高(3%/8%)，高血压(4%/5%)，肺炎(3%/5%)，皮疹(1%/4%)，脂肪酶升高(3%/2%)，局限性肺炎(2%/3%)。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000682', 'ALK:nonsynonymous SNV:exon22:p.T1151_L1152insT:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.T1151_L1152insT', '.', 'In vitro studies with this highly selective ALK inhibitor show a five-fold greater sensitivity of NSCLC cells positive for EM4-ALK fusion, compared to crizotinib. Additionally, two independent studies showed AP26113 could overcome crizotinib resistance mediated by acquired a L1196M mutation, as evidenced by an in vivo xenograft model (PMID:21502504;PMID:23239810).', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000683', 'ALK:nonsynonymous SNV:exon22:p.L1152R:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.L1152R', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000684', 'ALK:nonsynonymous SNV:exon22:p.L1152P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.L1152P', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000685', 'ALK:nonsynonymous SNV:exon22:p.C1156Y:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.C1156Y', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000686', 'ALK:nonsynonymous SNV:exon22:p.I1171N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171N', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000687', 'ALK:nonsynonymous SNV:exon23:p.F1174C:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174C', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000688', 'ALK:nonsynonymous SNV:exon23:p.F1174L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000689', 'ALK:nonsynonymous SNV:exon23:p.F1174V:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174V', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000690', 'ALK:nonsynonymous SNV:exon23:p.V1180L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.V1180L', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000691', 'ALK:nonsynonymous SNV:exon23:p.L1196M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1196M', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000692', 'ALK:nonsynonymous SNV:exon23:p.L1198F:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1198F', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000693', 'ALK:nonsynonymous SNV:exon23:p.G1202R:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.G1202R', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000694', 'ALK:nonsynonymous SNV:exon23:p.D1203N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.D1203N', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000695', 'ALK:nonsynonymous SNV:exon23:p.S1206F:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.S1206F', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000696', 'ALK:nonsynonymous SNV:exon23:p.S1206Y:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.S1206Y', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000697', 'ALK:nonsynonymous SNV:exon25:p.E1210K:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.E1210K', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000698', 'ALK:nonsynonymous SNV:exon25:p.G1269A:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.G1269A', '.', '.', '在ALK+细胞系中，brigatinib可以抑制ALK活性(IC50，10 nmol/L)，效价比crizotinib高12倍。皮下或颅内植入ALK+肿瘤的小鼠也观察到了brigatinib的抑瘤效果。细胞系研究发现，brigatinib对于17个有ALK耐药突变(T1151Tins，l1152R/P，C1156Y，I1171N，F1174L，F1174V，L1196M，G1202R，D1203N，G1269A，V1180L，L1198F等)的ALK融合仍然保持相当的活性，并且在临床浓度下比crizotinib，ceritinib和alectinib相比表现出更强的抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:cobimetinib_Revised: 1/2018', '.', 'guideline:FDA', '1', 'vemurafenib + cobimetinib', 'vemurafenib + cobimetinib', 'vemurafenib + cobimetinib', '维莫非尼 + cobimetinib', 'vemurafenib + cobimetinib|维莫非尼 + cobimetinib', '4', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_000699', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '英国伦敦皇家马斯登医院Larkin J等报告的Ⅲ期临床试验显示，维莫非尼(vemurafenib)和Cobimetinib联合用药可显著改善携带BRAF V600突变转移性黑色素瘤患者的PFS，而不良反应有些许增加（N Engl J Med. 2014;371:1867-76）。目前认为在具有BRAF突变的黑色素瘤患者中联用BRAF和MEK抑制剂可以延迟BRAF抑制剂耐药的出现。这项评价维莫非尼和Cobimetinib联用的Ⅲ期临床试验入组不可切除的局部进展期或IV期、具有BRAF V600突变的初治患者共计495例，随机接受维莫非尼联合Cobimetinib或维莫非尼联合安慰剂治疗。主要研究终点为研究者评估的无进展生存（PFS）。结果显示，中位PFS在联用组为9.9个月，单药组6.2个月（死亡或疾病进展HR=0.51，95%CI 0.39-0.68，P<0.001）。完全或部分缓解率在联用组为68%，单药组45%（P<0.001）；CR率联用组10%，单药组4%。对OS的中期分析显示9个月生存率在联用组为81%（95%CI 75-87%），单药组73%（95%CI 65-80%）。联用组3级以上不良反应较单药组发生率高（65%和59%），但数据不具有统计学意义，与停药率无关。继发皮肤肿瘤率在联用组较低(NCT01689519)。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27979383', 'NCT02008227', 'clinical trial - phase3', '4', 'atezolizumab', 'atezolizumab', 'atezolizumab', '阿替利珠单抗', 'atezolizumab|阿替利珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000700', 'EGFR:nonsynonymous SNV:exon21:p.L858R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', '2017年1月，权威医学杂志《柳叶刀》公布了罗氏的PD-L1抗体Atezolizumab对比多西他赛用于晚期非小细胞肺癌的三期临床数据，一共招募了1225位患者。其主要结果表明PD-L1抑制剂对非小细胞肺癌的治疗可以改善其总体生存期。但是，其中有85位EGFR突变并且靶向药耐药的患者，42位接受PD-L1抗体治疗，43位使用多西他赛。结果表明，PD-L1抗体Atezolizumab的效果和多西他赛相比还差一些（median overall survival:10.5 vs 16.2月，HR:1.24 [95% CI 0.71–2.18])。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27979383', 'NCT02008227', 'clinical trial - phase3', '4', 'atezolizumab', 'atezolizumab', 'atezolizumab', '阿替利珠单抗', 'atezolizumab|阿替利珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000701', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', '2017年1月，权威医学杂志《柳叶刀》公布了罗氏的PD-L1抗体Atezolizumab对比多西他赛用于晚期非小细胞肺癌的三期临床数据，一共招募了1225位患者。其主要结果表明PD-L1抑制剂对非小细胞肺癌的治疗可以改善其总体生存期。但是，其中有85位EGFR突变并且靶向药耐药的患者，42位接受PD-L1抗体治疗，43位使用多西他赛。结果表明，PD-L1抗体Atezolizumab的效果和多西他赛相比还差一些（median overall survival:10.5 vs 16.2月，HR:1.24 [95% CI 0.71–2.18])。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:nivolumab_Revised_07/2017', '.', 'guideline:FDA', '1', 'nivolumab', 'nivolumab', 'nivolumab', '纳武利尤单抗', 'nivolumab|纳武利尤单抗', '4', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_000704', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '纳武利尤单抗（Nivolumab）适用于单药治疗BRAF V600野生型不可切除或转移性黑色素瘤；作为单药治疗BRAF V600突变阳性的不可切除的或转移性黑色素瘤；联合伊匹木单抗治疗不可切除的或转移性黑色素瘤。FDA批准纳武单抗单药治疗BRAF V600突变型不可切除的转移性黑色素瘤，其安全性和有效性是基于一项随机开放的Ⅲ期临床试验结果。试验中纳入了370名患者按2：1随机分配至纳武单抗治疗组或化疗治疗组（达卡巴嗪单药治疗或卡铂+紫杉醇治疗），患者对ipilimumab治疗有疾病进展。纳武单抗的有效性评价是基于纳武单抗治疗组至少随访6个月的120名患者相关的单臂、非对比、计划性期中分析。这些人群中的主要疗效指标由独立审查委员会（IRC）根据RECIST 1.1评估的客观响应率（ORR）和反应持续时间。IRC评估的ORR为32%（95% CI: 23, 41），其中4位完全响应，34位部分响应。在38位产生响应的患者中，33名患者（87%）具有持续响应，响应时间范围为2.6+-10+个月，其中13名患者持续响应6个月以上。在携带和非携带BRAF V600突变阳性的黑色素瘤患者中均存在客观响应(NCT01721746)。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:niraparib_Revised_3/2017', '.', 'guideline:FDA', '1', 'niraparib', 'niraparib', 'niraparib', '尼拉帕利', 'niraparib|尼拉帕利', '3', 'ovarian', '.', '卵巢癌', 'na', 'sensitivity', 'EVI_000710', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2017.3.27，FDA批准了TESARO公司研发的PARP类口服抑制剂Niraparib，作为维持治疗用于治疗对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。此处和奥拉帕尼批准的适应症相比，少了BRCA胚系突变的要求，就是使用Niraparib可以不需要进行BRCA胚系突变检测。III期临床试验NOVA中，纳入553例之前传统治疗失败的对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。随机分配至Niraparib（300mg每天口服）组及安慰剂组。而且患者人群按照是否有胚系突变的BRCA基因而划分两组。结果无论有无BRCA胚系突变（gBRCA），Niraparib都展现出强势的生存优势。在生殖细胞带有BRCA突变的组里，经过niraparib治疗的患者无进展生存期的中位数长达21个月，比对照组的5.5个月得到了显著延长。在生殖细胞不带有BRCA基因突变的组里，niraparib同样疗效显著。经治后，患者的无进展生存期中位数为9.3个月，而对照组中的这一数字仅为3.9个月。将此类患者的整体死亡风险下调55%。18个月随访节点，30%的患者还未出现疾病进展。在这些患者里，niraparib对那些肿瘤上带有同源重组修复突变（HRD）的患者的治疗效果更为出色。由于HRD能影响双链DNA修复，研究人员设想在niraparib对DNA修复机制的进一步抑制下，肿瘤细胞会因为出现大量DNA损伤而死亡。这个设想在临床试验中得到了证实，对肿瘤细胞带有HRD的患者来说，niraparib治疗能将她们的无进展生存期中位数从3.8个月（对照组）延长到12.9个月（试验组）。目前市面上已经上市了两类PARP抑制剂药物奥拉帕尼（olaparib）以及卢卡帕利（rucaparib）。但这两种药物在批准时都需要患者具有BRCA基因的突变。而新上市的PARP抑制剂新药Niraparib试验结果表明，不仅在BRCA胚系突变的患者中表现出优势（21:5.5月），在无BRCA胚系突变的患者中也同样具有明显的生存优势（9.3:3.9月）。因而在FDA批准时并未要求患者一定要具有BRCA的突变，而只是提及铂类敏感，因为顺铂、卡铂等铂类药物也是作用于DNA结构，对铂类药物的敏感性一定程度上反映了肿瘤细胞对DNA破坏类药物（如PARP抑制剂）的潜在敏感性，提高适用人群的筛选性。另外，铂类与PARP先后顺序也存在相互协同治疗作用。这意味着卵巢癌患者近期对铂类治疗敏感（达到PR以上）的患者都可以尝试使用Niraparib，适用患者人群范围大大增加。同时该药物主要口服用药，增加治疗便利。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:niraparib_Revised_3/2017', '.', 'guideline:FDA', '1', 'niraparib', 'niraparib', 'niraparib', '尼拉帕利', 'niraparib|尼拉帕利', '3', 'fallopian tube', '.', '输卵管癌', 'na', 'sensitivity', 'EVI_000711', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2017.3.27，FDA批准了TESARO公司研发的PARP类口服抑制剂Niraparib，作为维持治疗用于治疗对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。此处和奥拉帕尼批准的适应症相比，少了BRCA胚系突变的要求，就是使用Niraparib可以不需要进行BRCA胚系突变检测。III期临床试验NOVA中，纳入553例之前传统治疗失败的对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。随机分配至Niraparib（300mg每天口服）组及安慰剂组。而且患者人群按照是否有胚系突变的BRCA基因而划分两组。结果无论有无BRCA胚系突变（gBRCA），Niraparib都展现出强势的生存优势。在生殖细胞带有BRCA突变的组里，经过niraparib治疗的患者无进展生存期的中位数长达21个月，比对照组的5.5个月得到了显著延长。在生殖细胞不带有BRCA基因突变的组里，niraparib同样疗效显著。经治后，患者的无进展生存期中位数为9.3个月，而对照组中的这一数字仅为3.9个月。将此类患者的整体死亡风险下调55%。18个月随访节点，30%的患者还未出现疾病进展。在这些患者里，niraparib对那些肿瘤上带有同源重组修复突变（HRD）的患者的治疗效果更为出色。由于HRD能影响双链DNA修复，研究人员设想在niraparib对DNA修复机制的进一步抑制下，肿瘤细胞会因为出现大量DNA损伤而死亡。这个设想在临床试验中得到了证实，对肿瘤细胞带有HRD的患者来说，niraparib治疗能将她们的无进展生存期中位数从3.8个月（对照组）延长到12.9个月（试验组）。目前市面上已经上市了两类PARP抑制剂药物奥拉帕尼（olaparib）以及卢卡帕利（rucaparib）。但这两种药物在批准时都需要患者具有BRCA基因的突变。而新上市的PARP抑制剂新药Niraparib试验结果表明，不仅在BRCA胚系突变的患者中表现出优势（21:5.5月），在无BRCA胚系突变的患者中也同样具有明显的生存优势（9.3:3.9月）。因而在FDA批准时并未要求患者一定要具有BRCA的突变，而只是提及铂类敏感，因为顺铂、卡铂等铂类药物也是作用于DNA结构，对铂类药物的敏感性一定程度上反映了肿瘤细胞对DNA破坏类药物（如PARP抑制剂）的潜在敏感性，提高适用人群的筛选性。另外，铂类与PARP先后顺序也存在相互协同治疗作用。这意味着卵巢癌患者近期对铂类治疗敏感（达到PR以上）的患者都可以尝试使用Niraparib，适用患者人群范围大大增加。同时该药物主要口服用药，增加治疗便利。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:niraparib_Revised_3/2017', '.', 'guideline:FDA', '1', 'niraparib', 'niraparib', 'niraparib', '尼拉帕利', 'niraparib|尼拉帕利', '3', 'primary peritoneal cancer', '.', '腹膜癌', 'na', 'sensitivity', 'EVI_000712', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2017.3.27，FDA批准了TESARO公司研发的PARP类口服抑制剂Niraparib，作为维持治疗用于治疗对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。此处和奥拉帕尼批准的适应症相比，少了BRCA胚系突变的要求，就是使用Niraparib可以不需要进行BRCA胚系突变检测。III期临床试验NOVA中，纳入553例之前传统治疗失败的对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。随机分配至Niraparib（300mg每天口服）组及安慰剂组。而且患者人群按照是否有胚系突变的BRCA基因而划分两组。结果无论有无BRCA胚系突变（gBRCA），Niraparib都展现出强势的生存优势。在生殖细胞带有BRCA突变的组里，经过niraparib治疗的患者无进展生存期的中位数长达21个月，比对照组的5.5个月得到了显著延长。在生殖细胞不带有BRCA基因突变的组里，niraparib同样疗效显著。经治后，患者的无进展生存期中位数为9.3个月，而对照组中的这一数字仅为3.9个月。将此类患者的整体死亡风险下调55%。18个月随访节点，30%的患者还未出现疾病进展。在这些患者里，niraparib对那些肿瘤上带有同源重组修复突变（HRD）的患者的治疗效果更为出色。由于HRD能影响双链DNA修复，研究人员设想在niraparib对DNA修复机制的进一步抑制下，肿瘤细胞会因为出现大量DNA损伤而死亡。这个设想在临床试验中得到了证实，对肿瘤细胞带有HRD的患者来说，niraparib治疗能将她们的无进展生存期中位数从3.8个月（对照组）延长到12.9个月（试验组）。目前市面上已经上市了两类PARP抑制剂药物奥拉帕尼（olaparib）以及卢卡帕利（rucaparib）。但这两种药物在批准时都需要患者具有BRCA基因的突变。而新上市的PARP抑制剂新药Niraparib试验结果表明，不仅在BRCA胚系突变的患者中表现出优势（21:5.5月），在无BRCA胚系突变的患者中也同样具有明显的生存优势（9.3:3.9月）。因而在FDA批准时并未要求患者一定要具有BRCA的突变，而只是提及铂类敏感，因为顺铂、卡铂等铂类药物也是作用于DNA结构，对铂类药物的敏感性一定程度上反映了肿瘤细胞对DNA破坏类药物（如PARP抑制剂）的潜在敏感性，提高适用人群的筛选性。另外，铂类与PARP先后顺序也存在相互协同治疗作用。这意味着卵巢癌患者近期对铂类治疗敏感（达到PR以上）的患者都可以尝试使用Niraparib，适用患者人群范围大大增加。同时该药物主要口服用药，增加治疗便利。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:niraparib_Revised_3/2017', '.', 'guideline:FDA', '1', 'niraparib', 'niraparib', 'niraparib', '尼拉帕利', 'niraparib|尼拉帕利', '3', 'ovarian', '.', '卵巢癌', 'na', 'sensitivity', 'EVI_000713', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2017.3.27，FDA批准了TESARO公司研发的PARP类口服抑制剂Niraparib，作为维持治疗用于治疗对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。此处和奥拉帕尼批准的适应症相比，少了BRCA胚系突变的要求，就是使用Niraparib可以不需要进行BRCA胚系突变检测。III期临床试验NOVA中，纳入553例之前传统治疗失败的对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。随机分配至Niraparib（300mg每天口服）组及安慰剂组。而且患者人群按照是否有胚系突变的BRCA基因而划分两组。结果无论有无BRCA胚系突变（gBRCA），Niraparib都展现出强势的生存优势。在生殖细胞带有BRCA突变的组里，经过niraparib治疗的患者无进展生存期的中位数长达21个月，比对照组的5.5个月得到了显著延长。在生殖细胞不带有BRCA基因突变的组里，niraparib同样疗效显著。经治后，患者的无进展生存期中位数为9.3个月，而对照组中的这一数字仅为3.9个月。将此类患者的整体死亡风险下调55%。18个月随访节点，30%的患者还未出现疾病进展。在这些患者里，niraparib对那些肿瘤上带有同源重组修复突变（HRD）的患者的治疗效果更为出色。由于HRD能影响双链DNA修复，研究人员设想在niraparib对DNA修复机制的进一步抑制下，肿瘤细胞会因为出现大量DNA损伤而死亡。这个设想在临床试验中得到了证实，对肿瘤细胞带有HRD的患者来说，niraparib治疗能将她们的无进展生存期中位数从3.8个月（对照组）延长到12.9个月（试验组）。目前市面上已经上市了两类PARP抑制剂药物奥拉帕尼（olaparib）以及卢卡帕利（rucaparib）。但这两种药物在批准时都需要患者具有BRCA基因的突变。而新上市的PARP抑制剂新药Niraparib试验结果表明，不仅在BRCA胚系突变的患者中表现出优势（21:5.5月），在无BRCA胚系突变的患者中也同样具有明显的生存优势（9.3:3.9月）。因而在FDA批准时并未要求患者一定要具有BRCA的突变，而只是提及铂类敏感，因为顺铂、卡铂等铂类药物也是作用于DNA结构，对铂类药物的敏感性一定程度上反映了肿瘤细胞对DNA破坏类药物（如PARP抑制剂）的潜在敏感性，提高适用人群的筛选性。另外，铂类与PARP先后顺序也存在相互协同治疗作用。这意味着卵巢癌患者近期对铂类治疗敏感（达到PR以上）的患者都可以尝试使用Niraparib，适用患者人群范围大大增加。同时该药物主要口服用药，增加治疗便利。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:niraparib_Revised_3/2017', '.', 'guideline:FDA', '1', 'niraparib', 'niraparib', 'niraparib', '尼拉帕利', 'niraparib|尼拉帕利', '3', 'fallopian tube', '.', '输卵管癌', 'na', 'sensitivity', 'EVI_000714', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2017.3.27，FDA批准了TESARO公司研发的PARP类口服抑制剂Niraparib，作为维持治疗用于治疗对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。此处和奥拉帕尼批准的适应症相比，少了BRCA胚系突变的要求，就是使用Niraparib可以不需要进行BRCA胚系突变检测。III期临床试验NOVA中，纳入553例之前传统治疗失败的对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。随机分配至Niraparib（300mg每天口服）组及安慰剂组。而且患者人群按照是否有胚系突变的BRCA基因而划分两组。结果无论有无BRCA胚系突变（gBRCA），Niraparib都展现出强势的生存优势。在生殖细胞带有BRCA突变的组里，经过niraparib治疗的患者无进展生存期的中位数长达21个月，比对照组的5.5个月得到了显著延长。在生殖细胞不带有BRCA基因突变的组里，niraparib同样疗效显著。经治后，患者的无进展生存期中位数为9.3个月，而对照组中的这一数字仅为3.9个月。将此类患者的整体死亡风险下调55%。18个月随访节点，30%的患者还未出现疾病进展。在这些患者里，niraparib对那些肿瘤上带有同源重组修复突变（HRD）的患者的治疗效果更为出色。由于HRD能影响双链DNA修复，研究人员设想在niraparib对DNA修复机制的进一步抑制下，肿瘤细胞会因为出现大量DNA损伤而死亡。这个设想在临床试验中得到了证实，对肿瘤细胞带有HRD的患者来说，niraparib治疗能将她们的无进展生存期中位数从3.8个月（对照组）延长到12.9个月（试验组）。目前市面上已经上市了两类PARP抑制剂药物奥拉帕尼（olaparib）以及卢卡帕利（rucaparib）。但这两种药物在批准时都需要患者具有BRCA基因的突变。而新上市的PARP抑制剂新药Niraparib试验结果表明，不仅在BRCA胚系突变的患者中表现出优势（21:5.5月），在无BRCA胚系突变的患者中也同样具有明显的生存优势（9.3:3.9月）。因而在FDA批准时并未要求患者一定要具有BRCA的突变，而只是提及铂类敏感，因为顺铂、卡铂等铂类药物也是作用于DNA结构，对铂类药物的敏感性一定程度上反映了肿瘤细胞对DNA破坏类药物（如PARP抑制剂）的潜在敏感性，提高适用人群的筛选性。另外，铂类与PARP先后顺序也存在相互协同治疗作用。这意味着卵巢癌患者近期对铂类治疗敏感（达到PR以上）的患者都可以尝试使用Niraparib，适用患者人群范围大大增加。同时该药物主要口服用药，增加治疗便利。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:niraparib_Revised_3/2017', '.', 'guideline:FDA', '1', 'niraparib', 'niraparib', 'niraparib', '尼拉帕利', 'niraparib|尼拉帕利', '3', 'primary peritoneal cancer', '.', '腹膜癌', 'na', 'sensitivity', 'EVI_000715', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2017.3.27，FDA批准了TESARO公司研发的PARP类口服抑制剂Niraparib，作为维持治疗用于治疗对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。此处和奥拉帕尼批准的适应症相比，少了BRCA胚系突变的要求，就是使用Niraparib可以不需要进行BRCA胚系突变检测。III期临床试验NOVA中，纳入553例之前传统治疗失败的对铂类化疗敏感的复发上皮性卵巢癌、输卵管癌及原发性腹膜癌患者。随机分配至Niraparib（300mg每天口服）组及安慰剂组。而且患者人群按照是否有胚系突变的BRCA基因而划分两组。结果无论有无BRCA胚系突变（gBRCA），Niraparib都展现出强势的生存优势。在生殖细胞带有BRCA突变的组里，经过niraparib治疗的患者无进展生存期的中位数长达21个月，比对照组的5.5个月得到了显著延长。在生殖细胞不带有BRCA基因突变的组里，niraparib同样疗效显著。经治后，患者的无进展生存期中位数为9.3个月，而对照组中的这一数字仅为3.9个月。将此类患者的整体死亡风险下调55%。18个月随访节点，30%的患者还未出现疾病进展。在这些患者里，niraparib对那些肿瘤上带有同源重组修复突变（HRD）的患者的治疗效果更为出色。由于HRD能影响双链DNA修复，研究人员设想在niraparib对DNA修复机制的进一步抑制下，肿瘤细胞会因为出现大量DNA损伤而死亡。这个设想在临床试验中得到了证实，对肿瘤细胞带有HRD的患者来说，niraparib治疗能将她们的无进展生存期中位数从3.8个月（对照组）延长到12.9个月（试验组）。目前市面上已经上市了两类PARP抑制剂药物奥拉帕尼（olaparib）以及卢卡帕利（rucaparib）。但这两种药物在批准时都需要患者具有BRCA基因的突变。而新上市的PARP抑制剂新药Niraparib试验结果表明，不仅在BRCA胚系突变的患者中表现出优势（21:5.5月），在无BRCA胚系突变的患者中也同样具有明显的生存优势（9.3:3.9月）。因而在FDA批准时并未要求患者一定要具有BRCA的突变，而只是提及铂类敏感，因为顺铂、卡铂等铂类药物也是作用于DNA结构，对铂类药物的敏感性一定程度上反映了肿瘤细胞对DNA破坏类药物（如PARP抑制剂）的潜在敏感性，提高适用人群的筛选性。另外，铂类与PARP先后顺序也存在相互协同治疗作用。这意味着卵巢癌患者近期对铂类治疗敏感（达到PR以上）的患者都可以尝试使用Niraparib，适用患者人群范围大大增加。同时该药物主要口服用药，增加治疗便利。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28800861', 'NCT02162719', 'clinical trial - phase2', '4', 'GDC-0068', 'GDC-0068', 'ipatasertib + paclitaxel', 'ipatasertib + 紫杉醇', 'ipatasertib + paclitaxel|ipatasertib + 紫杉醇', '2', 'triple-negative breast cancer', 'breast cancer', '乳腺癌(三阴性)', '[ER(-);PR(-);HER2(-)]', 'sensitivity', 'EVI_000716', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '一项临床试验中，预设的PIK3CA/AKT/PTEN基因突变亚组共42名患者，其中Ipatasertib组26名患者中位PFS为9个月（95% CI 4.6个月-未达到），安慰剂组的16名患者中位PFS为4.9个月（95% CI 3.6-6.3个月，两组HR为0.44，p=0.041）。而在PIK3CA/AKT/PTEN基因未突变亚组的患者中，Ipatasertib组28名患者中位PFS为5.3个月（95% CI 3.6-7.3个月），安慰剂组的33名患者的中位PFS为3.7个月（95% CI 2.9-5.5，HR=0.76，p=0.36）。LOTUS研究结果表明，Ipatasertib联合紫杉醇对比安慰剂联合紫杉醇一线治疗三阴乳腺癌可以延长患者的PFS，中位PFS在ITT人群和低PTEN人群中适度延长，在PIK3CA/AKT1/PTEN变异人群显著延长。从整体而言Ipatasertib安全性良好。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28800861', 'NCT02162719', 'clinical trial - phase2', '4', 'GDC-0068', 'GDC-0068', 'ipatasertib + paclitaxel', 'ipatasertib + 紫杉醇', 'ipatasertib + paclitaxel|ipatasertib + 紫杉醇', '2', 'triple-negative breast cancer', 'breast cancer', '乳腺癌(三阴性)', '[ER(-);PR(-);HER2(-)]', 'sensitivity', 'EVI_000717', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项临床试验中，预设的PIK3CA/AKT/PTEN基因突变亚组共42名患者，其中Ipatasertib组26名患者中位PFS为9个月（95% CI 4.6个月-未达到），安慰剂组的16名患者中位PFS为4.9个月（95% CI 3.6-6.3个月，两组HR为0.44，p=0.041）。而在PIK3CA/AKT/PTEN基因未突变亚组的患者中，Ipatasertib组28名患者中位PFS为5.3个月（95% CI 3.6-7.3个月），安慰剂组的33名患者的中位PFS为3.7个月（95% CI 2.9-5.5，HR=0.76，p=0.36）。LOTUS研究结果表明，Ipatasertib联合紫杉醇对比安慰剂联合紫杉醇一线治疗三阴乳腺癌可以延长患者的PFS，中位PFS在ITT人群和低PTEN人群中适度延长，在PIK3CA/AKT1/PTEN变异人群显著延长。从整体而言Ipatasertib安全性良好。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28800861', 'NCT02162719', 'clinical trial - phase2', '4', 'GDC-0068', 'GDC-0068', 'ipatasertib + paclitaxel', 'ipatasertib + 紫杉醇', 'ipatasertib + paclitaxel|ipatasertib + 紫杉醇', '2', 'triple-negative breast cancer', 'breast cancer', '乳腺癌(三阴性)', '[ER(-);PR(-);HER2(-)]', 'sensitivity', 'EVI_000718', 'AKT1:nonsynonymous SNV:.:.:act', 'AKT1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项临床试验中，预设的PIK3CA/AKT/PTEN基因突变亚组共42名患者，其中Ipatasertib组26名患者中位PFS为9个月（95% CI 4.6个月-未达到），安慰剂组的16名患者中位PFS为4.9个月（95% CI 3.6-6.3个月，两组HR为0.44，p=0.041）。而在PIK3CA/AKT/PTEN基因未突变亚组的患者中，Ipatasertib组28名患者中位PFS为5.3个月（95% CI 3.6-7.3个月），安慰剂组的33名患者的中位PFS为3.7个月（95% CI 2.9-5.5，HR=0.76，p=0.36）。LOTUS研究结果表明，Ipatasertib联合紫杉醇对比安慰剂联合紫杉醇一线治疗三阴乳腺癌可以延长患者的PFS，中位PFS在ITT人群和低PTEN人群中适度延长，在PIK3CA/AKT1/PTEN变异人群显著延长。从整体而言Ipatasertib安全性良好。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28644771', 'NCT03091192', 'clinical trial - phase3', '4', 'savolitinib', 'savolitinib', 'savolitinib', '沃利替尼', 'savolitinib|沃利替尼', '2', 'advanced papillary renal cell carcinoma', 'kidney cancer', '肾癌', 'na', 'sensitivity', 'EVI_000719', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', '晚期乳头状肾细胞癌（PRCC）患者治疗方案有限。PRCC涉及MET通路的激活，例如基因扩增或突变。 Savolitinib（AZD6094，HMPL-504，volitinib）是高度选择性的MET酪氨酸激酶抑制剂。一项单臂，多中心，II期临床试验研究MET状态与savolitinib在PRCC患者中的安全性和有效性。患者为组织学证实局部晚期或转移性PRCC，每天口服一次600 mg savolitinib。患者MET基因发生激活突变（扩增或Exon14突变）。根据MET状态评估功效。在所有患者中评估了安全性，毒性和患者报告的与健康有关的生活质量结果。109例患者中，MET突变患者44例（40%），MET野生型为46例（42%），MET状态未知患者19（17%）。 MET驱动突变患者与治疗响应密切相关,8例MET突变患者取得部分响应，而所有MET野生型均无治疗响应。MET驱动突变和MET野生型的PRCC患者的中位无进展生存期分别为6.2个月（95%CI，4.1〜7.0个月）和1.4个月（95%CI，1.4〜2.7个月）（风险比为0.33; 95%CI，0.20〜0.52; log-rank P <0.001）。与savolitinib相关的最常见不良反应是恶心，疲劳，呕吐和外周水肿(NCT02127710)。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28644771', 'NCT03091192', 'clinical trial - phase3', '4', 'savolitinib', 'savolitinib', 'savolitinib', '沃利替尼', 'savolitinib|沃利替尼', '2', 'advanced papillary renal cell carcinoma', 'kidney cancer', '肾癌', 'na', 'sensitivity', 'EVI_000720', 'MET:nonsynonymous SNV:.:.:skipping_mut', 'MET', 'nonsynonymous SNV', 'None_pos', '.', '.', 'skipping_mut', '.', '晚期乳头状肾细胞癌（PRCC）患者治疗方案有限。PRCC涉及MET通路的激活，例如基因扩增或突变。 Savolitinib（AZD6094，HMPL-504，volitinib）是高度选择性的MET酪氨酸激酶抑制剂。一项单臂，多中心，II期临床试验研究MET状态与savolitinib在PRCC患者中的安全性和有效性。患者为组织学证实局部晚期或转移性PRCC，每天口服一次600 mg savolitinib。患者MET基因发生激活突变（扩增或Exon14突变）。根据MET状态评估功效。在所有患者中评估了安全性，毒性和患者报告的与健康有关的生活质量结果。109例患者中，MET突变患者44例（40%），MET野生型为46例（42%），MET状态未知患者19（17%）。 MET驱动突变患者与治疗响应密切相关,8例MET突变患者取得部分响应，而所有MET野生型均无治疗响应。MET驱动突变和MET野生型的PRCC患者的中位无进展生存期分别为6.2个月（95%CI，4.1〜7.0个月）和1.4个月（95%CI，1.4〜2.7个月）（风险比为0.33; 95%CI，0.20〜0.52; log-rank P <0.001）。与savolitinib相关的最常见不良反应是恶心，疲劳，呕吐和外周水肿(NCT02127710)。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/PO.16.00037', '.', 'clinical study', '4', 'trastuzumab', 'trastuzumab', 'trastuzumab', '曲妥珠单抗', 'trastuzumab|曲妥珠单抗', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_000723', 'ERBB2:nonframeshift insertion:exon20:.:exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', '一例雌激素受体/孕酮受体阳性、HER2阴性的晚期乳腺癌患者，对雌激素受体靶向治疗无效。该患者携带ERBB2 G776V，患者接受了曲妥珠单抗加帕妥珠单抗治疗，取得13个月的临床获益。体外实验表明，ERBB2 G776V是一种致癌驱动基因突变，可以激活ERBB2激酶结构域。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/PO.16.00037', '.', 'clinical study', '4', 'pertuzumab', 'pertuzumab', 'pertuzumab', '帕妥珠单抗', 'pertuzumab|帕妥珠单抗', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_000724', 'ERBB2:nonsynonymous SNV:.:.:act', 'ERBB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一例雌激素受体/孕酮受体阳性、HER2阴性的晚期乳腺癌患者，对雌激素受体靶向治疗无效。该患者携带ERBB2激活突变，患者接受了曲妥珠单抗加帕妥珠单抗治疗，取得13个月的临床获益。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28968163 ', 'NCT02246621', 'clinical trial - phase3', '4', '.', '.', 'abemaciclib', 'abemaciclib', 'abemaciclib|abemaciclib', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_000731', 'CDK4:CNV:.:.:gain', 'CDK4', 'CNV', 'CNV', '.', '.', 'gain', '.', 'MONARCH 3试验评估了礼来的abemaciclib在治疗乳腺癌上的潜力。Abemaciclib是一款在研的CDK4/6抑制剂。它与内分泌疗法联合使用后，能显著延长患者的无进展生存期（PFS），并降低疾病进展的风险达46%。在病情可以评估的患者群体内，组合疗法的客观缓解率（ORR）为59%，高于对照组的44%（p=0.004）。在初治患者中取得的数据也表明，abemaciclib有望被添加入乳腺癌治疗的一线疗法，为患者带来福音。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28968163 ', 'NCT02246621', 'clinical trial - phase3', '4', '.', '.', 'abemaciclib', 'abemaciclib', 'abemaciclib|abemaciclib', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_000732', 'CDK6:CNV:.:.:gain', 'CDK6', 'CNV', 'CNV', '.', '.', 'gain', '.', 'MONARCH 3试验评估了礼来的abemaciclib在治疗乳腺癌上的潜力。Abemaciclib是一款在研的CDK4/6抑制剂。它与内分泌疗法联合使用后，能显著延长患者的无进展生存期（PFS），并降低疾病进展的风险达46%。在病情可以评估的患者群体内，组合疗法的客观缓解率（ORR）为59%，高于对照组的44%（p=0.004）。在初治患者中取得的数据也表明，abemaciclib有望被添加入乳腺癌治疗的一线疗法，为患者带来福音。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23220880', '.', 'preclinical', '4', 'neratinib ', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阴性)', '[NA;NA;HER2(-)]', 'sensitivity', 'EVI_000738', 'ERBB2:nonframeshift deletion:exon19:p.L755_T759del:exon19del', 'ERBB2', 'nonframeshift deletion', 'Exact_pos', 'exon19', 'p.L755_T759del', 'exon19del', 'Data from 8 breast cancer genome-sequencing projects identified 25 patients with HER2 somatic mutations in cancers lacking HER2 gene amplification. To determine the phenotype of these mutations, we functionally characterized 13 HER2 mutations using in vitro kinase assays, protein structure analysis, cell culture, and xenograft experiments. Seven of these mutations are activating mutations, including G309A, D769H, D769Y, V777L, P780ins, V842I, and R896C. HER2 in-frame deletion 755-759, which is homologous to EGF receptor (EGFR) exon 19 in-frame deletions, had a neomorphic phenotype with increased phosphorylation of EGFR or HER3. L755S produced lapatinib resistance, but was not an activating mutation in our experimental systems. All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib. These findings show that HER2 somatic mutation is an alternative mechanism to activate HER2 in breast cancer and they validate HER2 somatic mutations as drug targets for breast cancer treatment.SIGNIFICANCE:We show that the majority of HER2 somatic mutations in breast cancer patients are activating mutations that likely drive tumorigenesis. Several patients had mutations that are resistant to the reversible HER2 inhibitor lapatinib, but are sensitive to the irreversible HER2 inhibitor, neratinib. Our results suggest that patients with HER2 mutation–positive breast cancers could benefit from existing HER2-targeted drugs.', '来自8个乳腺癌基因组测序项目的数据确定了25名HER2体细胞突变但缺乏HER2基因扩增的癌症患者。为了确定这些突变的表型，我们使用体外激酶测定，蛋白质结构分析，细胞培养和异种移植实验来功能分析其中13种HER2突变。这些突变中的7个是激活突变，包括G309A，D769H，D769Y，V777L，P780ins，V842I和R896C。HER2框内缺失755-759与EGF受体（EGFR）外显子19框内缺失同源，具有使EGFR或HER3磷酸化增加的新表型。L755S产生拉帕替尼耐药性，但不是我们的实验系统中的激活突变。所有这些突变对不可逆激酶抑制剂-neratinib敏感。这些研究结果表明，HER2体细胞突变是激活HER2在乳腺癌中的替代机制。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:neratinib_Revised: 07/2017', '.', 'guideline:FDA', '1', 'neratinib ', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_000739', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', 'FDA批准neratinib是基于ExteNET试验（NCT00878709），这是一项多中心，随机，双盲，安慰剂对照、曲妥珠单抗治疗后neratinib的有效性试验。 2840名女性，早期HER2阳性乳腺癌，曲妥珠单抗治疗两年后，患者被随机分为接受neratinib（n = 1420）或安慰剂（n = 1420）治疗。主要疗效结果指标是侵入性无病生存期（iDFS），定义为随机化日期与第一次入侵性复发（局部/区域，同侧或对侧乳腺癌）、远处复发或任何原因死亡之间的时间。 两年后，iDFS在接受neratinib治疗的患者中为94.2%，而安慰剂组为91.9%（HR 0.66; 95%CI：0.49,0.90，p = 0.008）。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26537258', '.', 'clinical study', '4', 'abiraterone', 'abiraterone', 'abiraterone', '阿比特龙', 'abiraterone|阿比特龙', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'resistance', 'EVI_000740', 'AR:nonsynonymous SNV:exon8:p.T878A:', 'AR', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.T878A', '.', 'Androgen receptor (AR) gene aberrations are rare in prostate cancer before primary hormone treatment but emerge with castration resistance. To determine AR gene status using a minimally invasive assay that could have broad clinical utility, we developed a targeted next-generation sequencing approach amenable to plasma DNA, covering all AR coding bases and genomic regions that are highly informative in prostate cancer. We sequenced 274 plasma samples from 97 castration-resistant prostate cancer patients treated with abiraterone at two institutions. We controlled for normal DNA in patients\' circulation and detected a sufficiently high tumor DNA fraction to quantify AR copy number state in 217 samples (80 patients). Detection of AR copy number gain and point mutations in plasma were inversely correlated, supported further by the enrichment of nonsynonymous versus synonymous mutations in AR copy number normal as opposed to AR gain samples. Whereas AR copy number was unchanged from before treatment to progression and no mutant AR alleles showed signal for acquired gain, we observed emergence of T878A or L702H AR amino acid changes in 13% of tumors at progression on abiraterone. Patients with AR gain or T878A or L702H before abiraterone (45%) were 4.9 and 7.8 times less likely to have a ≥50 or ≥90% decline in prostate-specific antigen (PSA), respectively, and had a significantly worse overall [hazard ratio (HR), 7.33; 95% confidence interval (CI), 3.51 to 15.34; P = 1.3 × 10(-9)) and progression-free (HR, 3.73; 95% CI, 2.17 to 6.41; P = 5.6 × 10(-7)) survival. Evaluation of plasma AR by next-generation sequencing could identify cancers with primary resistance to abiraterone.', '与AR基因野生型患者相比，AR基因扩增，或T878A、或L702H突变的患者接受abiraterone（阿比特龙）治疗后前列腺特异性抗原（PSA）降低的可能性低4.9~7.8倍，总生存率和无进展生存期更差（OS，HR=7.33; 95%置信区间（CI），3.51〜15.34; P = 1.3×10（-9））（PFS，HR=3.73; 95%CI，2.17〜6.41; P = 5.6×10（-7））。 说明这些AR基因突变可能与前列腺癌患者对abiraterone治疗耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25712683', '.', 'clinical study', '4', 'enzalutamide', 'enzalutamide', 'enzalutamide', '恩扎卢胺', 'enzalutamide|恩扎卢胺', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'resistance', 'EVI_000741', 'AR:nonsynonymous SNV:exon8:p.H874Y:', 'AR', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.H874Y', '.', '.', '临床研究中发现， 62例患者中有11例（18%）检测到AR外显子8突变，其中包括首例报告的enzalutamide耐药的F876L突变病例，7例耐药患者携带H874Y和T877A突变。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25712683', '.', 'clinical study', '4', 'enzalutamide', 'enzalutamide', 'enzalutamide', '恩扎卢胺', 'enzalutamide|恩扎卢胺', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'resistance', 'EVI_000742', 'AR:nonsynonymous SNV:exon8:p.T877A:', 'AR', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.T877A', '.', '.', '临床研究中发现， 62例患者中有11例（18%）检测到AR外显子8突变，其中包括首例报告的enzalutamide耐药的F876L突变病例，7例耐药患者携带H874Y和T877A突变。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26813233', '.', 'preclinical', '4', 'enzalutamide', 'enzalutamide', 'enzalutamide', '恩扎卢胺', 'enzalutamide|恩扎卢胺', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'resistance', 'EVI_000743', 'AR:nonsynonymous SNV:exon8:p.H875Y:', 'AR', 'nonsynonymous SNV', 'Exact_pos', 'exon8', 'p.H875Y', '.', '.', '体外试验表明，enzalutamide对具有H875Y突的AR受体有激动作用。这项研究提示携带该突变的前列腺癌患者可能对enzalutamide治疗耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27257132', '.', 'case report', '4', 'AZD9291', 'AZD9291', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000755', 'EGFR:nonsynonymous SNV:exon18:p.L718Q:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.L718Q', '.', '.', '一名71岁的晚期肺癌患者通过基因检测发现在EGFR基因上携带L858R突变，该患者从2012年3月开始接受吉非替尼的一线治疗，维持到2014年1月出现疾病进展。随后给予卡铂+培美曲塞进行了6个周期的化疗。2014年7月进行基因检测发现EGFR基因具有T790M突变。患者从2014年8月开始接受AZD9291（osimertinib）治疗，维持到2015年9月疾病发生进展。患者基因测序发现了L858R和T790M基因突变依然存在，但是不存在C797S耐药突变。同时，患者也不携带其他耐药突变，包括ALK基因重排，ERBB2、EGFR、MET和FGFR基因扩增，患者也不携带KRAS和BRAF基因突变。但是，该患者携带一种新的EGFR基因突变：L718Q，该突变可能与患者对AZD9291产生耐药有关。 ', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1038/nature17960', '.', 'preclinical', '4', '.', '.', 'EAI045 + cetuximab', 'EAI045 + 西妥昔单抗', 'EAI045 + cetuximab|EAI045 + 西妥昔单抗', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000756', 'EGFR:nonsynonymous SNV:exon20:p.C797S<顺式>:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<顺式>', '.', '.', '动物试验表明，EAI045联合EGFR单克隆抗体在肺癌EGFR（L858R/T790M）及EGFR（L858R/T790M/C797S）突变的动物模型中有效。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 35, 2017 (suppl 4S; abstract 520)', 'NCT02164916', 'clinical trial - phase2', '4', '.', '.', 'irinotecan + vemurafenib + cetuximab', '伊立替康 + 维莫非尼 + 西妥昔单抗', 'irinotecan + vemurafenib + cetuximab|伊立替康 + 维莫非尼 + 西妥昔单抗', '4', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000758', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'SWOG S1406临床试验表明，99例BRAF V600E突变但RAS野生型的mCRC患者，接受过至少一线治疗失败（不含EGFR单抗）后，随机接受伊立替康+西妥昔单抗加或不加BRAF抑制剂维莫非尼，结果显示主要终点PFS（无进展生存期）从2个月显著延长至4.4个月（HR 0.42，95% CI 0.26~0.66，P<0.001），次要终点ORR（客观缓解率）也显著改善（4%提高到16%，P=0.001）。而同时具有RAS基因突变的患者可能不能从该联合治疗方案中获益。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 35, 2017 (suppl 4S; abstract 520)', 'NCT02164916', 'clinical trial - phase2', '4', '.', '.', 'irinotecan + vemurafenib + cetuximab', '伊立替康 + 维莫非尼 + 西妥昔单抗', 'irinotecan + vemurafenib + cetuximab|伊立替康 + 维莫非尼 + 西妥昔单抗', '4', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000759', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'SWOG S1406临床试验表明，99例BRAF V600E突变但RAS野生型的mCRC患者，接受过至少一线治疗失败（不含EGFR单抗）后，随机接受伊立替康+西妥昔单抗加或不加BRAF抑制剂维莫非尼，结果显示主要终点PFS（无进展生存期）从2个月显著延长至4.4个月（HR 0.42，95% CI 0.26~0.66，P<0.001），次要终点ORR（客观缓解率）也显著改善（4%提高到16%，P=0.001）。而同时具有RAS基因突变的患者可能不能从该联合治疗方案中获益。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 35, 2017 (suppl; abstr 3513)', 'NCT01550055', 'clinical trial - phase3', '4', 'irinotecan + CMAB009', 'irinotecan + CMAB009', 'irinotecan + CMAB009', '伊立替康 + CMAB009', 'irinotecan + CMAB009|伊立替康 + CMAB009', '3', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000760', 'KRAS:wildtype:.:.:wildtype', 'KRAS', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', 'CMAB009是一种重组的人鼠嵌合抗体，主要作用靶点是EGFR（表皮生长因子受体），因此，可以说CMAB009是西妥昔单抗的生物类似药。ZJBIO009入组了512例KRAS野生型mCRC患者，全部为一线奥沙利铂+氟尿嘧啶治疗失败，然后按1:2随机分组接受伊立替康单药或者伊立替康联合CMAB009治疗，进展后伊立替康单药组可交叉到CMAB009治疗组，主要终点是ORR。结果显示CMAB009显著提高了ORR（33.2% 对 12.8%，P<0.0001），次要终点PFS也得到了显著延长（5.6个月对3.2个月，P<0.0001。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28077435', '.', 'clinical trial - phase1', '4', 'BLU-285', 'BLU-285', 'avapritinib', 'avapritinib', 'avapritinib|avapritinib', '1', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_000761', 'PDGFRA:nonsynonymous SNV:exon18:p.D842V:', 'PDGFRA', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.D842V', '.', '.', 'BLU285在I期临床研究中，治疗15例可评价的PDGFRA D842V突变的GIST患者，其中14例获得影响学肿瘤退缩，显示出了对D842V突变GIST前所未有的抑制效果。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28426120', 'NCT01316263', 'clinical trial - phase2', '4', 'olaratumab', 'olaratumab', 'olaratumab', 'olaratumab', 'olaratumab|olaratumab', '2', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_000762', 'PDGFRA:nonsynonymous SNV:exon18:p.D842V:', 'PDGFRA', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.D842V', '.', '.', 'Olaratumab在II期临床研究中，治疗D842V突变的GIST也获得较好的疗效。共入组30例患者，其中21例接受了≥1个剂量的olaratumab治疗，在可评估人群中，未见PR与CR病例，7例PDGFRA D842V突变GIST中，50%获得SD，12周临床获益率50%，mPFS 32.1周，mOS未达到；无PDGFRA突变GIST中，14.3%获得SD，12周临床获益率14.3%，mPFS 6.1周，mOS 24.9周;常见的不良反应为乏力(38.1%)、恶心(19.0%)，3度不良反应为晕厥与高血压。olaratumab耐受性好，可延长PDGFRA突变患者肿瘤控制时间，对非PDGFRA突变患者无明显疗效。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/jco.2015.33.3_suppl.59|PMID:30463996', 'NCT01522768', 'clinical trial - phase2', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'esophagogastric (EG) cancer', 'gastric cancer', '胃癌', 'na', 'sensitivity', 'EVI_000763', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项单中心的II期临床试验，入组HER2扩增的胃食管癌患者，接受了多个疗程的赫赛汀联合治疗后耐药。一组接受阿法替尼治疗，一组接受阿法替尼联合赫赛汀治疗。20名接受阿法替尼单药治疗的患者中，5人肿瘤缩小；12名接受阿法替尼联合赫赛汀治疗的患者中，1名患者肿瘤明显缩小，2人肿瘤稳定超过4个月；32名患者中，有24名患者有治疗前后，足够的标本进行全面的基因分析——结果显示，那些同时有HER2基因和EGFR基因扩增的病人，阿法替尼治疗效果好；而那些同时合并了KRAS、PI3K或MYC基因突变的病人，阿法替尼治疗效果差；4名被证实同时携带EGFR和HER2扩增的病人中，3人肿瘤明显缩小；另外1人治疗无效，原因是这个人同时有EGFR、HER2扩增之外，还有MYC扩增。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26581547', 'NCT01152853', 'clinical trial - phase2', '4', 'dacomitinib', '.', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '3', 'esophagogastric (EG) cancer', 'gastric cancer', '胃癌', 'na', 'sensitivity', 'EVI_000764', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', 'Dacomitinib属于Her家族酪氨酸激酶抑制剂。临床试验报道，27例接受一线或一线后治疗进展的HER2阳性晚期胃癌患者，应用dacomitinib单药治疗，中位PFS及OS分别为2.1个月及7.1个月，疾病控制率为40.7%（2例PR，9例SD）。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2017.09.377', '.', 'clinical trial - phase1', '4', '.', '.', 'osimertinib + savolitinib', '奥希替尼 + 沃利替尼', 'osimertinib + savolitinib|奥希替尼 + 沃利替尼', '2', '.', 'NSCLC', '肺癌', 'na', 'sensitivity', 'EVI_000765', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项临床试验中，年龄≥18岁且具有局部晚期或转移性EGFR突变型NSCLC的患者，他们在EGFR-TKI治疗后疾病进展并携带MET基因扩增（荧光原位杂交，MET基因拷贝 ≥5或MET/CEP7比≥2）。该研究评估患者随后接受osimertinib 80 mg加savolitinib 600 mg的疗效。截止2017年4月15日，该临床试验共纳入45例MET扩增（FISH）的患者，其中包括25例先前接受过第三代EGFR-TKI治疗的患者和20例未经第三代EGFR-TKI治疗（T790M阳性n＝13；T790M阳性n＝7）。先前用第三代EGFR-TKI治疗的患者中有5/25（20%）有部分响应；未使用EGFR-TKI的患者中，T790M阴性患者中5/12（42%）有部分响应，T790M阳性患者中3/7（43%）有部分响应。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2017.09.379', '.', 'clinical trial - phase2', '4', '.', '.', 'gefitinib + savolitinib', '吉非替尼 + 沃利替尼', 'gefitinib + savolitinib|吉非替尼 + 沃利替尼', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000766', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', '原发和/或获得性的MET扩增可导致EGFR突变晚期NSCLC患者对EGFR酪氨酸激酶抑制剂治疗耐药。Savolitinib（沃利替尼，HMPL-504,AZD6094），是一种高选择性的小分子MET-TKI，与吉非替尼联合治疗EGFR突变的NSCLC临床前模型比各自的单药具有更好的疗效。方法：本项开放性、多中心的Ib期临床研究（NCT02374645）评估了沃利替尼联合吉非替尼治疗既往EGFR TKI治疗后进展的中国晚期EGFR突变NSCLC中国患者。主要研究目标是安全性、耐受性和确定II期临床试验推荐剂量，次要研究目标包括初步抗肿瘤活性（RECIST 1.1）、药代动力学和EGFR T790M突变状态的ctDNA分析。入组患者（≥18岁）具有可测量的病变、治疗后出现影像学疾病进展、ECOG 评分0/1分和良好的器官功能。患者存在中心实验室评估的EGFR突变（基于血浆的BEAMing数字PCR）和中心实验室筛选出的MET扩增（FISH方法检测肿瘤组织；MET/CEP7 比值≥2或MET基因拷贝数≥5），并接受均为每天一次的吉非替尼250mg与沃利替尼600mg联合治疗。结果：直至数据截止日期（2017年3月），本研究共有44例患者接受了研究治疗。中位年龄为61岁，64%的患者为女性；6例EGFR T790M突变阳性，5例为T790M阴性（中期结果）。最常见（≥20%的患者）的所有因果关系不良事件包括呕吐（18例，41%）、恶心（17例，39%）、皮疹（16例，36%）、谷丙转氨酶ALT升高（14例，32%）、谷草转氨酶AST升高（13例，30%）、低白蛋白血症和γ-谷氨酰转肽酶GGT升高（均为11例，25%）以及血清碱性磷酸酶ALP升高（9例，21%）。报告3级以上的因果关系不良事件为14例（32%），以AST和ALT的升高最为常见（均为3例，7%）。3例（7%）死于不良事件（1例呼吸衰竭，2例肺癌），与治疗无关。研究观察到抗肿瘤活性，11/44（25%）例部分缓解，4例患者待确认疗效（确认与未确认疗效的比率为15/44[34%]）。12周后进行研究评估，共有20例（46%）患者持续接受治疗。沃利替尼和吉非替尼的药代动力学参数和初步达到稳定的药物浓度与以往数据一致。结论：研究的结果是鼓舞人心的，吉非替尼联合沃利替尼可以治疗EGFR突变并MET扩增的既往接受EGFR-TKI治疗后进展晚期的NSCLC患者。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24894453', '.', 'case report', '4', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000767', 'EGFR:nonsynonymous SNV:exon18:p.G724S:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.G724S', '.', '.', '一名结直肠癌患者通过基因测序发现在EGFR激酶活性域具有G724S突变。体外细胞实验表明，西妥昔单抗可以抑制携带G719S和G724S突变的结直肠癌肿瘤细胞增殖。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:enasidenib_Revised: 08/2017', '.', 'guideline:FDA', '1', 'AG-221', 'AG-221', 'enasidenib', 'enasidenib', 'enasidenib|enasidenib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000768', 'IDH2:nonsynonymous SNV:exon4:p.R140Q:', 'IDH2', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.R140Q', '.', '.', 'Enasidenib属于异柠檬酸脱氢酶2抑制剂，可以抑制多种促进细胞增殖的酶的活性。如果患者血液或骨髓样本中检测到了IDH2突变，便适用于接受enasidenib治疗。AML患者中携带IDH2突变的比例大约为8%-19%。AML为急性骨髓性白血病，是一种快速进展的血液和骨髓肿瘤，发病率随着年龄增高而显著升高，中位发病年龄为66岁。在美国的AML患者中，适合接受骨髓移植的患者不足10%，且大多数患者对化疗无响应并且会进展成复发或难治性AML，5年生存率只有约20%-25%。2017年美国新确诊的AML患者大约有21380例，死亡病例大约10590例。Enasidenib的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。结果显示，在接受最短6个月的治疗后，大约19%的患者实现完全缓解，中位缓解持续期为8.2个月。4%的患者实现部分血液学缓解，中位缓解持续期9.6个月。在157例因为AML需要输血或血小板的患者中，34%在接受enasidenib治疗后不再需要输血。Enasidenib最常见的不良反应包括恶心、呕吐、腹泻、胆红素升高、食欲下降。孕妇或哺乳期妇女禁止使用enasidenib。Enasidenib的药品标签中带有黑框警告，提示其具有分化综合症的风险，如果不经治疗，会有致命危险。分化综合征的症状主要包括发热、呼吸困难、急性呼吸抑制、肺炎、胸腔或心包积液、快速体重增加、外周性水肿、多器官功能衰竭等。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:enasidenib_Revised: 08/2017', '.', 'guideline:FDA', '1', 'AG-221', 'AG-221', 'enasidenib', 'enasidenib', 'enasidenib|enasidenib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000769', 'IDH2:nonsynonymous SNV:exon4:p.R140L:', 'IDH2', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.R140L', '.', '.', 'Enasidenib属于异柠檬酸脱氢酶2抑制剂，可以抑制多种促进细胞增殖的酶的活性。如果患者血液或骨髓样本中检测到了IDH2突变，便适用于接受enasidenib治疗。AML患者中携带IDH2突变的比例大约为8%-19%。AML为急性骨髓性白血病，是一种快速进展的血液和骨髓肿瘤，发病率随着年龄增高而显著升高，中位发病年龄为66岁。在美国的AML患者中，适合接受骨髓移植的患者不足10%，且大多数患者对化疗无响应并且会进展成复发或难治性AML，5年生存率只有约20%-25%。2017年美国新确诊的AML患者大约有21380例，死亡病例大约10590例。Enasidenib的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。结果显示，在接受最短6个月的治疗后，大约19%的患者实现完全缓解，中位缓解持续期为8.2个月。4%的患者实现部分血液学缓解，中位缓解持续期9.6个月。在157例因为AML需要输血或血小板的患者中，34%在接受enasidenib治疗后不再需要输血。Enasidenib最常见的不良反应包括恶心、呕吐、腹泻、胆红素升高、食欲下降。孕妇或哺乳期妇女禁止使用enasidenib。Enasidenib的药品标签中带有黑框警告，提示其具有分化综合症的风险，如果不经治疗，会有致命危险。分化综合征的症状主要包括发热、呼吸困难、急性呼吸抑制、肺炎、胸腔或心包积液、快速体重增加、外周性水肿、多器官功能衰竭等。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:enasidenib_Revised: 08/2017', '.', 'guideline:FDA', '1', 'AG-221', 'AG-221', 'enasidenib', 'enasidenib', 'enasidenib|enasidenib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000770', 'IDH2:nonsynonymous SNV:exon4:p.R140G:', 'IDH2', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.R140G', '.', '.', 'Enasidenib属于异柠檬酸脱氢酶2抑制剂，可以抑制多种促进细胞增殖的酶的活性。如果患者血液或骨髓样本中检测到了IDH2突变，便适用于接受enasidenib治疗。AML患者中携带IDH2突变的比例大约为8%-19%。AML为急性骨髓性白血病，是一种快速进展的血液和骨髓肿瘤，发病率随着年龄增高而显著升高，中位发病年龄为66岁。在美国的AML患者中，适合接受骨髓移植的患者不足10%，且大多数患者对化疗无响应并且会进展成复发或难治性AML，5年生存率只有约20%-25%。2017年美国新确诊的AML患者大约有21380例，死亡病例大约10590例。Enasidenib的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。结果显示，在接受最短6个月的治疗后，大约19%的患者实现完全缓解，中位缓解持续期为8.2个月。4%的患者实现部分血液学缓解，中位缓解持续期9.6个月。在157例因为AML需要输血或血小板的患者中，34%在接受enasidenib治疗后不再需要输血。Enasidenib最常见的不良反应包括恶心、呕吐、腹泻、胆红素升高、食欲下降。孕妇或哺乳期妇女禁止使用enasidenib。Enasidenib的药品标签中带有黑框警告，提示其具有分化综合症的风险，如果不经治疗，会有致命危险。分化综合征的症状主要包括发热、呼吸困难、急性呼吸抑制、肺炎、胸腔或心包积液、快速体重增加、外周性水肿、多器官功能衰竭等。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:enasidenib_Revised: 08/2017', '.', 'guideline:FDA', '1', 'AG-221', 'AG-221', 'enasidenib', 'enasidenib', 'enasidenib|enasidenib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000771', 'IDH2:nonsynonymous SNV:exon4:p.R140W:', 'IDH2', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.R140W', '.', '.', 'Enasidenib属于异柠檬酸脱氢酶2抑制剂，可以抑制多种促进细胞增殖的酶的活性。如果患者血液或骨髓样本中检测到了IDH2突变，便适用于接受enasidenib治疗。AML患者中携带IDH2突变的比例大约为8%-19%。AML为急性骨髓性白血病，是一种快速进展的血液和骨髓肿瘤，发病率随着年龄增高而显著升高，中位发病年龄为66岁。在美国的AML患者中，适合接受骨髓移植的患者不足10%，且大多数患者对化疗无响应并且会进展成复发或难治性AML，5年生存率只有约20%-25%。2017年美国新确诊的AML患者大约有21380例，死亡病例大约10590例。Enasidenib的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。结果显示，在接受最短6个月的治疗后，大约19%的患者实现完全缓解，中位缓解持续期为8.2个月。4%的患者实现部分血液学缓解，中位缓解持续期9.6个月。在157例因为AML需要输血或血小板的患者中，34%在接受enasidenib治疗后不再需要输血。Enasidenib最常见的不良反应包括恶心、呕吐、腹泻、胆红素升高、食欲下降。孕妇或哺乳期妇女禁止使用enasidenib。Enasidenib的药品标签中带有黑框警告，提示其具有分化综合症的风险，如果不经治疗，会有致命危险。分化综合征的症状主要包括发热、呼吸困难、急性呼吸抑制、肺炎、胸腔或心包积液、快速体重增加、外周性水肿、多器官功能衰竭等。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:enasidenib_Revised: 08/2017', '.', 'guideline:FDA', '1', 'AG-221', 'AG-221', 'enasidenib', 'enasidenib', 'enasidenib|enasidenib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000772', 'IDH2:nonsynonymous SNV:exon4:p.R172W:', 'IDH2', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.R172W', '.', '.', 'Enasidenib属于异柠檬酸脱氢酶2抑制剂，可以抑制多种促进细胞增殖的酶的活性。如果患者血液或骨髓样本中检测到了IDH2突变，便适用于接受enasidenib治疗。AML患者中携带IDH2突变的比例大约为8%-19%。AML为急性骨髓性白血病，是一种快速进展的血液和骨髓肿瘤，发病率随着年龄增高而显著升高，中位发病年龄为66岁。在美国的AML患者中，适合接受骨髓移植的患者不足10%，且大多数患者对化疗无响应并且会进展成复发或难治性AML，5年生存率只有约20%-25%。2017年美国新确诊的AML患者大约有21380例，死亡病例大约10590例。Enasidenib的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。结果显示，在接受最短6个月的治疗后，大约19%的患者实现完全缓解，中位缓解持续期为8.2个月。4%的患者实现部分血液学缓解，中位缓解持续期9.6个月。在157例因为AML需要输血或血小板的患者中，34%在接受enasidenib治疗后不再需要输血。Enasidenib最常见的不良反应包括恶心、呕吐、腹泻、胆红素升高、食欲下降。孕妇或哺乳期妇女禁止使用enasidenib。Enasidenib的药品标签中带有黑框警告，提示其具有分化综合症的风险，如果不经治疗，会有致命危险。分化综合征的症状主要包括发热、呼吸困难、急性呼吸抑制、肺炎、胸腔或心包积液、快速体重增加、外周性水肿、多器官功能衰竭等。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:enasidenib_Revised: 08/2017', '.', 'guideline:FDA', '1', 'AG-221', 'AG-221', 'enasidenib', 'enasidenib', 'enasidenib|enasidenib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000773', 'IDH2:nonsynonymous SNV:exon4:p.R172G:', 'IDH2', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.R172G', '.', '.', 'Enasidenib属于异柠檬酸脱氢酶2抑制剂，可以抑制多种促进细胞增殖的酶的活性。如果患者血液或骨髓样本中检测到了IDH2突变，便适用于接受enasidenib治疗。AML患者中携带IDH2突变的比例大约为8%-19%。AML为急性骨髓性白血病，是一种快速进展的血液和骨髓肿瘤，发病率随着年龄增高而显著升高，中位发病年龄为66岁。在美国的AML患者中，适合接受骨髓移植的患者不足10%，且大多数患者对化疗无响应并且会进展成复发或难治性AML，5年生存率只有约20%-25%。2017年美国新确诊的AML患者大约有21380例，死亡病例大约10590例。Enasidenib的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。结果显示，在接受最短6个月的治疗后，大约19%的患者实现完全缓解，中位缓解持续期为8.2个月。4%的患者实现部分血液学缓解，中位缓解持续期9.6个月。在157例因为AML需要输血或血小板的患者中，34%在接受enasidenib治疗后不再需要输血。Enasidenib最常见的不良反应包括恶心、呕吐、腹泻、胆红素升高、食欲下降。孕妇或哺乳期妇女禁止使用enasidenib。Enasidenib的药品标签中带有黑框警告，提示其具有分化综合症的风险，如果不经治疗，会有致命危险。分化综合征的症状主要包括发热、呼吸困难、急性呼吸抑制、肺炎、胸腔或心包积液、快速体重增加、外周性水肿、多器官功能衰竭等。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:enasidenib_Revised: 08/2017', '.', 'guideline:FDA', '1', 'AG-221', 'AG-221', 'enasidenib', 'enasidenib', 'enasidenib|enasidenib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000774', 'IDH2:nonsynonymous SNV:exon4:p.R172S:', 'IDH2', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.R172S', '.', '.', 'Enasidenib属于异柠檬酸脱氢酶2抑制剂，可以抑制多种促进细胞增殖的酶的活性。如果患者血液或骨髓样本中检测到了IDH2突变，便适用于接受enasidenib治疗。AML患者中携带IDH2突变的比例大约为8%-19%。AML为急性骨髓性白血病，是一种快速进展的血液和骨髓肿瘤，发病率随着年龄增高而显著升高，中位发病年龄为66岁。在美国的AML患者中，适合接受骨髓移植的患者不足10%，且大多数患者对化疗无响应并且会进展成复发或难治性AML，5年生存率只有约20%-25%。2017年美国新确诊的AML患者大约有21380例，死亡病例大约10590例。Enasidenib的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。结果显示，在接受最短6个月的治疗后，大约19%的患者实现完全缓解，中位缓解持续期为8.2个月。4%的患者实现部分血液学缓解，中位缓解持续期9.6个月。在157例因为AML需要输血或血小板的患者中，34%在接受enasidenib治疗后不再需要输血。Enasidenib最常见的不良反应包括恶心、呕吐、腹泻、胆红素升高、食欲下降。孕妇或哺乳期妇女禁止使用enasidenib。Enasidenib的药品标签中带有黑框警告，提示其具有分化综合症的风险，如果不经治疗，会有致命危险。分化综合征的症状主要包括发热、呼吸困难、急性呼吸抑制、肺炎、胸腔或心包积液、快速体重增加、外周性水肿、多器官功能衰竭等。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:enasidenib_Revised: 08/2017', '.', 'guideline:FDA', '1', 'AG-221', 'AG-221', 'enasidenib', 'enasidenib', 'enasidenib|enasidenib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000775', 'IDH2:nonsynonymous SNV:exon4:p.R172K:', 'IDH2', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.R172K', '.', '.', 'Enasidenib属于异柠檬酸脱氢酶2抑制剂，可以抑制多种促进细胞增殖的酶的活性。如果患者血液或骨髓样本中检测到了IDH2突变，便适用于接受enasidenib治疗。AML患者中携带IDH2突变的比例大约为8%-19%。AML为急性骨髓性白血病，是一种快速进展的血液和骨髓肿瘤，发病率随着年龄增高而显著升高，中位发病年龄为66岁。在美国的AML患者中，适合接受骨髓移植的患者不足10%，且大多数患者对化疗无响应并且会进展成复发或难治性AML，5年生存率只有约20%-25%。2017年美国新确诊的AML患者大约有21380例，死亡病例大约10590例。Enasidenib的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。结果显示，在接受最短6个月的治疗后，大约19%的患者实现完全缓解，中位缓解持续期为8.2个月。4%的患者实现部分血液学缓解，中位缓解持续期9.6个月。在157例因为AML需要输血或血小板的患者中，34%在接受enasidenib治疗后不再需要输血。Enasidenib最常见的不良反应包括恶心、呕吐、腹泻、胆红素升高、食欲下降。孕妇或哺乳期妇女禁止使用enasidenib。Enasidenib的药品标签中带有黑框警告，提示其具有分化综合症的风险，如果不经治疗，会有致命危险。分化综合征的症状主要包括发热、呼吸困难、急性呼吸抑制、肺炎、胸腔或心包积液、快速体重增加、外周性水肿、多器官功能衰竭等。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:enasidenib_Revised: 08/2017', '.', 'guideline:FDA', '1', 'AG-221', 'AG-221', 'enasidenib', 'enasidenib', 'enasidenib|enasidenib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000776', 'IDH2:nonsynonymous SNV:exon4:p.R172M:', 'IDH2', 'nonsynonymous SNV', 'Exact_pos', 'exon4', 'p.R172M', '.', '.', 'Enasidenib属于异柠檬酸脱氢酶2抑制剂，可以抑制多种促进细胞增殖的酶的活性。如果患者血液或骨髓样本中检测到了IDH2突变，便适用于接受enasidenib治疗。AML患者中携带IDH2突变的比例大约为8%-19%。AML为急性骨髓性白血病，是一种快速进展的血液和骨髓肿瘤，发病率随着年龄增高而显著升高，中位发病年龄为66岁。在美国的AML患者中，适合接受骨髓移植的患者不足10%，且大多数患者对化疗无响应并且会进展成复发或难治性AML，5年生存率只有约20%-25%。2017年美国新确诊的AML患者大约有21380例，死亡病例大约10590例。Enasidenib的疗效在一项纳入199例携带IDH2突变的复发或难治性AML患者的单臂研究中得到证实。结果显示，在接受最短6个月的治疗后，大约19%的患者实现完全缓解，中位缓解持续期为8.2个月。4%的患者实现部分血液学缓解，中位缓解持续期9.6个月。在157例因为AML需要输血或血小板的患者中，34%在接受enasidenib治疗后不再需要输血。Enasidenib最常见的不良反应包括恶心、呕吐、腹泻、胆红素升高、食欲下降。孕妇或哺乳期妇女禁止使用enasidenib。Enasidenib的药品标签中带有黑框警告，提示其具有分化综合症的风险，如果不经治疗，会有致命危险。分化综合征的症状主要包括发热、呼吸困难、急性呼吸抑制、肺炎、胸腔或心包积液、快速体重增加、外周性水肿、多器官功能衰竭等。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:abemaciclib_Revised: 9/2017', '.', 'guideline:FDA', '1', 'LY2835219', 'LY2835219', 'abemaciclib', 'abemaciclib', 'abemaciclib|abemaciclib', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_000777', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', '.', '2017年9月28日，FDA批准Abemaciclib (VERZENIO, Eli Lilly and Company)联合Fulvestrant 用于治疗经历过内分泌治疗的HR阳性，HER2阴性疾病进展或转移性乳腺癌女性患者。同时，FDA也批准了Abemaciclib用于单药治疗内分泌治疗或转移性患者化疗后疾病进展的HR阳性，HER2阴性的晚期或转移性乳腺癌成人患者。Monarch 1试验共入组了132例既往接受内分泌治疗及化疗进展的，HR+/HER-2-转移性乳腺癌患者，给予患者abemaciclib 200mg q12治疗，直到不能耐受或疾病进展，观察有效性及安全性。中位年龄为58岁，44%的患者ECOG评分为1分，90.2%有内脏转移，85.6%患者至少有2处以上转移灶。研究者确认的ORR为19.7%，疾病稳定（SD）超过6月以上的患者为22.7%，CBR为42.4%。中位TTP为3.7个月，中位DoR为8.6个月。安全性方面，白细胞减少（27.4%）、中性粒细胞减少（22.3%）为最常见的毒性。所有毒性中，仅中性粒细胞减少出现过4度以上，发生率为4.6%。3度以上不良反应发生率为24.2%，7.2%患者由于不良反应停药。49.2%的患者由于不良反应减药。主要减药的原因为腹泻（20.5%）和中性粒细胞减少（10.6%）。治疗期间2名患者死亡，1名患者在治疗后30天内死亡。Monarch 2是一个国际多中心的开放、Ⅲ期临床试验，669名患者以2:1的比例分至氟维司群联合abemaciclib和氟维司群联合安慰剂组。入组的患者为接受新辅助或辅助内分泌治疗期间或12月内进展的乳腺癌，或接受内分泌一线治疗进展的转移性乳腺癌患者。如果转移性乳腺癌患者既往接受过解救化疗或超过一线的内分泌治疗，其被排除入组。入组患者氟维司群 500mg和abemaciclib/安慰剂 150mg bid（初始abemaciclib剂量为200mg，后因先期178名患者出现腹泻等消化系统毒性概率较大而减量）。主要研究终点为PFS，次要研究终点包括OS、ORR、CBR和安全性。基线数据方面，82%患者已绝经，72%患者有可测量病灶，56%患者有内脏转移，25%患者既往内分泌治疗耐药。60%患者在辅助或新辅助治疗期间接受过化疗。379名ITT人群中，abemaciclib联合组中位PFS为16.4个月，对照组为9.3个月（HR, 0.553; 95%CI：0.449-0.681; p＜0.000001）。Abemaciclib联合组ORR达48.4%，CR率为3.5%。对照组中没有患者达到CR。对照组中位DoR为25.6个月，abemaciclib联合组尚未达到终点。OS数据尚不成熟。Abemaciclib联合组 vs 对照组最常见的全等级不良反应为腹泻（86.4% vs 24.7%），中性粒细胞减少（46.0% vs 4.0%），恶心（45.1% vs 22.9%）和乏力（39.9% vs 26.9%）。Abemaciclib联合组 vs 对照组两组最常见的3度以上毒性为中性粒细胞减少（23.6% vs 1.3%）和腹泻（13.4% vs 0.4%），4度中性粒细胞减少发生率分别为（2.9% vs 0.4%）。Abemaciclib联合组治疗相关死亡有3例，对照组中为0例。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24908064', '.', 'case report', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000779', 'EGFR:nonsynonymous SNV:exon20:p.V769A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.V769A', '.', 'Mutations of epidermal growth factor receptor (EGFR) gene are good predictors of response to treatment with EGFR tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer (NSCLC). It is well established that classic mutations, such as in-frame deletions in exon 19 and the point mutation L858R in exon 21, are associated with high sensitivity to EGFR TKIs. Though mutations in exon 20 are almost correlated with EGFR-TKIs resistance, the awareness that they might confer sensitivity to TKI treatment should be emphasized. Herein, we describe a novel mutation in exon 20 of EGFR in a Chinese male non-smoker, who was diagnosed with stage IV lung adenocarcinoma and characterized by the codon 769 point mutation GTG>GCG, which translates into alanine instead of valine (p.V769A). In this case, the patient showed a good clinical response to erlotinib after paclitaxel/cisplatin first-line and docetaxel second-line chemotherapies. Therefore, we suggest that this rare mutation (p.V769A) may be a sensitive EGFR mutation in NSCLC. The identification of novel EGFR mutations provides new predictive biomarkers for TKI treatment and is essential to the successful use of targeted therapies.', '一名中国男性非吸烟者中EGFR外显子20中的检测到新突变，其被诊断为IV期肺腺癌，并且特征在于密码子769点突变GTG> GCG，其翻译为丙氨酸而不是缬氨酸（p.V769A）。在该患者对紫杉醇/顺铂一线和多西紫杉醇二线化疗后的厄洛替尼治疗显示出良好的临床反应。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18794803', '.', 'preclinical', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000780', 'BRAF:nonsynonymous SNV:exon11:p.G469E:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.G469E', '.', '.', '细胞学试验表明，携带BRAF(G469E/D594G) 突变的肿瘤细胞可能对MEK抑制剂耐药，但是CRAF抑制剂（如索拉非尼）可以通过CRAF信号诱导肿瘤细胞发生凋亡，产生抗肿瘤作用。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18794803', '.', 'preclinical', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'melanoma', 'cancer cell lines_melanoma', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000781', 'BRAF:nonsynonymous SNV:exon15:p.D594G:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.D594G', '.', '.', '细胞学试验表明，携带BRAF(G469E/D594G) 突变的肿瘤细胞可能对MEK抑制剂耐药，但是CRAF抑制剂（如索拉非尼）可以通过CRAF信号诱导肿瘤细胞发生凋亡，产生抗肿瘤作用。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26422291', '.', 'case report', '4', 'ramucirumab', 'ramucirumab', 'ramucirumab', '雷莫芦单抗', 'ramucirumab|雷莫芦单抗', '4', 'metastatic rectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000783', 'KDR:nonsynonymous SNV:exon16:p.T771R:', 'KDR', 'nonsynonymous SNV', 'Exact_pos', 'exon16', 'p.T771R', '.', '.', '抑制血管生成是一种有效的抗癌策略，因为肿瘤需要丰富的血液供应。Ramucirumab，2014年获得美国食品和药物管理局批准用于治疗胃腺癌和非小细胞肺癌，靶向血管内皮生长因子2（VEGFR2）。一名携带VEGFR2（KDR）基因T771R突变的结直肠癌患者使用ramucirumab治疗后取得一定疗效。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24035431', '.', 'case report', '4', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'Lung adenocarcinoma', 'Lung adenocarcinoma', '肺癌', 'na', 'resistance', 'EVI_000784', 'BRAF:nonsynonymous SNV:exon11:p.G469L:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.G469L', '.', '.', 'BRAF V600E是肺癌新兴的靶点，但非V600 BRAF突变在肺癌等恶性肿瘤中的临床意义尚不明确。在这里，我们报告了一例转移性肺腺癌BRAF G469L突变对vemurafenib耐药的病例。该论文通过分子模拟计算了这种非常罕见的突变型BRAF激酶的结构模型，用来解释其导致耐药的分子机制。 ', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28572531', '.', 'case report', '4', 'Osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000785', 'EGFR:nonsynonymous SNV:exon20:p.G796D<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.G796D<顺式>', '.', '.', '一名56岁的IV期女性肺腺癌患者，并且具有多处远端脑转移和骨转移，下面是该患者的整个治疗史：首先该患者接受多线化疗治疗及吉非替尼治疗，疾病进展后行基因检测，发现有T790M突变。继而接受奥希替尼治疗，6.5个月后，疾病进展，随后进行放射治疗。为了找出患者对奥希替尼的潜在耐药原因，研究者选取了三个时间点（pre-gefitinib、gefitinib PD、osimertinib PD）采集血液得到血浆样本，通过NGS测序发现：在pre-gefitinib的样本中检测到4.28%的L858R，有意思的是还检测到0.61%的G796D；在gefitinib PD的样本中检测到1.85%的T790M，与组织结果一致；在osimertinib PD的样本中未检测到L858R及T790M突变，但G796D的突变含量从0.61%增加到1.91%。同时该研究也揭示了G796D突变对奥希替尼的耐药机制：是因为G796D突变导致奥希替尼与C797共价结合的空间位阻。突变的D796残基的亲水侧链CH2COOH插入奥希替尼的多脂中心结构，或者是将奥希替尼挤出目前的结合位置，或者是将结合环扭曲影响铰链结合，从而影响奥希替尼与激酶区的紧密结合，产生耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Acute Lymphoblastic Leukemia <2.2019>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'acute lymphoblastic leukemia', 'leukemia', '急性淋巴细胞白血病', 'na', 'sensitivity', 'EVI_000789', 'ABL1:nonsynonymous SNV:exon6:p.F317L:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.F317L', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变的Ph阳性ALL患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Acute Lymphoblastic Leukemia <2.2019>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'acute lymphoblastic leukemia', 'leukemia', '急性淋巴细胞白血病', 'na', 'sensitivity', 'EVI_000790', 'ABL1:nonsynonymous SNV:exon6:p.F317C:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.F317C', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变的Ph阳性ALL患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Acute Lymphoblastic Leukemia <2.2019>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'acute lymphoblastic leukemia', 'leukemia', '急性淋巴细胞白血病', 'na', 'sensitivity', 'EVI_000791', 'ABL1:nonsynonymous SNV:exon6:p.F317V:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.F317V', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变的Ph阳性ALL患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Acute Lymphoblastic Leukemia <2.2019>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'acute lymphoblastic leukemia', 'leukemia', '急性淋巴细胞白血病', 'na', 'sensitivity', 'EVI_000792', 'ABL1:nonsynonymous SNV:exon6:p.F317I:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.F317I', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变的Ph阳性ALL患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Acute Lymphoblastic Leukemia <2.2019>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'acute lymphoblastic leukemia', 'leukemia', '急性淋巴细胞白血病', 'na', 'sensitivity', 'EVI_000793', 'ABL1:nonsynonymous SNV:exon6:p.T315A:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.T315A', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变的Ph阳性ALL患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Acute Lymphoblastic Leukemia <2.2019>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'acute lymphoblastic leukemia', 'leukemia', '急性淋巴细胞白血病', 'na', 'sensitivity', 'EVI_000794', 'ABL1:nonsynonymous SNV:exon5:p.V299L:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon5', 'p.V299L', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变的Ph阳性ALL患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Chronic Myeloid Leukemia <2.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'Chronic Myelogenous Leukemia', 'leukemia', '慢性粒细胞白血病', 'na', 'resistance', 'EVI_000795', 'ABL1:nonsynonymous SNV:exon6:p.T315I:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.T315I', '.', 'Among the mutations in the ABL1 kinase domain, the presence of T315I mutation confers the highest resistance to imatinib, dasatinib, and nilotinib.(page:MS-29)', 'ABL1激酶活性域的突变，如T315I，会导致病人对伊马替尼，达沙替尼和尼洛替尼产生很强的耐药，病人使用这些药物可能无法获益。', 'S', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Chronic Myeloid Leukemia <2.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'Chronic Myelogenous Leukemia', 'leukemia', '慢性粒细胞白血病', 'na', 'sensitivity', 'EVI_000796', 'ABL1:nonsynonymous SNV:exon6:p.F317L:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.F317L', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变且对伊马替尼耐药的CML患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Chronic Myeloid Leukemia <2.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'Chronic Myelogenous Leukemia', 'leukemia', '慢性粒细胞白血病', 'na', 'sensitivity', 'EVI_000797', 'ABL1:nonsynonymous SNV:exon6:p.F317C:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.F317C', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变且对伊马替尼耐药的CML患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Chronic Myeloid Leukemia <2.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'Chronic Myelogenous Leukemia', 'leukemia', '慢性粒细胞白血病', 'na', 'sensitivity', 'EVI_000798', 'ABL1:nonsynonymous SNV:exon6:p.F317V:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.F317V', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变且对伊马替尼耐药的CML患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Chronic Myeloid Leukemia <2.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'Chronic Myelogenous Leukemia', 'leukemia', '慢性粒细胞白血病', 'na', 'sensitivity', 'EVI_000799', 'ABL1:nonsynonymous SNV:exon6:p.F317I:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.F317I', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变且对伊马替尼耐药的CML患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Chronic Myeloid Leukemia <2.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'Chronic Myelogenous Leukemia', 'leukemia', '慢性粒细胞白血病', 'na', 'sensitivity', 'EVI_000800', 'ABL1:nonsynonymous SNV:exon6:p.T315A:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.T315A', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变且对伊马替尼耐药的CML患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Chronic Myeloid Leukemia <2.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'Chronic Myelogenous Leukemia', 'leukemia', '慢性粒细胞白血病', 'na', 'sensitivity', 'EVI_000801', 'ABL1:nonsynonymous SNV:exon5:p.V299L:.', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon5', 'p.V299L', '.', '.', 'NCCN推荐ABL1基因出现F317L/V/I/C, T315A, 或者V299L突变且对伊马替尼耐药的CML患者使用尼洛替尼（Nilotinib）治疗（PMID:16775235）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18612151', '.', 'clinical trial - phase2', '4', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000803', 'EGFR:CNV:.:.:gain', 'EGFR', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项临床II期研究，共入组了229名晚期非小细胞肺癌患者，130名腺癌患者，42名鳞状细胞癌患者，57名其他亚型的肺癌患者。使用原位免疫荧光杂交试验（FISH）诊断出76名患者为EGFR基因扩增阳性，FISH阳性的判读标准为40%的癌细胞有4个以上的基因拷贝数。试验入组的患者随机分为两组：一组患者同时使用西妥昔单抗+化疗（紫杉醇联合卡铂）；另一组患者先使用化疗（紫杉醇联合卡铂），进展后再次使用西妥昔单抗。FISH检测EGFR基因扩增阳性患者，化疗联合西妥昔单抗使得患者的无进展生存期（PFS）和总生存期（OS）都明显好于EGFR基因扩增阴性患者。具体的数据如下：治疗应答率（包括完全应答和部分应答），FISH检测EGFR基因扩增阳性的为45%，而对照未扩增组的治疗应答率为26%。疾病控制率（包括完全应答、部分应答和病情稳定），EGFR基因扩增阳性组为81%，而未扩增组的疾病控制率为55%。中位无进展生存期，EGFR基因扩增阳性组为6个月，而未扩增组的疾病控制率为3个月。中位总生存期，EGFR基因扩增阳性组为15个月，而未扩增组的疾病控制率为7个月。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20942962', '.', 'preclinical', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000806', 'EGFR:nonsynonymous SNV:exon21:p.E868G:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.E868G', '.', '.', '在临床前研究中，特罗凯（厄洛替尼）可以抑制培养的表达EGFR E868G的细胞中的EGFR磷酸化，诱导肿瘤细胞凋亡。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27615706', '.', 'case report', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'Pituitary adenomas', 'brain cancer', '脑部肿瘤', 'na', 'sensitivity', 'EVI_000807', 'STK11:nonsynonymous SNV:exon7:p.F298L:inact', 'STK11', 'nonsynonymous SNV', 'None_pos', 'exon7', 'p.F298L', 'inact', '.', '一名携带mTOR途径STK11基因失活突变的广泛转移非典型垂体腺瘤患者对依维莫司治疗有大于6个月的临床改善和稳定。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25295501', '.', 'case report', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'anaplastic thyroid cancer', 'anaplastic thyroid cancer', '甲状腺癌', 'na', 'resistance', 'EVI_000809', 'MTOR:nonsynonymous SNV:exon45:p.F2108L:', 'MTOR', 'nonsynonymous SNV', 'Exact_pos', 'exon45', 'p.F2108L', '.', '.', '一名TSC2  p.Q1178*突变的甲状腺未分化癌患者经过18个月的依维莫司治疗反应后产生了耐药性，随后基因检测发现在MTOR基因上出现了F2108L突变，该突变可能与耐药有关。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26487584', '.', 'case report', '4', 'lapatinib', 'lapatinib', 'lapatinib', '拉帕替尼', 'lapatinib|拉帕替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000810', 'ERBB2:nonsynonymous SNV:exon21:p.L869Q:', 'ERBB2', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L869Q', '.', '.', '一名52岁的女性患者被诊断患有转移性乳腺癌且携带ERBB2突变，该患者对拉帕替尼和卡培他滨治疗显示出显著和长期的反应。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27102076', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'lung cancer', 'lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000813', 'EGFR:FUS:.:EGFR-.:', 'EGFR', 'FUS', 'FUS', '.', 'EGFR-.', '.', '.', '该研究中的4位非小细胞肺癌EGFR融合突变患者中3位接受厄洛替尼治疗，其中一位患者治疗在6个月治疗期内，疾病缓解，8个月后疾病进展。一位患者接受厄洛替尼治疗5个月后疾病缓解，但由于非医学原因已停止用药。一位患者已接受厄洛替尼治疗6个月，目前疾病缓解，正在持续治疗中。另一位还未开始厄洛替尼治疗。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26052929', '.', 'preclinical', '4', 'linsitinib', 'linsitinib', 'linsitinib', 'linsitinib', 'linsitinib|linsitinib', '2', 'non-small cell lung cancer (NSCLC) progression with leptomeningeal (LM) metastases', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000815', 'IGF1R:nonsynonymous SNV:::act', 'IGF1R', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '胰岛素样生长因子1受体（IGF1R）信号通路的激活导致携带T790M突变的NSCLC细胞对阿法替尼产生耐药。IGF1R基因敲除使耐药细胞对阿法替尼敏感，诱导耐药肿瘤细胞凋亡。另外，阿法替尼和linstinib的组合治疗在动物试验中也表明具有协同抗肿瘤作用。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26796526|PMID:23231951', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', 'na', 'resistance', 'EVI_000816', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '胃肠道间质瘤（GIST）的驱动基因突变通常包括受体酪氨酸激酶如KIT或PDGFRA。PI3K作为KIT信号通路的下游基因，在包括GIST的多种癌症类型中都发现也可能发生激活突变。由于二次KIT突变或KIT信号传导途径下游的激活（如PI3K/AKT/mTOR途径），可能导致患者对酪氨酸激酶抑制剂如伊马替尼产生耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26796526|PMID:23231951', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', 'na', 'resistance', 'EVI_000817', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '胃肠道间质瘤（GIST）的驱动基因突变通常包括受体酪氨酸激酶如KIT或PDGFRA。PI3K作为KIT信号通路的下游基因，在包括GIST的多种癌症类型中都发现也可能发生激活突变。由于二次KIT突变或KIT信号传导途径下游的激活（如PI3K/AKT/mTOR途径），可能导致患者对酪氨酸激酶抑制剂如伊马替尼产生耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26796526|PMID:23231951', '.', 'clinical study', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', 'na', 'resistance', 'EVI_000818', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', '.', '胃肠道间质瘤（GIST）的驱动基因突变通常包括受体酪氨酸激酶如KIT或PDGFRA。PI3K作为KIT信号通路的下游基因，在包括GIST的多种癌症类型中都发现也可能发生激活突变。由于二次KIT突变或KIT信号传导途径下游的激活（如PI3K/AKT/mTOR途径），可能导致患者对酪氨酸激酶抑制剂如伊马替尼产生耐药。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCT03218826', 'NCT03218826', 'clinical trial - phase1', '4', 'AZD8186', 'AZD8186', 'AZD8186', 'AZD8186', 'AZD8186|AZD8186', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000820', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'I期临床试验研究了PI3Kbeta抑制剂AZD8186与多西紫杉醇联合可以用于治疗PTEN或PIK3CB突变的实体瘤患者。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCT03218826', 'NCT03218826', 'clinical trial - phase1', '4', 'AZD8186', 'AZD8186', 'AZD8186', 'AZD8186', 'AZD8186|AZD8186', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000821', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', '.', 'I期临床试验研究了PI3Kbeta抑制剂AZD8186与多西紫杉醇联合用于治疗PTEN或PIK3CB突变的实体瘤患者。 PI3Kbeta抑制剂AZD8186可能通过阻断细胞生长所需的一些酶来阻止肿瘤细胞的生长。化疗中使用的药物，如多西紫杉醇，以不同的方式阻止肿瘤细胞的生长。给予PI3Kβ抑制剂AZD8186和多西紫杉醇可能更好地治疗实体瘤患者。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27499993|PMID:26339441|PMID:29673089', '.', 'case report', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000826', 'EGFR:nonsynonymous SNV:exon19:p.L747P:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747P', '.', '.', '已经证实EGFR基因的活性突变预测了EGFR-TKI的活性。最常见的突变是外显子19缺失和外显子21点突变，两者都对EGFR-TKI敏感。然而，罕见的EGFR突变或复杂的突变仍然存在，其中的数据是稀缺和争议。他们对EGFR-TKI的反应尚不确定。 我们发现了一个被诊断患有IV期肺腺癌的患者，在进行任何治疗之前，发现在外显子19（L747P）中有EGFR突变。含顺铂和培美曲塞化疗2个月后病情进展，给予厄洛替尼，但未见反应。因此，L747P可能与EGFR-TKI的耐药有关。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26206867', '.', 'case report', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000827', 'EGFR:nonsynonymous SNV:exon18:p.E709_T710delinsD:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.E709_T710delinsD', '.', '.', '携带外显子18突变的肺癌患者可能对阿法替尼或来那替尼治疗敏感。一名63岁的男性被诊断患有IV期肺腺癌，FFPE样品DNA中EGFR，KRAS，ALK，HER2和BRAF基因均未未发现突变。 最初，他接受了铂双线治疗（顺铂+培美曲塞和卡铂+吉西他滨）。 此后，对胸腔积液中细胞提取的RNA的直接测序揭示了EGFR Del18（delE709_T710insD）突变。 尽管尚不清楚该突变是否敏感，但还是开始使用150 mg厄洛替尼。 腿上出现严重的皮疹，迫使停止使用厄洛替尼治疗，但疾病趋于稳定。改用阿法替尼40 mg后，观察到明显的肿瘤缩小。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26206867', '.', 'preclinical', '4', 'neratinib', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000828', 'EGFR:nonsynonymous SNV:exon18:p.E709_T710delinsD:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.E709_T710delinsD', '.', '.', '携带外显子18突变的肺癌患者可能对阿法替尼或来那替尼治疗敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19625781', '.', 'preclinical', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000829', 'EGFR:nonsynonymous SNV:exon19:p.A750P:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.A750P', '.', '.', '细胞学试验表明，EGFR基因的A750P突变可能是激活突变，与癌症的发生相关。因此，携带突变的患者可能对EGFR抑制剂敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19625781', '.', 'preclinical', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000830', 'EGFR:nonsynonymous SNV:exon19:p.A750P:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.A750P', '.', '.', '细胞学试验表明，EGFR基因的A750P突变可能是激活突变，与癌症的发生相关。因此，携带突变的患者可能对EGFR抑制剂敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19625781', '.', 'preclinical', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000831', 'EGFR:nonsynonymous SNV:exon19:p.A750P:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.A750P', '.', '.', '细胞学试验表明，EGFR基因的A750P突变可能是激活突变，与癌症的发生相关。因此，携带突变的患者可能对EGFR抑制剂敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21422421', '.', 'case report', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000835', 'EGFR:nonsynonymous SNV:exon21:p.L833V:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L833V', '.', '.', 'EGFR基因的L833V突变可能是激活突变，与癌症的发生相关。因此，携带突变的患者可能对EGFR抑制剂敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21422421', '.', 'case report', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000836', 'EGFR:nonsynonymous SNV:exon21:p.L833V:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L833V', '.', '.', 'EGFR基因的L833V突变可能是激活突变，与癌症的发生相关。因此，携带突变的患者可能对EGFR抑制剂敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21422421', '.', 'case report', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000837', 'EGFR:nonsynonymous SNV:exon21:p.L833V:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L833V', '.', '.', 'EGFR基因的L833V突变可能是激活突变，与癌症的发生相关。因此，携带突变的患者可能对EGFR抑制剂敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21422421', '.', 'case report', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000838', 'EGFR:nonsynonymous SNV:exon21:p.H835L:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.H835L', '.', '.', 'EGFR基因的H835L突变可能是激活突变，与癌症的发生相关。因此，携带突变的患者可能对EGFR抑制剂敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21422421', '.', 'case report', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000839', 'EGFR:nonsynonymous SNV:exon21:p.H835L:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.H835L', '.', '.', 'EGFR基因的H835L突变可能是激活突变，与癌症的发生相关。因此，携带突变的患者可能对EGFR抑制剂敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21422421', '.', 'case report', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000840', 'EGFR:nonsynonymous SNV:exon21:p.H835L:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.H835L', '.', '.', 'EGFR基因的H835L突变可能是激活突变，与癌症的发生相关。因此，携带突变的患者可能对EGFR抑制剂敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23177515', 'NCT01271712', 'clinical trial - phase3', '4', 'regorafenib', 'regorafenib', 'regorafenib', '瑞戈非尼', 'regorafenib|瑞戈非尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_000850', 'KIT:nonsynonymous SNV:exon14:p.T670I:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.T670I', '.', '.', 'KIT基因exon14外显子上的T670I突变可能与伊马替尼耐药相关。临床研究表明，对伊马替尼耐药的胃肠道间质瘤患者，使用瑞戈非尼治疗可能有效。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25641662', '.', 'clinical study', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_000851', 'KIT:nonsynonymous SNV:exon14:p.T670I:.', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.T670I', '.', '.', 'KIT基因exon14外显子上的T670I突变可能与伊马替尼耐药相关。临床研究表明，对伊马替尼耐药的胃肠道间质瘤患者，使用舒尼替尼治疗可能有效。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23177515', 'NCT01271712', 'clinical trial - phase3', '4', 'regorafenib', 'regorafenib', 'regorafenib', '瑞戈非尼', 'regorafenib|瑞戈非尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_000852', 'KIT:nonsynonymous SNV:exon13:p.V654A:', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.V654A', '.', '.', 'KIT基因exon14外显子上的TT670I突变可能与伊马替尼耐药相关。临床研究表明，对伊马替尼耐药的胃肠道间质瘤患者，使用瑞戈非尼治疗可能有效。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26307133', '.', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_000853', 'KRAS:CNV:.:.:gain', 'KRAS', 'CNV', 'CNV', '.', '.', 'gain', '.', '基因拷贝数改变涉及黑素瘤发病机理。III期临床试验E2603评估了患者体内基因突变情况与治疗方案（CP:卡铂+紫杉醇；CPS:卡铂+紫杉醇+ 索拉非尼）的治疗效果。携带RAF1或CCND1基因拷贝数增多的患者接受CPS治疗比接受CP治疗后可以获得更长的无进展生存期；携带KRAS基因扩增的患者接受CPS方案比CP治疗方案可以获得更长的总体生存率。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22270724', '.', 'clinical study', '4', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_000854', 'EGFR:nonsynonymous SNV:exon12:p.S492R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon12', 'p.S492R', '.', '.', '抗表皮生长因子受体（EGFR）,包括西妥昔单抗和帕尼单抗，被广泛用于治疗结直肠癌。不幸的是，患者最终对这些药物产生耐药性。我们描述了一种获得性EGFR胞外域突变（S492R），可以阻止西妥昔单抗结合并赋予西妥昔单抗抗药性。 然而，具有这种突变的细胞保持与帕尼单抗的结合并抑制肿瘤生长。在西妥昔单抗治疗后，在这里研究的疾病进展的十个受试者中的两个获得了这种突变。具有西妥昔单抗抗性的携带S492R突变的受试者对帕尼单抗的治疗有反应。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22270724', '.', 'clinical study', '4', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000855', 'EGFR:nonsynonymous SNV:exon12:p.S492R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon12', 'p.S492R', '.', '.', '抗表皮生长因子受体（EGFR）,包括西妥昔单抗和帕尼单抗，被广泛用于治疗结直肠癌。不幸的是，患者最终对这些药物产生耐药性。我们描述了一种获得性EGFR胞外域突变（S492R），可以阻止西妥昔单抗结合并赋予西妥昔单抗抗药性。 然而，具有这种突变的细胞保持与帕尼单抗的结合并抑制肿瘤生长。在西妥昔单抗治疗后，在这里研究的疾病进展的十个受试者中的两个获得了这种突变。具有西妥昔单抗抗性的携带S492R突变的受试者对帕尼单抗的治疗有反应。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23578570', '.', 'case report', '4', 'Cetuximab', 'Cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', '.', 'head and neck cancer', '头颈部肿瘤', 'na', 'sensitivity', 'EVI_000858', 'EGFR:nonsynonymous SNV:exon14:p.P546S:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.P546S', '.', '.', '一位33岁未有吸烟饮酒史的男性患者被诊断患有浸润性头颈部鳞癌，表现为声音嘶哑，喉咙痛和吞咽痛。虽经过喉部放疗，但患者依旧出现复发并最终接受全喉切除术及选择性右侧淋巴结清扫术。之后患者状况依旧严峻，并选择西妥昔单抗治疗方案。该治疗方案将患者的疼痛控制的较好，也缓解了肿瘤的症状，但患者同时也出现了用药相关的皮肤毒性，并最终因西妥昔单抗皮肤反应伴继发性MRSA感染同时伴有多重耐药性大肠埃希菌肺炎继发感染性休克而死亡。患者在基因检测中鉴定出两种EGFR突变: 一个在激酶结构域(R705G)中，另一个在配体结合结构域(P546S)中。之后的细胞实验证实P546S突变对西妥昔单抗敏感，而R705G具有边际效应，双重突变P546S/R705G依旧对西妥昔单抗敏感。此结果证明 EGFR P546S突变可以使用西妥昔单抗进行应对。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26687137', '.', 'case report', '4', 'Vemurafenib', 'Vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'Cholangiocarcinoma', 'Cholangiocarcinoma', '胆管癌', 'na', 'sensitivity', 'EVI_000859', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '一位31岁的胆管癌患者经检查发现未出现淋巴结浸润，之后经过治愈手术并进行吉西他滨和奥沙利铂的联合化疗以控制疾病。之后患者进行CT扫描发现肺部仍有转移灶存在，随即进行基因检测病鉴定出BRAF V600E突变。研究人员讨论研究决定采用维莫非尼和帕尼单抗的联合治疗并辅以伊立替康，患者表现出临床完全反应，但出现2级不良反应包括恶心，腹泻，脱发等，以及3级的皮肤毒性，但最终通过各种手段成功的控制住。患者在治疗结束后生活质量较好。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23792568', '.', 'case report', '4', 'sorafenib + cetuximab', 'sorafenib + cetuximab', 'sorafenib + cetuximab', '索拉非尼 + 西妥昔单抗', 'sorafenib + cetuximab|索拉非尼 + 西妥昔单抗', '4', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000860', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '一位60岁的女性检查出结肠癌，且肿瘤已经浸润至周围组织及肺部。之后患者接受了切除手术并开始针对性治疗。她首先接受FOLFOX加贝伐单抗联合治疗方案，但随后的影像学显示胸腹部依然有淋巴结肿大，之后治疗方案改为mFOLFIRI加西妥昔单抗，疾病虽暂时稳定但随后的基因检测发现患者携带BRAF V600E突变，这可能预示患者的预后不甚良好。后经商讨，患者选择索拉非尼加西妥昔单抗的联合治疗，这种组合虽然之前并未在肿瘤患者中证实有效，但该患者在该方案下表现出超乎寻常的良好表现，疾病稳定且不良反应轻微。之后经过医生调整，患者改为瑞戈非尼与帕尼单抗的组合来优化治疗并避免可能出现的耐药性。患者一直表现良好，无严重的不良反应。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23792568', '.', 'case report', '4', 'panitumumab +  regorafenib', 'panitumumab +  regorafenib', 'panitumumab +  regorafenib', '帕尼单抗 +  瑞戈非尼', 'panitumumab +  regorafenib|帕尼单抗 +  瑞戈非尼', '4', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000861', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '一位60岁的女性检查出结肠癌，且肿瘤已经浸润至周围组织及肺部。之后患者接受了切除手术并开始针对性治疗。她首先接受FOLFOX加贝伐单抗联合治疗方案，但随后的影像学显示胸腹部依然有淋巴结肿大，之后治疗方案改为mFOLFIRI加西妥昔单抗，疾病虽暂时稳定但随后的基因检测发现患者携带BRAF V600E突变，这可能预示患者的预后不甚良好。后经商讨，患者选择索拉非尼加西妥昔单抗的联合治疗，这种组合虽然之前并未在肿瘤患者中证实有效，但该患者在该方案下表现出超乎寻常的良好表现，疾病稳定且不良反应轻微。之后经过医生调整，患者改为瑞戈非尼与帕尼单抗的组合来优化治疗并避免可能出现的耐药性。患者一直表现良好，无严重的不良反应。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27258816', '.', 'case report', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'Struma Ovarii', 'struma ovarii', '卵巢甲状腺癌', 'na', 'sensitivity', 'EVI_000863', 'KIT:nonsynonymous SNV:exon10:p.V530I:', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon10', 'p.V530I', '.', '.', '一位47岁的妇女因突然发生右下腹疼痛，并伴有不浑浊的非吐血呕吐症状而入院。CT检测其右侧卵巢存在12厘米的肿块，且阴道及子宫内膜活检发现非典型复杂性增生。于是患者接受全子宫切除及双侧输卵管卵巢切除术，并在三个月后再次进行全甲状腺切除术以准备放射性碘治疗。患者接受治疗后3年后未见有疾病复发或转移迹象。基因检测发现患者携带KIT 外显子10 p.V530I突变，且伴有p.M541L多态性，这些突变在所有测试样品中均被鉴定出来。患者没有携带其他例如BRAF和RAS的突变。这是首例携带KIT突变的卵巢甲状腺瘤患者报告，是种系KIT p.V530I突变的第一篇报道。关于这种罕见突变的知识非常有限，使用KIT p.V530I转染的细胞系的体外研究显示，p.V530I突变可导致KIT的组成型活化并增加突变细胞的增殖和凋亡。更有趣的是，这个突变体被发现对伊马替尼的敏感性增加，在药理剂量下，抑制浓度(IC50)比野生型细胞低5倍，且与在胃肠道间质瘤患者中常见的KIT p.V558D突变型相似。我们目前仍需更多的研究实验来确认该突变与肿瘤之间的关系以及作为靶向治疗的可能性。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28188185', '.', 'case report', '4', 'pembrolizumab', 'pembrolizumab', 'pembrolizumab', '帕博利珠单抗', 'pembrolizumab|帕博利珠单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_000864', 'POLE:nonsynonymous SNV:.:.:inact', 'POLE', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '临床研究证据表明，微卫星不稳定性(MSI)或错配修复 (MMR) 缺陷及高肿瘤突变负荷(TMB)可以预测转移性结直肠癌(mCRC)对PD-1抑制剂(pembrolizumab)的疗效。POLE基因参与DNA复制过程的校对修复，不同于微卫星不稳定的肿瘤， POLE基因的突变可能会导致结直肠癌产生超高突变率但微卫星稳定(MSS)的表型。一名81岁的难治性转移性结直肠癌男性患者，经NGS检测携带POLE基因突变及MSS的表型，该患者对pembrolizumab治疗有效。肿瘤免疫染色显示存在大量的CD8阳性肿瘤浸润淋巴细胞(TIL)，其中>90%表达PD-1。POLE基因突变可以作为预测转移性结直肠癌患者对PD-1抑制剂疗效的潜在标志物。', 'G;S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22426421|PMID:24737648', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'decrease', 'EVI_000865', 'BCL2L11:CNV:.:.:loss', 'BCL2L11', 'CNV', 'CNV', '.', '.', 'loss', '.', '在对EGFR-TKI具有抗性的EGFR突变NSCLC细胞系中鉴定了BIM（BCL2L11）缺失多态性。在先前的EGFR-抑制剂敏感的细胞系中引入这种多态性导致该肿瘤细胞对TKI耐药。在有EGFR突变的141例NSCLC患者中，BCL2L11多态性（N = 26）的存在预示EGFR-TKI治疗的PFS显著缩短（6.6个月比11.9个月，P = 0.0027）。患者仅接受吉非替尼（N = 136）或仅接受厄洛替尼（N = 5）。', 'G;S', '可能疗效减弱', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22426421|PMID:24737648', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'decrease', 'EVI_000866', 'BCL2L11:CNV:.:.:loss', 'BCL2L11', 'CNV', 'CNV', '.', '.', 'loss', '.', '在对EGFR-TKI具有抗性的EGFR突变NSCLC细胞系中鉴定了BIM（BCL2L11）缺失多态性。在先前的EGFR-抑制剂敏感的细胞系中引入这种多态性导致该肿瘤细胞对TKI耐药。在有EGFR突变的141例NSCLC患者中，BCL2L11多态性（N = 26）的存在预示EGFR-TKI治疗的PFS显著缩短（6.6个月比11.9个月，P = 0.0027）。患者仅接受吉非替尼（N = 136）或仅接受厄洛替尼（N = 5）。', 'G;S', '可能疗效减弱', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22426421|PMID:24737648', '.', 'clinical study', '4', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'decrease', 'EVI_000867', 'BCL2L11:CNV:.:.:loss', 'BCL2L11', 'CNV', 'CNV', '.', '.', 'loss', '.', '在对EGFR-TKI具有抗性的EGFR突变NSCLC细胞系中鉴定了BIM（BCL2L11）缺失多态性。在先前的EGFR-抑制剂敏感的细胞系中引入这种多态性导致该肿瘤细胞对TKI耐药。在有EGFR突变的141例NSCLC患者中，BCL2L11多态性（N = 26）的存在预示EGFR-TKI治疗的PFS显著缩短（6.6个月比11.9个月，P = 0.0027）。患者仅接受吉非替尼（N = 136）或仅接受厄洛替尼（N = 5）。', 'G;S', '可能疗效减弱', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25057940', '.', 'preclinical', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000868', 'EGFR:nonsynonymous SNV:exon21:p.V843I:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.V843I', '.', '.', 'V843I突变通过促进EGFR及其下游信号蛋白的磷酸化来促成肿瘤发生。该突变似乎也通过EGFR的结构修饰提供对EGFR-TKI的抗性。这些特征与EGFR T790M突变中的特征相当，提示具有生殖细胞系V843I或T790M突变的病例可归类为一类对EGFR-TKI具有抗性肺癌亚型。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25057940', '.', 'preclinical', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000869', 'EGFR:nonsynonymous SNV:exon21:p.V843I:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.V843I', '.', '.', 'V843I突变通过促进EGFR及其下游信号蛋白的磷酸化来促成肿瘤发生。该突变似乎也通过EGFR的结构修饰提供对EGFR-TKI的抗性。这些特征与EGFR T790M突变中的特征相当，提示具有生殖细胞系V843I或T790M突变的病例可归类为一类对EGFR-TKI具有抗性肺癌亚型。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25057940', '.', 'preclinical', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000870', 'EGFR:nonsynonymous SNV:exon21:p.V843I:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.V843I', '.', '.', 'V843I突变通过促进EGFR及其下游信号蛋白的磷酸化来促成肿瘤发生。该突变似乎也通过EGFR的结构修饰提供对EGFR-TKI的抗性。这些特征与EGFR T790M突变中的特征相当，提示具有生殖细胞系V843I或T790M突变的病例可归类为一类对EGFR-TKI具有抗性肺癌亚型。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25057940', '.', 'preclinical', '4', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '3', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000871', 'EGFR:nonsynonymous SNV:exon21:p.V843I:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.V843I', '.', '.', 'V843I突变通过促进EGFR及其下游信号蛋白的磷酸化来促成肿瘤发生。该突变似乎也通过EGFR的结构修饰提供对EGFR-TKI的抗性。这些特征与EGFR T790M突变中的特征相当，提示具有生殖细胞系V843I或T790M突变的病例可归类为一类对EGFR-TKI具有抗性肺癌亚型。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/1538-7445.AM2017-CT046', '.', 'clinical trial - phase1', '4', 'palbociclib + PD-0325901', 'palbociclib + PD-0325901', 'palbociclib + PD-0325901', '哌柏西利 + PD-0325901', 'palbociclib + PD-0325901|哌柏西利 + PD-0325901', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000873', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '2017年4月，在美国癌症研究协会年会（AACR2017）上，美国Dana-Farber癌症研究所的科学家报道了一项小型研究结果。对于一些RAS驱动的肺癌、卵巢癌、甲状腺癌的患者，通过使用两种药物组合(palbociclib+PD-0325901)可以使得患者长期获益，这两种药物都是抑制RAS基因下游信号通路的。这是一项I期临床研究，25例入组患者中的17例是KRAS突变驱动的肺癌，8例是其他癌种。1名患者的肿瘤病灶出现部分缩小，18名患者病情稳定，其中7名患者病情稳定的时间超过了6个月。研究者在AACR大会上报道，MEK抑制剂和哌柏西利的联合使用是安全、可耐受的，而且确定有患者能从这一组合用药中获益。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28967920|NCT02071862', 'NCT02071862', 'clinical trial - phase1', '4', '.', '.', 'CB-839', 'CB-839', 'CB-839|CB-839', '1', 'solid tumors', 'solid tumors', '非特定癌症', 'na', 'sensitivity', 'EVI_000874', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'RAS突变的癌细胞获取营养的另一种方法是自噬作用，癌细胞可以通过它来获取生长所必需的氨基酸、脂质和核酸等。氯喹类的抗疟药对于自噬作用有抑制效果，并且对于巨胞饮作用也有一定的抑制效果。氯喹在一个小鼠胰腺癌模型中取得了不错的效果，目前有一项临床试验正在评估羟氯喹在胰腺癌中的潜在疗效。此外，携带RAS突变的胰腺癌细胞被发现更依赖于从谷氨酰胺产生的NADPH，NADPH对于维持细胞内的氧化还原平衡起关键作用。正常细胞主要从葡萄糖产生NADPH，因此，抑制从谷氨酰胺产生NADPH的化学过程能够特异性针对癌细胞。目前，有一个抑制这个过程中的第一步谷氨酰胺酶的小分子药物CB-839正在临床试验中，用于评估其对白血病和多种肿瘤的效果。抑制这个过程中的其它参与者的药物也有多个在临床前研究中。近期发表在《Nature Medicine》上的一项研究指出一种新的策略来阻止KRAS突变的肿瘤，来自麻省理工学院科赫综合癌症研究所的研究人员发现了KRAS基因有一个弱点，利用这一弱点可以将癌细胞饿死。在KRAS突变的小鼠模型中，研究人员发现存在另一种叫做Keap 1的突变基因时，小鼠体内的肿瘤生长得更快。事实证明，Keap 1基因限制了肿瘤内的抗氧化和抗炎反应，这两种基因保护肿瘤细胞免受可能导致其死亡的损伤。只要Keap 1突变存在，这种保护性响应就持续进行；如果有药物能阻断谷氨酰胺的供应，就能有效遏制Keap 1突变，肿瘤就不能继续生长。被称为CB-839的药物，在小鼠模型的试验中证实了这一点。这一发现对临床潜在的新治疗方法有指导作用。目前正在申请人体临床实验。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28967920|NCT02071862', 'NCT02071862', 'clinical trial - phase1', '4', '.', '.', 'CB-839', 'CB-839', 'CB-839|CB-839', '1', 'solid tumors', 'solid tumors', '非特定癌症', 'na', 'sensitivity', 'EVI_000875', 'KEAP1:nonsynonymous SNV:.:.:inact', 'KEAP1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'RAS突变的癌细胞获取营养的另一种方法是自噬作用，癌细胞可以通过它来获取生长所必需的氨基酸、脂质和核酸等。氯喹类的抗疟药对于自噬作用有抑制效果，并且对于巨胞饮作用也有一定的抑制效果。氯喹在一个小鼠胰腺癌模型中取得了不错的效果，目前有一项临床试验正在评估羟氯喹在胰腺癌中的潜在疗效。此外，携带RAS突变的胰腺癌细胞被发现更依赖于从谷氨酰胺产生的NADPH，NADPH对于维持细胞内的氧化还原平衡起关键作用。正常细胞主要从葡萄糖产生NADPH，因此，抑制从谷氨酰胺产生NADPH的化学过程能够特异性针对癌细胞。目前，有一个抑制这个过程中的第一步谷氨酰胺酶的小分子药物CB-839正在临床试验中，用于评估其对白血病和多种肿瘤的效果。抑制这个过程中的其它参与者的药物也有多个在临床前研究中。近期发表在《Nature Medicine》上的一项研究指出一种新的策略来阻止KRAS突变的肿瘤，来自麻省理工学院科赫综合癌症研究所的研究人员发现了KRAS基因有一个弱点，利用这一弱点可以将癌细胞饿死。在KRAS突变的小鼠模型中，研究人员发现存在另一种叫做Keap 1的突变基因时，小鼠体内的肿瘤生长得更快。事实证明，Keap 1基因限制了肿瘤内的抗氧化和抗炎反应，这两种基因保护肿瘤细胞免受可能导致其死亡的损伤。只要Keap 1突变存在，这种保护性响应就持续进行；如果有药物能阻断谷氨酰胺的供应，就能有效遏制Keap 1突变，肿瘤就不能继续生长。被称为CB-839的药物，在小鼠模型的试验中证实了这一点。这一发现对临床潜在的新治疗方法有指导作用。目前正在申请人体临床实验。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26359568', '.', 'case report', '4', 'Sunitinib', 'Sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'hereditary paraganglioma-pheochromocytoma syndrome', 'hereditary paraganglioma-pheochromocytoma syndrome', '嗜铬细胞瘤', 'na', 'sensitivity', 'EVI_000876', 'SDHB:frameshift deletion:exon2:p.A25Pfs*52:', 'SDHB', 'frameshift deletion', 'Exact_pos', 'exon2', 'p.A25Pfs*52', '.', '.', '一位22岁的女性右肾上腺体积异常，最初活组织检查被诊断为神经母细胞瘤。她接受3个周期的顺铂/依托泊苷治疗，然后接受2个周期的环磷酰胺，多柔比星和长春新碱治疗，之后患者做了两次外科减瘤手术并被检测出为副神经节瘤。该患者携带SDHB突变(外显子2，c.73delG)，该突变与遗传性副神经节瘤-嗜铬细胞瘤(PGL/PCC)综合征有关。患者之后接受131I-间碘苄胍与舒尼替尼的联合治疗并且表现出完全缓解，虽然9个月后患者再次出现骨转移，但在治疗过程中患者的药物反应十分良好。', 'G;S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25569703', '.', 'case report', '4', 'Sunitinib', 'Sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'renal cell carcinoma', 'renal cell carcinoma', '肾癌', 'na', 'sensitivity', 'EVI_000877', 'VHL:nonsynonymous SNV:exon2:p.T133N:', 'VHL', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.T133N', '.', '.', '一位77岁的女性肾细胞癌患者接受了根治性肾切除术，在右肾的上三分之一进行了淋巴结清扫术并切除了肿块。六个月后，CT检查显示两个纵隔淋巴结肿大并确认为肾细胞癌转移灶。由于过于接近节点血管，手术无法进行，于是医师考虑进行舒尼替尼治疗。患者的病灶虽然有大幅缩小，但伴随着严重的不良反应包括3级高血压，3级恶心，2级腹泻和口腔炎，1级呕吐，疲劳和中性粒细胞减少。于是患者接受的用药剂量被减少至37.5mg每日，虽然疾病仍旧被控制，但仍未根绝副作用。经过讨论，患者的用药改为同等剂量的每日37.5mg，给药2周然后休息1周，至此药物毒性得到了完全改善。在8个药物周期的治疗结束后患者停药并接受密切随访，患者在停药几周内不在出现副作用，且在15个月后没有肿瘤复发的迹象。经过基因检测发现患者携带VHL基因T133N突变。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23392356', '.', 'case report', '4', 'Quizartinib', 'quizartinib', 'quizartinib', '奎扎替尼', 'quizartinib|奎扎替尼', '3', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'resistance', 'EVI_000878', 'FLT3:nonframeshift insertion:exon17:p.F691L:', 'FLT3', 'nonframeshift insertion', 'Exact_pos', 'exon17', 'p.F691L', '.', '.', '一名48岁的女性FLT3-ITD急性髓性白血病(AML)患者因内部串联突变(ITD)而介导了患者对FLT3抑制剂AC220(奎扎替尼)的耐药性。患者在体检时确认其白细胞等血细胞计数异常，在经过高剂量阿糖胞苷和米托蒽醌进行补救性化疗，以及使用人类白细胞抗原进行同种异体干细胞移植。患者在移植后第28天获得完全缓解，但在第88天，患者出现了复发的迹象，于是接受FLT3抑制剂索拉非尼的治疗方案。患者的反应良好，第二次达到完全缓解，但副作用皮疹和水肿较为严重，患者在用药4周后不得不停药。在移植后的252天，患者再次出现复发迹象，细胞遗传学和分子分析仍然显示出患者具有初始鉴定的NPM1-和FLT3-ITD突变的核型但没有其它改变。患者使用奎扎替尼来控制病情，但疾病在短暂稳定后还是出现了进展，直至接受第二次移植。在第二次移植前患者接受了基因检测，并鉴定出新的FLT3-ITD F691L突变。为验证该突变是否是引起奎扎替尼耐药及疾病复发的原因，研究人员进行了体外实验并建立了具有FLT3-ITD或FLT3-ITD F691L的稳定表达细胞。实验证明，FLT3-ITD F691L对AC220具有高度抗性。之后患者改为舒尼替尼治疗，最初舒尼替尼的药效十分良好，但患者却因颅内出血而死亡在一家小型社区医院，未能赶上下一次的骨髓活检。总结讨论: 本文中的实验证明了FLT3-ITD F691L继发突变是患者对FLT3抑制剂奎扎替尼耐药的原因，FLT3-ITD的继发性改变分析可能在FLT3-ITD阳性的白血病靶向治疗中起重要作用。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23392356', '.', 'case report', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_000879', 'FLT3:nonframeshift insertion:exon17:p.F691L:', 'FLT3', 'nonframeshift insertion', 'Exact_pos', 'exon17', 'p.F691L', '.', '.', '一名48岁的女性FLT3-ITD急性髓性白血病(AML)患者因内部串联突变(ITD)而介导了患者对FLT3抑制剂AC220(奎扎替尼)的耐药性。患者在体检时确认其白细胞等血细胞计数异常，在经过高剂量阿糖胞苷和米托蒽醌进行补救性化疗，以及使用人类白细胞抗原进行同种异体干细胞移植。患者在移植后第28天获得完全缓解，但在第88天，患者出现了复发的迹象，于是接受FLT3抑制剂索拉非尼的治疗方案。患者的反应良好，第二次达到完全缓解，但副作用皮疹和水肿较为严重，患者在用药4周后不得不停药。在移植后的252天，患者再次出现复发迹象，细胞遗传学和分子分析仍然显示出患者具有初始鉴定的NPM1-和FLT3-ITD突变的核型但没有其它改变。无奈之下患者使用奎扎替尼来控制病情，但疾病在短暂稳定后还是出现了进展，直至接受第二次移植。在第二次移植前患者接受了基因检测，并鉴定出新的FLT3-ITD F691L突变。为验证该突变是否是引起奎扎替尼耐药及疾病复发的原因，研究人员进行了体外实验并建立了具有FLT3-ITD或FLT3-ITD F691L的稳定表达细胞。实验证明，FLT3-ITD F691L对AC220具有高度抗性。之后患者改为舒尼替尼治疗，最初舒尼替尼的药效十分良好，但患者却因颅内出血而死亡在一家小型社区医院，未能赶上下一次的骨髓活检。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22995920', '.', 'case report', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'pediatric renal cell carcinoma', 'pediatric renal cell carcinoma', '肾癌', 'na', 'sensitivity', 'EVI_000880', 'TFE3:FUS:.:.-TFE3:', 'TFE3', 'FUS', 'FUS', '.', '.-TFE3', '.', '.', '一位11岁的女性因持续三天的无发热血尿及腰部疼痛而入院，同时伴有大量可触及的左侧腹部肿块，影像学显示其左侧肾脏有钙化的异质性肿块，CT显示其左侧基底胸膜改变，左下肺周围结节，之后通过穿刺活检确认为肾细胞癌，且有强烈的TFE3染色，确认为TFE3易位。患者接受了根治性肾切除术，包括13个肺门淋巴结切除术，术后3个月随访时，无症状，无发热。在此时间内患者使用舒尼替尼治疗方案，虽伴有腰痛，口腔溃疡，皮肤和头发色素损失及骨痛等不良反应，但药效反应十分良好，肺结节和纵隔淋巴结恢复正常大小。之后患者又接受了3次舒尼替尼治疗，且至今保持着良好状态。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:14679114', '.', 'clinical trial - phase2', '4', 'trastuzumab', 'trastuzumab', 'trastuzumab', '曲妥珠单抗', 'trastuzumab|曲妥珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000881', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', '虽然曲妥珠单抗在HER2阳性的乳腺癌中可以获得很好的临床疗效，但HER2阳性的非小细胞肺癌患者对其治疗获益较少。一项临床试验评估了103名HER2阳性非小细胞肺癌的患者采用吉西他滨+顺铂与吉西他滨+顺铂+曲妥珠单抗的临床疗效。结果表明，虽然其中6名患者取得了较好的临床疗效，但总体来说，两种治疗方案的结果相似（响应率:41% vs 36%,中位疾病进展时间：7.2月 vs 6.3月，无进展生存期：7月 vs 6.1月）。该临床试验表明，HER2阳性的非小细胞肺癌患者可能无法从曲妥珠单抗的治疗中获益。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23220880|DOI:10.1158/1538-7445.SABCS15-PD5-05', 'NCT01953926', 'clinical trial - phase2', '4', 'Neratinib', 'Neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000882', 'ERBB2:nonframeshift insertion:exon20:.:exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', 'ERBB2扩增/高表达可用于预测肿瘤患者对HER2靶向治疗药物的敏感度，这类药物包括lapatinib, afatinib, trastuzumab, pertuzumab, ado-trastuzumab (T-DM1)。这些制剂已被FDA批准用于治疗各种癌症。目前在ERBB2基因的细胞外结构域和激酶结构域还发现多个导致其功能持续活化的点突变（gain-of-function，例如Exon20插入，S310F/Y，L755S等），携带这些突变的肿瘤细胞可能对ERBB2抑制剂敏感。一项II期临床试验正在评估neratinib在携带ERBB2激活突变肿瘤患者中的疗效（NCT01953926）。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23220880|DOI:10.1158/1538-7445.SABCS15-PD5-05', 'NCT01953926', 'clinical trial - phase2', '4', 'Neratinib', 'Neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000883', 'ERBB2:nonsynonymous SNV:.:.:act', 'ERBB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'ERBB2 扩增/高表达可用于预测肿瘤患者对HER2靶向治疗药物的敏感度，这类药物包括lapatinib, afatinib, trastuzumab, pertuzumab, ado-trastuzumab (T-DM1)。这些制剂已被FDA批准用于治疗各种癌症。目前在ERBB2基因的细胞外结构域和激酶结构域还发现多个导致其功能持续活化的点突变（gain-of-function，例如Exon20插入，S310F/Y，L755S等），携带这些突变的肿瘤细胞可能对ERBB2抑制剂敏感。一项II期临床试验正在评估neratinib在携带ERBB2激活突变肿瘤患者中的疗效（NCT01953926）。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29056570|NCT02228369', 'NCT02228369', 'clinical trial - phase1', '4', 'AZD3759', 'AZD3759', 'AZD3759', 'AZD3759', 'AZD3759|AZD3759', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000885', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', 'AZD3759是一种有效的口服可逆性表皮生长因子受体（EGFR）抑制剂，对于EGFR敏感性突变，主要是L858R和Exon19Del，其与目前批准的EGFR TKIs相比，透过血脑屏障（BBB）的功能更强。在一项临床试验中，18名从未接受过EGFR TKI治疗且具有可评估的CNS（脑转移）靶病变的患者，经AZD3759治疗后，15（83%）获得客观响应（14个部分反应和1个完全反应）。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29056570|NCT02228369', 'NCT02228369', 'clinical trial - phase1', '4', 'AZD3759', 'AZD3759', 'AZD3759', 'AZD3759', 'AZD3759|AZD3759', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000886', 'EGFR:nonsynonymous SNV:exon21:p.L858R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', 'AZD3759是一种有效的口服可逆性表皮生长因子受体（EGFR）抑制剂，对于EGFR敏感性突变，主要是L858R和Exon19Del，其与目前批准的EGFR TKIs相比，透过血脑屏障（BBB）的功能更强。在一项临床试验中，18名从未接受过EGFR TKI治疗且具有可评估的CNS（脑转移）靶病变的患者，经AZD3759治疗后，15（83%）获得客观响应（14个部分反应和1个完全反应）。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28287083', '.', 'preclinical', '4', 'AP26113', 'AP26113', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_000888', 'EGFR:nonsynonymous SNV:exon20:p.C797S<顺式>:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<顺式>', '.', '.', '目前，尚无克服C797S/T790M/active mutation（三重突变）介导的EGFR-TKI耐药的有效治疗策略。在本研究中，我们发现brigatinib对体外和体内三重突变的肿瘤细胞有抑制作用。计算机模拟表明，brigatinib适合三突变EGFR的ATP结合口袋，可对其产生抑制作用。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26662311', '.', 'clinical study', '4', 'bevacizumab', 'bevacizumab', 'bevacizumab', '贝伐珠单抗', 'bevacizumab|贝伐珠单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'decrease', 'EVI_000890', 'KRAS:nonsynonymous SNV:exon2:p.G12.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', '.', '在35-45%的结直肠癌（CRC）病例中发现KRAS突变。尽管RAS信号传导与血管生成之间的关系众所周知，但用贝伐珠单抗治疗的患者中KRAS突变的阴性预测值尚未确定。这项研究的目的是评估具体的KRAS突变类型和贝伐珠单抗治疗转移性CRC患者的结果之间的关联。该研究纳入了404例贝伐珠单抗治疗的转移性CRC（mCRC）患者。回顾性分析从临床登记处CORECT获得的临床数据。携带G12V或G12A KRAS突变的肿瘤患者存活时间最短。携带野生型KRAS基因的患者中位无进展生存期（PFS）和总生存期（OS）分别为10.8和29.2个月；而携带G12V/A KRAS突变的肿瘤患者的中位无进展生存期（PFS）和总生存期（OS）分别为6.6和16.8，而携带其他KRAS突变类型的肿瘤患者的中位无进展生存期（PFS）和总生存期（OS）分别为11.6和26.3个月。在Cox多变量分析中，KRAS G12V/A突变类型仍然是预测PFS（HR = 2.18，p <0.001）和OS（HR = 2.58，p <0.001）的重要因素。总之，使用贝伐珠单抗治疗时，携带G12V/A KRAS突变的肿瘤患者与野生型患者相比，前者的PFS和OS都劣于后者。', 's', '可能疗效减弱', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:afatinib_Revised:01/2018', '.', 'guideline:FDA', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000892', 'EGFR:nonsynonymous SNV:exon21:p.L861Q:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L861Q', '.', 'Presence of EGFR-activating mutations represents a critical biological determinant for proper  therapy selection in patients with lung cancer.  There is a significant association between EGFR  mutations--especially exon 19 deletion and exon 21 (L858R, L861) and exon 18 (G719X, G719)  and exon 20 (S768I) mutations--and sensitivity to EGFR TKIs.', '阿法替尼扩大适应症的获批(FDA,2018)是基于3个不同研究的结果，包括2期临床试验LUX-Lung 2（LL2）和3期临床试验LUX-Lung 3（LL3）和LUX-Lung 6（LL6）。共有32名具有EGFR罕见突变（包括L861Q、G719X或S768I突变）的非小细胞肺癌患者参与了试验研究。结果显示，从客观缓解率、响应时间、疾病控制、无进展生存和总生存期等方面证实了阿法替尼对这些突变的有效性。总体而言，阿法替尼组患者的客观缓解率（ORR）为66%。在出现缓解的患者中，52%的患者的缓解持续时间≥12个月，33%的患者的缓解持续时间≥18个月。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:afatinib_Revised:01/2018', '.', 'guideline:FDA', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000893', 'EGFR:nonsynonymous SNV:exon20:p.S768I:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.S768I', '.', 'Presence of EGFR-activating mutations represents a critical biological determinant for proper  therapy selection in patients with lung cancer.  There is a significant association between EGFR  mutations--especially exon 19 deletion and exon 21 (L858R, L861) and exon 18 (G719X, G719)  and exon 20 (S768I) mutations--and sensitivity to EGFR TKIs.', '阿法替尼扩大适应症的获批(FDA,2018)是基于3个不同研究的结果，包括2期临床试验LUX-Lung 2（LL2）和3期临床试验LUX-Lung 3（LL3）和LUX-Lung 6（LL6）。共有32名具有EGFR罕见突变（包括L861Q、G719X或S768I突变）的非小细胞肺癌患者参与了试验研究。结果显示，从客观缓解率、响应时间、疾病控制、无进展生存和总生存期等方面证实了阿法替尼对这些突变的有效性。总体而言，阿法替尼组患者的客观缓解率（ORR）为66%。在出现缓解的患者中，52%的患者的缓解持续时间≥12个月，33%的患者的缓解持续时间≥18个月。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:afatinib_Revised:01/2018', '.', 'guideline:FDA', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000894', 'EGFR:nonsynonymous SNV:exon18:p.G719.:.', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon18', 'p.G719.', '.', 'Presence of EGFR-activating mutations represents a critical biological determinant for proper  therapy selection in patients with lung cancer.  There is a significant association between EGFR  mutations--especially exon 19 deletion and exon 21 (L858R, L861) and exon 18 (G719X, G719)  and exon 20 (S768I) mutations--and sensitivity to EGFR TKIs.', '阿法替尼扩大适应症的获批(FDA,2018)是基于3个不同研究的结果，包括2期临床试验LUX-Lung 2（LL2）和3期临床试验LUX-Lung 3（LL3）和LUX-Lung 6（LL6）。共有32名具有EGFR罕见突变（包括L861Q、G719X或S768I突变）的非小细胞肺癌患者参与了试验研究。结果显示，从客观缓解率、响应时间、疾病控制、无进展生存和总生存期等方面证实了阿法替尼对这些突变的有效性。总体而言，阿法替尼组患者的客观缓解率（ORR）为66%。在出现缓解的患者中，52%的患者的缓解持续时间≥12个月，33%的患者的缓解持续时间≥18个月。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25370471|NCT00876122', 'NCT00876122', 'clinical trial - phase1', '4', 'GDC-0941', 'GDC-0941', 'pictilisib', 'pictilisib', 'pictilisib|pictilisib', '1', 'solid tumors', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000895', 'PIK3CA:CNV:.:.:gain', 'PIK3CA', 'CNV', 'CNV', '.', '.', 'gain', '.', 'pictilisib(GDC-0941)是一种选择性PI3K抑制剂。I期临床试验表明，pictilisib的安全性和抗肿瘤活性良好。一名具有BRAF V600E突变的黑色素瘤患者和一名PTEN基因缺失+PIK3CA基因拷贝数扩增的卵巢癌患者，在pictilisib治疗后取得了部分响应（NCT00876122）。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25370471|NCT00876122', 'NCT00876122', 'clinical trial - phase1', '4', 'GDC-0941', 'GDC-0941', 'pictilisib', 'pictilisib', 'pictilisib|pictilisib', '1', 'solid tumors', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_000896', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'pictilisib (GDC-0941)是一种选择性PI3K抑制剂。I期临床试验表明，pictilisib的安全性和抗肿瘤活性良好。一名具有BRAF V600E突变的黑色素瘤患者和一名PTEN基因缺失+PIK3CA基因拷贝数扩增的卵巢癌患者，在pictilisib治疗后取得了部分响应（NCT00876122）。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24912489', 'NCT01197170', 'clinical trial - phase1', '4', 'everolimus', 'everolimus', 'everolimus + anastrozole', '依维莫司 + 阿那曲唑', 'everolimus + anastrozole|依维莫司 + 阿那曲唑', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_000898', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'One breast cancer patient harboring a PIK3CA mutation demonstrated a partial response to everolimus and anastrozole combination therapy.', '一名携带PIK3CA激活突变的病人使用依维莫司与阿那曲唑的联合治疗后取得了部分响应。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23408298', '.', 'case report', '4', 'everolimus', 'everolimus', 'everolimus', '依维莫司', 'everolimus|依维莫司', '4', 'oropharynx cancer', 'head and neck cancer', '头颈部肿瘤', 'na', 'sensitivity', 'EVI_000899', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'One patient with HPV-positive oropharyngeal cancer harboring the PIK3CA E545Q mutation demonstrated a 58% reduction in tumor burden after everolimus therapy.', '一名携带PIK3CA激活突变的口咽癌患者使用依维莫司后肿瘤减少了58%。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19844234', 'EGF100642|EGF104911', 'clinical trial - phase2', '4', 'lapatinib', 'lapatinib', 'lapatinib', '拉帕替尼', 'lapatinib|拉帕替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_000900', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Patients with tumours harbouring an H1047R PIK3CA mutation or low expression of PTEN derived clinical benefit from lapatinib. Patients with advanced HER2 positive breast cancer that also harbor PIK3CA mutations still derived some clinical benefit from lapatinib therapy (PMID:19844234).携带PIK3CA基因激活突变的HER2+乳腺癌患者可能依然对拉帕替尼有效。', '部分携带PIK3CA基因激活突变的HER2+乳腺癌患者可能依然对拉帕替尼有效。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22487539', '.', 'case report', '4', 'perifosine', 'perifosine', 'perifosine', '哌立福新', 'perifosine|哌立福新', '2', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_000901', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '哌立福新(Perifosine)是一杂环的烷基磷酸胆碱，是AKT的靶向抑制剂。一名携带PIK3CA激活突变的卵巢癌病人使用哌立福新联合多西他赛治疗后疾病稳定了4个月。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23470635', '.', 'clinical study', '4', 'dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'resistance', 'EVI_000902', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'A secondarily acquired H1047R mutation in a gastrointestinal stromal tumor with primary BRAF mutation may have contributed to dabrafenib therapy resistance.', '胃肠道间质瘤患者出现PIK3CA基因激活突变可能导致其对dabrafenib耐药。在胃肠道间质瘤(GIST)患者中激活的BRAF的致癌突变已得到了报道描述，但是用BRAF抑制剂治疗GIST和GIST中耐药性出现的机制尚未见报道。dabrafenib是一种有效的ATP竞争性BRAF激酶抑制剂，对激酶组的筛选，细胞系和异种移植物中的突变BRAF具有高度选择性。我们在用BRAF抑制剂治疗携带V600E BRAF突变的GIST的患者中，第一次报告了其抗肿瘤活性的延长的状况。我们在疾病进行时的肿瘤组织中使用全外显子组测序发现患者出现体细胞功能获得性PIK3CA突变(H1047R)以及CDKN2A的畸变，这可能会导致患者最终出现耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25231405', '.', 'case report', '4', 'CH5132799', 'CH5132799', 'CH5132799', 'CH5132799', 'CH5132799|CH5132799', '1', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_000903', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'One patient with PIK3CA H1047R-mutated clear cell ovarian cancer had a GCIG CA125 response having been treated at 48 mg twice daily and remained on study for 6 cycles.', '一名携带PIK3CA基因激活突变（H1047R）的卵巢癌患者对CH5132799（PI3K抑制剂）治疗有部分响应。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:19706758', '.', 'preclinical', '4', 'temsirolimus', 'temsirolimus', 'temsirolimus', '替西罗莫司', 'temsirolimus|替西罗莫司', '4', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_000904', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Expression of activating PIK3CA mutations in thyroid cancer cells increases cell sensitivity to temsirolimus (PMID:19706758).', '表达PIK3CA激活突变的肿瘤细胞株对temsirolimus敏感。携带PI3K/Akt基因激活突变的TPC1，Hth7，FTC133，OCUT1，K1和BCPAP细胞的增殖被Akt抑制剂哌立福新强烈抑制，而SW1736，Hth74，WRO，KAT18和TAD2细胞则没有携带突变或只有适度的回应。在这些细胞中观察到哌立福新抑制了Akt磷酸化。类似地，mTOR抑制剂替西罗莫司脂化物(temsirolimus)对细胞增殖的有效抑制也发生在具有遗传突变的细胞中，而在一些不具有遗传改变的细胞中只观察到适度的抑制。西罗莫司脂化物可以抑制mTOR底物p70S6K的磷酸化。通过shRNA方法敲除Akt1/2可以抑制携带PI3K/Akt遗传突变的FTC133和OCUT1细胞的增殖和集落形成，但对SW1736和KAT18细胞则没有影响。而PIK3CA突变体的转染极大地使SW1736细胞对哌立福新和西罗莫司脂化物敏感，同时哌立福新显著抑制裸鼠异种移植的FTC133细胞肿瘤的生长，但对SW1736细胞异种移植没有影响。这项工作首次表明，PI3K/Akt途径的基因突变赋予甲状腺癌细胞对该途径的依赖性，同时对靶向Akt和mTOR药物具有敏感性。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2017.09.399|IASLC 2019 World Conference on Lung Cancer, Sep 2019, abstract# PL02.08', 'NCT03157128', 'clinical trial - phase2', '4', 'LOXO-292', 'LOXO-292', 'selpercatinib', 'selpercatinib', 'selpercatinib|selpercatinib', '1', 'RET Fusion-Positive Lung ', 'lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000907', 'RET:FUS:.:.-RET:.', 'RET', 'FUS', 'FUS', '.', '.-RET', '.', '.', '临床前研究显示，Selpercatinib（LOXO-292）对RET基因的抑制很广泛，除了常见的KIF5B-RET融合外，对各种潜在的RET耐药变异如CCDC6-RET融合、RET基因点突变C634W、M918T、V804L/M等都有很好的抑制。更重要的一点就是LOXO-292入脑能力很强，可以防止RET基因融合的癌细胞躲在脑内作恶。目前LOXO-292正在招募RET基因融合的实体瘤患者进行I期临床试验（登记号NCT03157128），计划招募180名患者。试验中心包括美国、法国、韩国、西班牙，第1名患者已经于2017年5月入组。现有两例接受LOXO-292治疗的患者数据公布，两位患者治疗的疗效非常好。没有剂量限制性毒性，患者都是之前接受过重度治疗的非小细胞肺癌患者，其中一名患者还有脑转移。RET基因融合的靶向治疗，因为现有药物的选择性不高，一直进展缓慢。LOXO-292是一种高度选择性的口服RET抑制剂，而且能有效进入脑部。现有的病例显示LOXO-292治疗RET基因融合的非小细胞肺癌高效，低毒，对脑转移同样疗效良好，是非常有潜力的RET靶向药。在I/II期试验（LIBRETTO-001）中，Selpercatinib（LOXO-292）治疗导致RET融合阳性非小细胞肺癌患者的客观缓解率为68%（71/105）。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26314551', '.', 'case report', '4', 'trametinib ', 'trametinib ', 'trametinib ', '曲美替尼', 'trametinib |曲美替尼', '4', 'Spitzoid melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_000908', 'BRAF:FUS:.:.-BRAF:.', 'BRAF', 'FUS', 'FUS', '.', '.-BRAF', '.', '.', '一名46岁的白人女性，诊断为转移性Spitzoid黑色素瘤，携带ZKSCAN1-BRAF融合（ZKSCAN1外显子1-5;BRAF外显子10-18），对MEK抑制剂曲美替尼的治疗有效。 皮下肿瘤结节在治疗14天内表现出明显的临床反应，在第45天其右肺转移显示出明显的临床反应，患者随后接受了机器人辅助肺叶切除术。该患者在胸部手术后6个月内病情稳定。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26314551', '.', 'case report', '4', '.', '.', 'bevacizumab + temsirolimus + sorafenib', '贝伐珠单抗 + 替西罗莫司 + 索拉非尼', 'bevacizumab + temsirolimus + sorafenib|贝伐珠单抗 + 替西罗莫司 + 索拉非尼', '4', 'spindle cell tumor', 'spindle cell tumor', '梭形细胞肿瘤', 'na', 'sensitivity', 'EVI_000909', 'BRAF:FUS:.:.-BRAF:.', 'BRAF', 'FUS', 'FUS', '.', '.-BRAF', '.', '.', '一名胸壁恶性梭形细胞瘤患者，携带KIAA1549-BRAF融合（KIAA1549外显子1-15;BRAF外显子9-18），该患者对贝伐珠单抗，Temsirolimus（替西罗莫司）和索拉非尼的联合治疗有临床反应。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28539463', '.', 'case report', '4', '.', '.', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'resistance', 'EVI_000910', 'BRAF:FUS:.:.-BRAF:.', 'BRAF', 'FUS', 'FUS', '.', '.-BRAF', '.', '.', '一名携带BRAF V600基因突变的黑色素瘤患者，同时检测出BRAF融合基因突变，该突变可能是导致其对维莫非尼产生耐药的原因。', 'F', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29572003', '.', 'case report', '4', 'atezolizumab', 'atezolizumab', 'atezolizumab', '阿替利珠单抗', 'atezolizumab|阿替利珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000911', 'POLE:nonsynonymous SNV:.:.:inact', 'POLE', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'POLE基因在NSCLC患者中发生突变的频率较低。与野生型POLE相比，携带POLE基因突变的NSCLC患者，其TMB，PD-L1表达和CD8+肿瘤浸润淋巴细胞丰度在突变患者中都更高。 一项临床研究中入组了319例NSCLC患者，通过二代测序（NGS）方法检测POLE基因突变状态，并计算肿瘤突变负荷（TMB），同时通过免疫组化（IHC）评估PD-L1表达、错配修复（MMR）和CD8+肿瘤浸润淋巴细胞丰度。结果显示，2.8%（9/319）NSCLC患者伴有POLE基因突变，且都为肺腺癌。通过计算TMB，POLE突变NSCLC患者的TMB值明显高于其他患者（12.27/Mb vs 7.87/Mb)。根据NGS检测结果，将281例患者（38例未追溯）分成三组，1组为POLE基因突变；2组为EGFR/ALK突变，但POLE野生；3组为EGFR/ALK/POLE都为野生型。结果发现三组的中位总生存期分别为20.0，19.1和14.0个月（P<0.001)。其中三个患者同时伴有EGFR突变和POLE突变，接受EGFR-TKI治疗，PFS分别为5.2，4.0和1.5个月，TKI获益较低。9例携带POLE基因突变的NSCLC患者，7例含有高水平的CD8+T淋巴细胞浸润，5例PD-L1表达≥25%，未检出微卫星不稳定。其中一例接受atezolizumab治疗，出现部分缓解(PR), PFS>8个月。因此，POLE突变可能代表NSCLC患者对免疫治疗反应的候选生物标志物。', 'G;S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25899785', 'NCT00818441', 'clinical trial - phase2', '4', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '3', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000912', 'ERBB2:nonframeshift insertion:exon20::exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', '一项临床试验招募了30名HER2（ERBB2）突变的肺癌患者（n = 26，均发生于外显子20，包括25个插入突变和1个错义突变）或HER2扩增肺癌（n = 4）。每天给予口服dacomitinib 30-45毫克，进行28天的周期。携带HER2外显子20突变的26位肿瘤患者中有3位[12%; 95%可信区间（CI）2%-30%]的部分反应持续时间分别为3+个月，11个月和14个月。 4例HER2扩增肿瘤患者未出现部分反应。 HER2突变患者的中位总生存期为9个月（95%可信区间为7-21个月，总体范围为5-22个月）。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:17463250', '.', 'guideline:NCCN', '1', '.', '.', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000913', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', 'Engelman等于2007年首次提出原癌基因MET的扩増是第一代EGFR-TKI的一种继发性耐药机制。MET扩增的耐药机制为MET与ERBB3结合，绕过EGFR激活下游PIK3/AKT介导的信号通路，促使肿瘤细胞增殖，抑制凋亡。NCCN指南中也提出，肺癌患者对EGFR-TKI出现获得性耐药的原因包括：EGFR基因上的二次突变（如T790M），MET基因的扩增，NSCLC到SCLC的组织转化，以及上皮到间质的转化（EMT）。', 'A', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:17463250', '.', 'guideline:NCCN', '1', '.', '.', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000914', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', 'Engelman等于2007年首次提出原癌基因MET的扩増是第一代EGFR-TKI的一种继发性耐药机制。MET扩增的耐药机制为MET与ERBB3结合，绕过EGFR激活下游PIK3/AKT介导的信号通路，促使肿瘤细胞增殖，抑制凋亡。NCCN指南中也提出，肺癌患者对EGFR-TKI出现获得性耐药的原因包括：EGFR基因上的二次突变（如T790M），MET基因的扩增，NSCLC到SCLC的组织转化，以及上皮到间质的转化（EMT）。', 'A', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:17463250', '.', 'guideline:NCCN', '1', '.', '.', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000915', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', 'Engelman等于2007年首次提出原癌基因MET的扩増是第一代EGFR-TKI的一种继发性耐药机制。MET扩增的耐药机制为MET与ERBB3结合，绕过EGFR激活下游PIK3/AKT介导的信号通路，促使肿瘤细胞增殖，抑制凋亡。NCCN指南中也提出，肺癌患者对EGFR-TKI出现获得性耐药的原因包括：EGFR基因上的二次突变（如T790M），MET基因的扩增，NSCLC到SCLC的组织转化，以及上皮到间质的转化（EMT）。', 'A', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:17463250', '.', 'guideline:NCCN', '1', '.', '.', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000916', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', 'Engelman等于2007年首次提出原癌基因MET的扩増是第一代EGFR-TKI的一种继发性耐药机制。MET扩增的耐药机制为MET与ERBB3结合，绕过EGFR激活下游PIK3/AKT介导的信号通路，促使肿瘤细胞增殖，抑制凋亡。NCCN指南中也提出，肺癌患者对EGFR-TKI出现获得性耐药的原因包括：EGFR基因上的二次突变（如T790M），MET基因的扩增，NSCLC到SCLC的组织转化，以及上皮到间质的转化（EMT）。', 'A', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:17463250', '.', 'guideline:NCCN', '1', '.', '.', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000917', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', 'Engelman等于2007年首次提出原癌基因MET的扩増是第一代EGFR-TKI的一种继发性耐药机制。MET扩增的耐药机制为MET与ERBB3结合，绕过EGFR激活下游PIK3/AKT介导的信号通路，促使肿瘤细胞增殖，抑制凋亡。NCCN指南中也提出，肺癌患者对EGFR-TKI出现获得性耐药的原因包括：EGFR基因上的二次突变（如T790M），MET基因的扩增，NSCLC到SCLC的组织转化，以及上皮到间质的转化（EMT）。', 'A', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23435671', '.', 'clinical trial - phase3', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'resistance', 'EVI_000918', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项关于胰腺癌患者对厄洛替尼的临床试验中（AIO-PK0104），173例（70%）患者中有121例发生KRAS密码子突变。结果表明，KRAS状态与厄洛替尼疗效的客观反应无关（p = 0.40），但KRAS野生型患者OS有明显改善（HR 1.68，p = 0.005）。 KRAS野生型患者在（无厄洛替尼）2线化疗期间也观察到生存期增加的趋势，OS的HR为1.47（p = 0.10）。该临床试验的事后分析表明胰腺癌患者KRAS突变状态是其预后分析的一个生物标志物，而不能预测厄洛替尼的疗效。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/2159-8290.CD-18-0338', '.', 'clinical trial - phase1', '4', '.', '.', 'BLU-667', 'BLU-667', 'BLU-667|BLU-667', '1', 'RET Fusion-Positive Lung ', 'lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000919', 'RET:FUS:.:.-RET:.', 'RET', 'FUS', 'FUS', '.', '.-RET', '.', '.', '2018年AACR会议报道了BLU-667一期临床试验的早期结果，BLU-667表现出广泛的抗肿瘤活性，对于接受剂量≥60mg且具有至少1次基线后应答评估的RET改变患者，总体反应率（ORR）最高为37%（95%CI，20%-56%）；在具有RET融合和突变的患者中，ORR为45%。特别是非小细胞肺癌患者的ORR为50%。这40位患者中，18位患者肿瘤明显缩小，包括一位患者肿瘤完全消失；同时，20位患者肿瘤稳定不长大，肿瘤控制率高达90%。在14位可评估RET融合NSCLC中：7位部分缓解，5名稳定，客观缓解率50%，疾病稳定率86%，中位无进展生存期数据仍不成熟。BLU-667耐受性良好，主要3级不良反应有谷丙转氨酶升高（2%），高血压（8%），乏力（2%），腹泻（2%），中性粒细胞减少症（4%）和白细胞减少症（2%），没有4级和5级不良反应。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29563138', '.', 'clinical trial - phase2', '4', '.', '.', 'ensartinib', 'ensartinib', 'ensartinib|ensartinib', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_000920', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '一项I/II期临床试验中，13个入组单位招募了97名患者。剂量爬坡组包含37名患者，每日服用一次Ensartinib (X-396) ，剂量从25毫克至250毫克不等；剂量扩展组包含60名患者，只入组ALK阳性的非小细胞肺癌，每日使用225毫克的Ensartinib (X-396)。60名可评估的ALK阳性突变的患者，平均无进展生存时间（PFS）是9.2个月，36名达到了部分缓解（肿瘤病灶缩小30%以上），治疗应答率为60%。13名患者在经过2个疗程治疗后达到了病情稳定，也就是说Ensartinib (X-396) 对于ALK阳性的患者，将产生部分缓解和病情稳定的患者汇总起来的数据达到了81.7%。对于病情获得部分缓解或完全缓解的病人，从确定了缓解状态到病情再次发生进展这段时间称之为持续缓解时间，即DOR，60名ALK阳性患者的DOR为12.8个月。15名ALK阳性的患者从未接受靶向药物治疗，平均无进展生存期达到了26.2个月，平均持续缓解时间DOR为24.4个月，使用X-396后有12个患者肿瘤病灶显著缩小，部分缓解率达到80%。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27068398', '.', 'case report', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_000921', 'KIT:nonsynonymous SNV:exon17:p.D816.:', 'KIT', 'nonsynonymous SNV', 'Partial_pos', 'exon17', 'p.D816.', '.', '.', '一名具有15包/年吸烟史的38岁女性最初出现严重呼吸困难，咳嗽和体重减轻，最终被诊断为具有乳头状特征的IV期肺腺癌。FISH分析揭示了ROS1基因重排，KIT为野生型。患者开始用克唑替尼治疗，获得部分缓解，并伴有症状改善。在克唑替尼治疗约15个月后，在胸部发现病情进展。对克唑替尼耐药的肿瘤标本进行FISH分析，ROS1外显子的DNA测序显示没有任何突变存在。基因检测结果证明存在KIT p.D816G突变。该案例分析表明KIT基因的激活突变可能导致携带ROS1融合基因突变的肺癌患者对克唑替尼产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:osimertinib_Revised:04/2018', '.', 'guideline:FDA', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000924', 'EGFR:nonsynonymous SNV:exon21:p.L858R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', '2018年4月18日，美国食品和药物管理局批准osimertinib（奥希替尼，Tagrisso，AstraZeneca Pharmaceuticals LP）用于一线治疗转移性非小细胞肺癌（NSCLC），该肿瘤患有表皮生长因子受体（EGFR）外显子19缺失或外显子21 L858R突变。该项批准是基于一项多中心，国际，随机，双盲，主动对照临床试验（FLAURA，NCT02296125）。该临床试验入组556例EGFR外显子19缺失或外显子21 L858R突变阳性的、不可切除或转移性NSCLC患者。患者随机（1：1）口服每日一次口服osimertinib 80mg，口服250mg吉非替尼或150mg厄洛替尼150mg的“标准护理（SOC）”治疗。在那些随机接受SOC治疗的患者中，20%接受osimertinib作为抗肿瘤治疗的下一线。osimertinib组估计的中位无进展生存期（PFS）为18.9个月（95%CI：15.2-21.4），SOC组为10.2个月（95%CI：9.6-11.1）（危险比为0.46（95%CI ：0.37-0.57），p <0.0001）。经确认的整体缓解率为osimertinib组为77%，SOC组为69%。 osimertinib和SOC组的估计中位反应持续时间分别为17.6和9.6个月。目前分析阶段，由于死亡人数太少，尚无法准确评估生存率的差异。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:osimertinib_Revised:04/2018', '.', 'guideline:FDA', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000925', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', '2018年4月18日，美国食品和药物管理局批准osimertinib（奥希替尼，Tagrisso，AstraZeneca Pharmaceuticals LP）用于一线治疗转移性非小细胞肺癌（NSCLC），该肿瘤患有表皮生长因子受体（EGFR）外显子19缺失或外显子21 L858R突变。该项批准是基于一项多中心，国际，随机，双盲，主动对照临床试验（FLAURA，NCT02296125）。该临床试验入组556例EGFR外显子19缺失或外显子21 L858R突变阳性的、不可切除或转移性NSCLC患者。患者随机（1：1）口服每日一次口服osimertinib 80mg，口服250mg吉非替尼或150mg厄洛替尼150mg的“标准护理（SOC）”治疗。在那些随机接受SOC治疗的患者中，20%接受osimertinib作为抗肿瘤治疗的下一线。osimertinib组估计的中位无进展生存期（PFS）为18.9个月（95%CI：15.2-21.4），SOC组为10.2个月（95%CI：9.6-11.1）（危险比为0.46（95%CI ：0.37-0.57），p <0.0001）。经确认的整体缓解率为osimertinib组为77%，SOC组为69%。 osimertinib和SOC组的估计中位反应持续时间分别为17.6和9.6个月。目前分析阶段，由于死亡人数太少，尚无法准确评估生存率的差异。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:osimertinib_Revised:04/2018', '.', 'guideline:FDA', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000926', 'EGFR:nonsynonymous SNV:exon20:p.T790M:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', '.', 'AURA3临床试验评估了osimertinib（奥希替尼，Tagrisso，AstraZeneca Pharmaceuticals LP）的安全性，这是一项多中心、国际、开放标签随机（2：1）对照试验，419例不能切除或转移的EGFR T790M突变阳性的非小细胞肺癌患者进行一线EGFR TKI治疗后出现疾病进展。279名患者每天一次口服TAGRISSO 80mg，直至不耐受治疗，疾病进展或研究者确定患者不再受益于治疗。136名患者接受培美曲塞加卡铂或顺铂，每三周一次，最多6次循环；4个化疗周期后没有疾病进展的患者可继续维持培美曲塞维持治疗；直至出现一下情况：疾病进展、出现不可接受的毒性或研究者确定患者不再从治疗中获益。用TAGRISSO治疗的患者的中位治疗时间为8.1个月，化疗患者为4.2个月。试验人群特征为：中位年龄62岁，年龄小于65岁（58%），女性（64%），亚洲人（65%），从不吸烟者（68%）和ECOG PS 0或1（100%）。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.lungcan.2018.04.006', '.', 'case report', '4', 'Osimertinib', '.', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'advanced non-small-cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_000928', 'EGFR:nonsynonymous SNV:exon20:p.H773_V774delinsLM:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.H773_V774delinsLM', '.', '.', '一例有30年吸烟史的50岁男性IV期肺腺癌患者，经NGS检测发现EGFR H773L/V774M复合突变，相比于EGFR 20外显子短片段插入的变异形式， 20外显子内的错义突变更为罕见，根据文献报道，773和774位氨基酸的复合突变只在大约1%的EGFR突变NSCLC中发现，这种突变类型的患者对于TKIs的响应情况目前尚不清楚。本篇报道中，患者在前期化疗进展、吉非替尼单药治疗进展和吉非替尼联合贝伐单抗获得疾病稳定近10个月再次进展后，服用奥西替尼联合贝伐单抗疾病控制显著，观察到持续12个月的有效控制。蛋白结构模型预测结果表明，与野生型H773和V774残基相比，L773和M774对αE螺旋施加了直接的空间位阻冲突，这可能会削弱失活状态的稳定性并导致EGFR的组成性激活。该患者的临床治疗结果表明，H773L/V774M突变复合物对可逆性TKI吉非替尼不敏感，但可被不可逆TKI奥西替尼抑制。然而，对激活的EGFR激酶区域与吉非替尼或奥西替尼的复合物的结构模型预测显示突变位点并不与药物结合“口袋”直接接触，因此无法直接影响对这2种药物的结合亲和力。更有可能的是突变复合物导致更显著的结构改变，这在蛋白结构模型上无法证明。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23084521', 'EudraCT:2009-015522-10', 'clinical trial - phase1', '4', '.', '.', 'RG7112', 'RG7112', 'RG7112|RG7112', '1', 'liposarcoma', 'liposarcoma', '脂肪肿瘤', 'na', 'sensitivity', 'EVI_000929', 'MDM2:CNV:::gain', 'MDM2', 'CNV', 'CNV', '.', '.', 'gain', '.', '2010年6月3日至12月14日期间，共有20名患者参加了一项关于RG7112的临床药物试验。20例患者中，18例为TP53野生型肿瘤，2例携带错义TP53突变。 17名评估患者中，14名具有MDM2基因扩增。与基线水平相比，在给药后第八天，免疫组织化学评估的P53和P21浓度分别增加了4.86倍（IQR 4.38-7.77; P = 0.0001）和3.48倍（2.04-4.09; p = 0.0001）。MDM2 mRNA表达在基线时增加了3.03倍（1.23-4.93; p = 0.003）。 Ki-67阳性肿瘤细胞的基线中位数变化为-5.05%（IQR -12.55至0.05; p = 0.01）。1例患者确诊部分缓解，14例患者病情稳定。所有患者至少出现一种不良事件，主要为恶心14例，呕吐11例，无力9例，腹泻9例，血小板减少8例。在8名患者中有12名严重不良事件，其中最常见的是中性粒细胞减少症（6名患者）和血小板减少症（3名患者）。MDM2抑制剂可以活化P53途径并减少MDM2扩增的脂肪肉瘤的细胞增殖。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28202511', '.', 'preclinical', '4', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib|rociletinib', '3', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_000930', 'EGFR:CNV:::gain', 'EGFR', 'CNV', 'CNV', '.', '.', 'gain', '.', '细胞系研究表明，EGFR野生型等位基因扩增和伴随的EGFR配体表达导致肿瘤细胞对第三代EGFR-TKIs(如rociletinib,osimertinib)产生耐药性。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28202511', '.', 'preclinical', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_000931', 'EGFR:CNV:::gain', 'EGFR', 'CNV', 'CNV', '.', '.', 'gain', '.', '细胞系研究表明，EGFR野生型等位基因扩增和伴随的EGFR配体表达导致肿瘤细胞对第三代EGFR-TKIs(如rociletinib,osimertinib)产生耐药性。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21575866', '.', 'preclinical', '4', 'CH5424802', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000932', 'ALK:nonsynonymous SNV:exon23:p.L1196M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1196M', '.', '.', 'Alectinib（CH5424802）可以抑制具有L1196M突变的ALK融合蛋白活性，同时细胞试验也表明，Alectinib可以抑制携带EML4-ALK L1196M突变的肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24675041', '.', 'preclinical', '4', '.', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000933', 'ALK:nonsynonymous SNV:exon23:p.G1202R:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.G1202R', '.', 'In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK who acquired the secondary drug resistance mutation, ALK S1206Y, when treated with Xalkori (crizotinib) was subsequently treated with Zykadia (ceritinib), developed drug resistance, and was then found to have lost the ALK S1206Y mutation, but gained ALK G1202R (PMID:24675041). ', '在一项临床研究中，一名携带ALK融合基因的肺癌患者，其ALK融合基因同时具有S1206Y点突变，该患者接受crizotinib治疗发现耐药，随后接受ceritinib治疗，治疗一段时间再次出现耐药。ceritinib治疗后S1206Y突变消失，而出现新的G1202R点突变。因此，ALK融合基因上G1202R突变可能导致肿瘤患者对ceritinib产生耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21575866|PMID:26698910', '.', 'preclinical', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000935', 'ALK:nonsynonymous SNV:exon22:p.C1156Y:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.C1156Y', '.', '.', '在临床前研究中，携带ALK融合基因和C1156Y点突变的肿瘤细胞对alectinib抑制作用敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26698910', '.', 'case report', '4', 'AUY922', 'Luminespib', 'luminespib', 'luminespib', 'luminespib|luminespib', '2', '.', '.', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000936', 'ALK:nonsynonymous SNV:exon22:p.C1156Y:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.C1156Y', '.', 'In a clinical study, a patient with EML4-ALK positive non-small cell lung cancer with an ALK C1156Y secondary Xalkori (crizotinib) resistance mutation did not respond to Luminespib (AUY922) therapy (PMID: 26698910).', '一名携带ALK融合基因和C1156Y点突变的肿瘤患者对Luminespib (AUY922)治疗无效。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21613408', '.', 'preclinical', '4', '.', 'Ensartinib', 'Ensartinib', 'Ensartinib', 'Ensartinib|Ensartinib', '2', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000937', 'ALK:nonsynonymous SNV:exon22:p.C1156Y:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.C1156Y', '.', 'In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK C1156Y (PMID: 21613408).', '细胞学试验表明，ensartinib可以抑制携带ALK融合基因和C1156Y点突变的肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26939704', '.', 'preclinical', '4', 'Entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '2', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000938', 'ALK:nonsynonymous SNV:exon22:p.C1156Y:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.C1156Y', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK C1156Y were sensitive to Entrectinib (RXDX-101), resulting in anti-proliferative activity (PMID: 26939704).', '细胞学试验表明，Entrectinib可以抑制携带ALK融合基因和C1156Y点突变的肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000939', 'ALK:nonsynonymous SNV:exon23:p.D1203N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.D1203N', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID:27432227).', '细胞学试验表明，携带ALK融合基因同时发生D1203N点突变的肿瘤细胞对crizotinib的敏感度下降。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000940', 'ALK:nonsynonymous SNV:exon23:p.D1203N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.D1203N', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).', '细胞学试验表明，携带ALK融合基因同时发生D1203N点突变的肿瘤细胞对ceritinib依然敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000941', 'ALK:nonsynonymous SNV:exon23:p.D1203N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.D1203N', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).', '细胞学试验表明，携带ALK融合基因同时发生D1203N点突变的肿瘤细胞对Lorlatinib依然敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000942', 'ALK:nonsynonymous SNV:exon23:p.D1203N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.D1203N', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK D1203N demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).', '细胞学试验表明，携带ALK融合基因同时发生D1203N点突变的肿瘤细胞对Alectinib依然敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', '.', 'TAE684', 'TAE684', 'TAE684', 'TAE684|TAE684', '0', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000943', 'ALK:nonsynonymous SNV:exon23:p.D1203N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.D1203N', '.', 'In a preclinical study, transformed cells overexpressing ALK D1203N in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).', '细胞学试验表明，携带ALK融合基因同时发生D1203N点突变的肿瘤细胞对TAE684的敏感度下降。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000944', 'ALK:nonsynonymous SNV:exon25:p.E1210K:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.E1210K', '.', 'In a clinical case study, a lung cancer patient harboring EML4-ALK demonstrated progression when treated with Xalkori (crizotinib) due to the secondary acquired resistance mutation, ALK E1210K, however, in vitro transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Xalkori (crizotinib) in culture (PMID: 27432227).', '虽然细胞系研究表明crizotinib对携带ALK融合基因和E1210K点突变的肿瘤细胞有抑制作用，但临床上一名携带以上突变的肿瘤换对crizotinib的治疗无反应。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000945', 'ALK:nonsynonymous SNV:exon25:p.E1210K:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.E1210K', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).', '细胞学研究表明，lorlatinib可以抑制携带ALK融合基因和E1210K突变的肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000946', 'ALK:nonsynonymous SNV:exon25:p.E1210K:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.E1210K', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Alecensa (alectinib) in culture (PMID: 27432227).', '细胞学研究表明，alectinib可以抑制携带ALK融合基因和E1210K突变的肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000947', 'ALK:nonsynonymous SNV:exon25:p.E1210K:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.E1210K', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK E1210K demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).', '细胞学研究表明，ceritinib可以抑制携带ALK融合基因和E1210K突变的肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26698910', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000949', 'ALK:nonsynonymous SNV:exon23:p.F1174C:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174C', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK F1174C were resistant to growth inhibition mediated by Xalkori (crizotinib) in culture (PMID: 26698910).', '携带ALK融合基因和F1174C突变的肿瘤细胞对crizotinib的抑制作用不敏感。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26698910', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000950', 'ALK:nonsynonymous SNV:exon23:p.F1174C:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174C', '.', 'In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174C in culture (PMID: 26698910).', 'lorlatinib可以抑制携带ALK融合基因和F1174C突变的肿瘤细胞增殖。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000951', 'ALK:nonsynonymous SNV:exon23:p.F1174L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', 'In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).', 'Alectinib可以抑制携带ALK融合基因和F1174L突变的肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26144315', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000953', 'ALK:nonsynonymous SNV:exon23:p.F1174L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', 'In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK F1174L in the context of EML4-ALK in culture (PMID: 26144315).', 'Lorlatinib可以抑制携带ALK融合基因和F1174L突变的肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', '.', 'AZD3463', 'AZD3463', 'AZD3463', 'AZD3463|AZD3463', '0', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000954', 'ALK:nonsynonymous SNV:exon23:p.F1174L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', 'In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK F1174L in culture (PMID: 27009859).', 'AZD3463可以抑制携带ALK融合基因和F1174L突变的肿瘤细胞生长。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26464158', '.', 'case report', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', '.', '.', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_000955', 'ALK:nonsynonymous SNV:exon23:p.F1174V:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174V', '.', 'In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK initially responded to Xalkori (crizotinib), but then progressed due to acquisition of the secondary resistance mutation, ALK F1174V, and then responded to treatment with Alecensa (alectinib), demonstrating a complete response in one lung nodule and a 44% decrease in size in a second lung nodule (PMID: 26464158).', '临床试验中，一名携带ALK融合基因和F1174V突变的肺癌患者对alectinib的治疗敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26775591', '.', 'case report', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_000956', 'ALK:nonsynonymous SNV:exon24:p.F1245C:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon24', 'p.F1245C', '.', 'In a clinical case study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 demonstrated an initial response to treatment with Xalkori (crizotinib), but progressed after 27 months and was found to have acquired ALK F1245C (PMID: 26775591).', '在临床研究中，携带EML4-ALK融合基因的非小细胞肺癌患者在获得ALK F1245C突变后表现出对Xalkori（克唑替尼）治疗耐药，随后采用ceritinib治疗实现了完全的放射学应答，治疗后6个月时没有发现疾病进展。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26775591', '.', 'case report', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', '.', '.', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_000957', 'ALK:nonsynonymous SNV:exon24:p.F1245C:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon24', 'p.F1245C', '.', 'In a clinical study, a non-small cell lung cancer patient harboring EML4-ALK variant 3 that demonstrated resistance to treatment with Xalkori (crizotinib) after acquisition of ALK F1245C, achieved a complete radiographic response with no evidence of progression at 6 months following treatment with Zykadia (ceritinib) (PMID: 26775591).', '在临床研究中，携带EML4-ALK融合基因的非小细胞肺癌患者在获得ALK F1245C突变后表现出对Xalkori（克唑替尼）治疗耐药，随后采用ceritinib治疗实现了完全的放射学应答，治疗后6个月时没有发现疾病进展。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000958', 'ALK:nonframeshift deletion:exon23:p.G1202del:', 'ALK', 'nonframeshift deletion', 'Exact_pos', 'exon23', 'p.G1202del', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated moderate resistance to treatment with Alecensa (alectinib) in culture (PMID: 27432227).', '细胞学研究表明，携带ALK融合基因和G1202del突变的肿瘤细胞可能对alectinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000959', 'ALK:nonframeshift deletion:exon23:p.G1202del:', 'ALK', 'nonframeshift deletion', 'Exact_pos', 'exon23', 'p.G1202del', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).', '细胞学研究表明，携带ALK融合基因和G1202del突变的肿瘤细胞可能对Crizotinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000960', 'ALK:nonframeshift deletion:exon23:p.G1202del:', 'ALK', 'nonframeshift deletion', 'Exact_pos', 'exon23', 'p.G1202del', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated a decreased response to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).', '细胞学研究表明，携带ALK融合基因和G1202del突变的肿瘤细胞可能对Ceritinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000961', 'ALK:nonframeshift deletion:exon23:p.G1202del:', 'ALK', 'nonframeshift deletion', 'Exact_pos', 'exon23', 'p.G1202del', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202del demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).', '细胞学研究表明，携带ALK融合基因和G1202del突变的肿瘤细胞可能对Lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24736079', '.', 'preclinical', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'non-small cell lung carcinoma', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000962', 'ALK:nonsynonymous SNV:exon23:p.G1202R:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.G1202R', '.', 'In a clinical case study, a non-small cell lung carcinoma patient harboring EML4-ALK, who had developed resistance to Xalkori (crizotinib), was found to harbor ALK G1202R following treatment with Alecensa (alectinib) (PMID: 24736079).', '细胞学研究表明，携带ALK融合基因与G1202R突变的肿瘤细胞对alectinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26939704', '.', 'preclinical', '4', 'Entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000963', 'ALK:nonsynonymous SNV:exon23:p.G1202R:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.G1202R', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK G1202R were resistant to RXDX-101 (PMID: 26939704).', '细胞学研究表明，携带ALK融合基因与G1202R突变的肿瘤细胞对Entrectinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000964', 'ALK:nonsynonymous SNV:exon23:p.G1202R:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.G1202R', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK G1202R demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).', '细胞学研究表明，携带ALK融合基因与G1202R突变的肿瘤细胞对Lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/S0959-8049(16)32675-2', '.', 'preclinical', '4', '.', 'TPX-0005', 'TPX-0005', 'TPX-0005', 'TPX-0005|TPX-0005', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000965', 'ALK:nonsynonymous SNV:exon23:p.G1202R:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.G1202R', '.', 'In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK G1201R in the context of EML4-ALK in culture, resulted in tumor regression in cell line xenograft models (European Journal of Cancer , Volume 69, S32).', '细胞学研究表明，携带ALK融合基因与G1202R突变的肿瘤细胞对TPX-0005敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26849637', '.', 'case report', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'non-small cell lung carcinoma', '.', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_000966', 'ALK:nonsynonymous SNV:exon25:p.G1269A:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.G1269A', '.', 'In a clinical case study, a patient with EML4-ALK fusion positive non-small cell lung cancer with ALK G1269A had a partial response to Alecensa (alectinib) treatment (PMID: 26849637).', '一名携带ALK基因突变与G1269A突变的肺癌患者对alectinib治疗敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26939704', '.', 'preclinical', '4', 'Entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000967', 'ALK:nonsynonymous SNV:exon25:p.G1269A:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.G1269A', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A demonstrated a decreased response when treated with Entrectinib (RXDX-101) compared to cells expressing wild-type EML4-ALK (PMID: 26939704).', '细胞学试验表明携带ALK基因融合与G1269A突变的肿瘤细胞对entrectinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', '.', 'ASP3026', 'ASP3026', 'ASP3026', 'ASP3026|ASP3026', '1', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000968', 'ALK:nonsynonymous SNV:exon25:p.G1269A:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.G1269A', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK G1269A were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).', '细胞学试验表明携带ALK基因融合与G1269A突变的肿瘤细胞对ASP3026耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', '.', 'AZD3463', 'AZD3463', 'AZD3463', 'AZD3463|AZD3463', '0', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000969', 'ALK:nonsynonymous SNV:exon25:p.G1269A:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.G1269A', '.', 'In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK G1269A in culture (PMID: 27009859).', '细胞学试验表明携带ALK基因融合与G1269A突变的肿瘤细胞对AZD3463敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26144315', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'non-small cell lung carcinoma', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000970', 'ALK:nonsynonymous SNV:exon25:p.G1269A:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon25', 'p.G1269A', '.', 'In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and growth of non-small cell lung cancer (NSCLC) cells over expressing ALK G1269A in the context of EML4-ALK in culture and in cell line xenograft models, as well as inhibited growth of patient derived NSCLC cells harboring EML4-ALK ALK G1269A in culture (PMID: 26144315).', '细胞学试验表明携带ALK基因融合与G1269A突变的肿瘤细胞对Lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000971', 'ALK:nonsynonymous SNV:exon22:p.I1171N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171N', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).', '细胞学试验表明，携带ALK基因融合与I1171N突变的肿瘤细胞对Lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000972', 'ALK:nonsynonymous SNV:exon22:p.I1171N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171N', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated a decreased response to treatment with Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27432227).', '细胞学试验表明，携带ALK基因融合与I1171N突变的肿瘤细胞对Crizotinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000973', 'ALK:nonsynonymous SNV:exon22:p.I1171N:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171N', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171N demonstrated sensitivity to treatment with Zykadia (ceritinib) in culture (PMID: 27432227).', '细胞学试验表明，携带ALK基因融合与I1171N突变的肿瘤细胞对Ceritinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', '.', 'ASP3026', 'ASP3026', 'ASP3026', 'ASP3026|ASP3026', '1', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000975', 'ALK:nonsynonymous SNV:exon22:p.I1171S:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171S', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与I1171S突变的肿瘤细胞对ASP3026耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000977', 'ALK:nonsynonymous SNV:exon22:p.I1171S:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171S', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与I1171S突变的肿瘤细胞对Crizotinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000978', 'ALK:nonsynonymous SNV:exon22:p.I1171S:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171S', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).', '细胞学试验表明，携带ALK融合基因与I1171S突变的肿瘤细胞对Lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', '.', 'AZD3463', 'AZD3463', 'AZD3463', 'AZD3463|AZD3463', '0', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000979', 'ALK:nonsynonymous SNV:exon22:p.I1171S:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171S', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与I1171S突变的肿瘤细胞对AZD3463耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'preclinical', '4', '.', 'ASP3026', 'ASP3026', 'ASP3026', 'ASP3026|ASP3026', '1', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000980', 'ALK:nonsynonymous SNV:exon22:p.I1171T:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171T', '.', 'In a preclinical study, a transformed cell line expressing EML4-ALK with ALK I1171T was resistant to ASP3026 treatment in culture (PMID: 25228534).', '细胞学试验表明，携带ALK融合基因与I1171T突变的肿瘤细胞对ASP3026耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'preclinical', '4', '.', 'TAE684', 'TAE684', 'TAE684', 'TAE684|TAE684', '0', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000981', 'ALK:nonsynonymous SNV:exon22:p.I1171T:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171T', '.', 'In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534).', '细胞学试验表明，携带ALK融合基因与I1171T突变的肿瘤细胞对TAE684敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'preclinical', '4', 'brigatinib', 'brigatinib', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000982', 'ALK:nonsynonymous SNV:exon22:p.I1171T:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171T', '.', 'In a preclinical study, Alunbrig (brigatinib) inhibited growth of a transformed cell line expressing ALK I1171T in the context of EML4-ALK but to a lesser degree than cells expressing EML4-ALK in culture (PMID: 25228534).', '细胞学试验表明，携带ALK融合基因与I1171T突变的肿瘤细胞对Brigatinib耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27432227|PMID:26144315', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000983', 'ALK:nonsynonymous SNV:exon22:p.I1171T:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.I1171T', '.', 'In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171T demonstrated sensitivity to treatment with Lorlatinib (PF-06463922) in culture (PMID: 27432227).', '细胞学试验表明，携带ALK融合基因与I1171T突变的肿瘤细胞对Lorlatinib敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000985', 'ALK:nonsynonymous SNV:exon22:p.L1152P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.L1152P', '.', 'In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Zykadia (ceritinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).', '细胞学试验表明，携带ALK融合基因与L1152P突变的肿瘤细胞对ceritinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27780853', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000986', 'ALK:nonsynonymous SNV:exon22:p.L1152P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.L1152P', '.', 'In a preclinical study, transformed cells expressing ALK L1152P in the context of EML4-ALK demonstrated reduced sensitivity to Xalkori (crizotinib) compared to cells expressing EML4-ALK in culture (PMID: 27780853).', '细胞学试验表明，携带ALK融合基因与L1152P突变的肿瘤细胞对Crizotinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26144315', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000987', 'ALK:nonsynonymous SNV:exon22:p.L1152R:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.L1152R', '.', 'In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK L1152R in the context of EML4-ALK in culture (PMID: 26144315).', '细胞学试验表明，携带ALK融合基因与1152R突变的肿瘤细胞对lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21613408|PMID:26939704', '.', 'preclinical', '4', '.', 'Ensartinib', 'Ensartinib', 'Ensartinib', 'Ensartinib|Ensartinib', '2', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000988', 'ALK:nonsynonymous SNV:exon23:p.L1196M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1196M', '.', 'In a preclinical study, Ensartinib (X-396) inhibited growth and Alk phosphorylation in cells expressing the Xalkori (crizotinib) resistance mutation, EML4-ALK ALK L1196M (PMID: 21613408).', '细胞学试验表明，携带ALK融合基因与L1196M突变的肿瘤细胞对ensartinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/S0959-8049(16)32675-2', '.', 'preclinical', '4', '.', 'TPX-0005', 'TPX-0005', 'TPX-0005', 'TPX-0005|TPX-0005', '0', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000991', 'ALK:nonsynonymous SNV:exon23:p.L1196M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1196M', '.', 'In a preclinical study, TPX-0005 inhibited Alk activity and proliferation of transformed cells over expressing ALK L1196M in the context of EML4-ALK in culture (European Journal of Cancer , Volume 69, S32).', '细胞学试验表明，携带ALK融合基因与L1196M突变的肿瘤细胞对TPX-0005敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26144315', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'non-small cell lung carcinoma', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000993', 'ALK:nonsynonymous SNV:exon23:p.L1196M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1196M', '.', 'In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and proliferation of non-small cell lung carcinoma cells over expressing ALK L1196M in the context of EML4-ALK in culture, and resulted in tumor regression in cell line xenograft models (PMID: 26144315).', '细胞学试验表明，携带ALK融合基因与L1196M突变的肿瘤细胞对Lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26698910', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000995', 'ALK:nonsynonymous SNV:exon23:p.L1198F:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1198F', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with L1198F were resistant to growth inhibition mediated by Zykadia (ceritinib) in culture (PMID: 26698910).', '细胞学试验表明，携带ALK融合基因与L1198F突变的肿瘤细胞可能对ceritinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21948233', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000996', 'ALK:nonsynonymous SNV:exon23:p.L1198P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1198P', '.', 'In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to Xalkori (crizotinib) in culture (PMID: 21948233).', '细胞学试验表明，携带ALK融合基因与L1198F突变的肿瘤细胞可能对Crizotinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:21948233', '.', 'preclinical', '4', '.', 'TAE684', 'TAE684', 'TAE684', 'TAE684|TAE684', '0', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_000997', 'ALK:nonsynonymous SNV:exon23:p.L1198P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.L1198P', '.', 'In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233).', '细胞学试验表明，携带ALK融合基因与L1198F突变的肿瘤细胞可能对TAE684耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', '.', 'AZD3463', 'AZD3463', 'AZD3463', 'AZD3463|AZD3463', '0', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000998', 'ALK:nonsynonymous SNV:exon23:p.R1192P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.R1192P', '.', 'In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与L1198F突变的肿瘤细胞可能对AZD3463敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_000999', 'ALK:nonsynonymous SNV:exon23:p.R1192P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.R1192P', '.', 'In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与L1198F突变的肿瘤细胞可能对Crizotinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_001000', 'ALK:nonsynonymous SNV:exon23:p.R1192P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.R1192P', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to Zykadia (ceritinib) mediated growth inhibition in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与L1198F突变的肿瘤细胞可能对Ceritinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', '.', 'ASP3026', 'ASP3026', 'ASP3026', 'ASP3026|ASP3026', '1', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_001001', 'ALK:nonsynonymous SNV:exon23:p.R1192P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.R1192P', '.', 'In a preclinical study, transformed cells expressing EML4-ALK with ALK R1192P were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与L1198F突变的肿瘤细胞可能对ASP3026耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001002', 'ALK:nonsynonymous SNV:exon23:p.R1192P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.R1192P', '.', 'In a preclinical study, Alecensa (alectinib) inhibited growth of transformed cells overexpressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与L1198F突变的肿瘤细胞可能对Alectinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'brigatinib', 'brigatinib', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001003', 'ALK:nonsynonymous SNV:exon23:p.R1192P:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.R1192P', '.', 'In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK R1192P in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与L1198F突变的肿瘤细胞可能对Brigatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26144315', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001004', 'ALK:nonsynonymous SNV:exon23:p.S1206Y:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.S1206Y', '.', 'In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation and cell proliferation of transformed cells over expressing ALK S1206Y in the context of EML4-ALK in culture (PMID: 26144315).', '细胞学试验表明，携带ALK融合基因与S1206Y突变的肿瘤细胞对lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'brigatinib', 'brigatinib', 'brigatinib', '布加替尼', 'brigatinib|布加替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001005', 'ALK:nonsynonymous SNV:exon22:p.T1151M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.T1151M', '.', 'In a preclinical study, Alunbrig (brigatinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与T1151M突变的肿瘤细胞可能对brigatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'alectinib', 'alectinib', 'alectinib', '阿来替尼', 'alectinib|阿来替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001006', 'ALK:nonsynonymous SNV:exon22:p.T1151M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.T1151M', '.', 'In a preclinical study, Alecensa (alectinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与T1151M突变的肿瘤细胞可能对Alectinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001007', 'ALK:nonsynonymous SNV:exon22:p.T1151M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.T1151M', '.', 'In a preclinical study, Xalkori (crizotinib) inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与T1151M突变的肿瘤细胞可能对Crizotinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', '.', 'AZD3463', 'AZD3463', 'AZD3463', 'AZD3463|AZD3463', '0', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001008', 'ALK:nonsynonymous SNV:exon22:p.T1151M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.T1151M', '.', 'In a preclinical study, AZD3463 inhibited the growth of transformed cells expressing EML4-ALK with ALK T1151M in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与T1151M突变的肿瘤细胞可能对AZD3463敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', '.', 'ASP3026', 'ASP3026', 'ASP3026', 'ASP3026|ASP3026', '1', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_001009', 'ALK:nonsynonymous SNV:exon22:p.T1151M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.T1151M', '.', 'In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to ASP3026 in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与T1151M突变的肿瘤细胞可能对ASP3026耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27009859', '.', 'preclinical', '4', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_001010', 'ALK:nonsynonymous SNV:exon22:p.T1151M:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon22', 'p.T1151M', '.', 'In a preclinical study, transformed cell lines harboring EML4-ALK with ALK T1151M were resistant to Zykadia (ceritinib) in culture (PMID: 27009859).', '细胞学试验表明，携带ALK融合基因与T1151M突变的肿瘤细胞可能对Ceritinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'preclinical', '4', '.', 'ASP3026', 'ASP3026', 'ASP3026', 'ASP3026|ASP3026', '1', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001011', 'ALK:nonsynonymous SNV:exon23:p.V1180L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.V1180L', '.', 'In a preclinical study, ASP3026 inhibited growth of a transformed cell line expressing EML4-ALK with ALK V1180L in culture (PMID: 25228534).', '细胞学试验表明，携带ALK融合基因与V1180L突变的肿瘤细胞可能对ASP3026敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25228534', '.', 'preclinical', '4', '.', 'TAE684', 'TAE684', 'TAE684', 'TAE684|TAE684', '0', 'Advanced Solid Tumor', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001012', 'ALK:nonsynonymous SNV:exon23:p.V1180L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.V1180L', '.', 'In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing ALK V1180L in the context of EML4-ALK in culture (PMID: 25228534).', '细胞学试验表明，携带ALK融合基因与V1180L突变的肿瘤细胞可能对TAE684敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26144315', '.', 'preclinical', '4', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '2', 'non-small cell lung carcinoma', '.', '肿瘤细胞', '[ALK:FUS]', 'sensitivity', 'EVI_001013', 'ALK:nonsynonymous SNV:exon23:p.V1180L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.V1180L', '.', 'In a preclinical study, Lorlatinib (PF-06463922) inhibited Alk phosphorylation, reduced proliferation, and induced apoptosis of non-small cell lung carcinoma cells harboring ALK V1180L in the context of EML4-ALK in culture (PMID: 26144315).', '细胞学试验表明，携带ALK融合基因与V1180L突变的肿瘤细胞可能对Lorlatinib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26084990', 'NCT01370070', 'clinical trial - phase2', '4', '.', 'MK2206', 'MK-2206', 'MK-2206', 'MK-2206|MK-2206', '2', '.', 'nasopharynx carcinoma', '鼻咽癌', 'na', 'sensitivity', 'EVI_001014', 'PIK3CA:CNV:.:.:gain', 'PIK3CA', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项临床试验入选21例患者，1例患者获得部分缓解（5%），11例患者稳定（52%），中位PFS为3.5个月（95%置信区间，CI：0.9-7.3）。 6个月的PFS率为43%（95%CI：22-66%），中位OS为10个月（95%CI：5.9个月 - 未达到）。 7名患者（33%）经历3级毒性，可能与MK-2206有关。 黄斑-丘疹性皮疹最常见（n = 6），其次是高血糖症（n = 2）和疲劳（n = 1）。 在分析的12个肿瘤样本中，一个患者检测到PIK3CA扩增，其SD超过12个月。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29773459', '.', 'case report', '4', '.', '.', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001015', 'EGFR:nonframeshift insertion:exon19:.:exon19ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon19', '.', 'exon19ins', '.', '一名74岁的中国男性肺癌患者，有吸烟史，基因检测发现存在EGFR 19exon插入突变（p.I740_K745insIPVAIK），该患者随后接受了icotinib治疗，CT评估显示其取得了部分缓解。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23620576|PMID:15710330', '.', 'preclinical', '4', '.', 'PD-0325901', 'PD-0325901', 'PD-0325901', 'PD-0325901|PD-0325901', '2', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001016', 'PTPN11:nonsynonymous SNV:exon3:p.E76K:', 'PTPN11', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E76K', '.', '.', '临床前研究表明，表达PTPN11 E76K突变的细胞通过MEK/ERK途径增加了致瘤性信号传导，MEK抑制剂PD0325901可以抑制其生长。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23620576|PMID:15710330', '.', 'preclinical', '4', '.', 'U0126', 'U0126', 'U0126', 'U0126|U0126', '0', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001017', 'PTPN11:nonsynonymous SNV:exon3:p.E76K:', 'PTPN11', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E76K', '.', '.', '临床前研究表明，表达PTPN11 E76K突变的细胞对临床前MEK抑制剂U0126选择性敏感。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24553178', '.', 'preclinical', '4', '.', 'PD-0352901', 'PD-0352901', 'PD-0352901', 'PD-0352901|PD-0352901', '2', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001018', 'PTPN11:nonsynonymous SNV:exon3:p.D61Y:', 'PTPN11', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.D61Y', '.', '.', '临床前研究表明，表达PTPN11 D61Y突变的细胞对PD0352901治疗敏感，当与p110d抑制联合使用时反应更好。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24553178', '.', 'preclinical', '4', '.', 'idelalisib', 'idelalisib', 'idelalisib', 'idelalisib|idelalisib', '4', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001019', 'PTPN11:nonsynonymous SNV:exon3:p.D61Y:', 'PTPN11', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.D61Y', '.', '.', '临床前研究表明，表达PTPN11 D61Y突变的细胞对idelalisib和GS-9820(p110α特异性抑制剂)敏感。  ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24553178', '.', 'preclinical', '4', '.', 'GS-9820', 'acalisib', 'acalisib', 'acalisib|acalisib', '1', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001020', 'PTPN11:nonsynonymous SNV:exon3:p.D61Y:', 'PTPN11', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.D61Y', '.', '.', '临床前研究表明，表达PTPN11 D61Y突变的细胞对idelalisib和GS-9820(p110α特异性抑制剂)敏感。  ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22315502', '.', 'preclinical', '4', '.', 'GDC-0941', 'pictilisib', 'pictilisib', 'pictilisib|pictilisib', '2', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001021', 'PTPN11:nonsynonymous SNV:exon3:p.D61Y:', 'PTPN11', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.D61Y', '.', '.', '临床前研究表明，p110α抑制剂IC87114和pan-PI3K抑制剂GDC-0941也抑制携带PTPN11 D61Y突变的肿瘤细胞生长。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:22315502', '.', 'preclinical', '4', '.', 'IC-87114', 'IC-87114', 'IC-87114', 'IC-87114|IC-87114', '0', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001022', 'PTPN11:nonsynonymous SNV:exon3:p.D61Y:', 'PTPN11', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.D61Y', '.', '.', '临床前研究表明，p110α抑制剂IC87114和pan-PI3K抑制剂GDC-0941也抑制携带PTPN11 D61Y突变的肿瘤细胞生长。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:15710330', '.', 'preclinical', '4', 'rapamycin', '.', 'sirolimus', '西罗莫司', 'sirolimus|西罗莫司', '4', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001023', 'PTPN11:nonsynonymous SNV:exon3:p.E76K:', 'PTPN11', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E76K', '.', '.', '临床前研究表明，携带PTPN11 E76K突变的肿瘤细胞可能对mTOR抑制剂西罗莫司(sirolimus)敏感。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29703253', '.', 'clinical study', '4', '.', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', '.', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_001026', 'SMAD4:nonsynonymous SNV:.:.:inact', 'SMAD4', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '一项临床研究利用NGS分析了西妥昔单抗治疗前33名中国mCRC患者的突变概况。与携带野生型SMAD4（n = 25）或野生型NF1（n = 4）相比，携带SMAD4突变（n = 8）或NF1突变（= 29）的患者具有更短的PFS。当在治疗后12周评估时，SMAD4或NF1突变的患者对西妥昔单抗治疗无反应。在所有患者中，两名同时携带SMAD4或NF1突变患者的PFS最短。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29703253', '.', 'clinical study', '4', '.', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', '.', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_001027', 'NF1:nonsynonymous SNV:.:.:inact', 'NF1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '一项临床研究利用NGS分析了西妥昔单抗治疗前33名中国mCRC患者的突变概况。与携带野生型SMAD4（n = 25）或野生型NF1（n = 4）相比，携带SMAD4突变（n = 8）或NF1突变（= 29）的患者具有更短的PFS。当在治疗后12周评估时，SMAD4或NF1突变的患者对西妥昔单抗治疗无反应。在所有患者中，两名同时携带SMAD4或NF1突变患者的PFS最短。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29702285', '.', 'clinical study', '4', '.', 'afatinib + cetuximab', 'afatinib + cetuximab', '阿法替尼 + 西妥昔单抗', 'afatinib + cetuximab|阿法替尼 + 西妥昔单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001028', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', '这项研究来自荷兰癌症研究所，4名EGFR基因20外显子插入突变通过二代基因检测技术进行了确认，一个患者同时有EGFR的基因扩增，再无其它的基因突变形式。前3名患者每天使用40毫克的阿法替尼，每两周注射一次西妥昔单抗，西妥昔单抗的剂量为每两周每平方米体表面积500毫克，这种用药方案直至患者病情进展或不可耐受。第4名患者的阿法替尼也是每日40毫克，但是每两周的西妥昔单抗剂量降低了一半。另外患者还使用了甲氧氯普胺、地塞米松、米诺环素、皮肤霜和洛哌丁胺等，这些药物是用来缓解靶向药物的副作用的。这4名患者使用阿法替尼联合西妥昔单抗后，根据临床医学的评估标准，3名患者的肿瘤病灶显著缩小，达到了部分应答（肿瘤病灶缩小30%）。患者的平均无进展生存时间为5.4个月（最短的是2.7个月，最长的是17.6个月）。一名患者的无进展生存时间达到了17.6个月，经过10.5个月之后的治疗，患者因为假期而暂时中断治疗，2个月后影像学检查显示病情进展，于是再次使用阿法替尼联合西妥昔单抗治疗。之后仍然有效，时间长达6.5个月。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20633291', '.', 'preclinical', '4', 'motesanib', 'motesanib', 'motesanib', '莫替沙尼', 'motesanib|莫替沙尼', '3', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_001029', 'KIT:nonsynonymous SNV:exon11:.:exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', 'Motesanib inhibited Kit autophosphorylation in CHO cell lines expressing primary activating mutations in exon 9 (AYins503-504, IC50 = 18 nM) and exon 11 (V560 D, IC50 = 5 nM; Δ552-559, IC50 = 1 nM). Motesanib also demonstrated activity against kinase domain mutations conferring imatinib resistance (V560D/V654A, IC50 = 77 nM; V560D/T670I, IC50 = 277 nM; Y823 D, IC50 = 64 nM) but failed to inhibit the imatinib-resistant D816V mutant (IC50 > 3000 nM).', 'KIT和PDGFR激活突变可能是导致胃肠道间质瘤发病的重要机制。Motesanib是一种有效的VEGFR1/2/3、PDGFR和KIT的抑制剂。体内体外实验表明，motesanib可以抑制野生型或突变型KIT(V560D，552_559del，AYins503_504)的自磷酸化，抑制效果优于imatinib；且motesanib有效抑制imatinib耐药性KIT突变(近膜结构域双突变V560D/V654A和V560D/T670I，活化环突变Y823D)。所以motesanib在临床前试验中表现出对KIT的有效抑制活性，可能对胃肠道间质瘤中KIT的原发性或二次突变具有临床抑制作用。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:17699867', '.', 'preclinical', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', '胃肠间质瘤', 'sensitivity', 'EVI_001031', 'KIT:nonsynonymous SNV:exon11:.:exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', 'The growth of KIT WK557-8del cells was inhibited by dasatinib with an IC50 of 58 nmol/L, whereas imatinib, nilotinib, and sorafenib had an IC50 of 460, 83, and 211 nmol/L, respectively.Dasatinib inhibited the imatinib less-sensitive Ba/F3 KITAY502-3ins.Imatinib-resistant gatekeeper single KITT670I and double KITWK557-8del/T670I mutants are responsive to sorafenib but resistant to dasatinib and nilotinib.Nilotinib inhibited cell growth and induced apoptosis of imatinib-resistant KIT V560del/V654A mutant cells at lower doses than dasatinib and sorafenib.Imatinib-resistant KITV559D/D820Y was sensitive to nilotinib,dasatinib, and sorafenib inhibition.', '携带KIT基因exon11突变的肿瘤患者可能对sorafenib敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20970876', '.', 'case report', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'thymic carcinoma', 'thymic cancer', '胸腺肿瘤', 'na', 'sensitivity', 'EVI_001032', 'KIT:nonsynonymous SNV:exon11:.:exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', 'Twelve weeks after the initiation of sorafenib therapy, a positive response was detected by PET-CT.After the 6 months of the initiation of sorafenib treatment, she was still receiving with tolerable side effects. Complete symptomatic relief and very good\nresponse were registered.', '一例晚期胸腺癌患者，经免疫组化检测到C-KIT和CD5表达，随后发现了KIT exon11删除突变。患者在接受联合化疗后获得缓解，随后发生疾病进展。改变治疗方案使用索拉非尼，用药12周后获得阳性缓解，且肿瘤大小减少50%，心包结节消失，药物毒副作用可控；用药6个月后患者获得症状完全缓解。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29857056', '.', 'preclinical', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001034', 'EGFR:nonsynonymous SNV:exon20:p.G796R<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.G796R<顺式>', '.', '.', '在该研究中，作者建立了具有L858R/T790M/L792H（顺式）和L858R/T790M/G796R（顺式）突变的Ba/F3细胞株，以评估接受TKI治疗的疗效。结果显示：三个获批的药物erlotinib、afatinib、osimertinib均不能抑制这些突变细胞株的增殖。与L858R/T790M双突变相比，L858R/T790M/L792H 和L858R/T790M/G796R 三突变对奥希替尼的GI50值增加了25-110倍。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23932362', '.', 'case report', '4', 'dasatinib', 'dasatinib', 'dasatinib', '达沙替尼', 'dasatinib|达沙替尼', '4', 'squamous cell carcinoma (SQCC) of the lung', 'lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001035', 'DDR2:nonsynonymous SNV:.:.:act', 'DDR2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a case report, a patient with chronic myelogenous leukemia and squamous cell carcinoma of the lung harboring a DDR2 S768R mutation responded to dasatinib therapy (Pitini et al. 2013). A phase II clinical trial of dasatinib in patients with advanced cancer harboring a DDR2 mutation is ongoing.', '盘状结构域受体2(discoidin domain receptor2,DDR2)是一种受体酪氨酸激酶,其配体是细胞外基质中最为丰富的胶原。因此参与了细胞与细胞外基质间的信息交流,促进骨骼的发育,生殖细胞的产生和排出,脂肪代谢,上皮细胞的极性维持,细胞分化和存活等多项重要的功能。最新研究发现DDR2在肺鳞癌患者中存在突变，携带此种突变的肿瘤细胞对已经上市的小分子酪氨酸激酶抑制剂达沙替尼(Dasatinib)敏感，可能成为潜在靶向治疗的驱动基因。一名携带DDR2激活突变的肺鳞状细胞癌（SQCC）的患者对达沙替尼治疗有反应。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29906450', '.', 'case report', '4', '.', 'pembrolizumab', 'pembrolizumab', '帕博利珠单抗', 'pembrolizumab|帕博利珠单抗', '4', 'metastatic castration-resistant prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001036', 'CDK12:nonsynonymous SNV:.:.:inact', 'CDK12', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'CDK12是一种细胞周期蛋白依赖性激酶，参与“调节关键的细胞过程”以及“控制基因组的稳定性”（后者通过调节参与DNA损伤反应的基因来实现）。CDK12基因影响DNA的修复包括同源重组修复和炎症相关表型。一项纳入了418名前列腺癌患者的研究中，前列腺癌患者中CDK12基因突变约4.8%（20/418）。该研究中收集了360名晚期前列腺癌患者的肿瘤DNA。结果显示7%的患者肿瘤缺失了CDK12基因的拷贝。研究小组发现，“与CDK12基因拷贝缺失相关的这种基因变化模式”与“先前鉴定出的其他前列腺癌基因亚型”截然不同。独特的基因变化模式使得这类肿瘤成为了一种完全不同的疾病：新的前列腺癌亚型。具体来说，与其他形式的晚期前列腺癌相比，具有这种基因图谱（特征）的肿瘤含有更多的免疫细胞，且它们的表面拥有更多被称为“新抗原”的蛋白质片段。拥有大量免疫细胞以及新抗原的肿瘤往往能够更好地响应免疫疗法，因为免疫系统已经开始将癌细胞识别为“外来者”。在一项小型试点临床研究中，4名肿瘤携带CDK12基因失活突变的晚期前列腺癌患者中，有2人对免疫疗法药物pembrolizumab（一种PD-1抗体）产生了显著的响应。其中一位患者，在4次PD-1治疗后，肿块从2.4cm缩小到了1.1cm，PSA也下降到了0.9 ng/mL。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <3.2020>|PMID:29989854', '.', 'guideline:NCCN', '1', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', '恩美曲妥珠单抗', 'ado-trastuzumab emtansine|恩美曲妥珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001037', 'ERBB2:nonframeshift insertion:exon20:.:exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', '一项II期篮式临床试验(NCT02675829)评估了抗HER2靶向抗体偶联药物ado-trastuzumab emtansine(又称为trastuzumab emtansine，恩美曲妥珠单抗)的有效性和安全性，共计入组18例HER2突变的晚期肺癌患者，每3周静脉注射3.6mg/kg的恩美曲妥珠单抗，直到疾病进展。主要研究重点是按照根据实体瘤反应评估标准RECIST 1.1版确定的总缓解率(ORR)。研究结果显示：所有患者中位PFS为5个月(95% CI：3-9个月)，ORR为44%(95% CI：22%-69%)。此外，有39%患者病情稳定，最长达到11个月的持续疾病控制。无患者因毒性停止治疗或在研究中死亡。因此认为恩美曲妥珠单抗是HER2突变型肺癌的有效药物。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <3.2020>|PMID:29989854', '.', 'guideline:NCCN', '1', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', '恩美曲妥珠单抗', 'ado-trastuzumab emtansine|恩美曲妥珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001038', 'ERBB2:nonsynonymous SNV:.:.:act', 'ERBB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项II期篮式临床试验(NCT02675829)评估了抗HER2靶向抗体偶联药物ado-trastuzumab emtansine(又称为trastuzumab emtansine，恩美曲妥珠单抗)的有效性和安全性，共计入组18例HER2突变的晚期肺癌患者，每3周静脉注射3.6mg/kg的恩美曲妥珠单抗，直到疾病进展。主要研究重点是按照根据实体瘤反应评估标准RECIST 1.1版确定的总缓解率(ORR)。研究结果显示：所有患者中位PFS为5个月(95% CI：3-9个月)，ORR为44%(95% CI：22%-69%)。此外，有39%患者病情稳定，最长达到11个月的持续疾病控制。无患者因毒性停止治疗或在研究中死亡。因此认为恩美曲妥珠单抗是HER2突变型肺癌的有效药物。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18413839', '.', 'preclinical', '4', 'EXEL-7647', 'EXEL-7647', 'tesevatinib', 'tesevatinib', 'tesevatinib|tesevatinib', '2', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001040', 'ERBB2:nonframeshift insertion:exon20:.:exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'cells with this mutation are effectively inhibited by neratinib and EXEL-7647, like those with wild-type HER2, but they are resistant to lapatinib, in vitro (PMID:18413839;PMID:23220880).体外试验表明，携带ERBB2基因p.L755S的肿瘤细胞株可能对来那替尼或EXEL-7647敏感，而对拉帕替尼不太耐药。', '体外试验表明，携带ERBB2基因p.L755S的肿瘤细胞株可能对来那替尼或EXEL-7647（tesevatinib）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:18413839', '.', 'preclinical', '4', 'EXEL-7647', 'EXEL-7647', 'tesevatinib', 'tesevatinib', 'tesevatinib|tesevatinib', '2', 'cancer cell lines', 'cancer cell lines_', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001041', 'ERBB2:nonsynonymous SNV:.:.:act', 'ERBB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'cells with this mutation are effectively inhibited by neratinib and EXEL-7647, like those with wild-type HER2, but they are resistant to lapatinib, in vitro (PMID:18413839;PMID:23220880).体外试验表明，携带ERBB2基因p.L755S的肿瘤细胞株可能对来那替尼或EXEL-7647敏感，而对拉帕替尼不太耐药。', '体外试验表明，携带ERBB2基因激活突变的肿瘤细胞株可能对来那替尼或EXEL-7647（tesevatinib）敏感。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:dabrafenib_Revised:10/2019|Druglabel:trametinib_Revised:10/2019', '.', 'guideline:FDA', '1', '.', '.', 'trametinib + dabrafenib', '曲美替尼 + 达拉非尼', 'trametinib + dabrafenib|曲美替尼 + 达拉非尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001044', 'BRAF:nonsynonymous SNV:exon15:p.V600E:.', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.V600E', '.', 'The following targeted agents are recommended (category 2A) for patients with specific genetic alterations: crizotinib (for ROS1 rearrangements and for high-level MET amplification or MET exon 14 skipping mutation), dabrafenib (with or without trametinib) and vemurafenib (for BRAF V600E mutations), and cabozantinib (for RET rearrangements). ', '一项名为BRF113928（NCT01336634）的试验中发现，使用dabrafenib和trametinib联合治疗晚期BRAF V600E突变NSCLC患者同样取得了令人可喜的成果。该临床试验共招募了93名携带BRAF V600E突变的晚期NSCLC患者（36例初次接受治疗，57例曾接受过化疗）。经过治疗，初治患者群总体缓解率达到61%；而曾接受过化疗的患者群总体缓解率更是达到了63%，中位缓解持续时间为12.6个月，整体综合疗效值得期待。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28232670', '.', 'clinical study', '4', 'BAY1436032', 'BAY1436032', 'BAY1436032', 'BAY1436032', 'BAY1436032|BAY1436032', '4', ' acute myeloid leukemia', ' acute myeloid leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_001045', 'IDH1:nonsynonymous SNV:.:.:act', 'IDH1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Neomorphic mutations in isocitrate dehydrogenase 1 (IDH1) are frequently found in several human cancer types including acute myeloid leukemia (AML) and lead to the production of high levels of the oncometabolite (R)-2-hydroxyglutarate (R-2HG). Here we report the characterization of BAY1436032, a novel pan-mutant IDH1 inhibitor, both in vitro and in vivo. BAY1436032 specifically inhibits R-2HG production and colony growth, and induces myeloid differentiation of AML cells carrying IDH1R132H, IDH1R132C, IDH1R132G, IDH1R132L and IDH1R132S mutations. In addition, the compound impacts on DNA methylation and attenuates histone hypermethylation. Oral administration of BAY1436032 led to leukemic blast clearance, myeloid differentiation, depletion of leukemic stem cells and prolonged survival in two independent patient-derived xenograft IDH1 mutant AML mouse models. Together, BAY1436032 is highly effective against all major types of IDH1 mutant AML.', '异柠檬酸脱氢酶1（IDH1）的新突变常在急性髓性白血病（AML）中发现，研究显示其可产生高水平的代谢物—（R）-2-羟基戊二酸（R-2HG）。BAY1436032是一种新型泛突变体IDH1抑制剂,可特异性抑制R-2HG的产生和集落生长，并诱导携带IDH1 R132H，IDH1 R132C，IDH1 R132G，IDH1 R132L和IDH1 R132S突变的AML细胞的髓样分化。此外，该化合物可影响DNA甲基化并减弱组蛋白高甲基化。口服BAY1436032可引起白血病清除，骨髓分化。在两个独立患者的异种移植物IDH1突变体AML小鼠模型中，BAY1436032导致白血病干细胞的消耗和延长的存活。总之，BAY1436032对所有主要类型的IDH1突变体AML都非常有效。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:23558169', '.', 'preclinical', '4', 'AGI-5198', 'AGI-5198', 'AGI-5198', 'AGI-5198', 'AGI-5198|AGI-5198', '4', 'glioma ', 'glioma ', '神经胶质瘤', 'na', 'sensitivity', 'EVI_001046', 'IDH1:nonsynonymous SNV:.:.:act', 'IDH1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'One potential drug target is isocitrate dehydrogenase 1 (IDH1), which is mutated in multiple human cancers. A selective R132H-IDH1 inhibitor (AGI-5198) identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG). Under conditions of near-complete R-2HG inhibition, the mIDH1 inhibitor induced demethylation of histone H3K9me3 and expression of genes associated with gliogenic differentiation. Blockade of mIDH1 impaired the growth of IDH1-mutant--but not IDH1-wild-type--glioma cells without appreciable changes in genome-wide DNA methylation. ', '异柠檬酸脱氢酶1（IDH1）是一种潜在的药物靶标，其在多种人类癌症中发生突变。研究发现通过高通量筛选鉴定的选择性R132H-IDH1抑制剂（AGI-5198）可以剂量依赖性方式阻断突变酶（mIDH1）产生R-2-羟基戊二酸（R-2HG）的能力。 在近乎完全的R-2HG抑制条件下，AGI-5198抑制剂可诱导组蛋白H3K9me3的去甲基化和与胶质细胞分化相关的基因的表达。mIDH1的阻断抑制了IDH1突变型胶质瘤细胞的生长，其全基因组DNA甲基化没有明显变化。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:24668804', '.', 'preclinical', '4', 'ML309', 'ML309', 'ML309', 'ML309', 'ML309|ML309', '4', 'glioblastom; acute myeloid leukemia', 'glioblastoma and acute myeloid leukemia', '胶质母细胞瘤', 'na', 'sensitivity', 'EVI_001047', 'IDH1:nonsynonymous SNV:.:.:act', 'IDH1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', ' This rapidly equilibrating inhibitor is active in both biochemical and cellular assays. The (+) isomer is active (IC50 = 68 nm), whereas the (-) isomer is over 400-fold less active (IC50 = 29 μm) for IDH1 R132H inhibition. IDH1 R132C was similarly inhibited by (+)-ML309. WT IDH1 was largely unaffected by (+)-ML309 (IC50 >36 μm). Kinetic analyses combined with microscale thermophoresis and surface plasmon resonance indicate that this reversible inhibitor binds to IDH1 R132H competitively with respect to α-ketoglutarate and uncompetitively with respect to NADPH. A reaction scheme for IDH1 R132H inhibition by ML309 is proposed in which ML309 binds to IDH1 R132H after formation of the IDH1 R132H NADPH complex. ML309 was also able to inhibit 2-HG production in a glioblastoma cell line (IC50 = 250 nm) and had minimal cytotoxicity. In the presence of racemic ML309, 2-HG levels drop rapidly. This drop was sustained until 48 h, at which point the compound was washed out and 2-HG levels recovered.', 'ML309是一种IDH1突变体抑制剂，在生化和细胞试验中都具有活性，其（+）异构体对IDH1 R132H有效（IC50 = 68 nm），相比之下（-）异构体对IDH1 R132H的抑制活性（IC50 =29μm）低了400倍。IDH1 R132C可被（+）-ML309抑制。WT IDH1基本上不受（+）- ML309（IC50>36μm）的影响。结合微尺度热泳和表面等离子共振的动力学分析表明，这种可逆抑制剂可与α-酮戊二酸竞争性地结合IDH1 R132H，并且与NADPH无竞争性结合。ML309还能够抑制胶质母细胞瘤细胞系中的2-HG产生（IC50 = 250nm），并且具有最小的细胞毒性。在外消旋ML309存在下，2-HG水平迅速下降，而且这种下降可持续48小时。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>|J Clin Oncol 32:5s, 2014 (suppl; abstr LBA3) ', '.', 'guideline:NCCN', '1', 'FOLFOX+cetuximab', 'FOLFOX+cetuximab', 'FOLFOX + cetuximab', 'FOLFOX + 西妥昔单抗', 'FOLFOX + cetuximab|FOLFOX + 西妥昔单抗', '4', 'metastatic adenocarcinoma of the colon or rectum', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'sensitivity', 'EVI_001049', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', 'Background:Irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6), combined with bevacizumab (BV) or cetuximab (CET), are first-line treatments for metastatic adenocarcinoma of the colon or rectum (MCRC). The optimal antibody combination is unknown.Methods:Patients (pts) with KRAS wild-type (wt)(codons 12 and 13) MCRC and performance status 0-1 received FOLFIRI or mFOLFOX6 (MD/pt choice at enrollment) and randomized to either CET 400 mg/m2 X 1, then 250 mg/m2 qw or BV 5 mg/kg q2w. The original study included unselected MCRC pts receiving FOLFIRI or mFOLFOX6 and randomized to CET, BV, or both. After 1,420 pts accrued the study amended as follows: only pts with KRAS wt tumors (codon 12 and 13) were included and the combination CET + BV arm was deleted. Rx continued until progression, death, unacceptable toxicity, curative surgery; treatment holidays of 4 wks permitted. Subsequent Rx not mandated. Accrual goal was 1,142 pts. One° endpoint was overall survival (OS).Results:Between November 2005 and March 2012, 3,058 unselected pts enrolled, 2,334 KRAS wt pts randomized; final N =1137 (333 pre-amend eligible retrospective KRAS test, 804 post-amend), median f/u = 24 mos; Median age – 59 y; 61% male. Chemo/BV – 559; chemo/CET – 578. FOLFIRI = 26.6%, mFOLFOX6 = 73.4%. OS analysis planned at 849 events; efficacy futility boundary crossed at 10th interim analysis on 1/29/14. OS - chemo/BV v. chemo/CET = 29.04 (25.66 - 31.21) v. 29.93 (27.56 - 31.21) mos; HR = 0.92 (0.78, 1.09) (p value = 0.34). PFS (by investigator): chemo/BV v. chemo/CET: 10.84 (9.86 - 11.4) v. 10.45 (9.66 - 11.33) mos. There were 94 pts free of disease following surgery, median f/u 40 mos (range 8.0 - 86.0). Outcomes similar by gender. On-study toxicity and deaths as expected. Analyses underway: Expanded RAS, FOLFOX v. FOLFIRI, subsequent therapies, long-term survivors, correlates.Conclusions:Chemo/CET and chemo/BV equivalent in OS in pts KRAS wt (codons 12 + 13) MCRC; either is appropriate in first line. Overall OS of 29 + mos and 8% long-term survivors confirms progress in MCRC. The preference for FOLFOX limits chemotherapy comparison. Expanded RAS and other molecular and clinical analyses may identify subsets of pts who get more or less benefit from specific regimens. Clinical trial information: NCT00265850.', '伊立替康/5-FU/甲酰四氢叶酸（FOLFIRI）或奥沙利铂/5-FU/甲酰四氢叶酸（mFOLFOX6）联合贝伐单抗（BV）或西妥昔单抗（CET）是结肠或直肠转移性腺癌（ MCRC）的一线治疗方法，但最佳抗体组合未知。让KRAS（密码子12和13）为野生型（wt）的MCRC、性能状态为0-1的患者（pts）接受FOLFIRI或mFOLFOX6并随机分配至CET 400 mg/m2 X1，然后接受CET 250 mg/m2 qw或BV 5mg/kg q2w。最初的研究为让未经选择的MCRC患者接受FOLFIRI或mFOLFOX6并随机分配至CET组，BV组或两者组合治疗。在完成1,420名患者的实验后，该研究修改如下：只研究KRAS （密码子12和13）wt的肿瘤并且删除CET + BV的组合治疗。Rx持续到疾病进展，死亡，出现不可接受的毒性或采取治愈性手术;期间允许4周的治疗假期，随后的Rx没有强制要求。目标是再完成1,142名患者的临床试验。终点是总生存期（OS）。结果：2005年11月至2012年3月，共有3,058名未选择的患者入组，2,334 KRAS wt患者随机分组; 最终N = 1137，中位数f/u = 24 mos; 中位年龄-59岁; 61%是男性。Chemo/BV-559; chemo/CET-578. FOLFIRI = 26.6%，mFOLFOX6 = 73.4%。OS分析计划在849个事件中进行; 功效、无效边界在2014年1月29日的中期分析。OS - chemo/BV v. chemo/CET = 29.04（25.66 - 31.21）v.29.93（27.56 - 31.21）mos; HR = 0.92（0.78,1.09）（p= 0.34）。PFS（由研究者）：chemo/BV v.chemo/CET：10.84（9.86 - 11.4）v.10.45（9.66 - 11.33）mos。手术后有94例无疾病，中位数为f/u 40 mos（8.0-86.0）。不同性别有相似的结果。目前按预期研究毒性和死亡率。结论：KRAS（密码子12 + 13）wt的MCRC患者接受化疗/CET或化疗/BV的OS相当，都有一定治疗效果。临床试验信息：NCT00265850。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:cetuximab_Revised: 6/2018 ', '.', 'guideline:FDA', '1', 'FOLFIRI + cetuximab', 'FOLFIRI + cetuximab', 'FOLFIRI + cetuximab', 'FOLFIRI + 西妥昔单抗', 'FOLFIRI + cetuximab|FOLFIRI + 西妥昔单抗', '4', ' metastatic colorectal cancer ', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'sensitivity', 'EVI_001050', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', 'CRYSTAL (NCT00154102) was a randomized, open-label, multicenter, study of 1217 patients with EGFR-expressing, mCRC. Patients were randomized (1:1) to receive either a cetuximab product in combination with FOLFIRI or FOLFIRI alone as first-line treatment. Stratification factors were Eastern Cooperative Oncology Group (ECOG) performance status (0 and 1 versus 2) and region (Western Europe versus Eastern Europe versus other).FOLFIRI regimen included 14-day cycles of irinotecan (180 mg/m2 intravenously on Day 1), folinic acid (400 mg/m2 [racemic] or 200 mg/m2 [L-form] intravenously on Day 1), and fluorouracil (400 mg/m2 bolus on Day 1 followed by 2400 mg/m2 as a 46-hour continuous infusion). Cetuximab was administered intravenously as a 400 mg/m2 initial dose , followed by 250 mg/m2 weekly administered 1 hour prior to chemotherapy. Study treatment continued until disease progression or unacceptable toxicity. The main efficacy outcome measure was PFS assessed by an independent review committee (IRC). Other outcome measures were OS and ORR.Of the 1217 randomized patients, the median age was 61 years, 60% were male, 86% were White, and 96% had a baseline ECOG performance status 0–1, 60% had primary tumor localized in colon, 84% had 1–2 metastatic sites and 20% had received prior adjuvant and/or neoadjuvant chemotherapy. Demographics and baseline characteristics were similar between study arms.K-Ras mutation status was available for 89% of the patients: 63% had K-Ras wild-type tumors and 37% had K-Ras mutant tumors where testing assessed for the following somatic mutations in codons 12 and 13 (exon 2): G12A, G12D, G12R, G12C, G12S, G12V, G13D. Baseline characteristics and demographics in the K-Ras wild-type subset were similar to that seen in the overall population.A statistically significant improvement in PFS was observed for the cetuximab with FOLFIRI arm compared with the FOLFIRI arm (median PFS 8.9 vs. 8.1 months, HR 0.85 [95% CI 0.74, 0.99], p-value=0.036). OS was not significantly different at the planned, final analysis based on 838 events (HR=0.93, 95% CI [0.8, 1.1], p-value 0.327).Results of the planned PFS and ORR analysis in all randomized patients and post-hoc PFS and ORR analysis in subgroups of patients defined by K-Ras mutation status, and post-hoc analysis of updated OS based on additional follow- up (1000 events) in all randomized patients and in subgroups of patients defined by K-Ras mutation status are presented in Table 8 and Figure 2. The treatment effect in the all-randomized population for PFS was driven by treatment effects limited to patients who have K-Ras wild-type tumors. There is no evidence of effectiveness in the subgroup of patients with K-Ras mutant tumors.', 'CRYSTAL（NCT00154102）是一项随机，开放标签的多中心研究，共有1217名表达EGFR的mCRC患者参与。患者随机（1：1）接受西妥昔单抗、FOLFIRI联合或FOLFIRI单独作为一线治疗。FOLFIRI方案包括伊立替康14天/周期（两种方案分别是：第1天静脉注射伊立替康180 mg/m2+叶酸400 mg / m2 [外消旋]，或第1天静脉注射伊立替康200 mg/m2 [L-form]+氟尿嘧啶400第1天mg/m2推注，最后都是伊立替康2400 mg/m2连续输注46小时）。西妥昔单抗静脉内施用，以400 mg/m 2为初始剂量，然后在每周的化疗前1小时施用250 mg/m2。治疗持续到疾病进展或出现不可接受的毒性。主要疗效结果指标是由独立审查委员会（IRC）评估的PFS。其他结果指标是OS和ORR。在1217名随机患者中，中位年龄为61岁，60%为男性，86%为白人，96%基线ECOG表现状态0-1,60%原发肿瘤定位于结肠，84%有1- 2个转移部位，20%接受了先前的佐剂和/或新辅助化疗。研究组之间的人口统计学和基线特征相似。89%的患者可检测到KRAS状态，其中63%为KRAS野生型肿瘤，37%为KRAS突变肿瘤，对突变型，基因检测评估了密码子12和13中的这些体细胞突变（外显子2）：G12A，G12D，G12R，G12C，G12S，G12V，G13D。 KRAS野生型亚组的基线特征和人口统计学与总体人群中的基线特征和人口统计学相似。与FOLFIRI组相比，使用FOLFIRI+西妥昔单抗的患者可观察到PFS的统计学显著改善（中位PFS：8.9v8.1个月，HR 0.85 [95%CI 0.74,0.99]，p= 0.036）。在基于838名患者的最终分析中，OS没有显著差异（HR = 0.93,95%CI [0.8,1.1]，p=0.327）。在KRAS野生型亚组中，FOLFIRI+西妥昔单抗疗效优于FOLFIRI单独使用（中位PFS：9.5v8.1个月，HR 0.70[95%CI 0.57,0.86]），在KRAS突变的亚组中没有证据表明FOLFIRI+西妥昔单抗更为有效。详细疗效对比见：Druglabel:cetuximab_Revised: 6/2018 （Table 8 and Figure 2）。全随机人群的治疗效果受限于KRAS野生型的患者的治疗效果。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:panitumumab_Revised: 06/2017  ', '.', 'guideline:FDA', '1', 'FOLFOX + panitumumab', 'FOLFOX + panitumumab', 'FOLFOX + panitumumab', 'FOLFOX + 帕尼单抗', 'FOLFOX + panitumumab|FOLFOX + 帕尼单抗', '4', ' metastatic colorectal cancer ', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'sensitivity', 'EVI_001051', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', 'Study 20050203 was a multicenter, open-label trial that randomized (1:1) patients with mCRC who were previously untreated in the metastatic setting and who had received no prior oxaliplatin to receive Vectibix every 14 days in combination with FOLFOX or to FOLFOX alone every 14 days. Vectibix was administered at 6 mg/kg over 60 minutes prior to administration of chemotherapy. The FOLFOX regimen consisted of oxaliplatin 85 mg per m2 IV infusion over 120 minutes and leucovorin (dl-racemic) 200 mg per m2 intravenous infusion over 120 minutes at the same time on day 1 using a Y-line, followed on day 1 by 5-FU 400 mg per m2 intravenous bolus. The 5-FU bolus was followed by a continuous infusion of 5-FU 600 mg per m2 over 22 hours. On day 2, patients receivedleucovorin 200 mg per m2 followed by the bolus dose (400 mg per m2) and continuous infusion of 5-FU (600 mg per m2) over 22 hours. Study 20050203 excluded patients with known central nervous system metastases, clinically significant cardiac disease, interstitial lung disease, or active inflammatory bowel disease. The prespecified major efficacy measure was PFS in the subgroup of patients with wild-type KRAS mCRC as assessed by a blinded independent central review of imaging. Other key efficacy measures included OS and ORR.In Study 20050203, in the wild-type KRAS subgroup (n = 656), 64% of patients were men, 92% White, 2% Black, and 4% Hispanic or Latino. Sixty-six percent of patients had colon cancer and 34% had rectal cancer. ECOG performance was 0 in 56% of patients, 1 in 38% of patients, and 2 in 6% of patients. Median age was 61.5 years.The efficacy results in Study 20050203 in patients with wild-type KRAS mCRC are presented in Table 5 below.', 'NCT00364013是一项多中心，开放标签试验，随机分配（1：1）患有mCRC的患者，这些患者之前未接受转移治疗，也未接受过奥沙利铂或Vectibix联合FOLFOX或FOLFOX 单独治疗。在化疗前60分钟使用Vectibix，剂量为6 mg/kg。 FOLFOX方案内容为奥沙利铂每天静脉注射85mg，120分钟内滴注完成，亚利桑那（dl-外消旋）200mg/m2静脉输注，120分钟内输注完成，第1天Y线放射治疗，并急性5-FU 400 mg/m2静脉推注。 5-FU推注之后在22小时内连续输注5-FU 600mg/m2。第2天，患者先接受甲酰四氢叶酸200mg/m2，然后增加推注剂量（400mg/m2）、连续输注5-FU（600mg/m2）22小时。主要疗效指标是KRAS野生型 mCRC患者亚组的PFS，通过盲法独立的中心成像评估进行评估。其他关键功效测量包括OS和ORR。在野生型KRAS亚组（n = 656）中，64%的患者是男性，92%是白人，2%是黑人，4%是西班牙裔或拉丁裔。 66%的患者患有结肠癌，34%的患者患有直肠癌。 ECOG在56%的患者中表现为0，在38%的患者中为1，在6%的患者中为2，中位年龄为61.5岁。野生型KRAS mCRC的患者中，Vectibix(panitumumab)+FOLFOX的疗效优于单纯FOLFOX化疗（中位PFS：9.6v8.0个月，HR 0.80[95%CI 0.66, 0.97]，p= 0.02）。详细研究结果详见：Druglabel:panitumumab_Revised: 06/2017（Table 5）。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>|PMID:20921462', '.', 'guideline:NCCN', '1', 'FOLFIRI + panitumumab', 'FOLFIRI + panitumumab', 'FOLFIRI + panitumumab', 'FOLFIRI + 帕尼单抗', 'FOLFIRI + panitumumab|FOLFIRI + 帕尼单抗', '4', 'chemotherapy-refractory metastatic colorectal cancer ', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'sensitivity', 'EVI_001052', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', 'PURPOSE:Panitumumab is a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone after failure of initial treatment for mCRC by tumor KRAS status.PATIENTS AND METHODS:Patients with mCRC, one prior chemotherapy regimen for mCRC, Eastern Cooperative Oncology Group performance status 0 to 2, and available tumor tissue for biomarker testing were randomly assigned 1:1 to panitumumab 6.0 mg/kg plus FOLFIRI versus FOLFIRI every 2 weeks. The coprimary end points of PFS and overall survival (OS) were independently tested and prospectively analyzed by KRAS status.RESULTS:From June 2006 to March 2008, 1,186 patients were randomly assigned 1:1 and received treatment. KRAS status was available for 91% of patients: 597 (55%) with wild-type (WT) KRAS tumors, and 486 (45%) with mutant (MT) KRAS tumors. In the WT KRAS subpopulation, when panitumumab was added to chemotherapy, a significant improvement in PFS was observed (hazard ratio [HR] = 0.73; 95% CI, 0.59 to 0.90; P = .004); median PFS was 5.9 months for panitumumab-FOLFIRI versus 3.9 months for FOLFIRI. A nonsignificant trend toward increased OS was observed; median OS was 14.5 months versus 12.5 months, respectively (HR = 0.85, 95% CI, 0.70 to 1.04; P = .12); response rate was improved to 35% versus 10% with the addition of panitumumab. In patients with MT KRAS, there was no difference in efficacy. Adverse event rates were generally comparable across arms with the exception of known toxicities associated with anti-EGFR therapy.CONCLUSION:Panitumumab plus FOLFIRI significantly improved PFS and is well-tolerated as second-line treatment in patients with WT KRAS mCRC.', 'Panitumumab是一种完全人类抗表皮生长因子受体（EGFR）单克隆抗体，可改善化疗难治性转移性结直肠癌（mCRC）的无进展生存期（PFS）。该试验评估了panitumumab联合氟尿嘧啶，甲酰四氢叶酸和伊立替康（FOLFIRI）与单独使用FOLFIRI作为不同KRAS状态的mCRC的初始治疗的疗效和安全性。患者和方法：东部肿瘤协作组的性能状态为0至2的mCRC的患者以及用于生物标记物测试的可用肿瘤组织，以1：1的比例随机分配至帕尼单抗6.0mg/kg+FOLFIRI组与FOLFIRI组，每2周进行1次治疗。PFS和总生存期（OS）的为主要终点，通过KRAS状态进行独立测试和前瞻性分析。结果：2006年6月至2008年3月间，1,186名化疗难治性转移性结直肠癌（mCRC）患者以1：1的比例随机分配至帕尼单抗+FOLFIRI和单纯FOLFIRI组并接受相应治疗，其中91%的患者可检测到KRAS状态：597（55%）名患者的肿瘤中存在野生型（WT）KRAS，486（45%）名患者肿瘤中存在突变型（MT）KRAS。在WT KRAS亚群中，当帕尼单抗加入化疗时，可观察到PFS的显著改善（风险比[HR] = 0.73; 95%CI，0.59-0.90; P =0 .004）; 帕尼单抗-FOLFIRI的中位PFS为5.9个月，而单纯FOLFIRI的PFS为3.9个月。OS无显著增加趋势; 中位OS分别为14.5个月和12.5个月（HR = 0.85,95%CI，0.70-1.04; P =0 .12）; 加入帕尼单抗后，反应率提高至35%，而单纯FOLFIRI进提高10%。另外，在MT KRAS患者中，疗效无差异。结论：帕尼单抗加FOLFIRI可显著改善mCRC的PFS，并且作为WT KRAS mCRC患者的二线治疗具有良好的耐受性。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:encorafenib_Revised: 06/2018|Druglabel:binimetinib_Revised: 06/2018', '.', 'guideline:FDA', '1', 'encorafenib + binimetinib', 'encorafenib + binimetinib', 'encorafenib + binimetinib', 'encorafenib + binimetinib', 'encorafenib + binimetinib|encorafenib + binimetinib', '4', 'metastatic melanoma', 'metastatic melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_001053', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'BRAFTOVI in combination with binimetinib was evaluated in a randomized, active-controlled, open-label, multicenter trial (COLUMBUS; NCT01909453). Eligible patients were required to have BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, as detected using the bioMerieux THxID™BRAF assay. Patients were permitted to have received immunotherapy in the adjuvant setting and one prior line of immunotherapy for unresectable locally advanced or metastatic disease. Prior use of BRAF inhibitors or MEK inhibitors was prohibited. Randomization was stratified by American Joint Committee on Cancer (AJCC) Stage (IIIB, IIIC, IVM1a or IVM1b, versus IVM1c), Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1), and prior immunotherapy for unresectable or metastatic disease (yes versus no).Patients were randomized (1:1:1) to receive BRAFTOVI 450 mg once daily in combination with binimetinib 45 mg twice daily (BRAFTOVI in combination with binimetinib), BRAFTOVI 300 mg once daily, or vemurafenib 960 mg twice daily. Treatment continued until disease progression or unacceptable toxicity.Only the results of the approved dosing (BRAFTOVI 450 mg in combination with binimetinib 45 mg) are described below.The major efficacy outcome measure was progression-free survival (PFS) of BRAFTOVI in combination with binimetinib compared with vemurafenib as assessed by a blinded independent central review. PFS was defined as the time from the date of randomization to the date of the first documented disease progression or death due to any cause, whichever occurred first. Other outcome measures included overall survival (OS), objective response rate (ORR), and duration of response (DoR) as assessed by central review.A total of 577 patients were randomized, 192 to the BRAFTOVI in combination with binimetinib arm, 194 to the BRAFTOVI arm, and 191 to the vemurafenib arm. Of the 383 patients randomized to either the BRAFTOVI in combination with binimetinib or the vemurafenib arms, the median age was 56 years (20 to89 years), 59% were male, 91% were White, and 72% had baseline ECOG performance status of 0. Ninety- five percent (95%) had metastatic disease, 65% were Stage IVM1c, and 4% received prior CTLA-4, PD-1, or PD-L1 directed antibodies. Twenty-eight percent (28%) had elevated baseline serum lactate dehydrogenase (LDH), 45% had ≥ 3 organs with tumor involvement at baseline, and 3% had brain metastases. Based on centralized testing, 100% of patients’ tumors tested positive for BRAF mutations; BRAF V600E (88%), BRAF V600K (11%), or both (<1%).BRAFTOVI in combination with binimetinib demonstrated a statistically significant improvement in PFS compared to vemurafenib. Efficacy results are summarized in Table 5 and Figure 1.', '一项随机、开放标签的多中心试验（COLUMBUS; NCT01909453）评估encorafenib联合binimetinib治疗转移性黑色素瘤的疗效。研究对象为使用bioMerieux THxID™BRAF检测法确定为BRAF V600E或V600K突变阳性的不可切除或转移性黑素瘤患者。允许患者在辅助治疗中接受免疫治疗，对于不可切除的局部晚期或转移性疾病患者允许进行免疫治疗。禁止使用BRAF抑制剂或MEK抑制剂。分组标准为美国癌症联合委员会（AJCC）阶段（IIIB，IIIC，IVM1a或IVM1b，与IVM1c）、东部肿瘤协作组（ECOG）表现状态（0vs1）以及免疫治疗史综合考虑。患者随机分组（1：1：1）接受encorafenib 450 mg每日一次，binimetinib45 mg每日两次的联合治疗，或encorafenib 300 mg每日一次，或vemurafenib 960 mg每日两次的单独治疗。持续治疗直至疾病进展或出现不可接受的毒性。主要疗效结果指标是encorafenib与binimetinib联合治疗的无进展生存期（PFS），通过盲法独立的中心评价进行评估。其他结局指标包括总生存期（OS），客观缓解率（ORR）和反应持续时间（DoR）。共有577名患者参与随机分组​​，其中192名患者使用encorafenib与binimetinib联合治疗，194名患者仅使用encorafenib治疗，191名患者使用vemurafenib单独疗法。在随机接受encorafenib与binimetinib联合治疗和vemurafenib单独治疗的383名患者中，中位年龄为56岁（20至89岁），59%为男性，91%为白人，72%的基线ECOG表现状态为0 ，95%患有转移性疾病，65%为IVM1c期，4%曾接受过CTLA-4，PD-1或PD-L1定向抗体，28%基线血清乳酸脱氢酶（LDH）升高，45%有≥3个器官受累，3%有脑转移。基于集中测试，100%的患者肿瘤检测结果为BRAF突变阳性，比例为：BRAF V600E（88%），BRAF V600K（11%），两者皆突变（<1%）。与vemurafenib相比，encorafenib与binimetinib联合治疗的PFS显示出统计学上显著的改善（中位PFS：14.9v7.3个月，HR 0.54[95%CI 0.41, 0.71]，p<0.0001）。具体结果详见Druglabel:encorafenib_Revised: 06/2018（Table 5 and Figure 1）', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NMPA|DOI:10.1158/1538-7445.SABCS17-PD3-08', '.', 'guideline:NMPA', '1', 'pyrotinib + capecitabine', 'pyrotinib + capecitabine', 'pyrotinib + capecitabine', '吡咯替尼 + 卡培他滨', 'pyrotinib + capecitabine|吡咯替尼 + 卡培他滨', '2', 'metastatic breast cancer ', 'metastatic breast cancer ', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001054', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'Background:Pyrotinib is an oral, irreversible pan-ErbB receptor tyrosine kinase inhibitor (TKI) with activity against epidermal growth factor receptor (EGFR) / HER1, HER2, and HER4. Lapatinib in combination with capecitabine is one of the standards of care for patients with HER2-positive metastatic breast cancer (MBC) who have received prior taxanes, anthracyclines and/or trastuzumab.Methods: We conducted an open label, multicenter, randomized phase II trial to comparatively evaluate efficacy and safety of pyrotinib + capecitabine (PC) or lapatinib + capecitabine (LC) in women with HER2-positive MBC. Key eligibility criteria included prior treatment with taxanes, anthracyclines and/or trastuzumab, ≤2 prior chemotherapies for metastatic disease, no CNS metastases, and no prior treatment with HER2 targeted TKI. Eligible patients were randomized 1:1 to PC Arm (P 400 mg QD D1–21 + C 1000 mg/m2BID D1–14, 21-D cycle) or LC Arm (L 1250 mg QD D1–21 + C 1000 mg/m2BID D1–14, 21-D cycle). The primary endpoint was objective response rate (ORR) as assessed by investigator, and secondary endpoints included progression-free survival (PFS), time to progression (TTP), duration of response (DoR), overall survival (OS), and safety.Results: Between May 2015 and Mar 2016, 128 patients (65 in PC arm and 63 in LC arm) were enrolled in this study. Median age was 48 years (range 25-70), ECOG performance status was 0 (53.9%) or 1 (46.1%), 62.5% had hormone receptor-positive disease, 76.6% had visceral disease and 53.9% had received prior trastuzumab in (neo)adjuvant and/or mestastatic setting. Baseline characteristics were well balanced in two arms. Median follow-up time was 15.0 months. ORR was 78.5% in PC arm and 57.1% in LC arm (p=0.01), Median PFS was 18.1 months in PC arm and 7.0 months in LC arm (hazard ratio 0.363; 95% CI 0.228, 0.579; p<0.0001), PFS benefit in PC arm compared to LC arm was observed irrespective of prior trastuzumab or not. Treatment related Grade 3-4 toxicities occurred in >2% patients in PC arm vs LC arm included hand-foot syndrome (21.5% vs 19.0%), diarrhea (13.8% vs 4.8%), decreased neutrophil (7.7% vs 1.6%), decreased WBC (6.2% vs 1.6%), vomiting (4.6% vs 0%), increased AST (3.1% vs 1.6%), decreased hemoglobin (3.1% vs 1.6%), increased total bilirubin (0% vs 4.8%) and increased conjugated bilirubin (0% vs 3.2%).Conclusions: In women with HER2-positive MBC previously treated with taxanes, anthracyclines and/or trastuzumab, pyrotinib + capecitabine yield statistically significant better PFS and ORR than lapatinib + capecitabine in this randomized phase II trial. Phase III study is ongoing to validate this finding.', 'Pyrotinib（吡咯替尼）是一种口服，不可逆的泛ERBB受体酪氨酸激酶抑制剂（TKI），具有抗表皮生长因子受体EGFR/HER1，HER2和HER4的活性。拉帕替尼联合卡培他滨是HER2阳性转移性乳腺癌（MBC）的经典治疗方法之一。研究对象已接受过紫杉烷，蒽环类和/或曲妥珠单抗治疗。在一项开放标签，多中心，随机II期试验中，对比吡咯替尼联合卡培他滨和拉帕替尼联合卡培他滨，治疗既往用过/未用过曲妥珠单抗且既往≤2线化疗的HER2阳性晚期乳腺癌患者的疗效和安全性。符合条件的患者按1：1随机分配。主要终点是由研究者评估的客观反应率（ORR），次要终点包括无进展生存期（PFS），进展时间（TTP），反应持续时间（DoR），总生存期（OS）和安全性。结果：2015年5月至2016年3月期间，128名患者参加了本研究。中位年龄为48岁（范围25-70），ECOG表现状态为0（53.9%）或1（46.1%），62.5%有激素受体阳性疾病，76.6%有内脏疾病，53.9%曾接受曲妥珠单抗治疗（neo）佐剂和/或转移治疗。中位随访时间为15.0个月。吡咯替尼组对比拉帕替尼组可以显著提高患者的客观缓解率（ORR）：78.5% vs 57.1%，两组之间统计学差异显著（p=0.01）；进一步分析两组患者的无进展生存期（PFS），结果显示吡咯替尼组的中位PFS达18.1个月，显著优于拉帕替尼组的7.0个月（p＜0.0001）。在既往用过曲妥珠单抗的亚组，吡咯替尼组中位PFS显著优于拉帕替尼组（7.1月vs未达到，p=0.0031）；在既往未用过曲妥珠单抗亚组，吡咯替尼组中位PFS亦显著优于拉帕替尼组（18.1月vs 5.6月，p=0.0013）。提示吡咯替尼的抗肿瘤效果与既往是否用过曲妥珠单抗无关。腹泻是吡咯替尼组最常见的不良事件。结论：在此随机II期试验中，对于先前用紫杉烷类，蒽环类抗生素和/或曲妥珠单抗治疗的HER2阳性转移性乳腺癌女性，吡咯替尼+卡培他滨比拉帕替尼+卡培他滨能显著产生更好的PFS和ORR。2018年8月14日，国家药品监督管理总局正式批准中国自主研发的1.1类新药，泛-ErbB受体酪氨酸激酶抑制剂吡咯替尼用于人表皮生长因子受体 2（HER2）阳性的晚期乳腺癌治疗。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29967253', '.', 'preclinical', '4', '.', '.', 'osimertinib ', '奥希替尼', 'osimertinib |奥希替尼', '4', 'breast cancer cells', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001057', 'ERBB2:nonsynonymous SNV:.:.:act', 'ERBB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '细胞学试验表明，osimertinib对携带ERBB2激活突变的肿瘤细胞，如L755P和L755S，具有一定的抑制作用。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 36, 2018 (suppl; abstr LBA1006)', 'NCT02340221', 'clinical trial - phase3', '4', 'taselisib (GDC-0032) + fulvestrant (FULV)', '.', 'taselisib', 'taselisib', 'taselisib|taselisib', '3', 'estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC)', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001059', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'Taselisib是一种有效的选择性PI3K抑制剂，对PIK3CA的乳腺癌细胞具有抑制作用。一项临床3期研究评估了taselisib + FULV在ER阳性，HER2阴性，PIK3CA突变的局部晚期或转移性乳腺癌中的疗效。SANDPIPER（NCT02340221）是一项双盲，安慰剂（PBO）对照的随机III期研究。绝经后的患者，在芳香酶抑制剂治疗期间或之后疾病复发或疾病进展。所有患者以2：1随机化以接受taselisib（4mg口服，qd）或PBO + FULV（500mg）。主要终点是研究者评估PIK3CA突变肿瘤患者的无进展生存期（INV-PFS）。次要终点包括客观反应率（ORR），总生存期（OS），临床受益率（CBR），客观反应持续时间（DoR），盲法独立中央评价（BICR-PFS）的PFS和安全性。结果表明，在PIK3CA突变的意向治疗（ITT）人群中随机分配了516例患者。如BICR-PFS（HR 0.66）所证实，Taselisib + FULV显著改善了INV-PFS（风险比[HR] 0.70）。OS数据尚未达到。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30149884|PMID:28167203|PMID:30096481|PMID:26559459', '.', 'clinical study', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'Lung Adenocarcinoma', 'Lung Adenocarcinoma', '肺癌', 'na', 'sensitivity', 'EVI_001061', 'ERBB2:nonframeshift insertion:exon20:.:exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'INTRODUCTION:HER2 mutations are found in 2% to 4% of non-small-cell lung cancer cases and are usually mutually exclusive with other genetic alterations. We screened a large cohort of patients from multiple institutions in Korea, described the characteristics of HER2-mutant cases, and reported on several patients who were treated with pan-HER inhibitors.PATIENTS AND METHODS:The study population consisted of 360 patients diagnosed with adenocarcinoma from 4 institutions in Korea from June 2015 to September 2016. Tissue specimens from all participants were screened by direct sequencing, and next-generation sequencing was conducted only on specimens that were positive in direct sequencing. HER2-targeted therapy, either poziotinib or afatinib, was orally administrated.RESULTS:Next-generation sequencing was conducted in 129 patients, and finally 29 (8.1%) patients with HER2 mutation were identified. Most patients were female (58.6%), had never smoked (70.0%), and had stage IV non-small-cell lung cancer (55.2%). For all patients, the histologic type was adenocarcinoma, with no coexisting EGFR or ALK alterations. The most common type of HER2 mutation (48.3%) was c.2326_2327insTGT in exon 20. A partial response was observed in 2 patients who received poziotinib and 1 patient who received afatinib. The main toxicities of the pan-HER inhibitors were nausea, diarrhea, and mucositis.CONCLUSION:HER2 mutation was estimated at a frequency of approximately 8.1% in Korean patients with adenocarcinoma in the absence of known driver mutations. Because some of the HER2-mutant cases responded to poziotinib or afatinib, further studies are warranted.', '2%-4%的非小细胞肺癌患者可能发生HER2突变，该突变通常与其他基因变异相互排斥。研究人员筛选了来自韩国多个机构的患者，描述了HER2突变患者的特征，并报告了几例接受pan-HER抑制剂治疗的患者。患者和方法：研究人群为2015年6月至2016年9月间韩国4个机构的360名被诊断患有肺腺癌的患者。通过直接测序筛选组织标本，仅对直接测序阳性的标本进行新一代测序。 HER2靶向治疗方案为poziotinib或afatinib口服给药。结果：共有129名患者进行了新一代测序，最终确定了29名（8.1%）HER2突变患者。大多数患者为女性（58.6%），从未吸烟（70.0%），并且患有IV期非小细胞肺癌（55.2%）。对于所有患者，组织学类型是腺癌，没有共存的EGFR或ALK变异。最常见的HER2突变（48.3%）是外显子20中的c.2326_2327insTGT。在接受poziotinib的2名患者和接受afatinib的1名患者中观察到部分反应。泛HER抑制剂的主要毒性是恶心，腹泻和粘膜炎。在没有已知的驱动突变的情况下，韩国腺癌患者的HER2突变估计频率约为8.1%。由于一些HER2突变病例对poziotinib或afatinib有反应，因此需要进一步研究。文献PMID:30096481中，在12例有ERBB2突变类型的患者中，有10例存在p.A775_G776insYVMA突变，其中4例(40%持续响应超过1年以上，mTTF中位数为9.6个月，客观响应率为33%（2/6），疾病控制率为100%（6/6）)；研究人员对临床治疗的患者进一步分析也证明了afatinib在ERBB2突变阳性的NSCLC中的活性。文献PMID:26559459中，(Case report)一位HER2突变型(p.A775_G776insYVMA) IV期肺腺癌转移患者，其自然病史长，每天服用40 mg afatinib治疗，两个月后肺部肿瘤和肝转移消退，临床和放射学上都有响应，对阿法替尼有10个月的良好耐受性。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:doi.org/10.1016/j.jtho.2018.02.004', 'NCT02840604', 'clinical trial - phase1', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001062', 'EGFR:nonframeshift insertion:exon20:p.V769L:', 'EGFR', 'nonframeshift insertion', 'Exact_pos', 'exon20', 'p.V769L', '.', 'A 68-year-old female patient was admitted to our hospital in October 2016 for exploration of a 22-mm lesion in the lower left lobe that was associated with suspicious liver and adrenal gland nodules. She had no significant medical history but did have a smoking index of 50 pack-years. She benefited from microbiopsy of a liver nodule that exhibited histologic features of a lung adenocarcinoma. She was enrolled in the EXOMA trial (NCT02840604). Whole exome analysis by next-generation sequencing of the tumor and blood sample objectified two rare EGFR mutations in exon 20, p.Ser768Ile (S768I) and p.Val769Leu (V769L); one tumor protein p53 gene (TP53) mutation, p.Glu171dup; and one tuberous sclerosis 1 gene (TSC1 mutation), p.Tyr192Asn. In accordance with the national recommendation for the management of NSCLC, she benefited from first-line of treatment with afatinib, which was initially given at dose of 40 mg daily for 10 days. Because of diarrhea, the treatment was stopped for 10 days and was then been decreased to 20 mg daily for 30 days. Seven weeks after the patient started taking afatinib, cerebral, chest, and abdominopelvic computed tomography revealed progression of her primary pulmonary lesion and metastatic liver and adrenal gland localizations and apparition of metastatic localizations in brain and bones.', '2016年10月，一名68岁的女性患者入院治疗22 mm非小细胞肺癌病灶。患者没有重要的病史，有50包/年的吸烟史。患者参加了EXOMA试验（NCT02840604）。对肿瘤和血液样品进行下一代测序，全外显子组分析患者存在EGFR exon20 p.Ser768Ile（S768I）和p.Val769Leu（V769L）突变、TP53 p.Glu171dup突变、TSC1 p.Tyr192Asn突变。患者接受afatinib的一线治疗，最初每天给予40mg，持续10天。由于腹泻，治疗停止10天，然后减少至每天20mg，持续30天，有明显受益。患者服用afatinib 7周后，脑，胸，腹部CT显示出现原发病灶肝、肾上腺、脑转移。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2018.77.7326', 'NCT01610336', 'clinical trial - phase2', '4', 'capmatinib (INC280) & Gefitinib ', 'capmatinib (INC280) & Gefitinib ', 'capmatinib + gefitinib', 'capmatinib + 吉非替尼', 'capmatinib + gefitinib|capmatinib + 吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001063', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', 'Purpose：Mesenchymal-epithelial transition factor (MET) dysregulation occurs in up to 26% of non–small-cell lung cancers (NSCLCs) after epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) treatment. Capmatinib (INC280) is a potent and selective MET inhibitor with preclinical activity in combination with gefitinib in EGFR-mutant, MET-amplified/overexpressing models of acquired EGFR-TKI resistance. This phase Ib/II study investigated the safety and efficacy of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated (amplified/overexpressing) NSCLC who experienced disease progression while receiving EGFR-TKI treatment.Methods：Patients in phase Ib received capmatinib 100- to 800-mg capsules once per day or 200- to 600-mg capsules or tablets twice per day, plus gefitinib 250 mg once per day. Patients in phase II received the recommended phase II dose. The primary end point was the overall response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.Results：Sixty-one patients were treated in phase Ib, and 100 were treated in phase II. The recommended phase II dose was capmatinib 400 mg twice per day plus gefitinib 250 mg once per day. Preliminary clinical activity was observed, with an ORR across phase Ib/II of 27%. Increased activity was seen in patients with high MET-amplified tumors, with a phase II ORR of 47% in patients with a MET gene copy number ≥ 6. Across phases Ib and II, the most common drug-related adverse events were nausea (28%), peripheral edema (22%), decreased appetite (21%), and rash (20%); the most common drug-related grade 3/4 adverse events were increased amylase and lipase levels (both 6%). No significant drug-drug interactions between capmatinib and gefitinib were evident.Conclusion：This study, focused on a predominant EGFR-TKI resistance mechanism in patients with EGFR-mutated NSCLC, shows that the combination of capmatinib with gefitinib is a promising treatment for patients with EGFR-mutated, MET-dysregulated NSCLC, particularly MET-amplified disease.', '高达26%的EGFR-TKI治疗后的非小细胞肺癌（NSCLCs）中可能发生MET失调。 Capmatinib（INC280）是一种有效的选择性MET抑制剂，具有临床前活性，可与吉非替尼组合，作用于MET-扩增/过表达的获得性EGFR-TKI抗性细胞模型。这项Ib/II期研究调查了capmatinib联合吉非替尼治疗EGFR突变、MET失调（扩增/过度表达）的NSCLC患者的安全性和有效性，这些患者都在接受EGFR-TKI治疗时出现疾病进展。方法：Ib期患者接受了capmatinib治疗，方案为：每天一次100-800mg胶囊、或每天两次200至600mg胶囊或片剂，加上每天250mg吉非替尼。 II期患者接受推荐的II期剂量。主要终点是每个实体瘤反应评估标准（RECIST）1.1版的总反应率（ORR）。结果：61名患者在Ib期接受治疗，100名患者在II期接受治疗。推荐的II期剂量为每天两次400mg的capmatinib加上每天一次250mg的吉非替尼。观察到初步临床活动，Ib/II期的ORR为27%。MET扩增患者的疗效较好，MET基因拷贝数≥6的患者II期ORR为47%。在Ib和II期，最常见的药物相关不良事件为恶心（28 %），外周水肿（22%），食欲减退（21%）和皮疹（20%）;最常见的与药物相关的3/4级不良事件是淀粉酶和脂肪酶水平增加（均为6%）。capmatinib和吉非替尼之间没有明显的药物间相互作用。结论：本研究主要关注EGFR突变的NSCLC患者EGFR-TKI的主要耐药机制，结果表明，capmatinib与吉非替尼联合治疗是一种治疗EGFR突变，MET失调的NSCLC，特别是MET扩增类NSCLS的很有前景的治疗方法。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30152517 ', '.', 'preclinical', '4', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001066', 'BRCA2:.:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'PARP抑制剂在治疗缺乏DNA同源重组（HR）修复的患者（例如BRCA1或BRCA2功能缺失的患者）方面具有很大的前景。研究表明PARP抑制可通过与化疗剂组合来改善非小细胞肺癌（NSCLC）的疗效。在本研究中，我们发现了PARP 抑制剂talazoparib（BMN-673）与化疗药吉西他滨对NSCLC具有协同活性。此外，与单一疗法的任一药剂相比，该组合在NSCLC的H23异种移植模型中表现出显著的体内抗肿瘤活性，可在不损失HR修复效率的情况下发生这种协同作用。该组合可诱导协同的单链DNA断裂，导致体外和体内双链DNA损伤的毒性积累。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30152517 ', '.', 'preclinical', '4', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001067', 'BRCA1:.:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'PARP抑制剂在治疗缺乏DNA同源重组（HR）修复的患者（例如BRCA1或BRCA2功能缺失的患者）方面具有很大的前景。研究表明PARP抑制可通过与化疗剂组合来改善非小细胞肺癌（NSCLC）的疗效。在本研究中，我们发现了PARP 抑制剂talazoparib（BMN-673）与化疗药吉西他滨对NSCLC具有协同活性。此外，与单一疗法的任一药剂相比，该组合在NSCLC的H23异种移植模型中表现出显著的体内抗肿瘤活性，可在不损失HR修复效率的情况下发生这种协同作用。该组合可诱导协同的单链DNA断裂，导致体外和体内双链DNA损伤的毒性积累。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30171497', 'NCT00085553', 'clinical trial - phase1', '4', 'tipifarnib + erlotinib', 'tipifarnib + erlotinib', 'tipifarnib + erlotinib', 'tipifarnib + 厄洛替尼', 'tipifarnib + erlotinib|tipifarnib + 厄洛替尼', '1', 'Solid tumor', 'Solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001070', 'HRAS:nonsynonymous SNV:.:.:act', 'HRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '根据临床数据研究tipifarnib和厄洛替尼组合用药对实体瘤的细胞毒性，以评估其安全性、耐受性、最大耐受剂量（MTD）和有效性。方法：患者入组遵循传统的“3 + 3”剂量递增计划，通过4个剂量水平，范围从tipifarnib 200 mg每日两次加厄洛替尼 75 mg每日一次增至tipifarnib 300 mg每日两次加厄洛替尼每日一次150mg。结果：共有27名患者参加了研究。厄洛替尼 150mg，每天一次，联合替比法尼 300 mg，每天两次（3级腹泻）的治疗下一名患者中观察到剂量限制性毒性。所有等级组合最常见的副作用是腹泻（85.2%），疲劳（77.8%），皮疹（70.4%）和厌食（59.3%）。总体而言，2名患者（7.4%;分别为肝癌和黑色素瘤）有部分反应，10例（37%）病情稳定，11例有进展性疾病（40.7%），4例过早停止治疗评估。结论：实体瘤对tipifarnib和厄洛替尼组合的耐受性良好。Tipifarnib目前正在HRAS突变肿瘤中进行评估，为进一步测试这种组合提供了潜在的机会。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30171258', '.', 'preclinical', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001071', 'TWIST1:CNV:.:.:gain', 'TWIST1', 'CNV', 'CNV', '.', '.', 'gain', 'Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) have significantly benefited from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these therapies is limited due to de novo resistance (~30%) as well as acquired resistance. Epithelial-mesenchymal transition transcription factors (EMT-TFs), have been identified as drivers of EMT-mediated resistance to EGFR TKIs, however, strategies to target EMT-TFs are lacking. As the third generation EGFR TKI, osimertinib, has now been adopted in the first-line setting, the frequency of T790M mutations will significantly decrease in the acquired resistance setting. Previously less common mechanisms of acquired resistance to first generation EGFR TKIs including EMT are now being observed at an increased frequency after osimertinib. Importantly, there are no other FDA approved targeted therapies after progression on osimertinib. Here, we investigated a novel strategy to overcome EGFR TKI resistance through targeting the EMT-TF, TWIST1, in EGFR-mutant NSCLC. We demonstrated that genetic silencing of TWIST1 or treatment with the TWIST1 inhibitor, harmine, resulted in growth inhibition and apoptosis in EGFR-mutant NSCLC. TWIST1 overexpression resulted in erlotinib and osimertinib resistance in EGFR-mutant NSCLC cells. Conversely, genetic and pharmacological inhibition of TWIST1 in EGFR TKI-resistant EGFR-mutant cells increased sensitivity to EGFR TKIs. TWIST1-mediated EGFR TKI resistance was due in part to TWIST1 suppression of transcription of the pro-apoptotic BH3-only gene, BCL2L11 (BIM), by directly binding to BCL2L11 intronic regions and promoter. As such, pan-BCL2 inhibitor treatment overcame TWIST1-mediated EGFR TKI resistance and were more effective in the setting of TWIST1 overexpression. Finally, in a mouse model of autochthonous EGFR-mutant lung cancer, Twist1 overexpression resulted in erlotinib resistance and suppression of erlotinib-induced apoptosis. These studies establish TWIST1 as a driver of resistance to EGFR TKIs and provide rationale for use of TWIST1 inhibitors or BCL2 inhibitors as means to overcome EMT-mediated resistance to EGFR TKIs.', '研究显示EGFR突变的非小细胞肺癌（NSCLC）普遍可从EGFR酪氨酸激酶抑制剂（TKI）中显著受益。由于新生抗性（~30%）以及获得性抗性，这些疗法的长期疗效受到限制。上皮 - 间质转化转录因子（EMT-TFs）已经被鉴定为由EMT介导的EGFR TKI的抗性的驱动因子，但是目前缺乏靶向EMT-TF的策略。osimertinib现已在一线治疗中广泛采用，T790M的突变频率在获得性抗性出现后显著降低。过往罕见的第一代EGFR TKI（包括EMT）获得性耐药的机制现已在osimertinib治疗中逐渐观察到。重要的是，在osimertinib治疗发生进展后，并没有其他FDA批准的靶向治疗。研究人员提出通过靶向EGFR突变的NSCLC中的EMT-TF—TWIST1来研究克服EGFR TKI抗性的新策略。该研究证明了TWIST1的基因沉默或TWIST1抑制剂的使用可导致含EGFR突变体的NSCLC细胞生长抑制和凋亡。TWIST1过表达可导致EGFR突变的NSCLC厄洛替尼和osimertinib耐药。相反，产生EGFR TKI抗性的EGFR突变细胞中TWIST1的遗传和药理学抑制增加了对EGFR TKI的敏感性。TWIST1介导的EGFR TKI抗性是由于TWIST1通过直接结合BCL2L11内含子区和启动子而抑制促凋亡基因BH3和BCL2L11（BIM）的转录。因此，泛BCL2抑制剂治疗可克服TWIST1介导的EGFR TKI耐药性，并且在TWIST1过度表达的设定中更有效。最后，在原发性EGFR突变肺癌的小鼠模型中，TWIST1过表达可导致厄洛替尼抗性，抑制厄洛替尼诱导的细胞凋亡。这些研究确定TWIST1是EGFR TKI耐药的驱动因素，并提供使用TWIST1抑制剂或BCL2抑制剂作为克服EMT介导的对EGFR TKI耐药性的手段的理由。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30171258', '.', 'preclinical', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001072', 'TWIST1:CNV:.:.:gain', 'TWIST1', 'CNV', 'CNV', '.', '.', 'gain', 'Patients with EGFR-mutant non-small-cell lung cancer (NSCLC) have significantly benefited from the use of EGFR tyrosine kinase inhibitors (TKIs). However, long-term efficacy of these therapies is limited due to de novo resistance (~30%) as well as acquired resistance. Epithelial-mesenchymal transition transcription factors (EMT-TFs), have been identified as drivers of EMT-mediated resistance to EGFR TKIs, however, strategies to target EMT-TFs are lacking. As the third generation EGFR TKI, osimertinib, has now been adopted in the first-line setting, the frequency of T790M mutations will significantly decrease in the acquired resistance setting. Previously less common mechanisms of acquired resistance to first generation EGFR TKIs including EMT are now being observed at an increased frequency after osimertinib. Importantly, there are no other FDA approved targeted therapies after progression on osimertinib. Here, we investigated a novel strategy to overcome EGFR TKI resistance through targeting the EMT-TF, TWIST1, in EGFR-mutant NSCLC. We demonstrated that genetic silencing of TWIST1 or treatment with the TWIST1 inhibitor, harmine, resulted in growth inhibition and apoptosis in EGFR-mutant NSCLC. TWIST1 overexpression resulted in erlotinib and osimertinib resistance in EGFR-mutant NSCLC cells. Conversely, genetic and pharmacological inhibition of TWIST1 in EGFR TKI-resistant EGFR-mutant cells increased sensitivity to EGFR TKIs. TWIST1-mediated EGFR TKI resistance was due in part to TWIST1 suppression of transcription of the pro-apoptotic BH3-only gene, BCL2L11 (BIM), by directly binding to BCL2L11 intronic regions and promoter. As such, pan-BCL2 inhibitor treatment overcame TWIST1-mediated EGFR TKI resistance and were more effective in the setting of TWIST1 overexpression. Finally, in a mouse model of autochthonous EGFR-mutant lung cancer, Twist1 overexpression resulted in erlotinib resistance and suppression of erlotinib-induced apoptosis. These studies establish TWIST1 as a driver of resistance to EGFR TKIs and provide rationale for use of TWIST1 inhibitors or BCL2 inhibitors as means to overcome EMT-mediated resistance to EGFR TKIs.', '研究显示EGFR突变的非小细胞肺癌（NSCLC）普遍可从EGFR酪氨酸激酶抑制剂（TKI）中显著受益。由于新生抗性（~30%）以及获得性抗性，这些疗法的长期疗效受到限制。上皮 - 间质转化转录因子（EMT-TFs）已经被鉴定为由EMT介导的EGFR TKI的抗性的驱动因子，但是目前缺乏靶向EMT-TF的策略。osimertinib现已在一线治疗中广泛采用，T790M的突变频率在获得性抗性出现后显著降低。过往罕见的第一代EGFR TKI（包括EMT）获得性耐药的机制现已在osimertinib治疗中逐渐观察到。重要的是，在osimertinib治疗发生进展后，并没有其他FDA批准的靶向治疗。研究人员提出通过靶向EGFR突变的NSCLC中的EMT-TF—TWIST1来研究克服EGFR TKI抗性的新策略。该研究证明了TWIST1的基因沉默或TWIST1抑制剂的使用可导致含EGFR突变体的NSCLC细胞生长抑制和凋亡。TWIST1过表达可导致EGFR突变的NSCLC厄洛替尼和osimertinib耐药。相反，产生EGFR TKI抗性的EGFR突变细胞中TWIST1的遗传和药理学抑制增加了对EGFR TKI的敏感性。TWIST1介导的EGFR TKI抗性是由于TWIST1通过直接结合BCL2L11内含子区和启动子而抑制促凋亡基因BH3和BCL2L11（BIM）的转录。因此，泛BCL2抑制剂治疗可克服TWIST1介导的EGFR TKI耐药性，并且在TWIST1过度表达的设定中更有效。最后，在原发性EGFR突变肺癌的小鼠模型中，TWIST1过表达可导致厄洛替尼抗性，抑制厄洛替尼诱导的细胞凋亡。这些研究确定TWIST1是EGFR TKI耐药的驱动因素，并提供使用TWIST1抑制剂或BCL2抑制剂作为克服EMT介导的对EGFR TKI耐药性的手段的理由。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30118898', '.', 'case report', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', ' chronic myeloid leukemia ', ' chronic myeloid leukemia ', '白血病', 'na', 'resistance', 'EVI_001082', 'ABL1:nonsynonymous SNV:exon6:p.S348L:', 'ABL1', 'nonsynonymous SNV', 'Exact_pos', 'exon6', 'p.S348L', '.', 'A 52- year old female visited Haematology clinic, K.EM hospital, India on April 2010 for diagnosis and treatment of abdominal discomfort. An initial complete haemogram showed haemoglobin level of 14.2 g/dl, WBC count of 349 × 103 /μl and platelets were in normal range. Ultrasonography showed massive splenomegaly. Complete haemogram suggestive of CML-chronic phase (CP) later that was confirmed by bone marrow aspiration. Cytogenetic study using GTG-banding revealed 46,XX,t(9;22)(q34;q22.1) and fluorescence in situ hybridisation (FISH) using dual colour dual fusion Bcr/Abl probe (Vysis) showed single Bcr/Abl fusion(2G2RSF) in 100% of analysed cells. Molecular analysis revealed presence of b3a2 transcript (p210). Imatinib (Gleevac, Novartis) at standard doses of 400 mg was prescribed as first line therapy to the patient and started monitoring according to European leukemia net guidelines [5]. She achieved complete haematological response at 3 months (WBC count 3600/μl) and PCyR (partial cytogenetic response) at 6months (Ph+ cells < 6%). After receiving treatment course of 24 months (IM400 mg) she did not achieve major molecular response (Transcript level in international scale Bcr/Abl IS% > 0.1%) and developed cytopenia (ANC 1127/mm3 ). Because of cytopenia discontinuation of IM treatment was made for correction with supportive haematinics. Neutrophil count and Bcr/ Abl transcript level was monitored during treatment interruption and after correction again IM was started with standard dose (400 mg) but she was non-adherent to treatment. Further IM dose was increased up to 600 mg and 800 mg during the follow–up to obtain optimal molecular response but there was no significance reduction in level of Bcr/Abl transcript. Subsequently she lost cytogenetic response .In our case, mutation analysis of abl1 kinase domain of Bcr/Abl1 gene revealed presence of point mutation at position of 1043 nt C→A (S348) .In our study we found a point mutation at amino acid positions S348 (nt1043 c→A) that initiating premature termination of translation resulting in truncated Bcr/Abl protein. These truncated protein lacking activation loop hinge region, entire C- terminal region including DNA binding and actin binding region which interacts with SH2 domain and play important role in kinase activity by auto- regulation. Homology modelling and ligand docking study revealed that this mutation is reducing pocket size critically involved in IM binding and reduced binding affinity of −8.7 kcal/mol as compared to wild type ABL protein (−11.7 kcal/mol) with no interaction with IM drug. Mutation that we found is a new addition to rare class of mutation those were reported in earlier studies [18,19].', '2010年4月，1名52岁的女性出现腹部不适，初始完整血象显示血红蛋白水平为14.2 g/dl，WBC计数为349×103 /μl，血小板在正常范围内。超声检查显示严重脾肿大。完全血管造影提示CML-慢性期（CP），后经骨髓抽吸证实。使用双色双重融合Bcr/Abl探针（Vysis）的荧光原位杂交（FISH）显示单个Bcr/Abl融合，分子分析显示存在b3a2转录物（p210）。使用标准剂量为400 mg的伊马替尼（Gleevac，Novartis）用于患者的一线治疗，并根据欧洲白血病网络指南开始监测。患者在3个月（WBC计数3600 /μl）和6个月时出现PCyR（部分细胞遗传学反应）并达到完全血液学反应（Ph +细胞<6%）。在接受24个月的治疗后，她没有达到主要的分子反应并且发生血细胞减少（ANC 1127/mm3）。由于血细胞减少，IM治疗停止。在治疗中断期间监测​​中性粒细胞计数和Bcr/Abl转录物水平，并且在校正后再次以标准剂量（400mg）开始IM，但是此时患者对治疗不敏感。在随访期间，将IM剂量增加至600mg和800mg以获得最佳分子反应，但Bcr/Abl转录物水平没有显著降低，随后她失去了细胞遗传学反应，之后Bcr/Abl1基因的突变分析显示在Abl1基因在1043nt C→A（S348）的位置存在点突变。该研究显示，Abl1 S348（nt1043c→A）突变可引发翻译的过早终止，导致出现截短Bcr/Abl蛋白。这些截短的蛋白缺乏活化环铰链区、整个C-末端区域包括DNA结合和肌动蛋白结合区域，其可与SH2结构域相互作用并自动调节在激酶活性中的重要作用。同源建模和配体对接研究显示，与野生型ABL蛋白（-11.7 kcal/mol）相比，该突变减少了截短蛋白与IM结合密切相关的接口大小并降低了亲和力，且与IM药物没有相互作用。该突变是早期研究中报道的新增加的稀有类突变。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30115483', '.', 'preclinical', '4', 'alpelisib', 'alpelisib', 'alpelisib', 'alpelisib', 'alpelisib|alpelisib', '1', 'head and neck squamous cell cancer', 'head and neck squamous cell cancer', '头颈部肿瘤', 'na', 'resistance', 'EVI_001083', 'HRAS:nonsynonymous SNV:exon2:p.G12V:', 'HRAS', 'nonsynonymous SNV', 'Exact_pos', 'exon2', 'p.G12V', '.', 'OBJECTIVES:The PI3K/AKT/mTOR pathway is frequently altered in head and neck squamous cell cancer (HNSCC), making this pathway a logical therapeutic target. However, PI3K targeting is not universally effective. Biomarkers of response are needed to stratify patients likely to derive benefit and exclude those unlikely to respond.MATERIALS AND METHODS:We examined the sensitivity of cell lines with constitutively-active (G12V mutant) HRAS and wild-type HRAS to PI3K inhibition using flow cytometry and cell viability assays. We then overexpressed and silenced HRAS and measured sensitivity to the PI3K inhibitor BYL719. Immunoblotting was used to determine activation of the PI3K pathway. MEK and mTOR inhibitors were then tested in HRAS mutant cells to determine their efficacy.RESULTS:HRAS mutant cell lines were non-responsive to PI3K inhibition. Overexpression of HRAS led to reduced susceptibility to PI3K inhibition, while knockdown improved sensitivity. Immunoblotting revealed suppressed AKT phosphorylation upon PI3K inhibition in both wild-type and HRAS mutant cell lines, however mutant lines maintained phosphorylation of S6, downstream of mTOR. Targeting mTOR effectively reduced viability of HRAS mutant cells and we subsequently examined the ERK-TSC2-mTOR cascade as a mediator of resistance to PI3K inhibition.CONCLUSIONS:HRAS mutant cells are resistant to PI3K inhibition and our findings suggest the involvement of a signalling intersection of the MAPK and PI3K pathways at the level of ERK-TSC2, leading to persistent mTOR activity. mTOR inhibition alone or in combination with MAPK pathway inhibition may be a promising therapeutic strategy for this subset of HNSCC tumors.', 'PI3K/AKT/mTOR通路在头颈部鳞状细胞癌（HNSCC）中经常发生改变，使该途径成为合理的治疗靶点。研究人员使用流式细胞仪检测了HRAS G12V突变和HRAS野生型的细胞系对PI3K抑制剂的敏感性和细胞活力，随后检测HRAS过度表达、沉默对PI3K抑制剂alpelisib的敏感性，免疫印迹用于确定PI3K途径的活化，然后在HRAS突变细胞中测试MEK和mTOR抑制剂以确定它们的功效。HRAS突变细胞系对PI3K抑制剂无反应。 HRAS的过度表达可降低对PI3K抑制剂的易感性，而缺失或沉默则提高了敏感性。免疫印迹显示在HRAS突变/野生型细胞系中PI3K抑制剂皆可抑制AKT磷酸化，而突变体可维持mTOR下游的S6的磷酸化。靶向mTOR有效地降低了HRAS突变细胞的活力。研究人员随后发现ERK-TSC2-mTOR级联可作为PI3K抑制剂抗性的介质。HRAS突变细胞对PI3K抑制剂具有抗性，研究结果表明其参与了信号转导。MAPK和PI3K通路可在ERK-TSC2水平引发持续的mTOR活性。单独的mTOR抑制剂或与MAPK途径抑制剂组合的mTOR抑制可能是该亚组HNSCC肿瘤的有希望的治疗策略。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30115483', '.', 'preclinical', '4', 'alpelisib', 'alpelisib', 'alpelisib', 'alpelisib', 'alpelisib|alpelisib', '1', 'head and neck squamous cell cancer', 'head and neck squamous cell cancer', '头颈部肿瘤', 'na', 'resistance', 'EVI_001084', 'HRAS:CNV:::gain', 'HRAS', 'CNV', 'CNV', '.', '.', 'gain', 'OBJECTIVES:The PI3K/AKT/mTOR pathway is frequently altered in head and neck squamous cell cancer (HNSCC), making this pathway a logical therapeutic target. However, PI3K targeting is not universally effective. Biomarkers of response are needed to stratify patients likely to derive benefit and exclude those unlikely to respond.MATERIALS AND METHODS:We examined the sensitivity of cell lines with constitutively-active (G12V mutant) HRAS and wild-type HRAS to PI3K inhibition using flow cytometry and cell viability assays. We then overexpressed and silenced HRAS and measured sensitivity to the PI3K inhibitor BYL719. Immunoblotting was used to determine activation of the PI3K pathway. MEK and mTOR inhibitors were then tested in HRAS mutant cells to determine their efficacy.RESULTS:HRAS mutant cell lines were non-responsive to PI3K inhibition. Overexpression of HRAS led to reduced susceptibility to PI3K inhibition, while knockdown improved sensitivity. Immunoblotting revealed suppressed AKT phosphorylation upon PI3K inhibition in both wild-type and HRAS mutant cell lines, however mutant lines maintained phosphorylation of S6, downstream of mTOR. Targeting mTOR effectively reduced viability of HRAS mutant cells and we subsequently examined the ERK-TSC2-mTOR cascade as a mediator of resistance to PI3K inhibition.CONCLUSIONS:HRAS mutant cells are resistant to PI3K inhibition and our findings suggest the involvement of a signalling intersection of the MAPK and PI3K pathways at the level of ERK-TSC2, leading to persistent mTOR activity. mTOR inhibition alone or in combination with MAPK pathway inhibition may be a promising therapeutic strategy for this subset of HNSCC tumors.', 'PI3K/AKT/mTOR通路在头颈部鳞状细胞癌（HNSCC）中经常发生改变，使该途径成为合理的治疗靶点。研究人员使用流式细胞仪检测了HRAS G12V突变和HRAS野生型的细胞系对PI3K抑制剂的敏感性和细胞活力，随后检测HRAS过度表达、沉默对PI3K抑制剂alpelisib的敏感性，免疫印迹用于确定PI3K途径的活化，然后在HRAS突变细胞中测试MEK和mTOR抑制剂以确定它们的功效。HRAS突变细胞系对PI3K抑制剂无反应。 HRAS的过度表达可降低对PI3K抑制剂的易感性，而缺失或沉默则提高了敏感性。免疫印迹显示在HRAS突变/野生型细胞系中PI3K抑制剂皆可抑制AKT磷酸化，而突变体可维持mTOR下游的S6的磷酸化。靶向mTOR有效地降低了HRAS突变细胞的活力。研究人员随后发现ERK-TSC2-mTOR级联可作为PI3K抑制剂抗性的介质。HRAS突变细胞对PI3K抑制剂具有抗性，研究结果表明其参与了信号转导。MAPK和PI3K通路可在ERK-TSC2水平引发持续的mTOR活性。单独的mTOR抑制剂或与MAPK途径抑制剂组合的mTOR抑制可能是该亚组HNSCC肿瘤的有希望的治疗策略。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30115483', '.', 'preclinical', '4', 'alpelisib', 'alpelisib', 'alpelisib', 'alpelisib', 'alpelisib|alpelisib', '1', 'head and neck squamous cell cancer', 'head and neck squamous cell cancer', '头颈部肿瘤', 'na', 'sensitivity', 'EVI_001085', 'HRAS:CNV:::loss', 'HRAS', 'CNV', 'CNV', '.', '.', 'loss', 'OBJECTIVES:The PI3K/AKT/mTOR pathway is frequently altered in head and neck squamous cell cancer (HNSCC), making this pathway a logical therapeutic target. However, PI3K targeting is not universally effective. Biomarkers of response are needed to stratify patients likely to derive benefit and exclude those unlikely to respond.MATERIALS AND METHODS:We examined the sensitivity of cell lines with constitutively-active (G12V mutant) HRAS and wild-type HRAS to PI3K inhibition using flow cytometry and cell viability assays. We then overexpressed and silenced HRAS and measured sensitivity to the PI3K inhibitor BYL719. Immunoblotting was used to determine activation of the PI3K pathway. MEK and mTOR inhibitors were then tested in HRAS mutant cells to determine their efficacy.RESULTS:HRAS mutant cell lines were non-responsive to PI3K inhibition. Overexpression of HRAS led to reduced susceptibility to PI3K inhibition, while knockdown improved sensitivity. Immunoblotting revealed suppressed AKT phosphorylation upon PI3K inhibition in both wild-type and HRAS mutant cell lines, however mutant lines maintained phosphorylation of S6, downstream of mTOR. Targeting mTOR effectively reduced viability of HRAS mutant cells and we subsequently examined the ERK-TSC2-mTOR cascade as a mediator of resistance to PI3K inhibition.CONCLUSIONS:HRAS mutant cells are resistant to PI3K inhibition and our findings suggest the involvement of a signalling intersection of the MAPK and PI3K pathways at the level of ERK-TSC2, leading to persistent mTOR activity. mTOR inhibition alone or in combination with MAPK pathway inhibition may be a promising therapeutic strategy for this subset of HNSCC tumors.', 'PI3K/AKT/mTOR通路在头颈部鳞状细胞癌（HNSCC）中经常发生改变，使该途径成为合理的治疗靶点。研究人员使用流式细胞仪检测了HRAS G12V突变和HRAS野生型的细胞系对PI3K抑制剂的敏感性和细胞活力，随后检测HRAS过度表达、沉默对PI3K抑制剂alpelisib的敏感性，免疫印迹用于确定PI3K途径的活化，然后在HRAS突变细胞中测试MEK和mTOR抑制剂以确定它们的功效。HRAS突变细胞系对PI3K抑制剂无反应。 HRAS的过度表达可降低对PI3K抑制剂的易感性，而缺失或沉默则提高了敏感性。免疫印迹显示在HRAS突变/野生型细胞系中PI3K抑制剂皆可抑制AKT磷酸化，而突变体可维持mTOR下游的S6的磷酸化。靶向mTOR有效地降低了HRAS突变细胞的活力。研究人员随后发现ERK-TSC2-mTOR级联可作为PI3K抑制剂抗性的介质。HRAS突变细胞对PI3K抑制剂具有抗性，研究结果表明其参与了信号转导。MAPK和PI3K通路可在ERK-TSC2水平引发持续的mTOR活性。单独的mTOR抑制剂或与MAPK途径抑制剂组合的mTOR抑制可能是该亚组HNSCC肿瘤的有希望的治疗策略。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30089600', '.', 'clinical study', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_001087', 'ALK:nonsynonymous SNV:exon21:p.G1128A:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.G1128A', '.', 'OBJECTIVE:Acquired secondary mutations in the anaplastic lymphoma kinase (ALK) gene have been identified in ALK-rearranged non-small cell lung cancer (NSCLC) patients who are resistant to treatment with the ALK inhibitor crizotinib. We sought to uncover novel mutations that contribute to resistance in these patients.MATERIALS AND METHODS:Following clinical diagnosis and development of crizotinib treatment resistance, tissue and ctDNA samples were obtained from the 60-year-old patient and subjected to next-generation sequencing for identification of mutations contributing to drug resistance.RESULTS:We identified a novel acquired NSCLC ALK G1128A mutation in the ALK + NSCLC patient who progressed on crizotinib after a short partial response to the drug. This mutation, ALK G1128A, is located at the glycine loop (the P-loop) of the ALK tyrosine kinase domain. As a gain-of-function mutation, ALK G1128A increases kinase activity and transformation ability, perhaps conferring resistance to crizotinib.CONCLUSIONS:This case further illustrates the importance of comprehensive genomic profiling of resistant tumors for tailoring treatment decisions after disease progression on crizotinib in ALK + NSCLC in the era of rapidly developing new-generation ALK inhibitors and other therapeutic strategies.', '已经在ALK重排的非小细胞肺癌（NSCLC）患者中鉴定了间变性淋巴瘤激酶（ALK）基因的获得性二次突变，具有二次突变的患者对ALK抑制剂克唑替尼具有抗性，研究人员试图揭示导致这些患者抗药性的新突变。1名60岁的ALK +NSCLC患者在发生克唑替尼治疗耐药后，将其组织和ctDNA样品进行下一代测序，鉴定导致耐药性的突变。在ALK + NSCLC患者中发现了一种新的获得性ALK G1128A突变，该突变导致患者在克唑替尼的短暂部分反应后出现进展。ALK G1128A位于ALK酪氨酸激酶结构域的甘氨酸环（P环）。作为功​​能获得性突变，ALK G1128A可增加激酶活性和转化能力，可能赋予对克唑替尼的抗性。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29285266|PMID:25948633', '.', 'preclinical', '4', 'nazartinib', 'nazartinib', 'nazartinib', 'nazartinib', 'nazartinib|nazartinib', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001096', 'EGFR:nonsynonymous SNV:exon20:p.C797S<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<顺式>', '.', 'In a preclinical study, overexpression of EGFR C797S in addition to other EGFR activating mutations including L858R, T790M, and exon 19 deletion (L747_P753delinsS) conferred resistance to Nazartinib (EGF816) in transformed cells in culture (PMID:29285266).', '在临床前研究中，携带EGFR激活突变（包括L858R，T790M和外显子19缺失）的肿瘤细胞，同时存在EGFR C797S顺式突变的情况下可能对Nazartinib耐药。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29285266|PMID:25948633', '.', 'preclinical', '4', '.', '.', 'rociletinib', 'rociletinib', 'rociletinib|rociletinib', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001097', 'EGFR:nonsynonymous SNV:exon20:p.C797S<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<顺式>', '.', 'In a preclinical study, EGFR C797S conferred resistance to growth inhibition by Rociletinib (CO-1686) when expressed on the same allele as an EGFR exon 19 deletion mutation and T790M in transformed cells in culture (PMID: 25939061).', '在临床前研究中，携带EGFR激活突变（包括L858R，T790M和外显子19缺失）的肿瘤细胞，同时存在EGFR C797S顺式突变的情况下可能对rociletinib耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29978950', '.', 'clinical study', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001098', 'POLE:nonsynonymous SNV:.:.:inact', 'POLE', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'BACKGROUND:ALK-tyrosine kinase inhibitors (TKIs) have been proven effective for treating ALK-positive non-small cell lung cancer (NSCLC), although patients present with variable responses and disease progression courses. The detailed underlying molecular mechanisms require further investigation to yield a better prognosis.METHODS:Targeted next-generation sequencing (NGS) mutation profiling was performed on samples from 42 NSCLC patients confirmed positive for ALK rearrangements by fluorescence in situ hybridization or immunohistochemistry who experienced disease progression after crizotinib treatment.RESULTS:ALK rearrangements were not confirmed in six patients (14%) with other potential oncogenic drivers identified by NGS, who therefore did not respond to crizotinib and had significantly shorter overall survival (OS) compared to NGS ALK -positive patients. Fifteen ALK activating mutations were detected in 8 out of 26 post-treatment samples (31%), among which ALK L1196M and G1269A were the most common acquired mutations detected in half of the patients with ALK activating mutations. Dynamic monitoring of the genetic evolution in one patient revealed both spatial and temporal heterogeneity of resistant mechanisms during different ALK-TKI treatment courses. Activation of ALK downstream or bypass pathways was detected in patients without ALK activating mutations, such as genetic alterations in PIK3CA, MET, and KRAS. Interestingly, we identified two patients with acquired mutations in the DNA mismatch repair gene POLE, which resulted in a dramatically increased tumor mutation burden, and might contribute to the poor response to crizotinib.CONCLUSIONS:Heterogeneous resistant mechanisms have been identified and correlate to diverse responses to crizotinib. Comprehensive and dynamic mutation profiling is required to better predict clinical outcomes.', 'ALK-酪氨酸激酶抑制剂（TKIs）已被证实可有效治疗ALK阳性的非小细胞肺癌（NSCLC），但患者的反应和疾病进展过程有所不同，因此详细的潜在分子机制需要进一步研究。对42例NSCLC患者的样本进行靶向新一代测序（NGS）突变分析，这些患者通过荧光原位杂交或免疫组织化学证实ALK重排阳性且经历了疾病进展。克唑替尼治疗后，6例患者（14%）NGS显示ALK重排消失，但具有其他致癌驱动因子，与ALK重排阳性的患者相比，总生存期（OS）显著缩短。另外，在其他克唑替尼治疗后的患者中检测到15个ALK激活突变，其中ALK L1196M和G1269A是最常见的获得性突变，存在这些突变的患者同样对克唑替尼耐药。在没有ALK激活突变的患者中检测到ALK下游或旁路途径的激活，例如PIK3CA，MET和KRAS中的遗传改变。另外，研究人员确定了两名在DNA错配修复基因POLE中具有获得性突变的患者，该突变导致肿瘤突变负担显著增加，并可能导致对克唑替尼的不良反应。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29959202', '.', 'preclinical', '4', 'pertuzumab', 'pertuzumab', 'pertuzumab', '帕妥珠单抗', 'pertuzumab|帕妥珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001102', 'NRG1:FUS::SLC3A2-NRG1:', 'NRG1', 'FUS', 'FUS', '.', 'SLC3A2-NRG1', '.', 'We characterized the SLC3A2-NRG1 fusion gene in non-small cell lung cancer (NSCLC) and established an effective therapy for patients with SLC3A2-NRG1 fusion-positive cancer. The SLC3A2-NRG1 fusion product was composed of the SLC3A2 transmembrane domain and the EGF-like domain of the neuregulin 1 (NRG1) protein. The NRG1 family is classified as a ligand of the ERBB family. We identified ERBB3 and ERBB4 in the ERBB family as binding partners of the SLC3A2-NRG1 fusion protein via ligand and receptor binding assays. We confirmed that SLC3A2-NRG1 increased formation of a heterocomplex of ERBB3 with ERBB2. Activation of the ERBB2-ERBB3 heterocomplex by SLC3A2-NRG1 increased colony formation and tumor growth through PI3K-AKT and MAP kinase. The specific siRNAs for ERBB2 and ERBB3, pertuzumab, lumretuzumab, and afatinib all decreased ERBB2-ERBB3 heterocomplex formation, phosphorylation of each protein, and their downstream signaling. In addition, single treatment with pertuzumab, lumretuzumab, or afatinib decreased tumor volume and weight, whereas combination treatment with these drugs and taxol enhanced generation of cleaved caspase 3, PARP, and TUNEL-positive cells compared with each single treatment. Thus, the SLC3A2-NRG1 fusion gene plays an important role in lung cancer cell proliferation and tumor growth by promoting generation of the ERBB2-ERBB3 heterocomplex, its phosphorylation, and activation of the PI3K/ERK/mTOR signaling pathway. Inhibition of either ERBB2 or ERBB3 alone did not completely shut down downstream signaling of ERBB2 and ERBB3; however, inhibition of both ERBB2 and ERBB3 blocked downstream signaling activated by SLC3A2-NRG1 fusion. ERBB2 and ERBB3 might be promising targets for treatment of SLC3A2-NRG1-positive tumors. ', '研究人员在非小细胞肺癌（NSCLC）中发现了SLC3A2-NRG1融合基因，并为SLC3A2-NRG1融合阳性的癌症患者建立了有效的治疗方法。SLC3A2-NRG1融合产物由SLC3A2跨膜结构域和神经调节蛋白1（NRG1）的EGF样结构域组成。NRG1家族被归类为ERBB家族的配体。通过配体和受体结合分析将ERBB家族中的ERBB3和ERBB4鉴定为SLC3A2-NRG1融合蛋白的结合伴侣，证实SLC3A2-NRG1可增加ERBB3与ERBB2的异源复合物的形成。通过SLC3A2-NRG1激活ERBB2-ERBB3异源复合物，再通过PI3K-AKT和MAP激酶增加集落形成和肿瘤生长。帕妥珠单抗，lumretuzumab和阿法替尼均可降低ERBB2-ERBB3异源复合物形成、蛋白质的磷酸化及其下游信号传导。此外，使用帕妥珠单抗，lumretuzumab或阿法替尼的单一治疗可降低肿瘤体积和重量，而与这些单独治疗相比，用这些药物和紫杉醇的联合治疗可增强半胱天冬酶3裂解和PARP、TUNEL阳性细胞的产生。因此，SLC3A2-NRG1融合基因是通过促进ERBB2-ERBB3异源复合物的产生，进而磷酸化引起PI3K/ERK/mTOR信号传导途径的活化，在肺癌细胞增殖和肿瘤生长中起重要作用。单独抑制ERBB2或ERBB3并未完全关闭ERBB2和ERBB3的下游信号传导，而同时抑制ERBB2和ERBB3可阻断由SLC3A2-NRG1融合激活的下游信号传导。所以，ERBB2和ERBB3可能是治疗SLC3A2-NRG1阳性肿瘤的希望靶标。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29959202', '.', 'preclinical', '4', 'lumretuzumab', 'lumretuzumab', 'lumretuzumab', 'lumretuzumab', 'lumretuzumab|lumretuzumab', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001103', 'NRG1:FUS::SLC3A2-NRG1:', 'NRG1', 'FUS', 'FUS', '.', 'SLC3A2-NRG1', '.', 'We characterized the SLC3A2-NRG1 fusion gene in non-small cell lung cancer (NSCLC) and established an effective therapy for patients with SLC3A2-NRG1 fusion-positive cancer. The SLC3A2-NRG1 fusion product was composed of the SLC3A2 transmembrane domain and the EGF-like domain of the neuregulin 1 (NRG1) protein. The NRG1 family is classified as a ligand of the ERBB family. We identified ERBB3 and ERBB4 in the ERBB family as binding partners of the SLC3A2-NRG1 fusion protein via ligand and receptor binding assays. We confirmed that SLC3A2-NRG1 increased formation of a heterocomplex of ERBB3 with ERBB2. Activation of the ERBB2-ERBB3 heterocomplex by SLC3A2-NRG1 increased colony formation and tumor growth through PI3K-AKT and MAP kinase. The specific siRNAs for ERBB2 and ERBB3, pertuzumab, lumretuzumab, and afatinib all decreased ERBB2-ERBB3 heterocomplex formation, phosphorylation of each protein, and their downstream signaling. In addition, single treatment with pertuzumab, lumretuzumab, or afatinib decreased tumor volume and weight, whereas combination treatment with these drugs and taxol enhanced generation of cleaved caspase 3, PARP, and TUNEL-positive cells compared with each single treatment. Thus, the SLC3A2-NRG1 fusion gene plays an important role in lung cancer cell proliferation and tumor growth by promoting generation of the ERBB2-ERBB3 heterocomplex, its phosphorylation, and activation of the PI3K/ERK/mTOR signaling pathway. Inhibition of either ERBB2 or ERBB3 alone did not completely shut down downstream signaling of ERBB2 and ERBB3; however, inhibition of both ERBB2 and ERBB3 blocked downstream signaling activated by SLC3A2-NRG1 fusion. ERBB2 and ERBB3 might be promising targets for treatment of SLC3A2-NRG1-positive tumors. ', '研究人员在非小细胞肺癌（NSCLC）中发现了SLC3A2-NRG1融合基因，并为SLC3A2-NRG1融合阳性的癌症患者建立了有效的治疗方法。SLC3A2-NRG1融合产物由SLC3A2跨膜结构域和神经调节蛋白1（NRG1）的EGF样结构域组成。NRG1家族被归类为ERBB家族的配体。通过配体和受体结合分析将ERBB家族中的ERBB3和ERBB4鉴定为SLC3A2-NRG1融合蛋白的结合伴侣，证实SLC3A2-NRG1可增加ERBB3与ERBB2的异源复合物的形成。通过SLC3A2-NRG1激活ERBB2-ERBB3异源复合物，再通过PI3K-AKT和MAP激酶增加集落形成和肿瘤生长。帕妥珠单抗，lumretuzumab和阿法替尼均可降低ERBB2-ERBB3异源复合物形成、蛋白质的磷酸化及其下游信号传导。此外，使用帕妥珠单抗，lumretuzumab或阿法替尼的单一治疗可降低肿瘤体积和重量，而与这些单独治疗相比，用这些药物和紫杉醇的联合治疗可增强半胱天冬酶3裂解和PARP、TUNEL阳性细胞的产生。因此，SLC3A2-NRG1融合基因是通过促进ERBB2-ERBB3异源复合物的产生，进而磷酸化引起PI3K/ERK/mTOR信号传导途径的活化，在肺癌细胞增殖和肿瘤生长中起重要作用。单独抑制ERBB2或ERBB3并未完全关闭ERBB2和ERBB3的下游信号传导，而同时抑制ERBB2和ERBB3可阻断由SLC3A2-NRG1融合激活的下游信号传导。所以，ERBB2和ERBB3可能是治疗SLC3A2-NRG1阳性肿瘤的希望靶标。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29959202', '.', 'preclinical', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001104', 'NRG1:FUS::SLC3A2-NRG1:', 'NRG1', 'FUS', 'FUS', '.', 'SLC3A2-NRG1', '.', 'We characterized the SLC3A2-NRG1 fusion gene in non-small cell lung cancer (NSCLC) and established an effective therapy for patients with SLC3A2-NRG1 fusion-positive cancer. The SLC3A2-NRG1 fusion product was composed of the SLC3A2 transmembrane domain and the EGF-like domain of the neuregulin 1 (NRG1) protein. The NRG1 family is classified as a ligand of the ERBB family. We identified ERBB3 and ERBB4 in the ERBB family as binding partners of the SLC3A2-NRG1 fusion protein via ligand and receptor binding assays. We confirmed that SLC3A2-NRG1 increased formation of a heterocomplex of ERBB3 with ERBB2. Activation of the ERBB2-ERBB3 heterocomplex by SLC3A2-NRG1 increased colony formation and tumor growth through PI3K-AKT and MAP kinase. The specific siRNAs for ERBB2 and ERBB3, pertuzumab, lumretuzumab, and afatinib all decreased ERBB2-ERBB3 heterocomplex formation, phosphorylation of each protein, and their downstream signaling. In addition, single treatment with pertuzumab, lumretuzumab, or afatinib decreased tumor volume and weight, whereas combination treatment with these drugs and taxol enhanced generation of cleaved caspase 3, PARP, and TUNEL-positive cells compared with each single treatment. Thus, the SLC3A2-NRG1 fusion gene plays an important role in lung cancer cell proliferation and tumor growth by promoting generation of the ERBB2-ERBB3 heterocomplex, its phosphorylation, and activation of the PI3K/ERK/mTOR signaling pathway. Inhibition of either ERBB2 or ERBB3 alone did not completely shut down downstream signaling of ERBB2 and ERBB3; however, inhibition of both ERBB2 and ERBB3 blocked downstream signaling activated by SLC3A2-NRG1 fusion. ERBB2 and ERBB3 might be promising targets for treatment of SLC3A2-NRG1-positive tumors. ', '研究人员在非小细胞肺癌（NSCLC）中发现了SLC3A2-NRG1融合基因，并为SLC3A2-NRG1融合阳性的癌症患者建立了有效的治疗方法。SLC3A2-NRG1融合产物由SLC3A2跨膜结构域和神经调节蛋白1（NRG1）的EGF样结构域组成。NRG1家族被归类为ERBB家族的配体。通过配体和受体结合分析将ERBB家族中的ERBB3和ERBB4鉴定为SLC3A2-NRG1融合蛋白的结合伴侣，证实SLC3A2-NRG1可增加ERBB3与ERBB2的异源复合物的形成。通过SLC3A2-NRG1激活ERBB2-ERBB3异源复合物，再通过PI3K-AKT和MAP激酶增加集落形成和肿瘤生长。帕妥珠单抗，lumretuzumab和阿法替尼均可降低ERBB2-ERBB3异源复合物形成、蛋白质的磷酸化及其下游信号传导。此外，使用帕妥珠单抗，lumretuzumab或阿法替尼的单一治疗可降低肿瘤体积和重量，而与这些单独治疗相比，用这些药物和紫杉醇的联合治疗可增强半胱天冬酶3裂解和PARP、TUNEL阳性细胞的产生。因此，SLC3A2-NRG1融合基因是通过促进ERBB2-ERBB3异源复合物的产生，进而磷酸化引起PI3K/ERK/mTOR信号传导途径的活化，在肺癌细胞增殖和肿瘤生长中起重要作用。单独抑制ERBB2或ERBB3并未完全关闭ERBB2和ERBB3的下游信号传导，而同时抑制ERBB2和ERBB3可阻断由SLC3A2-NRG1融合激活的下游信号传导。所以，ERBB2和ERBB3可能是治疗SLC3A2-NRG1阳性肿瘤的希望靶标。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29880583', '.', 'case report', '4', 'dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', 'brain tumor', 'brain tumor', '脑部肿瘤', 'na', 'resistance', 'EVI_001108', 'BRAF:nonsynonymous SNV:exon13:p.L514V:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon13', 'p.L514V', '.', 'BRAFV600E hyperactivates ERK and signals as a RAF inhibitor-sensitive monomer. Although RAF inhibitors can produce impressive clinical responses in patients with mutant BRAF tumors, the mechanisms of resistance to these drugs are incompletely characterized. Here, we report a complete response followed by clinical progression in a patient with a BRAFV600E-mutant brain tumor treated with dabrafenib. Whole-exome sequencing revealed a secondary BRAFL514V mutation at progression that was not present in the pretreatment tumor. Expressing BRAFV600E/L514V induces ERK signaling, promotes RAF dimer formation, and is sufficient to confer resistance to dabrafenib. Newer RAF dimer inhibitors and an ERK inhibitor are effective against BRAFL514V-mediated resistance. Collectively, our results validate a novel biochemical mechanism of RAF inhibitor resistance mediated by a secondary mutation, emphasizing that, like driver mutations in cancer, the spectrum of mutations that drive resistance to targeted therapy are heterogeneous and perhaps emerge with a lineage-specific prevalence.Significance: In contrast to receptor tyrosine kinases, in which secondary mutations are often responsible for acquired resistance, second-site mutations in BRAF have not been validated in clinically acquired resistance to RAF inhibitors. We demonstrate a secondary mutation in BRAF (V600E/L514V) following progression on dabrafenib and confirm functionally that this mutation is responsible for resistance. ', 'BRAF V600E突变可过度激活ERK。虽然RAF抑制剂在BRAF突变的肿瘤患者中产生了令人印象深刻的临床反应，但是这些药物的耐药机制尚未完全证实。研究人员报告了用dabrafenib治疗BRAF V600E突变的脑肿瘤患者的完全反应与临床进展情况。全外显子组测序显示治疗前肿瘤中不存在的继发性BRAF L514V突变，治疗后发现表达BRAF V600E/L514V双突变，赋予肿瘤细胞对dabrafenib产生抗性。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29857126', '.', 'preclinical', '4', 'piribedil', 'piribedil', 'piribedil', 'piribedil', 'piribedil|piribedil', '3', ' acute myeloid leukemia', ' acute myeloid leukemia', '白血病', 'na', 'sensitivity', 'EVI_001109', 'MLL1:FUS::MLL1-WDR5:', 'MLL1', 'FUS', 'FUS', '.', 'MLL1-WDR5', '.', 'Targeting WT MLL for the treatment of MLL-r leukemia, which is highly aggressive and resistant to chemotherapy, has been shown to be a promising strategy. However, drug treatments targeting WT MLL are lacking. We used an in vitro histone methyltransferase assay to screen a library consists of 592 FDA-approved drugs for MLL1 inhibitors by measuring alterations in HTRF signal and found that Piribedil represented a potent activity. Piribedil specifically inhibited the proliferation of MLL-r cells by inducing cell-cycle arrest, apoptosis and myeloid differentiation with little toxicity to the non-MLL cells. Mechanism study showed Piribedil blocked the MLL1-WDR5 interaction and thus selectively reduced MLL1-dependent H3K4 methylation. Importantly, MLL1 depletion induced gene expression that was similar to that induced by Piribedil and rendered the MLL-r cells resistant to Piribedil-induced toxicity, revealing Piribedil exerted anti-leukemia effects by targeting MLL1. Furthermore, both the Piribedil treatment and MLL1 depletion sensitized the MLL-r cells to doxorubicin-induced apoptosis. Our study support the hypothesis that Piribedil could serve as a new drug for the treatment of MLL-r AML and provide new insight for further optimization of targeting MLL1 HMT activity.', '具有MLL1-WDR5的急性髓细胞白血病（AML）呈现高度侵袭性和对化疗的抗性，目前缺乏针对MLL1-WDR5-AML的药物治疗。研究人员使用体外组蛋白甲基转移酶试验在592种FDA批准的MLL1抑制剂组成的文库中通过测量HTRF信号的变化，发现Piribedil具有强效活性。Piribedil可通过诱导细胞周期停滞，细胞凋亡和骨髓分化特异性地抑制MLL1-WDR5-AML细胞的增殖，对非MLL1-WDR5-AML细胞几乎没有毒性。研究显示，Piribedil可阻断MLL1-WDR5相互作用，从而选择性地减少MLL1依赖性H3K4甲基化，揭示Piribedil通过靶向MLL1发挥抗白血病作用。此外，Piribedil治疗和MLL1耗竭均可使MLL1-WDR5-AML细胞对多柔比星诱导的细胞凋亡敏感。该研究支持Piribedil作为治疗MLL1-WDR5-AML的新药的假设，并为进一步优化靶向MLL1活性提供新的见解。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29807113', '.', 'preclinical', '4', 'danusertib', 'danusertib', 'danusertib', 'danusertib', 'danusertib|danusertib', '2', 'head and neck squamous cell carcinoma', 'head and neck squamous cell carcinoma', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001111', 'KMT2D:CNV:::loss', 'KMT2D', 'CNV', 'CNV', '.', '.', 'loss', 'To address the unmet need for effective biomarker-driven targeted therapy for human papillomavirus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) and cervical cancer, we conducted a high-throughput drug screen using 1122 compounds in 13 HPV-positive and 11 matched HPV-negative cell lines. The most effective drug classes were inhibitors of polo-like kinase, proteasomes, histone deacetylase, and Aurora kinases. Treatment with a pan-Aurora inhibitor, danusertib, led to G2M arrest and apoptosis in vitro. Furthermore, danusertib decreased tumor size compared with controls in patient derived xenograft models of HNSCC. To identify biomarkers predicting response, we determined associations between mutations and drug sensitivity. Our data and the Genomics of Drug Sensitivity in Cancer database showed that cancer cells with KMT2D mutations were more sensitive to Aurora kinase inhibitors than were cells without mutations. Knockdown of KMT2D in wild-type cells led to increased Aurora kinase inhibitor-induced apoptosis. We identified Aurora kinase inhibitors as effective and understudied drugs in HNSCC and CESC. This is the first published study to demonstrate that mutations in KMT2D, which are common in many cancers, correlate with drug sensitivity in two independent datasets.', '为了找寻人乳头瘤病毒（HPV）相关的头颈部鳞状细胞癌（HNSCC）和宫颈癌（CESC）的有效生物标志物，研究人员对13种HPV阳性细胞系、11种化合物和11个匹配的HPV阴性细胞系进行了高通量药物筛选。最有效的药物类别是polo样激酶，蛋白酶体，组蛋白脱乙酰基酶和Aurora激酶的抑制剂。用pan-Aurora抑制剂danusertib作用HPV阳性细胞系可导致体外细胞G2M阻滞和凋亡。此外，与患者来源的HNSCC异种移植模型相比，danusertib降低了肿瘤大小。为了确定可预测反应的生物标志物，研究人员确定了突变和药物敏感性之间的关联。数据和癌症药物敏感性基因组学数据库显示，具有KMT2D突变的癌细胞对Aurora激酶抑制剂比对没有突变的细胞更敏感。在敲除KMT2D的野生型细胞中，Aurora激酶抑制剂诱导的细胞凋亡增加。研究人员将Aurora激酶抑制剂鉴定为HNSCC和CESC中有效且未被充分研究的药物。这是首次发表的研究，证明KMT2D的突变在许多癌症中很常见，与药物敏感性相关。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29768711', '.', 'preclinical', '4', 'trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'Langerhans cell histiocytosis', 'Langerhans cell histiocytosis', '朗格汉斯细胞组织细胞增生症', 'na', 'resistance', 'EVI_001114', 'MAP2K1:nonframeshift deletion:exon3:p.L98_K104delinsQ:', 'MAP2K1', 'nonframeshift deletion', 'Exact_pos', 'exon3', 'p.L98_K104delinsQ', '.', 'Patients with Langerhans cell histiocytosis (LCH) harbor BRAF V600E and activating mutations of MAP2K1/MEK1 in 50% and 25% of cases, respectively. We evaluated a patient with treatment-refractory LCH for mutations in the RAS-RAF-MEK-ERK pathway and identified a novel mutation in the MAP2K1 gene resulting in a p.L98_K104 > Q deletion and predicted to be auto-activating. During treatment with the MEK inhibitor trametinib, the patient\'s disease showed significant progression. In vitro characterization of the MAP2K1 p.L98_K104 > Q deletion confirmed its effect on cellular activation of the ERK pathway and drug resistance.', '25%-50%的朗格汉斯细胞组织细胞增生症(LCH)患者携带BRAF V600E和激活MAP2K1/MEK1突变。研究人员评估了难治性LCH的患者的RAS-RAF-MEK-ERK途径中的突变，并鉴定了MAP2K1基因中的新突变，发现p.L98_K104delinsQ突变。在用MEK抑制剂trametinib治疗期间，患者的疾病出现显著的进展，表明该突变可能导致肿瘤对BRAF抑制剂耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29704676', '.', 'case report', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001118', 'EGFR:nonsynonymous SNV:exon20:p.P794L:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.P794L', '.', 'A 36-year-old life-long non-smoking Caucasian woman presented in July 2012 with a history of cough and dyspnea on exertion that had persisted for two years. She was diagnosed with a T4N2M0 non-small cell adenocarcinoma with an EGFR exon 19 deletion. The treatment trajectory and radiological images are shown in Figures 1 and 2. After 2 months of treatment with gefitinib, the cancer was restaged as T2aN2M0. A pneumonectomy of the right lung was performed followed by adjuvant chemotherapy / radiation therapy (RT) and completed in August 2013. Two months after finishing RT, a chest CT revealed multiple small nodules in the left hemithorax. The patient restarted gefitinib until radiologic progression in Sep 2015. A re-biopsy revealed adenocarcinoma with an EGFR exon 19 deletion and a c.2369C>T p.(T790M) mutation. In November 2015 she was enrolled in an osimertinib compassionate use program until July 2017 when a chest CT showed worsening of the coarse nodular parenchymal opacities. A liquid biopsy for ctDNA sequencing (Illumina TST-15) was obtained and revealed an EGFR triple mutation: p.(E746_S752del) and p.(P794L) in cis with p.(T790M). The p.(P794L) mutation was found in approximately one third of the reads containing p.(T790M). The neutral p.(P794L) mutation is located in the hinge region of the ATP cleft and is a known mechanism of resistance towards the discontinued irreversible EGFR inhibitor carnetinib [1]. Afatinib is clinically active in many TKI-pretreated patients with NSCLC harboring uncommon EGFR mutations. Heigener et al have demonstrated some activity of afatinib in patients with tumors carrying T790M and exon 20 insertion mutations[2]. Protein modeling indicated that afatinib can bind the EGFR p.(T790M)/p.(P794L) ATP cleft. The calculated lower binding affinity and higher Scorpion score (Table 1) suggests a stronger binding of afatinib to EGFR p.(T790M)/p.(P794L) than osimertinib. We, therefore, hypothesized that the p.(P794L) mutation may not interfere with afatinib binding. The patient started afatinib monotherapy 40 mg daily in August 2017 with a significant clinical and radiologic improvement after one month of therapy, and still alive six months after starting on afatinib. There was no need for dose reduction and minimal irritated skin around toenails resolved by applying Emo Cort cream. ', '一名36岁没有吸烟史的高加索女性2012年7月出现咳嗽和呼吸困难，持续了两年后，被诊断出患有T4N2M0非小细胞腺癌，EGFR exon19del。在用吉非替尼治疗2个月后，癌症被重新定为T2aN2M0。进行右肺全肺切除术，然后进行辅助化疗/放射治疗（RT），完成RT后两个月，胸部CT显示左半胸有多个小结节。患者在2015年9月重新开始使用吉非替尼直至放射学进展。再次活组织检查显示癌种为腺癌，具有EGFR exon19del和c.2369C>T p.T790M。 2015年11月，她参加了osimertinib同情使用计划，直到2017年7月胸部CT显示粗糙的结节性实质混浊恶化。ctDNA测序显示EGFR三重突变：p.E746_S752del、p.P794L与顺式p.T790M。在1/3含有p.T790M的组织中中发现了p.P794L突变。p.P794L突变位于ATP裂口的铰链区，是已知的对不可逆EGFR抑制剂carnetinib的耐药机制。Afatinib在许多TKI预治疗的具有罕见的EGFR突变的NSCLC患者中具有临床活性。研究人员假设p.P794L突变可能不会干扰afatinib结合。该患者于2017年8月开始每天40mg afatinib单药治疗，治疗一个月后临床和放射学改善显著，并且在afatinib治疗后6个月仍然存活。无需减少剂量，并且可以减少脚趾甲周围刺激性皮肤的发生。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:dabrafenib_Revised:10/2019', '.', 'guideline:FDA', '1', '.', '.', 'trametinib + dabrafenib', '曲美替尼 + 达拉非尼', 'trametinib + dabrafenib|曲美替尼 + 达拉非尼', '4', 'advanced or metastatic anaplastic thyroid cancer (ATC)', 'thyroid cancer', '甲状腺癌', '甲状腺癌', 'sensitivity', 'EVI_001119', 'BRAF:nonsynonymous SNV:exon15:p.V600E:.', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.V600E', '.', '.', '这是FDA批准的第一种针对这种侵袭性甲状腺癌(ATC)患者的治疗方案。该批准是基于BRF117019（NCT02034110）研究，这是一项9对列的非随机试验，共23例可评估的BRAF V600E突变ATC患者。总有效率为61%（95% CI: 39%, 80%），部分缓解率57%，完全缓解率4%。64%的患者反应持续时间在6个月以上。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:dacomitinib_Revised:09/2018|PMID:28958502', 'NCT01774721', 'guideline:FDA', '1', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001120', 'EGFR:nonsynonymous SNV:exon21:p.L858R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', 'ARCHER1050是一个国际多中心的，III期开放临床研究，在全球7个国家，71个中心进行。研究入组了组织学或细胞学确诊的IIIB/IV期NSCLC，至少有1个靶病灶，且靶病灶既往没有接受过放疗。要求患者在入组前接受了EGFR突变检测，肿瘤组织检测患者为EGFR敏感突变（exon19del或L858R突变，伴或不伴T790M突变）。主要的排除标准包括：混合型的组织学或细胞学类型，少见的EGFR突变，伴脑或脑膜转移，既往有或目前可疑弥漫性非感染性肺炎或间质性肺炎。患者随机1：1分配接受dacomitinib或吉非替尼，分层因素包括种族（日本 vs 中国 vs 其他亚裔 vs 非亚裔），EGFR突变类型（exon19del vs L858R）。主要研究终点为独立评估委员会（IRC）评估的意向性人群（ITT）的无进展生存期（PFS），次要研究终点包括研究者评估的PFS，IRC和研究者评估的ORR，OS，30个月的OS率。其他次要终点包括安全性评估和患者报告的生活质量。2013年5月9日至2015年3月20日，研究共筛查720例患者，其中452例符合入组标准，随机分配接受dacomitinib（227例）或吉非替尼（225例）。截至2017年7月29日，dacomitinib组患者的中位治疗周期为15.3个月，吉非替尼组患者的中位治疗周期为12个月。目前，两组分别还有66例（29%）和38例（17%）的患者仍在接受治疗。ITT人群的中位随访时间为22.1个月（95%CI：20.3-23.9），根据IRC的评估，dacomitinib组136例（60%）患者进展，吉非替尼组179例（80%）患者进展。dacomitinib组和吉非替尼组的中位PFS分别为14.7个月（95%CI：11.1-16.6）和9.2个月（95%CI：9.1-11.0）。安全性分析：两组患者发生任意级别的不良事件（AE）的患者分别为226例（>99%）和220例（98%）。Dacomitinib组最常见的AE为腹泻，甲沟炎，痤疮和口腔炎。吉非替尼组最常见的AE为腹泻，AST升高，ALT升高。两组患者3-4度AE发生率对比：痤疮（14% vs 0%），腹泻（8% vs 1%），AST升高（1% vs 8%）。两组患者任意原因的4度AE发生率相当，均为2%。治疗相关的严重AE发生率，Dacomitinib组为9%，吉非替尼组为4%。ARCHER 1050研究是第一个随机III期临床研究，直接对比二代EGFR TKI和标准的一代EGFR TKI吉非替尼，一线治疗EGFR突变的晚期NSCLC患者。结果显示，Dacomitinib的PFS显著优于吉非替尼组，这一研究结果支持Dacomitinib用于EGFR突变的晚期NSCLC一线治疗，为这类患者提供了一个新的治疗选择。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:dacomitinib_Revised:09/2018|PMID:28958502', 'NCT01774721', 'guideline:FDA', '1', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001121', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', 'ARCHER1050是一个国际多中心的，III期开放临床研究，在全球7个国家，71个中心进行。研究入组了组织学或细胞学确诊的IIIB/IV期NSCLC，至少有1个靶病灶，且靶病灶既往没有接受过放疗。要求患者在入组前接受了EGFR突变检测，肿瘤组织检测患者为EGFR敏感突变（exon19del或L858R突变，伴或不伴T790M突变）。主要的排除标准包括：混合型的组织学或细胞学类型，少见的EGFR突变，伴脑或脑膜转移，既往有或目前可疑弥漫性非感染性肺炎或间质性肺炎。患者随机1：1分配接受dacomitinib或吉非替尼，分层因素包括种族（日本 vs 中国 vs 其他亚裔 vs 非亚裔），EGFR突变类型（exon19del vs L858R）。主要研究终点为独立评估委员会（IRC）评估的意向性人群（ITT）的无进展生存期（PFS），次要研究终点包括研究者评估的PFS，IRC和研究者评估的ORR，OS，30个月的OS率。其他次要终点包括安全性评估和患者报告的生活质量。2013年5月9日至2015年3月20日，研究共筛查720例患者，其中452例符合入组标准，随机分配接受dacomitinib（227例）或吉非替尼（225例）。截至2017年7月29日，dacomitinib组患者的中位治疗周期为15.3个月，吉非替尼组患者的中位治疗周期为12个月。目前，两组分别还有66例（29%）和38例（17%）的患者仍在接受治疗。ITT人群的中位随访时间为22.1个月（95%CI：20.3-23.9），根据IRC的评估，dacomitinib组136例（60%）患者进展，吉非替尼组179例（80%）患者进展。dacomitinib组和吉非替尼组的中位PFS分别为14.7个月（95%CI：11.1-16.6）和9.2个月（95%CI：9.1-11.0）。安全性分析：两组患者发生任意级别的不良事件（AE）的患者分别为226例（>99%）和220例（98%）。Dacomitinib组最常见的AE为腹泻，甲沟炎，痤疮和口腔炎。吉非替尼组最常见的AE为腹泻，AST升高，ALT升高。两组患者3-4度AE发生率对比：痤疮（14% vs 0%），腹泻（8% vs 1%），AST升高（1% vs 8%）。两组患者任意原因的4度AE发生率相当，均为2%。治疗相关的严重AE发生率，Dacomitinib组为9%，吉非替尼组为4%。ARCHER 1050研究是第一个随机III期临床研究，直接对比二代EGFR TKI和标准的一代EGFR TKI吉非替尼，一线治疗EGFR突变的晚期NSCLC患者。结果显示，Dacomitinib的PFS显著优于吉非替尼组，这一研究结果支持Dacomitinib用于EGFR突变的晚期NSCLC一线治疗，为这类患者提供了一个新的治疗选择。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30179868', '.', 'case report', '4', 'sorafenib ', 'sorafenib ', 'sorafenib ', '索拉非尼', 'sorafenib |索拉非尼', '4', 'gastrointestinal stromal tumors', 'gastrointestinal stromal tumors', '胃肠间质瘤', 'na', 'resistance', 'EVI_001122', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'BACKGROUND:Sorafenib has shown efficacy in patients with imatinib-, sunitinib-, and regorafenib-resistant gastrointestinal stromal tumors (GISTs). No biomarker is currently available for predicting response to sorafenib in patients with GIST.METHODS:We herein report 3 patients with imatinib-, sunitinib-, and regorafenib-resistant metastasized GISTs, who were treated with sorafenib. Besides receptor tyrosine kinase KIT and platelet-derived growth factor receptor α, also BRAF was tested for mutations.RESULTS:Sorafenib therapy induced a long-term disease control in 2 out of 3 patients over a period of 49 and 19 months, respectively. Sorafenib-responsive GISTs were BRAF wild-type, whereas the sorafenib-resistant GIST carried a BRAF V600E mutation.CONCLUSION:We confirm sorafenib as an effective therapeutic option in patients with imatinib-, sunitinib-, and regorafenib-resistant GISTs. Larger studies are required to corroborate whether BRAF mutation may predict sorafenib resistance in GISTs.', '研究显示索拉非尼对伊马替尼，舒尼替尼和瑞格非尼耐药的胃肠道间质瘤（GIST）患者有效。目前没有生物标志物可用于预测GIST患者对索拉非尼的反应。研究人员报道了3例接受索拉非尼治疗的伊马替尼，舒尼替尼和瑞格非尼耐药的转移性GIST患者。除受体酪氨酸激酶KIT和血小板衍生生长因子受体α外，还对BRAF进行突变检测。结果：索拉非尼治疗分别在49和19个月的时间内诱导了2名患者的长期疾病控制。对索拉非尼敏感的GIST为BRAF野生型，而索拉非尼耐药的GIST携带BRAF V600E突变。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30246138', '.', 'case report', '4', 'dabrafenib + trametinib', 'dabrafenib + trametinib', 'trametinib + dabrafenib', '曲美替尼 + 达拉非尼', 'trametinib + dabrafenib|曲美替尼 + 达拉非尼', '4', 'low grade serous ovarian cancer ', 'low grade serous ovarian cancer ', '卵巢癌', 'na', 'sensitivity', 'EVI_001124', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'Low grade serous ovarian cancer (LGSOC) is a slowly growing, relatively chemoresistant neoplasm that is associated with a more favorable prognosis, especially compared to the disease\'s high-grade serous counterpart. We recount a case involving a 47-year-old, heavily pretreated LGSOC patient who presented with an elevated CA-125 of 1047 U/mL during her recent course of pemetrexed therapy. Thereafter, she underwent molecular profiling, which revealed a BRAF V600E mutation; accordingly, the patient was administered dabrafenib and trametinib combination therapy, a regimen that resulted in a precipitous decline of her CA-125 to 35 U/mL following the 6th cycle. The patient\'s favorable response to BRAF and MEK 1/2 inhibitor therapy underscores the significance of molecular profile testing and the use of targeted therapy regardless of tissue origin, especially in cases for whom standard management is limited or ineffective.', '一例47岁的低级别浆液性卵巢癌（LGSOC）患者在培美曲塞治疗过程中出现CA-125升高，值为1047 U/mL，基因检测发现了BRAF V600E突变。给予患者dabrafenib和trametinib联合治疗6个周期后，其CA-125急剧下降至35 U/mL。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30233215', '.', 'case report', '4', 'osimertinib + bevacizumab + brigatinib', 'osimertinib + bevacizumab + brigatinib', 'osimertinib + bevacizumab + brigatinib', '奥希替尼 + 贝伐珠单抗 +布加替尼', 'osimertinib + bevacizumab + brigatinib|奥希替尼 + 贝伐珠单抗 +布加替尼', '4', 'pulmonary adenocarcinoma', 'pulmonary adenocarcinoma', '肺癌', '肺癌', 'sensitivity', 'EVI_001126', 'EGFR:nonsynonymous SNV:exon20:p.C797S<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<顺式>', '.', 'Osimertinib is commonly used in pulmonary adenocarcinoma patients who are resistant to first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and carry the T790M mutation. However, the use of osimertinib may result in the development of further resistance, most commonly via the cis-C797S mutation. Herein, we report a case of a lung cancer patient harboring triple EGFR mutations of L858R, T790M, and cis-C797S who was treated with a combination of osimertinib, bevacizumab, and brigatinib. The above 3 mutations were detected by circulating tumor DNA analysis after osimertinib treatment. Subsequently, the patient received combination therapy of osimertinib and bevacizumab; the partial relief obtained was negated by later disease progression. The regimen was then changed to osimertinib, bevacizumab, and brigatinib combination therapy. Partial remission was observed, and a significant reduction in EGFR mutations was detected. This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and cis-C797S. These combination therapies may provide potential novel treatment options for pulmonary adenocarcinoma patients.', 'Osimertinib常用于对第一代表皮生长因子受体（EGFR）酪氨酸激酶抑制剂具有抗性并携带T790M突变的肺腺癌患者。然而，使用osimertinib可能导致进一步的耐药性，最常见的是cis-C797S突变所致。研究人员报道了一例肺癌患者，该患者携带L858R，T790M和cis-C797S的三重EGFR突变，用osimertinib，bevacizumab和brigatinib联合治疗。在osimertinib处理后通过循环肿瘤DNA分析检测上述3个突变。随后，患者接受了osimertinib和贝伐单抗的联合治疗，获得部分缓解，后发生疾病进展方案被否定。将该方案改为osimertinib，bevacizumab和brigatinib联合治疗，观察到部分缓解，并且检测到EGFR突变的显著减少。该病例首次证明1）osimertinib联合bevacizumab可显著减轻非小细胞肺癌患者的osimertinib耐药性，减轻肿瘤生长和呼吸道症状; 2）osimertinib，bevacizumab和brigatinib联合用药可治疗存在L858R，T790M和cis-C797S三重EGFR突变的肺腺癌。这些组合疗法可为肺腺癌患者提供潜在的新治疗选择。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30219714', '.', 'preclinical', '4', 'FPTI', 'FPTI', 'FPTI', 'FPTI', 'FPTI|FPTI', '0', 'synovial sarcoma', 'synovial sarcoma', '滑膜肉瘤', 'na', 'sensitivity', 'EVI_001130', 'SYT:FUS::SYT-SSX1:', 'SYT', 'FUS', 'FUS', '.', 'SYT-SSX1', '.', 'Synovial sarcoma (SS) is characterized by a tumour specific chromosomal translocation t(X;18) (p11;q11) which results in the formation of SYT-SSX1 fusion protein. This fusion protein represents a clear therapeutic target and molecules specifically targeting SYT-SSX1 fusion protein are currently not available. In this study, SYT-SSX1 fusion protein sequence was retrieved from Uniprot and 3D structure was generated using I-TASSER modeling program. A structure based computational screening approach has been employed using Glide docking software to identify potential SYT-SSX1 small molecule inhibitors that bind to the junction region of the fusion protein. The obtained inhibitors were further filtered based on the docking score and ADME/T properties. Ten best fit compounds were chosen for in vitro studies. The anti-proliferative activities of these 10 compounds were screened in Yamato, ASKA (carries SYT-SSX1 fusion protein) and other sarcoma cell lines such as A673, 143B to understand the specificity of inhibition of the chosen compounds. The in vitro activity was compared against HEK293 cell lines. The compound 5-fluoro-3-(1-phenyl-1H-tetraazol-5-yl)-1H-indole (FPTI) was found to be selectively cytotoxic in synovial sarcoma cell lines (Yamato and ASKA) and this compound also showed insignificant anti proliferative activity on other cell lines. Further, target gene expression study confirmed that FPTI treatment down-regulated SYT-SSX1 and modulated its downstream target genes. Cell cycle analysis revealed the involvement of an apoptotic mechanism of cell death. Further experimental validations may elucidate the therapeutic potentials of FPTI against SYT-SSX1 fusion protein.', '滑膜肉瘤（SS）的特征在于肿瘤特异性染色体易位t（X; 18）（p11; q11），其导致SYT-SSX1融合蛋白的形成。该融合蛋白代表了明确的治疗靶标，目前尚无特异性靶向SYT-SSX1融合蛋白的分子。在该研究中，从Uniprot中检索SYT-SSX1融合蛋白序列，并使用I-TASSER建模程序生成3D结构。使用基于结构的计算筛选方法，用Glide对接软件来鉴定结合融合蛋白连接区潜在的SYT-SSX1小分子抑制剂。根据对接评分和ADME/T特性进一步过滤获得的抑制剂。选择十种最适合的化合物用于体外研究。在Yamato，ASKA（携带SYT-SSX1融合蛋白）和其他肉瘤细胞系如A673,143B中筛选这10种化合物的抗增殖活性，以了解抑制所选化合物的特异性。将体外活性与HEK293细胞系进行比较。发现化合物5-氟-3-（1-苯基-1H-四唑-5-基）-1H-吲哚（FPTI）在滑膜肉瘤细胞系（Yamato和ASKA）中具有选择性细胞毒性，对其他细胞系也具有抗增殖活性。此外，靶基因表达研究证实FPTI处理下调SYT-SSX1并调节其下游靶基因。细胞周期分析揭示了细胞死亡的细胞凋亡机制的参与。进一步的实验验证可以阐明FPTI对SYT-SSX1融合蛋白的治疗潜力。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30201002', '.', 'preclinical', '4', 'JQ1', 'JQ1', 'JQ1', 'JQ1', 'JQ1|JQ1', '0', 'pancreatic ductal adenocarcinoma', 'pancreatic ductal adenocarcinoma', '胰腺癌', 'na', 'sensitivity', 'EVI_001135', 'FBP1:CNV:.:.:gain', 'FBP1', 'CNV', 'CNV', '.', '.', 'gain', 'BACKGROUND:Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal tumor types worldwide. BET inhibitors display anti-tumor activity in pancreatic cancer, however the cells often develop resistance after a long-term treatment and the underlying molecular basis is not fully understood.METHODS:Drug screening assay in Fructose-1, 6-biphosphatase (FBP1) knockdown or overexpressing pancreatic cancer cells was performed. Tumor cell motility, FBP1 protein and mRNA changes were investigated after BET inhibitors treatment. The interaction between TRIM28 and FBP1 after BET inhibitors treatment was examined by Co-immunoprecipitation (IP) and GST pull-down. The relationship between FBP1 and c-Myc was examined by western blot, RT-qPCR and immunohistochemistry (IHC).RESULTS:The expression of FBP1 protein increased the sensitivity of pancreatic cancer cells to JQ1. Furthermore, we showed that JQ1 stabilized FBP1 protein level by disrupting the interaction between FBP1 and TRIM28 in pancreatic cancer cells. Moreover, we demonstrated that FBP1 promoted c-Myc degradation through disrupting the ERK-c-Myc axis.CONCLUSIONS:FBP1 modulates the sensitivity of pancreatic cancer cells to BET inhibitors by decreasing the expression of c-Myc. These findings highlight FBP1 could be used as a therapeutic niche for patient-tailored therapies.', '胰腺导管腺癌（PDAC）是世界上最致命的肿瘤类型之一。BET抑制剂在胰腺癌中显示出抗肿瘤活性，但是长期治疗后细胞通常会产生耐药性，并且潜在的分子基础尚未完全了解。果糖-1,6-双磷酸酶（FBP1）敲除或过表达的胰腺癌细胞在BET抑制剂处理后研究肿瘤细胞运动性、FBP1蛋白和mRNA变化。通过共免疫沉淀（IP）和GST pull-down检测BET抑制剂处理后TRIM28和FBP1之间的相互作用。采用免疫印迹，RT-qPCR和免疫组化（IHC）检测FBP1与c-Myc的关系。结果：FBP1蛋白的表达增加了胰腺癌细胞对JQ1的敏感性。此外，我们发现JQ1通过破坏胰腺癌细胞中FBP1和TRIM28之间的相互作用来稳定FBP1蛋白水平。此外，我们证实FBP1通过破坏ERK-c-Myc轴促进c-Myc降解。结论：FBP1通过降低c-Myc的表达来调节胰腺癌细胞对BET抑制剂的敏感性。这些发现突出了FBP1可以作为患者定制疗法的治疗契机。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30200630', '.', 'clinical study', '4', 'bevacizumab', 'bevacizumab', 'bevacizumab', '贝伐珠单抗', 'bevacizumab|贝伐珠单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_001136', 'PTPRT:nonsynonymous SNV:.:.:inact', 'PTPRT', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'BACKGROUND:Bevacizumab-based regimens are used as standard treatments for colorectal cancer. Unfortunately, there are no established predictive markers for bevacizumab response.METHODS:Tumor samples from 36 metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy were analyzed by next-generation sequencing of all coding exons of more than 400 genes. Single gene and signaling pathway analyses were performed to correlate genomic data with response.RESULTS:Among the genes most frequently mutated in our cohort, only mutations in PTPRT, a phosphatase involved in JAK/STAT signaling, were associated with response status, with deleterious mutations being enriched in non-responders. Pathway analysis revealed that deleterious mutations in genes of the JAK/STAT pathway, namely in PTPRT and the related gene PTPRD, correlated with resistance. Mutations in RTK/PI3K/RAS, Wnt and TGFβ pathways did not associate with response. Lack of response was observed in all patients with deleterious mutations or copy number loss of PTPRT/PTPRD (n = 10), compared to only 30.8% (n = 8) of patients without such alterations (relative risk, 3.25; 95% CI, 1.83⁻5.79, p = 0.0003). Similarly, PTPRT/PTPRD deleterious alterations were associated with shorter progression-free survival, an association that was retained in multivariate analysis (HR, 3.33; 95% CI, 1.47⁻7.54; p = 0.0038).CONCLUSION:Deleterious alterations in PTPRT/PTPRD are potential biomarkers for bevacizumab resistance.', '以贝伐单抗为基础的方案常用作结直肠癌的标准疗法，但尚未建立贝伐单抗反应的预测标志物。对来自36例贝伐单抗加化学疗法治疗后的转移性结直肠癌患者的400多个基因的外显子进行下一代测序进行分析，并进行单基因和信号通路分析，以将基因组数据与药物响应相关联。在队列最常突变的基因中，只有PTPRT（一种参与JAK/STAT信号传导的磷酸酶）的突变与响应状态相关。通路分析显示，JAK/STAT途径的有害基因突变，即PTPRT和PTPRD突变与抗性相关。 RTK/PI3K/RAS，Wnt和TGFβ途径中的突变与药物反应无关。所有具有PTPRT/PTPRD有害突变或拷贝数丢失的患者均缺乏药物反应（n = 10），PTPRT/PTPRD有害改变与较短的无进展生存期相关。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30200630', '.', 'clinical study', '4', 'bevacizumab', 'bevacizumab', 'bevacizumab', '贝伐珠单抗', 'bevacizumab|贝伐珠单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_001137', 'PTPRD:nonsynonymous SNV:.:.:inact', 'PTPRD', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'BACKGROUND:Bevacizumab-based regimens are used as standard treatments for colorectal cancer. Unfortunately, there are no established predictive markers for bevacizumab response.METHODS:Tumor samples from 36 metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy were analyzed by next-generation sequencing of all coding exons of more than 400 genes. Single gene and signaling pathway analyses were performed to correlate genomic data with response.RESULTS:Among the genes most frequently mutated in our cohort, only mutations in PTPRT, a phosphatase involved in JAK/STAT signaling, were associated with response status, with deleterious mutations being enriched in non-responders. Pathway analysis revealed that deleterious mutations in genes of the JAK/STAT pathway, namely in PTPRT and the related gene PTPRD, correlated with resistance. Mutations in RTK/PI3K/RAS, Wnt and TGFβ pathways did not associate with response. Lack of response was observed in all patients with deleterious mutations or copy number loss of PTPRT/PTPRD (n = 10), compared to only 30.8% (n = 8) of patients without such alterations (relative risk, 3.25; 95% CI, 1.83⁻5.79, p = 0.0003). Similarly, PTPRT/PTPRD deleterious alterations were associated with shorter progression-free survival, an association that was retained in multivariate analysis (HR, 3.33; 95% CI, 1.47⁻7.54; p = 0.0038).CONCLUSION:Deleterious alterations in PTPRT/PTPRD are potential biomarkers for bevacizumab resistance.', '以贝伐单抗为基础的方案常用作结直肠癌的标准疗法，但尚未建立贝伐单抗反应的预测标志物。对来自36例贝伐单抗加化学疗法治疗后的转移性结直肠癌患者的400多个基因的外显子进行下一代测序进行分析，并进行单基因和信号通路分析，以将基因组数据与药物响应相关联。在队列最常突变的基因中，只有PTPRT（一种参与JAK/STAT信号传导的磷酸酶）的突变与响应状态相关。通路分析显示，JAK/STAT途径的有害基因突变，即PTPRT和PTPRD突变与抗性相关。 RTK/PI3K/RAS，Wnt和TGFβ途径中的突变与药物反应无关。所有具有PTPRT/PTPRD有害突变或拷贝数丢失的患者均缺乏药物反应（n = 10），PTPRT/PTPRD有害改变与较短的无进展生存期相关。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30196106', 'EudraCT number:2009-017817-31', 'clinical trial - phase1', '4', 'epertinib', 'epertinib', 'epertinib', 'epertinib', 'epertinib|epertinib', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001140', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'BACKGROUND:Dose-escalation of epertinib (S-222611), a new potent oral EGFR/HER2 inhibitor, has established a recommended daily dose of 800 mg in patients with solid tumours. In this study, we have recruited a larger number of patients to assess further the safety, tolerability, pharmacokinetics (PKs) and antitumour activity.PATIENTS AND METHODS:Patients with solid tumours expressing EGFR or HER2 received a single dose of epertinib at 800 mg on Day 1 to assess PK over 7 days, followed by continuous once-daily dosing from Day 8.RESULTS:We treated 76 patients with breast (n = 27), upper gastrointestinal (GI; n = 30), head and neck (n = 12) or renal cancers (n = 7). Epertinib was well-tolerated with mostly grade I and II adverse events (AEs). The most frequent AE was diarrhoea, which was generally manageable with loperamide. The objective response rate (ORR) in patients with heavily pretreated breast and upper GI cancers was 16.0% (4 PRs) and 8.3% (1CR, 1PR), respectively. All six responding patients had HER2-positive tumours; the ORR for HER2-positive breast and upper GI cancer populations was 19.0% and 20.0%. Partial response in the brain disease of one breast cancer patient lasted 7.5 months.CONCLUSION:Once-daily dosing of epertinib at 800 mg was well-tolerated and demonstrated promising antitumour activity in patients with heavily pretreated HER2-positive breast and upper GI cancer, including those with brain metastases.', 'epertinib（S-222611）是一种新型强效口服EGFR/ERBB2抑制剂，实体肿瘤患者的推荐日剂量为800 mg。在这项研究中，研究人员招募了更多的患者，以进一步评估其安全性，耐受性，药代动力学（PKs）和抗肿瘤活性。患者和方法：表达EGFR或ERBB2的实体瘤患者接受单剂量的epertinib，剂量为800 mg/d，第1天评估PK后停药7天，然后从第8天开始连续每日一次给药。结果：研究人员治疗了76名乳腺癌患者（n = 27），上消化道（GI; n = 30），头颈部（n = 12）或肾癌（n = 7）。这些患者的epertinib耐受性良好，主要出现I级和II级不良事件（AEs）。最常见的AE是腹泻，通常可用洛哌丁胺治疗。重度预治疗的乳腺癌和上胃肠癌患者的客观缓解率（ORR）分别为16.0%（4个PR）和8.3%（1CR，1PR），这6名患者均有ERBB2阳性突变。HER2阳性乳腺癌和上消化道癌症人群的ORR分别为19.0%和20.0%。一名乳腺癌患者脑部疾病的部分反应持续7.5个月。结论：每日一次服用800mg epertinib耐受良好，可对ERBB2阳性乳腺癌和上消化道癌患者进行抗肿瘤治疗，包括有脑转移的人。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30192383', '.', 'clinical study', '4', 'afatinib + bevacizumab', 'afatinib + bevacizumab', 'afatinib + bevacizumab', '阿法替尼 + 贝伐珠单抗', 'afatinib + bevacizumab|阿法替尼 + 贝伐珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001143', 'EGFR:nonsynonymous SNV:exon20:p.T790M:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'BACKGROUND:Preclinical studies suggested that the addition of bevacizumab could overcome acquired resistance (AR) to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). The aim of this study was to evaluate the clinical efficacy and safety of a combination of afatinib and bevacizumab after AR.METHODS:Patients with EGFR-mutant non-small cell lung cancer after AR were enrolled during any line of therapy. Afatinib was prescribed at 30 mg, and 15 mg/kg bevacizumab was administered every 3 weeks until progression.RESULTS:Between October 2014 and May 2017, 32 eligible patients were evaluated. The mutation subtypes were Del-19 (20 [63%]), L858R (11 [34%]), and L861Q (1 [3%]). T790M was detected in 14 patients (44%). The median number of prior regimens was 4 (range, 1-10). Six patients obtained a partial response, and 23 had stable disease; this resulted in an objective response rate (ORR) of 18.8% (95% confidence interval [CI], 7.2%-36.4%) and a disease control rate of 90.7% (95% CI, 75.0%-98.0%). The median progression-free survival (PFS) was 6.3 months (95% CI, 3.9-8.7 months). The ORRs and median PFS times of T790M+ and T790M- patients were 14.3% and 22.2%, respectively, and 6.3 and 7.1 months, respectively; those of Del-19 and L858R patients were 20.0% and 11.1%, respectively, and 6.3 and 5.1 months, respectively. Grade 3 or higher adverse events (incidence ≥ 10%) included paronychia (25%), hypertension (41%), and proteinuria (19%). There were no treatment-related deaths, interstitial lung disease, or bevacizumab-associated severe bleeding.CONCLUSIONS:Afatinib plus bevacizumab demonstrated clinical efficacy and safety after AR to EGFR TKIs and could be a therapeutic salvage option for T790M- populations.', '临床前研究表明，贝伐单抗可以克服患者对表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKIs）的获得性抗性（AR）。本研究的目的是评估AR后阿法替尼和贝伐单抗联合治疗的临床疗效和安全性。方法：EGFR-TKI治疗后出现AR的EGFR突变型非小细胞肺癌患者在任何治疗期间入组。阿法替尼初始处方为30 mg，每3周施用15 mg/kg贝伐单抗直至进展。结果：2014年10月-2017年5月期间，对32名符合条件的患者进行了评估。突变亚型是Del-19（20 [63%]），L858R（11 [34%]）和L861Q（1 [3%]）。在14名患者（44%）中检测到T790M。6例患者获得部分缓解，23例患者病情稳定，客观反应率（ORR）为18.8%（95%置信区间[CI]，7.2%-36.4%），疾病控制率为90.7%（95%CI，75.0%-98.0%）。中位无进展生存期（PFS）为6.3个月（95%CI，3.9-8.7个月）。 T790M +和T790M-患者的ORR分别为14.3%和22.2%，中位PFS分别为6.3和7.1个月; Del-19和L858R患者ORR分别为20.0%和11.1%，中位PFS分别为6.3和5.1个月。3级或更高的不良事件（发生率≥10%）包括甲沟炎（25%），高血压（41%）和蛋白尿（19%）。没有与治疗相关的死亡，间质性肺病或贝伐单抗相关的严重出血。结论：阿法替尼联合贝伐单抗对EGFR TKIs治疗后的AR具有临床疗效和安全性，可能是T790M群体的治疗性补救选择。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:talazoparib_Revised:08/2018|PMID:30110579', 'NCT01945775', 'guideline:FDA', '1', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_001144', 'BRCA2:.:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'talazoparib对BRCA1和BRCA2（BRCA1/2）种系突变的晚期乳腺癌患者具有抗肿瘤活性。研究人员进行了一项随机，开放标签的3期临床试验。以2：1的比例分配，患有晚期乳腺癌和种系BRCA1/2突变的患者接受talazoparib（1 mg每日一次）或医生选择的标准单药治疗（卡培他滨，艾日布林，吉西他滨或长春瑞滨连续21天循环）。主要终点是无进展生存期，通过盲法独立中心评价进行评估。结果：431例接受随机分组的患者中，287人接受talazoparib，144人接受标准治疗。talazoparib组中位无进展生存期显著长于标准治疗组（8.6个月vs5.6个月;疾病进展或死亡风险比，0.54; 95%置信区间[CI]，0.41-0.71; P <0.001）。死亡的中期中位数风险比为0.76（95%CI，0.55-1.06; P = 0.11 ）。talazoparib组的客观缓解率高于标准治疗组（62.6%vs27.2%;优势比5.0; 95%CI，2.9~8.8; P <0.001）。接受talazoparib治疗的患者中有55%发生血液学3-4级不良事件（主要是贫血），38%接受标准治疗的患者发生血液学3-4级不良事件（主要是贫血）;32%和38%的患者发生了非血液学3级不良事件。患者报告的结果观察到显著的总体改善和临床恶化的显著延迟。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:talazoparib_Revised:08/2018|PMID:30110579', 'NCT01945775', 'guideline:FDA', '1', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_001145', 'BRCA1:.:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'talazoparib对BRCA1和BRCA2（BRCA1/2）种系突变的晚期乳腺癌患者具有抗肿瘤活性。研究人员进行了一项随机，开放标签的3期临床试验。以2：1的比例分配，患有晚期乳腺癌和种系BRCA1/2突变的患者接受talazoparib（1 mg每日一次）或医生选择的标准单药治疗（卡培他滨，艾日布林，吉西他滨或长春瑞滨连续21天循环）。主要终点是无进展生存期，通过盲法独立中心评价进行评估。结果：431例接受随机分组的患者中，287人接受talazoparib，144人接受标准治疗。talazoparib组中位无进展生存期显著长于标准治疗组（8.6个月vs5.6个月;疾病进展或死亡风险比，0.54; 95%置信区间[CI]，0.41-0.71; P <0.001）。死亡的中期中位数风险比为0.76（95%CI，0.55-1.06; P = 0.11 ）。talazoparib组的客观缓解率高于标准治疗组（62.6%vs27.2%;优势比5.0; 95%CI，2.9~8.8; P <0.001）。接受talazoparib治疗的患者中有55%发生血液学3-4级不良事件（主要是贫血），38%接受标准治疗的患者发生血液学3-4级不良事件（主要是贫血）;32%和38%的患者发生了非血液学3级不良事件。患者报告的结果观察到显著的总体改善和临床恶化的显著延迟。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:palbociclib_Revised: 2/2018', '.', 'guideline:FDA', '1', '.', '.', 'palbociclib + fulvestrant', '哌柏西利 + 氟维司群', 'palbociclib + fulvestrant|哌柏西利 + 氟维司群', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001148', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', '.', '基于一项名为 PALOMA-3 的 III 期临床研究，现在palbociclib可以与氟维司群联合应用于HR+/HER2-的乳腺癌治疗。PALOMA-3 是随机（2:1），多中心，双盲的3期试验，目的是评估palbociclib（每日一次 125 mg，四分之三周重复）与氟维司群的组合，相比氟维司群（第1周期的1和15天肌肉注射500 mg，然后在后续每28天一个周期的第1天注射）与安慰剂的组合治疗HR+/HER2- 转移性乳腺癌疾病进展中或内分泌治疗之后的妇女，两组无进展生存期之间的差异。无进展生存期被定义为疾病有进展或任何原因造成死亡之前的时间。PALOMA-3是一个多中心试验，全球有150多个中心521位患者参与。Palbociclib联合氟维司群治疗组的无进展生存期（PFS）为9.5月（95%CI：9.2，11.0），对照组安慰剂联合氟维司群为4.6月（95%CI：3.5-5.6）（HR = 0.461，95%CI：0.360-0.591, p<0.0001）。由研究者评估存在可测量病灶患者的客观缓解率（ORR）为 24.6%，对照组为 10.9%。palbociclib联合氟维司群组的缓解持续时间为9.3月，对照组为7.6月。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30217491', '.', 'case report', '4', 'cabozantinib', 'cabozantinib', 'cabozantinib', '卡博替尼', 'cabozantinib|卡博替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001159', 'ROS1:FUS:.:.-ROS1:.', 'ROS1', 'FUS', 'FUS', '.', '.-ROS1', '.', 'Crizotinib and ceritinib are effective first-line treatments for ROS1-positive NSCLC.2 Unfortunately, unlike for ALK or EGFR-positive NSCLC, there is no approved second-line targeted therapy that can be offered over chemotherapy once resistance develops. There is very limited and conflicting data regarding ceritinib as a second-line TKI, with report of partial response seen in 1 patient but disease progression in a separate report of 2 patients.3, 5 In our three patients who received second-line ceritinib, it was ineffective in controlling systemic and intracranial disease, despite its efficacy in the first-line setting. Prior studies have found that ceritinib and entrectinib are not effective in treating crizotinib resistant patients, but that lorlatinib may be.3, 6, 7 Preclinical data, and two, single-patient case reports, have suggested cabozantinib can be effective in such patients, by binding to ROS1 despite resistant solvent front mutation.8-11 Here, we report four patients who received cabozantinib and achieved 100% disease control rate, 25% objective response rate and PFS ranging from 4.9 to 13.8 months (Table 1). To our knowledge, we report for the first time the efficacy of cabozantinib in patients with primary ceritinib resistance, and its apparent intracranial activity in patients with secondary crizotinib and primary ceritinib resistance. Patient 3, for example, had longer stable brain metastases on cabozantinib than on crizotinib or ceritinib. Due to lack of tissue, we were unable to characterize the crizotinib-resistance mutations that developed in these four patients that were ultimately susceptible to cabozantinib. It is encouraging that regardless of the respective mutation that developed in each of the four patients, they all responded to cabozantinib.', 'crizotinib和ceritinib是ROS1阳性NSCLC的有效一线治疗方法，与ALK或EGFR阳性的NSCLC不同，一旦出现耐药性，就没有经过批准的二线靶向治疗，目前关于ceritinib作为二线TKI的数据非常有限且相互矛盾。相关研究中，1例患者报告部分缓解，2例患者单独报告疾病进展。接受二线ceritinib治疗的患者的治疗结果显示，尽管ceritinib在一线治疗中有效，但其在控制全身和颅内疾病方面无效。曾有研究发现，ceritinib和entrectinib对crizotinib耐药的患者无效，但lorlatinib可能有效。临床前数据和两例单一病例报告表明cabozantinib对此类患者有效，尽管有抗药性溶剂前突变，但仍然可与ROS1结合。本研究中，研究人员报告了4例接受cabozantinib治疗的继发性crizotinib耐药和/或原发性ceritinib耐药的ROS1阳性NSCLC患者，实现了100%的疾病控制率，25%的客观缓解率，PFS为4.9~13.8个月。研究人员首次报道了cabozantinib对原发性ceritinib耐药患者的疗效，以及其对合并继发性crizotinib和原发性ceritinib耐药患者的明显颅内活动的作用。cabozantinib比crizotinib或ceritinib上更能控制脑转移的稳定。尽管用药后患者又各自发生了相应的突变，但依旧对cabozantinib有反应。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30098066', '.', 'preclinical', '4', 'trametinib + taselisib', 'trametinib + taselisib', 'trametinib + taselisib', '曲美替尼 + taselisib', 'trametinib + taselisib|曲美替尼 + taselisib', '0', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001171', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', 'Compensatory activation of the signal transduction pathways is one of the major obstacles for the targeted therapy of non-small cell lung cancer (NSCLC). Herein, we present the therapeutic strategy of combined targeted therapy against the MEK and phosphoinositide-3 kinase (PI3K) pathways for acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in NSCLC. We investigated the efficacy of combined trametinib plus taselisib therapy using experimentally established EGFR-TKI-resistant NSCLC cell lines. The results showed that the feedback loop between MEK/ERK and PI3K/AKT pathways had developed in several resistant cell lines, which caused the resistance to single-agent treatment with either inhibitor alone. Meanwhile, the combined therapy successfully regulated the compensatory activation of the key intracellular signals and synergistically inhibited the cell growth of those cells in vitro and in vivo. The resistance mechanisms for which the dual kinase inhibitor therapy proved effective included (MET) mesenchymal-epithelial transition factor amplification, induction of epithelial-to-mesenchymal transition (EMT) and EGFR T790M mutation. In further analysis, the combination therapy induced the phosphorylation of p38 MAPK signaling, leading to the activation of apoptosis cascade. Additionally, long-term treatment with the combination therapy induced the conversion from EMT to mesenchymal-to-epithelial transition in the resistant cell line harboring EMT features, restoring the sensitivity to EGFR-TKI. In conclusion, our results indicate that the combined therapy using MEK and PI3K inhibitors is a potent therapeutic strategy for NSCLC with the acquired resistance to EGFR-TKIs.', '信号转导途径的补偿性激活是非小细胞肺癌（NSCLC）靶向治疗的主要障碍之一。研究人员提出针对MEK和磷酸肌醇-3激酶（PI3K）途径的组合靶向治疗，用于治疗对EGFR-TKI具有获得性抗性的NSCLC患者。他们利用实验建立的EGFR-TKI抗性NSCLC细胞系研究了曲美替尼与taselisib联合治疗的疗效。结果显示MEK/ERK和PI3K/AKT途径之间的反馈环在几种抗性细胞系中均有发展，这种发展导致单药治疗的抗性，而联合治疗可成功地调节细胞内关键信号的代偿性激活，并在体外和体内协同抑制这些细胞的生长。双激酶抑制剂治疗在包括（MET）间充质-上皮细胞转换因子扩增，上皮-间质转化（EMT）和EGFR T790M突变等抗性机制中有显著疗效。在进一步分析中，联合疗法可诱导p38、MAPK信号传导的磷酸化，导致凋亡级联的激活。此外，联合疗法的长期治疗诱导了具有EMT特征的抗性细胞系中从EMT向间充质至上皮转变的转化，恢复了对EGFR-TKI的敏感性。总之，结果表明，使用MEK和PI3K抑制剂的联合治疗是NSCLC的有效治疗策略，可针对EGFR-TKI的获得性抗性。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282', 'NCT01988493', 'clinical trial - phase2', '4', 'tepotinib', 'tepotinib', 'tepotinib', 'tepotinib', 'tepotinib|tepotinib', '2', 'Hepatocellular carcinoma', 'Hepatocellular carcinoma', '肝癌', 'na', 'sensitivity', 'EVI_001175', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', '试验纳入90例MET+的晚期肝细胞肝癌患者，要求肝功能评分CHILD-PUGH A级，ECOG评分0-1，既往未接受全身治疗，MET的判定必须是免疫组化2+或3+。患者按照1：1分为2组，tepotinib组或索拉非尼组。tepotinib组的剂量为500mg，一日一次；索拉非尼组的剂量为400mg，一日2次。主要终点：TTP，次要终点：安全性，PFS，OS，肿瘤缓解。TTP：tepotinib组2.8月，sorafenib组1.4月；HR (90% CI): 0.42 (0.26, 0.70);p = 0.0043)。mPFS：tepotinib组2.8月，sorafenib组1.4月; HR (90% CI): 0.53 (0.33, 0.84);p = 0.0229)。mOS：tepotinib 组9.3 个月，sorafenib 组8.6个月；HR [90%CI] ：0.73 [0.43, 1.12];p = 0.3039)。ORR：tepotinib组 10.5%  ，sorafenib组 0%。DCR：tepotinib组50%，sorafenib组21.6%。在MET+的亚洲晚期肝癌患者中，tepotinib对比索拉非尼可延长TTP及PFS，并且安全性可以接受。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:regorafenib_Revised: 4/2017', '.', 'guideline:FDA', '1', 'regorafenib', 'regorafenib', 'regorafenib', '瑞戈非尼', 'regorafenib|瑞戈非尼', '4', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001176', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', 'FDA批准regorafenib用于KRAS野生型的转移性结直肠癌患者的治疗，该审批基于一项包含760例经治转移性结直肠癌患者的研究结果。随机分配到regorafenib加最佳支持治疗组的患者，中位总生存时间为6.4个月，而接受安慰剂加最佳支持治疗的患者的中位生存时间仅为5个月。Regorafenib组和安慰剂组的中位无进展生存时间分别为2个月和1.7个月。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:lorlatinib_Revised:11/2018', '.', 'guideline:FDA', '1', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '4', 'lung cancer', 'lung cancer', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_001178', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '该批准基于215例ALK阳性转移性NSCLC患者，之前用一种或多种ALK激酶抑制剂治疗（研究B7461001;NCT01970865）。 患者的总缓解率（ORR）达到48%（95% CI: 42%-55%），完全缓解率为4%，部分缓解率为44%。 估计的中位反应持续时间为12.5个月（95% CI:8.4-23.7）。在这项试验中，69%的患者有过大脑转移瘤历史，颅内缓解率达到60%（95% CI:49%-70%），完全缓解率为21%和部分缓解率为38%，估计的中位反应持续时间为19.5个月（95% CI:12.4-未达到）。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29997994', '.', 'case report', '4', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001179', 'EGFR:CNV:::KDD', 'EGFR', 'CNV', 'CNV', '.', '.', 'KDD', 'A 63-year-old Chinese female, who was a non-smoker, presented to our hospital for evaluation of a left lung mass on physical examination. A computed tomography (CT) scan showed a mass in the superior lobe of the left lung, and close to a pleural nodule (Figure 1). For staging purposes, surgery was performed. Hematoxylin and eosin staining of the surgical specimen showed a typical morphology for adenocarcinoma cells and surgical specimens from the left lobe tumor and pleural nodes (2.3 cm × 1.3 cm × 1.0 cm) showed lung adenocarcinoma (Figure 2). The immunohistochemical results [TTF-1 (+), NapsinA (+), CK7 (+)] According to the 7th edition of TNM staging, the patient was classified as stage IV (T1N0M1). The patient was wild-type for sensitive EGFR variants, including EGFR 18–21, by ARMS (AmoyDx, Xiamen, China) detection. Using an NGS assay (Illumina, San Diego, CA, USA), we found that the tumor had EGFR-KDD (3D Medicines, Shanghai, China) (Figure 3), and the most common types of EGFR mutations were wild. The patient received icotinib (125 mg/tid) treatment and showed a stable tumor response according to the Response Evaluation Criteria in Solid Tumors guidelines (version 1.1). During treatment with icotinib, there were no treatment-related adverse events, including hepatic and renal function, gastrointestinal reactions, rashes, and cordis damage. To date, the disease is stable after 11 months and she is continuing treatment with icotinib. Our case is the first report of an EGFR-KDD mutation in the Asian population. Considering this rare EGFR mutation and response to TKI treatment, we conclude that the incidence of rare EGFR gene mutations in NSCLC patients should be studied.', '一名63岁的中国女性，非吸烟者，计算机断层扫描（CT）显示左肺上叶肿块，靠近胸膜结节。左叶肿瘤和胸膜淋巴结（2.3 cm×1.3 cm×1.0 cm）的手术标本显示肺腺癌。免疫组织化学结果[TTF-1（+），NapsinA（+），CK7（+）]，根据TNM分期，患者被定义为IV期（T1N0M1）。通过NGS发现肿瘤具有EGFR-KDD，并且最常见的EGFR突变类型皆为是野生型。患者接受了icotinib（125 mg/tid）治疗，并根据标准指南（1.1版）评估实体肿瘤反应，结果显示具有稳定的肿瘤反应。在用icotinib治疗期间，没有与治疗相关的不良事件，包括肝和肾功能，胃肠道反应，皮疹和心脏损伤。迄今为止，该疾病在治疗11个月后是稳定的，并且患者继续用icotinib治疗。该案例是第一例亚洲人群中的EGFR-KDD突变报告。考虑到这种罕见的EGFR突变对TKI治疗的反应，研究人员认为应该注意NSCLC患者中罕见EGFR基因突变的发生率。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30271179', '.', 'case report', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'intrahepatic cholangiocarcinoma', 'intrahepatic cholangiocarcinoma', '肝内胆管癌', 'na', 'sensitivity', 'EVI_001183', 'BRCA2:.:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'olaparib是一种口服聚PARP抑制剂，在BRCA1和BRCA2（BRCA1/2）种系突变相关的乳腺癌和卵巢癌中具有活性。目前没有使用olaparib治疗BRCA1/2突变的肝内胆管细胞癌的报道。该研究旨在观察olaparib单药治疗难治性BRCA1/2突变型肝内胆管细胞癌（ICC）患者的疗效和安全性，他们分析了用olaparib治疗的BRCA突变的难治性晚期ICC患者的临床记录。给予患者olaparib（口服400mg，每日两次），随访11个月，在olaparib治疗4周后评估临床肿瘤反应，然后每8周评估一次（两个治疗周期）。通过计算机断层扫描（CT）确认患者获得部分反应，体液分析显示肿瘤标志物CA19.9，CA50和CA125水平显著降低，生活质量显著提高。主要不良事件是疲劳，血小板减少，白细胞减少和贫血，这些都可通过药物治疗。患者仍在接受治疗。olaparib治疗BRCA突变相关的难治性晚期ICC是有效的，并且可以耐受不良反应。应进行大规模研究以进一步采用基因组分析，这可能有助于临床医生确定适合ICC治疗的生物标志物。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30271179', '.', 'case report', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'intrahepatic cholangiocarcinoma', 'intrahepatic cholangiocarcinoma', '肝内胆管癌', 'na', 'sensitivity', 'EVI_001184', 'BRCA1:.:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'olaparib是一种口服聚PARP抑制剂，在BRCA1和BRCA2（BRCA1/2）种系突变相关的乳腺癌和卵巢癌中具有活性。目前没有使用olaparib治疗BRCA1/2突变的肝内胆管细胞癌的报道。该研究旨在观察olaparib单药治疗难治性BRCA1/2突变型肝内胆管细胞癌（ICC）患者的疗效和安全性，他们分析了用olaparib治疗的BRCA突变的难治性晚期ICC患者的临床记录。给予患者olaparib（口服400mg，每日两次），随访11个月，在olaparib治疗4周后评估临床肿瘤反应，然后每8周评估一次（两个治疗周期）。通过计算机断层扫描（CT）确认患者获得部分反应，体液分析显示肿瘤标志物CA19.9，CA50和CA125水平显著降低，生活质量显著提高。主要不良事件是疲劳，血小板减少，白细胞减少和贫血，这些都可通过药物治疗。患者仍在接受治疗。olaparib治疗BRCA突变相关的难治性晚期ICC是有效的，并且可以耐受不良反应。应进行大规模研究以进一步采用基因组分析，这可能有助于临床医生确定适合ICC治疗的生物标志物。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30241001', 'NCT01610284', 'clinical trial - phase3', '4', 'buparlisib + fulvestrant', 'buparlisib + fulvestrant', 'buparlisib + fulvestrant', 'buparlisib + 氟维司群', 'buparlisib + fulvestrant|buparlisib + 氟维司群', '3', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001185', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', 'BACKGROUND:Buparlisib, a pan-phosphatidylinositol 3-kinase (PI3K) inhibitor, plus fulvestrant in the BELLE-2 study significantly improved progression-free survival (PFS) in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.PATIENTS AND METHODS:In this phase III study, patients were randomised 1:1 to buparlisib (100 mg/day; continuously in 28-day cycles) or placebo, plus fulvestrant (500 mg on cycle 1 day 15, and day 1 of subsequent cycles). Overall survival (OS) was assessed in the overall population and patients with known PI3K pathway status (both had shown significant PFS improvements). OS by PIK3CA status in circulating tumour DNA (ctDNA) was an exploratory end-point.RESULTS:A total of 2025 patients were screened for eligibility between 7th September 2012 and 10th September 2014, and 1178 received fulvestrant (500 mg) during a run-in phase; 31 discontinued. Of 1147 patients (median age 62 years), 98% had the Eastern Cooperative Oncology Group performance status ≤1, and 59% had visceral disease. Median follow-up from randomisation to data cut-off (23rd December 2016) was 37.6 months. Median OS trended in favour of the buparlisib arm in the overall population (33.2 versus 30.4 months; P = 0.045) and among patients with known PI3K pathway status (30.9 versus 28.9 months; P = 0.144); neither outcome was statistically significant. Median OS also trended in favour of buparlisib among patients with PIK3CA-mutant ctDNA (26.0 versus 24.8 months). Grade III/IV adverse events with ≥10% difference between the buparlisib versus placebo arms were elevated alanine aminotransferase (26% versus 1%), elevated aspartate aminotransferase (18% versus 3%) and hyperglycemia (15% versus <1%).CONCLUSIONS:OS results were in favour of buparlisib plus fulvestrant versus placebo plus fulvestrant; however, there is no statistical significance and more frequent grade III/IV adverse events were reported. Use of more selective PI3K inhibitors might provide the greatest clinical benefit and tolerable safety profile in this setting. Further evaluation of the predictive benefit of PIK3CA-mutant ctDNA is warranted.', '背景：buparlisib是一种泛磷脂酰肌醇3-激酶（PI3K）抑制剂，与氟维司群联用可显著改善激素受体阳性，ERBB2阴性晚期乳腺癌患者的无进展生存期（PFS）。患者和方法：在这项III期研究中，已知PI3K途径状态的患者按1：1随机分配至buparlisib（100 mg /天;连续28天周期）加氟维司群的实验组和安慰剂加氟维司群的对照组，评估总体存活（OS）（两组均显示出显著的PFS改善）。循环肿瘤DNA（ctDNA）检测PI3K途径状态并将OS作为探索性终点。结果：在2012年9月7日至2014年9月10日期间，共有2025名患者接受了资格筛查，1178名患者分别接受了两组方案的治疗，其中有31人提前停止治疗。在1147名患者（中位年龄62岁）中，98%的患者东部肿瘤协作组的表现状态≤1，59%患有内脏疾病。中位数随访（2016年12月23日）为37.6个月。中位OS：buparlisib组（33.2对30.4个月; P = 0.045），对照组（30.9对28.9个月; P = 0.144）;结果均无统计学意义。在PIK3CA突变的患者中，buparlisib组的中位OS为（26.0对24.8个月）​​。Buparlisib组与安慰剂组之间差异≥10%，III/IV级不良事件为丙氨酸氨基转移酶升高（26%对1%），天冬氨酸氨基转移酶升高（18%对3%）和高血糖（15%对<1%）。结论：OS的结果支持buparlisib加氟维司群治疗激素受体阳性，ERBB2阴性晚期乳腺癌患者。在这种情况下，使用更具选择性的PI3K抑制剂可能会提供最大的临床益处和可耐受的安全性。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30232224', '.', 'clinical trial - phase2', '4', 'alisertib', 'alisertib', 'alisertib', 'alisertib', 'alisertib|alisertib', '3', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001188', 'MYCN:nonsynonymous SNV:.:.:act', 'MYCN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of prostate cancer that may develop de novo or as a mechanism of treatment resistance. N-myc is capable of driving NEPC progression. Alisertib inhibits the interaction between N-myc and its stabilizing factor Aurora-A, inhibiting N-myc signaling, and suppressing tumor growth.Experimental Design: Sixty men were treated with alisertib 50 mg twice daily for 7 days every 21 days. Eligibility included metastatic prostate cancer and at least one: small-cell neuroendocrine morphology; ≥50% neuroendocrine marker expression; new liver metastases without PSA progression; or elevated serum neuroendocrine markers. The primary endpoint was 6-month radiographic progression-free survival (rPFS). Pretreatment biopsies were evaluated by whole exome and RNA-seq and patient-derived organoids were developed.Results: Median PSA was 1.13 ng/mL (0.01-514.2), number of prior therapies was 3, and 68% had visceral metastases. Genomic alterations involved RB1 (55%), TP53 (46%), PTEN (29%), BRCA2 (29%), and AR (27%), and there was a range of androgen receptor signaling and NEPC marker expression. Six-month rPFS was 13.4% and median overall survival was 9.5 months (7.3-13). Exceptional responders were identified, including complete resolution of liver metastases and prolonged stable disease, with tumors suggestive of N-myc and Aurora-A overactivity. Patient organoids exhibited concordant responses to alisertib and allowed for the dynamic testing of Aurora-N-myc complex disruption.Conclusions: Although the study did not meet its primary endpoint, a subset of patients with advanced prostate cancer and molecular features supporting Aurora-A and N-myc activation achieved significant clinical benefit from single-agent alisertib. ', '神经内分泌前列腺癌（NEPC）是一种侵袭性前列腺癌，可能是前列腺癌从头发展，或是治疗抵抗后的结果。N-myc能够推动NEPC进展。alisertib可抑制N-myc与其稳定因子Aurora-A之间的相互作用，抑制N-myc信号传导，从而抑制肿瘤生长。实验设计：60名男性每周两次用alisertib50 mg，每隔21天治疗7天。入组资格为包括转移性前列腺癌和至少一种以下症状：小细胞神经内分泌形态; ≥50%神经内分泌标志物表达;没有PSA进展的新肝转移;升高的血清神经内分泌标志物。主要终点是6个月的放射学无进展生存期（rPFS）。结果：6个月的rPFS为13.4%，中位总生存期为9.5个月（7.3-13）。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30225883', '.', 'preclinical', '4', 'dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', '.', '.', '非特定癌症', 'na', 'resistance', 'EVI_001191', 'BRAF:nonsynonymous SNV:exon12:p.N486_P490del:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon12', 'p.N486_P490del', '.', 'BRAF kinase is an essential target for anti-cancer drug development. Emergence of the β3-αC loop deletion mutation (ΔNVTAP) in BRAF kinase frequently occurred in human cancers seriously compromises the therapeutic efficacy of some BRAF kinase inhibitors, such as dabrafenib and vemurafenib. However, the mechanism of this resistance is still not well understood. In this study, the influence of the β3-αC deletion mutation on the binding profiles of three BRAF kinase inhibitors (AZ628, dabrafenib, and vemurafenib) with BRAFV600E or BRAFΔNVTAP was explored by conventional molecular dynamics (MD) simulations and binding free energy calculations. The simulation results indicated that the β3-αC deletion mutation enhances the flexibility of the αC helix and alters their conformations, which amplify the conformational entropy change (-TΔS) and weaken the interactions between the inhibitors and BRAF. The further per-residue binding free energy decomposition analysis revealed that the ΔNVTAP mutation changed the contributions of a few key residues to the bindings of dabrafenib or vemurafenib, such as L57, L66, W83, C84, F135, G145, and F147, but did not have obvious impact on the contributions of these residues to AZ628. Our results provide valuable clues to understand the mechanisms of drug resistance conferred by the β3-αC deletion mutation.', 'BRAF激酶是抗癌药物开发的重要靶标。人类癌症中BRAF β3-αC环缺失突变（ΔNVTAP）的出现严重损害了一些BRAF激酶抑制剂（例如dabrafenib和vemurafenib）的治疗功效。该耐药机制仍然不是很清楚。该研究通过常规分子动力学（MD）模拟，结合自由能计算研究了BRAFΔNVTAP结合谱对三种BRAF激酶抑制剂（AZ628，dabrafenib和vemurafenib）的影响。模拟结果表明，β3-αC缺失突变增强了αC螺旋的弹性，改变了它们的构象，扩大了构象熵变（-TΔS），减弱了抑制剂与BRAF之间的相互作用。残基结合自由能分解分析显示，ΔNVTAP改变了几个关键残基对dabrafenib或vemurafenib结合的贡献，如L57，L66，W83，C84，F135，G145和F147，但是对这些残留物对AZ628的作用没有明显影响。该研究结果为了解β3-αC缺失突变所赋予的耐药机制提供了有价值的线索。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30225883', '.', 'preclinical', '4', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', '.', '.', '非特定癌症', 'na', 'resistance', 'EVI_001192', 'BRAF:nonsynonymous SNV:exon12:p.N486_P490del:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon12', 'p.N486_P490del', '.', 'BRAF kinase is an essential target for anti-cancer drug development. Emergence of the β3-αC loop deletion mutation (ΔNVTAP) in BRAF kinase frequently occurred in human cancers seriously compromises the therapeutic efficacy of some BRAF kinase inhibitors, such as dabrafenib and vemurafenib. However, the mechanism of this resistance is still not well understood. In this study, the influence of the β3-αC deletion mutation on the binding profiles of three BRAF kinase inhibitors (AZ628, dabrafenib, and vemurafenib) with BRAFV600E or BRAFΔNVTAP was explored by conventional molecular dynamics (MD) simulations and binding free energy calculations. The simulation results indicated that the β3-αC deletion mutation enhances the flexibility of the αC helix and alters their conformations, which amplify the conformational entropy change (-TΔS) and weaken the interactions between the inhibitors and BRAF. The further per-residue binding free energy decomposition analysis revealed that the ΔNVTAP mutation changed the contributions of a few key residues to the bindings of dabrafenib or vemurafenib, such as L57, L66, W83, C84, F135, G145, and F147, but did not have obvious impact on the contributions of these residues to AZ628. Our results provide valuable clues to understand the mechanisms of drug resistance conferred by the β3-αC deletion mutation.', 'BRAF激酶是抗癌药物开发的重要靶标。人类癌症中BRAF β3-αC环缺失突变（ΔNVTAP）的出现严重损害了一些BRAF激酶抑制剂（例如dabrafenib和vemurafenib）的治疗功效。该耐药机制仍然不是很清楚。该研究通过常规分子动力学（MD）模拟，结合自由能计算研究了BRAFΔNVTAP结合谱对三种BRAF激酶抑制剂（AZ628，dabrafenib和vemurafenib）的影响。模拟结果表明，β3-αC缺失突变增强了αC螺旋的弹性，改变了它们的构象，扩大了构象熵变（-TΔS），减弱了抑制剂与BRAF之间的相互作用。残基结合自由能分解分析显示，ΔNVTAP改变了几个关键残基对dabrafenib或vemurafenib结合的贡献，如L57，L66，W83，C84，F135，G145和F147，但是对这些残留物对AZ628的作用没有明显影响。该研究结果为了解β3-αC缺失突变所赋予的耐药机制提供了有价值的线索。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30224486', '.', 'case report', '4', 'JNJ-38877605', 'JNJ-38877605', 'JNJ-38877605', 'JNJ-38877605', 'JNJ-38877605|JNJ-38877605', '0', '.', '.', '非特定癌症', 'na', 'resistance', 'EVI_001194', 'BRAF:nonsynonymous SNV:exon11:p.G469A:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.G469A', '.', 'Cancer clonal evolution is based on accrual of driving genetic alterations that are expected to cooperate and progressively increase malignancy. Little is known on whether any genetic alteration can hinder the oncogenic function of a coexisting alteration, so that therapeutic targeting of the one can, paradoxically, revive the function of the other. We report the case of a driver oncogene (MET) that is not only bypassed, but also disabled by the mutation of a downstream transducer (BRAF), and reignited by inhibition of the latter. In a metastasis originated from a cancer of unknown primary (CUP), the MET oncogene was amplified eightfold, but unexpectedly, the kinase was dephosphorylated and inactive. As result, specific drugs targeting MET (JNJ-38877605) failed to inhibit growth of xenografts derived from the patient. In addition to MET amplification, the patient harbored, as sole proliferative driver, a mutation hyperactivating BRAF (G469A). Surprisingly, specific blockade of the BRAF pathway was equally ineffective, and it was accompanied by rephosphorylation of the amplified MET oncoprotein and by revived addiction to MET. Mechanistically, MET inactivation in the context of the BRAF-activating mutation is driven through a negative feedback loop involving inactivation of PP2A phosphatase, which in turn leads to phosphorylation on MET inhibitory Ser985. Disruption of this feedback loop allows PP2A reactivation, removing the inhibitory phosphorylation from Ser985 and thereby unleashing MET kinase activity. Evidence is provided for a mechanism of therapeutic resistance to single-oncoprotein targeting, based on reactivation of a genetic alteration functionally dormant in targeted cancer cells.', '研究人员报告了驱动癌基因（MET）的情况，发现其可被旁路和下游基因（BRAF）突变所抑制，可通过抑制后者而重新激活。他们发现在源头未知的原发性癌症（CUP）转移中，MET基因被扩增8倍，但该激酶被去磷酸化并且无活性，导致靶向MET的特异性药物（JNJ-38877605）未能抑制源自患者的异种移植物的生长。除MET扩增外，患者还具有BRAF（G469A）突变。令人惊讶的是，BRAF途径的特异性阻断同样无效，还可伴随着扩增的MET癌蛋白的再磷酸化，导致MET的重新激活。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30264293', '.', 'case report', '4', 'E6201', 'E6201', 'E6201', 'E6201', 'E6201|E6201', '1', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_001214', 'BRAF:nonsynonymous SNV:exon15:p.V600.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'Malignant melanoma (MM) exhibits a high propensity for central nervous system dissemination with ~50% of metastatic MM patients developing brain metastases (BM). Targeted therapies and immune checkpoint inhibitors have improved overall survival for MM patients with BM. However, responses are usually of short duration and new agents that effectively penetrate the blood brain barrier (BBB) are needed. Here, we report a MM patient with BM who experienced an exceptional response to E6201, an ATP-competitive MEK1 inhibitor, on a Phase 1 study, with ongoing near-complete response and overall survival extending beyond 8 years. Whole exome and transcriptome sequencing revealed a high mutational burden tumor (22 mutations/Megabase) with homozygous BRAF V600E mutation. Correlative preclinical studies demonstrated broad activity for E6201 across BRAF V600E mutant melanoma cell lines and effective BBB penetration in vivo. Together, these results suggest that E6201 may represent a potential new treatment option for BRAF-mutant MM patients with BM.', '恶性黑色素瘤（MM）具有高度中枢神经系统传播倾向，约50%的转移性MM患者发生脑转移（BM）。靶向治疗和免疫检查点抑制剂改善了MM患者的总生存期。然而，反应通常持续时间短，因此需要能够有效穿透血脑屏障（BBB）的新药物。研究人员报告了一名患有脑转移的恶性黑色素瘤患者，他在1期研究中对E6201（ATP竞争性MEK1抑制剂）有特殊反应，且持续近乎完全的反应，总生存期超过8年。全外显子组和转录组测序揭示其具有纯合BRAF V600E突变。相关的临床前研究证明了E6201可有效穿透具有BRAF V600E突变的黑素瘤患者的血脑屏障并具有广泛活性。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ribociclib_Revised: 7/2018', '.', 'guideline:FDA', '1', '.', '.', 'ribociclib + letrozole ', '瑞波西利 + 来曲唑', 'ribociclib + letrozole |瑞波西利 + 来曲唑', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001218', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', '.', 'MONALEESA-2是一项随机、双盲、安慰剂对照、多中心研究，入组了668例HR+/HER2-乳腺癌患者。患者随机接受Ribociclib+来曲唑联合治疗或来曲唑单药治疗。主要终点是PFS，次要终点包括OS、ORR、临床获益率（CBR）等，预计在2019年8月结束。结果显示，Ribociclib+来曲唑治疗组患者PFS为19.3个月，使死亡或肿瘤进展风险降低44%，肿瘤缩小30%以上的患者比例为53%。来曲唑单药组PFS为14.7个月，肿瘤缩小30%以上的患者比例为37%。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ribociclib_Revised: 7/2018', '.', 'guideline:FDA', '1', '.', '.', 'ribociclib + fulvestrant', '瑞波西利 + 氟维司群', 'ribociclib + fulvestrant|瑞波西利 + 氟维司群', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001219', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', '.', 'MONALEESA-3研究收录了726名荷尔蒙受体阳性且HER2受体阴性晚期乳癌患者，按2:1比例随机进入治疗组与安慰剂组，治疗组给予Ribociclib (600 mg/天; 每三周停一周) 联合Fulvestrant（每4周肌肉注射500 mg），对照组给予安慰剂和Fulvestrant（每4周肌肉注射500 mg）。主要研究目的为研究者评估的疾病控制时间(PFS)，次要研究终点包括OS、整体有效率(ORR)、临床获益率(CBR)与安全指标。中位追踪时间为20.4个月，已达到主要研究终点。治疗组PFS较对照组显著延长（中位PFS:20.5 mo vs. 12.8 mo，HR=0.593)。这意味着Ribociclib联合Fulvestrant较单用Fulvestrant组可降低41%的疾病进展风险。第一线及二线Ribociclib联合Fulvestrant群疗效均优于单用Fulvestrant组。在所有患者中，Fulvestrant基础上加入Ribociclib使ORR率从21.5%显著地提高至32.4%，CBR从62.8%显著地提高至70.2%；而在临床病灶可测量的患者中，Fulvestrant基础上加入Ribociclib使ORR率从29%显著地提高至41%，CBR从60%提显著地提高至69% (p = 0.015)。由于尚未到达预设界限，OS资料仍需进一步追踪后才能明确。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ribociclib_Revised: 7/2018', '.', 'guideline:FDA', '1', '.', '.', 'ribociclib + tamoxifen  + goserelin', '瑞波西利 + 他莫昔芬 + 戈舍瑞林', 'ribociclib + tamoxifen  + goserelin|瑞波西利 + 他莫昔芬 + 戈舍瑞林', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001221', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', '.', '作为国际多中心大型III期临床试验，MONALEESA-7入组患者要求为绝经或围绝经期HR+/HER2-晚期乳腺癌，ECOG PS≤1；允许患者在疾病晚期阶段接受≤1线化疗，和（或）≤14天的他莫昔芬/NSAI±OFS治疗，排除接受CDK4/6抑制剂治疗。研究共入组晚期患者672例，1:1随机分配进入Ribociclib组（n=335）或安慰剂组（n=337），两组均以他莫昔芬（20 mg/d）+卵巢功能抑制（OFS;goserelin）或NSAI（来曲唑2.5mg/d，阿那曲唑1mg/d）+卵巢功能抑制（OFS;goserelin）为基础用药。分层因素包括：肺转移或肝转移、既往治疗、内分泌联合药物类型。MONALEESA-7的主要研究终点为无进展生存（PFS），次要终点包括总生存（OS）、安全性、耐受性、缓解率、临床获益率、持续缓解时间以及生活质量等。采集受试者的血液样本供生物标志物和药代动力学分析。MONALESSA-7研究中，Ribociclib组的客观缓解率明显优于安慰剂组，分别为50.5% vs 36.2%。Ribociclib对比安慰剂的患者中位PFS分别为27.5个月 vs 13.8个月（HR=0.569; 95% CI: 0.436-0.743）。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30351341', 'NCT01854034', 'clinical trial - phase2', '4', 'luminespib', 'luminespib', 'luminespib', 'luminespib', 'luminespib|luminespib', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001222', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'BACKGROUND:There are currently no approved targeted therapies for non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertions (ins20), a subgroup of EGFR mutations that are generally refractory to first/second generation EGFR inhibitors. We report the final results of a phase II trial evaluating the activity of the Hsp90 inhibitor luminespib (AUY922) in NSCLC patients with EGFR ins20.PATIENTS AND METHODS:Twenty-nine patients with stage IV NSCLC with EGFR ins20 identified on local testing and at least one prior therapy were enrolled on the trial between August 2013 and October 2016. The primary end point was objective response rate (ORR), with a pre-determined target rate of effectiveness [defined as the rate of partial response (PR) plus stable disease (SD) lasting ≥3 months] of 20%. Secondary end points were PFS, overall survival (OS), safety and response by EGFR ins20 subtype.RESULTS:Among the 29 patients (18 females, median age 60 years) the ORR was 17%, median progression-free survival was 2.9 months (95% CI 1.4-5.6) and median OS (mOS) was 13 months (95% CI 4.9-19.5). The results exceeded the pre-determined target rate of effectiveness with 11/29 (38%) patients having a PR or an SD ≥3 months. The most common luminespib-related toxicities were diarrhea (83%), visual changes (76%) and fatigue (45%). All study treatment was stopped on 28 February 2017 due to dissolution of study drug availability; 3 patients were on treatment at study termination.CONCLUSION:The study met its primary end point, suggesting that luminespib may be an active therapy for advanced NSCLC patients with EGFR ins20. Luminespib is generally well-tolerated, though reversible low-grade ocular toxicity is common. Further study of luminespib and other hsp90 inhibitors in this population is warranted.', '一项囊括了29例患者的II期试验评估了Hsp90抑制剂luminespib（AUY922）在EGFR ins20的NSCLC患者中的活性。主要终点是客观反应率（ORR），次要终点为PFS，总生存期（OS），对EGFR ins20亚型患者的安全性和反应。29例患者中（18例女性，中位年龄60岁）ORR为17%，中位无进展生存期为2.9个月（ 95%CI 1.4-5.6），中位OS（mOS）为13个月（95%CI 4.9-19.5）。最常见的与luminespib有关的毒性是腹泻（83%），视力变化（76%）和疲劳（45%）。该研究符合其主要终点，提示luminespib可能是EGFR ins20晚期NSCLC患者的积极治疗方法。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30323086', '.', 'case report', '4', 'dabrafenib + trametinib', 'dabrafenib + trametinib', 'trametinib + dabrafenib', '曲美替尼 + 达拉非尼', 'trametinib + dabrafenib|曲美替尼 + 达拉非尼', '4', 'salivary duct carcinoma ', 'salivary duct carcinoma ', '涎腺导管癌', 'na', 'sensitivity', 'EVI_001223', 'BRAF:nonsynonymous SNV:exon15:p.V600.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'Salivary duct carcinoma (SDC) is a rare and aggressive malignancy for which limited data exist to guide treatment decisions. With the advent of advanced molecular testing and tumor genomic profiling, clinicians now have the ability to identify potential therapeutic targets in difficult-to-treat cancers such as SDC. This report presents a male patient with widely metastatic SDC found on targeted next-generation sequencing to have a BRAF p.V600E mutation. He experienced a prolonged and robust response to first-line systemic chemotherapy with dabrafenib and trametinib. During his response interval, new data emerged to justify subsequent treatment with both an immune checkpoint inhibitor and androgen blockade after his disease progressed. To our knowledge, this is the first report of frontline BRAF-directed therapy eliciting a response in metastatic SDC.', '唾液导管癌（SDC）是一种罕见且具有侵袭性的恶性肿瘤。一名广泛转移的SDC男性患者基因检测结果显示存在BRAF p.V600E突变，他对dabrafenib和trametinib的一线全身治疗有长期和强烈的反应，疾病进展后用免疫检查点抑制剂和雄激素阻断治疗。这是针对BRAF突变定向治疗转移性SDC反应的第一份报告。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30274985', '.', 'preclinical', '4', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib|avapritinib', '1', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001227', 'KIT:nonsynonymous SNV:exon11:.:exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', 'Purpose: Gastrointestinal stromal tumors (GIST) are commonly treated with tyrosine kinase inhibitors (TKI). The majority of patients with advanced GIST ultimately become resistant to TKI due to acquisition of secondary KIT mutations, whereas primary resistance is mainly caused by PDGFRA p.D842V mutation. We tested the activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT mutations, with differential sensitivity to standard TKI.Experimental Design: NMRI nu/nu mice (n = 93) were transplanted with human GIST xenografts with KIT exon 11+17 (UZLX-GIST9 KIT 11+17 ), exon 11 (UZLX-GIST3 KIT 11 ), or exon 9 (UZLX-GIST2B KIT9 ) mutations, respectively. We compared avapritinib (10 and 30 mg/kg/once daily) versus vehicle, imatinib (50 mg/kg/bid) or regorafenib (30 mg/kg/once daily; UZLX-GIST9 KIT11+17 ); avapritinib (10, 30, 100 mg/kg/once daily) versus vehicle or imatinib [UZLX-GIST3 KIT11 ]; and avapritinib (10, 30, 60 mg/kg/once daily) versus vehicle, imatinib (50, 100 mg/kg/twice daily), or sunitinib (40 mg/kg/once daily; UZLX-GIST2B KIT9 ).Results: In all models, avapritinib resulted in reduction of tumor volume, significant inhibition of proliferation, and reduced KIT signaling. In two models, avapritinib led to remarkable histologic responses, increase in apoptosis, and inhibition of MAPK-phosphorylation. Avapritinib showed superior (UZLX-GIST9 KIT 11+17 and -GIST2B KIT 9 ) or equal (UZLX-GIST3 KIT 11 ) antitumor activity to the standard dose of imatinib. In UZLX-GIST9 KIT 11+17 , the antitumor effects of avapritinib were significantly better than with imatinib or regorafenib.Conclusions: Avapritinib has significant antitumor activity in GIST PDX models characterized by different KIT mutations and sensitivity to established TKI. These data provide strong support for the ongoing clinical trials with avapritinib in patients with GIST (NCT02508532, NCT03465722). ', '胃肠道间质瘤（GIST）通常用酪氨酸激酶抑制剂（TKI）治疗。大多数晚期GIST患者由于继发性KIT突变最终对TKI产生抗性，而原发性抗性主要由PDGFRA p.D842V突变引起。研究人员在携带不同KIT突变的三个GIST-PDX模型中测试了avapritinib（一种有效且高选择性的KIT和PDGFRA抑制剂）的活性。试验表明，avapritinib对携带KIT 9,11,17外显子突变的肿瘤细胞均有抑制作用。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30274985', '.', 'preclinical', '4', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib|avapritinib', '1', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001228', 'KIT:nonsynonymous SNV:exon17:.:exon17act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon17', '.', 'exon17act', 'Purpose: Gastrointestinal stromal tumors (GIST) are commonly treated with tyrosine kinase inhibitors (TKI). The majority of patients with advanced GIST ultimately become resistant to TKI due to acquisition of secondary KIT mutations, whereas primary resistance is mainly caused by PDGFRA p.D842V mutation. We tested the activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT mutations, with differential sensitivity to standard TKI.Experimental Design: NMRI nu/nu mice (n = 93) were transplanted with human GIST xenografts with KIT exon 11+17 (UZLX-GIST9 KIT 11+17 ), exon 11 (UZLX-GIST3 KIT 11 ), or exon 9 (UZLX-GIST2B KIT9 ) mutations, respectively. We compared avapritinib (10 and 30 mg/kg/once daily) versus vehicle, imatinib (50 mg/kg/bid) or regorafenib (30 mg/kg/once daily; UZLX-GIST9 KIT11+17 ); avapritinib (10, 30, 100 mg/kg/once daily) versus vehicle or imatinib [UZLX-GIST3 KIT11 ]; and avapritinib (10, 30, 60 mg/kg/once daily) versus vehicle, imatinib (50, 100 mg/kg/twice daily), or sunitinib (40 mg/kg/once daily; UZLX-GIST2B KIT9 ).Results: In all models, avapritinib resulted in reduction of tumor volume, significant inhibition of proliferation, and reduced KIT signaling. In two models, avapritinib led to remarkable histologic responses, increase in apoptosis, and inhibition of MAPK-phosphorylation. Avapritinib showed superior (UZLX-GIST9 KIT 11+17 and -GIST2B KIT 9 ) or equal (UZLX-GIST3 KIT 11 ) antitumor activity to the standard dose of imatinib. In UZLX-GIST9 KIT 11+17 , the antitumor effects of avapritinib were significantly better than with imatinib or regorafenib.Conclusions: Avapritinib has significant antitumor activity in GIST PDX models characterized by different KIT mutations and sensitivity to established TKI. These data provide strong support for the ongoing clinical trials with avapritinib in patients with GIST (NCT02508532, NCT03465722). ', '胃肠道间质瘤（GIST）通常用酪氨酸激酶抑制剂（TKI）治疗。大多数晚期GIST患者由于继发性KIT突变最终对TKI产生抗性，而原发性抗性主要由PDGFRA p.D842V突变引起。研究人员在携带不同KIT突变的三个GIST-PDX模型中测试了avapritinib（一种有效且高选择性的KIT和PDGFRA抑制剂）的活性。试验表明，avapritinib对携带KIT 9,11,17外显子突变的肿瘤细胞均有抑制作用。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30274985', '.', 'preclinical', '4', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib|avapritinib', '1', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001229', 'KIT:nonsynonymous SNV:exon9:.:exon9act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon9', '.', 'exon9act', 'Purpose: Gastrointestinal stromal tumors (GIST) are commonly treated with tyrosine kinase inhibitors (TKI). The majority of patients with advanced GIST ultimately become resistant to TKI due to acquisition of secondary KIT mutations, whereas primary resistance is mainly caused by PDGFRA p.D842V mutation. We tested the activity of avapritinib, a potent and highly selective inhibitor of mutated KIT and PDGFRA, in three patient-derived xenograft (PDX) GIST models carrying different KIT mutations, with differential sensitivity to standard TKI.Experimental Design: NMRI nu/nu mice (n = 93) were transplanted with human GIST xenografts with KIT exon 11+17 (UZLX-GIST9 KIT 11+17 ), exon 11 (UZLX-GIST3 KIT 11 ), or exon 9 (UZLX-GIST2B KIT9 ) mutations, respectively. We compared avapritinib (10 and 30 mg/kg/once daily) versus vehicle, imatinib (50 mg/kg/bid) or regorafenib (30 mg/kg/once daily; UZLX-GIST9 KIT11+17 ); avapritinib (10, 30, 100 mg/kg/once daily) versus vehicle or imatinib [UZLX-GIST3 KIT11 ]; and avapritinib (10, 30, 60 mg/kg/once daily) versus vehicle, imatinib (50, 100 mg/kg/twice daily), or sunitinib (40 mg/kg/once daily; UZLX-GIST2B KIT9 ).Results: In all models, avapritinib resulted in reduction of tumor volume, significant inhibition of proliferation, and reduced KIT signaling. In two models, avapritinib led to remarkable histologic responses, increase in apoptosis, and inhibition of MAPK-phosphorylation. Avapritinib showed superior (UZLX-GIST9 KIT 11+17 and -GIST2B KIT 9 ) or equal (UZLX-GIST3 KIT 11 ) antitumor activity to the standard dose of imatinib. In UZLX-GIST9 KIT 11+17 , the antitumor effects of avapritinib were significantly better than with imatinib or regorafenib.Conclusions: Avapritinib has significant antitumor activity in GIST PDX models characterized by different KIT mutations and sensitivity to established TKI. These data provide strong support for the ongoing clinical trials with avapritinib in patients with GIST (NCT02508532, NCT03465722). ', '胃肠道间质瘤（GIST）通常用酪氨酸激酶抑制剂（TKI）治疗。大多数晚期GIST患者由于继发性KIT突变最终对TKI产生抗性，而原发性抗性主要由PDGFRA p.D842V突变引起。研究人员在携带不同KIT突变的三个GIST-PDX模型中测试了avapritinib（一种有效且高选择性的KIT和PDGFRA抑制剂）的活性。试验表明，avapritinib对携带KIT 9,11,17外显子突变的肿瘤细胞均有抑制作用。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29466156|Druglabel:larotrectinib_Revised:11/2018', '.', 'guideline:FDA', '1', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001231', 'NTRK1:FUS:.:.-NTRK1:.', 'NTRK1', 'FUS', 'FUS', '.', '.-NTRK1', '.', '.', 'FDA根据以下三项临床实验的结果，包括成人I期研究，儿童I-II期研究，以及青少年和成人II期研究（NCT02122913，NCT02637687和NCT02576431），批准用于治疗携带NTRK融合基因突变的成人或儿童局部晚期或转移性实体瘤患者，该基因上并未同时发生已知耐药性突变。这些临床实验共有55名患者，年龄从4个月到76岁不等，包括阑尾癌，乳腺癌，胆管癌，结直肠癌，胃肠道间质瘤（GIST），婴儿纤维肉瘤，肺癌，黑色素瘤，胰腺癌，甲状腺癌等17种肿瘤。这些患者都是通过检测确定属于NTRK1、NTRK2或者NTRK3融合，之前进行过治疗。主要研究终点为总响应率。根据研究者的评估，总体有效率为75%。在1年时，71%的患者持续响应，55%的患者无进展。尚未达到中位持续时间和无进展生存期。平均随访9.4个月，86%的患者（44例患者中有38例）正在继续治疗或接受了旨在治愈的手术。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29466156|Druglabel:larotrectinib_Revised:11/2018', '.', 'guideline:FDA', '1', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001232', 'NTRK2:FUS:.:.-NTRK2:.', 'NTRK2', 'FUS', 'FUS', '.', '.-NTRK2', '.', '.', 'FDA根据以下三项临床实验的结果，包括成人I期研究，儿童I-II期研究，以及青少年和成人II期研究（NCT02122913，NCT02637687和NCT02576431），批准用于治疗携带NTRK融合基因突变的成人或儿童局部晚期或转移性实体瘤患者，该基因上并未同时发生已知耐药性突变。这些临床实验共有55名患者，年龄从4个月到76岁不等，包括阑尾癌，乳腺癌，胆管癌，结直肠癌，胃肠道间质瘤（GIST），婴儿纤维肉瘤，肺癌，黑色素瘤，胰腺癌，甲状腺癌等17种肿瘤。这些患者都是通过检测确定属于NTRK1、NTRK2或者NTRK3融合，之前进行过治疗。主要研究终点为总响应率。根据研究者的评估，总体有效率为75%。在1年时，71%的患者持续响应，55%的患者无进展。尚未达到中位持续时间和无进展生存期。平均随访9.4个月，86%的患者（44例患者中有38例）正在继续治疗或接受了旨在治愈的手术。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29466156|Druglabel:larotrectinib_Revised:11/2018', '.', 'guideline:FDA', '1', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001233', 'NTRK3:FUS:.:.-NTRK3:.', 'NTRK3', 'FUS', 'FUS', '.', '.-NTRK3', '.', '.', 'FDA根据以下三项临床实验的结果，包括成人I期研究，儿童I-II期研究，以及青少年和成人II期研究（NCT02122913，NCT02637687和NCT02576431），批准用于治疗携带NTRK融合基因突变的成人或儿童局部晚期或转移性实体瘤患者，该基因上并未同时发生已知耐药性突变。这些临床实验共有55名患者，年龄从4个月到76岁不等，包括阑尾癌，乳腺癌，胆管癌，结直肠癌，胃肠道间质瘤（GIST），婴儿纤维肉瘤，肺癌，黑色素瘤，胰腺癌，甲状腺癌等17种肿瘤。这些患者都是通过检测确定属于NTRK1、NTRK2或者NTRK3融合，之前进行过治疗。主要研究终点为总响应率。根据研究者的评估，总体有效率为75%。在1年时，71%的患者持续响应，55%的患者无进展。尚未达到中位持续时间和无进展生存期。平均随访9.4个月，86%的患者（44例患者中有38例）正在继续治疗或接受了旨在治愈的手术。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28751539', '.', 'preclinical', '4', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001235', 'NTRK1:nonsynonymous SNV:exon15:p.G667C:', 'NTRK1', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.G667C', '.', '.', '神经营养性受体酪氨酸激酶1（NTRK1）基因重排导致NTRK1的组成型活化，从而导致该基因具有致癌基因活性。已经在几种癌症类型中鉴定出NTRK重排的癌症，例如胶质母细胞瘤，非小细胞肺癌和结肠直肠癌。几种酪氨酸激酶抑制剂，例如entrectinib和LOXO-101，正在进行临床试验。本研究的目的是确定对NTRK抑制剂耐药的潜在机制，并找到克服耐药性的潜在治疗策略。我们检测了TPM3-NTRK1转化的Ba/F3细胞和携带TPM3-NTRK1的KM12细胞对多种NTRK抑制剂的敏感性。通过N-乙基-N-亚硝基脲诱变用Ba/F3-TPM3-NTRK1细胞或通过用NTRK-TKI连续处理的KM12细胞建立NTRK-TKI抗性细胞来筛选获得的NTRK抑制剂抗性突变。我们在NTRK1激酶结构域中鉴定了多种新的NTRK-TKI抗性突变，包括G595R和胰岛素生长因子受体1型（IGF1R）旁路途径介导的抗性。在确定抗性机制后，我们用小分子抑制剂进行药物筛选以克服抗性。结果，我们发现ponatinib和nintedanib有效抑制TPM3-NTRK1-G667C的存活，但不能抑制G595R突变体的存活。两种突变均显示对entrectinib或larotrectinib（LOXO-101）的抗性。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28662863', '.', 'case report', '4', '.', '.', 'osimertinib + erlotinib', '奥希替尼 + 厄洛替尼', 'osimertinib + erlotinib|奥希替尼 + 厄洛替尼', '4', 'pulmonary adenocarcinoma', 'pulmonary adenocarcinoma', '肺癌', 'na', 'sensitivity', 'EVI_001236', 'EGFR:nonsynonymous SNV:exon20:p.C797S<反式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<反式>', '.', '.', '一名男性患者，43岁，无吸烟史。该患者入组afatinib临床实验，用药一个月后获得部分缓解(PR)。但在12.8个月之后疾病进展。采用ARMS-PCR法对活检组织标本进行检测，显示患者此时携带EGFR 19 del突变和T790M耐药突变。患者换服奥希替尼且获得部分缓解（PR）。缓解持续了7.4个月后患者出现腹膜淋巴结病灶转移，再次疾病进展。此时，通过对血浆ctDNA进行NGS检测，发现患者携带EGFR 19 del, T790M, C797S三种突变。而且T790M和C797S突变之间呈反式存在，即T790M与C797S突变各自位于不同的等位基因上。患者随后接受一代和三代EGFR-TKI联合用药治疗（厄洛替尼+奥希替尼），用药后一周内患者临床症状明显缓解，且一个月后再次进行ctDNA液体活检，C797S突变消失，两个月后，再行ctDNA液体活检，T790M突变亦消失。影像学评估也与基因检测结果相符，联合治疗进行一个月时，影像评价提示患者部分缓解，两个月时，影像评价确认了此部分缓解的疗效。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28843359', '.', 'case report', '4', '.', '.', 'osimertinib + gefitinib', '奥希替尼 + 吉非替尼', 'osimertinib + gefitinib|奥希替尼 + 吉非替尼', '4', 'pulmonary adenocarcinoma', 'pulmonary adenocarcinoma', '肺癌', 'na', 'sensitivity', 'EVI_001237', 'EGFR:nonsynonymous SNV:exon20:p.C797S<反式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<反式>', '.', '.', '一名肺癌患者在多次治疗后疾病发生进展，使用Oncomine Lung cfDNA Assay对患者的血浆进行测序。随后通过液滴数字聚合酶链反应监测血浆中的循环肿瘤DNA。结果表明，该患者EGFR基因上存在T790M和C797S的反式突变。该患者接受吉非替尼和奥希替尼的联合治疗。在开始联合治疗的2周内，发生了快速的临床改善。与此同时，检测到血浆中C797S突变亚克隆的快速下降。然而，循环肿瘤DNA中EGFR外显子19缺失驱动突变和T790M抗性突变的水平持续升高，并且患者在开始联合治疗后6周死于进行性疾病。联合治疗没有发现不良事件。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30273505', '.', 'case report', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'resistance', 'EVI_001239', 'ALK:FUS:.:CMTR1-ALK:', 'ALK', 'FUS', 'FUS', '.', 'CMTR1-ALK', '.', 'The targeted treatment of advanced non-small cell lung cancer (NSCLC) harboring genomic rearrangement of ALK is a paradigm for personalized oncology. More than 15 different ALK fusion partners have been discovered in NSCLC patients. Most of these ALK fusions responded well to the ALK inhibitor crizotinib. Crizotinib is an oral MET/ALK inhibitor used as first-line therapy in the treatment of advanced NSCLC harboring ALK rearrangement. An understanding of the mechanisms by which tumors harbor primary drug resistance or acquired resistance to targeted therapies is critical for predicting which patients will respond to a specific therapy and for the identification of additional targetable pathways to maximize clinical benefits. Cap methyltransferase 1(CMTR1) also known as hMTr1, which is translate a human cap1 2\'-o-ribose methyltransferase. Here, we report the newly found ALK fusion, CMTR1-ALK, in a patient who has no response to the ALK inhibitor crizotinib. The results remind us that detecting ALK status is important, but that determining the ALK fusion type and function may be more important for patient.', 'ALK基因组重排的晚期非小细胞肺癌（NSCLC）的靶向治疗是个体化肿瘤学的范例。在NSCLC患者中发现了超过15种不同的ALK融合伴侣。这些ALK融合物大多数对ALK抑制剂克唑替尼反应良好。克唑替尼是一种口服MET/ALK抑制剂，用于治疗携带ALK重排的晚期NSCLC。了解肿瘤原发性耐药性或对靶向治疗获得性耐药的机制对于预测哪些患者对特定治疗有反应以及确定其他可靶向途径以最大化临床益处至关重要。研究人员新发现的ALK融合蛋白CMTR1-ALK对ALK抑制剂克唑替尼没有反应。该结果提示对NSCLC患者来说，不仅要检测ALK状态，同时还应确定ALK融合类型和功能。', 'F', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30268483', 'NCT01482377', 'clinical trial - phase1', '4', 'lumretuzumab', 'lumretuzumab', 'lumretuzumab', 'lumretuzumab', 'lumretuzumab|lumretuzumab', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001241', 'NRG1:FUS::.-NRG1:', 'NRG1', 'FUS', 'FUS', '.', '.-NRG1', '.', 'Rearrangements of NRG1 have been identified in invasive mucinous adenocarcinoma of the lung (IMA), formerly referred to as mucinous bronchioloalveolar carcinoma. NRG1 ligand signals through induction of ERBB2-ERBB3 heterodimers, thus leading to PI3K-AKT pathway activation. Therefore, targeting ERBB2, ERBB3 and the downstream pathway may be a hypothesis-driven strategy for IMA with NRG1 fusion. Herein we reported two patients who benefited from lumretuzumab, a monoclonal anti-ERBB3 antibody, in combination of erlotinib during a clinical trial (NCT01482377). At least sixteen weeks of progression-free survival were achieved without any unacceptable toxicity.', '目前已在侵袭性粘液性肺腺癌（IMA）中发现NRG1的重排，NRG1配体可诱导下游ERBB2-ERBB3异二聚体发出信号，导致PI3K-AKT途径激活。研究人员报道了两名在临床试验期间从厄洛替尼联合抗ERBB3抗体lumretuzumab的治疗中获益的IMA患者（NCT01482377），他们在没有任何不可接受的毒性的情况下实现了至少十六周的无进展存活。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2018.78.6558 Journal of Clinical Oncology 36, no. 31 (November 2018) 3134-3143.', '.', 'clinical trial - phase2', '4', 'lurbinectedin', 'lurbinectedin', 'lurbinectedin', 'lurbinectedin', 'lurbinectedin|lurbinectedin', '2', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_001245', 'BRCA2:.:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Purpose：This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance.Patients and Methods：Two arms were evaluated according to germline BRCA1/2 status: BRCA1/2 mutated (arm A; n = 54) and unselected (BRCA1/2 wild-type or unknown status; arm B; n = 35). Lurbinectedin starting dose was a 7-mg flat dose and later, 3.5 mg/m2 in arm A. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST). The translational substudy of resistance mechanisms included exome sequencing (n = 13) and in vivo experiments with patient-derived xenografts (n = 11) from BRCA1/2-mutated tumors.Results：ORR was 41% (95% CI, 28% to 55%) in arm A and 9% (95% CI, 2% to 24%) in arm B. In arm A, median progression-free survival was 4.6 months (95% CI, 3.0 to 6.0 months), and median overall survival was 20.0 months (95% CI, 11.8 to 26.6 months). Patients with BRCA2 mutations showed an ORR of 61%, median progression-free survival of 5.9 months, and median overall survival of 26.6 months. The safety profile improved with lurbinectedin dose adjustment to body surface area. The most common nonhematologic adverse events seen at 3.5 mg/m2 were nausea (74%; grade 3, 5%) and fatigue (74%; grade 3, 21%). Neutropenia was the most common severe hematologic adverse event (grade 3, 47%; grade 4, 10%). Exome sequencing showed mutations in genes related to the nucleotide excision repair pathway in four of seven tumors at primary or acquired resistance and in one patient with short-term stable disease. In vivo, sensitivity to cisplatin and lurbinectedin was evidenced in lurbinectedin-resistant (one of two) and cisplatin-resistant (two of three) patient-derived xenografts.Conclusion：Lurbinectedin showed noteworthy activity in patients with BRCA1/2 mutations. Response and survival was notable in those with BRCA2 mutations. Additional clinical development in this subset of patients with metastatic breast cancer is warranted.', '一项多中心II期试验评估了lurbinectedin（PM01183）对晚期乳腺癌患者的临床活性和耐药的潜在机制。根据种系BRCA1/2状态将患者分为两组：BRCA1/2突变（A组; n = 54）和BRCA1/2野生型或未知状态（B组; n = 35）。lurbinectedin起始剂量为7 mg，主要终点是每个实体瘤反应评估标准（RECIST）的客观反应率（ORR）。结果：A组的总体ORR为41%，B组为9%。在A组，中位无进展生存期为4.6个月，总体中位数生存期为20.0个月。 BRCA2突变患者的ORR为61%，中位无进展生存期为5.9个月，中位总生存期为26.6个月。随着lurbinectedin剂量调整，安全性得到改善。计量稳定时最常见的非血液学不良事件为恶心和疲劳。中性粒细胞减少症是最常见的严重血液学不良事件。外显子组测序显示，5/7的原发性或获得性耐药与核苷酸切除修复途径相关的基因突变有关。lurbinectedin在BRCA1/2突变患者中显示出显著的活性。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2018.78.6558 Journal of Clinical Oncology 36, no. 31 (November 2018) 3134-3143.', '.', 'clinical trial - phase2', '4', 'lurbinectedin', 'lurbinectedin', 'lurbinectedin', 'lurbinectedin', 'lurbinectedin|lurbinectedin', '2', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_001246', 'BRCA1:.:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Purpose：This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor of active transcription of protein-coding genes, in patients with metastatic breast cancer. A unicenter translational substudy assessed potential mechanisms of lurbinectedin resistance.Patients and Methods：Two arms were evaluated according to germline BRCA1/2 status: BRCA1/2 mutated (arm A; n = 54) and unselected (BRCA1/2 wild-type or unknown status; arm B; n = 35). Lurbinectedin starting dose was a 7-mg flat dose and later, 3.5 mg/m2 in arm A. The primary end point was objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST). The translational substudy of resistance mechanisms included exome sequencing (n = 13) and in vivo experiments with patient-derived xenografts (n = 11) from BRCA1/2-mutated tumors.Results：ORR was 41% (95% CI, 28% to 55%) in arm A and 9% (95% CI, 2% to 24%) in arm B. In arm A, median progression-free survival was 4.6 months (95% CI, 3.0 to 6.0 months), and median overall survival was 20.0 months (95% CI, 11.8 to 26.6 months). Patients with BRCA2 mutations showed an ORR of 61%, median progression-free survival of 5.9 months, and median overall survival of 26.6 months. The safety profile improved with lurbinectedin dose adjustment to body surface area. The most common nonhematologic adverse events seen at 3.5 mg/m2 were nausea (74%; grade 3, 5%) and fatigue (74%; grade 3, 21%). Neutropenia was the most common severe hematologic adverse event (grade 3, 47%; grade 4, 10%). Exome sequencing showed mutations in genes related to the nucleotide excision repair pathway in four of seven tumors at primary or acquired resistance and in one patient with short-term stable disease. In vivo, sensitivity to cisplatin and lurbinectedin was evidenced in lurbinectedin-resistant (one of two) and cisplatin-resistant (two of three) patient-derived xenografts.Conclusion：Lurbinectedin showed noteworthy activity in patients with BRCA1/2 mutations. Response and survival was notable in those with BRCA2 mutations. Additional clinical development in this subset of patients with metastatic breast cancer is warranted.', '一项多中心II期试验评估了lurbinectedin（PM01183）对晚期乳腺癌患者的临床活性和耐药的潜在机制。根据种系BRCA1/2状态将患者分为两组：BRCA1/2突变（A组; n = 54）和BRCA1/2野生型或未知状态（B组; n = 35）。lurbinectedin起始剂量为7 mg，主要终点是每个实体瘤反应评估标准（RECIST）的客观反应率（ORR）。结果：A组的总体ORR为41%，B组为9%。在A组，中位无进展生存期为4.6个月，总体中位数生存期为20.0个月。 BRCA2突变患者的ORR为61%，中位无进展生存期为5.9个月，中位总生存期为26.6个月。随着lurbinectedin剂量调整，安全性得到改善。计量稳定时最常见的非血液学不良事件为恶心和疲劳。中性粒细胞减少症是最常见的严重血液学不良事件。外显子组测序显示，5/7的原发性或获得性耐药与核苷酸切除修复途径相关的基因突变有关。lurbinectedin在BRCA1/2突变患者中显示出显著的活性。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/jco.2015.33.3_suppl.59|PMID:30463996', 'NCT01522768', 'clinical trial - phase2', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'esophagogastric (EG) cancer', 'gastric cancer', '食管癌', 'na', 'sensitivity', 'EVI_001247', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项单中心的II期临床试验，入组HER2扩增的胃食管癌患者，接受了多个疗程的赫赛汀联合治疗后耐药。一组接受阿法替尼治疗，一组接受阿法替尼联合赫赛汀治疗。20名接受阿法替尼单药治疗的患者中，5人肿瘤缩小；12名接受阿法替尼联合赫赛汀治疗的患者中，1名患者肿瘤明显缩小，2人肿瘤稳定超过4个月；32名患者中，有24名患者有治疗前后，足够的标本进行全面的基因分析——结果显示，那些同时有HER2基因和EGFR基因扩增的病人，阿法替尼治疗效果好；而那些同时合并了KRAS、PI3K或MYC基因突变的病人，阿法替尼治疗效果差；4名被证实同时携带EGFR和HER2扩增的病人中，3人肿瘤明显缩小；另外1人治疗无效，原因是这个人同时有EGFR、HER2扩增之外，还有MYC扩增。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28751539', '.', 'preclinical', '4', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001248', 'NTRK1:nonsynonymous SNV:exon14:p.V573M:', 'NTRK1', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.V573M', '.', '.', '一项临床前研究NRKT蛋白TRKA激酶结构域中鉴定出三种KD突变：V573M和F589L，G667S。与未突变的MPRIP-NTRK1相比，这些突变导致BA/F3细胞对LOXO-101（larotrectinib）存在显著的耐药性。正常药物剂量不能对携带这些突变的TRKA激酶产生抑制作用。TRKA区域F589位置与ALK中的L1196或EGFR中的T790同源，并且是抗药性突变的共同位置。TRKA区域的G667位于ATP/药物结合口袋中的F589位置附近，在ALK激酶结构域中也观察到类似的抗性突变。V573也位于ATP/药物结合口袋中的G667和F589残基附近。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26884591', 'NCT02097810', 'clinical trial - phase1', '4', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '1', '.', '.', '类似乳腺分泌性癌', 'na', 'resistance', 'EVI_001251', 'NTRK3:nonsynonymous SNV:exon16:p.G623R:', 'NTRK3', 'nonsynonymous SNV', 'Exact_pos', 'exon16', 'p.G623R', '.', '.', '患有乳腺类似物分泌癌（MASC）的患者的病例报告，其携带etv6-ntrk3融合体。患者接受了entrectinib治疗，并且在7个月后表现出部分反应，随后是疾病进展。在进行性肿瘤中鉴定出NTRK3外显子16 G623R（c.1867G>A）突变。细胞系和结构模型显示该突变赋予对entrectinib的相对抗性。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29466156', '.', 'clinical study', '4', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001252', 'NTRK3:nonsynonymous SNV:exon16:p.G623R:', 'NTRK3', 'nonsynonymous SNV', 'Exact_pos', 'exon16', 'p.G623R', '.', '.', '该临床试验中有6名患者对larotrectinib具有原发耐药性。一名患者先前接受过另一种TRK抑制剂治疗，并且在给予larotrectinib之前进行肿瘤测序，发现激酶结构域的ATP结合位点有NTRK3 G623R突变。NTRK3 G623R突变及其NTRK1 G595R旁系被称为“solvent front mutation\"。是因为它们改变了激酶结构域核苷酸结合环的亲水性溶剂暴露部分，在空间上干扰了laotrectinib的结合，并降低了laotrectinib的抑制效力。该临床试验还分析了10名产生获得性耐药的患者。在7名患者中发现NTRK1 G595R或NTRK3 G623R突变；在两名患者中发现NTRK1 F589L突变，在两名患者中发现NTRK1 G667S或NTRK3 G696A。在3名患者中，发现了一种以上的获得性抗性突变。根据他们的治疗医师的判断，在10名患有获得性耐药的患者中，因为持续的临床获益，8名（80%）继续仍使用larotrectinib进行治疗。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29466156', '.', 'clinical study', '4', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001253', 'NTRK1:nonsynonymous SNV:exon14:p.G595R:', 'NTRK1', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.G595R', '.', '.', '该临床试验中有6名患者对larotrectinib具有原发耐药性。一名患者先前接受过另一种TRK抑制剂治疗，并且在给予larotrectinib之前进行肿瘤测序，发现激酶结构域的ATP结合位点有NTRK3 G623R突变。NTRK3 G623R突变及其NTRK1 G595R旁系被称为“solvent front mutation\"。是因为它们改变了激酶结构域核苷酸结合环的亲水性溶剂暴露部分，在空间上干扰了laotrectinib的结合，并降低了laotrectinib的抑制效力。该临床试验还分析了10名产生获得性耐药的患者。在7名患者中发现NTRK1 G595R或NTRK3 G623R突变；在两名患者中发现NTRK1 F589L突变，在两名患者中发现NTRK1 G667S或NTRK3 G696A。在3名患者中，发现了一种以上的获得性抗性突变。根据他们的治疗医师的判断，在10名患有获得性耐药的患者中，因为持续的临床获益，8名（80%）继续仍使用larotrectinib进行治疗。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29466156', '.', 'clinical study', '4', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001254', 'NTRK1:nonsynonymous SNV:exon14:p.F589L:', 'NTRK1', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.F589L', '.', '.', '该临床试验中有6名患者对larotrectinib具有原发耐药性。一名患者先前接受过另一种TRK抑制剂治疗，并且在给予larotrectinib之前进行肿瘤测序，发现激酶结构域的ATP结合位点有NTRK3 G623R突变。NTRK3 G623R突变及其NTRK1 G595R旁系被称为“solvent front mutation\"。是因为它们改变了激酶结构域核苷酸结合环的亲水性溶剂暴露部分，在空间上干扰了laotrectinib的结合，并降低了laotrectinib的抑制效力。该临床试验还分析了10名产生获得性耐药的患者。在7名患者中发现NTRK1 G595R或NTRK3 G623R突变；在两名患者中发现NTRK1 F589L突变，在两名患者中发现NTRK1 G667S或NTRK3 G696A。在3名患者中，发现了一种以上的获得性抗性突变。根据他们的治疗医师的判断，在10名患有获得性耐药的患者中，因为持续的临床获益，8名（80%）继续仍使用larotrectinib进行治疗。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29466156', '.', 'clinical study', '4', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001255', 'NTRK1:nonsynonymous SNV:exon15:p.G667S:', 'NTRK1', 'nonsynonymous SNV', 'Exact_pos', 'exon15', 'p.G667S', '.', '.', '该临床试验中有6名患者对larotrectinib具有原发耐药性。一名患者先前接受过另一种TRK抑制剂治疗，并且在给予larotrectinib之前进行肿瘤测序，发现激酶结构域的ATP结合位点有NTRK3 G623R突变。NTRK3 G623R突变及其NTRK1 G595R旁系被称为“solvent front mutation\"。是因为它们改变了激酶结构域核苷酸结合环的亲水性溶剂暴露部分，在空间上干扰了laotrectinib的结合，并降低了laotrectinib的抑制效力。该临床试验还分析了10名产生获得性耐药的患者。在7名患者中发现NTRK1 G595R或NTRK3 G623R突变；在两名患者中发现NTRK1 F589L突变，在两名患者中发现NTRK1 G667S或NTRK3 G696A。在3名患者中，发现了一种以上的获得性抗性突变。根据他们的治疗医师的判断，在10名患有获得性耐药的患者中，因为持续的临床获益，8名（80%）继续仍使用larotrectinib进行治疗。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29466156', '.', 'clinical study', '4', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001256', 'NTRK3:nonsynonymous SNV:exon17:p.G696A:', 'NTRK3', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.G696A', '.', '.', '该临床试验中有6名患者对larotrectinib具有原发耐药性。一名患者先前接受过另一种TRK抑制剂治疗，并且在给予larotrectinib之前进行肿瘤测序，发现激酶结构域的ATP结合位点有NTRK3 G623R突变。NTRK3 G623R突变及其NTRK1 G595R旁系被称为“solvent front mutation\"。是因为它们改变了激酶结构域核苷酸结合环的亲水性溶剂暴露部分，在空间上干扰了laotrectinib的结合，并降低了laotrectinib的抑制效力。该临床试验还分析了10名产生获得性耐药的患者。在7名患者中发现NTRK1 G595R或NTRK3 G623R突变；在两名患者中发现NTRK1 F589L突变，在两名患者中发现NTRK1 G667S或NTRK3 G696A。在3名患者中，发现了一种以上的获得性抗性突变。根据他们的治疗医师的判断，在10名患有获得性耐药的患者中，因为持续的临床获益，8名（80%）继续仍使用larotrectinib进行治疗。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:gilteritinib_Revised: 11/2018', '.', 'guideline:FDA', '1', 'Gilteritinib', 'gilteritinib', 'gilteritinib', 'gilteritinib', 'gilteritinib|gilteritinib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_001257', 'FLT3:nonframeshift insertion:exon14:.:ITD', 'FLT3', 'nonframeshift insertion', 'None_pos', 'exon14', '.', 'ITD', '.', 'gilteritinib的批准基于ADMIRAL试验（NCT02421939）的中期分析，其包括138名患有复发或难治性AML的成年患者，这些患者通过LeukoStrat CDx FLT3测定发现携带FLT3 ITD，D835或I836突变。Gilteritinib以每日120 mg的剂量口服给药，直至出现不可接受的毒性或缺乏临床益处。中位随访4.6个月（范围：2.8至15.8）后，29例患者达到完全缓解（CR）或部分血液学恢复CR（CRh）（21%，95%CI：14.5-28.8）。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:gilteritinib_Revised: 11/2018', '.', 'guideline:FDA', '1', 'Gilteritinib', 'gilteritinib', 'gilteritinib', 'gilteritinib', 'gilteritinib|gilteritinib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_001258', 'FLT3:nonsynonymous SNV:exon20:p.D835.:ITD', 'FLT3', 'nonsynonymous SNV', 'Partial_pos', 'exon20', 'p.D835.', 'ITD', '.', 'gilteritinib的批准基于ADMIRAL试验（NCT02421939）的中期分析，其包括138名患有复发或难治性AML的成年患者，这些患者通过LeukoStrat CDx FLT3测定发现携带FLT3 ITD，D835或I836突变。Gilteritinib以每日120 mg的剂量口服给药，直至出现不可接受的毒性或缺乏临床益处。中位随访4.6个月（范围：2.8至15.8）后，29例患者达到完全缓解（CR）或部分血液学恢复CR（CRh）（21%，95%CI：14.5-28.8）。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:gilteritinib_Revised: 11/2018', '.', 'guideline:FDA', '1', 'Gilteritinib', 'gilteritinib', 'gilteritinib', 'gilteritinib', 'gilteritinib|gilteritinib', '4', 'acute myeloid leukemia', 'leukemia', '急性髓性白血病', 'na', 'sensitivity', 'EVI_001259', 'FLT3:nonsynonymous SNV:exon20:p.I836.:ITD', 'FLT3', 'nonsynonymous SNV', 'Partial_pos', 'exon20', 'p.I836.', 'ITD', '.', 'gilteritinib的批准基于ADMIRAL试验（NCT02421939）的中期分析，其包括138名患有复发或难治性AML的成年患者，这些患者通过LeukoStrat CDx FLT3测定发现携带FLT3 ITD，D835或I836突变。Gilteritinib以每日120 mg的剂量口服给药，直至出现不可接受的毒性或缺乏临床益处。中位随访4.6个月（范围：2.8至15.8）后，29例患者达到完全缓解（CR）或部分血液学恢复CR（CRh）（21%，95%CI：14.5-28.8）。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30244854', '.', 'case report', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001260', 'MET:FUS::MET-UBE2H:', 'MET', 'FUS', 'FUS', '.', 'MET-UBE2H', '.', 'A 43-year-old female nonsmoker patient presented to our hospital in September 2014 with a 2-month history of coughing and a 1-month history of back pain. A bronchoscopic biopsy showed that the patient had a stage IV (T2N2M1) lung adenocarcinoma (Fig. 1) and magnetic resonance imaging revealed lumbar and brain metastases. The patient was treated with 2 cycles of chemotherapy (pemetrexed and cisplatin), followed by bone radiotherapy (T8-T10, DT3000 cGy) and wholebrain radiotherapy (DT3000 cGy). The efficacy was stable disease. The amplification refractory mutation system method showed that the adenocarcinoma cells harbored an exon 19 deletion of the EGFR gene. We analyzed the initial tissue upon which was only found EGFR p.E746_S752delinsV by next-generation sequencing (3D Medicines, Shanghai, China). Thus, the patient was administrated erlotinib (150 mg daily) from November 2014 to August 2017. Thus far, no progression of the original lung mass has been identified; however, multiple bone, liver, and adrenal metastases were noted, and the brain metastases had enlarged according to the Response Evaluation Criteria in Solid Tumors version 1.1 in August 2017. Hence, we concluded that the patient had EGFR–tyrosine kinase inhibitor (TKI) resistance. Therefore, a repeat liquid biopsy was performed, which showed an acquired MET-UBE2H fusion gene by next-generation sequencing (3D Medicines) (Fig. 2). The disease progressed, so the patient was switched to crizotinib (250 mg twice daily) in September 2017 (Fig. 3A). She achieved a partial response and progression-free survival at more than 6.5 months (Fig. 3B).', '1名43岁的女性非吸烟患者于2014年9月入院，有2个月的咳嗽史和1个月的背痛史。支气管镜活检显示患者患有IV期（T2N2M1）肺腺癌，磁共振成像显示腰椎和脑转移。患者接受2个周期的化疗（培美曲塞和顺铂），然后进行骨放疗（T8-T10，DT3000 cGy）和全脑放疗（DT3000 cGy），疾病稳定。检测结果显示腺癌细胞携带EGFR基因的外显子19缺失，仅发现了EGFR p.E746_S752delinsV。从2014年11月到2017年8月，患者给予厄洛替尼（每日150mg）治疗，到目前为止尚未发现原始肺部肿块的进展，根据2017年8月的实体肿瘤1.1版的反应评估标准，发现有多个骨，肝和肾上腺转移，并且脑转移扩大。因此判定患者出现了EGFR-酪氨酸激酶抑制剂（TKI）抗性。重复液体活检结果显示肿瘤细胞中出现获得性MET-UBE2H融合基因。因为疾病进展，患者转为克唑替尼（250 mg，每日两次）治疗。她实现了6.5个月以上的部分缓解和无进展生存。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30177482', '.', 'case report', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_001266', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', 'A 63-year old woman was diagnosed with left breast cancer in July 2012. Left mastectomy with sentinel lymph node biopsy was carried out in August 2012, and pathology revealed ductal carcinoma in situ (high grade), with volume 1.5 1.5 1.2 cm and minor invasion in focal. Further immunohistochemistry revealed estrogen receptor-negative, progesterone receptor-negative, c-erbB2 (3þ), cytokerin 5/6-negative, P63-negative, P53-positive, human type II topoisomerase 20%þ, E-cadherin-positive, EGFR (þ/), and Ki-67 (30%þ). The patient received no adjuvant chemotherapy and radiotherapy. In January 2015, the patient complained of low back pain, and a bone scan revealed multiple bone metastases, including cranial, multiple vertebrae, double ribs, pelvic, and proximal right femurs. The patient then received a total of 6 cycles of docetaxel/cyclophosphamide chemotherapy with trastuzumab from February 2015, and then used trastuzumab as maintenance therapy for about 2 years until intolerance of cardiotoxicity. The assessment result of the treatment was stable disease (SD). The patient further received regular gemcitabine and lapatinib as second-line chemotherapy because of elevated CA-125. However, the condition of the patient decreased gradually as her low back pain increased. On July 4, 2017, the patient suffered from coughing while swallowing, blurred vision and ghosting, poor speech, and left excursion. Enhanced magnetic resonance imaging (MRI) of her head revealed multiple nodular metastases in the brain parenchyma with tumor-invaded cerebral ventricles, which suggested that there might be tumor cells invading into the cerebrospinal fluid (CSF); further whole spine MRI revealed nodular metastases within the seventh cervical spinal cord, and linear leptomeningeal metastasis (type A, according to European association of Neuro-OncologyeEuropean Society for Medical Oncology Clinical Practice Guidelines)11 on cervical and thoracic spinal cord. Because of inhalation pneumonia and poor performance status, the patient could not tolerate radiotherapy and cytotoxic chemotherapy. Although the patient was given mannitol, glycerol fructose, and corticosteroids (5 mg/day), the conscious state deteriorated rapidly in the next week into a state of lethargy. Because permission for lumbar puncture was not given by the patient’s family, next-generation sequencing was then carried out using plasma instead of CSF. The result revealed EGFR Exon19 c.2239-2253 del15(p.L747-T751del) mutation, suggesting that the tumor might be sensitive to EGFR tyrosine kinase inhibitors.Considering the reported drug concentration in CNS, erlotinib could be chosen as the main choice. After the patient provided written, informed consent, the EGFR inhibitor erlotinib was given with a regular dose of 150 mg once daily. Following 2 weeks of targeted drug therapy, the symptoms relieved significantly, which was considered to be an obvious clinical response. Sanity gradually returned to normal, coughing decreased, and blurred vision disappeared. Tumor markers decreased rapidly (Figure 1). Enhanced MRI 1 month after erlotinib therapy showed a partial response, according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria (Figures 2 and 3). The patient then continued to use erlotinib as maintenance therapy. Three months later, the patient returned to normal life completely with her low back pain almost disappeared. To date, the patient already has a PFS time of more than 9 months. No hematologic toxicities were observed. The only toxicity the patient experienced was mild skin rash. No severe toxicities (grade 3-4) and other treatment-related adverse events were reported and detected.', '2012年7月，1名63岁的女性被诊断患有左侧乳腺癌，2012年8月进行了左侧乳房切除术和前哨淋巴结活检，病理学显示为原位导管癌（高级）。2015年1月，患者出现腰痛，骨扫描显示多处骨转移，包括颅骨，多椎骨，双肋骨，骨盆和右近端股骨。患者从2015年2月开始接受6个周期的多西紫杉醇/环磷酰胺化疗与曲妥珠单抗治疗，然后使用曲妥珠单抗作为维持治疗约2年，直至不耐心脏活性。治疗的评估结果是稳定的疾病（SD）。由于CA-125升高，患者进一步接受常规吉西他滨和拉帕替尼作为​​二线化疗。 2017年7月4日，患者出现吞咽困难，视力模糊和重影，言语不良。MRI显示脑实质内有多处结节性转移，肿瘤侵犯脑室，这表明可能有肿瘤细胞侵入脑脊液（CSF）。进一步的全脊柱MRI显示第七颈脊髓内的结节转移和线性软脑膜转移。由于出现吸入性肺炎和不良表现状态，患者不能耐受放疗和细胞毒性化疗。虽然患者给予甘露醇，甘油果糖和皮质类固醇（5mg/天），但意识状态在下一周迅速恶化为昏睡状态。测序结果显示EGFR外显子19 c.2239-2253 del15（p.L747-T751del）突变，提示肿瘤可能对EGFR酪氨酸激酶抑制剂敏感。开始EGFR抑制剂厄洛替尼治疗，2周后症状明显缓解。患者理智逐渐恢复正常，咳嗽减少，视力模糊消失，肿瘤标志物迅速下降。根据实体瘤反应评估标准（RECIST）1.1标准，厄洛替尼治疗1个月后的增强MRI显示部分反应。患者继续使用厄洛替尼作为维持治疗，三个月后，患者完全恢复正常生活，腰痛几乎消失。迄今为止，患者的PFS时间已超过9个月。没有观察到血液学毒性。患者唯一的毒性是轻度皮疹。没有报告和检测到严重毒性（3-4级）和其他治疗相关的不良事件。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30076657', '.', 'preclinical', '4', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', '恩美曲妥珠单抗', 'ado-trastuzumab emtansine|恩美曲妥珠单抗', '4', 'breast cancer', 'breast cancer', '肿瘤细胞', 'na', 'resistance', 'EVI_001270', 'LIFR:CNV:::gain', 'LIFR', 'CNV', 'CNV', '.', '.', 'gain', 'Trastuzumab-emtansine (T-DM1) is an antibody-drug conjugate that has been approved for the treatment of human epidermal growth factor receptor 2 (ERBB2)-positive metastatic breast cancer. Despite the remarkable efficacy of T-DM1 in many patients, resistance to this therapeutic has emerged as a significant clinical problem. In the current study, we used BT-474/KR cells, a T-DM1-resistant cell line established from ERBB2-positive BT-474 breast cancer cells, as a model to investigate mechanisms of T-DM1 resistance and explore effective therapeutic regimens. We show here for the first time that activation of signal transducer and activator of transcription 3 (STAT3) mediated by leukemia inhibitory factor receptor (LIFR) overexpression confers resistance to T-DM1. Moreover, secreted factors induced by activated STAT3 in resistant cells limit the responsiveness of cells that were originally sensitive to T-DM1. Importantly, STAT3 inhibition sensitizes resistant cells to T-DM1, both in vitro and in vivo, suggesting that the combination T-DM1 with STAT3-targeted therapy is a potential treatment for T-DM1-refractory patients.', '曲妥珠单抗-小分子偶联物（T-DM1）已被批准用于治疗人表皮生长因子受体2（ERBB2）阳性转移性乳腺癌。尽管T-DM1在许多患者中具有显著的功效，但该治疗剂的抗性已成为一个重要的临床问题。BT-474/KR细胞是一种由ERBB2阳性BT-474乳腺癌细胞建立的T-DM1抗性细胞系，研究人员用其作为研究T-DM1抗性机制并探索有效治疗方案的模型。研究人员发现白血病抑制因子受体（LIFR）过表达介导的信号转导和转录激活因子3（STAT3）的激活可赋予肿瘤对T-DM1的抗性。此外，活化的STAT3在抗性细胞中诱导的分泌因子可限制了最初对T-DM1敏感的细胞的反应性。重要的是，STAT3抑制在体外和体内均使T-DM1的抗性细胞敏感，这表明T-DM1与STAT3靶向治疗的组合是T-DM1难治性患者的潜在治疗方法。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29247021', 'NCT01781429', 'clinical trial - phase1', '4', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib|ulixertinib', '1', 'melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001272', 'NRAS:nonsynonymous SNV:::act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In dose expansion, the tumor response and duration on study for each cohort are depicted in Fig. 4A and B, respectively. PRs were seen in 11 of 81 (14%) evaluable patients, including 3 of 18 with NRAS-mutant melanoma, 3 of 12 with BRAF-mutant lung cancer (2 with V600E and 1 with L597Q), 1 of 15 with BRAF/MEK inhibitor–refractory BRAF V600E–mutant melanoma, and 4 of 21 with other BRAF-mutant cancers. These include one each of BRAF L485W gallbladder cancer (Fig. 5A), BRAF V600E glioblastoma multiforme (Fig. 5B), BRAF G469A head and neck cancer, and BRAF G469A small-bowel cancer. Of these patients, two of the responses lasted greater than 4.9 months. The maximal tumor responses for patients with BRAF non-V600 mutations (n = 28) are shown in Fig. 4C and are classified by their kinase activity (12, 40). Of note, central nervous system (CNS) responses were seen in a patient with BRAF V600E–mutant lung cancer with metastases, and another with BRAF V600E–mutant glioblastoma mulitforme.', '一项Ulixertinib (BVD-523)的临床试验中，81例（14%）可评估患者中有11例出现部分缓解，其中包括3例NRAS突变黑色素瘤，3例BRAF突变肺癌（V600E 2例，L597Q 1例），1例BRAF/MEK抑制剂难治性BRAF V600E突变黑色素瘤，以及4例其他BRAF突变型癌症：包括BRAF L485W胆囊癌，BRAF V600E多形性胶质母细胞瘤，BRAF G469A头颈癌和BRAF G469A小肠癌各一种。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29247021', 'NCT01781429', 'clinical trial - phase1', '4', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib|ulixertinib', '1', 'lung cancer', '.', '肺癌', 'na', 'sensitivity', 'EVI_001273', 'BRAF:nonsynonymous SNV:exon15:p.L597.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.L597.', '.', 'In dose expansion, the tumor response and duration on study for each cohort are depicted in Fig. 4A and B, respectively. PRs were seen in 11 of 81 (14%) evaluable patients, including 3 of 18 with NRAS-mutant melanoma, 3 of 12 with BRAF-mutant lung cancer (2 with V600E and 1 with L597Q), 1 of 15 with BRAF/MEK inhibitor–refractory BRAF V600E–mutant melanoma, and 4 of 21 with other BRAF-mutant cancers. These include one each of BRAF L485W gallbladder cancer (Fig. 5A), BRAF V600E glioblastoma multiforme (Fig. 5B), BRAF G469A head and neck cancer, and BRAF G469A small-bowel cancer. Of these patients, two of the responses lasted greater than 4.9 months. The maximal tumor responses for patients with BRAF non-V600 mutations (n = 28) are shown in Fig. 4C and are classified by their kinase activity (12, 40). Of note, central nervous system (CNS) responses were seen in a patient with BRAF V600E–mutant lung cancer with metastases, and another with BRAF V600E–mutant glioblastoma mulitforme.', '一项Ulixertinib (BVD-523)的临床试验中，81例（14%）可评估患者中有11例出现部分缓解，其中包括3例NRAS突变黑色素瘤，3例BRAF突变肺癌（V600E 2例，L597Q 1例），1例BRAF/MEK抑制剂难治性BRAF V600E突变黑色素瘤，以及4例其他BRAF突变型癌症：包括BRAF L485W胆囊癌，BRAF V600E多形性胶质母细胞瘤，BRAF G469A头颈癌和BRAF G469A小肠癌各一种。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29247021', 'NCT01781429', 'clinical trial - phase1', '4', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib|ulixertinib', '1', 'lung cancer', '.', '肺癌', 'na', 'sensitivity', 'EVI_001274', 'BRAF:nonsynonymous SNV:exon15:p.V600.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'In dose expansion, the tumor response and duration on study for each cohort are depicted in Fig. 4A and B, respectively. PRs were seen in 11 of 81 (14%) evaluable patients, including 3 of 18 with NRAS-mutant melanoma, 3 of 12 with BRAF-mutant lung cancer (2 with V600E and 1 with L597Q), 1 of 15 with BRAF/MEK inhibitor–refractory BRAF V600E–mutant melanoma, and 4 of 21 with other BRAF-mutant cancers. These include one each of BRAF L485W gallbladder cancer (Fig. 5A), BRAF V600E glioblastoma multiforme (Fig. 5B), BRAF G469A head and neck cancer, and BRAF G469A small-bowel cancer. Of these patients, two of the responses lasted greater than 4.9 months. The maximal tumor responses for patients with BRAF non-V600 mutations (n = 28) are shown in Fig. 4C and are classified by their kinase activity (12, 40). Of note, central nervous system (CNS) responses were seen in a patient with BRAF V600E–mutant lung cancer with metastases, and another with BRAF V600E–mutant glioblastoma mulitforme.', '一项Ulixertinib (BVD-523)的临床试验中，81例（14%）可评估患者中有11例出现部分缓解，其中包括3例NRAS突变黑色素瘤，3例BRAF突变肺癌（V600E 2例，L597Q 1例），1例BRAF/MEK抑制剂难治性BRAF V600E突变黑色素瘤，以及4例其他BRAF突变型癌症：包括BRAF L485W胆囊癌，BRAF V600E多形性胶质母细胞瘤，BRAF G469A头颈癌和BRAF G469A小肠癌各一种。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29247021', 'NCT01781429', 'clinical trial - phase1', '4', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib|ulixertinib', '1', 'melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001275', 'BRAF:nonsynonymous SNV:exon15:p.V600.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'In dose expansion, the tumor response and duration on study for each cohort are depicted in Fig. 4A and B, respectively. PRs were seen in 11 of 81 (14%) evaluable patients, including 3 of 18 with NRAS-mutant melanoma, 3 of 12 with BRAF-mutant lung cancer (2 with V600E and 1 with L597Q), 1 of 15 with BRAF/MEK inhibitor–refractory BRAF V600E–mutant melanoma, and 4 of 21 with other BRAF-mutant cancers. These include one each of BRAF L485W gallbladder cancer (Fig. 5A), BRAF V600E glioblastoma multiforme (Fig. 5B), BRAF G469A head and neck cancer, and BRAF G469A small-bowel cancer. Of these patients, two of the responses lasted greater than 4.9 months. The maximal tumor responses for patients with BRAF non-V600 mutations (n = 28) are shown in Fig. 4C and are classified by their kinase activity (12, 40). Of note, central nervous system (CNS) responses were seen in a patient with BRAF V600E–mutant lung cancer with metastases, and another with BRAF V600E–mutant glioblastoma mulitforme.', '一项Ulixertinib (BVD-523)的临床试验中，81例（14%）可评估患者中有11例出现部分缓解，其中包括3例NRAS突变黑色素瘤，3例BRAF突变肺癌（V600E 2例，L597Q 1例），1例BRAF/MEK抑制剂难治性BRAF V600E突变黑色素瘤，以及4例其他BRAF突变型癌症：包括BRAF L485W胆囊癌，BRAF V600E多形性胶质母细胞瘤，BRAF G469A头颈癌和BRAF G469A小肠癌各一种。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29247021', 'NCT01781429', 'clinical trial - phase1', '4', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib|ulixertinib', '1', 'gallbladder cancer', '.', '胆囊癌', 'na', 'sensitivity', 'EVI_001276', 'BRAF:nonsynonymous SNV:exon12:p.L485W:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon12', 'p.L485W', '.', 'In dose expansion, the tumor response and duration on study for each cohort are depicted in Fig. 4A and B, respectively. PRs were seen in 11 of 81 (14%) evaluable patients, including 3 of 18 with NRAS-mutant melanoma, 3 of 12 with BRAF-mutant lung cancer (2 with V600E and 1 with L597Q), 1 of 15 with BRAF/MEK inhibitor–refractory BRAF V600E–mutant melanoma, and 4 of 21 with other BRAF-mutant cancers. These include one each of BRAF L485W gallbladder cancer (Fig. 5A), BRAF V600E glioblastoma multiforme (Fig. 5B), BRAF G469A head and neck cancer, and BRAF G469A small-bowel cancer. Of these patients, two of the responses lasted greater than 4.9 months. The maximal tumor responses for patients with BRAF non-V600 mutations (n = 28) are shown in Fig. 4C and are classified by their kinase activity (12, 40). Of note, central nervous system (CNS) responses were seen in a patient with BRAF V600E–mutant lung cancer with metastases, and another with BRAF V600E–mutant glioblastoma mulitforme.', '一项Ulixertinib (BVD-523)的临床试验中，81例（14%）可评估患者中有11例出现部分缓解，其中包括3例NRAS突变黑色素瘤，3例BRAF突变肺癌（V600E 2例，L597Q 1例），1例BRAF/MEK抑制剂难治性BRAF V600E突变黑色素瘤，以及4例其他BRAF突变型癌症：包括BRAF L485W胆囊癌，BRAF V600E多形性胶质母细胞瘤，BRAF G469A头颈癌和BRAF G469A小肠癌各一种。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29247021', 'NCT01781429', 'clinical trial - phase1', '4', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib|ulixertinib', '1', 'glioblastoma multiforme', '.', '多形性胶质母细胞瘤', 'na', 'sensitivity', 'EVI_001277', 'BRAF:nonsynonymous SNV:exon15:p.V600.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'In dose expansion, the tumor response and duration on study for each cohort are depicted in Fig. 4A and B, respectively. PRs were seen in 11 of 81 (14%) evaluable patients, including 3 of 18 with NRAS-mutant melanoma, 3 of 12 with BRAF-mutant lung cancer (2 with V600E and 1 with L597Q), 1 of 15 with BRAF/MEK inhibitor–refractory BRAF V600E–mutant melanoma, and 4 of 21 with other BRAF-mutant cancers. These include one each of BRAF L485W gallbladder cancer (Fig. 5A), BRAF V600E glioblastoma multiforme (Fig. 5B), BRAF G469A head and neck cancer, and BRAF G469A small-bowel cancer. Of these patients, two of the responses lasted greater than 4.9 months. The maximal tumor responses for patients with BRAF non-V600 mutations (n = 28) are shown in Fig. 4C and are classified by their kinase activity (12, 40). Of note, central nervous system (CNS) responses were seen in a patient with BRAF V600E–mutant lung cancer with metastases, and another with BRAF V600E–mutant glioblastoma mulitforme.', '一项Ulixertinib (BVD-523)的临床试验中，81例（14%）可评估患者中有11例出现部分缓解，其中包括3例NRAS突变黑色素瘤，3例BRAF突变肺癌（V600E 2例，L597Q 1例），1例BRAF/MEK抑制剂难治性BRAF V600E突变黑色素瘤，以及4例其他BRAF突变型癌症：包括BRAF L485W胆囊癌，BRAF V600E多形性胶质母细胞瘤，BRAF G469A头颈癌和BRAF G469A小肠癌各一种。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29247021', 'NCT01781429', 'clinical trial - phase1', '4', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib|ulixertinib', '1', 'head and neck cancer', '.', '头颈部肿瘤', 'na', 'sensitivity', 'EVI_001278', 'BRAF:nonsynonymous SNV:exon11:p.G469A:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.G469A', '.', 'In dose expansion, the tumor response and duration on study for each cohort are depicted in Fig. 4A and B, respectively. PRs were seen in 11 of 81 (14%) evaluable patients, including 3 of 18 with NRAS-mutant melanoma, 3 of 12 with BRAF-mutant lung cancer (2 with V600E and 1 with L597Q), 1 of 15 with BRAF/MEK inhibitor–refractory BRAF V600E–mutant melanoma, and 4 of 21 with other BRAF-mutant cancers. These include one each of BRAF L485W gallbladder cancer (Fig. 5A), BRAF V600E glioblastoma multiforme (Fig. 5B), BRAF G469A head and neck cancer, and BRAF G469A small-bowel cancer. Of these patients, two of the responses lasted greater than 4.9 months. The maximal tumor responses for patients with BRAF non-V600 mutations (n = 28) are shown in Fig. 4C and are classified by their kinase activity (12, 40). Of note, central nervous system (CNS) responses were seen in a patient with BRAF V600E–mutant lung cancer with metastases, and another with BRAF V600E–mutant glioblastoma mulitforme.', '一项Ulixertinib (BVD-523)的临床试验中，81例（14%）可评估患者中有11例出现部分缓解，其中包括3例NRAS突变黑色素瘤，3例BRAF突变肺癌（V600E 2例，L597Q 1例），1例BRAF/MEK抑制剂难治性BRAF V600E突变黑色素瘤，以及4例其他BRAF突变型癌症：包括BRAF L485W胆囊癌，BRAF V600E多形性胶质母细胞瘤，BRAF G469A头颈癌和BRAF G469A小肠癌各一种。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29247021', 'NCT01781429', 'clinical trial - phase1', '4', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib', 'ulixertinib|ulixertinib', '1', 'small-bowel cancer', '.', '小肠癌', 'na', 'sensitivity', 'EVI_001279', 'BRAF:nonsynonymous SNV:exon11:p.G469A:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.G469A', '.', 'In dose expansion, the tumor response and duration on study for each cohort are depicted in Fig. 4A and B, respectively. PRs were seen in 11 of 81 (14%) evaluable patients, including 3 of 18 with NRAS-mutant melanoma, 3 of 12 with BRAF-mutant lung cancer (2 with V600E and 1 with L597Q), 1 of 15 with BRAF/MEK inhibitor–refractory BRAF V600E–mutant melanoma, and 4 of 21 with other BRAF-mutant cancers. These include one each of BRAF L485W gallbladder cancer (Fig. 5A), BRAF V600E glioblastoma multiforme (Fig. 5B), BRAF G469A head and neck cancer, and BRAF G469A small-bowel cancer. Of these patients, two of the responses lasted greater than 4.9 months. The maximal tumor responses for patients with BRAF non-V600 mutations (n = 28) are shown in Fig. 4C and are classified by their kinase activity (12, 40). Of note, central nervous system (CNS) responses were seen in a patient with BRAF V600E–mutant lung cancer with metastases, and another with BRAF V600E–mutant glioblastoma mulitforme.', '一项Ulixertinib (BVD-523)的临床试验中，81例（14%）可评估患者中有11例出现部分缓解，其中包括3例NRAS突变黑色素瘤，3例BRAF突变肺癌（V600E 2例，L597Q 1例），1例BRAF/MEK抑制剂难治性BRAF V600E突变黑色素瘤，以及4例其他BRAF突变型癌症：包括BRAF L485W胆囊癌，BRAF V600E多形性胶质母细胞瘤，BRAF G469A头颈癌和BRAF G469A小肠癌各一种。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29932283', '.', 'case report', '4', 'tocilizumab', 'tocilizumab', 'tocilizumab', 'tocilizumab', 'tocilizumab|tocilizumab', '.', 'angiomatoid fibrous histiocytoma', 'angiomatoid fibrous histiocytoma', '血管样纤维组织细胞瘤', 'na', 'sensitivity', 'EVI_001282', 'EWSR1:FUS::EWSR1-.:', 'EWSR1', 'FUS', 'FUS', '.', 'EWSR1-.', '.', 'Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor that has been associated with EWSR1-CREB1 gene fusion. Outcome in patients with unresectable distant metastases is generally fatal. Interleukin-6 (IL-6) secretion has been described in tumors with EWSR1-CREB1 fusion, and may promote tumor growth due to autocrine stimulation. Tocilizumab is an IL-6 receptor antibody that has potential benefit as a targeted therapy in refractory neoplasms with IL-6 secretion. We describe a child with metastatic AFH with EWSR1-CREB1 fusion and elevated IL-6 whose disease progressed during treatment with traditional chemotherapeutic agents, but improved after targeted therapy with tocilizumab.', '血管样纤维组织细胞瘤（AFH）是一种罕见的软组织肿瘤，与EWSR1-CREB1基因融合有关，无法切除的远处转移患者的预后极差。在具有EWSR1-CREB1融合的肿瘤中白细胞介素-6（IL-6）的分泌增加并且促进由自分泌刺激引起的肿瘤生长。 tocilizumab是一种IL-6受体抗体，具有作为IL-6分泌难治性肿瘤靶向治疗的潜在益处。一名携带EWSR1-CREB1融合的转移性AFH患儿在化疗期间疾病进展，IL-6升高，但在用tocilizumab靶向治疗后有所改善。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29912633', '.', 'preclinical', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'resistance', 'EVI_001283', 'ANXA2:CNV:::gain', 'ANXA2', 'CNV', 'CNV', '.', '.', 'gain', 'Triple negative breast cancer (TNBC) patients cannot benefit from EGFR-targeted therapy even though the EGFR is highly expressed, because patients exhibit resistance to these drugs. Unfortunately, the molecular mechanisms remain relatively unknown. ANXA2, highly expressed in invasive breast cancer cells, is closely related with poor prognosis, and acts as a molecular switch to EGFR activation. In this study, MDA-MB-231 cells and MCF7 cells were used. Our results showed that ANXA2 expression is inversely correlated with cell sensitivity to gefitinib. Knockdown of ANXA2 expression in MDA-MB-231 cells increased the gefitinib induced cell death. When ANXA2 was overexpressed in MCF7 cells, the gefitinib induced cell death was decreased. Furthermore, we demonstrated that phosphorylation of ANXA2 at Tyr23 is negatively correlated with the sensitivity of TNBC to gefitinib. Altogether, our results suggest a new role of ANXA2 in regulating sensitivity of TNBC MDA-MB-231 cells to the EGFR inhibitor gefitinib.', '即使EGFR高表达，三阴性乳腺癌（TNBC）患者也不能从EGFR靶向治疗中受益，因为患者对这些药物表现出抗性，其分子机制仍然相对未知。 ANXA2在浸润性乳腺癌细胞中高表达，与预后不良密切相关，并可作为EGFR激活的分子转换器。研究人员分析了MDA-MB-231细胞和MCF7细胞，结果显示ANXA2表达与细胞对吉非替尼的敏感性呈负相关，在MDA-MB-231细胞中敲除ANXA2表达增加了吉非替尼诱导的细胞死亡，当ANXA2在MCF7细胞中过表达时，吉非替尼诱导的细胞死亡减少。结果表明ANXA2在调节TNBC MDA-MB-231细胞对EGFR抑制剂吉非替尼的敏感性中的作用。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:20479403', 'NCT00266877', 'clinical trial - phase2', '4', 'neratinib', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001291', 'EGFR:nonsynonymous SNV:exon18:p.G719.:', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon18', 'p.G719.', '.', '.', '来那替尼是不可逆的二代酪氨酸激酶抑制剂。一项II期临床试验评估了来那替尼在晚期非小细胞肺癌患者中的安全性和有效性。4例携带EGFR G719X突变的患者中有3例部分有效，另一例患者病情稳定达40周。这4例患者的中位无进展生存期为52.7周 (Sequist et al., 2010)。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/1538-7445.AM2017-694', 'NCT02657005', 'clinical trial - phase1', '4', 'TK-216', 'TK-216', 'TK-216', 'TK-216', 'TK-216|TK-216', '1', 'ewing sarcoma', 'ewing sarcoma', '尤文肉瘤', 'na', 'sensitivity', 'EVI_001296', 'EWS:FUS::EWS-FLI1:', 'EWS', 'FUS', 'FUS', '.', 'EWS-FLI1', '.', 'One of the most significant challenges in creating more potent, less toxic treatments for patients is to identify new cancer therapeutic targets that distinguish the malignant from normal cells. EWS-FLI1 is a well-established Ewing sarcoma (ES) oncogene that has the potential to be an ideal therapeutic target by directly impacting malignant cells. We have previously reported the discovery and characterization of YK-4-279, an enantiomer-specific inhibitor of EWS-FLI1, which has been demonstrated to induce apoptosis, inhibit EWS-FLI1 transcription, block RNA helicase A co-immunoprecipitation with EWS-FLI1, and result in alternative splicing to mimic EWS-FLI1 knockdown. Continuous efforts in structure-guided medicinal chemistry has yielded TK-216, an analog of YK-4-279 inhibitor of EWS-FLI1, which is 3-4 fold more potent with excellent drug-like properties. TK-216 potently inhibits the proliferation of ES cells. Induces apoptosis in a dose -dependent manner as measured by caspase-3 activity in multiple ES cell lines with distinct translocation variants. The effects of TK-216 on alternative splicing (AS) were further validated using genes including ARID1A, CLK1, CASP3, PPFIBP1 and RUNX2. The splicing pattern was similar between TK-216 and YK-4-279. In addition to the in vitro activity of TK-216 , we show that TK-216 displays anti-tumor activity in a number of ES xenograft models. In summary, TK-216, a novel, first-in-class therapeutic which directly inhibits EWS-FLI1, offers a promising approach for the treatment of Ewing Sarcoma and is currently in Phase 1 clinical trials in patients with relapsed or refractory Ewing Sarcoma (clinicaltrials.gov - NCT02657005).', 'EWS-FLI1是一种成熟尤文肉瘤（ES）致癌基因，可直接影响恶性细胞，有可能成为理想的治疗靶点。YK-4-279是EWS-FLI1对映体的特异性抑制剂，已被证明可诱导细胞凋亡，抑制EWS-FLI1转录，阻断RNA解旋酶A与EWS-FLI1的共免疫沉淀，导致EWS-FLI1敲除效应。TK-216可有效抑制ES细胞的增殖，研究人员进一步验证了TK-216对EWS-FLI1选择性剪接（AS）的影响。TK-216和YK-4-279之间的剪接模式相似。除了TK-216的体外活性外，研究人员还发现TK-216在许多ES异种移植模型中显示出抗肿瘤活性。总之，TK-216是一种可直接抑制EWS-FLI1的新型治疗药物，为治疗尤文肉瘤提供了一种有前景的方法。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27764830', '.', 'clinical study', '4', 'crizotinib + pazopanib', 'crizotinib + pazopanib', 'crizotinib + pazopanib', '克唑替尼 + 培唑帕尼', 'crizotinib + pazopanib|克唑替尼 + 培唑帕尼', '4', ' gastrointestinal neuroectodermal tumor', ' gastrointestinal neuroectodermal tumor', '胃肠道神经外胚层瘤', 'na', 'sensitivity', 'EVI_001297', 'EWSR1:FUS::EWSR1-.:', 'EWSR1', 'FUS', 'FUS', '.', 'EWSR1-.', '.', 'Malignant gastrointestinal neuroectodermal tumor (GNET) is an aggressive rare tumor, primarily occurring in young adults with frequent local-regional metastases and recurrence after local control. The tumor is characterized by the presence of EWSR1-ATF1 or EWSR1-CREB1 and immunohistochemical positivity for S-100 protein without melanocytic marker positivity. Due to poor responses to standard sarcoma regimens, GNET has a poor prognosis, and development of effective systemic therapy is desperately needed to treat these patients. Herein, we present a patient with a small bowel GNET who experienced recurrent hepatic and skeletal metastases after a primary resection. Comprehensive genomic profiling (CGP) in the course of clinical care with DNA and RNA sequencing demonstrated the presence of an exon 7 to exon 6 EWSR1-CREB1 fusion in the context of a diploid genome with no other genomic alterations. In a clinical trial, the patient received a combination of 250 mg crizotinib with 600 mg pazopanib quaque die and achieved partial response and durable clinical benefit for over 2.8 years, and with minimal toxicity from therapy. Using a CGP database of over 50,000 samples, we identified 11 additional cases that harbor EWSR1-CREB1 and report clinicopathologic characteristics, as these patients may also benefit from such a regimen.', '恶性胃肠道神经外胚层瘤（GNET）是一种侵袭性罕见肿瘤，肿瘤可能存在EWSR1-ATF1或EWSR1-CREB1融合基因变异。一个小肠GNET患者在初次切除后经历了复发性肝和骨骼转移，综合基因组分析（CGP）证明存在EWSR1-CREB1融合，没有其他基因组改变。患者接受了250mg克唑替尼与600mg培唑帕尼的组合治疗，获得了部分反应和持久的临床益处，并且治疗毒性极小。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2017.35.15_suppl.TPS2618 Journal of Clinical Oncology 35, no. 15_suppl ', 'NCT02383927', 'clinical trial - phase2', '4', 'tipifarnib', 'tipifarnib', 'tipifarnib', 'tipifarnib', 'tipifarnib|tipifarnib', '2', 'neck squamous cell carcinomas', 'neck squamous cell carcinomas', '头颈部肿瘤', 'na', 'sensitivity', 'EVI_001298', 'HRAS:nonsynonymous SNV:.:.:act', 'HRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Background: HRAS is a proto-oncogene overexpressed and mutated in head and neck squamous cell carcinomas (HNSCC), bladder, thyroid and salivary gland tumors, among others. Although discovered over 40 years ago, no therapies are yet approved targeting mutant HRAS. Tipifarnib is a potent and highly selective inhibitor of farnesyltransferase, a critical enzyme required for the proper function of HRAS. This Phase 2 study (NCT02383927) was conducted to test the hypothesis that inhibition of HRAS oncogenic activity could translate to objective responses in solid tumors.Methods: The study was designed to enroll patients (pts) into 2 single-arm study cohorts: Cohort 1 (thyroid cancer) and Cohort 2 (other solid tumors), each one with a 2-stage design to determine overall response rate (ORR) as the primary objective. This design has 80% power to detect a difference between 10% and 30% ORR at one-sided significance level of 0.087. A study cohort was to be considered positive if at least 4 responses were observed (N = 36, 18 evaluable subjects/cohort). For enrollment, pts must have an HRAS mutation, locally advanced/unresectable and/or metastatic, and RECIST v1.1 measurable disease. Tipifarnib was dosed at 900 mg orally twice daily on days 1-7 and 15-21 of 28-day cycles.Results: As of May 1, 2018, 37 pts have been treated, including 11 pts with HRAS mutated HNSCC and 2 pts with HRAS mutated SCC. Tipifarnib was generally well tolerated, with fatigue, myelosuppression, nausea and vomiting constituting the most common adverse events (all grades). 7 HNSCC pts are currently evaluable for efficacy; 5 (71%) achieved a confirmed partial response with a median duration of response of 14.1 months (95% CI: 1.4-17.3 mo), exceeding the pre-specified null hypothesis. Importantly, no HRAS mutated HNSCC pt experienced an objective response on their last therapy prior to receiving tipifarnib (including platinum, immunotherapy and cetuximab +/- chemotherapy regimens).Conclusions: Encouraging activity of tipifarnib was observed in pts with HRAS mutant HNSCCs. The study met its predefined success criteria and has been amended to continue enrolling HRAS mutant HNSCC pts, as well as pts with SCC, other than HNSCC, with HRAS mutations into a new Cohort 3.', 'HRAS是在头颈部鳞状细胞癌（HNSCC），膀胱，甲状腺和唾液腺肿瘤等肿瘤中过表达和突变的原癌基因。尽管在40多年前发现，但尚未批准针对突变HRAS的治疗方法。tipifarnib是一种有效的高选择性法呢基转移酶抑制剂，法呢基转移酶是HRAS正常功能所必需的关键酶。该研究将患者（pts）纳入2个单臂研究队列：队列1 （甲状腺癌）和队列2（其他实体瘤），每一个都采用2阶段设计，以总体反应率（ORR）为主要目标。如果观察到至少4个反应，则研究群组被认为是阳性的。研究对象为具有HRAS突变，局部晚期/不可切除和/或转移，以及RECIST v1.1可测量的肿瘤患者。以28天为一周期，tipifarnib在第1-7天和第15-21天口服给药900mg，每天两次。结果：截至2018年5月1日，已经治疗37例实体瘤患者，包括11例患有HRAS突变的HNSCC。tipifarnib一般耐受性良好，疲劳，骨髓抑制，恶心和呕吐是最常见的不良事件（所有等级）。目前HNSCC患者的疗效可评估：5例达到确诊的部分缓解，中位反应持续时间为14.1个月。结论：在HRAS突变HNSCC的患者中观察到了tipifarnib的潜在活性。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2016.09.010', 'NCT01901653', 'clinical trial - phase2', '4', 'Rovalpituzumab tesirine', 'Rovalpituzumab tesirine', 'rovalpituzumab tesirine', 'rovalpituzumab tesirine', 'rovalpituzumab tesirine|rovalpituzumab tesirine', '2', 'small cell lung cancer', 'small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001299', 'DLL3:CNV:::gain', 'DLL3', 'CNV', 'CNV', '.', '.', 'gain', 'Background：Small cell lung cancer (SCLC) remains among the most deadly of malignancies. Rovalpituzumab tesirine (Rova-T™) is a first-in-class antibody-drug conjugate (ADC) comprised of a humanized monoclonal antibody against DLL3, a dipeptide linker, and a pyrrolobenzodiazepine (PBD) dimer toxin. DLL3 is highly expressed in neuroendocrine tumors, including approximately 80% of SCLC. The emerging results of the SCLC patients in a first-in-human study (NCT01901653) are reported here.Methods：Patients with progressive SCLC after at least one previous systemic therapy were eligible. Efficacy was assessed by the investigator via RECIST v1.1, and toxicity graded per CTCAE v4.03. When available, archived tumor tissue was assessed retrospectively for DLL3 expression by immunohistochemistry.Results：Seventy-four (74) patients were enrolled at dose levels ranging from 0.05 to 0.8 mg/kg at either q3w or q6w. Among all evaluable patients treated at doses of 0.2 to 0.4 mg/kg, 18% (11 of 60) achieved a confirmed best response of partial response (PR) or complete response (CR), and 68% (41 of 60) achieved clinical benefit with a best response of at least stable disease (SD). Among patients with available archive tissue specimens and ≥ 50% of cells expressing DLL3 (DLL3hi, an intended companion diagnostic cutoff), 39% (10 of 26) achieved a confirmed best response of PR or CR, and 89% (23 of 26) had clinical benefit. Independent central review largely confirmed investigator assessed responses. The response rate and 1-year overall survival (OS) observed here compares favorably to existing second- and third-line treatment options (Horita et al. Sci Rep 2015 and Simos et al. Clin Lung Cancer 2014, respectively). In the second-line setting, Rova-T delivered a 43% and 14% confirmed overall response rate (cORR) among patients sensitive or refractory to frontline therapy, and 1-year OS was 38% and 19%, respectively. In the third-line setting, Rova-T conveyed a 50% cORR and a 33% 1-year OS benefit. Among all SCLC patients, the most common grade 3+ toxicities considered study drug-related have included thrombocytopenia (12%), serosal effusions (11%), and skin reactions (8%).Conclusion：With manageable toxicity, Rova-T demonstrated encouraging single agent anti-tumor activity and durability in recurrent or refractory SCLC. A single-arm pivotal study in third-line DLL3-expressing SCLC is currently enrolling (NCT02674568).', '小细胞肺癌（SCLC）是最致命的恶性肿瘤之一。Rovalpituzumab tesirine（Rova-T™）是一种一流的抗体-药物偶联物（ADC），由针对DLL3的人源化单克隆抗体，二肽接头和吡咯并苯并二氮杂（PBD）二聚体毒素组成。 DLL3在约80%的SCLC中高度表达。研究对象为至少一次全身治疗后的进行性SCLC患者。研究人员通过RECIST v1.1评估功效，并按CTCAE v4.03评定毒性，通过免疫组织化学回顾性评估存档的肿瘤组织中DLL3的表达。74名患者在q3w或q6w时的剂量水平范围为0.05至0.8mg/kg。在0.2至0.4 mg/kg剂量治疗的所有可评估患者中，18%获得了部分缓解（PR）或完全缓解（CR），68%获得了稳定疾病（SD）。在DLL3表达≥50%的可获得的存档组织标本中，39%获得PR或CR的确认最佳反应，89%有临床益处。独立的中央审查在很大程度上证实了该应答率和1年总生存期（OS）优于现有的二线和三线治疗选择。在二线治疗中，Rova-T在前线治疗敏感或难治的SCLC患者中确认了43%和14%的总体反应率（cORR），1年OS分别为38%和19%。在三线治疗中，Rova-T实现了50%的cORR和33%的1年OS。在所有SCLC患者中，最常见的3级以上毒性包括血小板减少症（12%），浆膜渗出液（11%）和皮肤反应（8%）。Rova-T在复发性或难治性SCLC中具有单药抗肿瘤活性和耐久性，还具有可控毒性。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28093244|PMID:27913578', '.', 'preclinical', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001300', 'EGFR:nonsynonymous SNV:exon20:p.L792.<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon20', 'p.L792.<顺式>', '.', '.', 'Osimertinib是一种不可逆的第三代EGFR酪氨酸激酶抑制剂（TKI），在治疗EGFR T790M阳性的晚期非小细胞肺癌方面表现出色，但获得性抵抗往往不可避免的发生。EGFR C797S是最显著的耐药分子机制，但也可能存在其他EGFR突变。 研究发现了三个肺腺癌患者对osimertinib有抗性。通过测序在复发肿瘤患者中存在EGFR Leu792突变，而且该突变在治疗前的肿瘤样本中并不存在，可能是药物诱导的新发突变。结构预测表明Leu792突变可能中断osimerbinib与EGFR的结合，从而引起耐药性。在另一项研究中，作者建立了具有L858R/T790M/L792H（顺式）和L858R/T790M/G796R（顺式）突变的Ba/F3细胞株，以评估接受TKI治疗的疗效。结果显示：三个获批的药物erlotinib、afatinib、osimertinib均不能抑制这些突变细胞株的增殖。与L858R/T790M双突变相比，L858R/T790M/L792H 和L858R/T790M/G796R 三突变对奥希替尼的GI50值增加了25-110倍。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30420181', '.', 'clinical trial - phase1', '4', 'trebananib', 'trebananib', 'trebananib', 'trebananib', 'trebananib|trebananib', '1', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001301', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'INTRODUCTION:Trebananib, a peptide-Fc fusion protein, blocks angiogenesis by inhibiting binding of angiopoietin-1/2 to the receptor tyrosine kinase Tie2. Trebananib plus trastuzumab and paclitaxel was evaluated in human epidermal growth factor receptor 2-positive breast cancer in an open-label phase 1b clinical study.PATIENTS AND METHODS:Women with human epidermal growth factor receptor 2-positive breast cancer received weekly paclitaxel (80 mg/m2), trastuzumab (8 mg/m2 then 6 mg/kg every 3 weeks), and intravenous trebananib (10 mg/kg or 30 mg/kg weekly) beginning week 2. The primary end point was the incidence of dose-limiting toxicities. Secondary end points included incidence of adverse events (AEs), pharmacokinetics, and tumor response (objective response and duration of response).RESULTS:Forty women were enrolled; 2 experienced dose-limiting toxicities (grade 3 ocular transient ischemic attack [10 mg/kg cohort] and grade 3 elevation in γ-glutamyl transferase [30 mg/kg cohort]). The most common treatment-emergent AEs were peripheral edema (n = 28), diarrhea (n = 27), alopecia (n = 26), fatigue (n = 24), and nausea (n = 24). Maximum observed concentration and area under the concentration-time curve increased proportionally with the trebananib dose. Objective response was confirmed in 31 patients. In the 10 mg/kg cohort, 16 patients (80%) experienced partial response, and none experienced complete response. In the 30 mg/kg cohort, 12 patients (71%) experienced partial response and 3 (18%) experienced complete response. Median (95% confidence interval) duration of response in the 10 and 30 mg/kg cohorts was 12.6 (4.3-20.2) and 16.6 (8.2-not estimable) months, respectively.CONCLUSION:This phase 1b study showed that trebananib was tolerated with manageable AEs at a dose up to 30 mg/kg weekly. Trebananib demonstrated anticancer activity, as indicated by objective response and duration of response.', '一项开放标签1b期临床研究评估了trebananib联合曲妥珠单抗和紫杉醇治疗ERBB2+乳腺癌的疗效。患有ERBB2+乳腺癌的女性每周接受紫杉醇80 mg/m2，曲妥珠单抗（初次剂量为8 mg/m2，然后每3周6 mg /kg），从第2周开始静脉注射trebananib（10 mg/kg或30 mg/kg每周）。主要终点是剂量限制毒性发生率，次要终点包括不良事件发生率（AEs），药代动力学和肿瘤反应（客观反应和反应持续时间）。共40名女性入组，2名经历了剂量限制性毒性，最常见的治疗后AE是外周性水肿。共31例患者确诊客观反应。在10 mg/kg组中，80%经历了部分反应，没有人经历完全反应。在30 mg/kg组中，71%经历了部分反应，18%经历了完全反应。两组的中位数响应持续时间分别为12.6和16.6个月。该研究显示trebananib具有抗癌活性，耐受每周剂量可高达30 mg/kg，期间AE可控。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30297384', '.', 'case report', '4', 'alisertib', 'alisertib', 'alisertib', 'alisertib', 'alisertib|alisertib', '3', 'INI-1-deficient carcinoma', 'INI-1-deficient carcinoma', 'INI-1缺陷性癌症', 'na', 'sensitivity', 'EVI_001303', 'SMARCB1:nonsynonymous SNV:.:.:inact', 'SMARCB1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Integrase interactor 1 (INI-1)-deficient carcinoma is a rare cancer characterized by the loss of the SWItch/Sucrose Non-Fermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 gene (SMARCB1) and tends to follow an aggressive clinical course. There is no currently available standard therapy option, although a few promising treatment strategies, including enhancer of zeste homolog 2 (EZH2) inhibition, are under active investigation. This report describes a 30-year-old woman with INI-1-deficient carcinoma who progressed on combination chemotherapy and an EZH2 inhibitor. Next-generation-sequencing-based targeted cancer-related gene assay confirmed SMARCB1 loss and revealed other mutations in breast cancer 1 gene and checkpoint kinase 2 gene, which may have impacted her clinical course. After discussion at the molecular tumor board, she was offered alisertib, an aurora A kinase inhibitor, on a single-patient expanded-use program and achieved prolonged disease stabilization. Aurora A kinase inhibition may have an important role in the management of patients with INI-1-deficient tumors, warranting further evaluation in clinical studies.', '整合素相互作用1（INI-1）缺陷性癌是一种罕见的癌症，其特征SMARCB1基因的缺失突变，目前没有可用的标准治疗选择，一些有希望的治疗策略包括zeste同源物2（EZH2）抑制的增强剂正在积极研究中。研究描述了一名患有INI-1缺陷性癌症的30岁女性，她在联合化疗和EZH2抑制剂作用下取得了进展。靶向癌症的相关基因检测证实了SMARCB1缺失，这可能影响了她的临床过程。患者开始使用alisertib并实现了长期疾病稳定。alisertib可能在INI-1缺陷肿瘤患者的管理中起重要作用，这需要在临床研究中进一步评估。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30262418', '.', 'case report', '4', 'trastuzumab', 'trastuzumab', 'trastuzumab', '曲妥珠单抗', 'trastuzumab|曲妥珠单抗', '4', 'metastatic cholangiocarcinoma', 'metastatic cholangiocarcinoma', '胆管癌', 'na', 'sensitivity', 'EVI_001306', 'ERBB2:nonsynonymous SNV:.:.:act', 'ERBB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Here, we describe a unique case report of two metastatic cholangiocarcinoma patients with different ERBB2 gene aberrations who had received anti-ERBB2 targeted therapy but presented significantly different responses, suggesting the importance of individualized medicine for the management of BTC patients, even those with similar mutation profiles. A 76-year-old female patient presented with mild abdominal distension and anorexia in May 2016. Five months later, her abdominal distension significantly worsened, and she was almost unable to eat, so she was admitted to Beijing Ditan Hospital. Magnetic resonance imaging (MRI) results showed multiple intrahepatic lesions in the right lobe of the liver with soft tissue invasion in the hilar area and gallbladder lesions. Abdominal computed tomography (CT)-guided liver biopsy followed by pathological examination demonstrated moderate differentiated bile duct adenocarcinoma. The patient underwent an endoscopic retrograde cholangiopancreatography (ERCP) combined with plastic stent implantation and presented postoperative pancreatitis. She underwent NGS of her tumor tissue. The results revealed ERBB2 gene amplification and PDK1 gene amplification. The patient had an Eastern Cooperation Oncology Group (ECOG) score of 3, and she refused chemotherapy, accordingly, she started to receive oral lapatinib (1250 mg, daily), but the disease progressed, showing increased intrahepatic lesions, retroperitoneal and intraperitoneal lymph node metastasis and right lung multiple metastasis. The patient was nonresponsive to lapatinib treatment and was eventually deceased one month later.  A 29-year-old man underwent an abdominal CT examination due to abdominal pain, and the results showed solid intrahepatic lesions. In April 2016, the patient underwent CT-guided liver lesion biopsy under general anesthesia Shulan (Hangzhou) Hospital. Pathological examination revealed poorly differentiated cholangiocarcinoma with multiple intrahepatic metastases and chronic cholangitis. NGS testing of his tumor tissue showed ERBB2 gene S310F mutation, TP53 gene S127F mutation and NOTCH3, RUNX1T1, and GNA13 gene mutations. Subsequently, the patient received oral lapatinib (1250 mg, daily) in combination with gemcitabine 1000 mg/m2 day 1 and 8, every 21 days. Six months later MRI examination presented multiple intrahepatic metastases, portal vein and left branch thrombosis, bile duct wall thickness and multiple enlarged lymph nodes in the hilar and retroperitoneal area, suggesting the progression of the disease. His blood workup was normal. The therapeutic regimen was switched to intravenous trastuzumab 8 mg/m2 for first cycle and 6 mg/m2 for subsequent cycles on day 1 combined with gemcitabine 1000 mg/m2 day 1 and 8, every 21 days. Although hypoalbuminemia, rash and fever appeared during chemotherapy, these symptoms alleviated after albumin infusion and anti-allergy treatment. Three months later, follow-up imaging revealed regression of the primary tumor as well as improvement in the metastatic lesions (Fig. 1). The patient has continued this regimen until the present.', '研究人员描述了两个具有不同ERBB2基因畸变的转移性胆管癌患者（BTC）的独特病例报告，这些患者接受了抗ERBB2靶向治疗但呈现出显著不同的反应，这表明个体化药物对于BTC患者的管理的重要性。一名76岁的女性患者于2016年5月出现轻度腹胀和厌食症。五个月后，她的腹胀明显恶化，几乎无法进食，因此被送往医院。磁共振成像（MRI）结果显示肝右叶有多处肝内病变，肺门区和胆囊病变有软组织侵犯。腹部计算机断层扫描（CT）引导的肝活检病理检查显示中度分化的胆管腺癌。患者接受了内镜逆行胰胆管造影术（ERCP）结合塑料支架置入并出现术后胰腺炎。她接受了肿瘤组织的NGS。结果显示ERBB2基因扩增和PDK1基因扩增。该患者的东部肿瘤协作组（ECOG）评分为3分，她拒绝化疗，开始接受口服拉帕替尼（每日1250mg），但病情进展，肝内病变增加，腹膜后和腹膜内淋巴结增多转移和右肺多发转移。患者对拉帕替尼治疗没有反应，最终在一个月后死亡。一名29岁男性因腹痛进行腹部CT检查，结果显示肝内病变。 2016年4月，患者在医院接受CT引导下肝脏病变活检。病理检查显示低分化的胆管癌伴多发性肝内转移和慢性胆管炎。他的肿瘤组织的NGS检测显示ERBB2基因S310F突变，TP53基因S127F突变和NOTCH3，RUNX1T1和GNA13基因突变。随后，患者每21天接受口服拉帕替尼（1250mg，每日）与吉西他滨。 6个月后，MRI检查显示肝门和腹膜后区域有多处肝内转移，门静脉和左支血栓形成，胆管壁厚度和多个淋巴结肿大，提示该疾病的进展。他的血液检查正常。治疗方案转换为静脉曲妥珠单抗，每21天与吉西他滨结合使用。虽然化疗期间出现低蛋白血症，皮疹和发热，但这些症状在输注白蛋白和抗过敏治疗后有所缓解。三个月后，随访成像显示原发肿瘤消退以及转移性病变改善。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ribociclib_Revised: 7/2018', '.', 'guideline:FDA', '1', '.', '.', 'ribociclib + letrozole + goserelin', '瑞波西利 + 来曲唑 + 戈舍瑞林', 'ribociclib + letrozole + goserelin|瑞波西利 + 来曲唑 + 戈舍瑞林', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001307', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', '.', '作为国际多中心大型III期临床试验，MONALEESA-7入组患者要求为绝经或围绝经期HR+/HER2-晚期乳腺癌，ECOG PS≤1；允许患者在疾病晚期阶段接受≤1线化疗，和（或）≤14天的他莫昔芬/NSAI±OFS治疗，排除接受CDK4/6抑制剂治疗。研究共入组晚期患者672例，1:1随机分配进入Ribociclib组（n=335）或安慰剂组（n=337），两组均以他莫昔芬（20 mg/d）+卵巢功能抑制（OFS;goserelin）或NSAI（来曲唑2.5mg/d，阿那曲唑1mg/d）+卵巢功能抑制（OFS;goserelin）为基础用药。分层因素包括：肺转移或肝转移、既往治疗、内分泌联合药物类型。MONALEESA-7的主要研究终点为无进展生存（PFS），次要终点包括总生存（OS）、安全性、耐受性、缓解率、临床获益率、持续缓解时间以及生活质量等。采集受试者的血液样本供生物标志物和药代动力学分析。MONALESSA-7研究中，Ribociclib组的客观缓解率明显优于安慰剂组，分别为50.5% vs 36.2%。Ribociclib对比安慰剂的患者中位PFS分别为27.5个月 vs 13.8个月（HR=0.569; 95% CI: 0.436-0.743）。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ribociclib_Revised: 7/2018', '.', 'guideline:FDA', '1', '.', '.', 'ribociclib + anastrozole + goserelin', '瑞波西利 + 阿那曲唑 + 戈舍瑞林', 'ribociclib + anastrozole + goserelin|瑞波西利 + 阿那曲唑 + 戈舍瑞林', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001308', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', '.', '作为国际多中心大型III期临床试验，MONALEESA-7入组患者要求为绝经或围绝经期HR+/HER2-晚期乳腺癌，ECOG PS≤1；允许患者在疾病晚期阶段接受≤1线化疗，和（或）≤14天的他莫昔芬/NSAI±OFS治疗，排除接受CDK4/6抑制剂治疗。研究共入组晚期患者672例，1:1随机分配进入Ribociclib组（n=335）或安慰剂组（n=337），两组均以他莫昔芬（20 mg/d）+卵巢功能抑制（OFS;goserelin）或NSAI（来曲唑2.5mg/d，阿那曲唑1mg/d）+卵巢功能抑制（OFS;goserelin）为基础用药。分层因素包括：肺转移或肝转移、既往治疗、内分泌联合药物类型。MONALEESA-7的主要研究终点为无进展生存（PFS），次要终点包括总生存（OS）、安全性、耐受性、缓解率、临床获益率、持续缓解时间以及生活质量等。采集受试者的血液样本供生物标志物和药代动力学分析。MONALESSA-7研究中，Ribociclib组的客观缓解率明显优于安慰剂组，分别为50.5% vs 36.2%。Ribociclib对比安慰剂的患者中位PFS分别为27.5个月 vs 13.8个月（HR=0.569; 95% CI: 0.436-0.743）。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30420614', 'NCT01752920', 'clinical trial - phase2', '4', 'ARQ 087', 'ARQ 087', 'ARQ-087', 'ARQ-087', 'ARQ-087|ARQ-087', '2', 'intrahepatic cholangiocarcinoma', 'intrahepatic cholangiocarcinoma', '肝内胆管癌', 'na', 'sensitivity', 'EVI_001310', 'FGFR2:FUS:.:FGFR2-.:.', 'FGFR2', 'FUS', 'FUS', '.', 'FGFR2-.', '.', '.', 'Derazantinib（ARQ 087）是一项I/II期，开放性标记，剂量递增，多中心临床研究，纳入29名肝内胆管癌晚期患者，经NGS或者FISH测定为FGFR2融合突变。其中2名患者，400 mg一日一次；其他患者300 mg一日一次。28天一个周期。主要研究终点是总生存期（OS）和无进展生存期（PFS），其他次要终点是总体响应率（ORR） 和疾病控制率（DCR）。入组的29名患者没有人达到CR（完全缓解），20.7%的患者达到PR（部分缓解），62.1%的患者达到SD（稳定），17.2%患者进展。药物的客观缓解率（ORR）为20.7%，中位持续缓解时间（DOR）为4.6个月，疾病控制率（DCR）高达82.8%。至截稿期，中位随访20个月，中位无进展生存期（PFS）为5.7个月，效果好于二线化疗。唯一的不足，是总生存期（OS）的终点没有达到。', 'F', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27924059|PMID:19692680|PMID:21670455', '.', 'clinical trial - phase2', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'decrease', 'EVI_001311', 'EGFR:CNV:.:.:gain', 'EGFR', 'CNV', 'CNV', '.', '.', 'gain', '.', '表皮生长因子受体（EGFR）抑制剂在携带EGFR激活突变的NSCLC患者中是有效的。厄洛替尼在EGFR基因拷贝数高的患者中的活性被认为是有争议的。进行了一项多中心，开放标签的单臂II期临床试验，以测试厄洛替尼在NSCLC患者的一线治疗中的疗效，所述非小细胞肺癌患者具有在≥40%细胞中定义为≥4拷贝的高EGFR基因拷贝数。2007年12月至2011年4月期间，通过荧光原位杂交（FISH）筛查了149名受试者的肿瘤样品的EGFR基因拷贝数。在49名EGFR FISH阳性的患者中，45名接受了厄洛替尼治疗。意向治疗人群中位PFS为3.3个月（95%CI：1.8-3.9个月），中位总生存期为7.9个月（95%CI：5.1-12.6个月）。越来越多的证据表明EGFR基因拷贝数不应该用于选择NSCLC患者进行EGFR TKI一线治疗，由于道德问题，因此试验过早停止。该试验反对使用EGFR高基因拷贝数选择NSCLC患者进行EGFR TKIs的一线治疗。另外，在比较吉非替尼与卡铂+紫杉醇的IPASS研究中，EGFR阳性突变肿瘤患者使用吉非替尼治疗有明显的PFS优势，而野生型EGFR患者使用化疗有明显的PFS优势[PMID:19692680]。 与化疗相比，在没有EGFR突变、但是存在EGFR基因拷贝数增加的患者中，吉非替尼的PFS显著缩短（HR = 3.85）[PMID:21670455]。 ', 'A', '可能疗效减弱', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27924059|PMID:19692680|PMID:21670455', '.', 'clinical trial - phase2', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'decrease', 'EVI_001312', 'EGFR:CNV:.:.:gain', 'EGFR', 'CNV', 'CNV', '.', '.', 'gain', '.', '表皮生长因子受体（EGFR）抑制剂在携带EGFR激活突变的NSCLC患者中是有效的。厄洛替尼在EGFR基因拷贝数高的患者中的活性被认为是有争议的。进行了一项多中心，开放标签的单臂II期临床试验，以测试厄洛替尼在NSCLC患者的一线治疗中的疗效，所述非小细胞肺癌患者具有在≥40%细胞中定义为≥4拷贝的高EGFR基因拷贝数。2007年12月至2011年4月期间，通过荧光原位杂交（FISH）筛查了149名受试者的肿瘤样品的EGFR基因拷贝数。在49名EGFR FISH阳性的患者中，45名接受了厄洛替尼治疗。意向治疗人群中位PFS为3.3个月（95%CI：1.8-3.9个月），中位总生存期为7.9个月（95%CI：5.1-12.6个月）。越来越多的证据表明EGFR基因拷贝数不应该用于选择NSCLC患者进行EGFR TKI一线治疗，由于道德问题，因此试验过早停止。该试验反对使用EGFR高基因拷贝数选择NSCLC患者进行EGFR TKIs的一线治疗。另外，在比较吉非替尼与卡铂+紫杉醇的IPASS研究中，EGFR阳性突变肿瘤患者使用吉非替尼治疗有明显的PFS优势，而野生型EGFR患者使用化疗有明显的PFS优势[PMID:19692680]。 与化疗相比，在没有EGFR突变、但是存在EGFR基因拷贝数增加的患者中，吉非替尼的PFS显著缩短（HR = 3.85）[PMID:21670455]。 ', 'A', '可能疗效减弱', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30307354', '.', 'case report', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001321', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'BACKGROUND:Substantial progress has been made in metastatic colorectal cancer (mCRC) treatment, but there is still a fraction of patients cannot find any effective therapeutic strategy after guideline-recommended standard chemotherapy and molecular targeted therapy.CASE PRESENTATION:Here we present a KRAS/NRAS/BRAF wild-type mCRC patient who has been previously treated with FOLFIRI (fluorouracil, leucovorin, and irinotecan), XELOX (capecitabine and oxaliplatin), cetuximab and bevacizumab, and then received the next generation sequencing (NGS) and whose metastatic subcutaneous nodule was resected to generate patient-derived xenograft (PDX) models. The NGS revealed HER-2 amplification as well as an activating mutation S310F and PDX models tested several drugs finding that afatinib was the optimal agent with notable efficacy and well tolerance among 6 regimens. Therefore, this patient started to take afatinib orally and achieved 3 months progression-free survival (PFS) and relief of clinical symptoms without severe adverse effects.CONCLUSIONS:NGS and PDX models have great significance for precision and individualized medicine in the mCRC treatment, especially for patients whose diseases have been progressed after multiline standard therapies.', '转移性结直肠癌（mCRC）的治疗取得了实质性进展，但在指南推荐的标准化疗和分子靶向治疗后，仍有一小部分患者找不到任何有效的治疗策略。一名KRAS/NRAS/BRAF野生型mCRC患者，之前曾用FOLFIRI（氟尿嘧啶，甲酰四氢叶酸和伊立替康），XELOX（卡培他滨和奥沙利铂），西妥昔单抗和贝伐单抗治疗，然后接受下一代测序（NGS）及其转移性皮下结节切除生成异种移植物（PDX）模型。 NGS显示存在ERBB2扩增以及活化突变S310F。PDX模型测试了几种药物，发现afatinib是最佳药物，在6种方案中具有显著的疗效和良好的耐受性。因此，该患者开始口服afatinib，实现3个月无进展生存期（PFS），缓解临床症状，无严重不良反应。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30307354|PMID:26243863', '.', 'case report', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001322', 'ERBB2:nonsynonymous SNV::.:act', 'ERBB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'BACKGROUND:Substantial progress has been made in metastatic colorectal cancer (mCRC) treatment, but there is still a fraction of patients cannot find any effective therapeutic strategy after guideline-recommended standard chemotherapy and molecular targeted therapy.CASE PRESENTATION:Here we present a KRAS/NRAS/BRAF wild-type mCRC patient who has been previously treated with FOLFIRI (fluorouracil, leucovorin, and irinotecan), XELOX (capecitabine and oxaliplatin), cetuximab and bevacizumab, and then received the next generation sequencing (NGS) and whose metastatic subcutaneous nodule was resected to generate patient-derived xenograft (PDX) models. The NGS revealed HER-2 amplification as well as an activating mutation S310F and PDX models tested several drugs finding that afatinib was the optimal agent with notable efficacy and well tolerance among 6 regimens. Therefore, this patient started to take afatinib orally and achieved 3 months progression-free survival (PFS) and relief of clinical symptoms without severe adverse effects.CONCLUSIONS:NGS and PDX models have great significance for precision and individualized medicine in the mCRC treatment, especially for patients whose diseases have been progressed after multiline standard therapies.', '转移性结直肠癌（mCRC）的治疗取得了实质性进展，但在指南推荐的标准化疗和分子靶向治疗后，仍有一小部分患者找不到任何有效的治疗策略。一名KRAS/NRAS/BRAF野生型mCRC患者，之前曾用FOLFIRI（氟尿嘧啶，甲酰四氢叶酸和伊立替康），XELOX（卡培他滨和奥沙利铂），西妥昔单抗和贝伐单抗治疗，然后接受下一代测序（NGS）及其转移性皮下结节切除生成异种移植物（PDX）模型。 NGS显示存在ERBB2扩增以及活化突变S310F。PDX模型测试了几种药物，发现afatinib是最佳药物，在6种方案中具有显著的疗效和良好的耐受性。因此，该患者开始口服afatinib，实现3个月无进展生存期（PFS），缓解临床症状，无严重不良反应。另外，细胞试验表明，Gilotrif (afatinib)可以抑制携带ERBB2 (HER2) V842I突变的结直肠癌肿瘤细胞增殖。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30318721', '.', 'case report', '4', 'sorafenib ', 'sorafenib ', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'osteosarcoma', 'osteosarcoma', '骨癌', 'na', 'sensitivity', 'EVI_001323', 'PDGFRA:nonsynonymous SNV:exon18:p.D846V:', 'PDGFRA', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.D846V', '.', 'Outcome for patients with metastatic or recurrent/refractory osteosarcoma remains poor. Responses to sorafenib, a multikinase inhibitor, have been seen in recurrent/refractory osteosarcoma, although specific biomarkers of response have not been described. We report a partial response in a 7-year-old with refractory osteosarcoma treated with sorafenib 200 mg twice daily. Toxicities included Common Terminology Criteria for Adverse Events Grade 2 skin toxicities and growth suppression. After 51 months of therapy, he suffered a recurrence. Tumor sequencing later revealed a PDGFRA D846V mutation that was not identified in the relapse specimen. This case demonstrates prolonged partial response to sorafenib and provides a potential biomarker for response.', '转移性或复发性/难治性骨肉瘤患者的预后很差。一名7岁难治性骨肉瘤患者每天两次用sorafenib 200mg治疗，有部分反应。毒性及不良事件为2级皮肤毒性和生长抑制。治疗51个月后，患者复发。肿瘤测序揭示复发标本中不存在PDGFRA D846V突变。该病例证实了难治性骨肉瘤患者对索拉非尼的长期部分反应，也提供了复发的潜在生物标志物。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:olaparib_Revised: 12/2018 ', '.', 'guideline:FDA', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'breast cancer', 'breast cancer', '腹膜癌', 'na', 'sensitivity', 'EVI_001324', 'BRCA2:.:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Approval was based on SOLO-1 (NCT01844986), a randomized, double-blind, placebo-controlled, multi-center trial that compared the efficacy of olaparib with placebo in patients with BRCA-mutated (BRCAm) advanced ovarian, fallopian tube, or primary peritoneal cancer following first-line platinum-based chemotherapy. Patients were randomized (2:1) to receive olaparib tablets 300 mg orally twice daily (n=260) or placebo (n=131).The primary efficacy outcome was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The trial demonstrated a statistically significant improvement in investigator-assessed PFS for olaparib compared to placebo. Estimated median PFS was not reached in the olaparib arm and was 13.8 months in the placebo arm (HR 0.30; 95% CI: 0.23-0.41; p<0.0001). At the time of the analysis of PFS, overall survival data were not mature.Most common (≥10%) adverse reactions of any grade occurring in patients who received olaparib in SOLO-1 were nausea, fatigue, abdominal pain, vomiting, anemia, diarrhea, upper respiratory tract infection/influenza/nasopharyngitis/bronchitis, constipation, dysgeusia, decreased appetite, dizziness, neutropenia, dyspepsia, dyspnea, urinary tract infection (UTI), leukopenia, thrombocytopenia, and stomatitis.', '该药物的批准基于SOLO-1（NCT01844986），这是一项随机，双盲，安慰剂对照，多中心试验，比较olaparib与安慰剂对一线铂类化疗后的BRCA突变（BRCAm）晚期卵巢，输卵管或原发性腹膜癌的疗效。患者随机（2：1）接受olaparib 300 mg，每日口服2次（n = 260）或安慰剂（n = 131）。主要疗效结果为无进展生存期（PFS）、根据反应和实体瘤标准（RECIST）1.1评估肿瘤。该试验表明，与安慰剂相比，olaparib的PFS有统计学意义上的显著改善。olaparib组未达到估计的中位PFS，安慰剂组为13.8个月（HR 0.30; 95%CI：0.23-0.41; p <0.0001）。在分析PFS时，总体生存数据并不成熟。在SOLO-1中接受olaparib治疗的患者中出现的常见（≥10%）不良反应是恶心，疲劳，腹痛，呕吐，贫血，腹泻，上呼吸道感染/流感/鼻咽炎/支气管炎，便秘，味觉障碍，食欲减退，头晕，中性粒细胞减少，消化不良，呼吸困难，尿路感染（UTI），白细胞减少，血小板减少和口腔炎。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:olaparib_Revised: 12/2018 ', '.', 'guideline:FDA', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'breast cancer', 'breast cancer', '腹膜癌', 'na', 'sensitivity', 'EVI_001325', 'BRCA1:.:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Approval was based on SOLO-1 (NCT01844986), a randomized, double-blind, placebo-controlled, multi-center trial that compared the efficacy of olaparib with placebo in patients with BRCA-mutated (BRCAm) advanced ovarian, fallopian tube, or primary peritoneal cancer following first-line platinum-based chemotherapy. Patients were randomized (2:1) to receive olaparib tablets 300 mg orally twice daily (n=260) or placebo (n=131).The primary efficacy outcome was investigator-assessed progression-free survival (PFS) evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The trial demonstrated a statistically significant improvement in investigator-assessed PFS for olaparib compared to placebo. Estimated median PFS was not reached in the olaparib arm and was 13.8 months in the placebo arm (HR 0.30; 95% CI: 0.23-0.41; p<0.0001). At the time of the analysis of PFS, overall survival data were not mature.Most common (≥10%) adverse reactions of any grade occurring in patients who received olaparib in SOLO-1 were nausea, fatigue, abdominal pain, vomiting, anemia, diarrhea, upper respiratory tract infection/influenza/nasopharyngitis/bronchitis, constipation, dysgeusia, decreased appetite, dizziness, neutropenia, dyspepsia, dyspnea, urinary tract infection (UTI), leukopenia, thrombocytopenia, and stomatitis.', '该药物的批准基于SOLO-1（NCT01844986），这是一项随机，双盲，安慰剂对照，多中心试验，比较olaparib与安慰剂对一线铂类化疗后的BRCA突变（BRCAm）晚期卵巢，输卵管或原发性腹膜癌的疗效。患者随机（2：1）接受olaparib 300 mg，每日口服2次（n = 260）或安慰剂（n = 131）。主要疗效结果为无进展生存期（PFS）、根据反应和实体瘤标准（RECIST）1.1评估肿瘤。该试验表明，与安慰剂相比，olaparib的PFS有统计学意义上的显著改善。olaparib组未达到估计的中位PFS，安慰剂组为13.8个月（HR 0.30; 95%CI：0.23-0.41; p <0.0001）。在分析PFS时，总体生存数据并不成熟。在SOLO-1中接受olaparib治疗的患者中出现的常见（≥10%）不良反应是恶心，疲劳，腹痛，呕吐，贫血，腹泻，上呼吸道感染/流感/鼻咽炎/支气管炎，便秘，味觉障碍，食欲减退，头晕，中性粒细胞减少，消化不良，呼吸困难，尿路感染（UTI），白细胞减少，血小板减少和口腔炎。', 'G;S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29880291', 'NCT01972217', 'clinical trial - phase2', '4', 'olaparib + abiraterone', 'olaparib + abiraterone', 'olaparib + abiraterone', '奥拉帕利 + 阿比特龙', 'olaparib + abiraterone|奥拉帕利 + 阿比特龙', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001326', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'Study 08（NCT01972217）是在欧洲和北美11个国家进行的一项双盲，随机，多中心的II期临床试验。在2014年11月25日和2015年7月14日期间共有142例转移性去势抵抗性前列腺癌患者随机分为两组（1：1），分别接受口服olaparib（300mg，每日两次）+ 阿比特龙（n = 71）或安慰剂 + 阿比特龙（n = 71），所有患者均给予每日两次泼尼松或泼尼松龙（5mg BID）治疗。主要终点是研究者评估的放射学无进展生存期（rPFS）。次要终点为病情二次进展或死亡的时间（PFS2)、总生存期（OS）以及健康相关生活质量。研究显示，olaparib和阿比特龙组的中位rPFS为13.8个月，而安慰剂和阿比特龙组为8.2个月，风险比为0.65（95%CI，0.44-0.97; P = 0.034）。中位PFS2分别为23.3个月和18.5个月（HR=0.79，95%CI:0.51-1.21）、中位OS分别为22.7个月和20.9个月（HR=0.91，95%CI:0.60-1.38）。研究人员根据HRR突变状态进行了预先设定的亚组分析。在21例HRR突变患者中，olaparib组11例患者中有8例（73%）出现放射学进展或死亡，而安慰剂组为10例（70%）。在确认野生型HRR的35例患者中，olaparib组（53%）和安慰剂组（85%）有进展或死亡。olaparib和阿比特龙联合用药的安全性通常是可管理的，与阿比特龙相比，对生命质量没有不利影响。最常见的1-2级不良事件为恶心，便秘和背部疼痛。与阿比特龙单药治疗相比，联合用药组3级及以上不良事件发生率较高。联合用药组最常见的3级不良事件为贫血（21%）、肺炎（6%）、心肌梗死（6%）。', 'G;S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29880291', 'NCT01972217', 'clinical trial - phase2', '4', 'olaparib + abiraterone', 'olaparib + abiraterone', 'olaparib + abiraterone', '奥拉帕利 + 阿比特龙', 'olaparib + abiraterone|奥拉帕利 + 阿比特龙', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001327', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'Study 08（NCT01972217）是在欧洲和北美11个国家进行的一项双盲，随机，多中心的II期临床试验。在2014年11月25日和2015年7月14日期间共有142例转移性去势抵抗性前列腺癌患者随机分为两组（1：1），分别接受口服olaparib（300mg，每日两次）+ 阿比特龙（n = 71）或安慰剂 + 阿比特龙（n = 71），所有患者均给予每日两次泼尼松或泼尼松龙（5mg BID）治疗。主要终点是研究者评估的放射学无进展生存期（rPFS）。次要终点为病情二次进展或死亡的时间（PFS2)、总生存期（OS）以及健康相关生活质量。研究显示，olaparib和阿比特龙组的中位rPFS为13.8个月，而安慰剂和阿比特龙组为8.2个月，风险比为0.65（95%CI，0.44-0.97; P = 0.034）。中位PFS2分别为23.3个月和18.5个月（HR=0.79，95%CI:0.51-1.21）、中位OS分别为22.7个月和20.9个月（HR=0.91，95%CI:0.60-1.38）。研究人员根据HRR突变状态进行了预先设定的亚组分析。在21例HRR突变患者中，olaparib组11例患者中有8例（73%）出现放射学进展或死亡，而安慰剂组为10例（70%）。在确认野生型HRR的35例患者中，olaparib组（53%）和安慰剂组（85%）有进展或死亡。olaparib和阿比特龙联合用药的安全性通常是可管理的，与阿比特龙相比，对生命质量没有不利影响。最常见的1-2级不良事件为恶心，便秘和背部疼痛。与阿比特龙单药治疗相比，联合用药组3级及以上不良事件发生率较高。联合用药组最常见的3级不良事件为贫血（21%）、肺炎（6%）、心肌梗死（6%）。', 'G;S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30352902', '.', 'clinical study', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001328', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Purpose: MET exon 14 splice site alterations that cause exon skipping at the mRNA level (METex14) are actionable oncogenic drivers amenable to therapy with MET tyrosine kinase inhibitors (TKI); however, secondary resistance eventually arises in most cases while other tumors display primary resistance. Beyond relatively uncommon on-target MET kinase domain mutations, mechanisms underlying primary and acquired resistance remain unclear.Experimental Design: We examined clinical and genomic data from 113 patients with lung cancer with METex14. MET TKI resistance due to KRAS mutation was functionally evaluated using in vivo and in vitro models.Results: Five of 113 patients (4.4%) with METex14 had concurrent KRAS G12 mutations, a rate of KRAS cooccurrence significantly higher than in other major driver-defined lung cancer subsets. In one patient, the KRAS mutation was acquired post-crizotinib, while the remaining 4 METex14 patients harbored the KRAS mutation prior to MET TKI therapy. Gene set enrichment analysis of transcriptomic data from lung cancers with METex14 revealed preferential activation of the KRAS pathway. Moreover, expression of oncogenic KRAS enhanced MET expression. Using isogenic and patient-derived models, we show that KRAS mutation results in constitutive activation of RAS/ERK signaling and resistance to MET inhibition. Dual inhibition of MET or EGFR/ERBB2 and MEK reduced growth of cell line and xenograft models.Conclusions: KRAS mutation is a recurrent mechanism of primary and secondary resistance to MET TKIs in METex14 lung cancers. Dual inhibition of MET or EGFR/ERBB2 and MEK may represent a potential therapeutic approach in this molecular cohort.', 'MET exon 14剪接位点改变导致mRNA水平的外显子跳跃（MET ex14）是可操作的致癌驱动因素，适合用MET酪氨酸激酶抑制剂（TKI）治疗，但大多数时候会出现原发耐药和获得性耐药。除了相对不常见的MET激酶结构域突变外，原发性和获得性耐药的机制尚不清楚。研究人员检测了113例含MET ex14的肺癌患者的临床和基因组数据，对KRAS突变引起的MET TKI耐药性进行了功能评估。113例患者中有5例（4.4%）患有MET ex14并发KRAS G12突变，发生率显著高于其他主要驱动因素的肺癌亚组。其中一名患者在克唑替尼治疗后获得了KRAS突变，其余4名MET ex14患者在MET TKI治疗前即携带KRAS突变，致癌KRAS的表达增强了MET表达，结果显示KRAS突变可导致RAS/ERK信号传导的组成型激活和对MET抑制的抗性。结论：KRAS突变是MET ex14肺癌中MET TKIs的耐药机制之一，MET或EGFR/ERBB2和MEK的双重抑制可能是该肿瘤分子亚型的潜在治疗方法。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30527195', '.', 'preclinical', '4', 'poziotinib', 'poziotinib', 'poziotinib', 'poziotinib', 'poziotinib|poziotinib', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', 'na', 'resistance', 'EVI_001330', 'ERBB2:nonsynonymous SNV:exon20:p.C805S:', 'ERBB2', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C805S', '.', 'OBJECTIVES:Oncogenic ERBB2 mutations are present in 2-4% of lung adenocarcinomas, but the relevant clinical trials are unsatisfactory. The novel ERBB2 inhibitor poziotinib was recently developed and clinical trials are ongoing. We compared poziotinib with nine tyrosine kinase inhibitors (TKIs), and derived poziotinib-resistant clones to investigate the resistant mechanism.MATERIALS AND METHODS:We introduced three common ERBB2 mutations A775_G776insYVMA (YVMA), G776delinsVC (VC) and P780_Y781insGSP (GSP), which account for 94% of ERBB2 exon 20 insertions in the literature, into Ba/F3 cells. We then compared the activity of poziotinib with that of nine TKIs (erlotinib, afatinib, dacomitinib, neratinib, osimertinib, AZ5104, pyrotinib, lapatinib, and irbinitinib), determined the 90% inhibitory concentration (IC90) through a growth inhibition assay, and defined a sensitivity index (SI) as IC90 divided by the trough concentration at the recommended dose as a surrogate for drug activity in humans. We also generated resistant clones by exposure to poziotinib in the presence of N-ethyl-N-nitrosourea, and ERBB2 secondary mutations that might serve as a resistance mechanism were searched.RESULTS:YVMA showed resistance to all tested drugs except neratinib, poziotinib and pyrotinib. Poziotinib was the only drug with an SI less than 10 for YVMA, the most common ERBB2 exon 20 insertion. We established 62 poziotinib-resistant clones, and among these, only C805S of ERBB2, which is homologous to C797S of the EGFR, was identified as a secondary mutation in 19 clones. We also revealed that heat shock protein (HSP) 90 inhibitors show potent anti-growth activity to the C805S secondary mutant clone.CONCLUSIONS:Poziotinib showed the most potent activity against ERBB2 exon 20 mutations. We identified the secondary C805S at the covalent binding site of ERBB2 to poziotinib as a potential mechanism of acquired resistance. HSP90 inhibitors might be a therapeutic strategy for the C805S secondary mutation.', '2-4%肺腺癌中存在致癌ERBB2突变，但相关的临床试验并不令人满意，新的ERBB2抑制剂poziotinib的临床试验正在进行中。研究人员引入了三种常见的ERBB2突变A775_G776insYVMA，G776delinsVC和P780_Y781insGSP进Ba/F3细胞，比较了poziotinib与9种TKIs(厄洛替尼，阿法替尼，dacomitinib，neratinib，osimertinib，AZ5104，pyrotinib，lapatinib和irbinitinib)的活性，通过生长抑制试验测定了90%抑制浓度(IC90)，并定义了IC90的敏感指数(SI)作为人体药物活性的替代指标，搜索可能作为抗性机制的ERBB2二次突变。除了neratinib，poziotinib和pyrotinib之外，YVMA显示对所有测试药物的抗性。对于YVMA，Poziotinib是唯一一种SI小于10的药物。研究人员建立了62个poziotinib抗性克隆，其中只有与EGFR的C797S同源的ERBB2的C805S被鉴定为二次突变，可能与poziotinib的耐药性相关。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29298799', '.', 'preclinical', '4', 'osimertinib', 'osimertinib', 'osimertinib + JQ1', '奥希替尼 + JQ1', 'osimertinib + JQ1|奥希替尼 + JQ1', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001332', 'ERBB2:nonframeshift insertion:exon20:.:exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', '肺癌是导致癌症死亡的主要原因，并且直接针对肺癌中ERBB2突变的疗法仍然未满足的临床。一项体外研究生成了三个小鼠模型：ERBB2野生型，ERBB2与EGFR同时突变型，ERBB2突变型。 结果显示，第三代酪氨酸激酶抑制剂osimertinib并非对所有HER2突变都有效。osimertinib与BET抑制剂JQ1的组合对HER2突变型有效。 ', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001333', 'ROS1:FUS:.:.-ROS1:.', 'ROS1', 'FUS', 'FUS', '.', '.-ROS1', '.', '.', 'ROS1重排是非小细胞肺癌（NSCLC）独特的分子亚组。2013年6月7日至2016年2月1日，404名患者接受了ROS1基因重排的预筛选，32名患者发现携带ROS1重排。其中两名患者前期接受过crizotinib治疗。这些患者每天一次给予Ceritinib 750mg。在数据截止时，这些患者的中位随访时间为14.0个月，18例患者（56%）已停止治疗。在入组的32名患者中，28名通过独立的放射学评估后，客观反应率为62%（95%CI，45%至77%）；其中一名患者取得完全反应，19名患者取得部分反应；反应持续时间为21.0个月（95%CI，17至25个月），疾病控制率为81%（95%CI，65%至91%）。所有患者的中位无进展生存期为9.3个月（95%CI，0至22个月）。前期未接受过克唑替尼治疗的患者，中位无进展生存期为19.3个月（95%CI，1至37个月）。中位总生存期为24个月（95%CI，5至43个月）。在8例脑转移患者中，有5例报告了颅内疾病控制（63%; 95%CI，31%至86%）。NCCN指南根据以上临床数据推荐携带ROS1重排的非小细胞肺癌患者可以接受Ceritinib治疗。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25688157', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'cancer cell lines_lung', 'cancer cell lines_lung', '肿瘤细胞', '[ROS:FUS]', 'resistance', 'EVI_001334', 'ROS1:nonsynonymous SNV:exon38:p.L2026M:', 'ROS1', 'nonsynonymous SNV', 'Exact_pos', 'exon38', 'p.L2026M', '.', '.', '与表达野生型CD74-ROS1的Ba/F3细胞，表达CD74-ROS1 L2026M突变的Ba/F3细胞显示出对克唑替尼的抗性（IC50值高约10倍）。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:26673800', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'cancer cell lines_lung', 'cancer cell lines_lung', '肿瘤细胞', '[ROS:FUS]', 'resistance', 'EVI_001335', 'ROS1:nonsynonymous SNV:exon38:p.D2033N:', 'ROS1', 'nonsynonymous SNV', 'Exact_pos', 'exon38', 'p.D2033N', '.', '.', '细胞学试验表明，CD74-ROS1（D2033N）突变对克唑替尼的抗肿瘤作用明显降低。分子动力学模拟显示，由于D2033残基与克唑替尼之间的静电相互作用影响了克唑替尼与ROS1的结合。相反，cabozantinib结合不受D2033N突变的影响，并且保留了对ROS1融合蛋白的抑制效力。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:25351743', '.', 'preclinical', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'cancer cell lines_lung', 'cancer cell lines_lung', '肿瘤细胞', '[ROS:FUS]', 'resistance', 'EVI_001336', 'ROS1:nonsynonymous SNV:exon36:p.L1951R:', 'ROS1', 'nonsynonymous SNV', 'Exact_pos', 'exon36', 'p.L1951R', '.', '.', '细胞学试验表明，携带CD74-ROS1融合基因，同时具有L1951R和G2032R突变的Ba/F3细胞对crizotinib，ceritinib和AP26113均出现耐药性。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2016.34.15_suppl.9049', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001337', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', '第一代EGFR酪氨酸激酶抑制剂（TKIs）和具有双重EGFR/HER2抑制作用的第二代TKI药物在EGFR突变的NSCLC中具有较强的抗肿瘤作用。肿瘤细胞HER2（ERBB2）扩增可能是其对第一代EGFR TKI产生耐药的分子机制。为了进一步了解HER2改变作为EGFR TKIs的耐药机制，一项研究评估了携带EGFR突变的NSCLC患者对TKI耐药后ERBB2基因扩增突变的情况。研究收集了耐药后患者的肿瘤组织细胞，通过FISH评估HER2/CEP17比率和平均HER2拷贝数。使用IHC测定HER2蛋白表达。该研究共收录了83例对EGFR TKIs耐药的患者。最终从49名患者中收集了55个样本。其中，44例样本来自厄洛替尼耐药患者，9例来自阿法替尼+西妥昔单抗耐药患者，2例来自阿法替尼耐药患者。厄洛替尼耐药患者中发现3例（6.8%）携带HER2扩增。在对阿法替尼+西妥昔单抗耐药的9个患者中，发现2个患者（22.2%)携带HER2扩增，其中一个病例治疗后拷贝数增加4倍。阿法替尼治疗耐药后的2例患者均发现HER2扩增。该研究表明HER2扩增可能是肺癌患者对厄洛替尼或阿法替尼+西妥昔单抗产生耐药的分子机制。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2016.34.15_suppl.9049', '.', 'clinical study', '4', 'erlotinib', 'afatinib + cetuximab', 'afatinib + cetuximab', '阿法替尼 + 西妥昔单抗', 'afatinib + cetuximab|阿法替尼 + 西妥昔单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001338', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', '第一代EGFR酪氨酸激酶抑制剂（TKIs）和具有双重EGFR/HER2抑制作用的第二代TKI药物在EGFR突变的NSCLC中具有较强的抗肿瘤作用。肿瘤细胞HER2（ERBB2）扩增可能是其对第一代EGFR TKI产生耐药的分子机制。为了进一步了解HER2改变作为EGFR TKIs的耐药机制，一项研究评估了携带EGFR突变的NSCLC患者对TKI耐药后ERBB2基因扩增突变的情况。研究收集了耐药后患者的肿瘤组织细胞，通过FISH评估HER2/CEP17比率和平均HER2拷贝数。使用IHC测定HER2蛋白表达。该研究共收录了83例对EGFR TKIs耐药的患者。最终从49名患者中收集了55个样本。其中，44例样本来自厄洛替尼耐药患者，9例来自阿法替尼+西妥昔单抗耐药患者，2例来自阿法替尼耐药患者。厄洛替尼耐药患者中发现3例（6.8%）携带HER2扩增。在对阿法替尼+西妥昔单抗耐药的9个患者中，发现2个患者（22.2%)携带HER2扩增，其中一个病例治疗后拷贝数增加4倍。阿法替尼治疗耐药后的2例患者均发现HER2扩增。该研究表明HER2扩增可能是肺癌患者对厄洛替尼或阿法替尼+西妥昔单抗产生耐药的分子机制。', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28274957', '.', 'case report', '4', 'neratinib', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'sensitivity', 'EVI_001339', 'ERBB2 :nonsynonymous SNV:exon20:p.T798I:', 'ERBB2 ', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T798I', '.', 'We report a ERBB2T798I gatekeeper mutation in a patient with ERBB2L869R-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that ERBB2L869R is a neratinib-sensitive, gain-of-function mutation that upon dimerization with mutant HER3E928G, also present in the breast cancer, amplifies ERBB2 signaling. The patient was treated with neratinib and exhibited a sustained partial response. Upon clinical progression, ERBB2T798I was detected in plasma tumor cell-free DNA. Structural modeling of this acquired mutation suggested that the increased bulk of isoleucine in ERBB2T798I reduces neratinib binding. Neratinib blocked ERBB2-mediated signaling and growth in cells expressing ERBB2L869R but not ERBB2L869R/T798I In contrast, afatinib and the osimertinib metabolite AZ5104 strongly suppressed ERBB2L869R/T798I-induced signaling and cell growth. Acquisition of ERBB2T798I upon development of resistance to neratinib in a breast cancer with an initial activating ERBB2 mutation suggests ERBB2L869R is a driver mutation. ERBB2T798I-mediated neratinib resistance may be overcome by other irreversible ERBB2 inhibitors like afatinib.Significance: We found an acquired ERBB2 gatekeeper mutation in a patient with ERBB2-mutant breast cancer upon clinical progression on neratinib. We speculate that ERBB2T798I may arise as a secondary mutation following response to effective ERBB2 tyrosine kinase inhibitors (TKI) in other cancers with ERBB2-activating mutations. This resistance may be overcome by other irreversible ERBB2 TKIs, such as afatinib. ', 'ERBB2基因上的T798I突变属于激活突变，可以导致癌细胞ERBB2信号通路的组成性激活。一名携带ERBB2 T798I突变的乳腺癌患者使用neratinib后取得部分缓解。该患者疾病进展后通过ctDNA检测，发现在ERBB2基因上出现新的L869R突变。计算机结构模拟显示该突变可能导致neratinib与ERBB2基因结合效率降低，从而对其产生耐药。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28274957', '.', 'case report', '4', 'neratinib', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'resistance', 'EVI_001340', 'ERBB2 :nonsynonymous SNV:exon21:p.L869R:', 'ERBB2 ', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L869R', '.', 'We report a ERBB2T798I gatekeeper mutation in a patient with ERBB2L869R-mutant breast cancer with acquired resistance to neratinib. Laboratory studies suggested that ERBB2L869R is a neratinib-sensitive, gain-of-function mutation that upon dimerization with mutant HER3E928G, also present in the breast cancer, amplifies ERBB2 signaling. The patient was treated with neratinib and exhibited a sustained partial response. Upon clinical progression, ERBB2T798I was detected in plasma tumor cell-free DNA. Structural modeling of this acquired mutation suggested that the increased bulk of isoleucine in ERBB2T798I reduces neratinib binding. Neratinib blocked ERBB2-mediated signaling and growth in cells expressing ERBB2L869R but not ERBB2L869R/T798I In contrast, afatinib and the osimertinib metabolite AZ5104 strongly suppressed ERBB2L869R/T798I-induced signaling and cell growth. Acquisition of ERBB2T798I upon development of resistance to neratinib in a breast cancer with an initial activating ERBB2 mutation suggests ERBB2L869R is a driver mutation. ERBB2T798I-mediated neratinib resistance may be overcome by other irreversible ERBB2 inhibitors like afatinib.Significance: We found an acquired ERBB2 gatekeeper mutation in a patient with ERBB2-mutant breast cancer upon clinical progression on neratinib. We speculate that ERBB2T798I may arise as a secondary mutation following response to effective ERBB2 tyrosine kinase inhibitors (TKI) in other cancers with ERBB2-activating mutations. This resistance may be overcome by other irreversible ERBB2 TKIs, such as afatinib.', 'ERBB2基因上的T798I突变属于激活突变，可以导致癌细胞ERBB2信号通路的组成性激活。一名携带ERBB2 T798I突变的乳腺癌患者使用neratinib后取得部分缓解。该患者疾病进展后通过ctDNA检测，发现在ERBB2基因上出现新的L869R突变。计算机结构模拟显示该突变可能导致neratinib与ERBB2基因结合效率降低，从而对其产生耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30196106', 'EudraCT number 2009-017817-31', 'clinical trial - phase1', '4', 'epertinib', 'epertinib', 'epertinib', 'epertinib', 'epertinib|epertinib', '1', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001341', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'BACKGROUND:Dose-escalation of epertinib (S-222611), a new potent oral EGFR/ERBB2 inhibitor, has established a recommended daily dose of 800 mg in patients with solid tumours. In this study, we have recruited a larger number of patients to assess further the safety, tolerability, pharmacokinetics (PKs) and antitumour activity.PATIENTS AND METHODS:Patients with solid tumours expressing EGFR or ERBB2 received a single dose of epertinib at 800 mg on Day 1 to assess PK over 7 days, followed by continuous once-daily dosing from Day 8.RESULTS:We treated 76 patients with breast (n = 27), upper gastrointestinal (GI; n = 30), head and neck (n = 12) or renal cancers (n = 7). Epertinib was well-tolerated with mostly grade I and II adverse events (AEs). The most frequent AE was diarrhoea, which was generally manageable with loperamide. The objective response rate (ORR) in patients with heavily pretreated breast and upper GI cancers was 16.0% (4 PRs) and 8.3% (1CR, 1PR), respectively. All six responding patients had ERBB2-positive tumours; the ORR for ERBB2-positive breast and upper GI cancer populations was 19.0% and 20.0%. Partial response in the brain disease of one breast cancer patient lasted 7.5 months.CONCLUSION:Once-daily dosing of epertinib at 800 mg was well-tolerated and demonstrated promising antitumour activity in patients with heavily pretreated ERBB2-positive breast and upper GI cancer, including those with brain metastases.', 'epertinib（S-222611）是一种新型强效口服EGFR/ERBB2抑制剂，实体肿瘤患者的推荐日剂量为800 mg。在这项研究中，研究人员招募了更多的患者，以进一步评估其安全性，耐受性，药代动力学（PKs）和抗肿瘤活性。患者和方法：表达EGFR或ERBB2的实体瘤患者接受单剂量的epertinib，剂量为800 mg/d，第1天评估PK后停药7天，然后从第8天开始连续每日一次给药。结果：研究人员治疗了76名乳腺癌患者（n = 27），上消化道（GI; n = 30），头颈部（n = 12）或肾癌（n = 7）。这些患者的epertinib耐受性良好，主要出现I级和II级不良事件（AEs）。最常见的AE是腹泻，通常可用洛哌丁胺治疗。重度预治疗的乳腺癌和上胃肠癌患者的客观缓解率（ORR）分别为16.0%（4个PR）和8.3%（1CR，1PR），这6名患者均有ERBB2阳性突变。HER2阳性乳腺癌和上消化道癌症人群的ORR分别为19.0%和20.0%。一名乳腺癌患者脑部疾病的部分反应持续7.5个月。结论：每日一次服用800mg epertinib耐受良好，可对ERBB2阳性乳腺癌和上消化道癌患者进行抗肿瘤治疗，包括有脑转移的人。', 'a', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30196106', 'EudraCT number 2009-017817-31', 'clinical trial - phase1', '4', 'epertinib', 'epertinib', 'epertinib', 'epertinib', 'epertinib|epertinib', '1', 'gastrointestinal stromal tumor', 'gastrointestinal cancer', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001342', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'BACKGROUND:Dose-escalation of epertinib (S-222611), a new potent oral EGFR/ERBB2 inhibitor, has established a recommended daily dose of 800 mg in patients with solid tumours. In this study, we have recruited a larger number of patients to assess further the safety, tolerability, pharmacokinetics (PKs) and antitumour activity.PATIENTS AND METHODS:Patients with solid tumours expressing EGFR or ERBB2 received a single dose of epertinib at 800 mg on Day 1 to assess PK over 7 days, followed by continuous once-daily dosing from Day 8.RESULTS:We treated 76 patients with breast (n = 27), upper gastrointestinal (GI; n = 30), head and neck (n = 12) or renal cancers (n = 7). Epertinib was well-tolerated with mostly grade I and II adverse events (AEs). The most frequent AE was diarrhoea, which was generally manageable with loperamide. The objective response rate (ORR) in patients with heavily pretreated breast and upper GI cancers was 16.0% (4 PRs) and 8.3% (1CR, 1PR), respectively. All six responding patients had ERBB2-positive tumours; the ORR for ERBB2-positive breast and upper GI cancer populations was 19.0% and 20.0%. Partial response in the brain disease of one breast cancer patient lasted 7.5 months.CONCLUSION:Once-daily dosing of epertinib at 800 mg was well-tolerated and demonstrated promising antitumour activity in patients with heavily pretreated ERBB2-positive breast and upper GI cancer, including those with brain metastases.', 'epertinib（S-222611）是一种新型强效口服EGFR/ERBB2抑制剂，实体肿瘤患者的推荐日剂量为800 mg。在这项研究中，研究人员招募了更多的患者，以进一步评估其安全性，耐受性，药代动力学（PKs）和抗肿瘤活性。患者和方法：表达EGFR或ERBB2的实体瘤患者接受单剂量的epertinib，剂量为800 mg/d，第1天评估PK后停药7天，然后从第8天开始连续每日一次给药。结果：研究人员治疗了76名乳腺癌患者（n = 27），上消化道（GI; n = 30），头颈部（n = 12）或肾癌（n = 7）。这些患者的epertinib耐受性良好，主要出现I级和II级不良事件（AEs）。最常见的AE是腹泻，通常可用洛哌丁胺治疗。重度预治疗的乳腺癌和上胃肠癌患者的客观缓解率（ORR）分别为16.0%（4个PR）和8.3%（1CR，1PR），这6名患者均有ERBB2阳性突变。HER2阳性乳腺癌和上消化道癌症人群的ORR分别为19.0%和20.0%。一名乳腺癌患者脑部疾病的部分反应持续7.5个月。结论：每日一次服用800mg epertinib耐受良好，可对ERBB2阳性乳腺癌和上消化道癌患者进行抗肿瘤治疗，包括有脑转移的人。', 'a', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28796048', '.', 'clinical study', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001343', 'SDHA:nonsynonymous SNV:.:.:inact', 'SDHA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '与大多数GIST一样，非激酶突变驱动的胃肠道间质瘤（GIST）经常显示琥珀酸脱氢酶（SDH）复合物的功能丧失，临床分类为SDH缺陷型GIST。与传统GIST相比，SDH缺陷型GIST具有许多独特的特征。一项临床研究分析了这些不常见GIST的临床病理特征，治疗和预后。该回顾性观察研究从335名GIST患者中筛选出12例SDH缺陷型GIST患者，这些患者于2013年10月31日至2016年10月31日期间通过琥珀酸脱氢酶亚基B染色确定SDH缺失。这些患者中有8名男性和4名女性患者，中位年龄为57岁（范围21-73岁）。 其中10名患者（83.3%）在大于或等于40岁时被诊断出患有胃GIST，占所有老年患者的7.2%（10/138）。肿瘤大小为3至19厘米（中位数，7厘米）；原发肿瘤多灶性6例（50%），肿瘤有多结节或丛状结构10例（83.3%）。 10例患者（83.3%）显示纯上皮样形态，其余2例（16.7%）显示混合组织学亚型。50%（3/6）患者在初次切除时发现淋巴结转移。 4例（33.3%）出现远处转移。 4例患者（33.3%）在初次手术后采用伊马替尼治疗，但疾病进展，当治疗改为舒尼替尼靶向治疗时，所有这些患者都恢复了疾病控制。SDH缺陷型GIST仅在胃中出现，占胃GIST的约7.4%（12/162）。此外，40岁以上人群的患者并不罕见，舒尼替尼可能适用于伊马替尼治疗失败的该类患者。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28796048', '.', 'clinical study', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001344', 'SDHB:nonsynonymous SNV:.:.:inact', 'SDHB', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '与大多数GIST一样，非激酶突变驱动的胃肠道间质瘤（GIST）经常显示琥珀酸脱氢酶（SDH）复合物的功能丧失，临床分类为SDH缺陷型GIST。与传统GIST相比，SDH缺陷型GIST具有许多独特的特征。一项临床研究分析了这些不常见GIST的临床病理特征，治疗和预后。该回顾性观察研究从335名GIST患者中筛选出12例SDH缺陷型GIST患者，这些患者于2013年10月31日至2016年10月31日期间通过琥珀酸脱氢酶亚基B染色确定SDH缺失。这些患者中有8名男性和4名女性患者，中位年龄为57岁（范围21-73岁）。 其中10名患者（83.3%）在大于或等于40岁时被诊断出患有胃GIST，占所有老年患者的7.2%（10/138）。肿瘤大小为3至19厘米（中位数，7厘米）；原发肿瘤多灶性6例（50%），肿瘤有多结节或丛状结构10例（83.3%）。 10例患者（83.3%）显示纯上皮样形态，其余2例（16.7%）显示混合组织学亚型。50%（3/6）患者在初次切除时发现淋巴结转移。 4例（33.3%）出现远处转移。 4例患者（33.3%）在初次手术后采用伊马替尼治疗，但疾病进展，当治疗改为舒尼替尼靶向治疗时，所有这些患者都恢复了疾病控制。SDH缺陷型GIST仅在胃中出现，占胃GIST的约7.4%（12/162）。此外，40岁以上人群的患者并不罕见，舒尼替尼可能适用于伊马替尼治疗失败的该类患者。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28796048', '.', 'clinical study', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001345', 'SDHC:nonsynonymous SNV:.:.:inact', 'SDHC', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '与大多数GIST一样，非激酶突变驱动的胃肠道间质瘤（GIST）经常显示琥珀酸脱氢酶（SDH）复合物的功能丧失，临床分类为SDH缺陷型GIST。与传统GIST相比，SDH缺陷型GIST具有许多独特的特征。一项临床研究分析了这些不常见GIST的临床病理特征，治疗和预后。该回顾性观察研究从335名GIST患者中筛选出12例SDH缺陷型GIST患者，这些患者于2013年10月31日至2016年10月31日期间通过琥珀酸脱氢酶亚基B染色确定SDH缺失。这些患者中有8名男性和4名女性患者，中位年龄为57岁（范围21-73岁）。 其中10名患者（83.3%）在大于或等于40岁时被诊断出患有胃GIST，占所有老年患者的7.2%（10/138）。肿瘤大小为3至19厘米（中位数，7厘米）；原发肿瘤多灶性6例（50%），肿瘤有多结节或丛状结构10例（83.3%）。 10例患者（83.3%）显示纯上皮样形态，其余2例（16.7%）显示混合组织学亚型。50%（3/6）患者在初次切除时发现淋巴结转移。 4例（33.3%）出现远处转移。 4例患者（33.3%）在初次手术后采用伊马替尼治疗，但疾病进展，当治疗改为舒尼替尼靶向治疗时，所有这些患者都恢复了疾病控制。SDH缺陷型GIST仅在胃中出现，占胃GIST的约7.4%（12/162）。此外，40岁以上人群的患者并不罕见，舒尼替尼可能适用于伊马替尼治疗失败的该类患者。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28796048', '.', 'clinical study', '4', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001346', 'SDHD:nonsynonymous SNV:.:.:inact', 'SDHD', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '与大多数GIST一样，非激酶突变驱动的胃肠道间质瘤（GIST）经常显示琥珀酸脱氢酶（SDH）复合物的功能丧失，临床分类为SDH缺陷型GIST。与传统GIST相比，SDH缺陷型GIST具有许多独特的特征。一项临床研究分析了这些不常见GIST的临床病理特征，治疗和预后。该回顾性观察研究从335名GIST患者中筛选出12例SDH缺陷型GIST患者，这些患者于2013年10月31日至2016年10月31日期间通过琥珀酸脱氢酶亚基B染色确定SDH缺失。这些患者中有8名男性和4名女性患者，中位年龄为57岁（范围21-73岁）。 其中10名患者（83.3%）在大于或等于40岁时被诊断出患有胃GIST，占所有老年患者的7.2%（10/138）。肿瘤大小为3至19厘米（中位数，7厘米）；原发肿瘤多灶性6例（50%），肿瘤有多结节或丛状结构10例（83.3%）。 10例患者（83.3%）显示纯上皮样形态，其余2例（16.7%）显示混合组织学亚型。50%（3/6）患者在初次切除时发现淋巴结转移。 4例（33.3%）出现远处转移。 4例患者（33.3%）在初次手术后采用伊马替尼治疗，但疾病进展，当治疗改为舒尼替尼靶向治疗时，所有这些患者都恢复了疾病控制。SDH缺陷型GIST仅在胃中出现，占胃GIST的约7.4%（12/162）。此外，40岁以上人群的患者并不罕见，舒尼替尼可能适用于伊马替尼治疗失败的该类患者。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27401242', '.', 'case report', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ROS:FUS]', 'resistance', 'EVI_001347', 'ROS1:nonsynonymous SNV::p.S1986Y:', 'ROS1', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.S1986Y', '.', '.', '一名携带EZR-ROS1融合基因的转移性NSCLC的患者对ALK/ROS1抑制剂crizotinib产生获得性耐药。基因测序发现在其ROS1激酶结构域中发生了双重突变，S1986Y和S1986F。体外功能性研究证明ROS1含有S1986Y或S1986F突变时可以导致肿瘤细胞对crizotinib或ceritinib耐药，但对lorlatinib（PF-06463922）抑制敏感。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:27401242', '.', 'case report', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ROS:FUS]', 'resistance', 'EVI_001348', 'ROS1:nonsynonymous SNV::p.S1986F:', 'ROS1', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.S1986F', '.', '.', '一名携带EZR-ROS1融合基因的转移性NSCLC的患者对ALK/ROS1抑制剂crizotinib产生获得性耐药。基因测序发现在其ROS1激酶结构域中发生了双重突变，S1986Y和S1986F。体外功能性研究证明ROS1含有S1986Y或S1986F突变时可以导致肿瘤细胞对crizotinib或ceritinib耐药，但对lorlatinib（PF-06463922）抑制敏感。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('AACR 2019 (abstr CT234)', 'NCT03140670', 'clinical trial - phase2', '4', 'rucaparib', 'rucaparib', 'rucaparib', '芦卡帕利', 'rucaparib|芦卡帕利', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_001349', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '一项正在进行的单臂II期研究正在评估Rubrac(600mg，每日2次)用于一线维持治疗的疗效和安全性。该研究将入组42例晚期胰腺癌患者，这些患者肿瘤携带致病性的种系或体细胞BRCA1、BRCA2或PALB2突变，接受了至少4个月的含铂化疗后病情没有进展。研究的主要终点是无进展生存期(PFS)，实体瘤疗效评价标准(RECIST v1.1)评价。在中期分析中，19例可评估患者的中位PFS为278天或9.1个月(从Rubraca治疗开始)。在中位随访244天时，中位总生存期(OS)未达到。在最后一次数据截止时评估的19名患者中，1例患者实现完全缓解(CR)，另外6例患者实现部分缓解(PR)，包括种系BRCA2突变(n=4)、种系PALB2突变(n=2)和体细胞BRCA2突变(n=1)患者。19例患者中有8例接受Rubraca治疗了6个月以上，2例治疗了1年以上(13个月和15个月)。第8周随访的疾病控制率(定义为CR+PR+稳定疾病)为89.5%。总的来说，本研究中的Rubraca治疗耐受性良好，无剂量限制性毒性。', 'G;S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('AACR 2019 (abstr CT234)', 'NCT03140670', 'clinical trial - phase2', '4', 'rucaparib', 'rucaparib', 'rucaparib', '芦卡帕利', 'rucaparib|芦卡帕利', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_001350', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '一项正在进行的单臂II期研究正在评估Rubrac(600mg，每日2次)用于一线维持治疗的疗效和安全性。该研究将入组42例晚期胰腺癌患者，这些患者肿瘤携带致病性的种系或体细胞BRCA1、BRCA2或PALB2突变，接受了至少4个月的含铂化疗后病情没有进展。研究的主要终点是无进展生存期(PFS)，实体瘤疗效评价标准(RECIST v1.1)评价。在中期分析中，19例可评估患者的中位PFS为278天或9.1个月(从Rubraca治疗开始)。在中位随访244天时，中位总生存期(OS)未达到。在最后一次数据截止时评估的19名患者中，1例患者实现完全缓解(CR)，另外6例患者实现部分缓解(PR)，包括种系BRCA2突变(n=4)、种系PALB2突变(n=2)和体细胞BRCA2突变(n=1)患者。19例患者中有8例接受Rubraca治疗了6个月以上，2例治疗了1年以上(13个月和15个月)。第8周随访的疾病控制率(定义为CR+PR+稳定疾病)为89.5%。总的来说，本研究中的Rubraca治疗耐受性良好，无剂量限制性毒性。', 'G;S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('AACR 2019 (abstr CT234)', 'NCT03140670', 'clinical trial - phase2', '4', 'rucaparib', 'rucaparib', 'rucaparib', '芦卡帕利', 'rucaparib|芦卡帕利', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_001351', 'PALB2:nonsynonymous SNV:.:.:inact', 'PALB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '一项正在进行的单臂II期研究正在评估Rubrac(600mg，每日2次)用于一线维持治疗的疗效和安全性。该研究将入组42例晚期胰腺癌患者，这些患者肿瘤携带致病性的种系或体细胞BRCA1、BRCA2或PALB2突变，接受了至少4个月的含铂化疗后病情没有进展。研究的主要终点是无进展生存期(PFS)，实体瘤疗效评价标准(RECIST v1.1)评价。在中期分析中，19例可评估患者的中位PFS为278天或9.1个月(从Rubraca治疗开始)。在中位随访244天时，中位总生存期(OS)未达到。在最后一次数据截止时评估的19名患者中，1例患者实现完全缓解(CR)，另外6例患者实现部分缓解(PR)，包括种系BRCA2突变(n=4)、种系PALB2突变(n=2)和体细胞BRCA2突变(n=1)患者。19例患者中有8例接受Rubraca治疗了6个月以上，2例治疗了1年以上(13个月和15个月)。第8周随访的疾病控制率(定义为CR+PR+稳定疾病)为89.5%。总的来说，本研究中的Rubraca治疗耐受性良好，无剂量限制性毒性。', 'G;S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29673089', '.', 'case report', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001353', 'EGFR:nonsynonymous SNV:exon19:p.L747P:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747P', '.', '.', ' 一名被诊断患有IV期肺腺癌的中国女性，基因检测发现其携带罕见的EGFR L747P（2239-2240 TT>CC）突变，该患者使用吉非替尼和osimertinib治疗未能达到预期效果。 ', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'dabrafenib + trametinib + cetuximab', '曲美替尼 + 达拉非尼 + 西妥昔单抗', 'dabrafenib + trametinib + cetuximab|曲美替尼 + 达拉非尼 + 西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001354', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '该方案基于NCT01750918研究。研究纳入经治BRAF突变的晚期结直肠癌患者，随机分组三组：D+T组、D+P组、D+T+P组（D:dabrafenib；T：trametinib；P:panitumumab）。在35例接受三药方案组的患者中，最终整体有效率为26%，有1例患者达到完全缓解，疾病控制率为83%。有效率方面远高于两药联合的10%ORR。也因此成为此类患者可选方案之一。NCCN推荐携带BRAF突变的晚期结直肠癌可以采用dabrafenib + trametinib + panitumumab/cetuximab的联合用药方案。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'dabrafenib + trametinib + panitumumab', '曲美替尼 + 达拉非尼 + 帕尼单抗', 'dabrafenib + trametinib + panitumumab|曲美替尼 + 达拉非尼 + 帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001355', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '该方案基于NCT01750918研究。研究纳入经治BRAF突变的晚期结直肠癌患者，随机分组三组：D+T组、D+P组、D+T+P组（D:dabrafenib；T：trametinib；P:panitumumab）。在35例接受三药方案组的患者中，最终整体有效率为26%，有1例患者达到完全缓解，疾病控制率为83%。有效率方面远高于两药联合的10%ORR。也因此成为此类患者可选方案之一。NCCN推荐携带BRAF突变的晚期结直肠癌可以采用dabrafenib + trametinib + panitumumab/cetuximab的联合用药方案。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'encorafenib + binimetinib + cetuximab', 'encorafenib + binimetinib + 西妥昔单抗', 'encorafenib + binimetinib + cetuximab|encorafenib + binimetinib + 西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001356', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '该方案基于III期BEACON CRC研究。Encorafenib是BRAF抑制剂、binimetinib是MEK抑制剂。采用三种药物联合方案治疗30例经治进展的BRAFV600E突变的转移性结直肠癌患者，有效率可达到48%，其中有3位患者达到完全缓解，疾病控制率可达93%。中位PFS为8个月，中位OS为15.3个月。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'encorafenib + binimetinib + panitumumab', 'encorafenib + binimetinib + 帕尼单抗', 'encorafenib + binimetinib + panitumumab|encorafenib + binimetinib + 帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001357', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '该方案基于III期BEACON CRC研究。Encorafenib是BRAF抑制剂、binimetinib是MEK抑制剂。采用三种药物联合方案治疗30例经治进展的BRAFV600E突变的转移性结直肠癌患者，有效率可达到48%，其中有3位患者达到完全缓解，疾病控制率可达93%。中位PFS为8个月，中位OS为15.3个月。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:dasatinib_Revised:08/2015', 'Revised:08/2015', 'guideline:FDA', '1', '.', '.', 'dasatinib', '达沙替尼', 'dasatinib|达沙替尼', '.', 'chronic myeloid leukemia;acute lymphoblastic leukemia', 'leukemia', '白血病', 'na', 'sensitivity', 'EVI_001359', 'ABL1:FUS:.:BCR-ABL1:.', 'ABL1', 'FUS', 'FUS', '.', 'BCR-ABL1', '.', '.', '达沙替尼(Dasatinib)适用于治疗：(1)新诊断的慢性期费城染色体阳性的慢性粒细胞白血病成人患者；（2）对先期治疗（包括伊马替尼）耐药或对不耐受的费城染色体阳性的慢性期、加速期或骨髓或淋巴急变期的慢性粒细胞白血病；（3）对先期治疗耐药或不能耐受的费城染色体阳性的急性淋巴细胞白血病。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:nilotinib_Revised:10/2015', 'Revised:10/2015', 'guideline:FDA', '1', '.', '.', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '.', 'chronic myeloid leukemia', 'leukemia', '白血病', 'na', 'sensitivity', 'EVI_001360', 'ABL1:FUS:.:BCR-ABL1:.', 'ABL1', 'FUS', 'FUS', '.', 'BCR-ABL1', '.', '.', '尼洛替尼（Nilotinib）（1）适用于治疗新诊断的、费城染色体阳性、慢性期慢性粒性白血病成年患者（2）适用于治疗慢性期、加速期、费城染色体阳性慢性粒细胞性白血病成年患者，患者对包含伊马替尼的先期治疗耐药或不能耐。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:bosutinib_Revised:04/2016', 'Revised:04/2016', 'guideline:FDA', '1', '.', '.', 'bosutinib', '博舒替尼', 'bosutinib|博舒替尼', '.', 'chronic myelogenous leukemia', 'leukemia', '白血病', 'na', 'sensitivity', 'EVI_001361', 'ABL1:FUS:.:BCR-ABL1:.', 'ABL1', 'FUS', 'FUS', '.', 'BCR-ABL1', '.', '.', '博舒替尼（Bosutinib）适用于对既往治疗耐药或不耐受的慢性期、加速期或急变期费城染色体阳性慢性髓细胞性白血病患者。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:imatinib_Revised:01/2015', 'Revised:01/2015', 'guideline:FDA', '1', '.', '.', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '.', 'chronic myelogenous leukemia;acute lymphoblastic leukemia;', 'leukemia', '白血病', 'na', 'sensitivity', 'EVI_001362', 'ABL1:FUS:.:BCR-ABL1:.', 'ABL1', 'FUS', 'FUS', '.', 'BCR-ABL1', '.', '.', '伊马替尼(Imatinib  mesylate)：（1）适用于治疗新诊断的慢性期、费城染色体阳性的慢性粒性白血病成人和儿童患者；（2）适用于急变期、加速期或慢性期费城染色体阳性慢性粒细胞白血病，患者既往接受干扰素-α治疗失败；（3）适用于复发性或难治型费城染色体阳性的急性淋巴细胞性白血病；（4）联合其他化疗治疗新诊断的费城染色体阳性急性淋巴细胞性白血病儿童患者；', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ponatinib_Revised:06/2016', 'Revised:06/2016', 'guideline:FDA', '1', '.', '.', 'ponatinib', '帕纳替尼', 'ponatinib|帕纳替尼', '4', 'acute lymphoblastic leukemia', 'leukemia', '白血病', 'na', 'sensitivity', 'EVI_001364', 'ABL1:FUS::BCR-ABL1:.', 'ABL1', 'FUS', 'FUS', '.', 'BCR-ABL1', '.', '.', '帕纳替尼（Ponatinib）适用于（1）T315I阳性的慢性粒细胞白血病（慢性期、加速期或急变期）成人患者或T315I阳性、费城染色体阳性的急性淋巴细胞性白血病成人患者（2）未有其他酪氨酸激酶抑制剂适用治疗的慢性期、加速期或急变期的慢性粒细胞白血病或费城染色体阳性的急性淋巴细胞性白血病成人患者。这些适应症是基于响应率。没有实验证明帕纳替尼可以改善疾病相关症状或延长生存期。局限性：帕纳替尼不适用于且不推荐用于新诊断的慢性期慢性粒细胞白血病患者。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29158193', 'NCT00981058', 'clinical trial - phase3', '4', '.', '.', 'necitumumab + cisplatin + gemcitabine', '耐昔妥珠单抗 + 顺铂 + 吉西他滨', 'necitumumab + cisplatin + gemcitabine|耐昔妥珠单抗 + 顺铂 + 吉西他滨', '4', 'Squamous Lung Carcinomas', 'lung cancer', '肺鳞癌', 'na', 'sensitivity', 'EVI_001367', 'EGFR:CNV:.:.:gain', 'EGFR', 'CNV', 'CNV', '.', '.', 'gain', '.', 'Necitumumab是靶向EGFR的单克隆抗体。在SQUIRE临床试验中，将necitumumab加入化疗方案，治疗鳞状细胞肺癌可显著提高总生存期（OS）（风险比[HR] = 0.84）；随后分析发现，EGFR拷贝数增加与necitumumab添加而导致的OS（HR = 0.70）和无进展存活（PFS）（HR = 0.71）的改善有关。1093名患者中有557名患者可获得样本; 208例患者（37.3%）为EGFR阳性，其中167例（30.0%）为高多倍体（high polysomy），41例（7.4%）为基因扩增。对于高多倍体患者，加入necitumumab导致PFS显著增加（6.08对5.13个月[p = 0.044]），OS无显著性增加（12.6对9.5个月[p = 0.133]）;在基因扩增患者中，添加necitumumab并未显著改善PFS（7.4对5.6个月; [p = 0.334]），但确实改善OS（14.8对7.6个月; [p = 0.033]）。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28550065', '.', 'case report', '4', 'everolimus + exemestane', 'everolimus + exemestane', 'everolimus + exemestane', '依维莫司 + 依西美坦', 'everolimus + exemestane|依维莫司 + 依西美坦', '4', 'breast cancer', 'breast cancer', '乳腺癌(三阴性)', '[ER(-);PR(-);HER2(-)]', 'sensitivity', 'EVI_001368', 'STK11:nonsynonymous SNV:.:.:inact', 'STK11', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '转移性三阴性乳腺癌占乳腺癌的12%-17%，相对于其他亚型三阴性乳腺癌预后较差。该疾病的治疗方案主要限于全身化疗。大多数评估晚期乳腺癌患者对靶向药物疗效的临床研究尚未使用基因突变作为其生物标志物。最近的研究表明，携带PI3K/AKT/mTOR信号通路基因突变的乳腺癌患者可以从mTOR抑制剂类治疗中获益。一位1997年确诊早期乳腺癌，接受了手术、化疗、内分泌治疗的女性患者，2009年首次出现肝脏转移，此后又接受了多种常见的化疗、放疗、内分泌治疗，到2014年肝脏转移进展并出现骨转移。患者进行了穿刺活检，结果提示携带有STK11基因致病突变，可能会导致mTOR信号通路异常活化。在2014年8月，患者开始服用内分泌治疗药物依西美坦，同时联合mTOR抑制剂依维莫司。除了皮疹外，患者的副作用轻微。用药后，患者肿瘤逐步缓解，最终达到了接近完全缓解的状态，肿瘤标志物也全面恢复正常，临床反应时间超过14个月。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2018.36.15_suppl.9015|DOI:10.1200/JCO.2019.37.15_suppl.9007 ', 'NCT02716116', 'clinical trial - phase2', '4', 'AP32788', 'AP32788', 'AP32788', 'AP32788', 'AP32788|AP32788', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001369', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', '非小细胞肺癌（NSCLC）中EGFR Exon20插入突变约1.6%-3.4%，HER2突变约2%-4%，其中主要为Exon20插入突变。临床前试验显示武田制药的不可逆酪氨酸激酶抑制剂TAK-788（AP32788）可以有效抑制EGFR和HER2 Exon20插入突变，1/2期临床试验正在进行中。该临床试验包括57名晚期非小细胞肺癌患者（中位年龄61岁，女性67%，经二线以上治疗79%，EGFR Exon 20插入突变39名，HER2 Exon 20插入突变 13名，其它EGFR突变7名）。AP32788在80mg-160 mg剂量范围内时，18名EGFR Exon 20插入突变患者中有6名部分缓解（其中3名待确认），1名完全缓解，6名疾病稳定，客观有效率为39%，疾病控制率为94%，4名已确认有效的患者中位有效持续时间超过222天，其中3名仍在临床组中。只有1名HER2 Exon 20插入突变部分缓解，而且有待确认。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29807405', '.', 'case report', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001373', 'EGFR:nonsynonymous SNV:exon20:p.C797G<顺式>:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797G<顺式>', '.', '.', '表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂（TKI）是EGFR突变型非小细胞肺癌（NSCLC）的有效临床治疗药物。Osimertinib是第三代EGFR TKI，已被证明可有效对抗T790M突变。然而，绝大多数患者在成功治疗后获得抗药性。一名患有转移性NSCLC的59岁女性患者在osimertinib治疗43周后出现耐药。基因检测发现该患者携带EGFR C797G突变（等位基因频率为72%），先前存在的顺式T790M突变（73%）和外显子19缺失（87%）。另一名53岁女性患者在奥西替尼治疗10个月后出现全身性进展。肺活组织检查发现携带EGFR L718Q突变（等位基因频率为7%），同时发现PIK3CA E545K（12.90%）和预先存在的EGFR L858R（38%），但T790M突变丢失。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:erdafitinib_Revised: 04/2019', '.', 'guideline:FDA', '1', 'JNJ-42756493', 'JNJ-42756493', 'erdafitinib', 'erdafitinib', 'erdafitinib|erdafitinib', '4', 'urinary system cancer', 'bladder cancer', '膀胱癌', 'na', 'sensitivity', 'EVI_001375', 'FGFR3:nonsynonymous SNV:.:.:act', 'FGFR3', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'Erdafitinib的加速批准基于一项二期临床试验BLC2001的结果。试验中，Erdafitinib诱导局部晚期或转移性膀胱癌患者的总应答率(ORR)为32.2%，包括2.3%的完全应答率和29.9%的部分应答率。其中有一部分是先前对PD-1/PD-L1治疗无反应的患者。BLC2001是一项开放标签、单臂、多中心的临床试验，包括87例转移性或手术不可切除性尿路上皮癌伴FGFR基因组改变的患者。经中心实验室证实，患者有FGFR3基因突变(R248C、S249C、 G370C、Y373C)或FGFR基因融合(FGFR3-TACC3、FGFR3-BAIAP2L1、FGFR2-BICC1、FGFR2-CASP7)。此外，所有患者在先前的化疗后或化疗时都有疾病进展。患者中位年龄为67岁(36-87)，74%为白人，79%为男性。92%的ECOG表现为0或1，66%的患者有内脏转移。24%的患者先前接受过PD-1/PD-L1抑制剂，几乎所有(97%)的患者都曾接受过顺铂或卡铂治疗，其中10%同时接受过顺铂和卡铂的治疗。3名患者在仅接受含铂新辅助治疗或辅助治疗后有进展。患者使用Erdafitinib的初始剂量为每天8毫克。在14和17天之间，血清磷酸盐水平低于5.5 mg/dL的患者(占41%)剂量增加到每天9毫克。响应的中位持续时间为5.4个月。64例FGFR3基因点突变患者的ORR为40.6%，18例FGFR3融合患者的ORR为11.1%。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:erdafitinib_Revised: 04/2019', '.', 'guideline:FDA', '1', 'JNJ-42756493', 'JNJ-42756493', 'erdafitinib', 'erdafitinib', 'erdafitinib|erdafitinib', '4', 'urinary system cancer', 'bladder cancer', '膀胱癌', 'na', 'sensitivity', 'EVI_001376', 'FGFR3:FUS:.:FGFR3-.:.', 'FGFR3', 'FUS', 'FUS', '.', 'FGFR3-.', '.', '.', 'Erdafitinib的加速批准基于一项二期临床试验BLC2001的结果。试验中，Erdafitinib诱导局部晚期或转移性膀胱癌患者的总应答率(ORR)为32.2%，包括2.3%的完全应答率和29.9%的部分应答率。其中有一部分是先前对PD-1/PD-L1治疗无反应的患者。BLC2001是一项开放标签、单臂、多中心的临床试验，包括87例转移性或手术不可切除性尿路上皮癌伴FGFR基因组改变的患者。经中心实验室证实，患者有FGFR3基因突变(R248C、S249C、 G370C、Y373C)或FGFR基因融合(FGFR3-TACC3、FGFR3-BAIAP2L1、FGFR2-BICC1、FGFR2-CASP7)。此外，所有患者在先前的化疗后或化疗时都有疾病进展。患者中位年龄为67岁(36-87)，74%为白人，79%为男性。92%的ECOG表现为0或1，66%的患者有内脏转移。24%的患者先前接受过PD-1/PD-L1抑制剂，几乎所有(97%)的患者都曾接受过顺铂或卡铂治疗，其中10%同时接受过顺铂和卡铂的治疗。3名患者在仅接受含铂新辅助治疗或辅助治疗后有进展。患者使用Erdafitinib的初始剂量为每天8毫克。在14和17天之间，血清磷酸盐水平低于5.5 mg/dL的患者(占41%)剂量增加到每天9毫克。响应的中位持续时间为5.4个月。64例FGFR3基因点突变患者的ORR为40.6%，18例FGFR3融合患者的ORR为11.1%。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ceritinib_Revised:3/2019 ', '.', 'guideline:FDA', '1', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_001377', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', 'FDA基于以下两项临床试验批准塞瑞替尼用于ALK阳性非小细胞肺癌的治疗。临床试验（ASCEND-1,NCT01283516）在163例经克唑替尼治疗后病情恶化或对克唑替尼不耐受的ALK+ 非小细胞肺癌患者中开展。该研究群体中，肿瘤转移的最常见部位为脑（60%）、肝脏（42%）、骨骼（42%）。研究数据表明，塞瑞替尼治疗取得了54.6%的总响应率（ORR），平均响应持续时间为7.4个月。另一个大型的III期临床试验（ASCEND-4, NCT01828099）中，招募了376位3B期/4期的初诊ALK阳性非小肺癌患者：189位使用塞瑞替尼，每天口服750 mg；187位使用化疗，培美曲塞+顺铂/卡铂，即以化疗组作为对照。患者使用塞瑞替尼的有效率(ORR)73%，无进展生存期(PFS)是16.6个月，而使用化疗的有效率27%，PFS只有8.1个月，塞瑞替尼减少了45%的进展和死亡的风险。', 'F', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>|PMID:23348520|PMID:30952821|J Clin Oncol 34, 2016 (suppl; abstr 3517)', '.', 'guideline:NCCN', '1', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_001378', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NCCN指南表示，HER2（ERBB2）扩增/过表达的结直肠癌患者可能对靶向EGFR的单克隆抗体药物具有耐药性。在一项临床研究中，队列1中的RAS/BRAF野生型患者中有14例（14%）观察到HER扩增。在该队列中，一线治疗未使用抗EGFR抗体药物，中位OS（29.1 v 45.1 个月，P = 0.78）和PFS（9.7 v 8.4个月，P = 0.70）与HER扩增状态无关。一线治疗后，队列1中共有66位患者接受抗EGFR抗体。与HER2阴性癌症患者相比，携带HER扩增的患者的中位PFS明显缩短（2.9 vs 8.1 m，HR：5.0，P <0.0001）。这些发现在队列2中得到了证实，其中69例患者在一线治疗后接受了抗EGFR抗体治疗，HER扩增患者的中位PFS明显短于HER2阴性患者（2.8 vs 9.3 m，HR：6.6，P <0.0001）。 ', 'A', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>|PMID:23348520|PMID:30952821|J Clin Oncol 34, 2016 (suppl; abstr 3517)', '.', 'guideline:NCCN', '1', 'panitumumab', 'panitumumab', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_001379', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NCCN指南表示，HER2（ERBB2）扩增/过表达的结直肠癌患者可能对靶向EGFR的单克隆抗体药物具有耐药性。在一项临床研究中，队列1中的RAS/BRAF野生型患者中有14例（14%）观察到HER扩增。在该队列中，一线治疗未使用抗EGFR抗体药物，中位OS（29.1 v 45.1 个月，P = 0.78）和PFS（9.7 v 8.4个月，P = 0.70）与HER扩增状态无关。一线治疗后，队列1中共有66位患者接受抗EGFR抗体。与HER2阴性癌症患者相比，携带HER扩增的患者的中位PFS明显缩短（2.9 vs 8.1 m，HR：5.0，P <0.0001）。这些发现在队列2中得到了证实，其中69例患者在一线治疗后接受了抗EGFR抗体治疗，HER扩增患者的中位PFS明显短于HER2阴性患者（2.8 vs 9.3 m，HR：6.6，P <0.0001）。 ', 'A', '耐药', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:ivosidenib_Revised:05/2019', '.', 'guideline:FDA', '1', 'ivosidenib', 'ivosidenib', 'ivosidenib', 'ivosidenib', 'ivosidenib|ivosidenib', '1', ' acute myeloid leukemia', ' acute myeloid leukemia', '白血病', 'na', 'sensitivity', 'EVI_001380', 'IDH1:nonsynonymous SNV:.:.:act', 'IDH1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'ivosidenib的获批是通过一项单臂试验中确定的。该试验纳入174名IDH1突变的复发或难治性急性髓系白血病成人患者。患者以每日500毫克ivosidenib的起始剂量口服给药，直至疾病进展、发生不可接受的毒性或需要进行造血干细胞移植。研究的主要终点是联合的完全缓解(CR)和有部分血液学改善的完全缓解(CRh)率。在为期8.3个月的中位随访时间里，32.8%患者达到了CR或CRh，其中完全缓解的为24.7%，部分血液学改善的完全缓解率为8%，对于达到CR或CRh的患者，获得最佳缓解的中位时间为2.0个月，并且中位缓解时间持续8.2个月。在试验开始时因疾病需要红细胞或血小板输注的110位患者中，有37%在治疗后至少56天无需输注。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NMPA|PMID:29946728', '.', 'guideline:NMPA', '1', '.', '.', 'fruquintinib', '呋喹替尼', 'fruquintinib|呋喹替尼', '4', 'metastatic colorectal cancer ', 'metastatic colorectal cancer ', '结直肠癌', 'na', 'sensitivity', 'EVI_001381', 'KRAS:wildtype:.:.:wildtype', 'KRAS', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', '呋喹替尼用于治疗既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子 （VEGF）治疗、抗表皮生长因子受体（EGFR）治疗 (RAS野生型）的转移性结直肠癌 （mCRC）患者。主要临床证据为FRESCO研究。试验设计：对2线或以上标准化疗失败的转移性结直肠癌患者进入筛选，筛选人数519例，随机人数416例，以2:1随机入组：呋喹替尼+BSC,5mg qd,服用3周停1周（4周为一疗程），N=278；安慰剂+BSC，N=138。治疗直至疾病进展、毒性不能耐受或者撤回知情同意。这是一项随机、双盲、安慰剂对照、全国多中心的III期临床研究，随机分层因素包括既往抗VEGF使用情况，以及患者K-Ras基因状态。结果：总生存期OS：9.30 vs. 6.57m (HR=0.65，P<0.001)；无进展生存期PFS: 3.71 vs. 1.84m (HR=0.65，P<0.001)；肿瘤客观反应率ORR: 4.7% vs.0 (P=0.012)；疾病控制率DCR：62.2% vs.12.3%（P<0.001）。预设的所有亚组分析均提示，OS和PFS皆倾向于呋喹替尼组获益：既往无论是否接受过抗VEGF或抗EGFR治疗，呋喹替尼组均能显著获益；既往没有接受过抗VEGF的人群中，呋喹替尼的mOS可延长至10.4个月；既往没有接受过抗VEGF的人群，呋喹替尼的死亡风险降低32%；K-RAS野生型的人群中，呋喹替尼的mOS可延长至10.7个月，较安慰剂组延长近5个月；K-RAS突变的人群中，呋喹替尼的死亡风险降低25%。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30478962', '.', 'clinical study', '4', 'trastuzumab + pertuzumab', 'trastuzumab + pertuzumab', 'trastuzumab + pertuzumab', '曲妥珠单抗 + 帕妥珠单抗', 'trastuzumab + pertuzumab|曲妥珠单抗 + 帕妥珠单抗', '4', 'salivary duct carcinoma', 'salivary duct carcinoma', '涎腺导管癌', 'na', 'sensitivity', 'EVI_001382', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'BACKGROUND:Alterations in the human epidermal growth factor receptor-2 (ERBB2) pathway have been identified in a subset of salivary duct carcinomas. Dual ERBB2 inhibition with trastuzumab and pertuzumab has superior antitumor efficacy to trastuzumab monotherapy in ERBB2-positive breast cancer, yet its efficacy in ERBB2-positive salivary duct carcinoma is unknown.METHODS:We report 2 cases of exceptional responses of ERBB2-positive salivary duct carcinomas to dual ERBB2 blockade and docetaxel combination and their molecular characteristics.RESULTS:A 54-year-old man with recurrent metastatic ERBB2 expressing salivary duct carcinoma of the parotid gland after definitive concurrent chemoradiation achieved a complete response (CR) after 6 cycles of trastuzumab, pertuzumab, and docetaxel (TPH). A 42-year-old woman with ERBB2-positive salivary duct carcinoma of the parotid gland with bone and liver metastases had CR with TPH and remains in remission on maintenance trastuzumab and pertuzumab.CONCLUSION:Dual ERBB2 blockage resulted in CR in patients with HER expressing salivary duct carcinoma and warrants further evaluation in this patient population.', '人类表皮生长因子受体-2（ERBB2）途径的改变已经在涎腺导管癌中被发现。在ERBB2阳性乳腺癌中，曲妥珠单抗和帕妥珠单抗的双重ERBB2抑制比曲妥珠单抗单药治疗具有更高的抗肿瘤效果，但其在ERBB2阳性涎腺导管癌中的疗效尚不清楚。研究人员报道了2例ERBB2阳性涎腺导管癌患者在曲妥珠单抗和帕妥珠单抗与多西紫杉醇联合用药下的反应。一名54岁男性ERBB2阳性涎腺导管癌患者在同步放化疗后复发转移，经过6个周期的曲妥珠单抗联合帕妥珠单抗和多西紫杉醇治疗后达到完全缓解（CR）。另一名42岁女性患者患有ERBB2阳性涎腺导管癌伴骨和肝转移，在曲妥珠单抗联合帕妥珠单抗和多西紫杉醇治疗后仍有缓解。', 'a', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30462564', '.', 'clinical study', '4', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', 'anaplastic oligoastrocytoma', 'anaplastic oligoastrocytoma', '间变性少突细胞瘤', 'na', 'sensitivity', 'EVI_001383', 'BRAF:nonsynonymous SNV:exon15:p.V600.:inact', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'BACKGROUND:Extracranial metastasis is a rare phenomenon of anaplastic oligoastrocytoma. When patients progress after comprehensive treatment, there is often no effective treatment. Rapid development of gene detection technology makes precision treatment of glioma possible.PATIENT AND METHODS:A 22-year-old girl was firstly diagnosed with anaplastic oligoastrocytoma WHO grade III-IV in 2014, and progressed rapidly after chemoradiotherapy in multiple extraneural lesions in 2016. She was expected to have a short life and Next-Generation Sequencing (NGS) was applied.RESULTS:Mutation of BRAF (V600E) was reported by 1st NGS and oral vemurafenib stabilized her disease for 6 months. PIK3CA was reported by 2nd NGS after her progression of vemurafenib. The oral administration of everolimus together with vemurafenib stabilized her disease for another 6 months. However, the patient died due to the rapid progression of the disease on 24 February 2018.CONCLUSION:We successfully treated a BRAF V600E-mutated anaplastic oligoastrocytoma with multiple extraneural metastases with vemurafenib and everolimus. For late-staged patients who have no clear and effective treatment plan, NGS may serve as an effective option.', '颅外转移是间变性少突细胞瘤的罕见现象，患者综合治疗后一旦发生进展便缺乏有效的治疗方法，基因检测技术的快速发展使得胶质瘤的精确治疗成为可能。1名22岁的女孩在2014年首次被诊断为WHO III-IV级间变性少突细胞瘤，2016年在多个神经外病变的放化疗后进展迅速。第一次NGS报告了BRAF V600E突变，口服vemurafenib使其病情稳定6个月。疾病进展后，第二次NGS报道了PIK3CA突变。everolimus与vemurafenib的联合治疗使其病情再稳定了6个月。然而，该患者于2018年2月24日因疾病的快速进展而死亡。vemurafenib可有效治疗BRAF V600E突变的间变性少突细胞瘤，everolimus与vemurafenib的联合治疗对PIK3CA突变的多发性神经外转移有效。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:盐酸埃克替尼片_Revised: 08/2017|中国埃克替尼治疗非小细胞肺癌专家共识（2016年版）', '.', 'guideline:NMPA', '1', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001386', 'EGFR:nonsynonymous SNV:exon20:p.S768I:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.S768I', '.', '埃克替尼(Icotinib)单药适用于治疗既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌（NSCLC），既往化疗主要是指以铂类为基础的联合化疗。该适应症主要基于一项随机、对照、双盲研究中显示出盐酸埃克替尼（以下简称埃克替尼）对于这类患者无进展生存期的疗效不劣于吉非替尼，进一步的总生存数据尚在收集中。该研究中获得表皮生长因子受体（EGFR）突变检测结果的亚组人群初步分析结果显示，EGFR突变型患者疗效优于野生型患者，但对于EGFR突变型或野生型亚组人群的作用差别尚需进一步大样本研究证实。对于不同病理类型的亚组人群分析结果初步提示，非鳞癌患者疗效优于鳞癌患者。同样，对于鳞癌和非鳞癌亚组人群的作用差别尚需进一步大样本研究证实。建议医生结合同类药物相关研究结果及患者自身状况综合考虑适宜的治疗选择。', 'icotinib适用于治疗1.表皮生长因子受体(EGFR)基因具有敏感突变(L858R/19del/L861/G719等)的局部晚期或转移性非小细胞肺癌(NSCLC)患者的一线治疗；2.既往接受过至少一个化疗方案失败后的局部晚期或转移性非小细胞肺癌(NSCLC)，既往化疗主要是指以铂类为基础的联合化疗。不推荐本品用于EGFR野生型非小细胞肺癌患者。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2016.34.15_suppl.5571 ', 'NCT02098343', 'clinical trial - phase1', '4', 'APR-246', 'APR-246', 'APR-246', 'APR-246', 'APR-246|APR-246', '3', 'Ovarian Cancer', 'Ovarian Cancer', '卵巢癌', 'na', 'sensitivity', 'EVI_001387', 'TP53:nonsynonymous SNV:.:.:inact', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'APR-246是全新的、新类型P53蛋白激活剂，对P53失活突变的患者可能有效。Aprea的1b/2期PiSARRO试验研究了APR-246与卡铂及阿霉素合并用药二线治疗高级别严重卵巢癌患者的安全性及有效性。该研究1b期头24名患者的初步结果已经宣布，其中有8名患者完成了APR-246合并用药所有6轮的化疗。试验结束时,依据RECIST标准，研究中所有治疗患者的疾病得到稳定或好转。此外，14名可评价患者中有13名患者在治疗3轮后获得GCIG CA-125（肿瘤抗原生物标志物）响应。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:alpelisib_Revised:05/2019 ', 'NCT02437318', 'guideline:FDA', '1', 'alpelisib + fulvestrant', 'alpelisib + fulvestrant', 'alpelisib + fulvestrant', 'alpelisib + 氟维司群', 'alpelisib + fulvestrant|alpelisib + 氟维司群', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001388', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '本次获批的临床依据是名为SOLAR-1 (NCT02437318)的3期临床数据。共有572名PIK3CA基因突变的HR+/HER2-晚期或转移性乳腺癌患者接受了Piqray（alpelisib）+氟维司群，或安慰剂+氟维司群治疗。其中与对照组相比，Piqray（alpelisib）+氟维司群的mPFS（中位无进展生存期）为11.0个月，而安慰剂+氟维司群的mPFS为5.7个月。PFS接近两倍。有效率方面，安慰剂联合氟维司群组是16.2%，而Alpelisb联合氟维司群组是35.7%。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28451792|PMID:28039262|PMID:27467949', '.', 'clinical study', '4', 'pembrolizumab', 'pembrolizumab', 'pembrolizumab', '帕博利珠单抗', 'pembrolizumab|帕博利珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001389', 'KRAS:nonsynonymous SNV:exon2:p.G12.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', '.', '最近Chen等[PMID:28451792]的研究纳入216例NSCLC患者，69例为EGFR/ALK野生型肺腺癌患者，其中19例患者携带KRAS突变。通过倾向匹配评分分析后与50例EGFR/ALK/KRAS野生型患者中38例患者的基线特征相匹配。最后，通过免疫组织化学检测匹配后的57例患者组织中的细胞程式死亡-配体1（programmed cell death 1 ligand 1, PD-L1）表达。表明肺腺癌伴KRAS突变患者PDL-1表达明显高于KRAS野生型，并且发现KRAS G12D突变激活了磷酸化细胞外信号调节激酶1/2（phosphorylated extracellular regulated kinase 1/2, p-ERK1/2）和磷酸化AKT（p-AKT），应用ERK1/2抑制剂（SCH772984）抑制p-ERK，进一步导致PD-L1表达的降低。表明PD-L1表达受KRAS G12D突变的调控。此外Dong等[PMID:28039262]研究支持TP53和KRAS突变可作为指导抗PD-1/PD-L1免疫治疗的一对潜在预测因素。基于MSKCC的数据统计分析表明，与接受pembrolizumab治疗的野生型患者相比，TP53或KRAS突变患者获得显著延长的无进展生存期（PFS）（中位PFS，TP53-mut与KRAS-mut对比野生型：14.5 vs. 14.7 vs. 3.5个月，P = 0.012）。 大多数TP53或KRAS突变患者在治疗期间享有持久的临床益处，而大多数野生型患者显示没有持久益处。更重要的是，同时携带TP53和KRAS突变的4名肺腺癌患者表现出优异的PFS，并且所有患者都具有持久的临床益处。同时，这些患者表现出高突变负担，较高的颠换 (transversion)类型变异和PD-L1强染色。Scheel等[PMID:27467949]发现具有突变型KRAS，突变型TP53和野生型STK11的标本中PD-L1阳性表达最高。相反，具有野生型KRAS，野生型TP53和突变型STK11的标本PD-L1阳性表达最低。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28894382', '.', 'case report', '4', 'apatinib', 'apatinib', 'apatinib', '阿帕替尼', 'apatinib|阿帕替尼', '4', 'lung adenocarcinoma', 'lung adenocarcinoma', '肺癌', 'na', 'sensitivity', 'EVI_001390', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '作为血管内皮生长因子受体-2（VEGFR-2）酪氨酸激酶的小分子抑制剂，阿帕替尼已被证明在晚期胃癌和乳腺癌中具有显著疗效。一项临床研究中，4名携带KRAS突变的晚期肺腺癌患者在二线治疗后采用口服阿帕替尼（250mg/d）治疗。 一名患者疾病进展，而3名患者表现稳定，中位无进展生存期（PFS）为3.8个月（1.5-5.5个月）。主要毒性是声音嘶哑和咯血。因此，apatinib可能是二线治疗后KRAS突变的晚期肺腺癌患者的可能选择。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29270615|PMID:26673119', '.', 'case report', '4', 'nivolumab', 'nivolumab', 'nivolumab', '纳武利尤单抗', 'nivolumab|纳武利尤单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001391', 'KRAS:nonsynonymous SNV:exon2:p.G12.:.', 'KRAS', 'nonsynonymous SNV', 'Partial_pos', 'exon2', 'p.G12.', '.', '.', '使用PD-1/PD-L1抑制剂能够恢复抗肿瘤的免疫力，并且已经在广泛的肿瘤类型（鳞状、腺癌）中表现出功效。涉及3025例患者的荟萃分析显示免疫检查抑制剂延长KRAS突变亚组的总生存期（HR=0.65; 95%CI: 0.44-0.97; P=0.03）[PMID:29270615]。而在Diwakar Davar的报告中，描述了在伴KRAS突变综合治疗后的晚期肺腺癌患者，单剂量nivolumab治疗后复查发现所有病变均明显缩小（接近完全缓解），2个非靶病变（左胸膜结节和食管旁淋巴结）完全消失[PMID:26673119]。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26728409', '.', 'preclinical', '4', 'trametinib + palbociclib', 'trametinib + palbociclib', 'trametinib + palbociclib', '曲美替尼 + 哌柏西利', 'trametinib + palbociclib|曲美替尼 + 哌柏西利', '4', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001392', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项研究发现肿瘤细胞对MEK抑制剂的敏感性与RB/p16/CDK4途径相关，并且敲除RB基因可以诱导对MEK抑制剂敏感的肿瘤细胞产生耐药性。此外，p16的过表达和CDK4的抑制可以使耐药细胞重新对药物敏感。体内外试验都表明MEK抑制剂（trametinib，GSK112012）与CDK4/6抑制剂（palbociclib，PD0332991）合用可以强烈降低KRAS突变型肺癌细胞活性。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29906251', '.', 'clinical trial - phase2', '4', 'temozolomide + veliparib', 'temozolomide + veliparib', 'temozolomide + veliparib', '替莫唑胺 + 维利帕尼', 'temozolomide + veliparib|替莫唑胺 + 维利帕尼', '4', 'small cell lung cancer', 'small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001393', 'SLFN11:CNV:.:.:gain', 'SLFN11', 'CNV', 'CNV', '.', '.', 'gain', 'Purpose Both temozolomide (TMZ) and poly (ADP-ribose) polymerase (PARP) inhibitors are active in small-cell lung cancer (SCLC). This phase II, randomized, double-blind study evaluated whether addition of the PARP inhibitor veliparib to TMZ improves 4-month progression-free survival (PFS). Patients and Methods A total of 104 patients with recurrent SCLC were randomly assigned 1:1 to oral veliparib or placebo 40 mg twice daily, days 1 to 7, and oral TMZ 150 to 200 mg/m2/day, days 1 to 5, of a 28-day cycle until disease progression, unacceptable toxicity, or withdrawal of consent. Response was determined by imaging at weeks 4 and 8, and every 8 weeks thereafter. Improvement in PFS at 4 months was the primary end point. Secondary objectives included overall response rate (ORR), overall survival (OS), and safety and tolerability of veliparib with TMZ. Exploratory objectives included PARP-1 and SLFN11 immunohistochemical expression, MGMT promoter methylation, and circulating tumor cell quantification. Results No significant difference in 4-month PFS was noted between TMZ/veliparib (36%) and TMZ/placebo (27%; P = .19); median OS was also not improved significantly with TMZ/veliparib (8.2 months; 95% CI, 6.4 to 12.2 months; v 7.0 months; 95% CI, 5.3 to 9.5 months; P = .50). However, ORR was significantly higher in patients receiving TMZ/veliparib compared with TMZ/placebo (39% v 14%; P = .016). Grade 3/4 thrombocytopenia and neutropenia more commonly occurred with TMZ/veliparib: 50% versus 9% and 31% versus 7%, respectively. Significantly prolonged PFS (5.7 v 3.6 months; P = .009) and OS (12.2 v 7.5 months; P = .014) were observed in patients with SLFN11-positive tumors treated with TMZ/veliparib. Conclusion Four-month PFS and median OS did not differ between the two arms, whereas a significant improvement in ORR was observed with TMZ/veliparib. SLFN11 expression was associated with improved PFS and OS in patients receiving TMZ/veliparib, suggesting a promising biomarker of PARP-inhibitor sensitivity in SCLC.', '替莫唑胺(TMZ)和PARP抑制剂在小细胞肺癌(SCLC)中都有活性。这项II期随机双盲研究评估了TMZ联合PARP抑制剂veliparib对SCLC的无进展生存期(PFS)的影响。104例复发性SCLC患者1：1随机分配，一组口服veliparib联合TMZ,一组口服安慰剂+TMZ ，直至疾病进展或出现不可接受的毒性。PFS是主要终点，次要目标包括总体反应率(ORR)，总生存期(OS)以及安全性和耐受性。探索性目标包括PARP-1和SLFN11的免疫组织化学表达，MGMT的启动子甲基化和循环肿瘤细胞定量。两组患者的4个月PFS无显著差异，TMZ+veliparib的中位OS也没有显著改善。然而，与TMZ+安慰剂相比，接受TMZ+veliparib的患者的ORR显著升高。TMZ+veliparib更常发生3/4级血小板减少和中性粒细胞减少。其中，TMZ+veliparib治疗的SLFN11阳性肿瘤患者PFS和OS显著延长。', 'a', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30692501', '.', 'case report', '4', 'eribulin + trastuzumab + pertuzumab', 'eribulin + trastuzumab + pertuzumab', 'eribulin + trastuzumab + pertuzumab', 'eribulin + 曲妥珠单抗 + 帕妥珠单抗', 'eribulin + trastuzumab + pertuzumab|eribulin + 曲妥珠单抗 + 帕妥珠单抗', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001394', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'The patient was an 82-year-oldwoman. She consultedour hospital with a chief complaint of left breast mass. MRI showed enhancedtumor with skin andextensive pectoral muscle invasion, so it was unresectable. Immunohistopathological analysis revealeda ERBB2-positive lesion. We administerederibulin, trastuzumab andpertuzumab, after which the tumor became resectable. Histological examination revealedremarkable response. Combination therapy of eribulin, trastuzumab andpertuzumab was well toleratedandconsid eredto be effective.', '1名82岁的女性出现左乳房肿块，MRI显示肿瘤胸肌入侵扩张，因此无法切除。免疫组织病理学分析显示为ERBB2突变阳性乳腺癌。给予Eribulin，trastuzumab和pertuzumab联合治疗，之后肿瘤转为可切除状态，组织学检查显示有显著的反应。 ERBB2突变阳性的乳腺癌患者对Eribulin，trastuzumab和pertuzumab的联合治疗耐受性良好，并且有效。', 'a', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30093446', '.', 'case report', '4', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', '恩美曲妥珠单抗', 'ado-trastuzumab emtansine|恩美曲妥珠单抗', '4', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_001396', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'PURPOSE:Patients with BRAF V600 wild-type melanoma whose tumors progress on checkpoint inhibition currently have limited therapeutic options, and additional rational treatment targets are needed. ERBB2 alterations may be amenable to targeted inhibition, but the rate of ERBB2 alterations across melanoma subtypes is not well described.PATIENTS AND METHODS:All patients with nonuveal melanoma (cutaneous, acral, mucosal, and unknown primary) whose tumors underwent multigene sequencing with MSK-IMPACT at Memorial Sloan Kettering Cancer Center (New York, NY) from 2014 to 2018 were reviewed for known or likely oncogenic somatic alterations in ERBB2 and the other known canonical driver genes BRAF, NRAS, KIT, NF1, GNAQ, and GNA11.RESULTS:A patient with acral melanoma resistant to checkpoint inhibition was found to have ERBB2 amplification and achieved a durable complete response to trastuzumab emtansine. Tumor sequencing results from 732 melanoma cases were analyzed for ERBB2 and canonical driver gene alterations. ERBB2 amplifications were detected in acral (3%) and mucosal (3%) melanomas. ERBB2 mutations were found in cutaneous (1%), acral (2%), and mucosal (2%) subtypes and frequently cooccurred with NF1 alterations. Among the 140 patients whose tumors lacked canonical driver alterations, ERBB2 amplifications were detected in acral (7%) and mucosal (6%) melanomas.CONCLUSIONS:ERBB2 amplification is present in a minority of acral lentiginous and mucosal melanomas. Activating mutations in ERBB2 were identified in nonuveal melanoma subtypes and are frequently comutated with canonical drivers. ERBB2 could represent a therapeutically relevant target across melanoma subtypes.', '一名患有非妊娠性黑色素瘤（皮肤，肢端，粘膜和未知原发）的患者。使用MSK-IMPACT审查ERBB2和其他已知的经典驱动基因BRAF，NRAS，KIT，NF1，GNAQ和GNA11中可能的致癌体细胞改变。结果发现其携带ERBB2扩增，该患者对对曲妥珠单抗-小分子偶联物治疗具有现持久的完全反应。', 'a', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1056/NEJMoa1903387|J Clin Oncol 37, 2019 (suppl; abstr LBA4)|NCCN Guideline: Pancreatic Adenocarcinoma <1.2020>', 'NCT02184195', 'guideline:NCCN', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_001397', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'POLO研究是一项国际性、随机、双盲、安慰剂对照III期临床试验，纳入曾接受转移性疾病治疗、在完成至少16周的一线含铂联合化疗（PBC）后未进展的携带gBRCA突变的胰腺癌患者，按3:2的比例随机分配接受奥拉帕利（300 mg，口服，bid）或安慰剂维持治疗。患者在最后一次PBC治疗后4~8周进行随机分组并启动维持治疗，持续至研究者评估的疾病进展或出现不可接受的毒性。研究主要终点为经盲法独立中心评价（改良RECIST 1.1）的PFS；次要研究终点包括总生存期（OS）、全球健康相关生活质量（HRQoL）评分、奥拉帕利的安全性和耐受性等。研究共筛选患者3315例，其中携带gBRCA突变患者247例，对154例患者进行随机分组（奥拉帕利组92例，安慰剂组62例），151例患者接受治疗（奥拉帕利组90例，安慰剂组61例）。研究结果发现，经16周一线化疗及后续维持治疗，奥拉帕利组与安慰剂组相比，PFS得到显著改善（中位PFS为7.4个月对3.8个月；风险比（HR）为0.53，95%CI 0.35，0.82；P=0.0038）。从第6个月起，奥拉帕利组患者的PFS率为安慰剂组患者2倍，且在12个月、18个月和2年评估均为安慰剂组的2倍以上。在中期总生存（OS）分析（成熟度46%）中， HR为0.91（95%CI 0.56,1.46；P=0.68）。安全性方面，奥拉帕利组有40%的患者发生了3级或以上不良事件（AE），安慰剂组为23%。奥拉帕利组和安慰剂组分别有5.5%和1.7%的患者因AE停止治疗。在患者报告的生活质量方面，奥拉帕利组HRQoL评分较基线平均变化为-1.20±1.42，安慰剂组为1.27±1.95，两组HRQoL评分较基线未出现具有临床意义的变化。同时，两组间HRQoL评分较基线平均变化的差异并无临床意义。目前，NCCN推荐将olaparib作为维持治疗方案，用于在一线铂类化疗16周内无疾病进展、携带有害生殖细胞BRCA1/2基因突变、PS评分良好的转移性胰腺癌。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1056/NEJMoa1903387|J Clin Oncol 37, 2019 (suppl; abstr LBA4)|NCCN Guideline: Pancreatic Adenocarcinoma <1.2020>', 'NCT02184195', 'guideline:NCCN', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'pancreatic cancer', 'pancreatic cancer', '胰腺癌', 'na', 'sensitivity', 'EVI_001398', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'POLO研究是一项国际性、随机、双盲、安慰剂对照III期临床试验，纳入曾接受转移性疾病治疗、在完成至少16周的一线含铂联合化疗（PBC）后未进展的携带gBRCA突变的胰腺癌患者，按3:2的比例随机分配接受奥拉帕利（300 mg，口服，bid）或安慰剂维持治疗。患者在最后一次PBC治疗后4~8周进行随机分组并启动维持治疗，持续至研究者评估的疾病进展或出现不可接受的毒性。研究主要终点为经盲法独立中心评价（改良RECIST 1.1）的PFS；次要研究终点包括总生存期（OS）、全球健康相关生活质量（HRQoL）评分、奥拉帕利的安全性和耐受性等。研究共筛选患者3315例，其中携带gBRCA突变患者247例，对154例患者进行随机分组（奥拉帕利组92例，安慰剂组62例），151例患者接受治疗（奥拉帕利组90例，安慰剂组61例）。研究结果发现，经16周一线化疗及后续维持治疗，奥拉帕利组与安慰剂组相比，PFS得到显著改善（中位PFS为7.4个月对3.8个月；风险比（HR）为0.53，95%CI 0.35，0.82；P=0.0038）。从第6个月起，奥拉帕利组患者的PFS率为安慰剂组患者2倍，且在12个月、18个月和2年评估均为安慰剂组的2倍以上。在中期总生存（OS）分析（成熟度46%）中， HR为0.91（95%CI 0.56,1.46；P=0.68）。安全性方面，奥拉帕利组有40%的患者发生了3级或以上不良事件（AE），安慰剂组为23%。奥拉帕利组和安慰剂组分别有5.5%和1.7%的患者因AE停止治疗。在患者报告的生活质量方面，奥拉帕利组HRQoL评分较基线平均变化为-1.20±1.42，安慰剂组为1.27±1.95，两组HRQoL评分较基线未出现具有临床意义的变化。同时，两组间HRQoL评分较基线平均变化的差异并无临床意义。目前，NCCN推荐将olaparib作为维持治疗方案，用于在一线铂类化疗16周内无疾病进展、携带有害生殖细胞BRCA1/2基因突变、PS评分良好的转移性胰腺癌。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30584328', '.', 'case report', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺鳞癌', 'na', 'sensitivity', 'EVI_001399', 'ERBB2:nonsynonymous SNV::p.S310.:', 'ERBB2', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.S310.', '.', 'BACKGROUND:ERBB2 mutations are identified in approximately 2% of non-small-cell lung cancer (NSCLC) cases and are predominantly observed in non-smokers, females, and adenocarcinoma patients. Although afatinib is recommended for treating NSCLC patients with ERBB2 mutation, the therapy is most efficacious in patients harboring ERBB2 exon 20 insertions, especially the in-frame insertion YVMA. Research on the treatment of the extracellular domain mutation is relatively rare.CASE PRESENTATION:We discuss a 76-year-old Chinese man with a heavy-smoking history who was diagnosed with stage IV squamous cell lung carcinoma. First-line treatment with the angiogenesis inhibitor endostar and systemic chemotherapy with docetaxel plus cisplatin were administered, but the patient ceased treatment because of chemotherapy-induced adverse events. Based on the test result from an amplification refractory mutation system PCR, EGFR-inhibitor icotinib was prescribed, but there was still no evidence of a response. Then, next-generation sequencing identified an ERBB2 S310Y mutation, and afatinib therapy resulted in a gradual, but substantial reduction in tumor size.CONCLUSION:This is the first published case report of the successful management of ERBB2 S310Y mutation squamous cell lung carcinoma with afatinib. Considering the fact that this rare ERBB2 mutation clinically benefited from afatinib treatment, attention should be paid to the incidence of ERBB2 in NSCLC patients with inconsistent histological characteristics compared with those previous published. With the guidance of a precise diagnosis, we should realize the significance of other ERBB2 gene mutations and next-generation sequencing as a diagnostic method.', '一名有重度吸烟史的76岁中国男性被诊断出患有IV期鳞状细胞肺癌，一线治疗采用血管生成抑制剂endostar和多西紫杉醇联合顺铂全身化疗，但患者因化疗引起的不良事件停止治疗。根据PCR测试结果使用EGFR抑制剂icotinib，但没有理想反应。NGS鉴定出ERBB2 S310Y突变，afatinib治疗使肿瘤逐渐缩小，数量也逐渐减少。这是首次使用afatinib成功治疗ERBB2 S310Y突变的肺鳞癌的病例报告。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 3003)', 'NCT03600883', 'clinical trial - phase1', '4', 'AMG 510', 'AMG 510', 'AMG 510', 'AMG 510', 'AMG 510|AMG 510', '1', 'solid tumors', 'solid tumors', '非特定癌症', 'na', 'sensitivity', 'EVI_001400', 'KRAS:nonsynonymous SNV::p.G12C:', 'KRAS', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.G12C', '.', 'Background: The KRASG12C mutation is found in approximately 13% of lung adenocarcinomas and 1–3% of other solid tumors, but there is no approved therapy that targets this mutation. AMG 510 is a novel small molecule that specifically and irreversibly inhibits KRASG12C by locking it in an inactive GDP-bound state. Methods: This phase 1, first-in-human, open-label, multicenter study (NCT03600883) is evaluating the safety, tolerability, PK, and efficacy of AMG 510 in adult patients (pts) with locally-advanced or metastatic KRASG12C mutant solid tumors. The primary endpoint is safety; key secondary endpoints include PK, ORR (assessed every 6 weeks [wks]), DOR, and PFS. Key inclusion criteria: KRASG12C mutation identified through DNA sequencing, measurable or evaluable disease, ECOG PS ≤2, life expectancy >3 months (mo). Key exclusion criteria: active brain metastases, myocardial infarction within 6 mo. A dose exploration will determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D). A dose expansion will enroll pts with NSCLC, CRC, and other advanced solid tumors carrying the KRASG12C mutation. AMG 510 will be given PO until disease progression, intolerance, or withdrawal of consent. Results: 22 pts (8 men, 14 women; median age 55.5 y) were enrolled in the first 3 dose cohorts. Tumor types: 6 NSCLC, 15 CRC, 1 other. Most pts (n=17) had ≥3 prior lines of treatment (tx). Median tx duration was 28 d (range: 8–134). 5 pts reported 10 treatment-related AEs (grade 1, n=9; grade 2, n=1); there were no DLTs. Tumor response was evaluated in 9 pts (4 with ≥2 assessments); 13 pts have not reached their first assessment.1 pt had a PR (NSCLC at wks 6 and 12, tx ongoing), 6 pts had SD (4 CRC and 2 NSCLC; median tx duration 9.7 wks [range: 6.3–19.1], tx ongoing), 2 pts had PD. 20 pts are continuing to receive AMG 510. A second PR (NSCLC at wk 6, tx ongoing) was reported after data cutoff. Conclusions: AMG 510 has been well tolerated at the dose levels tested and has shown antitumor activity when administered as monotherapy to patients with advanced KRASG12C mutant solid tumors. MTD has not been determined, and enrollment into the dose exploration is ongoing. Clinical trial information: NCT03600883', '在约13%肺腺癌和1-3%其他实体瘤中发现了KRAS G12C突变，但目前尚未有针对这种突变的已批准疗法。AMG 510是一种新型小分子，可将KRAS G12C锁定为无活性的GDP结合状态，从而特异性且不可逆地抑制KRAS G12C。在一项多人，开放标签，多中心研究(NCT03600883)中评估AMG 510在局部晚期或转移性KRAS G12C突变的成人肿瘤患者中的安全性，耐受性，PK和疗效。主要终点是安全性，关键的次要终点包括PK，ORR，DOR和PFS。 患者被给予AMG 510，直到疾病进展，不耐受或撤回同意。22名患者参加了3个剂量组的治疗。治疗的中位持续时间为28天。5例患者出现了治疗相关不良反应，10例患者没有剂量限制性毒性。肿瘤反应评估为9分，13例未达到第一次评估标准。1例患者有部分缓解，6例疾病稳定，2例有疾病进展。其中20例患者继续接受AMG 510，后又有一名患者出现了部分缓解。AMG 510在所测试的剂量水平下具有良好的耐受性，作为晚期KRAS G12C突变的实体瘤患者的单一疗法显示出抗肿瘤活性。 MTD尚未确定，并且正在进行剂量探索。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr e20522)', 'NCT02047344', 'clinical trial - phase2', '4', 'Antroquinonol', 'Antroquinonol', 'antroquinonol', 'antroquinonol', 'antroquinonol|antroquinonol', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001402', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '评估Antroquinonol对两种抗癌治疗失败后的IV期NSCLC患者的疗效。30名患者(15名KRAS阳性，15名KRAS阴性)每天接受600mg Antroquinonol，主要终点是从治疗开始到第12周的无进展生存期，疾病控制率和总生存率是关键的次要终点。73%的患者至少接受过两次化疗。7例先前接受过2次化疗的患者的中位PFS为22.9周，在接受过2次以上化疗的11例患者中，中位PFS为11.9周，1年PFS为11.4%，中位总生存率为47.3周，1年总生存率为39.3%，总体疾病控制率为72.7%。没有观察到全身毒性。KRAS阴性患者各项终点皆比KRAS阳性患者好得多。Antroquinonol单药治疗可提高疾病控制率，延长无进展生存期和总生存期。虽然疗效有差，但Antroquinonol仍然也适用于KRAS阳性患者。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1093/annonc/mdy424.030', 'NCT02150967', 'clinical trial - phase2', '4', 'infigratinib', 'infigratinib', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '2', 'intrahepatic cholangiocarcinomas ', 'intrahepatic cholangiocarcinomas ', '肝内胆管癌', 'na', 'sensitivity', 'EVI_001403', 'FGFR2:FUS:.:FGFR2-.:', 'FGFR2', 'FUS', 'FUS', '.', 'FGFR2-.', '.', 'Background: Fibroblast growth factor receptor 2 (FGFR2) fusions occur in 13–17% of intrahepatic cholangiocarcinomas (IHC). A multicenter, open-label, phase II study (NCT02150967) evaluated the antitumor activity of infigratinib, an ATP-competitive FGFR1–3-selective oral tyrosine kinase inhibitor, in patients (pts) with previously-treated advanced IHC containing FGFR2 fusions.Methods: Pts received infigratinib 125 mg orally daily for 21 days of 28-day cycles until unacceptable toxicity, disease progression, investigator discretion, or withdrawal of consent. Primary endpoint: investigator-assessed confirmed overall response rate (cORR, RECIST 1.1). Secondary endpoints: progression-free survival (PFS), disease control rate (DCR), best overall response, overall survival (OS), safety, pharmacokinetics.Results: 71 pts (62% women; median age 53 years; median 2 prior lines of therapy) with FGFR2 fusions/translocations were included. At the prespeciﬁed data cutoff (8-Aug-2018), median duration of treatment was 5.5 months, median duration of follow-up was 8.4 months, and 62 pts had discontinued treatment. The ORR (confirmed and unconfirmed) was 31.0% (95% CI 20.5–43.1%) and the cORR (in pts with potential for confirmation) was 26.9% (95% CI 16.8–39.1%). Other efficacy findings: cORR in pts receiving ≤1 prior lines of treatment was 39.3% (n = 28), and ≥2 17.9% (n = 39); DCR 83.6% (95% CI 72.5–91.5%); median duration of response 5.4 (95% CI 3.7–7.4) months; median PFS 6.8 (95% CI 5.3–7.6) months; median OS 12.5 (95% CI 9.9–16.6) months. Most common any-grade treatment-emergent adverse events (TEAEs): hyperphosphatemia (73.2%), fatigue (49.3%), stomatitis (45.1%), alopecia (38.0%), constipation (35.2%). Grade 3/4 TEAEs occurred in 47 pts (66.2%), including hypophosphatemia (14.1%), hyperphosphatemia (12.7%), and hyponatremia (11.3%).Conclusions: Infigratinib-associated toxicity is manageable, and our efficacy findings suggest clinically meaningful activity after chemotherapy in pts with IHC containing FGFR2 fusions. The efficacy of infigratinib in this study supports FGFR2 as a therapeutic target in FGFR2-fusion IHC.Clinical trial identification: NCT02150967.', 'FGFR2融合在13-17%的肝内胆管细胞癌(IHC)中发生。一项多中心，开放标签的II期研究(NCT02150967)评估了infigratinib对曾接受过过往治疗的含有FGFR2融合的晚期IHC患者的抗肿瘤活性。患者每天口服infigratinib 125 mg，持续21天-28天，直至出现不可接受的毒性、疾病进展或患者撤回同意。主要终点:研究者评估确认的总体反应率(cORR，RECIST 1.1)。次要终点:无进展生存期(PFS)，疾病控制率(DCR)，最佳总体反应，总生存期(OS)，安全性，药代动力学。71例存在FGFR2融合的IHC患者参与研究。治疗的中位持续时间为5.5个月，中位随访时间为8.4个月，62例患者已停止治疗。 ORR为31.0%，cORR为26.9%。其他结果:接受≤1疗程治疗的患者的cORR为39.3%; DCR为83.6%;中位反应持续时间为5.4个月;中位PFS为6.8个月;中位OS为12.5个月。最常见的任何级别治疗-紧急不良事件(TEAE)为高磷血症(73.2%)，疲劳(49.3%)，口腔炎(45.1%)，脱发(38.0%)，便秘(35.2%)。3/4 TEAE发生率为66.2%，包括低磷血症(14.1%)，高磷血症(12.7%)和低钠血症(11.3%)。Infigratinib相关毒性是可控的。infigratinib在该研究中的功效支持FGFR2作为FGFR2-融合IHC中的治疗靶标。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28162944', '.', 'case report', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001405', 'EGFR:nonsynonymous SNV:exon19:p.E749Q:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.E749Q', '.', '.', '一名携带EGFR基因E749Q突变的肺癌患者，服用gefitinib一个月后疾病出现进展，可能该突变导致患者对TKI药物耐药。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26412456|PMID:27765535|MID:29270615', '.', 'clinical trial - phase3', '4', 'nivolumab', 'nivolumab', 'nivolumab', '纳武利尤单抗', 'nivolumab|纳武利尤单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001406', 'EGFR:nonsynonymous SNV:exon21:p.L858R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', 'Checkmate 057临床试验证表明，经铂类化疗药物治疗后进展的非鳞状非小细胞肺癌患者，使用nivolumab治疗比docetaxel能够获得更长的生存期。然而，随后进行的亚组分析却发现，checkmate 057临床试验中82名携带EGFR激活突变的患者在PFS和OS上并没有获益。一项汇总分析包括了三项临床研究（checkmate 057, keynote 010, and POPLAR），证实了免疫检查点抑制剂不能增强EGFR突变患者的OS。另一项汇总的分析涵盖了五项临床试验（Checkmate 017，Checkmate 057，Keynote 010，OAK和POPLAR），证实免疫抑制剂可以在EGFR野生型亚组中观察到OS的延长，但在EGFR突变亚组中没有观察到。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26412456|PMID:27765535|MID:29270615', '.', 'clinical trial - phase3', '4', 'nivolumab', 'nivolumab', 'nivolumab', '纳武利尤单抗', 'nivolumab|纳武利尤单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001407', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', 'Checkmate 057临床试验证表明，经铂类化疗药物治疗后进展的非鳞状非小细胞肺癌患者，使用nivolumab治疗比docetaxel能够获得更长的生存期。然而，随后进行的亚组分析却发现，checkmate 057临床试验中82名携带EGFR激活突变的患者在PFS和OS上并没有获益。一项汇总分析包括了三项临床研究（checkmate 057, keynote 010, and POPLAR），证实了免疫检查点抑制剂不能增强EGFR突变患者的OS。另一项汇总的分析涵盖了五项临床试验（Checkmate 017，Checkmate 057，Keynote 010，OAK和POPLAR），证实免疫抑制剂可以在EGFR野生型亚组中观察到OS的延长，但在EGFR突变亚组中没有观察到。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2018) 29 (suppl_8): viii493-viii547', '.', 'clinical study', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001410', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', '在荷兰的四个机构中，17名携带EGFR外显子20插入的晚期NSCLC患者每天一次用osimertinib 80 mg治疗。中位年龄为63岁（范围35-81），71%为女性。 10名患者（59%）接受过铂类化疗；2名患者阿法替尼，其中1名患者病情稳定11个月，另一名患者表现出进展。在所有接受osimertinib治疗的患者中，我们观察到1例部分缓解，13例患有稳定疾病，3例患疾病进展。两名患者在截止日期仍在接受osimertinib治疗。中位PFS为3.7个月（95%CI：2.3 - 5.4个月）。 对于EGFR外显子20突变的NSCLC患者，osimertinib的抗肿瘤活性有限，ORR为6%。一小部分患者（35%）似乎可以从osimertinib治疗中获益超过五个月。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2018.08.243', 'NCT03066206', 'clinical trial - phase2', '4', 'Poziotinib', 'Poziotinib', 'poziotinib', 'poziotinib', 'poziotinib|poziotinib', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001412', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', '一项临床试验评估了poziotinib对携带EGFR或HER2外显子20（EGFR T790M除外）插入突变的NSCLC患者的疗效。入组患者每天服用Poziotinib 16 mg直至进展、死亡或退出。主要终点是基于RECIST v1.1的客观响应率（ORR）。每八周评估一次反应。次要终点包括DCR，PFS，OS和安全性。截至2018年5月3日，50名患者计划的EGFR突变队列完成登记，评估了40名患者的反应。65.1%的患者至少接受过两次转移性疾病治疗。60%的患者≥3级不良事件中最常见的是皮疹（27.5%）和腹泻（12.5%）。45.0%的患者需要将剂量减少至12 mg，而17.5%需要将剂量减少至8 mg。一名患者因3级皮疹而停止治疗。8周的ORR为58%（95%-CI 40.9-73.0），DCR为90%（95%-CI 76.3-97.2）。23例获得部分缓解的患者中，15例随后扫描确诊，5例未确诊，3例正在等待确认。先前使用过TKI治疗的8/13（62%）患者中观察到治疗响应。中位PFS为5.6个月（95%-CI 5.06-NA）。此外，13名患者参加了HER2队列。毒性与EGFR队列相似。评估12名患者的反应，8周时ORR为50%（95%CI 21.1-78.9），DCR为83%。poziotinib可能对携带EGFR或HER2外显子20突变的患者有一定疗效，临床试验正在进行中（NCT03066206）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2018.08.243', 'NCT03066206', 'clinical trial - phase2', '4', 'poziotinib', 'poziotinib', 'poziotinib', 'poziotinib', 'poziotinib|poziotinib', '2', 'Lung Adenocarcinoma', 'Lung Adenocarcinoma', '肺癌', 'na', 'sensitivity', 'EVI_001413', 'ERBB2:nonframeshift insertion:exon20:.:exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', '一项临床试验评估了poziotinib对携带EGFR或HER2外显子20（EGFR T790M除外）插入突变的NSCLC患者的疗效。入组患者每天服用Poziotinib 16 mg直至进展、死亡或退出。主要终点是基于RECIST v1.1的客观响应率（ORR）。每八周评估一次反应。次要终点包括DCR，PFS，OS和安全性。截至2018年5月3日，50名患者计划的EGFR突变队列完成登记，评估了40名患者的反应。65.1%的患者至少接受过两次转移性疾病治疗。60%的患者≥3级不良事件中最常见的是皮疹（27.5%）和腹泻（12.5%）。45.0%的患者需要将剂量减少至12 mg，而17.5%需要将剂量减少至8 mg。一名患者因3级皮疹而停止治疗。8周的ORR为58%（95%-CI 40.9-73.0），DCR为90%（95%-CI 76.3-97.2）。23例获得部分缓解的患者中，15例随后扫描确诊，5例未确诊，3例正在等待确认。先前使用过TKI治疗的8/13（62%）患者中观察到治疗响应。中位PFS为5.6个月（95%-CI 5.06-NA）。此外，13名患者参加了HER2队列。毒性与EGFR队列相似。评估12名患者的反应，8周时ORR为50%（95%CI 21.1-78.9），DCR为83%。poziotinib可能对携带EGFR或HER2外显子20突变的患者有一定疗效，临床试验正在进行中（NCT03066206）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001414', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001415', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001416', 'ATM:nonsynonymous SNV:.:.:inact', 'ATM', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001417', 'FANCA:nonsynonymous SNV:.:.:inact', 'FANCA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001418', 'CHEK2:nonsynonymous SNV:.:.:inact', 'CHEK2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001419', 'PALB2:nonsynonymous SNV:.:.:inact', 'PALB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001420', 'HDAC2:nonsynonymous SNV:.:.:inact', 'HDAC2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)|PMID:28359295|NCT03344965', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001421', 'RAD51:nonsynonymous SNV:.:.:inact', 'RAD51', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001422', 'MLH3:nonsynonymous SNV:.:.:inact', 'MLH3', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001423', 'ERCC3:nonsynonymous SNV:.:.:inact', 'ERCC3', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001424', 'MRE11:nonsynonymous SNV:.:.:inact', 'MRE11', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 5005)', 'NCT01682772', 'clinical trial - phase2', '4', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'prostate cancer', 'prostate cancer', '前列腺癌', 'na', 'sensitivity', 'EVI_001425', 'NBN:nonsynonymous SNV:.:.:inact', 'NBN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'TOPARP研究是一项评估奥拉帕利对转移性去势抵抗前列腺癌（mCRPC）患者疗效的II期临床试验，在之前TOPARP-A实验中，研究了奥拉帕利在未经分子标记物筛选的转移性去势抵抗性前列腺癌（mCRPC）患者中的抗肿瘤活性，总体反应性为33%，但DNA修复相关基因（DRG）存在异常的患者对奥拉帕利响应率达到88%，研究者针对这一发现进行了进一步的TOPARP-B研究。TOPARP-B评估了奥拉帕利对紫杉醇化疗≥1次后靶向测序DDR基因改变（种系或体细胞；单或双等位基因）的患者的疗效，最终92例患者纳入终点分析，结果显示：总体人群的综合反应率（composite response rate）为46.7%，亚组分析显示：BRCA1/2突变亚组的综合反应率达到83.3%。ATM突变组综合反应率为36.8%，CDK12突变组综合反应率为25.0%，PALB2突变组的综合反应率为57.1%，其他组的综合反应率为20.0%。', 'G;S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27785061', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001426', 'EGFR:nonsynonymous SNV:exon18:p.E709_T710delinsD:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.E709_T710delinsD', '.', '.', '一项回顾性临床研究发现，在3146名患者中，有1689名（53.7%）患有EGFR突变。其中包括726例外显子19缺失的患者，733例L858R患者和230例（13.6%）其他EGFR突变患者。在具有其他突变的230名患者中，25名（1.5%）患者具有罕见的E709X突变。 20名患者具有复杂的E709X突变(同时含有其它EGFR激活突变），5名具有单个E709X突变：delE709-T710insD（不携带其他EGFR激活突变）。在这25名患者中，有18名患者接受了吉非替尼或厄洛替尼治疗。 TKI治疗的有效率为50.0%，中位无进展生存期为6.2个月。所有5名delE709-T710insD患者对TKI治疗无反应。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27785061', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001427', 'EGFR:nonsynonymous SNV:exon18:p.E709_T710delinsD:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.E709_T710delinsD', '.', '.', '一项回顾性临床研究发现，在3146名患者中，有1689名（53.7%）患有EGFR突变。其中包括726例外显子19缺失的患者，733例L858R患者和230例（13.6%）其他EGFR突变患者。在具有其他突变的230名患者中，25名（1.5%）患者具有罕见的E709X突变。 20名患者具有复杂的E709X突变(同时含有其它EGFR激活突变），5名具有单个E709X突变：delE709-T710insD（不携带其他EGFR激活突变）。在这25名患者中，有18名患者接受了吉非替尼或厄洛替尼治疗。 TKI治疗的有效率为50.0%，中位无进展生存期为6.2个月。所有5名delE709-T710insD患者对TKI治疗无反应。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001428', 'BRAF:nonsynonymous SNV:exon15:p.L597.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.L597.', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明携带BRAF外显子15近V600位点附近的点突变（尤其是L597和K601）的肿瘤患者可能对MEK抑制剂（如trametinib）或者BRAF抑制剂和MEK抑制的组合用药（如trametinib + dabrafenib，encorafenib + binimetinib）敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'trametinib + dabrafenib', 'trametinib + dabrafenib', 'trametinib + dabrafenib', '曲美替尼 + 达拉非尼', 'trametinib + dabrafenib|曲美替尼 + 达拉非尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001429', 'BRAF:nonsynonymous SNV:exon15:p.L597.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.L597.', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明携带BRAF外显子15近V600位点附近的点突变（尤其是L597和K601）的肿瘤患者可能对MEK抑制剂（如trametinib）或者BRAF抑制剂和MEK抑制的组合用药（如trametinib + dabrafenib，encorafenib + binimetinib）敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'encorafenib + binimetinib', 'encorafenib + binimetinib', 'encorafenib + binimetinib', 'encorafenib + binimetinib', 'encorafenib + binimetinib|encorafenib + binimetinib', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001430', 'BRAF:nonsynonymous SNV:exon15:p.L597.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.L597.', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明携带BRAF外显子15近V600位点附近的点突变（尤其是L597和K601）的肿瘤患者可能对MEK抑制剂（如trametinib）或者BRAF抑制剂和MEK抑制的组合用药（如trametinib + dabrafenib，encorafenib + binimetinib）敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001431', 'BRAF:nonsynonymous SNV:exon15:p.K601.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.K601.', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明携带BRAF外显子15近V600位点附近的点突变（尤其是L597和K601）的肿瘤患者可能对MEK抑制剂（如trametinib）或者BRAF抑制剂和MEK抑制的组合用药（如trametinib + dabrafenib，encorafenib + binimetinib）敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'trametinib + dabrafenib', 'trametinib + dabrafenib', 'trametinib + dabrafenib', '曲美替尼 + 达拉非尼', 'trametinib + dabrafenib|曲美替尼 + 达拉非尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001432', 'BRAF:nonsynonymous SNV:exon15:p.K601.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.K601.', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明携带BRAF外显子15近V600位点附近的点突变（尤其是L597和K601）的肿瘤患者可能对MEK抑制剂（如trametinib）或者BRAF抑制剂和MEK抑制的组合用药（如trametinib + dabrafenib，encorafenib + binimetinib）敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'encorafenib + binimetinib', 'encorafenib + binimetinib', 'encorafenib + binimetinib', 'encorafenib + binimetinib', 'encorafenib + binimetinib|encorafenib + binimetinib', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001433', 'BRAF:nonsynonymous SNV:exon15:p.K601.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.K601.', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明携带BRAF外显子15近V600位点附近的点突变（尤其是L597和K601）的肿瘤患者可能对MEK抑制剂（如trametinib）或者BRAF抑制剂和MEK抑制的组合用药（如trametinib + dabrafenib，encorafenib + binimetinib）敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001434', 'KIT:nonsynonymous SNV:exon13:.:exon13act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon13', '.', 'exon13act', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001435', 'KIT:nonsynonymous SNV:exon13:.:exon13act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon13', '.', 'exon13act', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001436', 'KIT:nonsynonymous SNV:exon13:.:exon13act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon13', '.', 'exon13act', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001437', 'KIT:nonsynonymous SNV:exon11:.:exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001438', 'KIT:nonsynonymous SNV:exon11:.:exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001439', 'KIT:nonsynonymous SNV:exon11:.:exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'resistance', 'EVI_001440', 'KIT:nonsynonymous SNV:exon17:p.D816H:', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D816H', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'resistance', 'EVI_001441', 'KIT:nonsynonymous SNV:exon17:p.D816H:', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D816H', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'resistance', 'EVI_001442', 'KIT:nonsynonymous SNV:exon17:p.D816H:', 'KIT', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.D816H', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'sunitinib', 'sunitinib', 'sunitinib', '舒尼替尼', 'sunitinib|舒尼替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'resistance', 'EVI_001443', 'KIT:CNV:.:.:gain', 'KIT', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'resistance', 'EVI_001444', 'KIT:CNV:.:.:gain', 'KIT', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'nilotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'resistance', 'EVI_001445', 'KIT:CNV:.:.:gain', 'KIT', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NCCN指南（皮肤黑色素瘤）中表明,KIT基因突变可能出现在多个‘hotspot’位点，从而导致携带KIT基因突变的患者对KIT抑制剂（如sunitinib，imatinib，nilotinib）的敏感性不同。其中KIT基因11号外显子和13号外显子上的多个位点（如W557,V559,L576P,K642E）对KIT抑制剂的敏感性最强。KIT exon17外显子突变（如D816H）可能对KIT抑制剂不敏感。KIT基因扩增也可能导致患者对KIT抑制剂不敏感。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9009)', 'NCT02609776', 'clinical trial - phase1', '4', 'JNJ-372', 'JNJ-372', 'JNJ-372', 'JNJ-372', 'JNJ-372|JNJ-372', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001446', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', '.', 'JNJ-372的一项I期临床研究（NCT02609776）纳入了108例经治EGFR突变晚期NSCLC患者，其中包括了58例EGFR三代药耐药患者，27例EGFR EXON 20插入突变患者。58例EGFR三代药耐药患者的总有效率为28%，16例肿瘤部分缓解患者里包括了8例C797S突变，3例MET扩增，5例其它耐药机制（非EGFR耐药突变或MET扩增）。27例EGFR EXON 20插入突变患者的总有效率为30%，8例肿瘤部分缓解患者里包括了1例波齐替尼耐药患者。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28062673', '.', 'clinical trial - phase2', '4', 'dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', 'Pediatric Glioma', 'Pediatric Glioma', '神经胶质瘤', 'na', 'sensitivity', 'EVI_001448', 'BRAF:nonsynonymous SNV:exon15:p.V600.:gain', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '对于儿科低级别胶质瘤，BRAF V600E是一种潜在的高靶向性肿瘤突变，17%的患者在接受化疗治疗后表现不佳.最近在dabrafenib的1/2期试验评估中纳入32例复发或难治性低级别胶质瘤患儿，客观缓解率为38%，另有44%的患者病情稳定.', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28284557|NCCN Guideline: Cutaneous Melanoma <1.2020>', 'NCT01763164', 'clinical trial - phase3', '1', 'binimetinib', 'binimetinib', 'binimetinib', 'binimetinib', 'binimetinib|binimetinib', '4', 'melanoma', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_001449', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '尽管存在免疫疗法，但还没有针对NRAS突变黑素瘤特异性的既定疗法。一项临床试验用以评估MEK抑制剂binimetinib与达卡巴嗪在晚期NRAS突变黑色素瘤患者中的疗效和安全性。NEMO是一项持续的，随机的，开放性的3期研究，在26个国家的118家医院进行。患有晚期、不可切除的IIIC期或IV期NRAS突变黑色素瘤的患者，他们之前未接受治疗或在之前的免疫治疗之后进展，随机（2：1）接受每日两次口服binimetinib 45 mg或达卡巴嗪每3周静脉注射1000 mg/m2。主要终点是意向治疗人群的无进展生存期。2013年8月19日至2015年4月28日期间，共有402名患者入组并随机分配，其中269名为binimetinib组，133名为达卡巴嗪组。中位随访时间为1.7个月（IQR 1.4-4.1）。binimetinib组中位无进展生存期为2.8个月（95%CI 2.8-3.6），达卡巴嗪组为1.5个月（1.5-1.7）（危险比为0.62 [95%CI 0.47-0.80];单侧p <0.001）。与达卡巴嗪相比，Binimetinib改善了肿瘤患者的无进展生存期。对于免疫治疗失败后NRAS突变黑色素瘤患者，Binimetinib可能是一种新的治疗选择。NCCN指南表示少数NRAS突变患者可能会对MEK抑制剂治疗产生响应。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29301960', '.', 'clinical study', '4', 'nivolumab', 'nivolumab', 'nivolumab', '纳武利尤单抗', 'nivolumab|纳武利尤单抗', '4', 'clear cell renal cell carcinoma', 'clear cell renal cell carcinoma', '肾癌', 'na', 'sensitivity', 'EVI_001450', 'PBRM1:nonsynonymous SNV:::inact', 'PBRM1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '为了鉴定ccRCC（转移性肾透明细胞癌）中与免疫检查点抑制剂反应相关的基因组改变，我们对来自35名患者的转移性ccRCC进行了全外显子组测序。我们发现临床获益与PBRM1基因中的功能丧失突变相关（P = 0.012），其编码PBAF开关-蔗糖不可发酵（SWI/SNF）染色质重塑复合物的亚基。我们在单独或与抗-CTLA-4（细胞毒性T淋巴细胞相关蛋白4）治疗联合治疗的63例ccRCC患者中中证实了这一发现（P = 0.0071）。PBAF缺陷的ccRCC细胞系和PBRM1缺陷肿瘤的基因表达分析显示JAK-STAT（Janus激酶-信号转导和转录激活因子），缺氧和免疫信号传导途径中的转录输出改变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29301960', '.', 'clinical study', '4', 'atezolizumab', 'atezolizumab', 'atezolizumab', '阿替利珠单抗', 'atezolizumab|阿替利珠单抗', '4', 'clear cell renal cell carcinoma', 'clear cell renal cell carcinoma', '肾癌', 'na', 'sensitivity', 'EVI_001451', 'PBRM1:nonsynonymous SNV:::inact', 'PBRM1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '为了鉴定ccRCC（转移性肾透明细胞癌）中与免疫检查点抑制剂反应相关的基因组改变，我们对来自35名患者的转移性ccRCC进行了全外显子组测序。我们发现临床获益与PBRM1基因中的功能丧失突变相关（P = 0.012），其编码PBAF开关-蔗糖不可发酵（SWI/SNF）染色质重塑复合物的亚基。我们在单独或与抗-CTLA-4（细胞毒性T淋巴细胞相关蛋白4）治疗联合治疗的63例ccRCC患者中中证实了这一发现（P = 0.0071）。PBAF缺陷的ccRCC细胞系和PBRM1缺陷肿瘤的基因表达分析显示JAK-STAT（Janus激酶-信号转导和转录激活因子），缺氧和免疫信号传导途径中的转录输出改变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9009)', 'NCT02609776', 'clinical trial - phase1', '4', 'JNJ-372', 'JNJ-372', 'JNJ-372', 'JNJ-372', 'JNJ-372|JNJ-372', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001452', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', 'JNJ-372的一项I期临床研究（NCT02609776）纳入了108例经治EGFR突变晚期NSCLC患者，其中包括了58例EGFR三代药耐药患者，27例EGFR EXON 20插入突变患者。58例EGFR三代药耐药患者的总有效率为28%，16例肿瘤部分缓解患者里包括了8例C797S突变，3例MET扩增，5例其它耐药机制（非EGFR耐药突变或MET扩增）。27例EGFR EXON 20插入突变患者的总有效率为30%，8例肿瘤部分缓解患者里包括了1例波齐替尼耐药患者。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292', 'NCT01982955', 'clinical trial - phase2', '4', 'tepotinib', 'tepotinib', 'tepotinib', 'tepotinib', 'tepotinib|tepotinib', '2', 'NSCLC', 'NSCLC', '肺癌', 'na', 'sensitivity', 'EVI_001454', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NSCLC可通过MET激活获得对EGFR酪氨酸激酶抑制剂（EGFR TKIs）的抗性；MET/EGFR双重抑制可能在对EGFR TKI耐药的NSCLC中具有一定疗效。tepotinib是一种有效的选择性MET抑制剂。我们报告[tepotinib + gefitinib]与化疗[培美曲塞+顺铂/卡铂]在MET+、EGFR+、T790M-、NSCLC患者中的疗效（NCT01982955）。具有高度MET +（IHC2 +，IHC3 +，基因扩增）的亚洲NSCLC患者，对一线EGFR TKI的耐药。肿瘤具有EGFR活化突变（T790M-）。患者每天一次接受tepotinib + gefitinib 500 /250mg。主要终点：无进展生存期（PFS）。次要终点：安全性，抗肿瘤活性，药代动力学。结果由于招募率低，55名患者被随机分配到tepotinib + gefitinib（n = 31）或化疗（n = 24）后停止入组。MET免疫组化IHC 3+的患者中位无进展生存期为8.3个月；MET基因扩增（GCN ≥5 or MET/CEP7 ratio ≥2/EGFR T790M-)的患者中位无进展生存期达到21.2个月。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'FOLFOXIRI + cetuximab', 'FOLFOXIRI + 西妥昔单抗', 'FOLFOXIRI + cetuximab|FOLFOXIRI + 西妥昔单抗', '4', 'Colon Cancer', 'Colon Cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001455', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', 'NCCN指南中推荐KRAS，NRAS，BRAF野生型的转移性肠癌患者可以使用FOLFOXIRI + cetuximab联合治疗。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'FOLFOXIRI + panitumumab', 'FOLFOXIRI + 帕尼单抗', 'FOLFOXIRI + panitumumab|FOLFOXIRI + 帕尼单抗', '4', 'Colon Cancer', 'Colon Cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001456', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', 'NCCN指南中推荐KRAS，NRAS，BRAF野生型的转移性肠癌患者可以使用FOLFOXIRI + panitumumab联合治疗。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'irinotecan + panitumumab', '伊立替康 + 帕尼单抗', 'irinotecan + panitumumab|伊立替康 + 帕尼单抗', '4', 'Colon Cancer', 'Colon Cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001457', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', 'NCCN指南中推荐KRAS，NRAS，BRAF野生型的转移性肠癌患者可以使用irinotecan + panitumumab联合治疗。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'irinotecan + cetuximab', '伊立替康 + 西妥昔单抗', 'irinotecan + cetuximab|伊立替康 + 西妥昔单抗', '4', 'Colon Cancer', 'Colon Cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001458', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', 'NCCN指南中推荐KRAS，NRAS，BRAF野生型的转移性肠癌患者可以使用irinotecan + cetuximab联合治疗。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'irinotecan + cetuximab + vemurafenib', '伊立替康 + 西妥昔单抗 + 维莫非尼', 'irinotecan + cetuximab + vemurafenib|伊立替康 + 西妥昔单抗 + 维莫非尼', '4', 'Colon Cancer', 'Colon Cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001459', 'BRAF:nonsynonymous SNV:exon15:p.V600.:gain', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', 'NCCN指南中推荐BRAF V600E突变的转移性肠癌患者可以使用irinotecan + cetuximab + vemurafenib联合治疗。SWOG S1406临床试验表明，99例BRAF V600E突变但RAS野生型的mCRC患者，接受过至少一线治疗失败（不含EGFR单抗）后，随机接受伊立替康+西妥昔单抗加或不加BRAF抑制剂维莫非尼，结果显示主要终点PFS（无进展生存期）从2个月显著延长至4.4个月，次要终点ORR（客观缓解率）也显著改善（4%提高到16%）。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', '.', '.', 'irinotecan + panitumumab + vemurafenib', '伊立替康 + 帕尼单抗 + 维莫非尼', 'irinotecan + panitumumab + vemurafenib|伊立替康 + 帕尼单抗 + 维莫非尼', '4', 'Colon Cancer', 'Colon Cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001460', 'BRAF:nonsynonymous SNV:exon15:p.V600.:wildtype', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', 'NCCN指南中推荐BRAF V600E突变的转移性肠癌患者可以使用irinotecan + panitumumab + vemurafenib联合治疗。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9011)', 'NCT03093116', 'clinical trial - phase1', '4', 'repotrectinib', 'repotrectinib', 'repotrectinib', 'repotrectinib', 'repotrectinib|repotrectinib', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001461', 'ROS1:FUS:.:.-ROS1:.', 'ROS1', 'FUS', 'FUS', '.', '.-ROS1', '.', '.', 'Repotrectinib是新型ROS1/TRK/ALK TKI，效力比克唑替尼高90倍。临床前研究显示，repotrectinib对所有已知的ROS1融合基因的耐药突变都具有较强的激酶抑制活性，包括对最常见的ROS1溶剂界面突变（SFM）G2032R也同样有效。在一项正在进行的I期研究（NCT03093116）中，患有晚期ROS1/TRK/ALK+实体瘤的TKI敏感或TKI耐药（≥1 TKI）患者接受了repotrectinib治疗。终点包括安全性，PK和总体反应（cORR）。对所有患者（n=75）进行安全性分析，并对参与研究的ROS1+ NSCLC患者（n=28）进行疗效分析。截至2018年10月31日，75例患者接受40 mg QD-200 mg BID剂量水平的repotrectinib治疗。大多数不良事件（AE）是可管理的并且等级为（Gr）1-2。常见（>20%）治疗相关的AE有头晕（49%），味觉障碍（48%），感觉异常（28%）和便秘（20%）。发生4例剂量限制性毒性（DL）并作剂量修改。尚未达到最大耐受剂量（MTD）。在10名可评估的TKI-敏感ROS1+ NSCLC患者中，ORR为90%，中位反应持续时间（DOR）未达到；在18例TKI预处理的患者中，ORR为28%，缓解持续时间（DOR）为10.2个月。亚组分析显示，以160 mg QD或以上的剂量水平进行治疗的9例先前接受TKI的ROS1+ NSCLC患者的cORR为44%。在具有可测量的CNS病变的患者中，Repotrectini的客观缓解率为100%。Repotrectinib具有良好的耐受性，并且在ROS1融合的患者中表现出令人鼓舞的整体和颅内临床活性。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9011)', 'NCT03093116', 'clinical trial - phase1', '4', 'repotrectinib', 'repotrectinib', 'repotrectinib', 'repotrectinib', 'repotrectinib|repotrectinib', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '[ROS:FUS]', 'sensitivity', 'EVI_001462', 'ROS1:nonsynonymous SNV:exon38:p.G2032R:', 'ROS1', 'nonsynonymous SNV', 'Exact_pos', 'exon38', 'p.G2032R', '.', '.', 'Repotrectinib是新型ROS1/TRK/ALK TKI，效力比克唑替尼高90倍。临床前研究显示，repotrectinib对所有已知的ROS1融合基因的耐药突变都具有较强的激酶抑制活性，包括对最常见的ROS1溶剂界面突变（SFM）G2032R也同样有效。在一项正在进行的I期研究（NCT03093116）中，患有晚期ROS1/TRK/ALK+实体瘤的TKI敏感或TKI耐药（≥1 TKI）患者接受了repotrectinib治疗。终点包括安全性，PK和总体反应（cORR）。对所有患者（n=75）进行安全性分析，并对参与研究的ROS1+ NSCLC患者（n=28）进行疗效分析。截至2018年10月31日，75例患者接受40 mg QD-200 mg BID剂量水平的repotrectinib治疗。大多数不良事件（AE）是可管理的并且等级为（Gr）1-2。常见（>20%）治疗相关的AE有头晕（49%），味觉障碍（48%），感觉异常（28%）和便秘（20%）。发生4例剂量限制性毒性（DL）并作剂量修改。尚未达到最大耐受剂量（MTD）。在10名可评估的TKI-敏感ROS1+ NSCLC患者中，ORR为90%，中位反应持续时间（DOR）未达到；在18例TKI预处理的患者中，ORR为28%，缓解持续时间（DOR）为10.2个月。亚组分析显示，以160 mg QD或以上的剂量水平进行治疗的9例先前接受TKI的ROS1+ NSCLC患者的cORR为44%。在具有可测量的CNS病变的患者中，Repotrectini的客观缓解率为100%。Repotrectinib具有良好的耐受性，并且在ROS1融合的患者中表现出令人鼓舞的整体和颅内临床活性。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9010)', 'NCT03260491', 'clinical trial - phase1', '4', 'U3-1402', 'U3-1402', 'U3-1402', 'U3-1402', 'U3-1402|U3-1402', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001463', 'ERBB3:CNV:.:.:gain', 'ERBB3', 'CNV', 'CNV', '.', '.', 'gain', 'Background: Treatment options are limited for EGFRm NSCLC resistant to EGFR TKIs. ERBB3 is expressed in a majority of NSCLC tumors. U3-1402 is a ERBB3-targeted antibody drug conjugate with a fully human ERBB3-targeted antibody, novel cleavable peptide-based linker, and topoisomerase I inhibitor payload. Methods: An ongoing multicenter phase 1 dose escalation and expansion study is assessing U3-1402 safety/tolerability and preliminary activity in metastatic or unresectable EGFRm NSCLC patients (pts) who are T790M negative after disease progression while on erlotinib, gefitinib or afatinib; or develop disease progression while on osimertinib regardless of T790M status. Dose escalation is based on dose-limiting toxicities (DLTs) and guided by the modified Continuous Reassessment Method. U3-1402 is administered via intravenous infusion in 21-day cycles. Pretreatment tumor tissue is required. Results: As of 11 Nov 2018, 15 pts (6 M; 9 F) were enrolled across 3 dose levels (3.2, 4.8, 6.4 mg/kg). Median age was 63 y; 10 pts had EGFR exon 19 deletion and 5 EGFR L858R mutation. Median sum of longest diameters (SLD) at baseline was 69 (range 22–143) mm. All pts had prior EGFR TKIs; 14 had 2nd line or later osimertinib. Six had prior chemotherapy. All 11 evaluable tumors demonstrated ERBB3 expression (median ERBB3 membrane H-score 188, range 150–290). Five pts discontinued treatment: 4 due to progressive disease, 1 due to adverse event (AE). All Grade (Gr) treatment-emergent AEs (TEAEs) in ≥20% of pts were nausea (60%), vomiting (40%), fatigue (33%), decreased appetite (27%), and alopecia (20%). Gr≥3 TEAEs were nausea (1/15; Gr3; related), hypoxia (1/15; Gr3; unrelated), and platelet count decreased (2/15; both Gr4 at 6.4 mg/kg and considered DLTs). In 13 evaluable pts, all but 1 had a decrease in SLD (median best change −29%, range +10% to −67%), 2 had confirmed partial response per RECIST v1.1 (best changes −44%, −67%). Conclusions: U3-1402 showed a manageable safety profile and preliminary antitumor activity in EGFR TKI-resistant EGFRm NSCLC. Evaluation of candidate biomarkers, including ERBB3 expression, which correlate with U3-1402 response is ongoing. Clinical trial information: NCT03260491', 'ERBB3在大多数NSCLC中表达，U3-1402是靶向ERBB3的抗体药物缀合物。一项多中心I期临床试验正在评估U3-1402在转移性或不可切除的EGFRm NSCLC患者中的初步活性、安全性、耐受性。U3-1402以21天为一个周期静脉内输注给药。15名患者参加了3个剂量水平的U3-1402治疗。患者中位年龄为63岁，10例存在EGFR外显子19缺失，5例存在EGFR L858R突变。所有患者过往皆曾接受EGFR-TKIs治疗，其中14例患者曾接受过osimertinib治疗，六人事先接受过化疗。11例患者存在可评估的肿瘤组织，皆显示ERBB3表达。5例患者停止治疗，4例因疾病进展，1例因不良事件(AE)。≥20%患者的治疗急症AEs(TEAEs)为恶心(60%)，呕吐(40%)，疲劳(33%)，食欲减退(27%)和脱发(20%)。Gr≥3的TEAE是恶心，缺氧，血小板计数减少。在13个可评估的患者中，12名患者的肿瘤最长直径之和(SLD)下降，2名确认存在部分反应。U3-1402在EGFR TKI耐药的EGFRm NSCLC中显示出可控的安全性和初步抗肿瘤活性。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 1076)', 'NCT03535961', 'clinical trial - phase2', '4', 'apatinib +  etoposide', 'apatinib +  etoposide', 'apatinib +  etoposide', '阿帕替尼 + 依托泊苷', 'apatinib +  etoposide|阿帕替尼 + 依托泊苷', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001464', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', 'Background: There is no standard treatment strategy for patients with locally advanced or metastatic breast cancer suffering progression after one prior chemotherapy with metastasis setting. Apatinib is a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2(VEGFR-2). Etoposide is a highly active chemo-drug in the treatment of advanced breast cancer, both as a single agent or in combination regimens, and is well tolerated, with a low incidence of severe toxicity. This study is performed to assessed the efficacy and safety of apatinib and oral etoposide in patients with ERBB2 negative locally advanced or metastatic breast cancer for whom at least one lines of prior chemotherapy had failed. Methods: This open-label, single arm study enrolled patients with ERBB2-negative breast cancer, pretreated with anthracycline, taxanes, and who failed in the metastatic setting at least one prior chemotherapy regimens and at least one endocrine drug for hormone receptor-positive patients. Apatinib was administered 425/500mg daily according to patients ECOG(Eastern Cooperative Oncology Group) status, oral etoposide was administered 50mg/m2 for first 10 days in a 21-days cycle. The primary end point of this study was progression free survival (PFS). Secondary end points included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and toxicity. The treatment duration is until disease progression or intolerability of apatinib or oral etoposide. Results: 20 eligible patients were enrolled in this, open-label, single arm study and received apatinib and oral etoposide with a median age of 54 years old(range 36 to 66 years). Median follow-up time was 11months. 20 patients were eligible for efficacy analysis. Median PFS was 5.6 months (95% confidence interval (CI), 4.01 m – 8.42 m). ORR was 20% (4/20). DCR was 70% (14/20). Median OS was 11.2 months (95% CI, 9.6 m – 14.95 m). The most common grade 3/4 treatment-related AEs were hypertension (30%), and proteinuria (5%), nausea (5%). 35%(7/20) patients had dose reduction because of adverse events, after that all adverse events can return to less than 2 grade. Conclusions: Apatinib with oral etoposide exhibited objective efficacy in pretreated, metastatic ERBB2-negative breast cancer with manageable toxicity. Prospective studies enrolling more patients are needed. Clinical trial information: NCT03535961', '阿帕替尼是靶向血管内皮生长因子受体2(VEGFR-2)的酪氨酸激酶抑制剂，依托泊苷是治疗晚期乳腺癌的高活性化学药物，无论是单一药物还是联合用药皆耐受性良好，严重毒性发生率低。该研究旨在评估阿帕替尼和口服依托泊苷对ERBB2阴性局部晚期或转移性乳腺癌患者的疗效和安全性。这项开放标签的单臂研究纳入曾用蒽环类药物、紫杉烷类药物进行预处理，至少有一种化疗方案失败并且至少使用过一种内分泌药物的ERBB2阴性、激素受体阳性乳腺癌患者，根据患者ECOG状态，每天服用阿帕替尼425/500 mg，以21天为一个周期，在前10天口服依托泊苷50 mg/m2。该研究的主要终点是无进展生存期(PFS)。次要终点包括客观反应率(ORR)，疾病控制率(DCR)，总生存期(OS)和毒性。治疗持续至疾病进展或不耐受。20名符合条件的患者参加了这项研究，中位年龄为54岁，中位随访时间为11个月，中位PFS为5.6个月，ORR为20%，DCR为70%，中位OS为11.2个月。最常见的3/4级治疗相关AE是高血压(30%)，蛋白尿(5%)，恶心(5%)。35%患者因不良事件而减少剂量，之后所有不良事件均可控制至低于2级。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:rucaparib_Revised:4/2018', '.', 'guideline:FDA', '1', 'rucaparib', 'rucaparib', 'rucaparib', '芦卡帕利', 'rucaparib|芦卡帕利', '4', 'fallopian tube', 'fallopian tube', '输卵管癌', 'na', 'sensitivity', 'EVI_001465', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2018年4月6日，美国FDA批准rucaparib用于对铂类化疗有完全或部分反应的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的维持治疗。本次获批是基于2017年9月在ESMO公布的ARIEL3试验数据。ARIEL3是一项随机、安慰剂对照、双盲的Ⅲ期临床试验，共纳入了564名在二线或三线治疗中对铂敏感的进展期卵巢癌、原发性腹膜癌或输卵管癌患者。将患者按照2:1的比例随机分入rucaparib维持治疗组和安慰剂组。主要终点为无进展生存期。患者在以下三组中依次进行评估：1) BRCA突变型（n=196）；2) BRCA突变型或伴有高度LOH的BRCA野生型（统称为同源重组缺陷或HRD）（n=354）；3) 意向治疗人群中的全部患者（n=564）。如果前一个组可见获益，则继续评估下一个组。整体研究人群中，rucaparib维持治疗组的中位无进展生存期（PFS）为10.8个月，安慰剂组为5.4个月。对于生殖细胞或体细胞BRCA突变的患者，使用rucaparib与安慰剂相比，进展或死亡风险降低77%（HR,0.23; 95%CI, 0.16-0.34; P<0.0001）。此外，rucaparib的中位PFS为16.6个月（95%CI,13.4-22.9），而安慰剂为5.4个月（95%CI,3.4-6.7）。在BRCA野生型肿瘤和HRD的患者中观察到类似的PFS益处。无论BRCA突变状态如何，rucaparib均能显着提高PFS。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:rucaparib_Revised:4/2018', '.', 'guideline:FDA', '1', 'rucaparib', 'rucaparib', 'rucaparib', '芦卡帕利', 'rucaparib|芦卡帕利', '4', 'fallopian tube', 'fallopian tube', '输卵管癌', 'na', 'sensitivity', 'EVI_001466', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2018年4月6日，美国FDA批准rucaparib用于对铂类化疗有完全或部分反应的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的维持治疗。本次获批是基于2017年9月在ESMO公布的ARIEL3试验数据。ARIEL3是一项随机、安慰剂对照、双盲的Ⅲ期临床试验，共纳入了564名在二线或三线治疗中对铂敏感的进展期卵巢癌、原发性腹膜癌或输卵管癌患者。将患者按照2:1的比例随机分入rucaparib维持治疗组和安慰剂组。主要终点为无进展生存期。患者在以下三组中依次进行评估：1) BRCA突变型（n=196）；2) BRCA突变型或伴有高度LOH的BRCA野生型（统称为同源重组缺陷或HRD）（n=354）；3) 意向治疗人群中的全部患者（n=564）。如果前一个组可见获益，则继续评估下一个组。整体研究人群中，rucaparib维持治疗组的中位无进展生存期（PFS）为10.8个月，安慰剂组为5.4个月。对于生殖细胞或体细胞BRCA突变的患者，使用rucaparib与安慰剂相比，进展或死亡风险降低77%（HR,0.23; 95%CI, 0.16-0.34; P<0.0001）。此外，rucaparib的中位PFS为16.6个月（95%CI,13.4-22.9），而安慰剂为5.4个月（95%CI,3.4-6.7）。在BRCA野生型肿瘤和HRD的患者中观察到类似的PFS益处。无论BRCA突变状态如何，rucaparib均能显着提高PFS。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:rucaparib_Revised:4/2018', '.', 'guideline:FDA', '1', 'rucaparib', 'rucaparib', 'rucaparib', '芦卡帕利', 'rucaparib|芦卡帕利', '4', 'primary peritoneal cancer', 'primary peritoneal cancer', '腹膜癌', 'na', 'sensitivity', 'EVI_001467', 'BRCA1:nonsynonymous SNV:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2018年4月6日，美国FDA批准rucaparib用于对铂类化疗有完全或部分反应的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的维持治疗。本次获批是基于2017年9月在ESMO公布的ARIEL3试验数据。ARIEL3是一项随机、安慰剂对照、双盲的Ⅲ期临床试验，共纳入了564名在二线或三线治疗中对铂敏感的进展期卵巢癌、原发性腹膜癌或输卵管癌患者。将患者按照2:1的比例随机分入rucaparib维持治疗组和安慰剂组。主要终点为无进展生存期。患者在以下三组中依次进行评估：1) BRCA突变型（n=196）；2) BRCA突变型或伴有高度LOH的BRCA野生型（统称为同源重组缺陷或HRD）（n=354）；3) 意向治疗人群中的全部患者（n=564）。如果前一个组可见获益，则继续评估下一个组。整体研究人群中，rucaparib维持治疗组的中位无进展生存期（PFS）为10.8个月，安慰剂组为5.4个月。对于生殖细胞或体细胞BRCA突变的患者，使用rucaparib与安慰剂相比，进展或死亡风险降低77%（HR,0.23; 95%CI, 0.16-0.34; P<0.0001）。此外，rucaparib的中位PFS为16.6个月（95%CI,13.4-22.9），而安慰剂为5.4个月（95%CI,3.4-6.7）。在BRCA野生型肿瘤和HRD的患者中观察到类似的PFS益处。无论BRCA突变状态如何，rucaparib均能显着提高PFS。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:rucaparib_Revised:4/2018', '.', 'guideline:FDA', '1', 'rucaparib', 'rucaparib', 'rucaparib', '芦卡帕利', 'rucaparib|芦卡帕利', '4', 'primary peritoneal cancer', 'primary peritoneal cancer', '腹膜癌', 'na', 'sensitivity', 'EVI_001468', 'BRCA2:nonsynonymous SNV:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2018年4月6日，美国FDA批准rucaparib用于对铂类化疗有完全或部分反应的复发性上皮性卵巢癌、输卵管癌或原发性腹膜癌患者的维持治疗。本次获批是基于2017年9月在ESMO公布的ARIEL3试验数据。ARIEL3是一项随机、安慰剂对照、双盲的Ⅲ期临床试验，共纳入了564名在二线或三线治疗中对铂敏感的进展期卵巢癌、原发性腹膜癌或输卵管癌患者。将患者按照2:1的比例随机分入rucaparib维持治疗组和安慰剂组。主要终点为无进展生存期。患者在以下三组中依次进行评估：1) BRCA突变型（n=196）；2) BRCA突变型或伴有高度LOH的BRCA野生型（统称为同源重组缺陷或HRD）（n=354）；3) 意向治疗人群中的全部患者（n=564）。如果前一个组可见获益，则继续评估下一个组。整体研究人群中，rucaparib维持治疗组的中位无进展生存期（PFS）为10.8个月，安慰剂组为5.4个月。对于生殖细胞或体细胞BRCA突变的患者，使用rucaparib与安慰剂相比，进展或死亡风险降低77%（HR,0.23; 95%CI, 0.16-0.34; P<0.0001）。此外，rucaparib的中位PFS为16.6个月（95%CI,13.4-22.9），而安慰剂为5.4个月（95%CI,3.4-6.7）。在BRCA野生型肿瘤和HRD的患者中观察到类似的PFS益处。无论BRCA突变状态如何，rucaparib均能显着提高PFS。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28242752', 'NCT01286987', 'clinical trial - phase1', '4', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '4', '.', '.', '卵巢癌', 'na', 'sensitivity', 'EVI_001469', 'BRCA2:.:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'Talazoparib是一种PARP抑制剂，可以导致携带BRCA1/2有害突变的细胞死亡。一项开放标签，多中心，剂量递增的（NCT01286987）临床试验研究了Talazoparib在多个实体瘤中的抗肿瘤活性，MTD，药代动力学和药效学。在12例携带BRCA1/2有害突变的卵巢癌的患者中，Talazoparib 1.0 mg /天治疗后，ORR和CBR分别为42%和67%，中位PFS为36.4周。临床试验中的13例胰腺癌患者，4例具有临床获益（CBR，31%≥，16周）：2例患者部分缓解，1例携带BRCA2突变，另1例携带PALB2突变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28242752', 'NCT01286987', 'clinical trial - phase1', '4', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '4', '.', '.', '卵巢癌', 'na', 'sensitivity', 'EVI_001470', 'BRCA1:.:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'Talazoparib是一种PARP抑制剂，可以导致携带BRCA1/2有害突变的细胞死亡。一项开放标签，多中心，剂量递增的（NCT01286987）临床试验研究了Talazoparib在多个实体瘤中的抗肿瘤活性，MTD，药代动力学和药效学。在12例携带BRCA1/2有害突变的卵巢癌的患者中，Talazoparib 1.0 mg /天治疗后，ORR和CBR分别为42%和67%，中位PFS为36.4周。临床试验中的13例胰腺癌患者，4例具有临床获益（CBR，31%≥，16周）：2例患者部分缓解，1例携带BRCA2突变，另1例携带PALB2突变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28242752', 'NCT01286987', 'clinical trial - phase1', '4', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '4', '.', '.', '胰腺癌', 'na', 'sensitivity', 'EVI_001471', 'BRCA2:.:.:.:inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'Talazoparib是一种PARP抑制剂，可以导致携带BRCA1/2有害突变的细胞死亡。一项开放标签，多中心，剂量递增的（NCT01286987）临床试验研究了Talazoparib在多个实体瘤中的抗肿瘤活性，MTD，药代动力学和药效学。在12例携带BRCA1/2有害突变的卵巢癌的患者中，Talazoparib 1.0 mg /天治疗后，ORR和CBR分别为42%和67%，中位PFS为36.4周。临床试验中的13例胰腺癌患者，4例具有临床获益（CBR，31%≥，16周）：2例患者部分缓解，1例携带BRCA2突变，另1例携带PALB2突变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28242752', 'NCT01286987', 'clinical trial - phase1', '4', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '4', '.', '.', '胰腺癌', 'na', 'sensitivity', 'EVI_001472', 'BRCA1:.:.:.:inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'Talazoparib是一种PARP抑制剂，可以导致携带BRCA1/2有害突变的细胞死亡。一项开放标签，多中心，剂量递增的（NCT01286987）临床试验研究了Talazoparib在多个实体瘤中的抗肿瘤活性，MTD，药代动力学和药效学。在12例携带BRCA1/2有害突变的卵巢癌的患者中，Talazoparib 1.0 mg /天治疗后，ORR和CBR分别为42%和67%，中位PFS为36.4周。临床试验中的13例胰腺癌患者，4例具有临床获益（CBR，31%≥，16周）：2例患者部分缓解，1例携带BRCA2突变，另1例携带PALB2突变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28242752', 'NCT01286987', 'clinical trial - phase1', '4', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '4', '.', '.', '胰腺癌', 'na', 'sensitivity', 'EVI_001473', 'PALB2:nonsynonymous SNV:.:.:inact', 'PALB2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'Talazoparib是一种PARP抑制剂，可以导致携带BRCA1/2有害突变的细胞死亡。一项开放标签，多中心，剂量递增的（NCT01286987）临床试验研究了Talazoparib在多个实体瘤中的抗肿瘤活性，MTD，药代动力学和药效学。在12例携带BRCA1/2有害突变的卵巢癌的患者中，Talazoparib 1.0 mg /天治疗后，ORR和CBR分别为42%和67%，中位PFS为36.4周。临床试验中的13例胰腺癌患者，4例具有临床获益（CBR，31%≥，16周）：2例患者部分缓解，1例携带BRCA2突变，另1例携带PALB2突变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr e13000)', '.', 'clinical study', '4', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001476', 'EGFR:nonsynonymous SNV:exon7:p.A289.:', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon7', 'p.A289.', '.', 'Background:“Pan-negative” non-small cell lung cancer (NSCLC) patient specimens that lack mutations in known targetable genes. EGFR extracellular domain mutations (ECD) as novel oncogenic mutations are found in colorectal cancer, glioma, and neuroblastoma cases and has not yet reported in NSCLC. No enough evidence between icotinib treatment and ECD has been reported in NSCLC. Methods: Comprehensive mutational analyses were performed on 3279 NSCLC specimens. In this cohort of patients, common lung cancer oncogenic driver mutations were firstly detected in EGFR, as well as the KRAS, BRAF, ALK, ROS1 and RET genes by next generation sequencing tumor DNA (ctDNA) and apply icotinib for treatment for EGFR ECD. Results: Of this entire cohort, sixteen (0.49%) patients (3279 cases) were identified with EGFR ECD, including p.L62R (2), p.R98Q (1), p.I213M (1), p.A237F (1), p.A289V (1), p.A289T (1), p.T302H (1), p.T354K (1), p.T363N (1), p.D368Y (1), p.T430S (1), p.A508V (1), p.N528D (1), p.K593Q (1) and G598V (1). During the treatment by icotinib, two cases (p.A289V, p.A289T) had partial response to icotinib for four and six months, which suggested that icotinib conferred sensitivity to A289X mutation. EGFR A289X mutations were sensitive to icotinib treatment in BaF3 cell lines and in xenograft models. These results paralleled those seen with the well-described EGFR oncogenic driver mutation, L858R, suggesting similar mechanistic underpinnings for the mutations. Conclusions: Here, a new EGFR driver mutation, A289X, was identified in the ECD of two NSCLC specimens. NGS may expand the EGFR mutations spectrum for icotinib treatment in NSCLC, however, it needs to be confirmed in more patients with NSCLC in East Asian and other populations.', '“泛阴性”非小细胞肺癌(NSCLC)患者标本缺乏已知的可靶向的基因突变。EGFR细胞外结构域突变(ECD)是结直肠癌，神经胶质瘤和神经母细胞瘤病例中发现的新致癌突变，尚未在NSCLC患者中报道。对3279例NSCLC标本进行全面的突变分析，确定EGFR ECD患者并应用icotinib治疗。在整个队列中，16名患者被确定为EGFR ECD，在使用icotinib治疗期间，2例(p.A289V，p.A289T)对icotinib有4个月和6个月的部分反应，这表明icotinib对A289X突变具有敏感性，同时EGFR A289X突变导致BaF3细胞系和异种移植模型肿瘤模型对的icotinib抑制作用敏感，而且这些结果与EGFR L858R的结果平行，表明突变间具有相似的机制基础。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2016.11.1496', 'NCT02145637', 'clinical trial - phase1', '4', 'afatinib + ruxolitinib', 'afatinib + ruxolitinib', 'afatinib + ruxolitinib', '阿法替尼 + 芦可替尼', 'afatinib + ruxolitinib|阿法替尼 + 芦可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001477', 'EGFR:nonsynonymous SNV:exon20:p.T790M:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'Background：In non-small cell lung cancer (NSCLC) patients treated with EGFR tyrosine kinase inhibitors (TKIs), acquired resistance is attributed to the T790M mutation in exon 20 in approximately 50% of cases. Despite promising preclinical findings, afatinib did not improve survival of patients with the T790M mutation. In a recent preclinical study, we demonstrated that autocrine IL-6 induced JAK/STAT3 signaling pathway activation mediated adaptive resistance to afatinib in H1975 and PC9-GR cells harboring T790M mutations. Knockdown of STAT3 with siRNA or pharmacologic JAK1 inhibition increased the anti-tumor activity of afatinib in T790M-positive NSCLC cells. Based on the promising preclinical results, we conducted a phase Ib study to evaluate the safety and efficacy of the combination of afatinib and ruxolitinib, a selective JAK inhibitor, in NSCLC patients who had progressed on EGFR-TKIs.Methods：For dose escalation with the classical 3+3 design, patients with histologically diagnosed, EGFR mutant stage IV NSCLC were considered eligible. Patients should have documented disease progression on EGFR-TKIs with clinical definition of acquired resistance. Afatinib was administered alone once daily from day 1 through day 8 (run-in period), then ruxolitinib was orally administered twice daily concomitantly with afatinib until progression. The primary endpoint was to determine RP2D and DLT.Results：As of July 13, 2016, 15 patients (8 with exon19 deletion, 7 with exon21 L858R) were enrolled in the dose escalation cohort, 8 of which had T790M mutations. Patients were previously treated with erlotinib (n=5) or gefitinib (n=10). Patients received a median of 3 (range, 1-4) lines of chemotherapy. No DLT was observed at the highest dose level (afatinib 50 mg once daily plus ruxolitinib 25 mg twice daily). Frequent AEs included paronychia (G1 in 7 cases), diarrhea (G1 in 6 cases, G2 in 1 case), acneiform rash (G1 in 5 cases), and oral mucositis (G1 in 1 case, G2 in 3 cases). SAEs were reported in 4 patients, which were not related to the investigational products. Partial responses were observed in 6 patients (40%) with disease control rate (CR+PR+SD) of 86.7%. Median PFS was 8.8 months (95% CI, 1.8-15.8) and 6 patients remain on study. Dose expansion with pharmacodynamic study at the RP2D will be open for NSCLC patients with EGFR T790M.Conclusion：The combination of afatinib with ruxolitinib was well tolerated and had promising clinical activity with durable disease control in NSCLC with acquired resistance to EGFR-TKIs (NCT02145637).', '在用EGFR  TKIs 治疗的非小细胞肺癌（NSCLC）患者中，50%获得性抗性归因于EGFR外显子20中的T790M突变。尽管临床前研究结果很有希望，但afatinib并未改善T790M突变患者的生存率。在最近的临床前研究中，我们证明了自分泌IL-6诱导的JAK/STAT3信号通路激活介导了携带T790M突变的H1975和PC9-GR细胞对阿法替尼的适应性抗性。用siRNA抑制STAT3或药理学JAK1抑制增加了afatinib在T790M阳性NSCLC细胞中的抗肿瘤活性。因此，我们进行了一项Ib期研究（NCT02145637），以评估afatinib和ruxolitinib（一种选择性JAK抑制剂）联合用于EGFR-TKI进展的NSCLC患者的安全性和有效性。EGFR TKI耐药患者，从第1天至第8天，每天一次单独施用阿法替尼，然后每天两次口服ruxolitinib与阿法替尼，直至进展。主要终点是确定 II 期临床剂量（RP2D） 和剂量限制性毒性（DLT）。15名患者（8名外显子19缺失，7名外显子21 L858R）参加剂量递增队列，其中8名具有T790M突变。患者先前接受厄洛替尼（n = 5）或吉非替尼（n = 10）治疗。在最高剂量水平下没有观察到DLT（阿法替尼50 mg，每天一次加ruxolitinib 25 mg，每天两次）。在6名患者（40%）中观察到部分反应，疾病控制率（CR + PR + SD）为86.7%。中位PFS为8.8个月（95%CI，1.8-15.8），6名患者仍在研究中。阿法替尼与ruxolitinib联合应用具有良好的耐受性，具有良好的临床活性，对EGFC-TKIs具有获得性耐药的NSCLC具有持久的疾病控制。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr e15077)', '.', 'preclinical', '4', 'cetuximab', 'cetuximab', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', 'colorectal cancer', 'colorectal cancer', '结直肠癌', 'na', 'resistance', 'EVI_001478', 'KLF4 :nonsynonymous SNV:exon5:p.A472D:', 'KLF4 ', 'nonsynonymous SNV', 'Exact_pos', 'exon5', 'p.A472D', '.', 'Background: With the increase of treatment course, acquired resistance of epidermal growth factor receptor (EGFR) blockade is inevitable in patients with metastatic colorectal cancer (mCRC). KRAS mutations have been considered to be primary drivers of this acquired resistance; however, the potential function of other genes has not been extensively investigated. Methods: This study included 17 mCRC patients with acquired cetuximab resistance, and mutations in circulating tumor DNA (ctDNA) from plasma samples were identified using target-capture deep sequencing. Analysis of mutational prevalence in ctDNA, three CRC tissue-based datasets and one ctDNA dataset was performed. Mutation predicted with significant effect on acquired resistance was selected and the functional analysis was validated in CRC cells. Results: The prevalence of mutations identified in ctDNA was consistent with CRC tissue-based and ctDNA datasets. Clonal analysis revealed that 41.2% of patients were positive for at least one subclonal. Multiply resistance mechanisms of cetuximab were co-existed in individual patient, with one of them even harbored nine distinct mutations. In particularly, function analysis of Krüppel-like factor 4 (KLF4) mutation p.A472D revealed increased cetuximab resistance in CRC cells, which was associated with the increased phosphorylation of downstream EGFR signaling proteins. Conclusions: The KLF4 mutation p.A472D contributes to acquired cetuximab resistance in patients with mCRC and it may serve as a new biomarker useful in clinical application. Monitoring somatic mutations related to acquired cetuximab resistance in mCRC patients through ctDNA is an appropriate means of providing real-time insights useful for clinical reference and treatment planning.', '该研究纳入17例西妥昔单抗获得性耐药的mCRC患者，鉴定他们血浆样本中ctDNA的突变，分析了ctDNA的突变流行率。其中一例患者存在KLF4 p.A472D突变，功能分析显示该突变与CRC细胞对西妥昔单耐药相关，可能是该基因突变导致了下游EGFR信号传导蛋白的磷酸化增加。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 35, 2017 (suppl; abstr 2506)', 'NCT02407509', 'clinical trial - phase1', '4', '.', '.', 'RO5126766', 'RO5126766', 'RO5126766|RO5126766', '1', '.', '.', '肺癌', 'na', 'sensitivity', 'EVI_001479', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'RO5126766是一种有效的RAF和MEK抑制剂，在RAS和RAF突变的癌症的异种移植模型中具有抗肿瘤活性。一项临床试验中（NCT02407509），KRAS、NRAS或BRAF突变肿瘤患者使用RO5127566治疗：每周两次4 mg，每周期4周。最终对20名实体瘤患者（10名NSCLC，5名妇科癌症和5名其他癌症）和1名多发性骨髓瘤患者进行了评估。在10例KRAS突变的NSCLC患者中，6/10（60%）肿瘤减小，其中3/10（30%）获得部分反应。其中两名患者维持了超过1年的响应，一名患者在30个周期后仍在治疗。在妇科癌症中，3/5患者（60%）实现了部分反应（KRAS-突变子宫内膜癌和卵巢癌以及BRAF-突变卵巢癌）。在其他组中，4例结直肠癌患者（2例BRAF和2例NRAS）和1例NRAS突变黑色素瘤患者，均无应答。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 35, 2017 (suppl; abstr 2506)', 'NCT02407509', 'clinical trial - phase1', '4', '.', '.', 'RO5126766', 'RO5126766', 'RO5126766|RO5126766', '1', '.', '.', '子宫肿瘤', 'na', 'sensitivity', 'EVI_001480', 'KRAS:nonsynonymous SNV:.:.:', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'RO5126766是一种有效的RAF和MEK抑制剂，在RAS和RAF突变的癌症的异种移植模型中具有抗肿瘤活性。一项临床试验中（NCT02407509），KRAS、NRAS或BRAF突变肿瘤患者使用RO5127566治疗：每周两次4 mg，每周期4周。最终对20名实体瘤患者（10名NSCLC，5名妇科癌症和5名其他癌症）和1名多发性骨髓瘤患者进行了评估。在10例KRAS突变的NSCLC患者中，6/10（60%）肿瘤减小，其中3/10（30%）获得部分反应。其中两名患者维持了超过1年的响应，一名患者在30个周期后仍在治疗。在妇科癌症中，3/5患者（60%）实现了部分反应（KRAS-突变子宫内膜癌和卵巢癌以及BRAF-突变卵巢癌）。在其他组中，4例结直肠癌患者（2例BRAF和2例NRAS）和1例NRAS突变黑色素瘤患者，均无应答。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 35, 2017 (suppl; abstr 2506)', 'NCT02407509', 'clinical trial - phase1', '4', '.', '.', 'RO5126766', 'RO5126766', 'RO5126766|RO5126766', '1', '.', '.', '卵巢癌', 'na', 'sensitivity', 'EVI_001481', 'KRAS:nonsynonymous SNV:.:.:', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'RO5126766是一种有效的RAF和MEK抑制剂，在RAS和RAF突变的癌症的异种移植模型中具有抗肿瘤活性。一项临床试验中（NCT02407509），KRAS、NRAS或BRAF突变肿瘤患者使用RO5127566治疗：每周两次4 mg，每周期4周。最终对20名实体瘤患者（10名NSCLC，5名妇科癌症和5名其他癌症）和1名多发性骨髓瘤患者进行了评估。在10例KRAS突变的NSCLC患者中，6/10（60%）肿瘤减小，其中3/10（30%）获得部分反应。其中两名患者维持了超过1年的响应，一名患者在30个周期后仍在治疗。在妇科癌症中，3/5患者（60%）实现了部分反应（KRAS-突变子宫内膜癌和卵巢癌以及BRAF-突变卵巢癌）。在其他组中，4例结直肠癌患者（2例BRAF和2例NRAS）和1例NRAS突变黑色素瘤患者，均无应答。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 35, 2017 (suppl; abstr 2506)', 'NCT02407509', 'clinical trial - phase1', '4', '.', '.', 'RO5126766', 'RO5126766', 'RO5126766|RO5126766', '1', '.', '.', '卵巢癌', 'na', 'sensitivity', 'EVI_001482', 'BRAF:nonsynonymous SNV:exon15:p.V600.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', 'RO5126766是一种有效的RAF和MEK抑制剂，在RAS和RAF突变的癌症的异种移植模型中具有抗肿瘤活性。一项临床试验中（NCT02407509），KRAS、NRAS或BRAF突变肿瘤患者使用RO5127566治疗：每周两次4 mg，每周期4周。最终对20名实体瘤患者（10名NSCLC，5名妇科癌症和5名其他癌症）和1名多发性骨髓瘤患者进行了评估。在10例KRAS突变的NSCLC患者中，6/10（60%）肿瘤减小，其中3/10（30%）获得部分反应。其中两名患者维持了超过1年的响应，一名患者在30个周期后仍在治疗。在妇科癌症中，3/5患者（60%）实现了部分反应（KRAS-突变子宫内膜癌和卵巢癌以及BRAF-突变卵巢癌）。在其他组中，4例结直肠癌患者（2例BRAF和2例NRAS）和1例NRAS突变黑色素瘤患者，均无应答。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/jco.2012.30.15_suppl.7531 ', 'NCT00818675', 'clinical trial - phase2', '4', '.', '.', 'ridaforolimus', 'ridaforolimus', 'ridaforolimus|ridaforolimus', '2', '.', '.', '肺癌', 'na', 'sensitivity', 'EVI_001483', 'KRAS:nonsynonymous SNV:.:.:', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '约25%的晚期NSCLC患者存在KRAS突变。临床前数据表明mTOR信号通路在KRAS介导的肿瘤发生中有作用。Ridaforolimus是mTOR的抑制剂，已被证明在晚期子宫内膜癌和软组织肉瘤中具有肿瘤抑制作用。在一项临床试验中，患有KRAS突变的IIIB/IV期非小细胞肺癌患者，接受过化疗，开始口服ridaforolimus 40 mg，每日一次，每周5天。8周后，肿瘤缩小> 30%继续治疗，而肿瘤生长> 20%的患者停止治疗。该研究的主要终点是随机化后的无进展生存期（PFS）。79名患者入组（40名女性，中位年龄58岁）。8周时的总反应率（CR + PR）为1/79（1%，95%CI 0-7%）。将8周时疾病稳定的28名患者随机分配至ridaforolimus或安慰剂。ridaforolimus治疗组的中位PFS显着长于安慰剂组（4 vs 2个月，p = 0.013，HR 0.36）。ridaforolimus治疗组的中位OS为18个月，安慰剂治疗组中为5个月（HR 0.46，p = 0.09）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001484', 'MET:nonsynonymous SNV::p.V1092.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.V1092.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001485', 'MET:nonsynonymous SNV::p.G1163.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.G1163.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001486', 'MET:nonsynonymous SNV::p.D1164.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.D1164.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001487', 'MET:nonsynonymous SNV::p.L1195.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.L1195.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001488', 'MET:nonsynonymous SNV::p.D1228.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.D1228.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001489', 'MET:nonsynonymous SNV::p.Y1230.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.Y1230.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'capmatinib', 'capmatinib', 'capmatinib|capmatinib', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001490', 'MET:nonsynonymous SNV::p.D1228.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.D1228.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'capmatinib', 'capmatinib', 'capmatinib|capmatinib', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001491', 'MET:nonsynonymous SNV::p.Y1230.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.Y1230.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'tepotinib', 'tepotinib', 'tepotinib|tepotinib', '2', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001492', 'MET:nonsynonymous SNV::p.D1228.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.D1228.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'tepotinib', 'tepotinib', 'tepotinib|tepotinib', '2', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001493', 'MET:nonsynonymous SNV::p.Y1230.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.Y1230.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'savolitinib', '沃利替尼', 'savolitinib|沃利替尼', '2', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001494', 'MET:nonsynonymous SNV::p.D1228.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.D1228.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'savolitinib', '沃利替尼', 'savolitinib|沃利替尼', '2', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001495', 'MET:nonsynonymous SNV::p.Y1230.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.Y1230.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'cabozantinib', '卡博替尼', 'cabozantinib|卡博替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001496', 'MET:nonsynonymous SNV::p.L1195.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.L1195.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'cabozantinib', '卡博替尼', 'cabozantinib|卡博替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001497', 'MET:nonsynonymous SNV::p.F1200.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.F1200.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'cabozantinib', '卡博替尼', 'cabozantinib|卡博替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001498', 'MET:nonsynonymous SNV::p.D1228.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.D1228.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'merestinib', 'merestinib', 'merestinib|merestinib', '1', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001499', 'MET:nonsynonymous SNV::p.F1200.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.F1200.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'glesatinib', 'glesatinib', 'glesatinib|glesatinib', '1', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001500', 'MET:nonsynonymous SNV::p.L1195.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.L1195.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'glesatinib', 'glesatinib', 'glesatinib|glesatinib', '1', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001501', 'MET:nonsynonymous SNV::p.F1200.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.F1200.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31279006', '.', 'preclinical', '4', '.', '.', 'glesatinib', 'glesatinib', 'glesatinib|glesatinib', '1', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001502', 'MET:nonsynonymous SNV::p.D1228.:', 'MET', 'nonsynonymous SNV', 'Partial_pos', '.', 'p.D1228.', '.', '.', 'MET exon14编码的近膜结构域是MET的关键负性调控区，包含半胱天冬酶裂解序列（ESVD1002）和E3泛素连接酶c-CBL 酪氨酸结合位点(Y1003)，参与MET蛋白的泛素化和降解。近膜结构域的缺失可使MET蛋白泛素化障碍，MET 降解率减低，从而增加MET的稳定性和引起下游信号的持续激活。MET激酶抑制剂可以通过抑制MET的活性发挥抗肿瘤活性。携带MET exon14跳跃突变的肿瘤患者对MET抑制剂敏感。但是，MET基因上发生的二次突变可能干扰药物与c-MET蛋白的结合，导致肿瘤耐药。一项体外细胞学试验发现多个可能导致MET抑制剂耐药的二次突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:23239810', '.', 'preclinical', '4', '.', '.', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_001503', 'ALK:nonsynonymous SNV::p.L1196Q:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.L1196Q', '.', '.', '在体外研究中，表达NPM-ALK L1196Q突变的细胞系（K299 CR06和Ba/F3）对克唑替尼的抑制作用有抗性（IC50：分别为948 nmol/L和212 nmol/L），而表达野生型NPM-ALK融合基因的K299细胞和Ba/F3细胞IC50分别为23 nmol/L和35 nmol/L。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:18923525', '.', 'preclinical', '4', '.', '.', 'TAE684', 'TAE684', 'TAE684|TAE684', '0', '.', '.', '肿瘤细胞', '[ALK:FUS]', 'resistance', 'EVI_001504', 'ALK:nonsynonymous SNV::p.R1275Q:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.R1275Q', '.', '.', '携带R1275Q突变的SMS-KCNR细胞系对TAE684具有抗性。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28418267', '.', 'clinical study', '4', 'ibrutinib', 'ibrutinib', 'ibrutinib', '伊布替尼', 'ibrutinib|伊布替尼', '4', 'Chronic Lymphocytic Leukemia', 'CLL', '白血病', 'na', 'resistance', 'EVI_001505', 'BTK:nonsynonymous SNV::p.C481S:', 'BTK', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.C481S', '.', '.', 'ibrutinib治疗后复发的患者往往进展迅速且预后不良。一项研究对112名患者每隔3个月分析BTK和PLCG2整个编码区的突变。8名患者经历了临床复发，并且所有8名患者在复发前都出现BTK C481S突变并且克隆扩增。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27626698', '.', 'case report', '4', 'ibrutinib', 'ibrutinib', 'ibrutinib', '伊布替尼', 'ibrutinib|伊布替尼', '4', 'Chronic Lymphocytic Leukemia', 'CLL', '白血病', 'na', 'resistance', 'EVI_001506', 'BTK:nonsynonymous SNV::p.T316A:', 'BTK', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.T316A', '.', '.', '在一份ibrutinib治疗的CLL复发患者的病例报告中（在初始部分缓解10个月后），该患者的样品的测序揭示了复发时新的BTK T316突变（等位基因频率为75%）。该突变位于BTK的SH2结构域中。在ibrutinib敏感的淋巴瘤细胞系中引入该突变显示出其与已知的C481一样可以导致肿瘤细胞对药物耐药。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9008)', 'NCT03037385', 'clinical trial - phase1', '4', 'BLU-667', 'BLU-667', 'BLU-667', 'BLU-667', 'BLU-667|BLU-667', '1', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', 'na', 'sensitivity', 'EVI_001509', 'RET:FUS:.:.-RET:.', 'RET', 'FUS', 'FUS', '.', '.-RET', '.', 'Background: RET fusions are targetable oncogenic drivers in up to 2% of NSCLC, yet no selective RET inhibitors are approved. BLU-667 is an investigational highly potent and selective RET inhibitor targeting oncogenic RET alterations, including those that confer resistance to multikinase inhibitors (MKIs). We provide an update on the registration-enabling ARROW study (NCT03037385) of BLU-667 in pts with RET-fusion+ NSCLC. Methods: The global ARROW study includes DE (30-600 mg daily [QD or BID]) and dose expansion (DX) at the recommended phase 2 dose (RP2D; 400 mg QD) in pts with advanced solid tumors. Primary objectives are overall response rate (ORR; RECIST 1.1) and safety. Results: As of 19Dec2018, 79 pts (21 DE, 58 DX) with advanced RET fusion+ NSCLC (44 KIF5B, 16 CCDC6, 19 other/pending) received BLU-667. Median number of prior therapies was 2 (range 0-8) and includes chemotherapy (76%), immunotherapy (41%), and MKI (27%). 39% had baseline brain metastases. ORR among 57 response-evaluable pts with measurable disease and at least one follow-up disease assessment was 56% (95% CI: 42, 69; 32 partial responses (PR), 9 PR pending confirmation, 20 stable disease, 5 progressive disease). 91% (29/32) of responding pts remain on treatment; 6 have achieved response duration ≥ 6 months. Disease control rate (DCR) was 91% (52/57). Among 30 pts at the RP2D previously treated with platinum chemotherapy, ORR was 60% (18 PRs; 7 pending confirmation). Responses occur regardless of prior treatment or RET fusion genotypes. Intracranial activity has been observed with shrinkage of brain metastases. 80% of NSCLC pts treated at RP2D remain on treatment and only 3% discontinued due to related adverse event. In NSCLC patients, treatment-related toxicity (TRT), generally low-grade and reversible (28% had ≥ grade 3 events), included increased AST (22%), hypertension (18%), increased ALT (17%), constipation (17%), fatigue (15%) and decreased neutrophils (15%). Conclusions: BLU-667 demonstrated potent, durable and broad antitumor activity and was well tolerated in pts with advanced RET-fusion+ NSCLC. Enrollment of the expansion is ongoing with registrational intent. Clinical trial information: NCT03037385', 'RET融合可作为NSCLC患者(2%)的靶向致癌驱动因子。BLU-667是一种高效、选择性RET抑制剂，靶向致癌性RET改变。ARROW是一项全球性研究，晚期实体瘤患者接受BLU-667每日治疗(DE;30-600mg每日[QD或BID])和剂量扩展(DX;400mgQD)治疗。主要目标是总体响应率(ORR;RECIST1.1)和安全性。共79例(21例DE，58例DX)晚期RET融合的NSCLC(44例KIF5B，16例CCDC6，19例其他/未决)患者接受BLU-667。57例可评估患者ORR为56%（95%CI：42-69；32例部分缓解，20例稳定疾病，5例疾病进展）。91%(29/32)的应答者仍在接受治疗，6例患者的响应持续时间≥6个月。RP2D治疗后80%NSCLC患者仍在接受治疗，仅有3%因相关不良事件而停药。在NSCLC患者中，治疗相关毒性(TRT)多为低级和可逆，包括AST增加(22%)，高血压(18%)，ALT增加(17%)，便秘(17%)，疲劳(15%)和中性粒细胞减少(15%)。BLU-667显示出有效，持久和广泛的抗肿瘤活性，并且在晚期RET融合的NSCLC患者中具有良好的耐受性。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 6018)', 'NCT03037385', 'clinical trial - phase1', '4', 'BLU-667', 'BLU-667', 'BLU-667', 'BLU-667', 'BLU-667|BLU-667', '1', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', 'na', 'sensitivity', 'EVI_001510', 'RET:nonsynonymous SNV:.:.:act', 'RET', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'BLU-667是一种高效、选择性RET抑制剂。ARROW是一项全球性研究，晚期实体瘤患者接受BLU-667治疗（30-600 mg每日[QD或BID]）和剂量扩展（DX; 400 mg QD）治疗。主要终点指标是ORR和安全性。研究对象中，60例为RET突变的晚期甲状腺髓样癌（MTC）患者，5例为甲状腺乳头状癌（PTC），58%的患者曾接受多激酶抑制剂（MKIs）治疗。在49名可评估的患者中，ORR为47%，96%患者继续治疗；15例患者反应持续时间≥6个月。50%可评估的PTC患者有部分缓解（PR）。无论先前是否存在MKI抗性均对治疗有响应，疾病控制率为98%。研究观察到RET变体的快速血浆清除和CEA、降钙素的显著降低。MTC/PTC患者的治疗相关毒性多为低级和可逆性事件，包括WBC减少，AST增加，ALT升高，血肌酐升高，磷酸盐，高血压和中性粒细胞减少。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr e20682)', '.', 'case report', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001511', 'BRAF:nonsynonymous SNV:exon15:p.V600.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'Background: There is growing insight in the mechanisms underlying resistance to the 3rdgeneration EGFR inhibitor osimertinib. Unlike resistance to 1stgeneration inhibitors, these mechanisms not necessarily lead to sequential targeted therapy approaches. Here we report on the treatment of two patients with acquired resistance to osimertinib with a new detected BRAF V600E mutation as resistance mechanism. Methods: We identified two patients with EGFR-T790M-mutant advanced NSCLC with progression on osimertinib and detection of a new BRAFV600E mutation in a tumor rebiopsy by next-generation sequencing (NGS). No other known resistance mechanism beside T790M loss in one patient was found. Osimertinib was discontinued and BRAF-targeted combination therapy with dabrafenib and trametinib at standard dose was initiated. We monitored the clinical course with sequential 18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) / computed tomography (CT) assessing maximum standard uptake value (SUVmax), sequencing based liquid biopsies and tumor marker assessment. Results: Patient (1) with EGFR del19 (E746_A750del), preserved T790M mutation and acquired BRAF V600E mutation showed reduction in FDG uptake of 18% after 2 weeks of dabrafenib/trametinib that demonstrated a slight increase of 12% in a FDG-PET/CT scan 4 weeks thereafter and combination treatment has been continued. Patient (2) with EGFR del19 (E746_A750del), T790M loss and new BRAF V600E mutation showed continuous metabolic (+8% and + 39%, respectively) and morphologic progression after 2 and 4 weeks of dabrafenib and trametinib. A tumor rebiopsy showed no additional molecular changes. We changed the treatment to osimertinib and dabrafenib combination and observed an impressive metabolic response (-33%) after 2 weeks by FDG-PET/CT. Conclusions:BRAF V600E mutation has recently been described as a novel molecular resistance mechanism in osimertinib-resistant EGFR-mutant NSCLC. We describe one patient where combined BRAF/MEK inhibition with no additional EGFR-inhibition resulted in a preliminary feasible tumor control, but confirmatory CT staging is pending. In a second patient, co-inhibition of EGFR and BRAF pathway with osimertinib and dabrafenib was needed to overcome BRAF-mediated osimertinib resistance resulting in an impressive early tumor response that was not observed to either single-target inhibition of EGFR or BRAF. FDG-PET/CT was able to monitor tumor dynamics. Updated data will be presented.', '研究人员报告了两名osimertinib获得性耐药患者的治疗，并认为新检测到的BRAF V600E突变可作为其抗性机制。研究人员通过NGS鉴定了两名存在EGFR T790M突变的晚期NSCLC患者，在使用osimertinib后疾病发生进展，重新检测发现了新的BRAF V600E突变。停用osimertinib并开始以标准剂量dabrafenib和trametinib进行BRAF靶向联合治疗。患者I存在EGFR exon19del（E746_A750del）、T790M突变和获得性BRAF V600E突变，dabrafenib/trametinib治疗2周后FDG摄取减少了18%，继续进行联合治疗。患者II存在EGFR exon19del（E746_A750del），T790M缺失和获得性BRAF V600E突变，dabrafenib和trametinib治疗2周和4周后发生了形态学进展。肿瘤重新检查没发现其他分子变化。将治疗改为osimertinib和dabrafenib组合，2周后通过FDG-PET/CT观察到显著的代谢反应（-33%）。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9005)', 'NCT02864992', 'clinical trial - phase2', '4', 'tepotinib', 'tepotinib', 'tepotinib', 'tepotinib', 'tepotinib|tepotinib', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001512', 'MET:skipping_mut:.:.:skipping_mut', 'MET', 'skipping_mut', 'None_pos', '.', '.', 'skipping_mut', 'Background: MET exon 14 skipping (METex14) mutations - reported in 3~4% of NSCLC patients (pts) - are activating, sensitive to MET inhibition and can be conveniently detected using liquid biopsy (LBx). We report data from an ongoing single-arm phase II study of tepotinib, a highly selective MET inhibitor, in NSCLC pts with METex14 mutations identified by LBx or tumor biopsy (TBx) (NCT02864992). Methods: Pts with advanced WT EGFR/ALK NSCLC, prospectively enrolled via either LBx (≥60 pts) or TBx (≥60 pts, overlap anticipated) central RNA-based METex14 mutation testing, receive tepotinib 500 mg QD until progression, intolerable toxicity or withdrawal. Primary endpoint: objective response rate (ORR) by independent review (IRC). Secondary endpoints: ORR by investigator assessment (INV) and safety. Results: To date, 85 pts have been enrolled (55 LBx pts and 52 TBx pts). At data cut-off (16 Oct 2018), in 35 evaluable LBx pts (≥2 post-baseline assessments or discontinuation for any reason), ORR was 51.4% by IRC and 63.9% by INV. In 41 evaluable TBx pts, ORR was 41.5% by IRC and 58.5% by INV. Median duration of response (mDoR) and ORR by line of treatment are shown in the table. Any grade treatment-related adverse events (TRAEs) reported by ≥10% of 69 pts evaluable for safety were peripheral edema (47.8%), diarrhea (18.8%), nausea (15.9%), asthenia (10.1%). No TRAEs were grade 4 or led to death. TRAEs led to permanent discontinuation in 2 (2.9%) pts (1 ILD, 1 diarrhea & nausea). Conclusions: Tepotinib has promising activity with a long DoR across treatment lines in NSCLC pts with METex14 mutations detected by LBx or TBx. The safety profile was favorable. Recruitment is ongoing. Clinical trial information: NCT02864992', '3-4%的NSCLC患者携带MET ex14跳跃突变，患者对MET抑制敏感。一项正在进行的单臂II期研究分析了一种高选择性MET抑制剂tepotinib对MET ex14突变NSCLC患者的疗效（NCT02864992）。晚期、MET ex14突变、EGFR/ALK野生型的NSCLC患者接受tepotinib 500 mg QD直至进展、出现无法忍受的毒性或退出。主要终点为客观反应率（ORR）。迄今已有85例患者入选。在35个可评估患者中（液体活检），IRC（独立评估）的ORR为51.4%，INV（研究者评估）的ORR为63.9%。在41个可评估患者中（组织活检），IRC的ORR为41.5%，INV的ORR为58.5%。治疗相关不良事件为外周性水肿（47.8%），腹泻（18.8%），恶心（15.9%），虚弱（10.1%）。没有4级或导致死亡的TRAEs。tepotinib在MET ex14突变的NSCLC患者中具有较好的活性和安全性。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9089)', 'NCT02834936', 'clinical trial - phase2', '4', 'pyrotinib', 'pyrotinib', 'pyrotinib', '吡咯替尼 ', 'pyrotinib|吡咯替尼 ', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001514', 'ERBB2:nonframeshift insertion:exon20:.:exon20ins', 'ERBB2', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'Background: ERBB2 exon 20 mutation is a well-known oncogenic driver in non-small cell lung cancer (NSCLC) and its testing is recommended by NCCN guidelines for NSCLC patients. However, up to now, there has been no approved targeted therapy for this patient population. Pyrotinib is an oral, irreversible pan-Her tyrosine kinase inhibitor (TKI) against HER1, ERBB2 and HER4, which, combined with chemotherapy, has recently been approved in China for ERBB2 positive advanced breast cancer. Methods: Stage IIIB or IV NSCLC patients with ERBB2 exon 20 mutation (confirmed in a central lab) and previously treated with at least one platinum-based chemotherapy were enrolled in this open-label, multi-center, single-arm phase II study. Patients with active brain metastases or prior use of ERBB2 TKI agents were excluded. Eligible patients received pyrotinib 400 mg once daily until disease progression, intolerable toxicity or withdrawal of consent. The primary endpoint was objective response rate (ORR) according to RECIST 1.1. Secondary endpoints included safety, progression-free survival (PFS), time to disease progression (TTP), duration of response (DOR) and overall survival (OS). This trial is registered on ClinicalTrials.gov (NCT02834936). Results: Between October 20, 2016 and December 10, 2018, 60 patients (33 female, 27 male) were enrolled. The median age was 57 years (range: 40, 72). A majority were stage IV patients (95%). Over 58% of patients have been treated with two or more prior chemotherapy regimens. As of Jan 21, 2019, the ORR as evaluated by investigators was 31.7% (95% CI 20.3%, 45.0%). Median DOR was 7.0 months (95% CI 5.5, 11.0) and median PFS was 6.8 months (95% CI 4.1, 8.3). 26.7% patients reported treatment-related grade 3 AEs. Diarrhea (20.0%) was the only treatment-related grade 3 AE that occurred in ≥ 2 patients. Treatment-related grade 4 AE was reported in 1 subject (elevated gamma-glutamyl transferase). The anti-tumor activities of pyrotinib was shown in various mutation types. Conclusions: Pyrotinib as a single agent demonstrated promising anti-tumor activity and acceptable safety profile in heavily pretreated ERBB2 mutant NSCLC patients. Clinical trial information: NCT02834936', 'ERBB2 exon20突变是非小细胞肺癌（NSCLC）的致癌驱动因子，目前为止尚未有批准的靶向治疗。pyrotinib是一种针对HER1，ERBB2和ERBB4的不可逆抑制剂TKI。曾至少接受过一种铂类化疗、携带ERBB2 exon20突变的IIIB或IV期NSCLC患者参加了一项开放标签，多中心，单臂II期研究。患者每天一次接受400 mg的pyrotinib直至疾病进展、出现无法忍受的毒性或撤回同意。主要终点是客观反应率（ORR），次要终点包括安全性，无进展生存期（PFS），疾病进展时间（TTP），反应持续时间（DOR）和总生存期（OS）。2016年10月20日至2018年12月10日期间共招募了60名患者（33名女性，27名男性），中位年龄为57岁，大多数是IV期患者（95%）。超过58%的患者曾接受两种或两种以上化疗方案的治疗。截至2019年1月21日，ORR为31.7%，中位DOR为7.0个月，中位PFS为6.8个月。26.7%的患者报告了与治疗相关的3级AE。在1名受试者中报道了与治疗相关的4级AE。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30373752', 'NCT01775072', 'clinical study', '4', 'sorafenib', 'sorafenib', 'sorafenib', '索拉非尼', 'sorafenib|索拉非尼', '4', 'Hepatocellular carcinoma', 'Hepatocellular carcinoma', '肝癌', 'na', 'decrease', 'EVI_001515', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'MSKCC癌症中心发表在clinical cancer research上的研究，通过二代测序NGS筛选出接受标准全身治疗优势人群，并根据基因检测结果为HCC患者提供潜在的靶向治疗的可能（NCT01775072）。81例索拉非尼治疗的患者中， PI3K-MTOR途径中存在活化突变的患者（n=12），其索拉非尼治疗的临床获益率较非PI3K-MTOR肿瘤患者（n=67）较低。DCR 8.3% vs 40.2%，（p = 0.05），且患者中位PFS也是较短 [1.9 vs. 5.3个月，HR 3.8（95%CI 2.0-7.5）p <0.0001]和中位OS也是较短[10.4对17.9个月，HR 2.5（95%CI 1.21-5.31），p = 0.01] 。', 's', '可能疗效减弱', 'n');
INSERT INTO `main_ori` VALUES ('PMID:25624430', '.', 'clinical study', '4', 'everolimus + letrozole', 'everolimus + letrozole', 'everolimus + letrozole', '依维莫司 + 来曲唑', 'everolimus + letrozole|依维莫司 + 来曲唑', '4', 'endometrial cancer', 'endometrial cancer', '子宫肿瘤', 'na', 'sensitivity', 'EVI_001516', 'CTNNB1:nonsynonymous SNV:.:.:act', 'CTNNB1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'PURPOSE:The phosphoinositol-3 kinase (PI3K) pathway is frequently dysregulated in endometrial cancer (EC). Hormonal manipulation leads to response in some patients with EC, but resistance derived from PI3K pathway activation has been documented. Targeting mammalian target of rapamycin (mTOR) may overcome endocrine resistance. We conducted a two-institution phase II trial of everolimus and letrozole in women with recurrent EC.PATIENTS AND METHODS:Patients were considered incurable, had measurable disease, and were treated with up to two prior cytotoxic regimens. Everolimus was administered orally at 10 mg daily and letrozole was administered orally at 2.5 mg daily. Each cycle consisted of 4 weeks of therapy. Patients were treated until progression, toxicity, or complete response (CR). The primary end point was the clinical benefit rate (CBR), which was defined as CR, partial response, or stable disease (≥ 16 weeks) by RECIST 1.0 criteria. Translational studies were performed to correlate biomarkers with response.RESULTS:Thirty-eight patients were enrolled (median age, 62 years; range, 24 to 82 years). Thirty-five patients were evaluable for response. The CBR was 40% (14 of 35 patients); the median number of cycles among responders was 15 (range, seven to 29 cycles). The confirmed objective response rate (RR) was 32% (11 of 35 patients; nine CRs and two partial responses; median, 15 cycles; range, eight to 29 cycles). Twenty percent of patients (seven of 35 patients) were taken off treatment after a prolonged CR and at the discretion of the treating clinician. None of the patients discontinued treatment as a result of toxicity. Serous histology was the best predictor of lack of response. Patients with endometrioid histology and CTNNB1 mutations responded well to everolimus and letrozole.CONCLUSION:Everolimus plus letrozole results in a high CBR and RR in patients with recurrent EC. Further development of this combination in recurrent endometrioid EC is under way.', '子宫内膜癌（EC）患者的PI3K通路经常失调，导致患者对内分泌治疗产生抗性，靶向mTOR可以克服内分泌抗性。在一项双机构II期试验中，研究人员对患有复发性EC的女性进行了依维莫司和来曲唑治疗。患者多患有无法治愈、可测量的疾病，曾接受一种以上细胞毒性治疗。依维莫司口服给药，每日10 mg，来曲唑口服，每日2.5 mg；4周的治疗为一个周期。治疗持续至患者进展，出现毒性或实现完全反应（CR）。主要终点是临床受益率（CBR），部分反应率（CR）。共38名CTNNB1+患者入选，35名患者具有可评估反应。 CBR为40%，响应者的中位数周期为15个，确诊的客观反应率（RR）为32%，20%的患者在长期CR后可根据实际情况持续治疗。没有患者因毒性而停止治疗。结果显示CTNNB1突变患者对依维莫司和来曲唑反应良好。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr e20661)', 'NCT03762122', 'clinical trial - phase2', '4', 'rogaratinib', 'rogaratinib', 'rogaratinib', 'rogaratinib', 'rogaratinib|rogaratinib', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001517', 'FGFR1:CNV:.:.:gain', 'FGFR1', 'CNV', 'CNV', '.', '.', 'gain', 'Background: FGFR1 gene amplifications are observed in squamous (sq) non-small cell lung cancer (NSCLC) and may suggest tractable oncogenic dependency. However, their value in predicting clinical activity of FGFR inhibitors is unclear. We explored tumor FGFR1-3 mRNA expression levels to select patients (pts) for treatment with rogaratinib, an oral, potent, small-molecule inhibitor of FGFR1-4. The first-in-human study of rogaratinib included pts with all NSCLC histologies. Methods: Pts with refractory advanced NSCLC were screened for elevated FGFR1-3 mRNA levels by RNA in situ hybridization (RNAscope) and NanoString assay in fresh or archival tumor samples, and FGFR1-3 overexpression was defined by pre-specified cut-offs. Pts received rogaratinib 800 mg BID on a continuous 21-day cycle. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors v1.1 after cycles 2, 5, and 8. Results: 260 NSCLC biopsies were screened for FGFR1-3 tumor mRNA expression; 244 (93.8%) were evaluable. FGFR1-3 mRNA overexpression was found in 47% of sq NSCLC, and only 14% of non-sq NSCLC, with FGFR3 being the most commonly overexpressed subtype. 40 FGFR mRNA-positive pts were enrolled and treated. Rogaratinib was well tolerated; hyperphosphatemia (75%), diarrhea (53%), and decreased appetite (35%) were the most frequent treatment-emergent adverse events. Events were mostly mild or moderate. 36 treated pts were evaluable for response. The overall response rate was 5.6% (2 partial responses, 1 lasting for > 16 months). Disease control rate was 64%. Disease stabilization was seen in pts with mRNA overexpression across all FGFR subtypes and also in pts who failed prior lines of therapy, including anti-PD-L1. Molecular studies are ongoing to identify additional predictors of response to improve pt selection. Conclusions: Rogaratinib has a favorable safety and tolerability profile and clinical activity in pts with refractory FGFR1-3 tumor mRNA-positive NSCLC. It has potential for further exploration in combination with other agents. A clinical trial is currently enrolling FGFR mRNA-overexpressing pts with advanced and pre-treated sq NSCLC. Clinical trial information: NCT03762122', '在鳞状NSCLC中观察到FGFR基因扩增，可能是该类肿瘤患者的驱动基因突变，然而其在预测FGFR抑制剂临床活性方面的价值尚不清楚。研究人员根据NSCLC患者的FGFR1-3 mRNA表达水平对其进行rogaratinib治疗。rogaratinib是一种口服，有效的FGFR1-4小分子抑制剂。FGFR1-3 mRNA表达异常的难治性晚期NSCLC患者以连续21天为一个周期接受rogaratinib 800 mg BID。在第2、5、8周后，通过实体肿瘤的响应评估标准评估治疗效果。招募并治疗40个FGFR mRNA表达异常的NSCLC患者。患者对Rogaratinib耐受性良好，高磷血症(75%)，腹泻(53%)和食欲减退(35%)是最常见的不良事件。36个接受治疗的患者具有可评估的反应。总体反应率为5.6%，疾病控制率为64%。在所有FGFR亚型中，mRNA过表达患者皆实现了疾病稳定。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr e20661)', 'NCT03762122', 'clinical trial - phase2', '4', 'rogaratinib', 'rogaratinib', 'rogaratinib', 'rogaratinib', 'rogaratinib|rogaratinib', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001518', 'FGFR2:CNV:.:.:gain', 'FGFR2', 'CNV', 'CNV', '.', '.', 'gain', 'Background: FGFR1 gene amplifications are observed in squamous (sq) non-small cell lung cancer (NSCLC) and may suggest tractable oncogenic dependency. However, their value in predicting clinical activity of FGFR inhibitors is unclear. We explored tumor FGFR1-3 mRNA expression levels to select patients (pts) for treatment with rogaratinib, an oral, potent, small-molecule inhibitor of FGFR1-4. The first-in-human study of rogaratinib included pts with all NSCLC histologies. Methods: Pts with refractory advanced NSCLC were screened for elevated FGFR1-3 mRNA levels by RNA in situ hybridization (RNAscope) and NanoString assay in fresh or archival tumor samples, and FGFR1-3 overexpression was defined by pre-specified cut-offs. Pts received rogaratinib 800 mg BID on a continuous 21-day cycle. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors v1.1 after cycles 2, 5, and 8. Results: 260 NSCLC biopsies were screened for FGFR1-3 tumor mRNA expression; 244 (93.8%) were evaluable. FGFR1-3 mRNA overexpression was found in 47% of sq NSCLC, and only 14% of non-sq NSCLC, with FGFR3 being the most commonly overexpressed subtype. 40 FGFR mRNA-positive pts were enrolled and treated. Rogaratinib was well tolerated; hyperphosphatemia (75%), diarrhea (53%), and decreased appetite (35%) were the most frequent treatment-emergent adverse events. Events were mostly mild or moderate. 36 treated pts were evaluable for response. The overall response rate was 5.6% (2 partial responses, 1 lasting for > 16 months). Disease control rate was 64%. Disease stabilization was seen in pts with mRNA overexpression across all FGFR subtypes and also in pts who failed prior lines of therapy, including anti-PD-L1. Molecular studies are ongoing to identify additional predictors of response to improve pt selection. Conclusions: Rogaratinib has a favorable safety and tolerability profile and clinical activity in pts with refractory FGFR1-3 tumor mRNA-positive NSCLC. It has potential for further exploration in combination with other agents. A clinical trial is currently enrolling FGFR mRNA-overexpressing pts with advanced and pre-treated sq NSCLC. Clinical trial information: NCT03762122', '在鳞状NSCLC中观察到FGFR基因扩增，可能是该类肿瘤患者的驱动基因突变，然而其在预测FGFR抑制剂临床活性方面的价值尚不清楚。研究人员根据NSCLC患者的FGFR1-3 mRNA表达水平对其进行rogaratinib治疗。rogaratinib是一种口服，有效的FGFR1-4小分子抑制剂。FGFR1-3 mRNA表达异常的难治性晚期NSCLC患者以连续21天为一个周期接受rogaratinib 800 mg BID。在第2、5、8周后，通过实体肿瘤的响应评估标准评估治疗效果。招募并治疗40个FGFR mRNA表达异常的NSCLC患者。患者对Rogaratinib耐受性良好，高磷血症(75%)，腹泻(53%)和食欲减退(35%)是最常见的不良事件。36个接受治疗的患者具有可评估的反应。总体反应率为5.6%，疾病控制率为64%。在所有FGFR亚型中，mRNA过表达患者皆实现了疾病稳定。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr e20661)', 'NCT03762122', 'clinical trial - phase2', '4', 'rogaratinib', 'rogaratinib', 'rogaratinib', 'rogaratinib', 'rogaratinib|rogaratinib', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001519', 'FGFR3:CNV:.:.:gain', 'FGFR3', 'CNV', 'CNV', '.', '.', 'gain', 'Background: FGFR1 gene amplifications are observed in squamous (sq) non-small cell lung cancer (NSCLC) and may suggest tractable oncogenic dependency. However, their value in predicting clinical activity of FGFR inhibitors is unclear. We explored tumor FGFR1-3 mRNA expression levels to select patients (pts) for treatment with rogaratinib, an oral, potent, small-molecule inhibitor of FGFR1-4. The first-in-human study of rogaratinib included pts with all NSCLC histologies. Methods: Pts with refractory advanced NSCLC were screened for elevated FGFR1-3 mRNA levels by RNA in situ hybridization (RNAscope) and NanoString assay in fresh or archival tumor samples, and FGFR1-3 overexpression was defined by pre-specified cut-offs. Pts received rogaratinib 800 mg BID on a continuous 21-day cycle. Tumor response was assessed by Response Evaluation Criteria in Solid Tumors v1.1 after cycles 2, 5, and 8. Results: 260 NSCLC biopsies were screened for FGFR1-3 tumor mRNA expression; 244 (93.8%) were evaluable. FGFR1-3 mRNA overexpression was found in 47% of sq NSCLC, and only 14% of non-sq NSCLC, with FGFR3 being the most commonly overexpressed subtype. 40 FGFR mRNA-positive pts were enrolled and treated. Rogaratinib was well tolerated; hyperphosphatemia (75%), diarrhea (53%), and decreased appetite (35%) were the most frequent treatment-emergent adverse events. Events were mostly mild or moderate. 36 treated pts were evaluable for response. The overall response rate was 5.6% (2 partial responses, 1 lasting for > 16 months). Disease control rate was 64%. Disease stabilization was seen in pts with mRNA overexpression across all FGFR subtypes and also in pts who failed prior lines of therapy, including anti-PD-L1. Molecular studies are ongoing to identify additional predictors of response to improve pt selection. Conclusions: Rogaratinib has a favorable safety and tolerability profile and clinical activity in pts with refractory FGFR1-3 tumor mRNA-positive NSCLC. It has potential for further exploration in combination with other agents. A clinical trial is currently enrolling FGFR mRNA-overexpressing pts with advanced and pre-treated sq NSCLC. Clinical trial information: NCT03762122', '在鳞状NSCLC中观察到FGFR基因扩增，可能是该类肿瘤患者的驱动基因突变，然而其在预测FGFR抑制剂临床活性方面的价值尚不清楚。研究人员根据NSCLC患者的FGFR1-3 mRNA表达水平对其进行rogaratinib治疗。rogaratinib是一种口服，有效的FGFR1-4小分子抑制剂。FGFR1-3 mRNA表达异常的难治性晚期NSCLC患者以连续21天为一个周期接受rogaratinib 800 mg BID。在第2、5、8周后，通过实体肿瘤的响应评估标准评估治疗效果。招募并治疗40个FGFR mRNA表达异常的NSCLC患者。患者对Rogaratinib耐受性良好，高磷血症(75%)，腹泻(53%)和食欲减退(35%)是最常见的不良事件。36个接受治疗的患者具有可评估的反应。总体反应率为5.6%，疾病控制率为64%。在所有FGFR亚型中，mRNA过表达患者皆实现了疾病稳定。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27870574', 'NCT01004224', 'clinical trial - phase1', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '1', 'bladder/urothelial cancer', 'bladder/urothelial cancer', '膀胱癌', 'na', 'sensitivity', 'EVI_001520', 'FGFR3:nonsynonymous SNV:.:.:act', 'FGFR3', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项BGJ398临床试验中，8名携带FGFR3突变的膀胱/尿路上皮癌患者使用≥100mg治疗，DCR为75%；3名患者（37.5%）达到PR，3名患者有SD。5名患者（62.5%）肿瘤负荷减轻，3名SD患者中有2名接近PR的肿瘤测量值降低（27%至28%）。值得注意的是，一名患有125mg FGFR1扩增的膀胱癌的患者在治疗11天后在第1周期中迅速进展。', 'S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27870574', 'NCT01004224', 'clinical trial - phase1', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001521', 'FGFR1:CNV:.:.:gain', 'FGFR1', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项BGJ398（infigratinib）临床试验中，36例使用连续剂量 ≥100mg治疗的FGFR1扩增sqNSCLC（鳞状非小细胞肺癌）患者的疾病控制率为50%（DCR：PR + SD）； 4名患者（11.1%）达到PR（部分缓解）（100 mg [n = 1]，125 mg [n = 3，2名已确认]），14名患者SD。 在连续125 mg治疗的31名患者的子集中，12名患者继续接受治疗> 8周，其中一半患者继续接受治疗 ≥16周。在 ≥100mg治疗的36名患者中，有27名患者进行了靶病变评估； 其中，11例（40.7%）肿瘤负荷减轻。 应答者继续研究39.9-76.6周（确认PR）和26.3周（未经证实的PR）。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2017.35.15_suppl.e20664 ', 'NCT01004224', 'clinical trial - phase1', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001522', 'MLL2:nonsynonymous SNV:.:.:inact', 'MLL2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'Background: Fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell non-small cell lung cancer (sqNSCLC) has been described as potential oncogenic and targetable driver in cell lines and murine models. However, a phase I study evaluating FGFR 1-3 inhibitor BGJ398 showed moderate response rate of 11% in FGFR1amplified sgNSCLC treated with dose ≥ 100mg. To identify underlying mechanisms of resistance, we analyzed tumor tissues of selected patients. Methods: Within the phase I BGJ398 study, patients (pts) with FGFR1amplified sqNSCLC were treated orally with escalating dose (5 to 150mg) of BGJ398 once daily (QD) or 50mg twice a day. In the expansion phase, pts received BGJ398 either continuously QD or on a 3-weeks on/1-week off schedule. CT scans for response were performed every 8 weeks. Available tumor tissue of pts treated with BGJ398 at our center was analyzed using hybrid capture–based massively parallel sequencing (CAGE). Results: Twenty-one pts with FGFR1 amplified sqNSCLC were treated with ≥ 100mg BGJ398 at our site. As best response, 3 pts showed partial response (PR), 7 pts stable disease (SD) and 7 pts progressive disease (PD). Two pts withdrew their consents and 2 pts died ahead of first CT scan: one due to infection and one due to sudden death. We performed CAGE covering 256 genes on 9 patients: on 3 pts with PR, 2 pts with SD, 2 pts with PD and 2 pts who died before first CT scan. All analyzed patients harbored mutations in TP53. Additionally, we detected two CDKN2A (one patient with PR and one patient who died before first CT) and three MLL2 stop codon and frame shift mutations (two patients with SD and one patient with PD). Of interest, we identified three patients with two canonical (one patient with SD and one patient who died before first CT) and one non-canonical mutations in PIK3CA(one patient with SD). Conclusions: In our analysis, MLL2 and PIK3CA mutations seem to have a negative impact on response in FGFR1 amplified pts treated with BGJ398. Further analysis with higher patient number is needed to identify the role of MLL2 and PIK3CA mutations in FGFR1 amplified sqNSCLC. Clinical trial information: NCT01004224.', '通过细胞系和小鼠模型的研究发现，鳞状非小细胞肺癌(sqNSCLC)中的FGFR扩增被认为是潜在的致癌和靶向驱动因子。然而，FGFR1-3抑制剂BGJ398（infigratinib）的I期研究显示，在FGFR1扩增的NSCLC中，剂量≥100mg的BGJ398的中度反应率只有11%。为了确定潜在的耐药机制，研究人员分析了所选患者的肿瘤组织。在第一阶段研究中，对存在FGFR1扩增的sqNSCLC患者进行BGJ398口服治疗，50 mg每日一次(QD)或每天两次，逐渐增加剂量(5-150mg)。在剂量扩张阶段，患者接受BGJ398持续QD或执行3周/1周的休息时间表。每8周进行一次CT扫描。使用杂交捕获的大规模平行测序分析患者的肿瘤组织DNA。用≥100mg的BGJ398治疗了22例FGFR1扩增的sqNSCLC患者。3例显示部分反应(PR)，7例稳定疾病(SD)、7例进行性疾病(PD)。在第一次CT扫描之前，2名患者撤回了同意，2名患者死亡。研究人员对3例PR，2例SD，2例PD，2例首次CT扫描前死亡的患者进行了包含256个基因的测序，发现这些患者都存在TP53突变。另外，研究人员检测到两个CDKN2A突变(1名PR患者、一名死亡患者)和三个MLL2终止密码子和移码突变(两名SD患者、一名PD患者)，同时确定2名患者存在PIK3CA经典突变(1名SD患者、一名死亡患者)、一名患者存在PIK3CA非典型突变(一名SD患者)。MLL2和PIK3CA突变似乎对使用BGJ398治疗的携带FGFR1扩增的患者具有负面影响。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2017.35.15_suppl.e20664 ', 'NCT01004224', 'clinical trial - phase1', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001523', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'Background: Fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell non-small cell lung cancer (sqNSCLC) has been described as potential oncogenic and targetable driver in cell lines and murine models. However, a phase I study evaluating FGFR 1-3 inhibitor BGJ398 showed moderate response rate of 11% in FGFR1amplified sgNSCLC treated with dose ≥ 100mg. To identify underlying mechanisms of resistance, we analyzed tumor tissues of selected patients. Methods: Within the phase I BGJ398 study, patients (pts) with FGFR1amplified sqNSCLC were treated orally with escalating dose (5 to 150mg) of BGJ398 once daily (QD) or 50mg twice a day. In the expansion phase, pts received BGJ398 either continuously QD or on a 3-weeks on/1-week off schedule. CT scans for response were performed every 8 weeks. Available tumor tissue of pts treated with BGJ398 at our center was analyzed using hybrid capture–based massively parallel sequencing (CAGE). Results: Twenty-one pts with FGFR1 amplified sqNSCLC were treated with ≥ 100mg BGJ398 at our site. As best response, 3 pts showed partial response (PR), 7 pts stable disease (SD) and 7 pts progressive disease (PD). Two pts withdrew their consents and 2 pts died ahead of first CT scan: one due to infection and one due to sudden death. We performed CAGE covering 256 genes on 9 patients: on 3 pts with PR, 2 pts with SD, 2 pts with PD and 2 pts who died before first CT scan. All analyzed patients harbored mutations in TP53. Additionally, we detected two CDKN2A (one patient with PR and one patient who died before first CT) and three MLL2 stop codon and frame shift mutations (two patients with SD and one patient with PD). Of interest, we identified three patients with two canonical (one patient with SD and one patient who died before first CT) and one non-canonical mutations in PIK3CA(one patient with SD). Conclusions: In our analysis, MLL2 and PIK3CA mutations seem to have a negative impact on response in FGFR1 amplified pts treated with BGJ398. Further analysis with higher patient number is needed to identify the role of MLL2 and PIK3CA mutations in FGFR1 amplified sqNSCLC. Clinical trial information: NCT01004224.', '通过细胞系和小鼠模型的研究发现，鳞状非小细胞肺癌(sqNSCLC)中的FGFR扩增被认为是潜在的致癌和靶向驱动因子。然而，FGFR1-3抑制剂BGJ398（infigratinib）的I期研究显示，在FGFR1扩增的NSCLC中，剂量≥100mg的BGJ398的中度反应率只有11%。为了确定潜在的耐药机制，研究人员分析了所选患者的肿瘤组织。在第一阶段研究中，对存在FGFR1扩增的sqNSCLC患者进行BGJ398口服治疗，50 mg每日一次(QD)或每天两次，逐渐增加剂量(5-150mg)。在剂量扩张阶段，患者接受BGJ398持续QD或执行3周/1周的休息时间表。每8周进行一次CT扫描。使用杂交捕获的大规模平行测序分析患者的肿瘤组织DNA。用≥100mg的BGJ398治疗了22例FGFR1扩增的sqNSCLC患者。3例显示部分反应(PR)，7例稳定疾病(SD)、7例进行性疾病(PD)。在第一次CT扫描之前，2名患者撤回了同意，2名患者死亡。研究人员对3例PR，2例SD，2例PD，2例首次CT扫描前死亡的患者进行了包含256个基因的测序，发现这些患者都存在TP53突变。另外，研究人员检测到两个CDKN2A突变(1名PR患者、一名死亡患者)和三个MLL2终止密码子和移码突变(两名SD患者、一名PD患者)，同时确定2名患者存在PIK3CA经典突变(1名SD患者、一名死亡患者)、一名患者存在PIK3CA非典型突变(一名SD患者)。MLL2和PIK3CA突变似乎对使用BGJ398治疗的携带FGFR1扩增的患者具有负面影响。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29182496', 'NCT02150967', 'clinical trial - phase2', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '2', 'Cholangiocarcinoma', 'Cholangiocarcinoma', '胆管癌', 'na', 'sensitivity', 'EVI_001524', 'FGFR2:FUS:.:FGFR2-.:.', 'FGFR2', 'FUS', 'FUS', '.', 'FGFR2-.', '.', '.', '一项多中心，开放标签的II期临床试验（NCT02150967）评估了BGJ398（infigratinib）对≥18岁、晚期或转移性胆管癌患者的疗效。这些胆管癌患者携带FGFR2融合或其他FGFR改变。患者每天一次接受BGJ398 125mg，持续21天，然后休息7天（28天循环）。主要终点总体反应率。携带FGFR2融合（n = 48）、突变（n = 8）或扩增（n = 3）的61名患者（35名女性；中位年龄57岁）。在预先指定的数据截止日期（2016年6月30日），50名患者停止治疗。总反应率为14.8%（FGFR2融合类患者为18.8%），疾病控制率为75.4%（FGFR2融合类患者为83.3%），估计中位无进展生存期为5.8个月（95%CI，4.3至7.6个月）。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29182496', 'NCT02150967', 'clinical trial - phase2', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '2', 'Cholangiocarcinoma', 'Cholangiocarcinoma', '胆管癌', 'na', 'sensitivity', 'EVI_001525', 'FGFR2:nonsynonymous SNV:.:.:act', 'FGFR2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项多中心，开放标签的II期临床试验（NCT02150967）评估了BGJ398（infigratinib）对≥18岁、晚期或转移性胆管癌患者的疗效。这些胆管癌患者携带FGFR2融合或其他FGFR改变。患者每天一次接受BGJ398 125mg，持续21天，然后休息7天（28天循环）。主要终点总体反应率。携带FGFR2融合（n = 48）、突变（n = 8）或扩增（n = 3）的61名患者（35名女性；中位年龄57岁）。在预先指定的数据截止日期（2016年6月30日），50名患者停止治疗。总反应率为14.8%（FGFR2融合类患者为18.8%），疾病控制率为75.4%（FGFR2融合类患者为83.3%），估计中位无进展生存期为5.8个月（95%CI，4.3至7.6个月）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29182496', 'NCT02150967', 'clinical trial - phase2', '4', 'BGJ398', 'BGJ398', 'infigratinib', 'infigratinib', 'infigratinib|infigratinib', '2', 'Cholangiocarcinoma', 'Cholangiocarcinoma', '胆管癌', 'na', 'sensitivity', 'EVI_001526', 'FGFR2:CNV:.:.:gain', 'FGFR2', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项多中心，开放标签的II期临床试验（NCT02150967）评估了BGJ398（infigratinib）对≥18岁、晚期或转移性胆管癌患者的疗效。这些胆管癌患者携带FGFR2融合或其他FGFR改变。患者每天一次接受BGJ398 125mg，持续21天，然后休息7天（28天循环）。主要终点总体反应率。携带FGFR2融合（n = 48）、突变（n = 8）或扩增（n = 3）的61名患者（35名女性；中位年龄57岁）。在预先指定的数据截止日期（2016年6月30日），50名患者停止治疗。总反应率为14.8%（FGFR2融合类患者为18.8%），疾病控制率为75.4%（FGFR2融合类患者为83.3%），估计中位无进展生存期为5.8个月（95%CI，4.3至7.6个月）。', 'a', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29191595', 'NCT01858389', 'clinical trial - phase2', '4', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001529', 'EGFR:nonsynonymous SNV:exon20:p.T790M:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', '.', '一项临床试验评估了间歇性达克替尼在携带或不携带EGFR T790M的肺癌患者中的安全性，药代动力学和功效（NCT01858389）。达克替尼治疗38例患者；在队列A中有16名EGFR T790M，在队列B有22名患者未确定分子亚型。在队列A中16名患者中有一名患者对研究治疗有部分反应（ORR 6.3%，95%CI 0.2-30.2%）。队列A的中位无进展生存期（PFS）为2.3个月，队列B的中位PFS为1.6个月。不良事件概况与标准日剂量达克替尼类似，最常见的治疗相关毒性发生在> 20%的患者中，包括腹泻，皮疹，口腔炎，恶心，皮肤干燥，甲沟炎，疲劳和食欲下降。间歇性dacomitinib安全且耐受性相对较好，但对于携带EGFR T790M的患者或未选择的非小细胞肺癌患者无效。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:entrectinib_Revised: 8/2019', '.', 'guideline:FDA', '1', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '4', 'non-small cell lung cancer/solid tumors', 'non-small cell lung cancer/solid tumors', '肺癌', 'na', 'sensitivity', 'EVI_001530', 'ROS1:FUS:.:.-ROS1:.', 'ROS1', 'FUS', 'FUS', '.', '.-ROS1', '.', '.', 'FDA批准Entrectinib（Rozlytrek）用于治疗携带ROS1基因突变的转移性非小细胞肺癌患者（NSCLC）。临床试验结果表明[临床试验：ALKA,STARTRK-1 (NCT02097810) and STARTRK-2 (NCT02568267)]，在51名ROS1阳性NSCLC患者中，总缓解率达到78%，完全缓解率达到6%，部分缓解73%。在肿瘤缩小的40名患者中，55%患者的缓解持续时间（DOR）超过12个月。', 'F', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:entrectinib_Revised: 8/2019', '.', 'guideline:FDA', '1', 'Entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001531', 'NTRK1:FUS:.:.-NTRK1:.', 'NTRK1', 'FUS', 'FUS', '.', '.-NTRK1', '.', '.', '2019.8月FDA批准Entrectinib（Rozlytrek）用于NTRK基因融合的实体瘤，这一批准是基于多项临床试验的结果，其中包括名为STARTRK-2的关键性2期临床试验，名为STARTRK-1和ALKA-372-001的1期临床试验。对这些试验数据的汇总分析表明，在54名NTRK融合阳性实体瘤患者中，Rozlytrek达到57%的客观缓解率（ORR），45%患者的缓解持续时间（DOR）超过12个月。多达10种不同类型的实体瘤患者对这一疗法产生响应。在54名成年患者中，4名在基线时具有可测量的CNS转移，这4名患者中的3名中观察到颅内病变的反应。', 'F', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:entrectinib_Revised: 8/2019', '.', 'guideline:FDA', '1', 'Entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001532', 'NTRK2:FUS:.:.-NTRK2:.', 'NTRK2', 'FUS', 'FUS', '.', '.-NTRK2', '.', '.', '2019.8月FDA批准Entrectinib（Rozlytrek）用于NTRK基因融合的实体瘤，这一批准是基于多项临床试验的结果，其中包括名为STARTRK-2的关键性2期临床试验，名为STARTRK-1和ALKA-372-001的1期临床试验。对这些试验数据的汇总分析表明，在54名NTRK融合阳性实体瘤患者中，Rozlytrek达到57%的客观缓解率（ORR），45%患者的缓解持续时间（DOR）超过12个月。多达10种不同类型的实体瘤患者对这一疗法产生响应。在54名成年患者中，4名在基线时具有可测量的CNS转移，这4名患者中的3名中观察到颅内病变的反应。', 'F', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:entrectinib_Revised: 8/2019', '.', 'guideline:FDA', '1', 'Entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001533', 'NTRK3:FUS:.:.-NTRK3:.', 'NTRK3', 'FUS', 'FUS', '.', '.-NTRK3', '.', '.', '2019.8月FDA批准Entrectinib（Rozlytrek）用于NTRK基因融合的实体瘤，这一批准是基于多项临床试验的结果，其中包括名为STARTRK-2的关键性2期临床试验，名为STARTRK-1和ALKA-372-001的1期临床试验。对这些试验数据的汇总分析表明，在54名NTRK融合阳性实体瘤患者中，Rozlytrek达到57%的客观缓解率（ORR），45%患者的缓解持续时间（DOR）超过12个月。多达10种不同类型的实体瘤患者对这一疗法产生响应。在54名成年患者中，4名在基线时具有可测量的CNS转移，这4名患者中的3名中观察到颅内病变的反应。', 'F', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 10009)', 'NCT02650401', 'clinical trial - phase1', '4', 'Entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '4', 'neuroblastoma', 'neuroblastoma', '脑部肿瘤', 'na', 'sensitivity', 'EVI_001534', 'ALK:nonsynonymous SNV:exon23:p.F1174L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', '.', '在儿科和青少年患者中开展的Entrectinib剂量递增和扩展研究（NCT02650401），纳入了29例复发或难治性颅外肿瘤患者或原发性CNS肿瘤儿童患者，这些患者携带NTRK1/2/3、ROS1或ALK基因融合。结果显示6例颅外肿瘤患者（脑外实体瘤，包括3例炎性肌纤维母细胞瘤，2例婴儿纤维肉瘤、1例黑素瘤）中，有1例（DCTN1-ALK融合）完全应答，5例（TFG1-ROS1，EML4-NTRK3，KIF5B-ALK，ETV6-NTRK3融合）部分应答；5例CNS肿瘤中有1例（ETV6-NTRK3融合）完全应答，4例（TPR-NTRK1，EEF1G-ROS1，EML1-NTRK2，GOPC-ROS1融合）部分应答。另有1例神经母细胞瘤患者（ALK-F1174L突变）为完全反应。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:25937522|NCCN Guideline: Colon Cancer <2.2019>', 'NCT00125034', 'guideline:NCCN', '1', 'FOLFOX+cetuximab', 'FOLFOX+cetuximab', 'FOLFOX + cetuximab', 'FOLFOX + 西妥昔单抗', 'FOLFOX + cetuximab|FOLFOX + 西妥昔单抗', '4', 'metastatic adenocarcinoma of the colon or rectum', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'resistance', 'EVI_001535', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '重新分析来自OPUS研究的患者样本，在31/118（26%）可评估的患者中检测到其他RAS突变。在RAS野生型肿瘤（n = 87）的扩展分析中，通过向FOLFOX4添加西妥昔单抗显着改善客观反应（58%对29%;优势比3.33 [95%可信区间1.36-8.17]; P = 0.0084 ）。但是，在具有任何RAS突变的患者的群体中，明显的不利影响与向FOLFOX4添加西妥昔单抗相关。总之，RAS突变型mCRC患者，FOLFOX4联合西妥昔单抗不能使患者受益，可能还会产生有害影响。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:25937522|NCCN Guideline: Colon Cancer <2.2019>', 'NCT00125034', 'guideline:NCCN', '1', 'FOLFOX+cetuximab', 'FOLFOX+cetuximab', 'FOLFOX + cetuximab', 'FOLFOX + 西妥昔单抗', 'FOLFOX + cetuximab|FOLFOX + 西妥昔单抗', '4', 'metastatic adenocarcinoma of the colon or rectum', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'resistance', 'EVI_001536', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '重新分析来自OPUS研究的患者样本，在31/118（26%）可评估的患者中检测到其他RAS突变。在RAS野生型肿瘤（n = 87）的扩展分析中，通过向FOLFOX4添加西妥昔单抗显着改善客观反应（58%对29%;优势比3.33 [95%可信区间1.36-8.17]; P = 0.0084 ）。但是，在具有任何RAS突变的患者的群体中，明显的不利影响与向FOLFOX4添加西妥昔单抗相关。总之，RAS突变型mCRC患者，FOLFOX4联合西妥昔单抗不能使患者受益，可能还会产生有害影响。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:24024839|PMID:27843597|NCCN Guideline: Colon Cancer <2.2019>', 'NCT00364013', 'guideline:NCCN', '1', 'FOLFOX + panitumumab', 'FOLFOX + panitumumab', 'FOLFOX + panitumumab', 'FOLFOX + 帕尼单抗', 'FOLFOX + panitumumab|FOLFOX + 帕尼单抗', '4', 'metastatic adenocarcinoma of the colon or rectum', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'resistance', 'EVI_001537', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项III期临床试验中，512例无RAS突变的患者中，帕尼单抗-FOLFOX4的无进展生存期为10.1个月，单独使用FOLFOX4为7.9个月。帕尼单抗-FOLFOX4组总生存期为26.0个月，单独FOLFOX4组为20.2个月。 共有108名患者（17%）无KRAS exon2突变，但携带其他RAS基因激活突变。携带这些突变的患者，帕尼单抗-FOLFOX4联合治疗后患者的无进展生存期和总生存率低于野生型患者。在一项正对1183例转移性结直肠癌患者的随机临床III期试验中，患者接受帕尼单抗联合FOLFOX或单独FOLFOX治疗。经过治疗后，在携带KRAS突变的患者中，与FOLFOX组患者相比，帕尼单抗联合FOLFOX组患者具有缩短的总生存期（15 vs 19.2个月，P=0.14）以及无进展生存期（7.4 vs 9.2个月，P=0.02）。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:24024839|PMID:27843597|NCCN Guideline: Colon Cancer <2.2019>', 'NCT00364013', 'guideline:NCCN', '1', 'FOLFOX + panitumumab', 'FOLFOX + panitumumab', 'FOLFOX + panitumumab', 'FOLFOX + 帕尼单抗', 'FOLFOX + panitumumab|FOLFOX + 帕尼单抗', '4', 'metastatic adenocarcinoma of the colon or rectum', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'resistance', 'EVI_001538', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项III期临床试验中，512例无RAS突变的患者中，帕尼单抗-FOLFOX4的无进展生存期为10.1个月，单独使用FOLFOX4为7.9个月。帕尼单抗-FOLFOX4组总生存期为26.0个月，单独FOLFOX4组为20.2个月。 共有108名患者（17%）无KRAS exon2突变，但携带其他RAS基因激活突变。携带这些突变的患者，帕尼单抗-FOLFOX4联合治疗后患者的无进展生存期和总生存率低于野生型患者。在一项正对1183例转移性结直肠癌患者的随机临床III期试验中，患者接受帕尼单抗联合FOLFOX或单独FOLFOX治疗。经过治疗后，在携带KRAS突变的患者中，与FOLFOX组患者相比，帕尼单抗联合FOLFOX组患者具有缩短的总生存期（15 vs 19.2个月，P=0.14）以及无进展生存期（7.4 vs 9.2个月，P=0.02）。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('DOI: 10.1200/JCO.2018.36.15_suppl.9056 ', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001542', 'EGFR:nonsynonymous SNV:exon19:p.L747_A750delinsP:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747_A750delinsP', '.', '.', '一项关于EGFR突变的临床研究中，收录24例常见的E746_A750突变，4例L747_P753>S和L747_A750>P突变。erlotinib治疗后发现，L747_A750>P突变的患者比E746_A750和L747_P753>S突变的患者的PFS，DOT和OS较差。E746_A750和L747_P753> S组之间没有差异。具有L747_A750>P突变的四个患者中的两个显示出对厄洛替尼的原发性抗性，而E746_A750或L747_P753>S突变的患者都没有出现原发性抗性。本研究显示EGFR ex19 del肿瘤中EGFR定向治疗的临床结果可能不同，特别是当用厄洛替尼治疗时，与具有E746_A750或L747_P753>S的患者相比，具有ex19 del L747_A750>P的患者具有较差的结果。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:23082000', '.', 'preclinical', '4', 'AZD4547', 'AZD4547', 'AZD4547', 'AZD4547', 'AZD4547|AZD4547', '3', 'lung cancer ', 'lung cancer ', '肺癌', 'na', 'sensitivity', 'EVI_001543', 'FGFR1:CNV:.:.:gain', 'FGFR1', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项临床研究发现，FGFR1基因扩增在非小细胞肺鳞癌中的发生率为12.5%，在非小细胞肺腺癌中的发生率为7%。细胞实验中，AZD-4547对携带FGFR1扩增的肺癌细胞的半数生长抑制浓度为0.003-0.111 umol/L。在五种FGFR1扩增的鳞状NSCLC PDTX模型（肿瘤异种移植模型）中，AZD-4547可以诱导其中4个模型的肿瘤停滞或退化。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:21666749', '.', 'preclinical', '4', 'PD173074', 'PD173074', 'PD173074', 'PD173074', 'PD173074|PD173074', '0', 'lung cancer ', 'lung cancer ', '肺癌', 'na', 'sensitivity', 'EVI_001544', 'FGFR1:CNV:.:.:gain', 'FGFR1', 'CNV', 'CNV', '.', '.', 'gain', '.', '使用SNP阵列分析，一项研究发现含有三个基因（WhSC1L1，LETM2和FGFR1）的染色体区段8p11-12，在3%的肺腺癌和21%的鳞状细胞肺癌中存在扩增。 此外，该实验证明了携带FGFR1扩增的非小细胞肺癌细胞系的增殖依赖于FGFR1蛋白酶活性，因为用FGFR1特异性shRNA或FGFR小分子酶抑制剂（PD173074或FIIN-1）处理该细胞系会导致肿瘤细胞生长抑制。PD173074或FIN-1对携带FGFR1扩增的肿瘤细胞系NCI-H1581的半数抑制浓度分别为14 nM和2.5 nM。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:21666749', '.', 'preclinical', '4', 'FIIN-1', 'FIIN-1', 'FIIN-1', 'FIIN-1', 'FIIN-1|FIIN-1', '0', 'lung cancer ', 'lung cancer ', '肺癌', 'na', 'sensitivity', 'EVI_001545', 'FGFR1:CNV:.:.:gain', 'FGFR1', 'CNV', 'CNV', '.', '.', 'gain', '.', '使用SNP阵列分析，一项研究发现含有三个基因（WhSC1L1，LETM2和FGFR1）的染色体区段8p11-12，在3%的肺腺癌和21%的鳞状细胞肺癌中存在扩增。 此外，该实验证明了携带FGFR1扩增的非小细胞肺癌细胞系的增殖依赖于FGFR1蛋白酶活性，因为用FGFR1特异性shRNA或FGFR小分子酶抑制剂（PD173074或FIIN-1）处理该细胞系会导致肿瘤细胞生长抑制。PD173074或FIN-1对携带FGFR1扩增的肿瘤细胞系NCI-H1581的半数抑制浓度分别为14 nM和2.5 nM。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27581340', '.', 'preclinical', '4', 'nintedanib', 'nintedanib', 'nintedanib', '尼达尼布', 'nintedanib|尼达尼布', '4', 'lung squamous cell carcinoma', 'lung squamous cell carcinoma', '肺癌', 'na', 'sensitivity', 'EVI_001546', 'FGFR1:CNV:.:.:gain', 'FGFR1', 'CNV', 'CNV', '.', '.', 'gain', '.', 'FGFR基因改变在肺鳞状细胞癌（LSCC）中相对频繁，并且是FGFR抑制剂治疗的潜在靶标。血管激酶抑制剂nintedanib在非小细胞肺癌的临床试验中显示出有希望的活性。一项研究中，用NGS来检测LSCC患者的FGFR改变，并验证了nintedanib在FGFR1拷贝数增加（CNG）阳性的LSCC细胞系中的抗肿瘤活性。该研究共筛选了75个临床LSCC标本的FGFR改变。Nintedanib在体外和体内可以抑制FGFR1 CNG阳性LSCC细胞系的增殖，这与FGFR1-ERK信号传导途径的减弱有关。通过NGS检测发现，在LSCC标本，FGFR1 CNG（10.7%），FGFR1突变（2.7%），FGFR2突变（2.7%），FGFR4突变（5.3%）和FGFR3融合（1.3%）。 FGFR阳性或阴性的LSCC患者的临床病理特征无差异。然而，在36例手术后复发的患者中，对于携带FGFR改变的患者，预后明显更差。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:24356622|NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'FOLFIRI + panitumumab', 'FOLFIRI + panitumumab', 'FOLFIRI + panitumumab', 'FOLFIRI + 帕尼单抗', 'FOLFIRI + panitumumab|FOLFIRI + 帕尼单抗', '4', 'metastatic adenocarcinoma of the colon or rectum', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'resistance', 'EVI_001547', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '在一项正对1186例转移结直肠癌患者的随机III期临床试验中，患者接受帕尼单抗联合FOLFIRI或单独FOLFIRI治疗。经过治疗后，在携带KRAS突变的患者中，帕尼单抗联合FOLFIRI组与FOLFIRI组患者具有相似的无进展生存期（5.3 vs 5.4个月；P=0.56）以及总生存期（11.8 vs 11.1个月；P=0.48）。结果表明，携带KRAS突变的患者可能不会从帕尼单抗联合FOLFIRI治疗中获益。一项随机多中心III期临床试验中，转移性结直肠癌接受帕尼单抗联合FOLFIRI或FOLFIRI作为患者的二线治疗（NCT0039183）。在所有患者中，RAS突变率为85%。其中， 18%KRAS 2号外显子野生型的肿瘤患者携带其他RAS突变。患有RAS突变的患者不太可能从帕尼单抗中获益。在KRAS 2号外显子野生型但有其他RAS基因突变的患者中，帕尼单抗联合FOLFIRI与FOLFIRI治疗后PFS的风险比（HR）为0.89（95%CI，0.56-1.42; P = 0.63）。在任何RAS突变的患者中，帕尼单抗联合FOLFIRI与FOLFIRI治疗后PFS的HR为0.86（95%CI，0.71-1.05; P = 0.14）。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26341920|PMID:24356622|NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'FOLFIRI + panitumumab', 'FOLFIRI + panitumumab', 'FOLFIRI + panitumumab', 'FOLFIRI + 帕尼单抗', 'FOLFIRI + panitumumab|FOLFIRI + 帕尼单抗', '4', 'metastatic adenocarcinoma of the colon or rectum', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'resistance', 'EVI_001548', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '在一项正对1186例转移结直肠癌患者的随机III期临床试验中，患者接受帕尼单抗联合FOLFIRI或单独FOLFIRI治疗。经过治疗后，在携带KRAS突变的患者中，帕尼单抗联合FOLFIRI组与FOLFIRI组患者具有相似的无进展生存期（5.3 vs 5.4个月；P=0.56）以及总生存期（11.8 vs 11.1个月；P=0.48）。结果表明，携带KRAS突变的患者可能不会从帕尼单抗联合FOLFIRI治疗中获益。一项随机多中心III期临床试验中，转移性结直肠癌接受帕尼单抗联合FOLFIRI或FOLFIRI作为患者的二线治疗（NCT0039183）。在所有患者中，RAS突变率为85%。其中， 18%KRAS 2号外显子野生型的肿瘤患者携带其他RAS突变。患有RAS突变的患者不太可能从帕尼单抗中获益。在KRAS 2号外显子野生型但有其他RAS基因突变的患者中，帕尼单抗联合FOLFIRI与FOLFIRI治疗后PFS的风险比（HR）为0.89（95%CI，0.56-1.42; P = 0.63）。在任何RAS突变的患者中，帕尼单抗联合FOLFIRI与FOLFIRI治疗后PFS的HR为0.86（95%CI，0.71-1.05; P = 0.14）。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:25088940|NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'FOLFIRI + cetuximab', 'FOLFIRI + cetuximab', 'FOLFIRI + cetuximab', 'FOLFIRI + 西妥昔单抗', 'FOLFIRI + cetuximab|FOLFIRI + 西妥昔单抗', '4', 'metastatic adenocarcinoma of the colon or rectum', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'resistance', 'EVI_001549', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '在一项开放标签的随机III期临床试验中，592例晚期结直肠癌患者呗随机分为两组，分别接受FOLFIRI联合西妥昔单抗或贝伐单抗治疗。对于携带任何KRAS、NRAS突变的患者，接受西妥昔单抗联合疗法的无进展生存期显著短于贝伐单抗联合疗法（6.1 vs 12.2个月；P=0.004）。而对于RAS的野生型患者，接受两种疗法的无进展生存期没有显著差异（10.4 vs 10.2个月，P=0.54）。这些结果表明，西妥昔单抗不能使携带RAS突变的患者生存获益，且毒副作用较大。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:25088940|NCCN Guideline: Colon Cancer <2.2019>', '.', 'guideline:NCCN', '1', 'FOLFIRI + cetuximab', 'FOLFIRI + cetuximab', 'FOLFIRI + cetuximab', 'FOLFIRI + 西妥昔单抗', 'FOLFIRI + cetuximab|FOLFIRI + 西妥昔单抗', '4', 'metastatic adenocarcinoma of the colon or rectum', ' metastatic colorectal cancer ', '结直肠癌', 'na', 'resistance', 'EVI_001550', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '在一项开放标签的随机III期临床试验中，592例晚期结直肠癌患者呗随机分为两组，分别接受FOLFIRI联合西妥昔单抗或贝伐单抗治疗。对于携带任何KRAS、NRAS突变的患者，接受西妥昔单抗联合疗法的无进展生存期显著短于贝伐单抗联合疗法（6.1 vs 12.2个月；P=0.004）。而对于RAS的野生型患者，接受两种疗法的无进展生存期没有显著差异（10.4 vs 10.2个月，P=0.54）。这些结果表明，西妥昔单抗不能使携带RAS突变的患者生存获益，且毒副作用较大。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/1538-7445.AM2019-CT031', 'NCT02897479', 'clinical trial - phase2', '4', 'savolitinib', 'savolitinib', 'savolitinib', '沃利替尼', 'savolitinib|沃利替尼', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001551', 'MET:nonsynonymous SNV:.:.:skipping_mut', 'MET', 'nonsynonymous SNV', 'None_pos', '.', '.', 'skipping_mut', '.', 'Savolitinib是一种新型有效的高选择性MET抑制剂。一项开放标签、单臂多中心II期研究用于评估savolitinib对MET exon14 skip突变的肺部肉瘤样癌(PSC)或其他类型NSCLC中的功效和安全性。符合条件的患者为携带MET exon14 skip突变、患有不可切除或转移性PSC或其他类型的NSCLC患者。Savolitinib 600 mg口服，每日一次，直至疾病进展。主要终点是RECIST 1.1的客观响应率(ORR)。共49例患者确认存在MET exon14 skip，34例(14例PSC；20例其他)接受治疗，中位年龄为69岁，68%的患者为男性。17例患者未接受过治疗，13例患者接受过1次治疗，4例患者接受2次治疗。12名患者确认了部分反应(PR)；10人病情稳定；2人有疾病进展；由于早期停药，3例患者的疗效无法评估。初步数据显示，在具有MET exon14 skip的NSCLC患者中使用savolitinib具有良好的抗肿瘤活性和可接受的安全性。', 'S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9034)', 'NCT03386955', 'clinical trial - phase2', '4', 'BPI-7711', 'BPI-7711', 'BPI-7711', 'BPI-7711', 'BPI-7711|BPI-7711', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001552', 'EGFR:nonsynonymous SNV:exon20:p.T790M:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'Background: BPI-7711 is a 3rd generation irreversible EGFR-TKI that is selectively against EGFR TKI–sensitizing mutations and the T790M resistance mutations. We are conducting a phase I study to determine the safety and efficacy of BPI-7711 in patients with advanced or recurrent EGFRm+/T790M+ NSCLC. Methods: NSCLC patients who had documented disease progression after 1st/2nd generation EGFR-TKI treatment and with EGFRm+/T790M+ confirmed by central lab were enrolled in the multicenter trial (NCT03386955) into \"3+3\" dose escalation or expansion cohorts. BPI-7711 was orally administered at doses of 30~240 mg in capsules. Patients in dose-escalation cohorts firstly received a single dose of BPI-7711 followed by a 7-day pharmacokinetic (PK) evaluation period then received the same dose daily until disease progression or intolerable toxicity(ies) per CTCAE V4.03. Treatment efficacy per RECIST 1.1 was evaluated every 6 weeks since daily treatment commence. Once efficacy was observed in a dose, its expansion cohort was opened to enroll patients for daily treatment. Results: As of 23 December 2018, 82 patients (median age 55, 27 males, 55 females) were enrolled into 5 dose escalation cohorts (30/60/120/180/240 mg) and 4 dose expansion cohorts (30/60/120/180 mg). No DLT was observed and MTD was not reached. For all safety-evaluable patients, most common treatment emergent adverse events (TEAEs) (≥10%) were white blood cell count decreased (21.3%), neutrophil count decreased (17.3%), upper respiratory tract infection (17.3%), vomiting (12.0%) and diarrhea (10.7%), and all were Grade 1 or 2. Grade 3~4 TEAEs were occurred in 8.0% patients and 4.0% of them were treatment-related per investigators’ judgement. SAEs were reported in 4.0% of patients, and 1.3% were treatment-related. For all efficacy-evaluable patients, the overall ORR of all doses was 54.5% (30/55) including 1.8% CR and 52.7% PR. The disease control rate (DCR) was 96.4%. For patients in 120/180 mg cohorts, the ORR was 64.1% (25/39) and DCR was 97.4%. PK analyses showed BPI-7711 exposure increased in a dose-proportional manner from 30 to 180 mg after single and multiple doses. Conclusions: BPI-7711 was well tolerated and highly effective in acquired T790M+ NSCLC patients. Phase II trials are under preparation. ', 'BPI-7711是第3代不可逆EGFR-TKI,可选择性地抑制EGFR TKI敏感突变和T790M抗性突变。一项I期研究旨在确定BPI-7711对晚期或复发性EGFRm+/T790M+ NSCLC患者中的安全性和有效性。第1代/第2代EGFR-TKI治疗后的EGFRm+/T790M+ NSCLC患者进入\"3+3\"剂量递增或扩增队列。BPI-7711以30-240mg的剂量口服给药。剂量递增组中的患者首先接受单剂量的BPI-7711,经过7天的药代动力学(PK)评估期,然后每天接受相同的剂量直至疾病进展或出现不可耐受的毒性。每6周评估一次治疗效果。82名患者(中位年龄55岁,27名男性,55名女性)参加了5个剂量递增队列(30/60/120/180/240mg)和4个剂量扩展队列(30/60/120/180mg)。没有观察到DLT并且未达到MTD。所有进行疗效评估的患者的总体ORR为54.5%(30/55),包括1.8%CR和52.7%PR。疾病控制率(DCR)为96.4%。120/180mg队列的患者的ORR为64.1%(25/39),DCR为97.4%。BPI-7711对获得性T790M+ NSCLC患者具有良好的耐受性和高效性。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 9091)', 'NCT02330367', 'clinical trial - phase1', '4', 'abivertinib', 'abivertinib', 'abivertinib', 'abivertinib', 'abivertinib|abivertinib', '1', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001553', 'EGFR:nonsynonymous SNV:exon20:p.T790M:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'Background: Abivertinib (AC0010) is a potent, selective third-generation EGFR tyrosine kinase inhibitor (TKI) that demonstrated clinical efficacy and manageable adverse events (AEs) in the phase 1 portion of the study in Chinese patients with EGFR T790M+ NSCLC. Here we report the results from patients enrolled to the phase 2 portion of the study (NCT02330367). Methods: The study enrolled locally advanced or metastatic NSCLC patients who were ≥ 18 years, progressed with the prior EGFR-TKI therapy, and must have T790M+ in tumor based on the central laboratory test. All patients received the recommended phase 2 doses of 300 mg twice daily [BID]. Results: As of March 5, 2018, 227 patients received treatment, majority of patients had adenocarcinoma (n = 220, 97%) with the median age of 59 years, 65% (n = 148) patients were female, most patients were non-smoker (n = 171, 75%), ECOG performance status of 1 (n = 162, 71%). The median treatment duration was 21 week. The treatment-related adverse events (AEs) were reported for 96.9% (n = 220) patients, mostly of grade 1 or 2 severity. The most common drug-related grade 3/4 AE (≥2%) was ALT increase (7.0%), AST increase (4.8%), diarrhea (4.4%), interstitial lung disease (4.0%), neutrophil count decrease (3.5%), and there was no drug-related grade 5 AEs. Among 209 response evaluable patients, per investigator’s assessment, 90.0% (n = 188) patients had tumor size reduction, the objective response rate (Complete Response + Partial Response [PR]) was 50.2% (n = 105; 95% CI 43.3%, 57.2%); 37.8% (n = 79) had stable disease, and the disease control rate was 88% (95% CI 82.9%, 92.1%). The median duration of response and progression-free survival estimated by Kaplan-Meier was 7.5 months (95% CI 6.0, 9.2) and was 7.5 months (95% CI 6.0, 8.8), respectively. Conclusions: Abivertinib demonstrated the clinical efficacy with manageable side-effects in patients with EGFR T790M+ NSCLC. Therefore, abivertinib could be a suitable treatment for patients with EGFR T790+ disease who have progressed on an EGFR-TKI. Clinical trial information: NCTNCT02330367.', 'Abiv​​ertinib(AC0010)是一种有效的第三代选择性EGFR酪氨酸激酶抑制剂(TKI),在中国EGFR T790M+ NSCLC患者的第1阶段研究中证实了其临床疗效和不良事件(AEs)。研究人员报告了参加第2阶段研究的部分患者的结果(NCT02330367)。该研究纳入了局部晚期或转移性NSCLC患者,年龄≥18岁,先前曾接受EGFR-TKI治疗,根据中心实验室检查确定肿瘤为T790M+。所有患者均接受abivertinib推荐的2期剂量300 mg,每日两次[BID]。截至2018年3月5日,227名患者接受了治疗,大多数患者患有腺癌,中位年龄为59岁,65%患者为女性,大多数患者为非吸烟患者,ECOG表现状态为1,中位治疗持续时间为21周。在209名应答的可评估患者中,90.0%患者的肿瘤减小,客观反应率为50.2%,37.8%病情稳定,疾病控制率为88%。Kaplan-Meier估计的中位反应持续时间和无进展生存期分别为7.5个月和7.5个月。Abiv​​ertinib在EGFR T790M+ NSCLC患者中表现出临床疗效和可控的副作用。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26712084|PMID:27765535|MID:29270615|PMID:29874546|NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', 'NCT02879994', 'guideline:NCCN', '1', 'pembrolizumab', '.', 'pembrolizumab', '帕博利珠单抗', 'pembrolizumab|帕博利珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001555', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', 'We conducted a phase II trial (NCT02879994) of pembrolizumab in TKI naive patients with EGFR mutation positive, advanced NSCLC and PD-L1 positive (≥1%, 22C3 antibody) tumors. Enrollment was ceased due to lack of efficacy after 11 of 25 planned patients were treated. 82% of trial patients were treatment naïve, 64% had sensitizing EGFR mutations, and 73% had PD-L1 expression ≥50%. Only 1 patient had an objective response (ORR: 9%), but repeat analysis of this patient’s tumor definitively showed the original report of an EGFR mutation to be erroneous. Observed treatment related adverse events were similar to prior experience with pembrolizumab, but two deaths within 6 months of enrollment, including one attributed to pneumonitis, were of concern. In summary, immature data suggests EGFR TKI efficacy is similar whether given before or after pembrolizumab. However, the lack of an objective response in 10 PD-L1 positive, EGFR-mutant patients, inclusive of 7 with PD-L1 expression >50%, was sobering. Further, the occurrence of one lifelong pembrolizumab associated adverse event, adrenal insufficiency, and the potential contribution of pembrolizumab to a case of fatal pneumonitis that occurred during subsequent TKI therapy, raise significant concern regarding this sequencing of therapies. Without greater ability to select appropriate patients, even among patients with EGFR mutations and PD-L1 expression of ≥50%, pembrolizumab is not an appropriate therapy prior to an EGFR TKI in patients with sensitizing EGFR mutations.', '一项pembrolizumab的II期试验(NCT02879994)显示，针对EGFR突变阳性且PD-L1阳性(≥1%，22C3抗体)的晚期NSCLC患者，无论是在pembrolizumab使用之前还是之后，EGFR TKI的疗效都是相似的。另外，在25例入组患者中，10例PD-L1阳性且EGFR突变（包括Exon 19del, Exon 20ins, p.L858R）的患者缺乏客观反应，包括7例PD-L1表达>50%的患者。此外，pembrolizumab相关不良事件的发生，肾上腺皮质功能不全，以及pembrolizumab对随后TKI治疗期间发生的致命性肺炎病例的潜在贡献，引起了对这两类药物治疗顺序的强烈关注。因此，在EGFR突变且PD-L1表达≥50%（22C3抗体）的患者中，pembrolizumab不是EGFR突变患者的合适治疗方案。KEYNOTE 010临床试验证明pembrolizumab可以延长PD-L1阳性非小细胞肺癌的OS，但是其中86名EGFR突变患者的亚组分析也显示无法从pembrolizumab治疗中获益。一项汇总分析包括了三项临床研究（checkmate 057, keynote 010, and POPLAR），证实了免疫检查点抑制剂不能增强EGFR突变患者的OS。另一项汇总的分析涵盖了五项临床试验（Checkmate 017，Checkmate 057，Keynote 010，OAK和POPLAR），证实免疫抑制剂可以在EGFR野生型亚组中观察到OS的延长，但在EGFR突变亚组中没有观察到。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26712084|PMID:27765535|MID:29270615|PMID:29874546|NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', 'NCT02879994', 'guideline:NCCN', '1', 'pembrolizumab', '.', 'pembrolizumab', '帕博利珠单抗', 'pembrolizumab|帕博利珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001556', 'EGFR:nonsynonymous SNV:exon21:p.L858R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', 'We conducted a phase II trial (NCT02879994) of pembrolizumab in TKI naive patients with EGFR mutation positive, advanced NSCLC and PD-L1 positive (≥1%, 22C3 antibody) tumors. Enrollment was ceased due to lack of efficacy after 11 of 25 planned patients were treated. 82% of trial patients were treatment naïve, 64% had sensitizing EGFR mutations, and 73% had PD-L1 expression ≥50%. Only 1 patient had an objective response (ORR: 9%), but repeat analysis of this patient’s tumor definitively showed the original report of an EGFR mutation to be erroneous. Observed treatment related adverse events were similar to prior experience with pembrolizumab, but two deaths within 6 months of enrollment, including one attributed to pneumonitis, were of concern. In summary, immature data suggests EGFR TKI efficacy is similar whether given before or after pembrolizumab. However, the lack of an objective response in 10 PD-L1 positive, EGFR-mutant patients, inclusive of 7 with PD-L1 expression >50%, was sobering. Further, the occurrence of one lifelong pembrolizumab associated adverse event, adrenal insufficiency, and the potential contribution of pembrolizumab to a case of fatal pneumonitis that occurred during subsequent TKI therapy, raise significant concern regarding this sequencing of therapies. Without greater ability to select appropriate patients, even among patients with EGFR mutations and PD-L1 expression of ≥50%, pembrolizumab is not an appropriate therapy prior to an EGFR TKI in patients with sensitizing EGFR mutations.', '一项pembrolizumab的II期试验(NCT02879994)显示，针对EGFR突变阳性且PD-L1阳性(≥1%，22C3抗体)的晚期NSCLC患者，无论是在pembrolizumab使用之前还是之后，EGFR TKI的疗效都是相似的。另外，在25例入组患者中，10例PD-L1阳性且EGFR突变（包括Exon 19del, Exon 20ins, p.L858R）的患者缺乏客观反应，包括7例PD-L1表达>50%的患者。此外，pembrolizumab相关不良事件的发生，肾上腺皮质功能不全，以及pembrolizumab对随后TKI治疗期间发生的致命性肺炎病例的潜在贡献，引起了对这两类药物治疗顺序的强烈关注。因此，在EGFR突变且PD-L1表达≥50%（22C3抗体）的患者中，pembrolizumab不是EGFR突变患者的合适治疗方案。KEYNOTE 010临床试验证明pembrolizumab可以延长PD-L1阳性非小细胞肺癌的OS，但是其中86名EGFR突变患者的亚组分析也显示无法从pembrolizumab治疗中获益。一项汇总分析包括了三项临床研究（checkmate 057, keynote 010, and POPLAR），证实了免疫检查点抑制剂不能增强EGFR突变患者的OS。另一项汇总的分析涵盖了五项临床试验（Checkmate 017，Checkmate 057，Keynote 010，OAK和POPLAR），证实免疫抑制剂可以在EGFR野生型亚组中观察到OS的延长，但在EGFR突变亚组中没有观察到。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26712084|PMID:27765535|MID:29270615|PMID:29874546|NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', 'NCT02879994', 'guideline:NCCN', '1', 'pembrolizumab', '.', 'pembrolizumab', '帕博利珠单抗', 'pembrolizumab|帕博利珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001557', 'EGFR:nonframeshift insertion:exon20:.:exon20ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon20', '.', 'exon20ins', 'We conducted a phase II trial (NCT02879994) of pembrolizumab in TKI naive patients with EGFR mutation positive, advanced NSCLC and PD-L1 positive (≥1%, 22C3 antibody) tumors. Enrollment was ceased due to lack of efficacy after 11 of 25 planned patients were treated. 82% of trial patients were treatment naïve, 64% had sensitizing EGFR mutations, and 73% had PD-L1 expression ≥50%. Only 1 patient had an objective response (ORR: 9%), but repeat analysis of this patient’s tumor definitively showed the original report of an EGFR mutation to be erroneous. Observed treatment related adverse events were similar to prior experience with pembrolizumab, but two deaths within 6 months of enrollment, including one attributed to pneumonitis, were of concern. In summary, immature data suggests EGFR TKI efficacy is similar whether given before or after pembrolizumab. However, the lack of an objective response in 10 PD-L1 positive, EGFR-mutant patients, inclusive of 7 with PD-L1 expression >50%, was sobering. Further, the occurrence of one lifelong pembrolizumab associated adverse event, adrenal insufficiency, and the potential contribution of pembrolizumab to a case of fatal pneumonitis that occurred during subsequent TKI therapy, raise significant concern regarding this sequencing of therapies. Without greater ability to select appropriate patients, even among patients with EGFR mutations and PD-L1 expression of ≥50%, pembrolizumab is not an appropriate therapy prior to an EGFR TKI in patients with sensitizing EGFR mutations.', '一项pembrolizumab的II期试验(NCT02879994)显示，针对EGFR突变阳性且PD-L1阳性(≥1%，22C3抗体)的晚期NSCLC患者，无论是在pembrolizumab使用之前还是之后，EGFR TKI的疗效都是相似的。另外，在25例入组患者中，10例PD-L1阳性且EGFR突变（包括Exon 19del, Exon 20ins, p.L858R）的患者缺乏客观反应，包括7例PD-L1表达>50%的患者。此外，pembrolizumab相关不良事件的发生，肾上腺皮质功能不全，以及pembrolizumab对随后TKI治疗期间发生的致命性肺炎病例的潜在贡献，引起了对这两类药物治疗顺序的强烈关注。因此，在EGFR突变且PD-L1表达≥50%（22C3抗体）的患者中，pembrolizumab不是EGFR突变患者的合适治疗方案。KEYNOTE 010临床试验证明pembrolizumab可以延长PD-L1阳性非小细胞肺癌的OS，但是其中86名EGFR突变患者的亚组分析也显示无法从pembrolizumab治疗中获益。一项汇总分析包括了三项临床研究（checkmate 057, keynote 010, and POPLAR），证实了免疫检查点抑制剂不能增强EGFR突变患者的OS。另一项汇总的分析涵盖了五项临床试验（Checkmate 017，Checkmate 057，Keynote 010，OAK和POPLAR），证实免疫抑制剂可以在EGFR野生型亚组中观察到OS的延长，但在EGFR突变亚组中没有观察到。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31417310|PMID:30798634|PMID:27780855', '.', 'clinical study', '4', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'NSCLC', 'NSCLC', '肺癌', 'na', 'resistance', 'EVI_001558', 'TP53:nonsynonymous SNV:.:.:nondisruptive', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'nondisruptive', '.', '一项临床研究中，104例患者接受了gefitinib治疗，27例接受了erlotinib治疗，3例接受了afatinib治疗，2例接受了dacomitinib治疗。相对于TKI治疗，TP53突变的存在与较低的DCR显着相关。具有TP53突变的患者的疾病进展风险是TP53 野生型患者的3倍(P = 0.019)。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31417310|PMID:30798634|PMID:27780855', '.', 'clinical study', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'NSCLC', 'NSCLC', '肺癌', 'na', 'resistance', 'EVI_001559', 'TP53:nonsynonymous SNV:.:.:nondisruptive', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'nondisruptive', '.', '在一项163例中国晚期NSCLC患者中，77例被确定为EGFR突变（47.2%）。 六名未接受TKI治疗的患者被排除在外。在其余71例EGFR基因改变患者中，TP53致病突变的频率为60.6%（43/71）。 在对TP53突变情况分析中，TP53突变型患者的中位PFS（mPFS）（6.5对14.0个月，P = 0.025）和中位OS（mOS）（28.0对52.0个月，P = 0.023）显著缩短。 TP53突变患者的总体DCR和ORR均低于TP53野生型患者（DCR：76.7%对89.3%，P = 0.160; ORR：25%对28%，P = 0.374）。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31417310|PMID:30798634|PMID:27780855', '.', 'clinical study', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'NSCLC', 'NSCLC', '肺癌', 'na', 'resistance', 'EVI_001560', 'TP53:nonsynonymous SNV:.:.:nondisruptive', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'nondisruptive', '.', '在一项163例中国晚期NSCLC患者中，77例被确定为EGFR突变（47.2%）。 六名未接受TKI治疗的患者被排除在外。在其余71例EGFR基因改变患者中，TP53致病突变的频率为60.6%（43/71）。 在对TP53突变情况分析中，TP53突变型患者的中位PFS（mPFS）（6.5对14.0个月，P = 0.025）和中位OS（mOS）（28.0对52.0个月，P = 0.023）显著缩短。 TP53突变患者的总体DCR和ORR均低于TP53野生型患者（DCR：76.7%对89.3%，P = 0.160; ORR：25%对28%，P = 0.374）。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31417310|PMID:30798634|PMID:27780855', '.', 'clinical study', '4', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'NSCLC', 'NSCLC', '肺癌', 'na', 'resistance', 'EVI_001561', 'TP53:nonsynonymous SNV:.:.:nondisruptive', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'nondisruptive', '.', '在一项163例中国晚期NSCLC患者中，77例被确定为EGFR突变（47.2%）。 六名未接受TKI治疗的患者被排除在外。在其余71例EGFR基因改变患者中，TP53致病突变的频率为60.6%（43/71）。 在对TP53突变情况分析中，TP53突变型患者的中位PFS（mPFS）（6.5对14.0个月，P = 0.025）和中位OS（mOS）（28.0对52.0个月，P = 0.023）显著缩短。 TP53突变患者的总体DCR和ORR均低于TP53野生型患者（DCR：76.7%对89.3%，P = 0.160; ORR：25%对28%，P = 0.374）。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31417310|PMID:30798634|PMID:27780855', '.', 'clinical study', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'NSCLC', 'NSCLC', '肺癌', 'na', 'resistance', 'EVI_001562', 'TP53:nonsynonymous SNV:.:.:nondisruptive', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'nondisruptive', '.', '一项临床研究中，104例患者接受了gefitinib治疗，27例接受了erlotinib治疗，3例接受了afatinib治疗，2例接受了dacomitinib治疗。相对于TKI治疗，TP53突变的存在与较低的DCR显着相关。具有TP53突变的患者的疾病进展风险是TP53 野生型患者的3倍(P = 0.019)。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30843662', '.', 'clinical study', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001563', 'TP53:nonsynonymous SNV:.:.:nondisruptive', 'TP53', 'nonsynonymous SNV', 'None_pos', '.', '.', 'nondisruptive', '.', '在64名ALK重排患者中，15名（23.4%）患者显示出TP53突变。 其中，6例具有破坏性突变（disruptive mutations），9例具有非破坏性突变（nondisruptive mutations）。TP53突变患者的客观缓解率（ORR）和疾病控制率（DCR）均显著低于TP53野生型患者（分别为p = 0.003和0.023）。与TP53野生型患者相比，TP53突变患者的无进展生存期（PFS）显着缩短（p = 0.045）。与ALK重排患者中的破坏性TP53突变相比，无破坏性TP53突变与较短的PFS相关（p = 0.069）。TP53突变降低肿瘤患者对TKI的反应并恶化EGFR突变患者的预后，特别是对于具有TP53非错义突变和非破坏性突变的患者，以及外显子6，外显子7和非DBD区域的突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('EMSO 2019 LBA10', 'NCT02989857', 'clinical trial - phase3', '4', 'ivosidenib', 'ivosidenib', 'ivosidenib', 'ivosidenib', 'ivosidenib|ivosidenib', '1', 'advanced cholangiocarcinoma', 'advanced cholangiocarcinoma', '胆管癌', 'na', 'sensitivity', 'EVI_001565', 'IDH1:nonsynonymous SNV:.:.:act', 'IDH1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', 'ClarIDHy研究由来自美国、英国、西班牙等多家肿瘤中心共同参与，研究者将mIDH1晚期胆管癌患者以2:1随机分组为IVO（500 mg qd）或匹配安慰剂（PBO），并根据之前的全身治疗的次数进行分层(1或2）。关键入组条件包括：不可切除或转移性胆管癌、PS 0-1、病灶可测量(RECIST v1.1）。影像学进展的患者可由PBO转向IVO。主要研究终点为独立影像中心（IRC）评估的PFS。次要终点包括安全性、客观缓解率（ORR）、PFS(研究者评估）和OS(ITT）。设定HR为0.5。截至2019年1月31日，185名患者被随机分到IVO组（n=124）或PBO组（n=61）。中位年龄62岁，M/F 68/117，91%为肝内胆管癌，92%为转移性疾病，43%曾接受过2次治疗。主要终点(IRC评估的PFS）达到预定目标：HR 0.37（95% CI 0.25-0.54，p<0.001）；IVO组和PBO组的中位PFS分别为2.7个月和1.4个月。IVO组6个月和12个月PFS率分别为32.0%、21.9%，PBO患者尚无患者PFS超过6个月。IVO组的ORR为2.4%，其中3例部分缓解（PR）；63例（50.8%）患者疾病稳定（SD）。PBO组ORR为0%，17例（27.9%）为SD。IVO组中位OS为10.8个月，稍高于PBO组的9.7个月（HR 0.69，单侧p=0.06）。PBO组57%的患者转入IVO组。交叉调整后PBO组的中位OS为6个月（HR 0.46，p=0.0008），PFS（研究者评估）HR=0.47（p<0.001）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFOX + bevacizumab', 'FOLFOX + 贝伐珠单抗', 'FOLFOX + bevacizumab|FOLFOX + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001566', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFIRI + bevacizumab', 'FOLFIRI + 贝伐珠单抗', 'FOLFIRI + bevacizumab|FOLFIRI + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001567', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'CapeOx + bevacizumab', 'CapeOx + 贝伐珠单抗', 'CapeOx + bevacizumab|CapeOx + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001568', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFOX + bevacizumab', 'FOLFOX + 贝伐珠单抗', 'FOLFOX + bevacizumab|FOLFOX + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001569', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'CapeOx + bevacizumab', 'CapeOx + 贝伐珠单抗', 'CapeOx + bevacizumab|CapeOx + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001570', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFIRI + bevacizumab', 'FOLFIRI + 贝伐珠单抗', 'FOLFIRI + bevacizumab|FOLFIRI + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001571', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFOXIRI + bevacizumab', 'FOLFOXIRI + 贝伐珠单抗', 'FOLFOXIRI + bevacizumab|FOLFOXIRI + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001572', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFOX + bevacizumab', 'FOLFOX + 贝伐珠单抗', 'FOLFOX + bevacizumab|FOLFOX + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001573', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'CapeOx + bevacizumab', 'CapeOx + 贝伐珠单抗', 'CapeOx + bevacizumab|CapeOx + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001574', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFIRI + bevacizumab', 'FOLFIRI + 贝伐珠单抗', 'FOLFIRI + bevacizumab|FOLFIRI + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001575', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFOXIRI + bevacizumab', 'FOLFOXIRI + 贝伐珠单抗', 'FOLFOXIRI + bevacizumab|FOLFOXIRI + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001576', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFOX + bevacizumab', 'FOLFOX + 贝伐珠单抗', 'FOLFOX + bevacizumab|FOLFOX + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001577', 'BRAF:nonsynonymous SNV:.:.:act', 'BRAF', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'CapeOx + bevacizumab', 'CapeOx + 贝伐珠单抗', 'CapeOx + bevacizumab|CapeOx + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001578', 'BRAF:nonsynonymous SNV:.:.:act', 'BRAF', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFIRI + bevacizumab', 'FOLFIRI + 贝伐珠单抗', 'FOLFIRI + bevacizumab|FOLFIRI + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001579', 'BRAF:nonsynonymous SNV:.:.:act', 'BRAF', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFOXIRI + bevacizumab', 'FOLFOXIRI + 贝伐珠单抗', 'FOLFOXIRI + bevacizumab|FOLFOXIRI + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001580', 'BRAF:nonsynonymous SNV:.:.:act', 'BRAF', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）|PMID:29946728', '.', 'guideline:CSCO', '1', '.', '.', 'fruquintinib', '呋喹替尼', 'fruquintinib|呋喹替尼', '4', 'metastatic colorectal cancer ', 'metastatic colorectal cancer ', '结直肠癌', 'na', 'sensitivity', 'EVI_001581', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '目前，中国临床肿瘤学会（CSCO）以1A类证据推荐已接受过奥沙利铂和伊立替康治疗的RAS或BRAF突变型结直肠癌可行呋喹替尼治疗。主要临床证据为FRESCO研究。试验设计：对2线或以上标准化疗失败的转移性结直肠癌患者进入筛选，筛选人数519例，随机人数416例，以2:1随机入组：呋喹替尼+BSC,5mg qd,服用3周停1周（4周为一疗程），N=278；安慰剂+BSC，N=138。治疗直至疾病进展、毒性不能耐受或者撤回知情同意。这是一项随机、双盲、安慰剂对照、全国多中心的III期临床研究，随机分层因素包括既往抗VEGF使用情况，以及患者K-Ras基因状态。结果：总生存期OS：9.30 vs. 6.57m (HR=0.65，P<0.001)；无进展生存期PFS: 3.71 vs. 1.84m (HR=0.65，P<0.001)；肿瘤客观反应率ORR: 4.7% vs.0 (P=0.012)；疾病控制率DCR：62.2% vs.12.3%（P<0.001）。预设的所有亚组分析均提示，OS和PFS皆倾向于呋喹替尼组获益：既往无论是否接受过抗VEGF或抗EGFR治疗，呋喹替尼组均能显著获益；既往没有接受过抗VEGF的人群中，呋喹替尼的mOS可延长至10.4个月；既往没有接受过抗VEGF的人群，呋喹替尼的死亡风险降低32%；K-RAS野生型的人群中，呋喹替尼的mOS可延长至10.7个月，较安慰剂组延长近5个月；K-RAS突变的人群中，呋喹替尼的死亡风险降低25%。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）|PMID:29946728', '.', 'guideline:CSCO', '1', '.', '.', 'fruquintinib', '呋喹替尼', 'fruquintinib|呋喹替尼', '4', 'metastatic colorectal cancer ', 'metastatic colorectal cancer ', '结直肠癌', 'na', 'sensitivity', 'EVI_001582', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '目前，中国临床肿瘤学会（CSCO）以1A类证据推荐已接受过奥沙利铂和伊立替康治疗的RAS或BRAF突变型结直肠癌可行呋喹替尼治疗。主要临床证据为FRESCO研究。试验设计：对2线或以上标准化疗失败的转移性结直肠癌患者进入筛选，筛选人数519例，随机人数416例，以2:1随机入组：呋喹替尼+BSC,5mg qd,服用3周停1周（4周为一疗程），N=278；安慰剂+BSC，N=138。治疗直至疾病进展、毒性不能耐受或者撤回知情同意。这是一项随机、双盲、安慰剂对照、全国多中心的III期临床研究，随机分层因素包括既往抗VEGF使用情况，以及患者K-Ras基因状态。结果：总生存期OS：9.30 vs. 6.57m (HR=0.65，P<0.001)；无进展生存期PFS: 3.71 vs. 1.84m (HR=0.65，P<0.001)；肿瘤客观反应率ORR: 4.7% vs.0 (P=0.012)；疾病控制率DCR：62.2% vs.12.3%（P<0.001）。预设的所有亚组分析均提示，OS和PFS皆倾向于呋喹替尼组获益：既往无论是否接受过抗VEGF或抗EGFR治疗，呋喹替尼组均能显著获益；既往没有接受过抗VEGF的人群中，呋喹替尼的mOS可延长至10.4个月；既往没有接受过抗VEGF的人群，呋喹替尼的死亡风险降低32%；K-RAS野生型的人群中，呋喹替尼的mOS可延长至10.7个月，较安慰剂组延长近5个月；K-RAS突变的人群中，呋喹替尼的死亡风险降低25%。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）|PMID:29946728', '.', 'guideline:CSCO', '1', '.', '.', 'fruquintinib', '呋喹替尼', 'fruquintinib|呋喹替尼', '4', 'metastatic colorectal cancer ', 'metastatic colorectal cancer ', '结直肠癌', 'na', 'sensitivity', 'EVI_001583', 'BRAF:nonsynonymous SNV:.:.:act', 'BRAF', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '目前，中国临床肿瘤学会（CSCO）以1A类证据推荐已接受过奥沙利铂和伊立替康治疗的RAS或BRAF突变型结直肠癌可行呋喹替尼治疗。主要临床证据为FRESCO研究。试验设计：对2线或以上标准化疗失败的转移性结直肠癌患者进入筛选，筛选人数519例，随机人数416例，以2:1随机入组：呋喹替尼+BSC,5mg qd,服用3周停1周（4周为一疗程），N=278；安慰剂+BSC，N=138。治疗直至疾病进展、毒性不能耐受或者撤回知情同意。这是一项随机、双盲、安慰剂对照、全国多中心的III期临床研究，随机分层因素包括既往抗VEGF使用情况，以及患者K-Ras基因状态。结果：总生存期OS：9.30 vs. 6.57m (HR=0.65，P<0.001)；无进展生存期PFS: 3.71 vs. 1.84m (HR=0.65，P<0.001)；肿瘤客观反应率ORR: 4.7% vs.0 (P=0.012)；疾病控制率DCR：62.2% vs.12.3%（P<0.001）。预设的所有亚组分析均提示，OS和PFS皆倾向于呋喹替尼组获益：既往无论是否接受过抗VEGF或抗EGFR治疗，呋喹替尼组均能显著获益；既往没有接受过抗VEGF的人群中，呋喹替尼的mOS可延长至10.4个月；既往没有接受过抗VEGF的人群，呋喹替尼的死亡风险降低32%；K-RAS野生型的人群中，呋喹替尼的mOS可延长至10.7个月，较安慰剂组延长近5个月；K-RAS突变的人群中，呋喹替尼的死亡风险降低25%。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30449794|PMID:20979472|NCCN Guideline: Soft Tissue Sarcoma <4.2019>', 'NCT00585195', 'guideline:NCCN', '1', 'ceritinib', 'ceritinib', 'ceritinib', '塞瑞替尼', 'ceritinib|塞瑞替尼', '4', 'Inflammatory Myofibroblastic Tumor', '.', '炎性肌纤维母细胞瘤', '[ALK:FUS]', 'sensitivity', 'EVI_001584', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '一名37岁炎性肌纤维母细胞瘤的女性患者，手术完全切除后肿瘤复发。基因检测发现其携带ALK融合基因突变，使用crizotinib治疗导致后获得完全缓解。在另一项临床试验中，一名携带ALK基因融合的炎性肌纤维母细胞瘤患者使用crizotinib治疗后获得部分缓解。NCCN指南目前也推荐携带ALK基因突变炎性肌纤维母细胞瘤（Inflammatory myofibroblastic tumor）的患者可以考虑使用crizotinb或ceritinib进行治疗。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30449794|PMID:20979472|NCCN Guideline: Soft Tissue Sarcoma <4.2019>', 'NCT00585195', 'guideline:NCCN', '1', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'Inflammatory Myofibroblastic Tumor', '.', '炎性肌纤维母细胞瘤', '[ALK:FUS]', 'sensitivity', 'EVI_001585', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '一名37岁炎性肌纤维母细胞瘤的女性患者，手术完全切除后肿瘤复发。基因检测发现其携带ALK融合基因突变，使用crizotinib治疗导致后获得完全缓解。在另一项临床试验中，一名携带ALK基因融合的炎性肌纤维母细胞瘤患者使用crizotinib治疗后获得部分缓解。NCCN指南目前也推荐携带ALK基因突变炎性肌纤维母细胞瘤（Inflammatory myofibroblastic tumor）的患者可以考虑使用crizotinb或ceritinib进行治疗。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:15897572', '.', 'case report', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001586', 'EGFR:nonsynonymous SNV:exon18:p.E709Q:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.E709Q', '.', '.', '一名55岁携带EGFR E709Q突变的女性肺腺癌患者，使用gefitinib治疗后取得部分响应。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29255376', '.', 'case report', '4', 'Osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001593', 'EGFR:nonsynonymous SNV:exon20:p.G796S<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.G796S<顺式>', '.', '.', '一名肺癌患者最初携带EGFR L858R突变，使用erlotinib后取得13个月的部分缓解，出现T790M后对erlotinib产生耐药。该患者更改治疗方案为osimertinib后获得12个月的部分缓解，随后疾病发生进展。后续的基因检测发现该患者EGFR基因上同时存在L858R、T790M和G796S三个点突变，其中G796S与T790M为顺式。G796S突变可能是导致患者对Osimertinib耐药的主要原因。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30405134', '.', 'preclinical', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '.', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001594', 'EGFR:nonsynonymous SNV:exon18:p.G724S:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.G724S', '.', '.', '该研究证明EGFR G724S突变在体外和体内都会限制第三代EGFR抑制剂（如osimertinib）的活性。结构分析和计算模型表明，EGFR G724S突变可能诱导产生一种富含甘氨酸环的构象，这与第三代TKI的结合不兼容。系统的抑制剂筛选和深入的动力学分析证实了以上发现，并表明第二代EGFR抑制剂（如afatinib）对该突变的EGFR蛋白依然具有一定的亲和力，能够克服EGFR G724S介导的耐药性。afatinib能够显著抑制携带EGFR G724S突变的肿瘤细胞集落形成和肿瘤生长。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30405134', '.', 'preclinical', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '.', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001595', 'EGFR:nonsynonymous SNV:exon18:p.G724S:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.G724S', '.', '.', '该研究证明EGFR G724S突变在体外和体内都会限制第三代EGFR抑制剂（如osimertinib）的活性。结构分析和计算模型表明，EGFR G724S突变可能诱导产生一种富含甘氨酸环的构象，这与第三代TKI的结合不兼容。系统的抑制剂筛选和深入的动力学分析证实了以上发现，并表明第二代EGFR抑制剂（如afatinib）对该突变的EGFR蛋白依然具有一定的亲和力，能够克服EGFR G724S介导的耐药性。afatinib能够显著抑制携带EGFR G724S突变的肿瘤细胞集落形成和肿瘤生长。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28572531', '.', 'case report', '4', 'Osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001596', 'EGFR:nonsynonymous SNV:exon20:p.G796D<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.G796D', '.', '.', '一名56岁的IV期女性肺腺癌患者，并且具有多处远端脑转移和骨转移，下面是该患者的整个治疗史：首先该患者接受多线化疗治疗及吉非替尼治疗，疾病进展后行基因检测，发现有T790M突变。继而接受奥希替尼治疗，6.5个月后，疾病进展，随后进行放射治疗。为了找出患者对奥希替尼的潜在耐药原因，研究者选取了三个时间点（pre-gefitinib、gefitinib PD、osimertinib PD）采集血液得到血浆样本，通过NGS测序发现：在pre-gefitinib的样本中检测到4.28%的L858R，有意思的是还检测到0.61%的G796D；在gefitinib PD的样本中检测到1.85%的T790M，与组织结果一致；在osimertinib PD的样本中未检测到L858R及T790M突变，但G796D的突变含量从0.61%增加到1.91%。同时该研究也揭示了G796D突变对奥希替尼的耐药机制：是因为G796D突变导致奥希替尼与C797共价结合的空间位阻。突变的D796残基的亲水侧链CH2COOH插入奥希替尼的多脂中心结构，或者是将奥希替尼挤出目前的结合位置，或者是将结合环扭曲影响铰链结合，从而影响奥希替尼与激酶区的紧密结合，产生耐药。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29857056', '.', 'preclinical', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', '.', '.', '肿瘤细胞', 'na', 'resistance', 'EVI_001598', 'EGFR:nonsynonymous SNV:exon20:p.G796R<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.G796R', '.', '.', '在该研究中，作者建立了具有L858R/T790M/L792H（顺式）和L858R/T790M/G796R（顺式）突变的Ba/F3细胞株，以评估接受TKI治疗的疗效。结果显示：三个获批的药物erlotinib、afatinib、osimertinib均不能抑制这些突变细胞株的增殖。与L858R/T790M双突变相比，L858R/T790M/L792H 和L858R/T790M/G796R 三突变对奥希替尼的GI50值增加了25-110倍。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28093244|PMID:27913578', '.', 'preclinical', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001599', 'EGFR:nonsynonymous SNV:exon20:p.L792.<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon20', 'p.L792.', '.', '.', 'Osimertinib是一种不可逆的第三代EGFR酪氨酸激酶抑制剂（TKI），在治疗EGFR T790M阳性的晚期非小细胞肺癌方面表现出色，但获得性抵抗往往不可避免的发生。EGFR C797S是最显著的耐药分子机制，但也可能存在其他EGFR突变。 研究发现了三个肺腺癌患者对osimertinib有抗性。通过测序在复发肿瘤患者中存在EGFR Leu792突变，而且该突变在治疗前的肿瘤样本中并不存在，可能是药物诱导的新发突变。结构预测表明Leu792突变可能中断osimerbinib与EGFR的结合，从而引起耐药性。在另一项研究中，作者建立了具有L858R/T790M/L792H（顺式）和L858R/T790M/G796R（顺式）突变的Ba/F3细胞株，以评估接受TKI治疗的疗效。结果显示：三个获批的药物erlotinib、afatinib、osimertinib均不能抑制这些突变细胞株的增殖。与L858R/T790M双突变相比，L858R/T790M/L792H 和L858R/T790M/G796R 三突变对奥希替尼的GI50值增加了25-110倍。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29807405', '.', 'case report', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001600', 'EGFR:nonsynonymous SNV:exon20:p.C797G<顺式>:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797G', '.', '.', '表皮生长因子受体（EGFR）-酪氨酸激酶抑制剂（TKI）是EGFR突变型非小细胞肺癌（NSCLC）的有效临床治疗药物。Osimertinib是第三代EGFR TKI，已被证明可有效对抗T790M突变。然而，绝大多数患者在成功治疗后获得抗药性。一名患有转移性NSCLC的59岁女性患者在osimertinib治疗43周后出现耐药。基因检测发现该患者携带EGFR C797G突变（等位基因频率为72%），先前存在的顺式T790M突变（73%）和外显子19缺失（87%）。另一名53岁女性患者在奥西替尼治疗10个月后出现全身性进展。肺活组织检查发现携带EGFR L718Q突变（等位基因频率为7%），同时发现PIK3CA E545K（12.90%）和预先存在的EGFR L858R（38%），但T790M突变丢失。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29255376', '.', 'case report', '4', 'Osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001601', 'EGFR:nonsynonymous SNV:exon20:p.G796S<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.G796S', '.', '.', '一名肺癌患者最初携带EGFR L858R突变，使用erlotinib后取得13个月的部分缓解，出现T790M后对erlotinib产生耐药。该患者更改治疗方案为osimertinib后获得12个月的部分缓解，随后疾病发生进展。后续的基因检测发现该患者EGFR基因上同时存在L858R、T790M和G796S三个点突变，其中G796S与T790M为顺式。G796S突变可能是导致患者对Osimertinib耐药的主要原因。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'regorafenib', '瑞戈非尼', 'regorafenib|瑞戈非尼', '4', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001602', 'KRAS:nonsynonymous SNV:.:.:act', 'KRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '目前，中国临床肿瘤学会（CSCO）以1A类证据推荐已接受过奥沙利铂和伊立替康治疗的RAS或BRAF突变型结直肠癌可行regorafenib治疗。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'regorafenib', '瑞戈非尼', 'regorafenib|瑞戈非尼', '4', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001603', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '目前，中国临床肿瘤学会（CSCO）以1A类证据推荐已接受过奥沙利铂和伊立替康治疗的RAS或BRAF突变型结直肠癌可行regorafenib治疗。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'regorafenib', '瑞戈非尼', 'regorafenib|瑞戈非尼', '4', 'colorectal carcinomas', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001604', 'BRAF:nonsynonymous SNV:.:.:act', 'BRAF', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '目前，中国临床肿瘤学会（CSCO）以1A类证据推荐已接受过奥沙利铂和伊立替康治疗的RAS或BRAF突变型结直肠癌可行regorafenib治疗。', 's', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:29236940|PMID:27020857', '.', 'clinical study', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'resistance', 'EVI_001605', 'RB1:nonsynonymous SNV:.:.:inact', 'RB1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '三名乳腺癌患者经CDK4/6抑制剂（palbociclib，ribociclib）治疗三个月后，发现循环肿瘤DNA（ctDNA）中可检测到的RB1突变。 RB1突变包括＃1患者中：RB1基因外显子8供体剪接位点的替换；#2患者中： RB1基因第22外显子供体剪接位点的替换，第2外显子的缺失和第3外显子的插入； ＃3患者中：RB1外显子16 H483Y突变。 这些RB1突变均未出现在CDK 4/6治疗前的患者肿瘤样本中。这些突变会导致Rb1的功能丧失，很可能是在CDK 4/6抑制剂选择性压力下出现的，可能导致肿瘤细胞对CDK4/6抑制剂耐药。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29236940|PMID:27020857', '.', 'clinical study', '4', 'ribociclib', 'ribociclib', 'ribociclib', '瑞波西利', 'ribociclib|瑞波西利', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'resistance', 'EVI_001606', 'RB1:nonsynonymous SNV:.:.:inact', 'RB1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '三名乳腺癌患者经CDK4/6抑制剂（palbociclib，ribociclib）治疗三个月后，发现循环肿瘤DNA（ctDNA）中可检测到的RB1突变。 RB1突变包括＃1患者中：RB1基因外显子8供体剪接位点的替换；#2患者中： RB1基因第22外显子供体剪接位点的替换，第2外显子的缺失和第3外显子的插入； ＃3患者中：RB1外显子16 H483Y突变。 这些RB1突变均未出现在CDK 4/6治疗前的患者肿瘤样本中。这些突变会导致Rb1的功能丧失，很可能是在CDK 4/6抑制剂选择性压力下出现的，可能导致肿瘤细胞对CDK4/6抑制剂耐药。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29236940|PMID:27020857', '.', 'clinical study', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'resistance', 'EVI_001607', 'RB1:nonsynonymous SNV:.:p.H483Y:', 'RB1', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.H483Y', '.', '.', '三名乳腺癌患者经CDK4/6抑制剂（palbociclib，ribociclib）治疗三个月后，发现循环肿瘤DNA（ctDNA）中可检测到的RB1突变。 RB1突变包括＃1患者中：RB1基因外显子8供体剪接位点的替换；#2患者中： RB1基因第22外显子供体剪接位点的替换，第2外显子的缺失和第3外显子的插入； ＃3患者中：RB1外显子16 H483Y突变。 这些RB1突变均未出现在CDK 4/6治疗前的患者肿瘤样本中。这些突变会导致Rb1的功能丧失，很可能是在CDK 4/6抑制剂选择性压力下出现的，可能导致肿瘤细胞对CDK4/6抑制剂耐药。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29236940|PMID:27020857', '.', 'clinical study', '4', 'ribociclib', 'ribociclib', 'ribociclib', '瑞波西利', 'ribociclib|瑞波西利', '4', 'breast cancer', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'resistance', 'EVI_001608', 'RB1:nonsynonymous SNV:.:p.H483Y:', 'RB1', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.H483Y', '.', '.', '三名乳腺癌患者经CDK4/6抑制剂（palbociclib，ribociclib）治疗三个月后，发现循环肿瘤DNA（ctDNA）中可检测到的RB1突变。 RB1突变包括＃1患者中：RB1基因外显子8供体剪接位点的替换；#2患者中： RB1基因第22外显子供体剪接位点的替换，第2外显子的缺失和第3外显子的插入； ＃3患者中：RB1外显子16 H483Y突变。 这些RB1突变均未出现在CDK 4/6治疗前的患者肿瘤样本中。这些突变会导致Rb1的功能丧失，很可能是在CDK 4/6抑制剂选择性压力下出现的，可能导致肿瘤细胞对CDK4/6抑制剂耐药。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31145688', '.', 'case report', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'ovarian cancer', 'ovarian cancer', '卵巢癌', 'na', 'resistance', 'EVI_001609', 'RB1:nonsynonymous SNV:.:.:inact', 'RB1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '一名PTEN蛋白缺失的患者对palbociclib治疗没有响应。基因检测发现其RB1基因存在p.R552X突变，会导致蛋白功能丧失，可能是该患者对palbociclib耐药的原因。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28349562', '.', 'preclinical', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001610', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', '.', 'PTEN是人类癌症中常见的突变基因之一，包括子宫内膜癌。PTEN的丢失会导致细胞分裂失调，并促进细胞周期复合物（如细胞周期蛋白D1-CDK 4/6）的积累，这是肿瘤重要特征表型之一。Palbociclib（PD-332991）特异性抑制CDK 4/6，已被FDA批准与来曲唑联合用于治疗转移性乳腺癌。一项临床前研究中，使用他莫昔芬诱导的PTEN基因敲除小鼠模型来评估细胞周期蛋白D1基因敲除或palbociclib对子宫内膜肿瘤的抗肿瘤作用。细胞周期蛋白D1敲除和palbociclib治疗均引起子宫内膜赘生物缩小。此外，palbociclib治疗可显着提高PTEN缺陷型小鼠的存活率，降低肿瘤细胞增殖。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26339441', '.', 'case report', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001611', 'EGFR:nonsynonymous SNV:exon19:p.L747P:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747P', '.', '.', '在约一半亚洲非小细胞肺癌（NSCLC）患者中发现EGFR突变。两种常见的EGFR突变（exon19 del和exon 21 L858R）对吉非替尼具有阳性反应，T790M和EGFR exon 21 ins对EGFR TKI治疗有抗性。一位66岁的中国男性，诊断为IV期肺腺癌，存在 EGFR exon19 L747P（2239-2240 TT>CC）突变。该患者用吉非替尼治疗2周，反应较差，CT扫描显示治疗后肝转移的数量和相对体积增加。这说明exon19 L747P（2239-2240 TT>CC）突变是罕见的EGFR突变，似乎可导致吉非替尼耐药并可能加速肝转移。', 's', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:30746257|PMID:31200815', '.', 'case report', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001613', 'EGFR:nonsynonymous SNV:exon19:p.L747P:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747P', '.', '.', '一名44岁的女性患者因头部意外受伤入院。在胸部CT和颅脑MRI检查后，于右侧肺尖段观察到软组织密度肿块，右侧脑顶叶被占据，患者同时伴有多囊性肝肾。ECT检查显示骨骼代谢正常，无骨转移，诊断为脑转移的晚期NSCLC。培美曲塞联合卡铂用于一线标准治疗，然后一个周期的培美曲塞用于维持化疗并用γ刀治疗脑部病变。定期随访的胸部CT显示右上肺病变增加。病灶NGS分析结果显示存在EGFR exon19 L747P（2239-2240 TT> CC）突变。开始口服阿法替尼，5个月后根据《实体肿瘤反应评估标准》 1.1版（RECIST 1.1），右上叶病变显示SD，右顶叶的脑转移状态也是如此，右肺的肿瘤病变保持稳定并实现PFS，这种状态维持了超过24个月。', 's', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:31200815|PMID:28424065', '.', 'clinical study', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '肺腺癌', 'sensitivity', 'EVI_001614', 'EGFR:nonsynonymous SNV:exon19:p.L747S:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747S', '.', '.', '一项临床研究分析了从2005年至2018年携带EGFR p.L747P或p.L747S突变的肺腺癌患者，并记录了他们的临床数据。12例符合条件的患者被纳入国立台湾大学医院（NTUH）的研究，另外还从文献中筛选了10例患者。在NTUH队列中，直接DNA测序的假阴性率为60.0%（5名患者中的3名），使用市售试剂盒都会导致EGFR p.L747P或p.L747S的错误识别。在接受EGFR TKI治疗的7例患者中，接受阿法替尼的5例IV期肺腺癌患者的客观缓解率（ORR）为80.0%，而接受吉非替尼或厄洛替尼治疗的2例患者的ORR为0%。阿法替尼和吉非替尼/厄洛替尼的中位无进展生存期（PFS）率分别为11.97和0.92个月（P = 0.012）。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'dabrafenib', 'dabrafenib', 'dabrafenib', '达拉非尼', 'dabrafenib|达拉非尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001615', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', 'The following targeted agents are recommended (category 2A) for patients with specific genetic alterations: crizotinib (for ROS1 rearrangements and for high-level MET amplification or MET exon 14 skipping mutation), dabrafenib (with or without trametinib) and vemurafenib (for BRAF V600E mutations), and cabozantinib (for RET rearrangements). ', 'NCCN以2A类证据推荐携带BRAF V600E的病人可以使用达拉非尼、达拉非尼与曲美替尼联合或者维莫非尼，尤其是对达拉非尼和曲美替尼联用不耐受的患者，可以采用达拉非尼或的维莫非尼单药治疗。一项研究对欧洲晚期BRAF突变型肺癌患者进行了一项回顾性多中心队列研究。数据匿名化，集中评估年龄，性别，吸烟，组织学，分期，局部分子诊断结果，全身治疗和生存。采用RECIST1.1评估最佳反应。35名患者在17个中心使用vemurafenib，达拉非尼或索拉非尼治疗。中位年龄63岁（范围42-85）;性别平衡;14（40%）从不吸烟;全部（100%）有腺癌;29（83%）有V600E突变;6（17%）有其他突变;其中一个具有伴随的KRAS突变。三十（86%）位患者首次化疗。一线治疗的总生存期，携带V600E突变患者为25.3个月，非V600E为11.8个月。三十一名患者接受一种BRAF抑制剂，另外四名接受了二种抑制剂。BRAF治疗的总体反应率为53%，疾病控制率为85%。BRAF抑制剂治疗中位无进展生存期为5.0个月，总生存期为10.8个月。该研究以Vemurafenib，达拉非尼为主（PMID:26200454）。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2019.37.15_suppl.2003', 'NCT03343197', 'clinical trial - phase1', '4', 'AG-120', 'AG-120', 'Ivosidenib', 'Ivosidenib', 'Ivosidenib|Ivosidenib', '4', 'glioma ', 'glioma ', '神经胶质瘤', 'na', 'sensitivity', 'EVI_001617', 'IDH1:nonsynonymous SNV:exon4:p.R132.:', 'IDH1', 'nonsynonymous SNV', 'Partial_pos', 'exon4', 'p.R132.', '.', '.', '在2019年神经肿瘤学年会（SNO）上，Agios公司公布了一项正在进行的两个队列围手术期研究最新数据：单药 Iivosidenib或Vorasidenib 在IDH1突变阳性低级别脑胶质瘤患者的新药效学和应答数据（NCT03343197）。数据截至2019年7月26日，共有49例患者在手术前被随机分配，还有39例仍在接受治疗。Vorasidenib的所有剂量术后中位持续时间为5.42个月（0.9-13.5），Ivosidenib为6.93个月（1.0-13.2）。每个队列中各组的基线特征相似。42例接受 Vorasidenib（n = 21）和 Ivosidenib（n = 21）疗效可评估的患者数据显示：术后接受50 mg Vorasidenib治疗的患者中，有4例（31%）达到了客观的肿瘤缓解，包括2例部分缓解（PR）和2例轻微缓解（RANO-LGG）；术后接受500 mg Ivosidenib 治疗的患者中，也有4例（31%）达到了客观的肿瘤缓解，包括2例部分缓解（PR）和2例轻微缓解（RANO-LGG）；此外，分别有15例和16例患者接受Vorasidenib和Ivosidenib治疗达到疾病稳定，因此 Vorasidenib和Ivosidenib的疾病控制率分别为90%和95%；Vorasidenib和Ivosidenib被证明具有脑渗透性，相较于未处理的样本来说，50 mg Vorasidenib和500mg Ivosidenib对2-HG的抑制率分别为92.6% 和91.1%。根据围手术期研究的两个队列的数据，有进一步的证据表明，Vorasidenib 具有出色的脑穿透能力，并能抑制IDH1突变型胶质瘤中2-羟戊二酸（2-HG）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2019.37.15_suppl.2003', 'NCT03343197', 'clinical trial - phase1', '4', 'AG-881', 'AG-881', 'vorasidenib', 'vorasidenib', 'vorasidenib|vorasidenib', '1', 'glioma ', 'glioma ', '神经胶质瘤', 'na', 'sensitivity', 'EVI_001618', 'IDH1:nonsynonymous SNV:exon4:p.R132.:', 'IDH1', 'nonsynonymous SNV', 'Partial_pos', 'exon4', 'p.R132.', '.', '.', '在2019年神经肿瘤学年会（SNO）上，Agios公司公布了一项正在进行的两个队列围手术期研究最新数据：单药 Iivosidenib或Vorasidenib 在IDH1突变阳性低级别脑胶质瘤患者的新药效学和应答数据（NCT03343197）。数据截至2019年7月26日，共有49例患者在手术前被随机分配，还有39例仍在接受治疗。Vorasidenib的所有剂量术后中位持续时间为5.42个月（0.9-13.5），Ivosidenib为6.93个月（1.0-13.2）。每个队列中各组的基线特征相似。42例接受 Vorasidenib（n = 21）和 Ivosidenib（n = 21）疗效可评估的患者数据显示：术后接受50 mg Vorasidenib治疗的患者中，有4例（31%）达到了客观的肿瘤缓解，包括2例部分缓解（PR）和2例轻微缓解（RANO-LGG）；术后接受500 mg Ivosidenib 治疗的患者中，也有4例（31%）达到了客观的肿瘤缓解，包括2例部分缓解（PR）和2例轻微缓解（RANO-LGG）；此外，分别有15例和16例患者接受Vorasidenib和Ivosidenib治疗达到疾病稳定，因此 Vorasidenib和Ivosidenib的疾病控制率分别为90%和95%；Vorasidenib和Ivosidenib被证明具有脑渗透性，相较于未处理的样本来说，50 mg Vorasidenib和500mg Ivosidenib对2-HG的抑制率分别为92.6% 和91.1%。根据围手术期研究的两个队列的数据，有进一步的证据表明，Vorasidenib 具有出色的脑穿透能力，并能抑制IDH1突变型胶质瘤中2-羟戊二酸（2-HG）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:25182956', '.', 'case report', '4', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', '.', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'resistance', 'EVI_001619', 'BRAF:nonsynonymous SNV:exon15:p.V600.:.', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', '一名携带KIT V559D突变的GIST患者在使用imatinib 18个月后发生耐药。随后的基因检测发现该患者在BRAF基因上出现了V600E突变。该研究提示BRAF基因突变可能是导致GIST患者对imatinib耐药的原因。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:25515853', '.', 'case report', '4', 'vemurafenib', 'vemurafenib', 'vemurafenib', '维莫非尼', 'vemurafenib|维莫非尼', '4', '.', 'melanoma', '黑色素瘤', 'na', 'resistance', 'EVI_001620', 'BRAF:nonsynonymous SNV::p.L505H:', 'BRAF', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.L505H', '.', '.', '携带BRAF基因V600突变的患者对vemurafenib治疗敏感，但BRAF基因的二次突变可能导致药物耐药。对一名vemurafenib耐药患者的基因检测发现，其BRAF基因上存在L505H突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31825192', 'NCT03248492', 'clinical trial - phase2', '4', 'trastuzumab deruxtecan', 'trastuzumab deruxtecan', 'trastuzumab deruxtecan', 'trastuzumab deruxtecan', 'trastuzumab deruxtecan|trastuzumab deruxtecan', '2', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001622', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', 'DESTINY-Breast01试验中, 在接受trastuzumab deruxtecan治疗的患者中,经独立中央评估确认，作为主要终点的客观缓解率（ORR）达到60.9%。入组患者此前接受过中位达6线（2-27）的针对转移性疾病的相关治疗。患者的疾病控制率（DCR）为97.3%，中位缓解持续时间（DoR）为14.8个月，中位无进展生存期（PFS）为16.4个月。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31682542', '.', 'clinical study', '4', 'gefitinib+ carboplatin + pemetrexed', 'gefitinib+ carboplatin + pemetrexed', 'gefitinib+ carboplatin + pemetrexed', '吉非替尼 + 卡铂 + 培美曲塞', 'gefitinib+ carboplatin + pemetrexed|吉非替尼 + 卡铂 + 培美曲塞', '4', 'Non-Small-Cell Lung Cancer', 'Non-Small-Cell Lung Cancer', '肺癌', 'na', 'sensitivity', 'EVI_001627', 'EGFR:nonsynonymous SNV:exon21:p.L858R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', 'NEJ009研究结果发表于《临床肿瘤学杂志》，该研究旨在评估吉非替尼+卡铂+培美曲塞对比吉非替尼用于EGFR敏感突变晚期NSCLC的疗效和安全性。结果显示，联合组和吉非替尼组的ORR分别为84%和67%（P＜0.001）。与吉非替尼组相比，联合组的PFS明显较长，分别为20.9个月和11.2个月（HR=0.49），联合组和吉非替尼组的中位生存期（MST）分别为50.9个月和38.8个月。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31682542', '.', 'clinical study', '4', 'gefitinib+ carboplatin + pemetrexed', 'gefitinib+ carboplatin + pemetrexed', 'gefitinib+ carboplatin + pemetrexed', '吉非替尼 + 卡铂 + 培美曲塞', 'gefitinib+ carboplatin + pemetrexed|吉非替尼 + 卡铂 + 培美曲塞', '4', 'Non-Small-Cell Lung Cancer', 'Non-Small-Cell Lung Cancer', '肺癌', 'na', 'sensitivity', 'EVI_001628', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', 'NEJ009研究结果发表于《临床肿瘤学杂志》，该研究旨在评估吉非替尼+卡铂+培美曲塞对比吉非替尼用于EGFR敏感突变晚期NSCLC的疗效和安全性。结果显示，联合组和吉非替尼组的ORR分别为84%和67%（P＜0.001）。与吉非替尼组相比，联合组的PFS明显较长，分别为20.9个月和11.2个月（HR=0.49），联合组和吉非替尼组的中位生存期（MST）分别为50.9个月和38.8个月。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31587882', 'NCT03046992', 'clinical trial - phase2', '4', 'Lazertinib', 'Lazertinib', 'lazertinib', 'lazertinib', 'lazertinib|lazertinib', '2', 'Non-Small-Cell Lung Cancer', 'Non-Small-Cell Lung Cancer', '肺癌', 'na', 'sensitivity', 'EVI_001629', 'EGFR:nonsynonymous SNV:exon20:p.T790M:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', '.', '首个评估lazertinib疗效的I-II期研究在韩国14家中心开展。研究的主要终点是安全性和耐受性，次要终点包括ORR等。该研究于今年11月份发表于《柳叶刀·肿瘤学》。结果显示，在127例可评估患者中（携带EGFR敏感突变和T790M耐药突变），独立评审委员会评估的ORR为54%，52%患者部分缓解，2%完全缓解，32%患者获得疾病稳定，87%的患者达到疾病控制，研究者评估的ORR为60%，疾病控制率为90%。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/PO.19.00124', 'NCT02693535', 'clinical trial - phase2', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', '.', '.', '胰腺癌', 'na', 'resistance', 'EVI_001630', 'CDKN2A:nonsynonymous SNV:.:.:inact', 'CDKN2A', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', 'II期临床试验（TAPUR）评估了12例和10例CDKN2A缺失或突变的胰腺癌和胆道癌患者使用Palbociclib后的疗效。分析包括20名可评估的患者（每组10名）。16周时没有患者有客观反应或疾病稳定。对所有患者进行安全性，PFS和OS评估。在胰腺癌队列中观察到中位PFS为7.2周（90%CI，4.0至8.0周），中位OS为12.4周（90%CI，4.7至23.1周）。在胆道癌队列研究中，观察到中位PFS为7.3周（90%CI，3.9至7.9周）和中位OS为11.1周（90%CI，5.1至14.0周）。 ', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/PO.19.00124', 'NCT02693535', 'clinical trial - phase2', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', '.', '.', '胆管癌', 'na', 'resistance', 'EVI_001631', 'CDKN2A:CNV:.:.:loss', 'CDKN2A', 'CNV', 'CNV', '.', '.', 'loss', '.', 'II期临床试验（TAPUR）评估了12例和10例CDKN2A缺失或突变的胰腺癌和胆道癌患者使用Palbociclib后的疗效。分析包括20名可评估的患者（每组10名）。16周时没有患者有客观反应或疾病稳定。对所有患者进行安全性，PFS和OS评估。在胰腺癌队列中观察到中位PFS为7.2周（90%CI，4.0至8.0周），中位OS为12.4周（90%CI，4.7至23.1周）。在胆道癌队列研究中，观察到中位PFS为7.3周（90%CI，3.9至7.9周）和中位OS为11.1周（90%CI，5.1至14.0周）。 ', 'A', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37，2019（suppl; abstr 9041）', 'NCT02693535', 'clinical trial - phase2', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001632', 'CDKN2A:nonsynonymous SNV:.:.:inact', 'CDKN2A', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在一项II期临床试验（TAPUR）中，Ibrance（palbociclib）治疗携带CDKN2A基因缺失或失活突变的非小细胞肺癌患者的疾病控制率为29%（在16周时:1名患者部分反应，6名患者病情稳定），中位无进展生存期为9.7周，中位总生存期为20.6个月。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37，2019（suppl; abstr 9041）', 'NCT02693535', 'clinical trial - phase2', '4', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001633', 'CDKN2A:CNV:.:.:loss', 'CDKN2A', 'CNV', 'CNV', '.', '.', 'loss', '.', '在一项II期临床试验（TAPUR）中，Ibrance（palbociclib）治疗携带CDKN2A基因缺失或失活突变的非小细胞肺癌患者的疾病控制率为29%（在16周时:1名患者部分反应，6名患者病情稳定），中位无进展生存期为9.7周，中位总生存期为20.6个月。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('AACR Annual Meeting 2019, Abstract CT015', 'NCT01915576', 'clinical trial - phase1', '4', 'BAY-1125976', 'BAY-1125976', 'BAY-1125976', 'BAY-1125976', 'BAY-1125976|BAY-1125976', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001634', 'AKT1:nonsynonymous SNV:exon3:p.E17K:', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', '.', '在一项I期试验中，BAY 1125976治疗后，仅有1%（1/78）的晚期实体瘤患者获得部分缓解和38%（30/78）的获得疾病稳定。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 3007)', 'NCT03188965', 'clinical trial - phase1', '4', '.', '.', 'BAY-1895344', 'BAY-1895344', 'BAY-1895344|BAY-1895344', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001637', 'ATM:nonsynonymous SNV:.:.:inact', 'ATM', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在一项I期临床试验中，晚期实体瘤患者经BAY 1895344治疗后，客观缓解率为30.7%（4/13），所有应答者均带有ATM蛋白表达缺失和/或ATM突变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 3007)', 'NCT03188965', 'clinical trial - phase1', '4', '.', '.', 'BAY-1895344', 'BAY-1895344', 'BAY-1895344|BAY-1895344', '1', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001638', 'ATM:CNV:.:.:loss', 'ATM', 'CNV', 'CNV', '.', '.', 'loss', '.', '在一项I期临床试验中，晚期实体瘤患者经BAY 1895344治疗后，客观缓解率为30.7%（4/13），所有应答者均带有ATM蛋白表达缺失和/或ATM突变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Cancer Res 2019;79(13 Suppl):Abstract nr 3506', '.', 'preclinical', '4', '.', '.', 'AZD7648 + olaparib', 'AZD7648 + 奥拉帕利', 'AZD7648 + olaparib|AZD7648 + 奥拉帕利', '0', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001639', 'ATM:nonsynonymous SNV:.:.:inact', 'ATM', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '在一项临床前研究中，AZD7648和Lynparza（olaparib）联合使用可以使得ATM基因敲除的头颈部癌细胞细胞周期停滞，诱导异种移植模型中肿瘤细胞消退。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Cancer Res 2019;79(13 Suppl):Abstract nr 3506', '.', 'preclinical', '4', '.', '.', 'AZD7648 + olaparib', 'AZD7648 + 奥拉帕利', 'AZD7648 + olaparib|AZD7648 + 奥拉帕利', '0', '.', '.', '肿瘤细胞', 'na', 'sensitivity', 'EVI_001640', 'ATM:CNV:.:.:loss', 'ATM', 'CNV', 'CNV', '.', '.', 'loss', '.', '在一项临床前研究中，AZD7648和Lynparza（olaparib）联合使用可以使得ATM基因敲除的头颈部癌细胞细胞周期停滞，诱导异种移植模型中肿瘤细胞消退。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 3000)', 'NCT02405065|NCT03118817', 'clinical trial - phase1', '4', '.', '.', 'belvarafenib', 'belvarafenib', 'belvarafenib|belvarafenib', '1', '.', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_001642', 'NRAS:nonsynonymous SNV:.:.:act', 'NRAS', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '在I期Belvarafenib（HM95573）剂量递增的临床试验中， 9例NRAS突变型黑色素瘤患者中有4例PR（ORR 44%）。剂量扩展研究中部分缓解患者包括：NRAS突变的黑色素瘤（2/9），BRAF突变的黑色素瘤（2/6）和BRAF突变的CRC（2/7）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 3000)', 'NCT02405065|NCT03118817', 'clinical trial - phase1', '4', '.', '.', 'belvarafenib', 'belvarafenib', 'belvarafenib|belvarafenib', '1', '.', 'melanoma', '黑色素瘤', 'na', 'sensitivity', 'EVI_001643', 'BRAF:nonsynonymous SNV:.:.:act', 'BRAF', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '在I期Belvarafenib（HM95573）剂量递增的临床试验中， 9例NRAS突变型黑色素瘤患者中有4例PR（ORR 44%）。剂量扩展研究中部分缓解患者包括：NRAS突变的黑色素瘤（2/9），BRAF突变的黑色素瘤（2/6）和BRAF突变的CRC（2/7）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 37, 2019 (suppl; abstr 3000)', 'NCT02405065|NCT03118817', 'clinical trial - phase1', '4', '.', '.', 'belvarafenib', 'belvarafenib', 'belvarafenib|belvarafenib', '1', '.', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001644', 'BRAF:nonsynonymous SNV:.:.:act', 'BRAF', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '在I期Belvarafenib（HM95573）剂量递增的临床试验中， 9例NRAS突变型黑色素瘤患者中有4例PR（ORR 44%）。剂量扩展研究中部分缓解患者包括：NRAS突变的黑色素瘤（2/9），BRAF突变的黑色素瘤（2/6）和BRAF突变的CRC（2/7）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001645', 'EGFR:nonsynonymous SNV:exon20:p.S768I:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.S768I', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001646', 'EGFR:nonsynonymous SNV:exon18:p.G719.:.', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon18', 'p.G719.', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 'S', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:22190593', '.', 'guideline:NCCN', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001647', 'EGFR:nonframeshift insertion:exon19:.:exon19ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon19', '.', 'exon19ins', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:22190593', '.', 'guideline:NCCN', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001648', 'EGFR:nonframeshift insertion:exon19:.:exon19ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon19', '.', 'exon19ins', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001649', 'EGFR:nonsynonymous SNV:exon18:p.G719.:.', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon18', 'p.G719.', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001650', 'EGFR:nonsynonymous SNV:exon20:p.S768I:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.S768I', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001651', 'EGFR:nonsynonymous SNV:exon21:p.L861Q:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L861Q', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:22190593', '.', 'guideline:NCCN', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001652', 'EGFR:nonframeshift insertion:exon19:.:exon19ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon19', '.', 'exon19ins', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001653', 'EGFR:nonsynonymous SNV:exon21:p.L861Q:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L861Q', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001654', 'EGFR:nonsynonymous SNV:exon18:p.G719.:', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon18', 'p.G719.', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001655', 'EGFR:nonsynonymous SNV:exon20:p.S768I:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.S768I', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:22190593', '.', 'guideline:NCCN', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001656', 'EGFR:nonframeshift insertion:exon19:.:exon19ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon19', '.', 'exon19ins', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001657', 'EGFR:nonsynonymous SNV:exon18:p.G719.:.', 'EGFR', 'nonsynonymous SNV', 'Partial_pos', 'exon18', 'p.G719.', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001658', 'EGFR:nonsynonymous SNV:exon20:p.S768I:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.S768I', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>', '.', 'guideline:NCCN', '1', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001659', 'EGFR:nonsynonymous SNV:exon21:p.L861Q:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L861Q', '.', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:22190593', '.', 'guideline:NCCN', '1', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001660', 'EGFR:nonframeshift insertion:exon19:.:exon19ins', 'EGFR', 'nonframeshift insertion', 'None_pos', 'exon19', '.', 'exon19ins', '.', '在NSCLC患者中，最常见的EGFR基因突变是外显子19的缺失（45%）和外显子21的点突变L858R（40%）。两种突变均导致酪氨酸激酶结构域的激活，并且均对小分子EGFR TKI（erlotinib, gefitinib, afatinib, osimertinib,dacomitinib）敏感。因此，这些突变被称为EGFR敏感突变。对EGFR TKI也敏感的其他较不常见的突变（10%）包括外显子19插入，p.L861Q，p.G719X和p.S768I。数据表明，对不携带EGFR敏感突变的患者，在任何治疗方案中均不应使用EGFR TKIs治疗。大约10%的白种人NSCLC患者中以及多达50%的亚洲患者存在这些EGFR敏感突变。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001661', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '约5%的NSCLC患者携带ALK基因重排。ALK重排的患者对EGFR TKI具有耐药性，但与EGFR突变的患者具有相似的临床特征（即腺癌组织学，轻度或从不吸烟）。区别携带EML4-ALK和EGFR突变的癌症类型具有重要的治疗意义 。EGFR突变的癌细胞对EGFR TKIs敏感，而EML4-ALK与EGFR TKIs耐药性密切相关。一项临床研究中，19例对厄洛替尼或吉非替尼有临床响应的患者中，16例（占84%）具有激活的EGFR突变，而没有任何患者携带EML4-ALK融合。相反，在34例对EGFR TKI难治的患者中，有10例（29%）患者携带EML4-ALK融合。这些发现与临床前研究一致，含有EML4-ALK融合突变的NSCLC细胞系H3122对厄洛替尼耐药。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001662', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '约5%的NSCLC患者携带ALK基因重排。ALK重排的患者对EGFR TKI具有耐药性，但与EGFR突变的患者具有相似的临床特征（即腺癌组织学，轻度或从不吸烟）。区别携带EML4-ALK和EGFR突变的癌症类型具有重要的治疗意义 。EGFR突变的癌细胞对EGFR TKIs敏感，而EML4-ALK与EGFR TKIs耐药性密切相关。一项临床研究中，19例对厄洛替尼或吉非替尼有临床响应的患者中，16例（占84%）具有激活的EGFR突变，而没有任何患者携带EML4-ALK融合。相反，在34例对EGFR TKI难治的患者中，有10例（29%）患者携带EML4-ALK融合。这些发现与临床前研究一致，含有EML4-ALK融合突变的NSCLC细胞系H3122对厄洛替尼耐药。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001663', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '约5%的NSCLC患者携带ALK基因重排。ALK重排的患者对EGFR TKI具有耐药性，但与EGFR突变的患者具有相似的临床特征（即腺癌组织学，轻度或从不吸烟）。区别携带EML4-ALK和EGFR突变的癌症类型具有重要的治疗意义 。EGFR突变的癌细胞对EGFR TKIs敏感，而EML4-ALK与EGFR TKIs耐药性密切相关。一项临床研究中，19例对厄洛替尼或吉非替尼有临床响应的患者中，16例（占84%）具有激活的EGFR突变，而没有任何患者携带EML4-ALK融合。相反，在34例对EGFR TKI难治的患者中，有10例（29%）患者携带EML4-ALK融合。这些发现与临床前研究一致，含有EML4-ALK融合突变的NSCLC细胞系H3122对厄洛替尼耐药。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001664', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '约5%的NSCLC患者携带ALK基因重排。ALK重排的患者对EGFR TKI具有耐药性，但与EGFR突变的患者具有相似的临床特征（即腺癌组织学，轻度或从不吸烟）。区别携带EML4-ALK和EGFR突变的癌症类型具有重要的治疗意义 。EGFR突变的癌细胞对EGFR TKIs敏感，而EML4-ALK与EGFR TKIs耐药性密切相关。一项临床研究中，19例对厄洛替尼或吉非替尼有临床响应的患者中，16例（占84%）具有激活的EGFR突变，而没有任何患者携带EML4-ALK融合。相反，在34例对EGFR TKI难治的患者中，有10例（29%）患者携带EML4-ALK融合。这些发现与临床前研究一致，含有EML4-ALK融合突变的NSCLC细胞系H3122对厄洛替尼耐药。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001665', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', '.', '约5%的NSCLC患者携带ALK基因重排。ALK重排的患者对EGFR TKI具有耐药性，但与EGFR突变的患者具有相似的临床特征（即腺癌组织学，轻度或从不吸烟）。区别携带EML4-ALK和EGFR突变的癌症类型具有重要的治疗意义 。EGFR突变的癌细胞对EGFR TKIs敏感，而EML4-ALK与EGFR TKIs耐药性密切相关。一项临床研究中，19例对厄洛替尼或吉非替尼有临床响应的患者中，16例（占84%）具有激活的EGFR突变，而没有任何患者携带EML4-ALK融合。相反，在34例对EGFR TKI难治的患者中，有10例（29%）患者携带EML4-ALK融合。这些发现与临床前研究一致，含有EML4-ALK融合突变的NSCLC细胞系H3122对厄洛替尼耐药。', 's', '耐药', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/1538-7445.AM2019-CT034', 'NCT02143466', 'clinical trial - phase1', '4', '.', '.', 'osimertinib + selumetinib', '奥希替尼 + 司美替尼 ', 'osimertinib + selumetinib|奥希替尼 + 司美替尼 ', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001666', 'EGFR:nonsynonymous SNV:exon21:p.L858R:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', '.', '在一项Ib期试验（TATTON）的剂量探索研究中，Tagrisso（osimertinib）和Selumetinib（AZD6244）联合治疗对EGFR突变型非小细胞肺癌患者的部分缓解率为42%（15/36），稳定疾病率为39%（14/36）；在剂量扩展组中，部分缓解为34%（16/47），稳定疾病率为23%（11/47）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/1538-7445.AM2019-CT034', 'NCT02143466', 'clinical trial - phase1', '4', '.', '.', 'osimertinib + selumetinib', '奥希替尼 + 司美替尼 ', 'osimertinib + selumetinib|奥希替尼 + 司美替尼 ', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001667', 'EGFR:nonframeshift deletion:exon19:.:exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', '.', '在一项Ib期试验（TATTON）的剂量探索研究中，Tagrisso（osimertinib）和Selumetinib（AZD6244）联合治疗对EGFR突变型非小细胞肺癌患者的部分缓解率为42%（15/36），稳定疾病率为39%（14/36）；在剂量扩展组中，部分缓解为34%（16/47），稳定疾病率为23%（11/47）。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27016228', '.', 'clinical trial - phase2', '4', '.', '.', 'Temsirolimus', '替西罗莫司', 'Temsirolimus|替西罗莫司', '4', 'endometrial cancer', 'endometrial cancer', '子宫肿瘤', 'na', 'sensitivity', 'EVI_001669', 'AKT1:nonsynonymous SNV:.:.:act', 'AKT1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '在一项II期临床试验的回顾性研究中，携带AKT1突变的晚期子宫内膜癌患者使用Torisel（temsirolimus）治疗后，无进展生存期和缓解率有所增加。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)', 'NCT01442090|NCT01455493', 'clinical trial - phase2', '4', '.', '.', 'apitolisib', 'apitolisib', 'apitolisib|apitolisib', '2', 'endometrial cancer', 'endometrial cancer', '子宫肿瘤', 'na', 'sensitivity', 'EVI_001670', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513))', '在一项II期临床试验中，Apitolisib（GDC-0980）的耐受性较差，但在具有PIK3CA，PTEN或AKT1突变的子宫内膜癌患者中显示出了疗效。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)', 'NCT01442090|NCT01455493', 'clinical trial - phase2', '4', '.', '.', 'apitolisib', 'apitolisib', 'apitolisib|apitolisib', '2', 'endometrial cancer', 'endometrial cancer', '子宫肿瘤', 'na', 'sensitivity', 'EVI_001671', 'AKT1:nonsynonymous SNV:.:.:act', 'AKT1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', 'In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513))', '在一项II期临床试验中，Apitolisib（GDC-0980）的耐受性较差，但在具有PIK3CA，PTEN或AKT1突变的子宫内膜癌患者中显示出了疗效。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)', 'NCT01442090|NCT01455493', 'clinical trial - phase2', '4', '.', '.', 'apitolisib', 'apitolisib', 'apitolisib|apitolisib', '2', 'endometrial cancer', 'endometrial cancer', '子宫肿瘤', 'na', 'sensitivity', 'EVI_001672', 'PTEN:CNV:.:.:loss', 'PTEN', 'CNV', 'CNV', '.', '.', 'loss', 'In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513))', '在一项II期临床试验中，Apitolisib（GDC-0980）的耐受性较差，但在具有PIK3CA，PTEN或AKT1突变的子宫内膜癌患者中显示出了疗效。', 'a', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 32:5s, 2014 (suppl; abstr 5513)', 'NCT01442090|NCT01455493', 'clinical trial - phase2', '4', '.', '.', 'apitolisib', 'apitolisib', 'apitolisib|apitolisib', '2', 'endometrial cancer', 'endometrial cancer', '子宫肿瘤', 'na', 'sensitivity', 'EVI_001673', 'PTEN:nonsynonymous SNV:.:.:inact', 'PTEN', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a Phase II trial, Apitolisib (GDC-0980) was poorly tolerated, but demonstrated efficacy in endometrial cancer patients harboring mutations in PIK3CA, PTEN, or AKT1 (J Clin Oncol 32:5s, 2014 (suppl; abstr 5513))', '在一项II期临床试验中，Apitolisib（GDC-0980）的耐受性较差，但在具有PIK3CA，PTEN或AKT1突变的子宫内膜癌患者中显示出了疗效。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30429128', 'NCT02465060', 'clinical trial - phase2', '4', '.', '.', 'capivasertib', 'capivasertib', 'capivasertib|capivasertib', '2', 'endometrioid adenocarcinoma', 'endometrioid adenocarcinoma', '子宫肿瘤', 'na', 'sensitivity', 'EVI_001674', 'AKT1:nonsynonymous SNV:exon3:p.E17K:', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in a patient with endometrioid adenocarcinoma harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).', '一项II期临床试验表明，携带AKT1基因突变的子宫内膜腺癌患者在Capivasertib治疗后可以获得部分缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26351323', 'NCT01353781', 'clinical trial - phase1', '4', '.', '.', 'capivasertib', 'capivasertib', 'capivasertib|capivasertib', '2', 'breast papillary carcinoma', 'breast papillary carcinoma', '乳腺癌(HR阳性,HER2阴性)', '[ER(+);PR(+);HER2(-)]', 'sensitivity', 'EVI_001675', 'AKT1:nonsynonymous SNV:exon3:p.E17K:', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'In a Phase I clinical trial, a patient with ER-positive, ERBB2 (HER2)-negative papillary breast carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 (PMID: 26351323).', '在一项I期临床试验中，一名ER阳性、HER2阴性且携带AKT1突变的乳腺癌患者，使用capivasertib治疗后获得部分缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30429128', 'NCT02465060', 'clinical trial - phase2', '4', '.', '.', 'capivasertib', 'capivasertib', 'capivasertib|capivasertib', '2', '.', 'oncocytic carcinoma of the parotid gland', '头颈部肿瘤', 'na', 'sensitivity', 'EVI_001676', 'AKT1:nonsynonymous SNV:exon3:p.E17K:', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in stable disease over 21 months in a patient with an oncocytic carcinoma of the parotid gland harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).', '在一项II期（MATCH）临床试验中，一名携带AKT1 E17K突变的腮腺癌患者使用Capivasertib（AZD5363）治疗后，21个月内病情稳定。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28489509', 'NCT01226316', 'clinical trial - phase1', '4', '.', '.', 'capivasertib', 'capivasertib', 'capivasertib|capivasertib', '2', '.', 'ESR1-positive breast cancer', '乳腺癌(HR阳性)', '[ER(+);PR(+);NA]', 'sensitivity', 'EVI_001677', 'AKT1:nonsynonymous SNV:exon3:p.E17K:', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'In a Phase I trial, Capivasertib (AZD5363) treatment resulted in confirmed partial response in 20% (4/20) and unconfirmed partial response in 10% (2/20) of patients with ESR1-positive breast cancer harboring AKT1 E17K (PMID: 28489509; NCT01226316).', '在一项临床试验中，携带AKT1 E17K突变的乳腺癌患者经Capivasertib (AZD5363)治疗后，确认的响应率为20% (4/20)，为确认的响应率为10% (2/20)。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30429128', 'NCT02465060', 'clinical trial - phase2', '4', '.', '.', 'capivasertib', 'capivasertib', 'capivasertib|capivasertib', '2', '.', 'uterus leiomyosarcoma', '平滑肌肉瘤', '.', 'sensitivity', 'EVI_001678', 'AKT1:nonsynonymous SNV:exon3:p.E17K:', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'In a Phase II (MATCH) trial, Capivasertib (AZD5363) treatment resulted in partial response in a patient with uterus leiomyosarcoma harboring AKT1 E17K mutation (PMID: 30429128; NCT02465060).', '在一项临床试验中，一名携带AKT1 E17K的子宫平滑肌肉瘤患者使用Capivasertib (AZD5363)治疗后获得部分缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31277699', 'NCT01277757', 'clinical trial - phase2', '4', '.', 'MK2206', 'MK-2206', 'MK-2206', 'MK-2206|MK-2206', '2', '.', 'breast cancer', '乳腺癌', '[NA;NA;NA]', 'resistance', 'EVI_001679', 'AKT1:nonsynonymous SNV:exon3:p.E17K:', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'In a Phase II trial, MK2206 treatment resulted in no objective response in 4 patients with advanced breast cancer harboring AKT1 E17K (PMID: 31277699; NCT01277757).', '在一项临床试验中，4名携带AKT1 E17K乳腺癌患者使用MK-2206治疗后并未取得临床响应。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26351323', 'NCT01353781', 'clinical trial - phase1', '4', '.', '.', 'capivasertib', 'capivasertib', 'capivasertib|capivasertib', '2', '.', 'endometrioid ovarian carcinoma', '卵巢癌', '.', 'sensitivity', 'EVI_001680', 'AKT1:nonsynonymous SNV:exon3:p.E17K:', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'In a Phase I clinical study, a patient with endometrioid ovarian carcinoma harboring AKT1 E17K had a sustained partial response to AZD5363 for more than two years (PMID: 26351323).', '一项临床研究中，一名携带AKT1 E17K的子宫内膜样卵巢癌患者使用Capivasertib治疗后获得了超过2年的部分响应。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27872130', 'NCT01090960', 'clinical trial - phase1', '4', '.', '.', 'ipatasertib', 'ipatasertib', 'ipatasertib|ipatasertib', '2', '.', 'ERBB2 (HER2)-receptor negative breast cancer', '乳腺癌(HER2阴性)', '[NA;NA;HER2(-)]', 'sensitivity', 'EVI_001681', 'AKT1:nonsynonymous SNV:exon3:p.E17K:', 'AKT1', 'nonsynonymous SNV', 'Exact_pos', 'exon3', 'p.E17K', '.', 'In a Phase I trial, a patient with ERBB2 (HER2)-receptor negative breast cancer harboring AKT1 E17K demonstrated a complete metabolic response when treated with Ipatasertib (GDC-0068) (PMID: 27872130).', '在一项临床试验中，一名携带AKT1 E17K突变的HRE2阴性的乳腺癌患者使用治疗Ipatasertib后获得完全代谢缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26633560', 'EudraCT Number: 2012-000148-88', 'clinical trial - phase1', '4', 'Entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '4', '.', 'colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001682', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', 'In a Phase I clinical trial, Rozlytrek (entrectinib) treatment resulted in partial response for more than 3 months in a colorectal cancer patient harboring a CAD-ALK gene fusion (PMID: 26633560).', '一项临床试验中，携带ALK融合基因的结直肠癌肿瘤患者使用entrectinib后获得了超过3个月的部分响应。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 36, 2018 (suppl; abstr 2513)', 'NCT03093116', 'clinical trial - phase1', '4', 'Entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '4', '.', 'advanced solid tumor', '非特定癌症', 'na', 'sensitivity', 'EVI_001683', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', 'In a Phase I (TRIDENT-1) trial, Repotrectinib (TPX-0005) treatment resulted in stable disease in 25% (4/16) of patient with advanced solid tumor harboring ALK fusions who completed 2 cycles of treatment (J Clin Oncol 36, 2018 (suppl; abstr 2513); NCT03093116).', '一项临床试验中，携带ALK融合的实体瘤患者使用Repotrectinib (TPX-0005)后25% (4/16)的患者获得疾病稳定。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28787259', 'NCT00939770', 'clinical trial - phase2', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', '.', 'anaplastic large cell lymphoma', '淋巴癌', 'na', 'sensitivity', 'EVI_001684', 'ALK:FUS:.:.-ALK:.', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', 'In a Phase Ib/II trial, treatment with Xalkori (crizotinib) resulted in an objective response rate of 83% (5/6, all complete responses), at the 165 mg dose, and 90% (18/20, with complete response in 80% (16/20), at the recommended phase 2 dose of 280 mg, in patients with anaplastic large cell lymphoma harboring an ALK fusion, with 72% of tested patients harboring NPM1-ALK (PMID: 28787259; NCT00939770).', '在Ib/II期临床试验中，对患有间变性大细胞淋巴瘤并携带ALK融合的患者，165 mg剂量Xalkori（crizotinib）治疗后客观缓解率为83%，2期剂量为280 mg治疗后客观缓解率90%。所有患者中72%具有NPM1-ALK基因融合。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:talazoparib_Revised:09/2019|PMID:30110579', 'NCT01945775', 'guideline:FDA', '1', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib', 'talazoparib|talazoparib', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阴性)', '[NA;NA;HER2(-)]', 'sensitivity', 'EVI_001685', 'ERBB2:CNV:.:.:wildtype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'wildtype', 'On October 16, 2018, the Food and Drug Administration approved talazoparib (TALZENNA, Pfizer Inc.), a poly (ADP-ribose) polymerase (PARP) inhibitor, for patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2‑negative locally advanced or metastatic breast cancer. Patients must be selected for therapy based on an FDA-approved companion diagnostic for talazoparib. Approval was based on EMBRACA (NCT01945775), an open‑label trial randomizing 431 patients (2:1) with gBRCAm HER2‑negative locally advanced or metastatic breast cancer to receive talazoparib (1 mg) or physician’s choice of chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine). All patients were required to have a known deleterious or suspected deleterious gBRCA mutation and must have received no more than 3 prior cytotoxic chemotherapy regimens for locally advanced or metastatic disease. Patients were required to have received treatment with an anthracycline and/or a taxane (unless contraindicated) in the neoadjuvant, adjuvant, and/or metastatic treatment setting. The primary efficacy outcome was progression-free survival (PFS) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, as assessed by blinded independent central review. Estimated median PFS was 8.6 and 5.6 months in the talazoparib and chemotherapy arms, respectively (HR 0.54; 95% CI: 0.41, 0.71; p<0.0001). ', '2018年10月16日，FDA基于一项开放标签试验EMBRACA (NCT01945775)，批准talazoparib适用于携带致病性或可能致病性胚系BRCA突变(gBRCAm)且HER2阴性的局部晚期或转移性乳腺癌患者。EMBRACA（NCT01945775）试验纳入431例gBRCAm，HER2阴性局部晚期或转移性乳腺癌患者，随机按照2：1比例接受talazoparib（1mg）或医生选择的化疗药物（卡培他滨，eribulin，吉西他滨，长春瑞滨）直至出现疾病进展或无法耐受毒性。根据RECIST 1.1评估标准，talazoparib与化疗组主要疗效中位PFS分别为8.6 vs 5.6个月(HR 0.54; 95% CI: 0.41, 0.71; p<0.0001)，客观缓解率高于化疗组（62.6%vs. 27.2%;优势比为5.0; 95%CI为2.9至8.8; P <0.001）。', 'A', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:lapatinib_Revised:12/2018', 'NCT00078572', 'guideline:FDA', '1', 'lapatinib + capecitabine', 'lapatinib + capecitabine', 'lapatinib + capecitabine', '拉帕替尼 + 卡培他滨', 'lapatinib + capecitabine|拉帕替尼 + 卡培他滨', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001687', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'The efficacy and safety of TYKERB in combination with capecitabine in breast cancer were evaluated in a randomized, Phase 3 trial. Patients eligible for enrollment had HER2 (ErbB2) overexpressing (IHC 3+ or IHC 2+ confirmed by FISH), locally advanced or metastatic breast cancer, progressing after prior treatment that included anthracyclines, taxanes, and trastuzumab. Patients were randomized to receive either TYKERB 1,250 mg once daily (continuously) plus capecitabine 2,000 mg/m2/day on Days 1-14 every 21 days, or to receive capecitabine alone at a dose of 2,500 mg/m2/day on Days 1-14 every 21 days. The endpoint was time to progression (TTP). ', 'FDA批准拉帕替尼联合卡培他滨治疗ERBB2阳性的晚期或转移性乳腺癌，患者先期接受过包含一种蒽环素类、一种紫杉烷类和曲妥珠单抗治疗。拉帕替尼联合卡培他滨治疗乳腺癌的安全性和有效性是基于随机的Ⅲ期试验结果。试验中纳入了399名局部晚期或转移性乳腺癌患者，且这些患者对包含一种蒽环素类、一种紫杉烷类和曲妥珠单抗治疗有疾病进展。患者肿瘤为ERBB2阳性（IHC 3+ 或IHC 2+），且经由FISH确定，按1：1分配至拉帕替尼+卡培他滨治疗组和卡培他滨治疗组。试验的临床终点是疾病进展时间（TTP）。独立审查委员会评估的拉帕替尼+卡培他滨治疗组和卡培他滨治疗组中位TTP分别为27.1 vs. 18.6周(HR 0.57, p=0.00013)，响应率为23.7% vs. 13.9%；研究者评估的两个治疗组的中位TTP分别为23.9 vs. 18.3周 (HR 0.72, p=0.00762)，响应率为 31.8% vs. 17.4 %(NCT00078572)。', 'A', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:lapatinib_Revised:12/2018', 'NCT00073528', 'guideline:FDA', '1', 'lapatinib + letrozole', 'lapatinib + letrozole', 'lapatinib + letrozole', '拉帕替尼 + 来曲唑', 'lapatinib + letrozole|拉帕替尼 + 来曲唑', '4', 'breast cancer', 'breast cancer', '乳腺癌(HR阳性,HER2阳性)', '[ER(+);PR(+);HER2(+)]', 'sensitivity', 'EVI_001688', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'The efficacy and safety of TYKERB in combination with letrozole were evaluated in a double-blind, placebocontrolled, multi-center study. A total of 1,286 postmenopausal women with hormone receptor-positive (ER positive and/or PgR positive) metastatic breast cancer, who had not received prior therapy for metastatic disease, were randomly assigned to receive either TYKERB (1,500 mg once daily) plus letrozole (2.5 mg once daily) (n = 642) or letrozole (2.5 mg once daily) alone (n = 644).In the HER2-positive subgroup (n = 219), the addition of TYKERB to letrozole resulted in an improvement in PFS. In the HER2-negative subgroup, there was no improvement in PFS of the combination of TYKERB plus letrozole compared to the letrozole plus placebo. Overall response rate (ORR) was also improved with the combination of TYKERB plus letrozole. The overall survival (OS) data were not mature.', 'FDA批准拉帕替尼联合来曲唑治疗ERBB2阳性、激素受体阳性的、适宜激素治疗的绝经后妇女转移性乳腺癌。此适应症的安全性和有效性是基于一项双盲、空白对照的、多中心试验结果。试验中纳入了1286名激素受体阳性绝经后妇女乳腺癌患病者，且这些患者没有接受过转移性疾病的治疗，将这些患者按1：1随机分配至拉帕替尼+来曲唑治疗组（N = 642）和来曲唑治疗组（N = 644）。219名（17%）患者的肿瘤为ERBB2阳性（定义为FISH ≥2或IHC 3+），952名（74%）的患者肿瘤为ERBB2阴性，115名（9%）患者的ERBB2状态未确定。试验的主要临床指标为无进展生存期（PFS）。在ERBB2阳性亚组中，拉帕替尼的添加使得患者的PFS延长，拉帕替尼+来曲唑治疗组和来曲唑治疗组的中位PFS分别为35.4周和13.0周 (HR = 0.71, p = 0.019)，总响应率分别为27.9%和14.8%。在ERBB2阴性亚组中，与来曲唑治疗组相比，拉帕替尼+来曲唑治疗组没有改善患者的PFS，两治疗组中的中位PFS分别为59.7和18.3周(NCT00073528)。', 'A', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29670367', '.', 'case report', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'myofibroblastoma', 'myofibroblastoma', '肌纤维母细胞瘤', 'na', 'sensitivity', 'EVI_001691', 'ALK:nonsynonymous SNV:exon5:p.R401:', 'ALK', 'nonsynonymous SNV', 'Partial_pos', 'exon5', 'p.R401', '.', 'The purpose of this article is to explore the targeted treatment of malignant myofibroblastoma and evaluate the role of neoplasm metabolite markers in the evaluation of efficacy after targeted therapy.This report described a case of myofibroblastic sarcoma with rare mutation ofALK R401in a 58-year-old man prescribed with crizotinib, to evaluate its curative effect by positron emission tomography coupled with computed tomography (PET-CT). After the progressive disease in the brain, bevacizumab combined with crizotinib was administered. The Response Evaluation Criteria in Solid Tumors (RECIST), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) were used to assess the efficacy. The efficacy was assessed by comparing changes in MTV and TLG.After the treatment of crizotinib, the tumor volume was decreased. However, bevacizumab combined with crizotinib had not improved the prognosis. The change of MTV and TLG was consistent with the efficacy. The increase of MTV and TLG is an early indicator of the poor prognosis of patients.The treatment of the crizotinib patient with the mutation ofALK R401was effective. The values of MTV and TLG reflected the prognosis earlier than RECIST.', '该研究旨在探讨恶性肌成纤维细胞瘤的靶向治疗方法，并评估肿瘤代谢物标志物在靶向治疗后疗效评估中的作用。一例58岁的具有ALK R401罕见突变的肌成纤维细胞肉瘤患者使用crizotinib治疗，实体瘤反应评估标准（RECIST），代谢肿瘤体积（MTV）和总病变糖酵解（TLG）用于评估疗效。治疗后肿瘤体积减小，但不能改善预后。MTV和TLG的改变与疗效一致。MTV和TLG的升高是患者预后不良的早期指标。crizotinib治疗ALK R401突变的患者是有效的。MTV和TLG的值比RECIST更能反映预后。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2016.34.15_suppl.e20522', 'NCT01820325|NCT01911325', 'clinical trial - phase2', '4', '.', '.', 'buparlisib', 'buparlisib', 'buparlisib|buparlisib', '2', 'non small-cell lung cancer', 'non small-cell lung cancer', '肺癌', 'na', 'resistance', 'EVI_001693', 'PIK3CA:nonsynonymous SNV:.:.:act', 'PIK3CA', 'nonsynonymous SNV', 'None_pos', '.', '.', 'act', '.', '在BASALT-2临床试验中，有6名患者接受了80 mg buparlisib治疗。中位年龄为69岁，其中50%为男性。在BASALT-3中，有27名患者接受80或100 mg buparlisib治疗。中位年龄为65岁，其中89%为男性。两项临床试验中，总体缓解率（完全缓解+ PR）在80 mg时为6%，在100 mg时为18%。所有患者均因疾病进展而终止治疗（80 mg时为38%，100 mg时为36%）。基于以上研究，buparlisib目前将不会在肺癌中进一步发展。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26966027', 'NCT01284192', 'clinical trial - phase1', '4', '.', 'ASP3026', 'ASP3026', 'ASP3026', 'ASP3026|ASP3026', '1', 'Advanced Solid Tumor', 'Advanced Solid Tumor', '非特定癌症', '[ALK:FUS]', 'sensitivity', 'EVI_001695', 'ALK:nonsynonymous SNV:exon23:p.F1174L:', 'ALK', 'nonsynonymous SNV', 'Exact_pos', 'exon23', 'p.F1174L', '.', 'In a Phase I trial, ASP3026 treatment resulted in a partial response in 50% (8/16) and stable disease in 44% (7/16) of patients with an advanced solid tumor harboring an ALK rearrangement or ALK F1174L (PMID:26966027; ).', '在I期临床试验中，携带ALK基因融合或F1174L突变的实体瘤患者使用ASP3026治疗后，50% (8/16)获得部分缓解，44% (7/16)患者疾病稳定。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26966027', 'NCT01284192', 'clinical trial - phase1', '4', '.', 'ASP3026', 'ASP3026', 'ASP3026', 'ASP3026|ASP3026', '1', 'Advanced Solid Tumor', 'Advanced Solid Tumor', '非特定癌症', '[ALK:FUS]', 'sensitivity', 'EVI_001696', 'ALK:FUS:.:.-ALK:', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', 'In a Phase I trial, ASP3026 treatment resulted in a partial response in 50% (8/16) and stable disease in 44% (7/16) of patients with an advanced solid tumor harboring an ALK rearrangement or ALK F1174L (PMID:26966027; ).', '在I期临床试验中，携带ALK基因融合或F1174L突变的实体瘤患者使用ASP3026治疗后，50% (8/16)获得部分缓解，44% (7/16)患者疾病稳定。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2019.08.1375', 'NCT03130881', 'clinical trial - phase1', '4', '.', '.', 'PLB1003', 'PLB1003', 'PLB1003|PLB1003', '1', 'non small-cell lung cancer', 'non small-cell lung cancer', '肺癌', '[ALK:FUS]', 'sensitivity', 'EVI_001697', 'ALK:FUS:.:.-ALK:', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', 'In a Phase Ia clinical trial, PLB1003 treatment resulted in a disease control rate of 86% with a 71% partial response (10/14) and 14% stable disease (2/14) in ALK rearranged non-small cell lung cancer patients with prior therapy (Journal of Thoracic Oncology, Volume 14, Issue 10, S651).', '在I期临床试验中，携带ALK基因融合的非小细胞肺癌患者使用PLB1003治疗后，71%(10/14)获得部分缓解，14%(2/14)患者疾病稳定。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 33, 2015 (suppl; abstr 8063)|J Clin Oncol 32, 2014 (suppl; abstr e19005)', 'NCT02048488', 'clinical trial - phase1', '4', '.', '.', 'belizatinib', 'belizatinib', 'belizatinib|belizatinib', '1', 'Advanced Solid Tumor', 'Advanced Solid Tumor', '非特定癌症', '[ALK:FUS]', 'sensitivity', 'EVI_001698', 'ALK:FUS:.:.-ALK:', 'ALK', 'FUS', 'FUS', '.', '.-ALK', '.', 'In a Phase I trial, Belizatinib (TSR-011) treatment resulted in a response in 100% (3/3) of patients with ALK positive advanced solid tumors when administered at higher doses, and stable disease for 7 months or longer in 56% (5/9) of patients at lower dose (J Clin Oncol 33, 2015 (suppl; abstr 8063)；NCT02048488.).', '一项I期临床试验中，ALK基因阳性的实体瘤患者使用高剂量Belizatinib治疗后，100%(3/3)患者有治疗响应；使用低剂量belizatinib治疗后56%(5/9)患者疾病稳定超过7个月。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:27601542', 'NCT01399918', 'clinical trial - phase2', '4', '.', '.', 'everolimus + bevacizumab', '依维莫司 + 贝伐珠单抗', 'everolimus + bevacizumab|依维莫司 + 贝伐珠单抗', '2', 'renal cell carcinom', 'renal cell carcinom', '肾癌', 'na', 'sensitivity', 'EVI_001699', 'ARID1A:nonsynonymous SNV:.:.:inact', 'ARID1A', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a Phase II trial, 100% (5/5) of renal cell carcinoma patients harboring ARID1A mutations achieved the primary endpoint of 6 month PFS when treated with the combination therapy Afinitor (everolimus) and Avastin (bevacizumab) (PMID:27601542).', '一项II期临床实验中，携带ARID1A基因突变的肾癌患者使用Afinitor (everolimus) + Avastin (bevacizumab)联合治疗后获得了6个月的PFS。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29103871', 'NCT01924533', 'clinical trial - phase3', '4', '.', '.', 'paclitaxel + olaparib', '紫杉醇 + 奥拉帕利', 'paclitaxel + olaparib|紫杉醇 + 奥拉帕利', '3', 'gastric cancer', 'gastric cancer', '胃癌', 'na', 'resistance', 'EVI_001701', 'ATM:nonsynonymous SNV:.:.:inact', 'ATM', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', 'In a Phase III trial (GOLD), addition of Lynparza (olaparib) to Taxol (paclitaxel) did not significantly improve overall survival (12.0 vs 10.0 months, HR=0.73, p=0.25) compared to Taxol (paclitaxel) alone in Asian patients with ATM-negative gastric cancer (PMID: 29103871; NCT01924533).', '一项临床III期试验中，相比paclitaxel单药，paclitaxel联合olaparib不能改善ATM缺失胃癌患者的总体生存期（12.0 vs 10.0 months, HR=0.73, p=0.25）。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29320312', 'NCT02091141', 'clinical trial - phase2', '4', 'trastuzumab + pertuzumab', 'trastuzumab + pertuzumab', 'trastuzumab + pertuzumab', '曲妥珠单抗 + 帕妥珠单抗', 'trastuzumab + pertuzumab|曲妥珠单抗 + 帕妥珠单抗', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001702', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'In a Phase II trial (MyPathway), Herceptin (trastuzumab) and Perjeta (pertuzumab) combination treatment resulted in objective response in 13% (2/16, all partial response) and stable disease lasting over 120 days in 13% (2/16) of patients with non-small cell lung cancer harboring ERBB2 (HER2) amplification or overexpression (PMID: 29320312; NCT02091141).', '在一项II期临床试验（MyPathway）中，携带ERBB2基因扩增或过表达的非小细胞肺癌患者使用Herceptin (trastuzumab)和Perjeta (pertuzumab) 联合治疗，客观缓解率为13%（2/16），病情稳定超过120天的患者为13%（2/16）。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2017.09.061', '.', 'case report', '4', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', '.', '.', '肺癌', 'na', 'resistance', 'EVI_001703', 'RET:FUS:.:.-RET:.', 'RET', 'FUS', 'FUS', '.', '.-RET', '.', '.', '一名EGFR外显子19缺失的肺癌患者最初对EGFR TKI治疗有反应，但是因为T790M突变产生了获得性耐药。随后，该患者采用了rociletinib治疗，然后采用osimertinib作为CNS进展的标准治疗方法，但疾病依然发生进展。除了EGFR del 19和T790M突变外，该患者还发现了一种CCDC6-RET融合基因突变，可能是其对osimertinib耐药的原因。', 'F', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:olaparib_Revised:12/2019', 'NCT02000622', 'guideline:FDA', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阴性)', '[NA;NA;HER2(-)]', 'sensitivity', 'EVI_001704', 'BRCA1:nonsynonymous SNV:::inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2018年1月12日FDA批准了阿斯利康Lynparza（olaparib，奥拉帕利）的新适应症，用于治疗携带BRCA胚系突变（gBRCA）的HER2阴性转移性乳腺癌。这是PARP抑制剂首次被批准用于治疗乳腺癌。该适应症获批是基于一项Ⅲ期临床试验(NCT02000622)，入组患者均是未超过二线以上化疗的晚期乳腺癌，经检测后确定伴有gBRCA突变。一共302例患者，按照2:1的比例分配到奥拉帕利组（300mg，口服，2次/日）或者是标准化疗组（三种方案：卡培他滨、艾立布林和长春瑞滨单药）。结果发现奥拉帕利组的有效率高达59.9%，比化疗高出1倍（28.8%）；无疾病进展时间（PFS）延长了接近3个月，奥拉帕利组是7个月，而化疗患者仅为4.2个月。在不良反应方面，奥拉帕利也明显低于化疗组。3级以上的毒性主要为血液学毒性：贫血（16.1%）、中性粒细胞减少（9.3%）和白细胞计数减少（3.4%）；3级以上的非血液学毒性发生率都在3%以下，主要表现在疲乏（2.9%）、头痛（1.0%）和谷丙转氨酶（1.5%）、谷草转氨酶（2.4%）的异常升高。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:olaparib_Revised:12/2019', 'NCT02000622', 'guideline:FDA', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阴性)', '[NA;NA;HER2(-)]', 'sensitivity', 'EVI_001705', 'BRCA2:nonsynonymous SNV:::inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2018年1月12日FDA批准了阿斯利康Lynparza（olaparib，奥拉帕利）的新适应症，用于治疗携带BRCA胚系突变（gBRCA）的HER2阴性转移性乳腺癌。这是PARP抑制剂首次被批准用于治疗乳腺癌。该适应症获批是基于一项Ⅲ期临床试验(NCT02000622)，入组患者均是未超过二线以上化疗的晚期乳腺癌，经检测后确定伴有gBRCA突变。一共302例患者，按照2:1的比例分配到奥拉帕利组（300mg，口服，2次/日）或者是标准化疗组（三种方案：卡培他滨、艾立布林和长春瑞滨单药）。结果发现奥拉帕利组的有效率高达59.9%，比化疗高出1倍（28.8%）；无疾病进展时间（PFS）延长了接近3个月，奥拉帕利组是7个月，而化疗患者仅为4.2个月。在不良反应方面，奥拉帕利也明显低于化疗组。3级以上的毒性主要为血液学毒性：贫血（16.1%）、中性粒细胞减少（9.3%）和白细胞计数减少（3.4%）；3级以上的非血液学毒性发生率都在3%以下，主要表现在疲乏（2.9%）、头痛（1.0%）和谷丙转氨酶（1.5%）、谷草转氨酶（2.4%）的异常升高。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:olaparib_Revised:12/2019|PMID:26723501', 'NCT01844986|NCT01078662', 'guideline:FDA', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'fallopian tube cancer', 'fallopian tube cancer', '输卵管癌', '.', 'sensitivity', 'EVI_001706', 'BRCA1:nonsynonymous SNV:::inact', 'BRCA1', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2014年12月FDA批准奥拉帕利作为单药治疗之前至少经过三次化疗的晚期卵巢癌患者，或者BRCA胚系突变（gBRCAm）的晚期卵巢癌。此适应症是基于一项国际性、单臂临床试验(NCT01078662)，试验纳入了137名gBRCAm相关且可测量的接受过三线或更多线化疗的卵巢癌患者，这些患者接受olaparib单药治疗直到出现疾病进展或不可接受的毒性。临床试验结果表明研究者评估的olaparib ORR为34% (95% CI: 26, 42)，中位反应持续时间为7.9个月 (95% CI: 5.6, 9.6)。欧盟药监局（EMA）也批准了奥拉帕利用于铂敏感复发性卵巢癌患者，对携带BRCA体细胞突变（sBRCA）的肿瘤患者也有一定作用。2018年12月19日，FDA批准奥拉帕利(LYNPARZA®, AstraZeneca Pharmaceuticals LP)维持治疗携带致病性或可能致病性的胚系或体细胞BRCA突变（gBRCAm或sBRCAm）的晚期上皮性卵巢癌、输卵管癌和原发性腹膜癌，这些患者对一线铂类化疗方案有完全或部分反应。此次获批基于一项随机、双盲、安慰剂做对照的多中心试验SOLO-1(NCT01844986)，试验纳入391名mBRCA患者，其中389名具有gBRCA突变，2例具有sBRCA突变，随机按照2:1比较了奥拉帕利（n=260）与安慰剂（n=131）对晚期卵巢癌、输卵管癌或原发性腹膜癌的疗效。与安慰剂组相比，奥拉帕利组PFS显示出统计学上显著改善。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:olaparib_Revised:12/2019|PMID:26723501', 'NCT01844986|NCT01078662', 'guideline:FDA', '1', 'olaparib', 'olaparib', 'olaparib', '奥拉帕利', 'olaparib|奥拉帕利', '4', 'fallopian tube cancer', 'fallopian tube cancer', '输卵管癌', '.', 'sensitivity', 'EVI_001707', 'BRCA2:nonsynonymous SNV:::inact', 'BRCA2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '2014年12月FDA批准奥拉帕利作为单药治疗之前至少经过三次化疗的晚期卵巢癌患者，或者BRCA胚系突变（gBRCAm）的晚期卵巢癌。此适应症是基于一项国际性、单臂临床试验(NCT01078662)，试验纳入了137名gBRCAm相关且可测量的接受过三线或更多线化疗的卵巢癌患者，这些患者接受olaparib单药治疗直到出现疾病进展或不可接受的毒性。临床试验结果表明研究者评估的olaparib ORR为34% (95% CI: 26, 42)，中位反应持续时间为7.9个月 (95% CI: 5.6, 9.6)。欧盟药监局（EMA）也批准了奥拉帕利用于铂敏感复发性卵巢癌患者，对携带BRCA体细胞突变（sBRCA）的肿瘤患者也有一定作用。2018年12月19日，FDA批准奥拉帕利(LYNPARZA®, AstraZeneca Pharmaceuticals LP)维持治疗携带致病性或可能致病性的胚系或体细胞BRCA突变（gBRCAm或sBRCAm）的晚期上皮性卵巢癌、输卵管癌和原发性腹膜癌，这些患者对一线铂类化疗方案有完全或部分反应。此次获批基于一项随机、双盲、安慰剂做对照的多中心试验SOLO-1(NCT01844986)，试验纳入391名mBRCA患者，其中389名具有gBRCA突变，2例具有sBRCA突变，随机按照2:1比较了奥拉帕利（n=260）与安慰剂（n=131）对晚期卵巢癌、输卵管癌或原发性腹膜癌的疗效。与安慰剂组相比，奥拉帕利组PFS显示出统计学上显著改善。', 'G;S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001708', 'EGFR:nonframeshift insertion:exon20:p.A763_Y764insFQEA:', 'EGFR', 'nonframeshift insertion', 'Exact_pos', 'exon20', 'p.A763_Y764insFQEA', '.', '.', 'NCCN指南表示，大多数EGFR外显子20插入突变会导致患者对EGFR TKI耐药。但是，罕见的EGFR外显子20插入突变(p.A763_Y764insFQEA)对EGFR TKI治疗敏感。 ', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001709', 'EGFR:nonframeshift insertion:exon20:p.A763_Y764insFQEA:', 'EGFR', 'nonframeshift insertion', 'Exact_pos', 'exon20', 'p.A763_Y764insFQEA', '.', '.', 'NCCN指南表示，大多数EGFR外显子20插入突变会导致患者对EGFR TKI耐药。但是，罕见的EGFR外显子20插入突变(p.A763_Y764insFQEA)对EGFR TKI治疗敏感。 ', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001710', 'EGFR:nonframeshift insertion:exon20:p.A763_Y764insFQEA:', 'EGFR', 'nonframeshift insertion', 'Exact_pos', 'exon20', 'p.A763_Y764insFQEA', '.', '.', 'NCCN指南表示，大多数EGFR外显子20插入突变会导致患者对EGFR TKI耐药。但是，罕见的EGFR外显子20插入突变(p.A763_Y764insFQEA)对EGFR TKI治疗敏感。 ', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'osimertinib', 'osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001711', 'EGFR:nonframeshift insertion:exon20:p.A763_Y764insFQEA:', 'EGFR', 'nonframeshift insertion', 'Exact_pos', 'exon20', 'p.A763_Y764insFQEA', '.', '.', 'NCCN指南表示，大多数EGFR外显子20插入突变会导致患者对EGFR TKI耐药。但是，罕见的EGFR外显子20插入突变(p.A763_Y764insFQEA)对EGFR TKI治疗敏感。 ', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <2.2020>|PMID:19667264', '.', 'guideline:NCCN', '1', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001712', 'EGFR:nonframeshift insertion:exon20:p.A763_Y764insFQEA:', 'EGFR', 'nonframeshift insertion', 'Exact_pos', 'exon20', 'p.A763_Y764insFQEA', '.', '.', 'NCCN指南表示，大多数EGFR外显子20插入突变会导致患者对EGFR TKI耐药。但是，罕见的EGFR外显子20插入突变(p.A763_Y764insFQEA)对EGFR TKI治疗敏感。 ', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Cutaneous Melanoma <1.2020>', '.', 'guideline:NCCN', '1', 'trametinib + dabrafenib', 'trametinib + dabrafenib', 'trametinib + dabrafenib', '曲美替尼 + 达拉非尼', 'trametinib + dabrafenib|曲美替尼 + 达拉非尼', '4', 'cutaneous melanoma', '.', '黑色素瘤', 'na', 'sensitivity', 'EVI_001713', 'BRAF:nonsynonymous SNV:exon15:p.V600.:', 'BRAF', 'nonsynonymous SNV', 'Partial_pos', 'exon15', 'p.V600.', '.', '.', 'NCCN指南（皮肤黑色素瘤）中表明携带BRAF外显子15近V600位点附近的点突变（尤其是L597和K601）的肿瘤患者可能对MEK抑制剂（如trametinib）或者BRAF抑制剂和MEK抑制的组合用药（如trametinib + dabrafenib，encorafenib + binimetinib）敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Esophageal and Esophagogastric Junction Cancers <4.2019>|PMID:20728210', '.', 'guideline:NCCN', '1', 'trastuzumab + cisplatin + 5-Fluorouracil', 'trastuzumab + cisplatin + 5-Fluorouracil', 'trastuzumab + cisplatin + 5-Fluorouracil', '曲妥珠单抗 + 顺铂 + 5-氟尿嘧啶', 'trastuzumab + cisplatin + 5-Fluorouracil|曲妥珠单抗 + 顺铂 + 5-氟尿嘧啶', '4', 'Esophageal and Esophagogastric Junction Cancers', 'Esophageal and Esophagogastric Junction Cancers', '食管癌', 'na', 'sensitivity', 'EVI_001714', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'The ToGA trial was the first randomized, prospective, multicenter, phase III trial that evaluated the efficacy and safety of trastuzumab in HER2-positive advanced gastric and EGJ adenocarcinoma In this trial, 594 patients with HER2-positive, locally advanced, recurrent, or metastatic gastric or EGJ adenocarcinoma were randomized to receive trastuzumab plus chemotherapy (cisplatin plus fluorouracil or capecitabine) or chemotherapy alone. The majority of patients had gastric cancer (80% in the trastuzumab group and 83% in the chemotherapy group). Median follow-up time was 19 months and 17 months, respectively, in the two groups. Results showed significant improvement in median OS with the addition of trastuzumab to chemotherapy in HER2-positive patients (13.8 vs.11 months, respectively; P = .046). This study established trastuzumab in combination with cisplatin and a fluoropyrimidine as the standard treatment for patients with HER2-positive metastatic gastroesophageal adenocarcinoma.', 'ToGA是第一个随机、前瞻性、多中心的III期临床试验，评估了trastuzumab在HER2阳性晚期胃癌和EGJ腺癌中的疗效和安全性。在该试验中，594例HER2阳性、局部晚期、复发或转移性胃癌或EGJ腺癌患者被随机分配接受trastuzumab加化疗（cisplatin + fluorouracil 或 capecitabine）或单独接受化疗。大多数患者为胃癌（trastuzumab组为80%，化疗组为83%）。两组的中位随访时间分别为19个月和17个月。 HER2阳性患者在化疗中加入trastuzumab后中位OS显着改善（分别为13.8和11个月； P = .046）。 这项研究建立了trastuzumab联合顺铂和氟嘧啶作为HER2阳性转移性胃食管腺癌患者的标准治疗方法。', 'A', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Esophageal and Esophagogastric Junction Cancers <4.2019>|PMID:20728210', '.', 'guideline:NCCN', '1', 'trastuzumab + cisplatin + capecitabine', 'trastuzumab + cisplatin + capecitabine', 'trastuzumab + cisplatin + capecitabine', '曲妥珠单抗 + 顺铂 + 卡培他滨', 'trastuzumab + cisplatin + capecitabine|曲妥珠单抗 + 顺铂 + 卡培他滨', '4', 'Esophageal and Esophagogastric Junction Cancers', 'Esophageal and Esophagogastric Junction Cancers', '食管癌', 'na', 'sensitivity', 'EVI_001715', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'The ToGA trial was the first randomized, prospective, multicenter, phase III trial that evaluated the efficacy and safety of trastuzumab in HER2-positive advanced gastric and EGJ adenocarcinoma In this trial, 594 patients with HER2-positive, locally advanced, recurrent, or metastatic gastric or EGJ adenocarcinoma were randomized to receive trastuzumab plus chemotherapy (cisplatin plus fluorouracil or capecitabine) or chemotherapy alone. The majority of patients had gastric cancer (80% in the trastuzumab group and 83% in the chemotherapy group). Median follow-up time was 19 months and 17 months, respectively, in the two groups. Results showed significant improvement in median OS with the addition of trastuzumab to chemotherapy in HER2-positive patients (13.8 vs.11 months, respectively; P = .046). This study established trastuzumab in combination with cisplatin and a fluoropyrimidine as the standard treatment for patients with HER2-positive metastatic gastroesophageal adenocarcinoma.', 'ToGA是第一个随机、前瞻性、多中心的III期临床试验，评估了trastuzumab在HER2阳性晚期胃癌和EGJ腺癌中的疗效和安全性。在该试验中，594例HER2阳性、局部晚期、复发或转移性胃癌或EGJ腺癌患者被随机分配接受trastuzumab加化疗（cisplatin + fluorouracil 或 capecitabine）或单独接受化疗。大多数患者为胃癌（trastuzumab组为80%，化疗组为83%）。两组的中位随访时间分别为19个月和17个月。 HER2阳性患者在化疗中加入trastuzumab后中位OS显着改善（分别为13.8和11个月； P = .046）。 这项研究建立了trastuzumab联合顺铂和氟嘧啶作为HER2阳性转移性胃食管腺癌患者的标准治疗方法。', 'A', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26980473', 'NCT01855854', 'clinical trial - phase2', '4', 'icotinib', 'icotinib', 'icotinib', '埃克替尼', 'icotinib|埃克替尼', '4', 'epidermal growth factor receptor', 'epidermal growth factor receptor', '食管癌', 'na', 'sensitivity', 'EVI_001716', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'INTRODUCTION:Epidermal growth factor receptor (EGFR) has been reported to be overexpressed and amplified in a high percentage of patients with esophageal squamous cell carcinoma (ESCC). The activity of icotinib, an EGFR tyrosine kinase inhibitor, was assessed in previously treated ESCC with EGFR overexpression or amplification.METHODS:For this phase 2, single-arm, multicenter trial undertaken at six hospitals in China, we included Chinese patients with previously treated, histologically confirmed advanced ESCC and EGFR overexpression (immunohistochemical staining sore of 3+) or amplification (positive fluorescence in situ hybridization result). These patients received oral icotinib (250 mg, three times daily).The primary end point was the proportion of patients with objective responses as assessed by an independent radiology review committee.RESULTS:Between December 5, 2013, and May 28, 2015, a total of 281 patients were screened. Fifty-four eligible patients were enrolled. Nine responses were observed, including one complete response and eight partial responses, and 16 patients had stable disease, resulting in a 16.7% objective response rate (95% confidence interval [CI]: 6.7-26.6) and 46.3% disease control rate (95% CI: 33.0-59.6). The median progression-free survival and overall survival times were 52 (95% CI: 40-95) days and 153 (95% CI: 139-218) days, respectively. A total of 43 patients experienced at least one adverse event, but most were only grade 1 to 2 in severity. The most frequent was rash (48.1%), followed by diarrhea (22.2%).CONCLUSIONS:Icotinib showed favorable activity in patients with advanced, previously treated ESCC with EGFR overexpression or amplification. These findings suggest further research into EGFR overexpression or amplification for selecting responsive patients.', '食管鳞状细胞癌（ESCC）患者中常发生表皮生长因子受体（EGFR）的过表达和扩增。一项研究在先具有EGFR过表达或扩增的ESCC患者中评估了EGFR酪氨酸激酶抑制剂icotinib的活性。在中国六家医院进行的单臂，多中心试验中，研究人员筛选了281名组织学证实具有EGFR过表达和扩增的晚期ESCC患者，共入选了54名合格患者，这些患者接受口服icotinib（250 mg，每天3次）的治疗，主要终点是独立放射学审查委员会评估的客观缓解患者的比例。其中9名患者有临床响应，包括1名患者完全缓解和8名患者部分缓解，另外还有16例患者病情稳定，客观缓解率为16.7%，疾病控制率为46.3%，中位无进展生存期和总生存时间分别为52天和153天。共有43位患者经历了至少一次不良事件，但大多数患者的严重程度仅为1-2级。该研究证明了icotinib在先前治疗过的具有EGFR过表达或扩增的ESCC患者中可能具有良好的活性。', 'A', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('Druglabel:avapritinib_01/2020', 'NCT02508532', 'guideline:FDA', '1', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib|avapritinib', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001721', 'PDGFRA:nonframeshift deletion:exon18:.:exon18act', 'PDGFRA', 'nonframeshift deletion', 'None_pos', 'exon18', '.', 'exon18act', '.', '2020年1月9日，FDA批准avapritinib(AYVAKITTM, Blueprint Medicines Corporation)用于治疗不可切除或转移性胃肠间质瘤(GIST)的成人患者，这类患者需携带PDGFRA第18号外显子突变，其中包括PDGFRA D842V突变。avapritinib是首个被批准用于携带PDGFRA第18号外显子突变的GIST患者的疗法。此次获批基于一项多中心、单臂、开放标签的有效性研究临床试验NAVIGATOR(NCT02508532)，共计纳入43例携带PDGFRA第18号外显子突变的GIST患者，包括38例PDGFRA D842V突变。试验最初以每日一次口服400 mg的起始剂量招募患者，后由于毒性降低到每日一次口服300 mg的推荐剂量，治疗直至疾病进展或出现无法耐受毒性。结果显示：携带PDGFRA第18号外显子突变患者，总体缓解率ORR为84% (95% CI: 69%, 93%)，完全缓解率为7%，部分缓解率为77%。对于具有PDGFRA D842V突变的患者亚组，ORR为89% (95% CI: 75%, 97%)，完全缓解率为8%，部分缓解率为82%。所有患者中位随访时间为10.6个月(0.3至24.9个月)，未达到中位反应持续时间。有61%的18号外显子突变患者持续6个月或更长的反应时间(持续反应患者中有31%随访时间少于6个月)。接受avapritinib治疗患者最常见不良反应(发生率≥20%)为水肿、恶心、疲劳乏力、认知障碍、呕吐、食欲下降、腹泻、头发颜色变化、流泪、腹痛、便秘、皮疹和头晕。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:avapritinib_01/2020', 'NCT02508532', 'guideline:FDA', '1', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib', 'avapritinib|avapritinib', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001722', 'PDGFRA:nonsynonymous SNV:exon18:p.D842V:', 'PDGFRA', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.D842V', '.', '.', '2020年1月9日，FDA批准avapritinib(AYVAKITTM, Blueprint Medicines Corporation)用于治疗不可切除或转移性胃肠间质瘤(GIST)的成人患者，这类患者需携带PDGFRA第18号外显子突变，其中包括PDGFRA D842V突变。avapritinib是首个被批准用于携带PDGFRA第18号外显子突变的GIST患者的疗法。此次获批基于一项多中心、单臂、开放标签的有效性研究临床试验NAVIGATOR(NCT02508532)，共计纳入43例携带PDGFRA第18号外显子突变的GIST患者，包括38例PDGFRA D842V突变。试验最初以每日一次口服400 mg的起始剂量招募患者，后由于毒性降低到每日一次口服300 mg的推荐剂量，治疗直至疾病进展或出现无法耐受毒性。结果显示：携带PDGFRA第18号外显子突变患者，总体缓解率ORR为84% (95% CI: 69%, 93%)，完全缓解率为7%，部分缓解率为77%。对于具有PDGFRA D842V突变的患者亚组，ORR为89% (95% CI: 75%, 97%)，完全缓解率为8%，部分缓解率为82%。所有患者中位随访时间为10.6个月(0.3至24.9个月)，未达到中位反应持续时间。有61%的18号外显子突变患者持续6个月或更长的反应时间(持续反应患者中有31%随访时间少于6个月)。接受avapritinib治疗患者最常见不良反应(发生率≥20%)为水肿、恶心、疲劳乏力、认知障碍、呕吐、食欲下降、腹泻、头发颜色变化、流泪、腹痛、便秘、皮疹和头晕。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PDGFRA in Gastrointestinal Stromal Tumours (GIST): ESMO Biomarker Factsheet(2019)|PMID:22089421|PMID:12949711|PMID:15928335|PMID:18955458|NCCN Guideline: Soft Tissue Sarcoma <4.2019>', '.', 'guideline:NCCN', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'Soft Tissue Sarcoma;GIST;Gastrointestinal Stromal Tumors', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001723', 'PDGFRA:nonframeshift deletion:exon18:.:exon18act', 'PDGFRA', 'nonframeshift deletion', 'None_pos', 'exon18', '.', 'exon18act', '.', '伊马替尼作用于PDGFR下游的酪氨酸激酶，PDGFRA Exon18及Exon12发生突变的多数GIST患者对格列卫敏感，但PDGFRA Exon18的D842V突变会导致GIST患者对伊马替尼原发耐药。NCCN指南中说明，大部分携带PDGFRA 18号外显子的突变的GIST患者对伊马替尼的治疗敏感。ESMO Biomarker Factsheet(2019)中说明，体外和临床研究表明，携带PDGFRA基因外显子18（不涉及D842）和外显子12突变的胃肠道间质瘤通常对伊马替尼治疗敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PDGFRA in Gastrointestinal Stromal Tumours (GIST): ESMO Biomarker Factsheet(2019)|PMID:22089421|PMID:12949711|PMID:15928335|PMID:18955458|NCCN Guideline: Soft Tissue Sarcoma <4.2019>', '.', 'guideline:NCCN', '1', 'imatinib', 'imatinib', 'imatinib', '伊马替尼', 'imatinib|伊马替尼', '4', 'Soft Tissue Sarcoma;GIST;Gastrointestinal Stromal Tumors', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001724', 'PDGFRA:nonframeshift deletion:exon12:.:exon12act', 'PDGFRA', 'nonframeshift deletion', 'None_pos', 'exon12', '.', 'exon12act', '.', '伊马替尼作用于PDGFR下游的酪氨酸激酶，PDGFRA Exon18及Exon12发生突变的多数GIST患者对格列卫敏感，但PDGFRA Exon18的D842V突变会导致GIST患者对伊马替尼原发耐药。NCCN指南中说明，大部分携带PDGFRA 18号外显子的突变的GIST患者对伊马替尼的治疗敏感。ESMO Biomarker Factsheet(2019)中说明，体外和临床研究表明，携带PDGFRA基因外显子18（不涉及D842）和外显子12突变的胃肠道间质瘤通常对伊马替尼治疗敏感。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394|EORTC-NCI-AACR 2016, Abs 7LBA', 'NCT03353753', 'clinical trial - phase3', '4', 'Ripretinib', 'Ripretinib', 'ripretinib', 'ripretinib', 'ripretinib|ripretinib', '4', 'Gastrointestinal Stromal Tumors', 'Gastrointestinal Stromal Tumors', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001725', 'PDGFRA:nonsynonymous SNV:exon18:.:exon18act', 'PDGFRA', 'nonsynonymous SNV', 'None_pos', 'exon18', '.', 'exon18act', 'Ripretinib is a switch-control kinase inhibitor that broadly inhibits KIT- and PDGFRA-mutated kinases by regulating the kinase switch pocket and activation loop.Patients (pts) with advanced GIST who received prior treatment with at least imatinib, sunitinib, and regorafenib were enrolled. Pts were randomized 2:1 to ripretinib 150 mg QD or placebo (P) and stratified by 3 v ≥ 4 prior therapies and ECOG 0 v 1-2. Patients with a PD on 150 mg QD were allowed to dose escalate and patients on P arm crossed over to ripretinib at PD. The primary end point was PFS per blinded independent central review. Secondary end points included objective response rate (ORR; key end point) and OS.129 pts were randomized as ITT. In the double-blind period, ripretinib improved median PFS over P (6.3 v 1 mo; HR = 0.15; 95%CI: 0.09,0.25; P < 0.0001). PFS rates at 6 mo were 51% (95%CI: 39.4,61.4) for ripretinib and 3.2% (95%CI: 0.2,13.8) for P. Analysis of PFS in pt subgroups assessed favored ripretinib. ORR was 9.4% for ripretinib and 0% for P (P = 0.0504; median duration not reached). Ripretinib demonstrated an improvement over P in median OS (15.1 v 6.6 mo; HR = 0.36; 95%CI: 0.20,0.62; nominal P = 0.0004). OS rates at 12 mo were 65.4% (95%CI: 51.6,76.1) for ripretinib and 25.9% (95%CI: 7.2,49.9) for P. Ripretinib was generally well tolerated. Any dose reductions were in 7 pts (8.2%) in ripretinib arm v 1 (2.3%) in P arm; interruptions were in 18 pts (21.2%) in ripretinib v 8 (18.6%) in P arm. Ripretinib improved PFS over P in advanced GIST patients after progression on standard treatments. Ripretinib was associated with a favorable tolerability profile. Ripretinib is a novel therapy in a population with no other approved therapy and may represent a new standard of care.', 'Ripretinib是一种开关控制激酶抑制剂，可通过调节激酶开关广泛抑制KIT和PDGFRA突变的激酶。一项临床实验中，研究对象为已接受过GIST治疗且至少接受过伊马替尼，舒尼替尼和雷戈拉非尼治疗的晚期GIST患者。患者按2：1的比例随机分配至ripretinib 150 umg QD组或安慰剂（P）组并进行分层。主要终点是PFS，次要终点包括客观反应率（ORR）和OS。在双盲期间，ripretinib组比起P组，PFS的中位数明显改善（P<0.0001）。ripretinib在6个月时的PFS率为51%，P组则为3.2%。ripretinib组的ORR为9.4%，P组的ORR为0%。ripretinib在中位OS方面比P组有改善（P ＝ 0.0004）。ripretinib在12个月时的OS率为65.4%，P组的OS为25.9%。ripretinib耐受良好。患者标准治疗进展后，比起P组，ripretinib可改善晚期GIST患者的PFS。另一项I期临床试验中，共8名携带KIT基因突变的患者经ripretinib治疗后获得部分缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31085175', '.', 'preclinical', '4', 'Ripretinib', 'Ripretinib', 'ripretinib', 'ripretinib', 'ripretinib|ripretinib', '4', 'Gastrointestinal Stromal Tumors', 'Gastrointestinal Stromal Tumors', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001726', 'PDGFRA:nonsynonymous SNV:exon18:p.D842V:.', 'PDGFRA', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.D842V', '.', 'In a preclinical study, Ripretinib (DCC-2618) inhibited proliferation of transformed cells expressing PDGFRA D842V in culture (PMID:31085175).', '细胞学试验表明，ripretinib可以抑制携带PDGFR D842V突变的肿瘤细胞生长。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394|EORTC-NCI-AACR 2016, Abs 7LBA', 'NCT03353753', 'clinical trial - phase3', '4', 'Ripretinib', 'Ripretinib', 'ripretinib', 'ripretinib', 'ripretinib|ripretinib', '4', 'Gastrointestinal Stromal Tumors', 'Gastrointestinal Stromal Tumors', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001727', 'PDGFRA:nonsynonymous SNV:exon12:.:exon12act', 'PDGFRA', 'nonsynonymous SNV', 'None_pos', 'exon12', '.', 'exon12act', 'Ripretinib is a switch-control kinase inhibitor that broadly inhibits KIT- and PDGFRA-mutated kinases by regulating the kinase switch pocket and activation loop.Patients (pts) with advanced GIST who received prior treatment with at least imatinib, sunitinib, and regorafenib were enrolled. Pts were randomized 2:1 to ripretinib 150 mg QD or placebo (P) and stratified by 3 v ≥ 4 prior therapies and ECOG 0 v 1-2. Patients with a PD on 150 mg QD were allowed to dose escalate and patients on P arm crossed over to ripretinib at PD. The primary end point was PFS per blinded independent central review. Secondary end points included objective response rate (ORR; key end point) and OS.129 pts were randomized as ITT. In the double-blind period, ripretinib improved median PFS over P (6.3 v 1 mo; HR = 0.15; 95%CI: 0.09,0.25; P < 0.0001). PFS rates at 6 mo were 51% (95%CI: 39.4,61.4) for ripretinib and 3.2% (95%CI: 0.2,13.8) for P. Analysis of PFS in pt subgroups assessed favored ripretinib. ORR was 9.4% for ripretinib and 0% for P (P = 0.0504; median duration not reached). Ripretinib demonstrated an improvement over P in median OS (15.1 v 6.6 mo; HR = 0.36; 95%CI: 0.20,0.62; nominal P = 0.0004). OS rates at 12 mo were 65.4% (95%CI: 51.6,76.1) for ripretinib and 25.9% (95%CI: 7.2,49.9) for P. Ripretinib was generally well tolerated. Any dose reductions were in 7 pts (8.2%) in ripretinib arm v 1 (2.3%) in P arm; interruptions were in 18 pts (21.2%) in ripretinib v 8 (18.6%) in P arm. Ripretinib improved PFS over P in advanced GIST patients after progression on standard treatments. Ripretinib was associated with a favorable tolerability profile. Ripretinib is a novel therapy in a population with no other approved therapy and may represent a new standard of care.', 'Ripretinib是一种开关控制激酶抑制剂，可通过调节激酶开关广泛抑制KIT和PDGFRA突变的激酶。一项临床实验中，研究对象为已接受过GIST治疗且至少接受过伊马替尼，舒尼替尼和雷戈拉非尼治疗的晚期GIST患者。患者按2：1的比例随机分配至ripretinib 150 umg QD组或安慰剂（P）组并进行分层。主要终点是PFS，次要终点包括客观反应率（ORR）和OS。在双盲期间，ripretinib组比起P组，PFS的中位数明显改善（P<0.0001）。ripretinib在6个月时的PFS率为51%，P组则为3.2%。ripretinib组的ORR为9.4%，P组的ORR为0%。ripretinib在中位OS方面比P组有改善（P ＝ 0.0004）。ripretinib在12个月时的OS率为65.4%，P组的OS为25.9%。ripretinib耐受良好。患者标准治疗进展后，比起P组，ripretinib可改善晚期GIST患者的PFS。另一项I期临床试验中，共8名携带KIT基因突变的患者经ripretinib治疗后获得部分缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394|EORTC-NCI-AACR 2016, Abs 7LBA', 'NCT03353753', 'clinical trial - phase3', '4', 'Ripretinib', 'Ripretinib', 'ripretinib', 'ripretinib', 'ripretinib|ripretinib', '4', 'Gastrointestinal Stromal Tumors', 'Gastrointestinal Stromal Tumors', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001728', 'KIT:nonsynonymous SNV:exon9:.:exon9act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon9', '.', 'exon9act', 'Ripretinib is a switch-control kinase inhibitor that broadly inhibits KIT- and PDGFRA-mutated kinases by regulating the kinase switch pocket and activation loop.Patients (pts) with advanced GIST who received prior treatment with at least imatinib, sunitinib, and regorafenib were enrolled. Pts were randomized 2:1 to ripretinib 150 mg QD or placebo (P) and stratified by 3 v ≥ 4 prior therapies and ECOG 0 v 1-2. Patients with a PD on 150 mg QD were allowed to dose escalate and patients on P arm crossed over to ripretinib at PD. The primary end point was PFS per blinded independent central review. Secondary end points included objective response rate (ORR; key end point) and OS.129 pts were randomized as ITT. In the double-blind period, ripretinib improved median PFS over P (6.3 v 1 mo; HR = 0.15; 95%CI: 0.09,0.25; P < 0.0001). PFS rates at 6 mo were 51% (95%CI: 39.4,61.4) for ripretinib and 3.2% (95%CI: 0.2,13.8) for P. Analysis of PFS in pt subgroups assessed favored ripretinib. ORR was 9.4% for ripretinib and 0% for P (P = 0.0504; median duration not reached). Ripretinib demonstrated an improvement over P in median OS (15.1 v 6.6 mo; HR = 0.36; 95%CI: 0.20,0.62; nominal P = 0.0004). OS rates at 12 mo were 65.4% (95%CI: 51.6,76.1) for ripretinib and 25.9% (95%CI: 7.2,49.9) for P. Ripretinib was generally well tolerated. Any dose reductions were in 7 pts (8.2%) in ripretinib arm v 1 (2.3%) in P arm; interruptions were in 18 pts (21.2%) in ripretinib v 8 (18.6%) in P arm. Ripretinib improved PFS over P in advanced GIST patients after progression on standard treatments. Ripretinib was associated with a favorable tolerability profile. Ripretinib is a novel therapy in a population with no other approved therapy and may represent a new standard of care.', 'Ripretinib是一种开关控制激酶抑制剂，可通过调节激酶开关广泛抑制KIT和PDGFRA突变的激酶。一项临床实验中，研究对象为已接受过GIST治疗且至少接受过伊马替尼，舒尼替尼和雷戈拉非尼治疗的晚期GIST患者。患者按2：1的比例随机分配至ripretinib 150 umg QD组或安慰剂（P）组并进行分层。主要终点是PFS，次要终点包括客观反应率（ORR）和OS。在双盲期间，ripretinib组比起P组，PFS的中位数明显改善（P<0.0001）。ripretinib在6个月时的PFS率为51%，P组则为3.2%。ripretinib组的ORR为9.4%，P组的ORR为0%。ripretinib在中位OS方面比P组有改善（P ＝ 0.0004）。ripretinib在12个月时的OS率为65.4%，P组的OS为25.9%。ripretinib耐受良好。患者标准治疗进展后，比起P组，ripretinib可改善晚期GIST患者的PFS。另一项I期临床试验中，共8名携带KIT基因突变的患者经ripretinib治疗后获得部分缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394|EORTC-NCI-AACR 2016, Abs 7LBA', 'NCT03353753', 'clinical trial - phase3', '4', 'Ripretinib', 'Ripretinib', 'ripretinib', 'ripretinib', 'ripretinib|ripretinib', '4', 'Gastrointestinal Stromal Tumors', 'Gastrointestinal Stromal Tumors', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001729', 'KIT:nonsynonymous SNV:exon11::exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', 'In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).', 'Ripretinib是一种开关控制激酶抑制剂，可通过调节激酶开关广泛抑制KIT和PDGFRA突变的激酶。一项临床实验中，研究对象为已接受过GIST治疗且至少接受过伊马替尼，舒尼替尼和雷戈拉非尼治疗的晚期GIST患者。患者按2：1的比例随机分配至ripretinib 150 umg QD组或安慰剂（P）组并进行分层。主要终点是PFS，次要终点包括客观反应率（ORR）和OS。在双盲期间，ripretinib组比起P组，PFS的中位数明显改善（P<0.0001）。ripretinib在6个月时的PFS率为51%，P组则为3.2%。ripretinib组的ORR为9.4%，P组的ORR为0%。ripretinib在中位OS方面比P组有改善（P ＝ 0.0004）。ripretinib在12个月时的OS率为65.4%，P组的OS为25.9%。ripretinib耐受良好。患者标准治疗进展后，比起P组，ripretinib可改善晚期GIST患者的PFS。另一项I期临床试验中，共8名携带KIT基因突变的患者经ripretinib治疗后获得部分缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394|EORTC-NCI-AACR 2016, Abs 7LBA', 'NCT03353753', 'clinical trial - phase3', '4', 'Ripretinib', 'Ripretinib', 'ripretinib', 'ripretinib', 'ripretinib|ripretinib', '4', 'Gastrointestinal Stromal Tumors', 'Gastrointestinal Stromal Tumors', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001730', 'KIT:nonsynonymous SNV:exon13::exon13act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon13', '.', 'exon13act', 'In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).', 'Ripretinib是一种开关控制激酶抑制剂，可通过调节激酶开关广泛抑制KIT和PDGFRA突变的激酶。一项临床实验中，研究对象为已接受过GIST治疗且至少接受过伊马替尼，舒尼替尼和雷戈拉非尼治疗的晚期GIST患者。患者按2：1的比例随机分配至ripretinib 150 umg QD组或安慰剂（P）组并进行分层。主要终点是PFS，次要终点包括客观反应率（ORR）和OS。在双盲期间，ripretinib组比起P组，PFS的中位数明显改善（P<0.0001）。ripretinib在6个月时的PFS率为51%，P组则为3.2%。ripretinib组的ORR为9.4%，P组的ORR为0%。ripretinib在中位OS方面比P组有改善（P ＝ 0.0004）。ripretinib在12个月时的OS率为65.4%，P组的OS为25.9%。ripretinib耐受良好。患者标准治疗进展后，比起P组，ripretinib可改善晚期GIST患者的PFS。另一项I期临床试验中，共8名携带KIT基因突变的患者经ripretinib治疗后获得部分缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Annals of Oncology (2019) 30 (suppl_5): v851-v934. 10.1093/annonc/mdz394|EORTC-NCI-AACR 2016, Abs 7LBA', 'NCT03353753', 'clinical trial - phase3', '4', 'Ripretinib', 'Ripretinib', 'ripretinib', 'ripretinib', 'ripretinib|ripretinib', '4', 'Gastrointestinal Stromal Tumors', 'Gastrointestinal Stromal Tumors', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001731', 'KIT:nonsynonymous SNV:exon17::exon17act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon17', '.', 'exon17act', 'In a Phase I trial, DCC-2618 demonstrated preliminary safety and efficacy in patients with advanced solid tumors, including KIT-mutant gastrointestinal stromal tumor (GIST), with 1 patient harboring KIT exon 11 and 17 mutations demonstrating a partial response, and 7/7 KIT-mutant GIST patients demonstrating a partial metabolic response (EORTC-NCI-AACR 2016, Abs 7LBA).', 'Ripretinib是一种开关控制激酶抑制剂，可通过调节激酶开关广泛抑制KIT和PDGFRA突变的激酶。一项临床实验中，研究对象为已接受过GIST治疗且至少接受过伊马替尼，舒尼替尼和雷戈拉非尼治疗的晚期GIST患者。患者按2：1的比例随机分配至ripretinib 150 umg QD组或安慰剂（P）组并进行分层。主要终点是PFS，次要终点包括客观反应率（ORR）和OS。在双盲期间，ripretinib组比起P组，PFS的中位数明显改善（P<0.0001）。ripretinib在6个月时的PFS率为51%，P组则为3.2%。ripretinib组的ORR为9.4%，P组的ORR为0%。ripretinib在中位OS方面比P组有改善（P ＝ 0.0004）。ripretinib在12个月时的OS率为65.4%，P组的OS为25.9%。ripretinib耐受良好。患者标准治疗进展后，比起P组，ripretinib可改善晚期GIST患者的PFS。另一项I期临床试验中，共8名携带KIT基因突变的患者经ripretinib治疗后获得部分缓解。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Soft Tissue Sarcoma <4.2019>|DOI:10.1200/jco.2011.29.15_suppl.10006', '.', 'guideline:NCCN', '1', 'dasatinib', 'dasatinib', 'dasatinib', '达沙替尼', 'dasatinib|达沙替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001733', 'PDGFRA:nonsynonymous SNV:exon18:p.D842V:.', 'PDGFRA', 'nonsynonymous SNV', 'Exact_pos', 'exon18', 'p.D842V', '.', '.', 'PDGFRA D842V突变是imatinib的主要耐药位点，但是该突变导致的PDGFRA激活可以被Dasatinib抑制。因此，Dasatinib 可能是imatinib耐药GIST患者的有效治疗选择。一项临床II期研究中，50例晚期GIST耐药患者经dasatinib治疗后，中位PFS和OS分别为2和19个月。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 29: 2011 (suppl; abstr 10006)', '.', 'clinical trial - phase2', '4', 'dasatinib', 'dasatinib', 'dasatinib', '达沙替尼', 'dasatinib|达沙替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001734', 'KIT:nonsynonymous SNV:exon11::exon11act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon11', '.', 'exon11act', 'In a Phase II clinical trial, Sprycel (dasatinib) demonstrated preliminary activity in patients with Gleevec (imatinib)-resistant gastrointestinal stromal tumor (GIST), including patients harboring KIT exon 11 mutations, with a partial response rate of 32% (15/47), median progression-free survival of 2.0 months, and overall survival of 19 months (J Clin Oncol 29: 2011 (suppl; abstr 10006)).', '一项II期临床试验中，dasatinib对imatinib耐药的GIST患者（包括含有Exon 11突变的患者）显示出初步的抗肿瘤活性，部分缓解率为32% (15/47)，PFS为2个月，OS为19个月。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Soft Tissue Sarcoma <4.2019>|PMID:22357255|PMID:22119758', '.', 'guideline:NCCN', '1', 'niluotinib', 'nilotinib', 'nilotinib', '尼洛替尼', 'nilotinib|尼洛替尼', '4', 'gastrointestinal stromal tumor', 'gastrointestinal stromal tumor', '胃肠间质瘤', 'na', 'sensitivity', 'EVI_001735', 'KIT:nonsynonymous SNV:exon17::exon17act', 'KIT', 'nonsynonymous SNV', 'None_pos', 'exon17', '.', 'exon17act', 'The clinical benefit associated with nilotinib may be specific to subsets of patients with KIT exon 17 mutations who were previously treated with imatinib and sunitinib.386 NCCN指南表示，对既往接受过imatinib和sunitinib的GIST患者，携带KIT exon 17突变的患者更有可能取得临床获益。', 'NCCN指南表示，对既往接受过imatinib和sunitinib的GIST患者，携带KIT exon 17突变的患者更有可能取得临床获益。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29216400', 'NCT01524926', 'clinical trial - phase2', '4', 'crizotinib', 'crizotinib', 'crizotinib', '克唑替尼', 'crizotinib|克唑替尼', '4', 'alveolar soft part sarcoma', 'alveolar soft part sarcoma', '肺泡软组织肉瘤', 'na', 'sensitivity', 'EVI_001737', 'TFE3:FUS:.:.-TFE3:', 'TFE3', 'FUS', 'FUS', '.', '.-TFE3', '.', 'Alveolar soft part sarcoma (ASPS) is an orphan malignancy associated with a rearrangement of transcription factor E3 (TFE3), leading to abnormal MET gene expression. We prospectively assessed the efficacy and safety of the MET tyrosine kinase inhibitor crizotinib in patients with advanced or metastatic ASPS.Eligible patients with reference pathology-confirmed ASPS received oral crizotinib 250 mg bd. By assessing the presence or absence of a TFE3 rearrangement, patients were attributed to MET+ and MET- sub-cohorts. The primary end point was the objective response rate (ORR) according to local investigator. Secondary end points included duration of response, disease control rate (DCR), progression-free survival (PFS), progression-free rate, overall survival (OS) and safety.Among 53 consenting patients, all had a centrally confirmed ASPS and 48 were treated. A total of 45 were eligible, treated and assessable. Among 40 MET+ patients, 1 achieved a confirmed partial response (PR) that lasted 215 days and 35 had stable disease (SD) as best response (ORR: 2.5%, 95% CI 0.6% to 80.6%). Further efficacy end points in MET+ cases were DCR: 90.0% (95% CI 76.3% to 97.2%), 1-year PFS rate: 37.5% (95% CI 22.9% to 52.1%) and 1-year OS rate: 97.4% (95% CI 82.8% to 99.6%). Among 4 MET- patients, 1 achieved a PR that lasted 801 days and 3 had SD (ORR: 25.0%, 95% CI 0.6% to 80.6%) for a DCR of 100% (95% CI 39.8% to 100.0%). The 1-year PFS rate in MET- cases was 50% (95% CI 5.8% to 84.5%) and the 1-year OS rate was 75% (95% CI 12.8% to 96.1%). One patient with unknown MET status due to technical failure achieved SD but stopped treatment due to progression after 17 cycles. The most common crizotinib-related adverse events were nausea [34/48 (70.8%)], vomiting [22/48 (45.8%)], blurred vision [22/48 (45.8%)], diarrhoea (20/48 (41.7%)] and fatigue [19/48 (39.6%)].According to European Organization for Research and Treatment of Cancer (EORTC) efficacy criteria for soft tissue sarcoma, our study demonstrated that crizotinib has activity in TFE3 rearranged ASPS MET+ patients.EORTC 90101, NCT01524926.', '肺泡软组织肉瘤（ASPS）是与TFE3重排相关的孤儿恶性肿瘤，常带有MET表达异常。一项前瞻性研究评估了crizotinib在晚期或转移性ASPS患者中的疗效和安全性。将患者分为MET+和MET-亚组，主要终点是当地研究人员判定的客观反应率（ORR），次要终点包括反应持续时间，疾病控制率（DCR），无进展生存率（PFS），无进展率，总生存率（OS）和安全性。共有45位患者接受治疗和评估。在40名MET+患者中，1名患者的部分缓解（PR）时间达215天，35名病情稳定（SD）的患者实现了最佳缓解。MET+病例的进一步疗效为：DCR：90.0%，1年PFS率：37.5%，1年OS率：97.4%。在4位MET-患者中，1位患者的PR持续了801天，另外3位患者的SD率、DCR为100%。MET-病例的1年PFS率为50%，1年OS率为75%。1名因技术故障导致MET状态未知的患者达到了SD，17个周期后因疾病进展而停止了治疗。与crizotinib相关的最常见不良事件为恶心，呕吐，视力模糊，腹泻和疲劳。根据欧洲癌症研究和治疗组织（EORTC）对软组织肉瘤的疗效标准，该研究表明crizotinib在TFE3重排的MET+ASPS患者中具有活性。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.apsb.2019.03.002', 'MRTX849-001', 'clinical trial - phase1', '4', 'MRTX849', 'MRTX849', 'MRTX849', 'MRTX849', 'MRTX849|MRTX849', '1', 'non small-cell lung cance/Colorectal cancer', 'non small-cell lung cance/Colorectal cancer', '肺癌', 'na', 'sensitivity', 'EVI_001738', 'KRAS:nonsynonymous SNV::p.G12C:', 'KRAS', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.G12C', '.', '.', '在一项验证KRAS G12C抑制剂MRTX849对携带KRAS G12C基因突变的非小细胞肺癌（NSCLC）和结直肠癌（CRC）患者疗效和安全性的一期临床研究（MRTX849-001）中，共招募了17名患者，其中包括10名NSCLC患者，4名CRC患者，3名其它癌症类型患者。他们接受不同剂量MRTX849的治疗，最低剂量为150 mg每天一次，最高剂量为600 mg每天两次。在接受所有剂量（All Doses）治疗的患者中，3/6能被评估的NSCLC患者和1/4能被评估的CRC患者达到部分缓解，在接受最高剂量（600 mg BID）治疗的患者中，3/5能被评估的NSCLC患者和1/2能被评估的CRC患者达到部分缓解，其它患者病情稳定。该临床初步结果显示，MRTX849对携带KRAS G12C基因突变的非小细胞肺癌（NSCLC）和结直肠癌（CRC）患者的治疗具有优秀的安全性和疗效。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.apsb.2019.03.002', 'MRTX849-001', 'clinical trial - phase1', '4', 'MRTX849', 'MRTX849', 'MRTX849', 'MRTX849', 'MRTX849|MRTX849', '1', 'non small-cell lung cance/Colorectal cancer', 'non small-cell lung cance/Colorectal cancer', '结直肠癌', 'na', 'sensitivity', 'EVI_001739', 'KRAS:nonsynonymous SNV::p.G12C:', 'KRAS', 'nonsynonymous SNV', 'Exact_pos', '.', 'p.G12C', '.', '.', '在一项验证KRAS G12C抑制剂MRTX849对携带KRAS G12C基因突变的非小细胞肺癌（NSCLC）和结直肠癌（CRC）患者疗效和安全性的一期临床研究（MRTX849-001）中，共招募了17名患者，其中包括10名NSCLC患者，4名CRC患者，3名其它癌症类型患者。他们接受不同剂量MRTX849的治疗，最低剂量为150 mg每天一次，最高剂量为600 mg每天两次。在接受所有剂量（All Doses）治疗的患者中，3/6能被评估的NSCLC患者和1/4能被评估的CRC患者达到部分缓解，在接受最高剂量（600 mg BID）治疗的患者中，3/5能被评估的NSCLC患者和1/2能被评估的CRC患者达到部分缓解，其它患者病情稳定。该临床初步结果显示，MRTX849对携带KRAS G12C基因突变的非小细胞肺癌（NSCLC）和结直肠癌（CRC）患者的治疗具有优秀的安全性和疗效。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Soft Tissue Sarcoma <4.2019>|PMID:23569312', 'NCT01209598', 'guideline:NCCN', '1', 'palbociclib', 'palbociclib', 'palbociclib', '哌柏西利', 'palbociclib|哌柏西利', '4', 'liposarcoma', 'liposarcoma', '脂肪肿瘤', 'na', 'sensitivity', 'EVI_001740', 'CDK4:CNV:.:.:gain', 'CDK4', 'CNV', 'CNV', '.', '.', 'gain', '.', '一项临床试验评估了PD0332991对高分化脂肪肉瘤（WDLS）和去分化脂肪肉瘤（DDLS）的安全性和有效性。年龄≥18岁的患者在入组前接受过全身治疗后并发生疾病进展。所有患者均需通过荧光原位杂交进行CDK4扩增检测，并通过免疫组织化学检测成视网膜细胞瘤蛋白（RB）表达。该临床试验共筛选了48例患者（其44例患者有CDK4扩增； 41例患者RB表达阳性）。最终30名患者被纳入研究，其中29名患者可以评估主要终点（PFS）。12周的PFS率为66%，中位PFS为18周。其中一名患者取得部分缓解。', 'A', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/JCO.2019.37.15_suppl.11005', 'NCT02494570', 'clinical trial - phase2', '4', 'ABI-009', 'ABI-009', 'ABI-009', 'ABI-009', 'ABI-009|ABI-009', '2', 'advanced malignant perivascular epithelioid cell tumors (PEComa)', 'advanced malignant perivascular epithelioid cell tumors (PEComa)', '血管周上皮样细胞肿瘤', 'na', 'sensitivity', 'EVI_001741', 'TSC2:nonsynonymous SNV:.:.:inact', 'TSC2', 'nonsynonymous SNV', 'None_pos', '.', '.', 'inact', '.', '晚期恶性血管周围上皮细胞瘤（PEComa）是一类罕见、侵袭性较强的肉瘤，目前尚未获批相应治疗药物，也未进行相关临床试验探索。个案报道提示，这类肿瘤可以提高TSC1或TSC2突变或缺失活化mTOR，因此mTOR抑制剂用于这类患者具有一定的疗效。ABI-009是一个结合了白蛋白的mTOR抑制剂，可以增加肿瘤对药物的摄取率。AMPECT研究是第一项在恶性PEComa患者中进行的前瞻性研究。目前先报道探索性分析和安全性结果，独立评估委员会仍在评估中。截至2019年2月12日，研究完成入组，共34例患者接受治疗，31例患者可评估疗效，42% (13/31) 的患者疗效仍在继续。研究者评估的ORR为42%，均为PR (13/31,95%CI: 24.5,60.9)；SD的患者占35%(11/31)；PD的患者占23%(7/31)。PR的患者中，69%达到第一次再分期(第6周)；69%的PRs患者疗效仍在继续，其中5例患者治疗>2年，2例患者治疗>2年（疗效仍在继续）。其他研究者评估的疗效终点：中位DOR尚未达到；6个月的PFS率为 66%；中位PFS为8.9个月(95%CI: 5.5, NR)。最常见的（>30%）的、任意级别的非血液学治疗相关AE (TRAEs)包括：粘膜炎(65%)、疲劳(53%)、恶心(35%)、体重减轻 (35%)、腹泻(32%)；最常见的(>15%)的血液学TRAEs包括：贫血(44%)和血小板减低(18%)。肺炎发生率为15%，均为1～2度。最常见的(>10%) 3度TRAEs包括: 粘膜炎(18%)、贫血(12%)；未观察到4度或以上的TRAEs。25例突变状态已知的患者中，TSC1或TSC2 突变患者分别为5例和9例(两类患者无覆盖)。在TSC2突变的患者中，PR率为100% (9/9)，TSC1突变患者中，PR率为20% (1/5)；在未合并TSC1或TSC2突变的患者中，PR率为9% (1/11)；采用FISH精确检验，3组疗效具有显著差异，P<0.0001；两两比较显示，TSC2突变的患者，PR率远高于未合并TSC1或TSC2突变的患者，P=0.0001；在TSC1或TSC2突变的患者和未合并上述突变的患者中，DCR率分别为93% (13/14) vs 55% (6/11)，差异无显著统计学意义。该临床试验研究者评估的初步结果显示，ABI-009治疗PEComa可以取得较高的缓解率和较持久疗效，且毒性可管理。TSC2突变与研究者评估的疗效相关。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:31227518', '.', 'case report', '4', 'binimetinib', 'binimetinib', 'binimetinib', 'binimetinib', 'binimetinib|binimetinib', '4', '.', 'Colon Cancer', '结直肠癌', 'na', 'resistance', 'EVI_001742', 'MAP2K1:nonframeshift deletion:exon6:p.V211D:', 'MAP2K1', 'nonframeshift deletion', 'Exact_pos', 'exon6', 'p.V211D', '.', '.', '一名携带BRAF K601E突变的结肠癌的患者，在经过MEK和EGFR抑制剂治疗后，MEK1基因发生了V211D突变。该突变体增加了MEK1的催化活性，并降低了其与binimetinib的亲和力，因此可能与binimetinib的耐药有关。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/2159-8290.CD-18-0839', 'NCT01877811', 'clinical trial - phase1', '4', 'agerafenib', 'agerafenib', 'agerafenib', 'agerafenib', 'agerafenib|agerafenib', '1', '.', '.', '肺癌', 'NSCLC', 'sensitivity', 'EVI_001743', 'RET:FUS:.:CCDC6-RET:', 'RET', 'FUS', 'FUS', '.', 'CCDC6-RET', '.', '.', 'RET融合是包括非小细胞肺癌(NSCLC)在内的多种肿瘤的驱动基因变异。一项I/Ib期临床试验探讨了RET抑制剂RXDX-105(agerafenib)的安全性和抗肿瘤活性。建议的每日推荐剂量275 mg。在未经RET抑制剂治疗的RET融合阳性NSCLC患者中，客观缓解率(ORR)为19%（95%CI，8%-38%，n = 6/31)。携带不同融合基因形式的患者的ORR差异很大(P<0.001，Fisher精确检验)：KIF5B-RET融合形式的ORR为0%(95%CI，0%–17%，n = 0/20)，非KIF5B-融合形式的ORR为67%(95%CI，30%–93%，n = 6/9)。尽管KIF5B-RET是非小细胞肺癌中最常见的RET融合体，但是RXDX-105仅对非KIF5B-RET融合的非小细胞肺癌有抑制作用。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/2159-8290.CD-18-0839', 'NCT01877811', 'clinical trial - phase1', '4', 'agerafenib', 'agerafenib', 'agerafenib', 'agerafenib', 'agerafenib|agerafenib', '1', '.', '.', '肺癌', 'NSCLC', 'sensitivity', 'EVI_001744', 'RET:FUS:.:PARD3-RET:', 'RET', 'FUS', 'FUS', '.', 'PARD3-RET', '.', '.', 'RET融合是包括非小细胞肺癌(NSCLC)在内的多种肿瘤的驱动基因变异。一项I/Ib期临床试验探讨了RET抑制剂RXDX-105(agerafenib)的安全性和抗肿瘤活性。建议的每日推荐剂量275 mg。在未经RET抑制剂治疗的RET融合阳性NSCLC患者中，客观缓解率(ORR)为19%（95%CI，8%-38%，n = 6/31)。携带不同融合基因形式的患者的ORR差异很大(P<0.001，Fisher精确检验)：KIF5B-RET融合形式的ORR为0%(95%CI，0%–17%，n = 0/20)，非KIF5B-融合形式的ORR为67%(95%CI，30%–93%，n = 6/9)。尽管KIF5B-RET是非小细胞肺癌中最常见的RET融合体，但是RXDX-105仅对非KIF5B-RET融合的非小细胞肺癌有抑制作用。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/2159-8290.CD-18-0839', 'NCT01877811', 'clinical trial - phase1', '4', 'agerafenib', 'agerafenib', 'agerafenib', 'agerafenib', 'agerafenib|agerafenib', '1', '.', '.', '肺癌', 'NSCLC', 'sensitivity', 'EVI_001745', 'RET:FUS:.:EML4-RET:', 'RET', 'FUS', 'FUS', '.', 'EML4-RET', '.', '.', 'RET融合是包括非小细胞肺癌(NSCLC)在内的多种肿瘤的驱动基因变异。一项I/Ib期临床试验探讨了RET抑制剂RXDX-105(agerafenib)的安全性和抗肿瘤活性。建议的每日推荐剂量275 mg。在未经RET抑制剂治疗的RET融合阳性NSCLC患者中，客观缓解率(ORR)为19%（95%CI，8%-38%，n = 6/31)。携带不同融合基因形式的患者的ORR差异很大(P<0.001，Fisher精确检验)：KIF5B-RET融合形式的ORR为0%(95%CI，0%–17%，n = 0/20)，非KIF5B-融合形式的ORR为67%(95%CI，30%–93%，n = 6/9)。尽管KIF5B-RET是非小细胞肺癌中最常见的RET融合体，但是RXDX-105仅对非KIF5B-RET融合的非小细胞肺癌有抑制作用。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29907952', '.', 'case report', '4', 'Osimertinib', 'Osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'decrease', 'EVI_001747', 'BCL2L11:CNV:.:.:loss', 'BCL2L11', 'CNV', 'CNV', '.', '.', 'loss', '.', 'Targeted Oncology上报道了一例携带EGFR L858R/T790M突变和BIM(BCL2L11)杂合缺失多态性的肺癌患者，该患者接受Osimertinib后的疗效受限，PFS仅为4个月，远低于AURA3临床试验结果(MPFS=10.1个月)。', 'G;S', '可能疗效减弱', 'o');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/1538-7445.AM2016-LB-118|PMID:30624546', '.', 'case report', '4', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001748', 'NTRK3:nonsynonymous SNV:exon16:p.F617L:', 'NTRK3', 'nonsynonymous SNV', 'Exact_pos', 'exon16', 'p.F617L', '.', '.', '在一项Larotrectinib的I期临床实验中，患者对治疗产生反应后，一名29岁的男性NSCLC患者和一名58岁的男性胃肠道间质瘤（GIST）患者可能由于继发突变导致对Larotrectinib耐药。NSCLC患者为TRKA结构域G595R和G667S突变，GIST患者为TRKC结构域F617L突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/1538-7445.AM2016-LB-118|PMID:30624546', '.', 'case report', '4', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib', 'larotrectinib|larotrectinib', '4', 'solid tumor', 'solid tumor', '非特定癌症', 'na', 'resistance', 'EVI_001749', 'NTRK2:nonsynonymous SNV:exon17:p.F617L:', 'NTRK2', 'nonsynonymous SNV', 'Exact_pos', 'exon17', 'p.F617L', '.', '.', '在一项Larotrectinib的I期临床实验中，患者对治疗产生反应后，一名29岁的男性NSCLC患者和一名58岁的男性胃肠道间质瘤（GIST）患者可能由于继发突变导致对Larotrectinib耐药。NSCLC患者为TRKA结构域G595R和G667S突变，GIST患者为TRKC结构域F617L突变。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:15184865', '.', 'preclinical', '4', 'vandetanib', 'vandetanib', 'vandetanib', '凡德他尼', 'vandetanib|凡德他尼', '4', 'thyroid cancer', 'thyroid cancer', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001750', 'RET:nonsynonymous SNV:exon14:p.V804M:', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.V804M', '.', 'RET mutations in certain inherited forms of medullary thyroid carcinoma, as in codon 804, seem to confer resistance to vandetanib', 'RET基因804密码子的基因突变(V804L、V804M)可能导致vandetanib的耐药，但V804G突变对vandetanib仍然敏感。', 'S', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:15184865', '.', 'preclinical', '4', 'vandetanib', 'vandetanib', 'vandetanib', '凡德他尼', 'vandetanib|凡德他尼', '4', 'thyroid cancer', 'thyroid cancer', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001751', 'RET:nonsynonymous SNV:exon14:p.V804G:', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon14', 'p.V804G', '.', 'RET mutations in certain inherited forms of medullary thyroid carcinoma, as in codon 804, seem to confer resistance to vandetanib', 'RET基因804密码子的基因突变(V804L、V804M)可能导致vandetanib的耐药，但V804G突变对vandetanib仍然敏感。', 'S', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:15184865', '.', 'preclinical', '4', 'vandetanib', 'vandetanib', 'vandetanib', '凡德他尼', 'vandetanib|凡德他尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001752', 'RET:nonsynonymous SNV:exon11:p.C634R:.', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon11', 'p.C634R', '.', 'In a preclinical study, Caprelsa (vandetanib) inhibited RET phosphorylation and decreased growth of transformed cells expressing RET C634R in culture (PMID: 15184865).', '细胞学试验表明，vandetanib可以抑制携带RET C634R突变的肿瘤细胞生长。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29420467', 'NCT01953926', 'case report', '4', 'neratinib', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', 'endometrial cancer', 'endometrial cancer', '子宫肿瘤', '子宫内膜癌', 'resistance', 'EVI_001753', 'ERBB2 :nonsynonymous SNV:exon21:p.V842I:act', 'ERBB2 ', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.V842I', 'act', 'In a Phase II trial (SUMMIT), Nerlynx (neratinib) treatment resulted in progressive disease with a progression-free survival of 1.8 months in a patient with endometrial cancer harboring ERBB2 (HER2) V842I (PMID: 29420467; NCT01953926). ', '一项临床II试验中，一名携带ERBB2突变的子宫内膜癌患者使用Nerlynx (neratinib)治疗后，疾病发生进展（PFS：1.8个月）。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:26294908', 'NCT01118065', 'clinical trial - phase2', '4', 'everolimus + letrozole', 'everolimus + letrozole', 'everolimus + letrozole', '依维莫司 + 来曲唑', 'everolimus + letrozole|依维莫司 + 来曲唑', '4', 'medullary thyroid cancer', '.', '甲状腺癌', '甲状腺髓样癌', 'sensitivity', 'EVI_001757', 'RET:nonsynonymous SNV:exon16:p.M918T:', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon16', 'p.M918T', '.', 'In a Phase II clinical trial, Afinitor (everolimus) treatment resulted in stable disease in 71% (5/7) of medullary thyroid cancer patients, and 4 of the 7 patients carried a RET M918T mutation (PMID:26294908).', '一项临床II期试验中，71% (5/7)的甲状腺癌患者使用Afinitor(everolimus)后疾病保持稳定，其中4名患者携带RET M918T基因突变。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/jco.2015.33.15_suppl.6012|PMID:27525386', 'NCT00704730', 'clinical trial - phase3', '4', 'cabozantinib', 'cabozantinib', 'cabozantinib', '卡博替尼', 'cabozantinib|卡博替尼', '4', 'medullary thyroid carcinoma', '.', '甲状腺癌', '甲状腺髓样癌', 'sensitivity', 'EVI_001758', 'RET:nonsynonymous SNV:exon16:p.M918T:', 'RET', 'nonsynonymous SNV', 'Exact_pos', 'exon16', 'p.M918T', '.', 'In a Phase III trial, Cometriq (cabozantinib) increased overall survival to 25.4 months in medullary thyroid carcinoma patients with RET M918T (J Clin Oncol 33, 2015, suppl; abstr 6012).', '一项临床III期试验中，携带RET M918T突变的甲状腺癌患者使用Cometriq (cabozantinib)后，总体生存期(OS)增加到25.4个月。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065', '.', 'preclinical', '4', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001759', 'EGFR:nonsynonymous SNV:exon19:p.L747S:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747S', '.', '.', '细胞学试验表明，dacomitinib对携带L858R突变的肿瘤细胞的IC50为0.27 nM，对携带L858R/L747S突变的肿瘤细胞的IC50为0.41 nM。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28424065', '.', 'preclinical', '4', 'neratinib', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001760', 'EGFR:nonsynonymous SNV:exon19:p.L747S:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747S', '.', '.', '细胞学试验表明，neratinib对携带L858R突变的肿瘤细胞的IC50为6.44 nM，对携带L858R/L747S突变的肿瘤细胞的IC50为13.91 nM。', 'S', '可能耐药', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28424065', '.', 'preclinical', '4', 'Osimertinib', 'Osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001761', 'EGFR:nonsynonymous SNV:exon19:p.L747S:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747S', '.', '.', '细胞学试验表明，osimertinib对携带L858R突变的肿瘤细胞的IC50为1.98 nM，对携带L858R/L747S突变的肿瘤细胞的IC50为1.74 nM。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28424065', '.', 'preclinical', '4', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib|rociletinib', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001762', 'EGFR:nonsynonymous SNV:exon19:p.L747S:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.L747S', '.', '.', '细胞学试验表明，rociletinib对携带L858R突变的肿瘤细胞的IC50为5.22 nM，对携带L858R/L747S突变的肿瘤细胞的IC50为4.69 nM。', 'S', '可能敏感', 'o');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001763', 'EGFR:nonsynonymous SNV:exon19:p.D761Y:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.D761Y', '.', '.', '细胞学试验表明，gefitinib对携带L858R突变的肿瘤细胞的IC50为3.38 nM，对携带L858R/D761Y突变的肿瘤细胞的IC50为29.4 nM。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001764', 'EGFR:nonsynonymous SNV:exon19:p.D761Y:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.D761Y', '.', '.', '细胞学试验表明，erlotinib对携带L858R突变的肿瘤细胞的IC50为1.82 nM，对携带L858R/D761Y突变的肿瘤细胞的IC50为11.1 nM。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001765', 'EGFR:nonsynonymous SNV:exon19:p.D761Y:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.D761Y', '.', '.', '细胞学试验表明，afatinib对携带L858R突变的肿瘤细胞的IC50为0.21 nM，对携带L858R/D761Y突变的肿瘤细胞的IC50为0.82 nM。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001766', 'EGFR:nonsynonymous SNV:exon19:p.D761Y:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.D761Y', '.', '.', '细胞学试验表明，dacomitinib对携带L858R突变的肿瘤细胞的IC50为0.27 nM，对携带L858R/D761Y突变的肿瘤细胞的IC50为1.16 nM。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'neratinib', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001767', 'EGFR:nonsynonymous SNV:exon19:p.D761Y:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.D761Y', '.', '.', '细胞学试验表明，neratinib对携带L858R突变的肿瘤细胞的IC50为6.44 nM，对携带L858R/D761Y突变的肿瘤细胞的IC50为23.8 nM。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'Osimertinib', 'Osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001768', 'EGFR:nonsynonymous SNV:exon19:p.D761Y:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.D761Y', '.', '.', '细胞学试验表明，osimertinib对携带L858R突变的肿瘤细胞的IC50为1.98 nM，对携带L858R/D761Y突变的肿瘤细胞的IC50为2.74 nM。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib|rociletinib', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001769', 'EGFR:nonsynonymous SNV:exon19:p.D761Y:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.D761Y', '.', '.', '细胞学试验表明，rociletinib对携带L858R突变的肿瘤细胞的IC50为5.22 nM，对携带L858R/D761Y突变的肿瘤细胞的IC50为6.71 nM。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'gefitinib', 'gefitinib', 'gefitinib', '吉非替尼', 'gefitinib|吉非替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001770', 'EGFR:nonsynonymous SNV:exon19:p.T854A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.T854A', '.', '.', '细胞学试验表明，gefitinib对携带L858R突变的肿瘤细胞的IC50为3.38 nM，对携带L858R/T854A突变的肿瘤细胞的IC50为222 nM。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001771', 'EGFR:nonsynonymous SNV:exon19:p.T854A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.T854A', '.', '.', '细胞学试验表明，erlotinib对携带L858R突变的肿瘤细胞的IC50为1.82 nM，对携带L858R/T854A突变的肿瘤细胞的IC50为85.9 nM。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'afatinib', 'afatinib', 'afatinib', '阿法替尼', 'afatinib|阿法替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001772', 'EGFR:nonsynonymous SNV:exon19:p.T854A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.T854A', '.', '.', '细胞学试验表明，afatinib对携带L858R突变的肿瘤细胞的IC50为0.21 nM，对携带L858R/T854A突变的肿瘤细胞的IC50为2.13 nM。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'dacomitinib', 'dacomitinib', 'dacomitinib', '达可替尼', 'dacomitinib|达可替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001773', 'EGFR:nonsynonymous SNV:exon19:p.T854A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.T854A', '.', '.', '细胞学试验表明，dacomitinib对携带L858R突变的肿瘤细胞的IC50为0.27 nM，对携带L858R/T854A突变的肿瘤细胞的IC50为3.19 nM。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'neratinib', 'neratinib', 'neratinib', '来那替尼', 'neratinib|来那替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'resistance', 'EVI_001774', 'EGFR:nonsynonymous SNV:exon19:p.T854A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.T854A', '.', '.', '细胞学试验表明，neratinib对携带L858R突变的肿瘤细胞的IC50为6.44 nM，对携带L858R/T854A突变的肿瘤细胞的IC50为77.2 nM。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'Osimertinib', 'Osimertinib', 'osimertinib', '奥希替尼', 'osimertinib|奥希替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001775', 'EGFR:nonsynonymous SNV:exon19:p.T854A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.T854A', '.', '.', '细胞学试验表明，osimertinib对携带L858R突变的肿瘤细胞的IC50为1.98 nM，对携带L858R/T854A突变的肿瘤细胞的IC50为1.98 nM。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28424065|PMID:17085664', '.', 'preclinical', '4', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib', 'rociletinib|rociletinib', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001776', 'EGFR:nonsynonymous SNV:exon19:p.T854A:.', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon19', 'p.T854A', '.', '.', '细胞学试验表明，rociletinib对携带L858R突变的肿瘤细胞的IC50为5.22 nM，对携带L858R/T854A突变的肿瘤细胞的IC50为6.94 nM。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/PO.16.00013', '.', 'case report', '4', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib', 'entrectinib|entrectinib', '4', '.', 'Acral Lentiginous Melanoma', '黑色素瘤', '肢端雀斑样痣性黑素瘤', 'sensitivity', 'EVI_001777', 'ROS1:FUS:.:GOPC-ROS1:.', 'ROS1', 'FUS', 'FUS', '.', 'GOPC-ROS1', '.', 'Targeted sequencing identified a GOPC-ROS1 fusion in a patient with ALM. The patient underwent a dramatic and durable response to entrectinib, with a RECIST (version 1.1) partial response of −38% at 3 months and −55% at 11 months. The response is ongoing, and the patient has not developed any new lesions. No additional ROS1 fusions were identified by immunohistochemistry, resulting in a frequency of 3.0% in ALM and 1.3% in all melanomas.', '一名黑色素瘤患者携带GOPC-ROS1融合蛋白。患者对entrectinib治疗反应良好，在3个月时部分反应为-38%(RECIST)，在11个月时为-55%。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1093/annonc/mdz394.031', 'EudraCT: 2016-002422-36', 'clinical trial - phase2', '4', 'pemigatinib', 'pemigatinib', 'pemigatinib', 'pemigatinib', 'pemigatinib|pemigatinib', '2', 'cholangiocarcinoma', 'cholangiocarcinoma', '胆管癌', '胆管癌', 'sensitivity', 'EVI_001781', 'FGFR2:FUS:.:FGFR2-.:.', 'FGFR2', 'FUS', 'FUS', '.', 'FGFR2-.', '.', '.', 'Pemigatinib二线治疗晚期胆管癌患者的FIGHT202研究更新数据显示，该研究共纳入146例经过≥1线治疗的晚期胆管癌患者，分为3个队列：A是FGFR2融合/重排（n=107），B是其他FGFR突变（n=20），C是非FGFR突变（n=18），1名患者未定。所有患者均接受Pemigatinib治疗（13.5mg qd 用2周歇1周）。结果显示，A组ORR为35.5%，其中3例患者完全缓解（CR），CR率为2.8%，DCR为82%。B组和C组的ORR为0%。相比其他两个队列，队列A的患者对药物有效响应的比例大很多，有效时间也长得多。A组的DOR中位数为7.5个月， PFS和OS中位数分别为6.9和21.1个月。相比其他两个队列，生存期得到大幅度延长，意味着的患者用Pemigatinib治疗效果非常不错。基于上述试验结果，2019年11月，美国FDA正式受理pemigatinib用于治疗复发的FGFR2基因融合或重排的局部晚期胆管癌的NDA，并授予其优先审评资格。', 'F', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/PO.16.00019 ', '.', 'preclinical', '4', 'erlotinib', 'erlotinib', 'erlotinib', '厄洛替尼', 'erlotinib|厄洛替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '肺腺癌', 'sensitivity', 'EVI_001782', 'EGFR:nonsynonymous SNV:exon20:p.V769M:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.V769M', '.', 'A 57-year-old man was found to have five distinct lung nodules and no mediastinal or hilar lymphadenopathy, which raised the possibility of multiple synchronous lung cancers. The patient was a remote former smoker (34 pack-years), quitting 21 years before presentation. He underwent several procedures to resect the five distinct lung nodules, each of which was determined to be lung adenocarcinoma. Molecular analysis was performed on the five tumors and each revealed an EGFR V769M alteration. In addition, the presence of distinct G719 mutations in EGFR in several tumors suggested that these tumors represented independent primary lung cancers. As V769M is predicted to have a significant functional impact (PolyPhen9), the possibility of a germline variant was considered. The patient was referred for genetic counseling and informed consent was obtained for germline testing. Sequencing of peripheral blood leukocyte DNA confirmed the presence of a germline EGFR V769M variant (Fig 1). The co-occurring somatic variant in exon 20 (EGFR S768I) was found on the same allele as the germline EGFR V769M. It was not possible to determine conclusively whether somatic mutations in exon 18 were similarly in cis with the germline variant given the genomic distance between the variants, which were captured separately and sequenced on distinct short reads in the genomic DNA-based assay that was performed. Although the patient had a maternal family history of various cancers, there was no history of lung cancers in the pedigree (Fig 2). Postoperatively, the patient has been treated with erlotinib as a result of several small lung nodules that were found. He has remained without evidence of progressive disease or new lesions for more than 3 years. To examine the sensitivity of EGFR V769M mutant cells to tyrosine kinase inhibition, transfected 293T cells were treated with increasing concentrations of erlotinib. Compared with cells with the sensitizing EGFR L858R mutation and those with the EGFR T790M gatekeeper mutation, EGFR V769M–bearing cells had intermediate sensitivity to erlotinib.', '一名57岁的男子出现了五个明显的肺结节，且无纵隔或肺门淋巴结病。该患者是一位前吸烟者（34包/年），于就诊前21年戒烟。患者接受了肺结节切除术，被确诊为肺腺癌。分子分析显示肿瘤中存在EGFR V769M突变，同时存在EGFR G719突变。患者接受遗传咨询，外周血白细胞DNA测序证实存在种系EGFR V769M变体，在exon20上发现了其等位基因的突变-EGFR S768I。术后患者接受了erlotinib治疗，三年多来，患者一直没有疾病进展或新病变的迹象。为了检查EGFR V769M突变细胞对酪氨酸激酶抑制的敏感性，研究人员用浓度递增的erlotinib处理EGFR V769M突变体转染的293T细胞。结果显示，与具有EGFR L858R突变和具有EGFR T790M突变的细胞相比，带有EGFR V769M的细胞对erlotinib具有中等敏感性。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Lung Cancer <3.2020>|PMID:31591063', 'NCT02411448', 'guideline:NCCN', '1', 'erlotinib + ramucirumab', 'erlotinib + ramucirumab', 'erlotinib + ramucirumab', '厄洛替尼 + 雷莫芦单抗', 'erlotinib + ramucirumab|厄洛替尼 + 雷莫芦单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001783', 'EGFR:nonsynonymous SNV:exon21:p.L858R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', 'Between Jan 28, 2016, and Feb 1, 2018, 449 eligible patients were enrolled and randomly assigned to treatment with ramucirumab plus erlotinib (n=224) or placebo plus erlotinib (n=225). Median duration of follow-up was 20·7 months (IQR 15·8-27·2). At the time of primary analysis, progression-free survival was significantly longer in the ramucirumab plus erlotinib group (19·4 months [95% CI 15·4-21·6]) than in the placebo plus erlotinib group (12·4 months [11·0-13·5]), with a stratified hazard ratio of 0·59 (95% CI 0·46-0·76; p<0·0001). Grade 3-4 treatment-emergent adverse events were reported in 159 (72%) of 221 patients in the ramucirumab plus erlotinib group versus 121 (54%) of 225 in the placebo plus erlotinib group. The most common grade 3-4 treatment-emergent adverse events in the ramucirumab plus erlotinib group were hypertension (52 [24%]; grade 3 only) and dermatitis acneiform (33 [15%]), and in the placebo plus erlotinib group were dermatitis acneiform (20 [9%]) and increased alanine aminotransferase (17 [8%]). Treatment-emergent serious adverse events were reported in 65 (29%) of 221 patients in the ramucirumab plus erlotinib group and 47 (21%) of 225 in the placebo plus erlotinib group. The most common serious adverse events of any grade in the ramucirumab plus erlotinib group were pneumonia (seven [3%]) and cellulitis and pneumothorax (four [2%], each); the most common in the placebo plus erlotinib group were pyrexia (four [2%]) and pneumothorax (three [1%]). One on-study treatment-related death due to an adverse event occurred (haemothorax after a thoracic drainage procedure for a pleural empyema) in the ramucirumab plus erlotinib group.', '一项多中心、随机、双盲、安慰剂对照的3期临床试验(RELAY)，2016年1月28日至2018年2月1日共纳入449例患者，其中EGFR突变(19del/L858R)患者280例。随机分配为厄洛替尼联合雷莫芦单抗(n=224，EGFR阳性122例)组与厄洛替尼联合安慰剂(n=225，EGFR阳性158例)组，中位随访时间为20.7个月，无进展生存期为19.4个月vs. 12.4个月。其中EGFR 突变患者亚组中，EGFR 19del中位无进展生存期为19.6 个月(95% CI：15.1–22.2) vs. 12.5个月(95% CI：11.1–15.3)；EGFR L858R中位无进展生存期为19.4 个月(95% CI：14.1–21.9) vs. 11.2个月(95% CI：9.6–13.8)。综上所述，RELAY试验方案对于EGFR阳性的转移性非小细胞肺癌的初始治疗是可行的新选择。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Lung Cancer <3.2020>|PMID:30975627', '.', 'guideline:NCCN', '1', 'erlotinib + bevacizumab', 'erlotinib + bevacizumab', 'erlotinib + bevacizumab', '厄洛替尼 + 贝伐珠单抗', 'erlotinib + bevacizumab|厄洛替尼 + 贝伐珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001784', 'EGFR:nonsynonymous SNV:exon21:p.L858R:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon21', 'p.L858R', '.', 'Between June 3, 2015, and Aug 31, 2016, 228 patients were randomly assigned to receive erlotinib plus bevacizumab (n=114) or erlotinib alone (n=114). 112 patients in each group were evaluable for efficacy, and safety was evaluated in 112 patients in the combination therapy group and 114 in the monotherapy group. Median follow-up was 12·4 months (IQR 7·0-15·7). At the time of interim analysis, median progression-free survival for patients in the erlotinib plus bevacizumab group was 16·9 months (95% CI 14·2-21·0) compared with 13·3 months (11·1-15·3) for patients in the erlotinib group (hazard ratio 0·605, 95% CI 0·417-0·877; p=0·016). 98 (88%) of 112 patients in the erlotinib plus bevacizumab group and 53 (46%) of 114 patients in the erlotinib alone group had grade 3 or worse adverse events. The most common grade 3-4 adverse event was rash (23 [21%] of 112 patients in the erlotinib plus bevacizumab group vs 24 [21%] of 114 patients in the erlotinib alone group). Nine (8%) of 112 patients in the erlotinib plus bevacizumab group and five (4%) of 114 patients in the erlotinib alone group had serious adverse events. The most common serious adverse events were grade 4 neutropenia (two [2%] of 112 patients in the erlotinib plus bevacizumab group) and grade 4 hepatic dysfunction (one [1%] of 112 patients in the erlotinib plus bevacizumab group and one [1%] of 114 patients in the erlotinib alone group). No treatment-related deaths occurred.', 'EGFR突变非小细胞肺癌(NSCLC)有超过一半接受EGFR-TKI单药治疗的患者在一年内都会经历复发或疾病进展。采用联合治疗策略可能会克服EGFR-TKI的耐药限制，因此，开展了一项厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗晚期EGFR突变(19del/L858R)的NSCLC的III期研究(NEJ026)。在2015年6月3日至2016年8月31日之间，共计入组228例患者，随机分配为厄洛替尼与贝伐珠单抗联合治疗(BE)组(n=112)和厄洛替尼单药治疗(E)组(n=114)，中位随访时间为12.4个月。中期分析显示该研究达到主要终点。在数据截止时(2017年9月21日)，BE组的中位PFS为16.9个月(95%CI: 14.2-21.0)，E组的中位PFS为13.3个月(95%CI: 11.1-15.3), (HR 0.605, 95%CI: 0.417-0.877, P=0.0157)。BE组的出血，蛋白尿和高血压等不良事件明显高于E组，其他毒性两组间无显著差异。E组出现5例中低度肺炎，BE组中无肺炎发生、没有与治疗有关的死亡。在这项研究中，厄洛替尼联合贝伐珠单抗被认为是EGFR突变(19del/L858R)的NSCLC中的新标准治疗。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Lung Cancer <3.2020>|PMID:31591063', 'NCT02411448', 'guideline:NCCN', '1', 'erlotinib + ramucirumab', 'erlotinib + ramucirumab', 'erlotinib + ramucirumab', '厄洛替尼 + 雷莫芦单抗', 'erlotinib + ramucirumab|厄洛替尼 + 雷莫芦单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001785', 'EGFR:nonframeshift deletion:exon19::exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', 'Between Jan 28, 2016, and Feb 1, 2018, 449 eligible patients were enrolled and randomly assigned to treatment with ramucirumab plus erlotinib (n=224) or placebo plus erlotinib (n=225). Median duration of follow-up was 20·7 months (IQR 15·8-27·2). At the time of primary analysis, progression-free survival was significantly longer in the ramucirumab plus erlotinib group (19·4 months [95% CI 15·4-21·6]) than in the placebo plus erlotinib group (12·4 months [11·0-13·5]), with a stratified hazard ratio of 0·59 (95% CI 0·46-0·76; p<0·0001). Grade 3-4 treatment-emergent adverse events were reported in 159 (72%) of 221 patients in the ramucirumab plus erlotinib group versus 121 (54%) of 225 in the placebo plus erlotinib group. The most common grade 3-4 treatment-emergent adverse events in the ramucirumab plus erlotinib group were hypertension (52 [24%]; grade 3 only) and dermatitis acneiform (33 [15%]), and in the placebo plus erlotinib group were dermatitis acneiform (20 [9%]) and increased alanine aminotransferase (17 [8%]). Treatment-emergent serious adverse events were reported in 65 (29%) of 221 patients in the ramucirumab plus erlotinib group and 47 (21%) of 225 in the placebo plus erlotinib group. The most common serious adverse events of any grade in the ramucirumab plus erlotinib group were pneumonia (seven [3%]) and cellulitis and pneumothorax (four [2%], each); the most common in the placebo plus erlotinib group were pyrexia (four [2%]) and pneumothorax (three [1%]). One on-study treatment-related death due to an adverse event occurred (haemothorax after a thoracic drainage procedure for a pleural empyema) in the ramucirumab plus erlotinib group.', '一项多中心、随机、双盲、安慰剂对照的3期临床试验(RELAY)，2016年1月28日至2018年2月1日共纳入449例患者，其中EGFR突变(19del/L858R)患者280例。随机分配为厄洛替尼联合雷莫芦单抗(n=224，EGFR阳性122例)组与厄洛替尼联合安慰剂(n=225，EGFR阳性158例)组，中位随访时间为20.7个月，无进展生存期为19.4个月vs. 12.4个月。其中EGFR 突变患者亚组中，EGFR 19del中位无进展生存期为19.6 个月(95% CI：15.1–22.2) vs. 12.5个月(95% CI：11.1–15.3)；EGFR L858R中位无进展生存期为19.4 个月(95% CI：14.1–21.9) vs. 11.2个月(95% CI：9.6–13.8)。综上所述，RELAY试验方案对于EGFR阳性的转移性非小细胞肺癌的初始治疗是可行的新选择。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Lung Cancer <3.2020>|PMID:30975627', '.', 'guideline:NCCN', '1', 'erlotinib + bevacizumab', 'erlotinib + bevacizumab', 'erlotinib + bevacizumab', '厄洛替尼 + 贝伐珠单抗', 'erlotinib + bevacizumab|厄洛替尼 + 贝伐珠单抗', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001786', 'EGFR:nonframeshift deletion:exon19::exon19del', 'EGFR', 'nonframeshift deletion', 'None_pos', 'exon19', '.', 'exon19del', 'Between June 3, 2015, and Aug 31, 2016, 228 patients were randomly assigned to receive erlotinib plus bevacizumab (n=114) or erlotinib alone (n=114). 112 patients in each group were evaluable for efficacy, and safety was evaluated in 112 patients in the combination therapy group and 114 in the monotherapy group. Median follow-up was 12·4 months (IQR 7·0-15·7). At the time of interim analysis, median progression-free survival for patients in the erlotinib plus bevacizumab group was 16·9 months (95% CI 14·2-21·0) compared with 13·3 months (11·1-15·3) for patients in the erlotinib group (hazard ratio 0·605, 95% CI 0·417-0·877; p=0·016). 98 (88%) of 112 patients in the erlotinib plus bevacizumab group and 53 (46%) of 114 patients in the erlotinib alone group had grade 3 or worse adverse events. The most common grade 3-4 adverse event was rash (23 [21%] of 112 patients in the erlotinib plus bevacizumab group vs 24 [21%] of 114 patients in the erlotinib alone group). Nine (8%) of 112 patients in the erlotinib plus bevacizumab group and five (4%) of 114 patients in the erlotinib alone group had serious adverse events. The most common serious adverse events were grade 4 neutropenia (two [2%] of 112 patients in the erlotinib plus bevacizumab group) and grade 4 hepatic dysfunction (one [1%] of 112 patients in the erlotinib plus bevacizumab group and one [1%] of 114 patients in the erlotinib alone group). No treatment-related deaths occurred.', 'EGFR突变非小细胞肺癌(NSCLC)有超过一半接受EGFR-TKI单药治疗的患者在一年内都会经历复发或疾病进展。采用联合治疗策略可能会克服EGFR-TKI的耐药限制，因此，开展了一项厄洛替尼联合贝伐珠单抗对比厄洛替尼单药治疗晚期EGFR突变(19del/L858R)的NSCLC的III期研究(NEJ026)。在2015年6月3日至2016年8月31日之间，共计入组228例患者，随机分配为厄洛替尼与贝伐珠单抗联合治疗(BE)组(n=112)和厄洛替尼单药治疗(E)组(n=114)，中位随访时间为12.4个月。中期分析显示该研究达到主要终点。在数据截止时(2017年9月21日)，BE组的中位PFS为16.9个月(95%CI: 14.2-21.0)，E组的中位PFS为13.3个月(95%CI: 11.1-15.3), (HR 0.605, 95%CI: 0.417-0.877, P=0.0157)。BE组的出血，蛋白尿和高血压等不良事件明显高于E组，其他毒性两组间无显著差异。E组出现5例中低度肺炎，BE组中无肺炎发生、没有与治疗有关的死亡。在这项研究中，厄洛替尼联合贝伐珠单抗被认为是EGFR突变(19del/L858R)的NSCLC中的新标准治疗。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1200/PO.17.00138 ', '.', 'case report', '4', 'trametinib', 'trametinib', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', 'metastatic melanoma', 'metastatic melanoma', '黑色素瘤', '黑色素瘤', 'sensitivity', 'EVI_001787', 'RAF1:FUS:.:ANO10-RAF1:.', 'RAF1', 'FUS', 'FUS', '.', 'ANO10-RAF1', '.', 'The patient was an 81-year-old gentleman diagnosed in May 2012 with metastatic melanoma to the subcutis in the occipital scalp without known primary melanoma. At that time, sentinel right neck lymph node biopsy was negative for metastasis. In October 2014, he had recurrent melanoma in the right cervical lymph node, and by December 2014, his disease had progressed in the cervical and intrathoracic lymph nodes and the liver. In January 2015, the patient started treatment with the combination of nivolumab and ipilimumab, but the treatment was discontinued after two doses because of the development of diabetic ketoacidosis. His disease responded to the therapy; however, in July 2015, his disease progressed again in the intra-abdominal lymph nodes and spleen. From August 2015 to March 2016, he was treated with single-agent nivolumab and subsequently nivolumab in combination with intralesional talimogene laherparepvec injection to the right cervical nodes, but by March 2016, the disease had progressed in the right neck nodes and liver. In April 2016, he underwent a debulking radical right neck lymph node dissection for a palliative purpose.In October 2016, the patient developed a painful right neck mass, and his performance status worsened (Eastern Cooperative Oncology Group performance status of 2). He was found to have rapid disease progression in the right supraclavicular, mediastinal, gastrohepatic, and portocaval lymph nodes; the liver; the spleen; and the T-12 spine. The metastatic melanoma specimen from the right neck node was analyzed for genetic alterations using a hybrid-capture–based NGS assay (FoundationOne).9 The results were wild type for BRAF, NRAS, and KIT; however, a number of genetic alterations, including a ANO10-RAF1 fusion, FLT1 R281Q, NOTCH3 splice site 4404-1G>A, ARID2 Q760fs*7, PBRM1 loss, SPTA1 Q1720*, and TERT promoter-146C>T, were detected. On the basis of the potential sensitivity of cancer cells with RAF1 fusions to MEK inhibitors, trametinib treatment (2 mg daily) was initiated in November 2016. Because of the development of significant skin toxicity, the dose was reduced to 1.5 mg/d after 4 weeks and further down to 1 mg/d in January 2017. The patient’s pain in the right neck and shoulder improved dramatically with the treatment, his performance status improved, and a computed tomography scan performed at 10 weeks showed significant regression of the metastatic lesions in the right supraclavicular, mediastinal, gastrohepatic, and portocaval lymph nodes; the liver; and the spleen (Fig 1). Nonetheless, the skin rash subsequently worsened, and in early February 2017 the dose of trametinib was lowered further, to 0.5 mg/d. Unfortunately, in May 2017, he had significant disease progression in all existing metastatic sites. Treatment with another MEK inhibitor was discussed with the patient, but because of rapid clinical deterioration and the concern for significant skin toxicity, he decided on palliative care, and he died in June 2017.', '一名81岁的男性患者于2012年5月被诊断为枕部头皮皮下转移性黑色素瘤，没有已知的原发性黑色素瘤，2014年10月其发生右颈淋巴结内黑色素瘤复发，2014年12月发生颈部和胸腔内淋巴结及肝脏进展。2015年1月，患者开始使用nivolumab和ipilimumab的组合治疗，但由于糖尿病性酮症酸中毒导致治疗只维持了两剂。患者对治疗有反应，但2015年7月患者又发生腹腔内淋巴结和脾脏进展。2015年8月-2016年3月，患者接受了单药nivolumab的治疗，随后接受nivolumab与talimogene laherparepvec的右颈淋巴结注射，2016年3月，患者发生右颈淋巴结和肝脏进展。2016年4月，患者接受右颈部淋巴结姑息性根治性切除手术。2016年10月，患者右颈部肿胀疼痛，东部合作肿瘤小组的工作状态恶化，在右锁骨上、纵隔、肝脏和门静脉淋巴结中进展迅速。NGS检测到许多遗传改变，包括ANO10-RAF1，FLT1 R281Q，NOTCH3 4404-1G> A，ARID2 Q760fs*7，PBRM1缺失，SPTA1 Q1720 *和TERT启动子-146C> T。根据RAF1融合的存在，患者于2016年11月开始使用trametinib治疗（2 mg/d）。由于出现明显的皮肤毒性，在第4次治疗后剂量降至1.5 mg/d，数周后下降至1 mg/d。该治疗使患者右颈部和肩部疼痛明显改善，病情得到缓解，10周后的CT结果显示转移性病变明显消退。但皮疹随后恶化，2017年2月上旬，trametinib的剂量进一步降低至0.5 mg/d。2017年5月，患者的所有转移部位都出现了明显的疾病进展。患者接受姑息治疗，并于2017年6月去世。', 'f', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('中国临床肿瘤学会（CSCO,2019）', '.', 'guideline:CSCO', '1', '.', '.', 'FOLFOXIRI + bevacizumab', 'FOLFOXIRI + 贝伐珠单抗', 'FOLFOXIRI + bevacizumab|FOLFOXIRI + 贝伐珠单抗', '4', '.', '.', '结直肠癌', 'na', 'sensitivity', 'EVI_001792', 'NRAS;KRAS;BRAF:wildtype:.:.:wildtype', 'NRAS;KRAS;BRAF', 'wildtype', 'wildtype', '.', '.', 'wildtype', '.', '一项大型回顾性分析评估了贝伐珠单抗联合化疗对KRAS野生型mCRC患者的疗效。分析结果与其他发表的关于贝伐珠单抗联合治疗的有效性和安全性的研究一致，而与KRAS突变状态无关。来自该分析的数据证实了贝伐珠单抗的有效性，即使是在野生型KRAS患者的亚组中也是如此。因此，在KRAS野生型患者中，使用哪一种单克隆抗体只需根据其不同毒理学特性进行选择。至于未来如何决策，正在进行中的RAS扩大分析研究和探寻中的贝伐珠单抗的预测生物标志物，或许可以更精确地筛选出主要受益于这种靶向治疗的患者亚群。目前，中国临床肿瘤学会（CSCO）以2A类证据推荐RAS、BRAF基因野生型或突变均可以行化疗联合贝伐珠单抗的治疗方案。', 's', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2020>|PMID:30857956', '.', 'guideline:NCCN', '1', '.', '.', 'trastuzumab + pertuzumab', '曲妥珠单抗 + 帕妥珠单抗', 'trastuzumab + pertuzumab|曲妥珠单抗 + 帕妥珠单抗', '4', 'colorectal cancer', '.', '结直肠癌', '结直肠癌', 'sensitivity', 'EVI_001793', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NCCN指南中推荐KRAS，NRAS，BRAF野生型，HER2阳性的转移性肠癌患者可以使用trastuzumab + pertuzumab联合治疗。一项正在进行的IIa期篮式临床试验MyPathway(NCT02091141)评估了trastuzumab和pertuzumab在HER2扩增的转移性结直肠癌患者中的活性。2014年10月20日至2017年6月22日，试验从美国16个州25家医院或诊所招收了57例HER2阳性的转移性结直肠癌患者进行相关治疗，主要终点是达到客观缓解的患者比例。截止到2017年8月1日，57例可评估患者中，1例(2%)完全缓解，17例(30%)部分缓解，共计18例患者达到客观缓解(32%，95% CI：20-45)。最常见的因治疗引发的不良事件是腹泻(19例)、疲劳(18例)和恶心(17例)，有21例记录了3-4级紧急不良事件，最常见的是低钾血症和腹痛。10例(18%)患者报告了严重的紧急不良事件，其中2例(4%)被认为与治疗相关，没有治疗相关的死亡时间。综合评估，trastuzumab联合pertuzumab的双HER2靶向治疗耐受性良好。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Colon Cancer <2.2020>|PMID:27108243', '.', 'guideline:NCCN', '1', '.', '.', 'trastuzumab + lapatinib', '曲妥珠单抗 + 拉帕替尼', 'trastuzumab + lapatinib|曲妥珠单抗 + 拉帕替尼', '4', 'colorectal cancer', '.', '结直肠癌', '结直肠癌', 'sensitivity', 'EVI_001794', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NCCN指南中推荐KRAS，NRAS，BRAF野生型，HER2阳性的转移性肠癌患者可以使用trastuzumab + lapatinib联合治疗。一项多中心、开放标签的II期临床试验HERACLES(NCT03225937)评估了trastuzumab和lapatinib在HER2阳性的结直肠癌患者中的抗肿瘤活性。在2012年8月27日至2015年5月15日期间，试验共计筛选了914例KRAS 2号外显子(12和13号密码子)野生型的转移性结直肠癌患者，其中有48例(5%)HER2阳性患者，27例符合试验条件，所有反应均可以评估，主要终点是达到客观缓解(定义为完全缓解或部分缓解)患者的比例。数据截止到2015年10月15日，平均随访时间为94周(IQR 51-127)，27例中有8例(30%，95% CI：14-50)达到客观缓解：1例(4%, 95% CI：3-11)完全缓解，7例(26%, 95% CI：9-43)部分缓解。12例(44%, 95% CI：25-63)病情稳定。27例患者中有6例(22%)出现3级不良事件，包括4例疲劳，1例皮疹和1例胆红素浓度升高，未报道4或5级不良事件。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Uterine Neoplasms <1.2019>|PMID:29584549', '.', 'guideline:NCCN', '1', '.', '.', 'carboplatin + paclitaxel + trastuzumab', '卡铂 + 紫杉醇 +曲妥珠单抗', 'carboplatin + paclitaxel + trastuzumab|卡铂 + 紫杉醇 +曲妥珠单抗', '4', 'Uterine serous carcinoma', '.', '子宫肿瘤', '子宫浆液性癌', 'sensitivity', 'EVI_001795', 'ERBB2:CNV:.:.:gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', '.', 'NCCN指南根据以下研究结果推荐III/IV期或复发的HER2表达阳性的子宫浆液性癌患者使用carboplatin+paclitaxel联合trastuzumab的组合治疗方案。一项II期多中心、随机临床试验比较了HER2过表达的晚期或复发性子宫浆液性癌患者使用carboplatin+paclitaxel联合trastuzumab和不联合trastuzumab 的治疗情况。2011年8月至2017年3月，随机分配61例患者。在所有患者中，对照组的中位无进展生存期为8.0个月，试验组为12.6个月。同样，在接受初次治疗的41例III或IV期患者中，对照组的中位无进展生存期为9.3，试验组为17.9月；在17例复发性疾病患者中，对照组中位无进展生存期为6.0，试验组为9.2个月。', 'A', '敏感', 'o');
INSERT INTO `main_ori` VALUES ('J Clin Oncol 34, 2016 (suppl; abstr 9067)', '.', 'clinical trial - phase1', '4', '.', '.', 'capmatinib', 'capmatinib', 'capmatinib|capmatinib', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', 'na', 'sensitivity', 'EVI_001796', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', 'In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 63% (5/8) of MET amplified non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).', '在一项临床I期试验中，携带MET扩增的非小细胞肺癌患者使用Capmatinib (INC280)治疗后，63%(5/8)取得部分响应。', 'A', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1016/j.jtho.2019.08.413', 'NCT02981108', 'clinical trial - phase2', '4', 'HS-10296', 'HS-10296', 'almonertinib', '阿美替尼', 'almonertinib|阿美替尼', '2', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001797', 'EGFR:nonsynonymous SNV:exon20:p.T790M:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.T790M', '.', 'HS-10296 is an oral, potent, high selective third generation EGFR tyrosine-kinase inhibitor (EGFR-TKI) for sensitizing mutations, and the EGFR Thr790Met (T790M) resistance mutation which has been demonstrated by phase I study. This phase II, open-label, multicenter single-arm study was designed to confirm the efficacy and safety of HS-10296 in a large population of non-small-cell lung cancer (NSCLC) patients with EGFR T790M mutation, who had progressed after first generation EGFR-TKI treatment. Method: Patients aged at least 18 years with centrally confirmed EGFR T790M-positive mutations, locally advanced or metastatic (stage IIIB/IV) NSCLC after first generation EGFR-TKI treatment received HS-10296 110 mg orally once daily until disease progression, or intolerable toxicity, or patient withdrawal. Patients with asymptomatic, stable brain metastases not requiring steroids were allowed to enroll. The primary endpoint was the objective response rate (ORR) by independent central review using Response Evaluation Criteria in Solid Tumors, version 1.1 every 6 weeks. Response endpoints (ORR and disease control rate [DCR]) were assessed in response analysis set. Secondary end points including progression-free survival (PFS), duration of response (DoR), depth of response (DepOR), overall survival (OS) and safety were evaluated in full analysis set. The final data cutoff was on Jan 5, 2019. The study is still ongoing. Result: Totally, 244 patients (median age 60.8) entered study in 36 sites in mainland China (189 patients) and Taiwan (55 patients) between May 16, 2018 to Oct 23, 2018. 2 patients were excluded from the evaluable for response analysis set (n¼242) due to absence of measurable disease at baseline by independent central review. At data cutoff, 182 (74.6%) patients remained on treatment. The median duration of follow-up was 4.7 months. 160 of 242 patients achieved confirmed partial responses by independent central review. The ORR was 66.1% (95% CI: 59.8-72.1). The DCR was 93.4% (95% CI: 89.5-96.2). The most common adverse reactions (≥10%) were blood creatine phosphokinase increased (43 [17.6%]), aspartate aminotransferase increased (29 [11.9%]), pruritus (28 [11.5%]), rash (28 [11.5%]) and alanine aminotransferase increased (26 [10.7%]). The most common all-causality grade 3 and 4 adverse events were blood creatine phosphokinase increased (14 [5.7%]) and hyponatraemia (4 [1.6%]). Serious adverse events were reported in 30 (12.3%) patients, of which 19 (7.8%) were investigator assessed as possibly treatment-related to HS-10296. Three deaths were due to adverse events; one was related to cardiopulmonary failure, other two events occurred after disease progression. There was no interstitial lung disease during study treatment. Conclusion: HS-10296 has demonstrated good clinical benefit with minimal toxicity in patients with EGFR T790M-positive NSCLC patients who have progressed after first generation EGFR-TKI treatment. The Phase III study has already launched comparing HS-10296 with gefinitib in advanced NSCLC patients with EGFR sensitizing mutations.', 'HS-10296(almonertinib，阿美替尼)是一种口服、强效、高选择性的第三代EGFR酪氨酸激酶抑制剂(EGFR-TKI)，主要用于EGFR T790M耐药位点突变，且在I期研究中已得到证实。一项开放标签、多中心的II期单臂临床研究(NCT02981108)，旨在确认HS-10296(阿美替尼)对于接受一代EGFR-TKI治疗后疾病进展且携带EGFR T790M突变的非小细胞肺癌(NSCLC)患者的有效性和安全性。此次试验共计纳入244例既往接受过一代EGFR-TKI治疗后疾病进展的EGFR T790M阳性的晚期或转移性NSCLC亚洲患者，其中189例来自中国大陆，55例来自中国台湾。所有患者每天口服110mg HS-10296，直至疾病进展或出现无法耐受毒性或中途退出。主要评估终点是每6周一次根据独立评审委员会按照实体瘤评估标准RECST v1.1确定的客观缓解率(ORR)和疾病控制率(DCR)，次要评估标准包括无进展生存期(PFS)，持续缓解时间(DOR)，治疗反应强度(DepOR)，总生存期(OR)和安全性。截止数据分析时，共计有182例患者仍在接受治疗，中位随访时间为4.7个月，242例患者中有160例获得部分缓解。ORR为66.1% (95% CI: 59.8-72.1)，DCR为93.4% (95% CI: 89.5-96.2)。最常见的不良反应(≥10%)是血肌酐磷酸激酶升高(n=43[17.6%])、天门冬氨酸氨基转移酶升高(n=29[11.9%])、瘙痒(n=28[11.5%])、皮疹(n=28[11.5%])和丙氨酸氨基转移酶升高(n=26[10.7%])。最常见的3级和4级不良事件是血肌酐磷酸激酶升高(n=14[5.7%])和低钠血症(n=4[1.6%])。HS-10296对一代EGFR-TKI治疗后疾病进展且EGFR T790M阳性的NSCLC患者具有良好的临床疗效和最小的毒性。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:30711650|PMID:28287083', '.', 'case report', '4', '.', '.', 'brigatinib + cetuximab', '布加替尼 + 帕尼单抗', 'brigatinib + cetuximab|布加替尼 + 帕尼单抗', '4', '.', '.', '肺癌', '肺腺癌', 'sensitivity', 'EVI_001798', 'EGFR:nonsynonymous SNV:exon20:p.C797S<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<顺式>', '.', '.', '一名女性Ⅳ期肺腺癌患者先进行化疗，基因检测显示为EGFR 19号外显子缺失，开始使用一代TKI药物治疗。一代TKI耐药后，发现患者出现T790M突变。因此，患者开始接受每日80 mg的osimertinib治疗，患者在一个月内达到了病情稳定（SD），CA125水平迅速下降，经过8个月的无进展生存期，患者肺左下叶出现新的病灶，胸腔积液增多，病情发展。患者再次基因检测发现T790M-C797S顺式突变，因此在2017年7月开始联合使用brigatinib和cetuximab，治疗一个月时，患者的疲劳和呼吸困难明显改善，CA125水平明显下降，直到2018年4月病情一直稳定（PFS为9个月），除了轻度疲劳外无其他的不良反应(PMID:30711650)。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:28287083', '.', 'preclinical', '4', '.', '.', 'brigatinib + panitumumab ', '布加替尼 + 西妥昔单抗', 'brigatinib + panitumumab |布加替尼 + 西妥昔单抗', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001799', 'EGFR:nonsynonymous SNV:exon20:p.C797S<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<顺式>', '.', '.', '细胞学试验表明cetuximab/panitumumab联合Brigatinib，可以增强Brigatinib对EGFR Del19/T790M/C797S顺式突变的活性，而cetuximab联合osimertinib对该突变无效。另外，接种EGFR Del19/T790M/C797S顺式突变肿瘤细胞的小鼠，接受Brigatinib 75mg/kg每天一次单药，以及联合cetuximab 1 mg每周三次(或panitumumab 0.5 mg 每周两次）。结果表明，Brigatinib联合cetuximab/panitumumab试验组小鼠的肿瘤体积持续缩小；而cetuximab和Brigatinib单药单药均不能导致肿瘤显著缩小。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('DOI:10.1158/1538-7445.AM2018-916', '.', 'preclinical', '4', '.', '.', 'Brigatinib + Selumetinib', '布加替尼 + 司美替尼', 'Brigatinib + Selumetinib|布加替尼 + 司美替尼', '4', '.', '.', '肿瘤细胞', '肿瘤细胞', 'sensitivity', 'EVI_001800', 'EGFR:nonsynonymous SNV:exon20:p.C797S<顺式>:', 'EGFR', 'nonsynonymous SNV', 'Exact_pos', 'exon20', 'p.C797S<顺式>', '.', '.', '2018年AACR会议上报道了一项体外肿瘤细胞株和活体模型实验研究，显示布加替尼(Brigatinib，AP26113)联合司美替尼(Selumetinib，AZD6244)可能可以克服C797S突变导致的奥希替尼(泰瑞沙，Osimertinib，AZD9291)耐药(DOI:10.1158/1538-7445.AM2018-916)。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Breast Cancer <2.2020>|PMID:20124182', 'NCT00301899', 'guideline:NCCN', '1', 'trastuzumab + pertuzumab', 'trastuzumab + pertuzumab', 'trastuzumab + pertuzumab', '曲妥珠单抗 + 帕妥珠单抗', 'trastuzumab + pertuzumab|曲妥珠单抗 + 帕妥珠单抗', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001801', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'Pertuzumab is active in patients beyond the first-line setting. The results of a multicenter, open-label, single-arm, phase II study (n = 66) show that the combination of pertuzumab and trastuzumab is active and well tolerated in patients with HER2-positive metastatic breast cancer that has progressed on prior trastuzumab therapy. The trial reported an objective response rate of 24.2% (16 patients out of 66). The median PFS time observed with pertuzumab and trastuzumab combination was 15.5 months (range, 0.9–17.0 months; 80% CI, 18-31 months. The reported median duration of response with the combination was 5.8 months (range, 2.9–15.3 months). To determine whether the clinical benefit seen in the study was from pertuzumab alone or was a result of the combined effect of pertuzumab and trastuzumab, a cohort of patients (n = 29) whose disease progressed during prior trastuzumab-based therapy received pertuzumab monotherapy until progressive disease or unacceptable toxicity. Of these, patients with disease progression (n=17) continued to receive pertuzumab with the addition of trastuzumab. In the 29 patients who received pertuzumab monotherapy, the objective response rate and clinical benefit rate reported were 3.4% and 10.3%, respectively, whereas in the patients who received dual blockade after progression on pertuzumab, the objective response rate and clinical benefit rate were 17.6% and 41.2%, respectively. According to the NCCN Panel, for patients with disease progression after treatment with trastuzumab-based therapy without pertuzumab, a line of therapy containing both trastuzumab plus pertuzumab with or without a cytotoxic agent (such as vinorelbine or taxane) may be considered. Further research is needed to determine the ideal sequencing strategy for HER2-targeted therapy.', '一项多中心、开放标签、单臂II期临床研究(n=66)的结果表明，帕妥珠单抗和曲妥珠单抗联合用于HER2阳性的转移性乳腺癌患者中是有效的，且耐受性良好。研究结果显示客观缓解率为24.2%(n=16)。帕妥珠单抗和曲妥珠单抗联合治疗的中位无进展生存期(mPFS)为15.5个月(范围为0.9-17.0个月；80% CI：18-31个月)，中位持续反应时间为5.8个月(范围为2.9-15.3个月)。为确定研究中心观察到的临床获益是帕妥珠单抗单药疗效还是帕妥珠单抗和曲妥珠单抗联合的作用，一组既往接受过基于曲妥珠单抗治疗后疾病进展的患者(n=29)接受了帕妥珠单抗单药治疗，直到疾病进展或出现不可耐受毒性。而出现疾病进展的患者(n=17)继续接受帕妥珠单抗联合曲妥珠单抗治疗。在29例接受帕妥珠单抗单药治疗的患者中，客观缓解率和临床获益率分别为3.4%和10.3%，而在帕妥珠单抗单药治疗进展后接受双重阻断治疗的患者中，客观缓解率和临床获益率分别为17.6%和41.2%。因此，根据NCCN小组的研究，对基于曲妥珠单抗(无帕妥珠单抗)联合方案治疗后疾病进展的患者，一线治疗可以考虑曲妥珠单抗和帕妥珠单抗联合，同时添加或不添加细胞毒性药物(长春瑞滨或紫杉烷)。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Breast Cancer <2.2020>|Druglabel:pertuzumab_Revised: 01/2020', 'NCT00567190', 'guideline:FDA', '1', 'pertuzumab + trastuzumab + docetaxel', 'pertuzumab + trastuzumab + docetaxel', 'pertuzumab + trastuzumab + docetaxel', '帕妥珠单抗 + 曲妥珠单抗 + 多西他赛', 'pertuzumab + trastuzumab + docetaxel|帕妥珠单抗 + 曲妥珠单抗 + 多西他赛', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001802', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'Pertuzumab is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. CLEOPATRA (NCT00567190) was a multicenter, double-blind, placebo-controlled trial of 808 patients with HER2-positive metastatic breast cancer. HER2 overexpression was defined as a score of 3+ IHC or FISH amplification ratio of 2.0 or greater as determined by a central laboratory. Patients were randomly allocated 1:1 to receive placebo plus trastuzumab and docetaxel or PERJETA plus trastuzumab and docetaxel. At the time of the final PFS analysis, 165 patients had died, and more deaths had occurred in the placebo-treated group (23.6%) compared with the PERJETA-treated group (17.2%); OS was not mature and interim OS analysis results did not meet the pre-specified stopping boundary for statistical significance. The final analysis of OS (Table 8, Figure 2) was performed when 389 patients had died (221 in the placebo-treated group and 168 in the PERJETA-treated group). A statistically significant OS improvement in favor of the PERJETA-treated group was demonstrated [HR=0.68 (95% CI; 0.56, 0.84), p=0.0002] with an increase in median OS of 15.7 months (median OS of 56.5 months in the PERJETA-treated group vs. 40.8 months in the placebo-treated group). OS results in patient subgroups were consistent with those observed for IRF-assessed PFS with the exception of the subgroup of patients with disease limited to non-visceral metastasis [HR=1.11 (95% CI: 0.66, 1.85)].', 'FDA批准帕妥珠单抗与曲妥珠单抗和多西他赛联合治疗HER2阳性的转移性乳腺癌患者(MBC)，且这类患者之前未接受过抗HER2治疗或转移性疾病化疗方案。此次获批基于一项多中心、双盲、安慰剂对照临床试验CLEOPATRA (NCT00567190)，共计纳入808例HER2阳性转移性乳腺癌患者，按照1：1随机分配为帕妥珠单抗与曲妥珠单抗和多西他赛联合治疗组(n=402)以及安慰剂与曲妥珠单抗和多西他赛(n=406)。患者接受相关药物治疗直至疾病进展、撤回同意或出现不可接受毒性反应。CLEOPATRA临床试验主要终点是独立审查机构(IRF)评估的无进展生存期(PFS)，其他终点包括总体生存期(OS)，研究者评估的PFS，客观缓解率(ORR)和持续缓解时间(DOR)。研究显示：与安慰剂联合方案组相比，帕妥珠单抗联合治疗组的PFS有统计学意义的显著改善[hazard ratio(HR)=0.62 (95% CI: 0.51, 0.75), p < 0.0001]，中位PFS增加6.1个月(帕妥珠单抗联合治疗组中位PFS为18.5个月，而安慰剂组为12.4个月)。进行最终PFS分析时，共计165例患者死亡，其中安慰剂组(23.6%)比帕妥珠单抗组(17.2%)死亡人数更多。进行OS最终分析时，入组患者共计死亡389例(安慰剂组221例，帕妥珠单抗组168例)，整体OS有统计学意义改善[HR=0.68 (95％CI; 0.56，0.84)，p=0.0002]，中位OS增加15.7个月(帕妥珠单抗组为56.5个月，安慰剂组为40.8个月)。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Breast Cancer <2.2020>|PMID:30796821', 'NCT01572038', 'guideline:NCCN', '1', 'pertuzumab + trastuzumab + docetaxel', 'pertuzumab + trastuzumab + docetaxel', 'pertuzumab + trastuzumab + docetaxel', '帕妥珠单抗 + 曲妥珠单抗 + 紫杉醇', 'pertuzumab + trastuzumab + docetaxel|帕妥珠单抗 + 曲妥珠单抗 + 紫杉醇', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001803', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'The NCCN Panel recommends pertuzumab plus trastuzumab in combination with a taxane as a preferred option for first-line treatment of patients with HER2-positive metastatic breast cancer. Pertuzumab plus trastuzumab in combination with docetaxel is an NCCN category 1 and in combination with paclitaxel is an NCCN category 2A recommendation. In the PERUSE study, patients (n=1436) with advanced HER2-positive breast cancer and no prior systemic therapy (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The preliminary results after 52 months median follow-up, show that median PFS was comparable between docetaxel, paclitaxel and nab-paclitaxel (median PFS reported was19.6, 23.0 and 18.1 months with docetaxel, paclitaxel and nab-paclitaxel, respectively). Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (31% vs. 16%), but less febrile neutropenia (1% vs. 11%) and mucositis (14% vs. 25%). Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. ', 'NCCN推荐帕妥珠单抗+曲妥珠单抗联合紫杉烷类(紫杉醇，白蛋白紫杉醇)作为一线治疗HER2阳性转移性乳腺癌患者的首选方案。一项多中心、单臂IIIb期临床试验PERUSE(NCT01572038)，旨在评估帕妥珠单抗与曲妥珠单抗联合紫杉烷类药物的安全性和有效性。共计入组1436例HER2阳性，未接受过系统治疗(内分泌治疗除外)的晚期乳腺癌患者，接受至少一种治疗剂量(多西他赛775例，紫杉醇589例，白蛋白紫杉醇65例)联合帕妥珠单抗和曲妥珠单抗治疗，直至疾病进展或出现不可耐受毒性。中位随访52个月后初步显示，三种治疗方案中位无进展生存期(mPFS)相当(含多西他赛组为19.6个月，含紫杉醇组为23.0个月，含白蛋白紫杉醇组为18.1个月)。与含多西他赛治疗组相比，含紫杉醇治疗组与较多神经病变(31% vs. 16%)有关，但发热中性粒细胞(1% vs. 11%)和粘膜炎(14% vs. 25%)较少。由此可见，帕妥珠单抗+曲妥珠单抗联合紫杉烷类(紫杉醇，白蛋白紫杉醇)作为HER2阳性局部复发或转移性乳腺癌患者一线治疗方案，与FDA基于CLEOPATRA (NCT00567190)批准的帕妥珠单抗与曲妥珠单抗联合多西他赛的治疗方案在安全性和有效性上结果一致。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Breast Cancer <2.2020>|PMID:30796821', 'NCT01572038', 'guideline:NCCN', '1', 'pertuzumab + trastuzumab + nab-paclitaxel', 'pertuzumab + trastuzumab + nab-paclitaxel', 'pertuzumab + trastuzumab + nab-paclitaxel', '帕妥珠单抗 + 曲妥珠单抗 + 白蛋白紫杉醇', 'pertuzumab + trastuzumab + nab-paclitaxel|帕妥珠单抗 + 曲妥珠单抗 + 白蛋白紫杉醇', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001804', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'The NCCN Panel recommends pertuzumab plus trastuzumab in combination with a taxane as a preferred option for first-line treatment of patients with HER2-positive metastatic breast cancer. Pertuzumab plus trastuzumab in combination with docetaxel is an NCCN category 1 and in combination with paclitaxel is an NCCN category 2A recommendation. In the PERUSE study, patients (n=1436) with advanced HER2-positive breast cancer and no prior systemic therapy (except endocrine therapy) received docetaxel, paclitaxel or nab-paclitaxel with trastuzumab and pertuzumab until disease progression or unacceptable toxicity. The preliminary results after 52 months median follow-up, show that median PFS was comparable between docetaxel, paclitaxel and nab-paclitaxel (median PFS reported was19.6, 23.0 and 18.1 months with docetaxel, paclitaxel and nab-paclitaxel, respectively). Compared with docetaxel-containing therapy, paclitaxel-containing therapy was associated with more neuropathy (31% vs. 16%), but less febrile neutropenia (1% vs. 11%) and mucositis (14% vs. 25%). Preliminary findings from PERUSE suggest that the safety and efficacy of first-line pertuzumab, trastuzumab and taxane for HER2-positive LR/MBC are consistent with results from CLEOPATRA. ', 'NCCN推荐帕妥珠单抗+曲妥珠单抗联合紫杉烷类(紫杉醇，白蛋白紫杉醇)作为一线治疗HER2阳性转移性乳腺癌患者的首选方案。一项多中心、单臂IIIb期临床试验PERUSE(NCT01572038)，旨在评估帕妥珠单抗与曲妥珠单抗联合紫杉烷类药物的安全性和有效性。共计入组1436例HER2阳性，未接受过系统治疗(内分泌治疗除外)的晚期乳腺癌患者，接受至少一种治疗剂量(多西他赛775例，紫杉醇589例，白蛋白紫杉醇65例)联合帕妥珠单抗和曲妥珠单抗治疗，直至疾病进展或出现不可耐受毒性。中位随访52个月后初步显示，三种治疗方案中位无进展生存期(mPFS)相当(含多西他赛组为19.6个月，含紫杉醇组为23.0个月，含白蛋白紫杉醇组为18.1个月)。与含多西他赛治疗组相比，含紫杉醇治疗组与较多神经病变(31% vs. 16%)有关，但发热中性粒细胞(1% vs. 11%)和粘膜炎(14% vs. 25%)较少。由此可见，帕妥珠单抗+曲妥珠单抗联合紫杉烷类(紫杉醇，白蛋白紫杉醇)作为HER2阳性局部复发或转移性乳腺癌患者一线治疗方案，与FDA基于CLEOPATRA (NCT00567190)批准的帕妥珠单抗与曲妥珠单抗联合多西他赛的治疗方案在安全性和有效性上结果一致。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Breast Cancer <2.2020>|Druglabel:ado-trastuzumab emtansine_Revised:05/2019', 'NCT00829166|NCT01772472', 'guideline:FDA', '1', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', 'ado-trastuzumab emtansine', '恩美曲妥珠单抗', 'ado-trastuzumab emtansine|恩美曲妥珠单抗', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001806', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'On May 3, 2019, the Food and Drug Administration approved ado-trastuzumab emtansine (KADCYLA, Genentech, Inc.) for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.Approval was based on KATHERINE (NCT01772472), a randomized, multicenter, open-label trial of 1486 patients with HER2-positive EBC. Breast tumor samples were required to demonstrate HER2 overexpression defined as 3+ IHC or ISH amplification ratio ≥ 2.0 determined at a central laboratory using Ventana’s PATHWAY anti-HER2-/neu (4B5) Rabbit Monoclonal Primary Antibody or INFORM HER2 Dual ISH DNA Probe Cocktail assays. Patients were required to have had neoadjuvant taxane and trastuzumab-based therapy with residual invasive tumor in the breast and/or axillary lymph nodes. Patients received radiotherapy and/or hormonal therapy concurrent with study treatment per local guidelines. Patients were randomized (1:1) to receive ado-trastuzumab emtansine 3.6 mg/kg intravenously or trastuzumab 6 mg/kg intravenously on day 1 of a 21-day cycle for 14 cycles.The trial’s primary endpoint was invasive disease-free survival (IDFS), defined as the time from the date of randomization to first occurrence of ipsilateral invasive breast tumor recurrence, ipsilateral local or regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, or death from any cause. After a median follow-up of 40 months, the trial demonstrated a statistically significant improvement in IDFS in patients who received ado-trastuzumab emtansine compared with those who received trastuzumab (HR 0.50; 95% CI: 0.39, 0.64; p<0.0001). Overall survival data were not mature at the time of the IDFS analysis.', '2019年5月3日，FDA基于一项随机、多中心、开放标签试验KATHERINE(NCT01772472)，批准ado-trastuzumab emtansine单药用于辅助治疗HER2阳性早期乳腺癌患者，这些患者既往接受过曲妥珠单抗联合紫杉烷新辅助治疗后仍残留浸润性疾病。试验共计纳入1486例HER2阳性早期乳腺癌(EBC)患者，要求对患者乳腺和/或腋窝淋巴结内残留的侵袭性肿瘤进行过曲妥珠单抗联合紫杉烷的新辅助治疗。根据当地治疗规范，患者接受放疗和/或激素治疗同时进行研究性治疗，随机(1：1)接受静脉注射ado-trastuzumab emtansine 3.6 mg/kg或静脉注射曲妥珠单抗6 mg/kg，为期21天，共计14个周期。经过40个月的随访，结果显示：接受ado-trastuzumab emtansine 较曲妥珠单抗治疗无侵袭性疾病生存(IDFS)上有统计学显著改善(HR 0.50；95% CI：0.39，0.64；p <0.0001)。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Breast Cancer <2.2020>|PMID:22689807', 'NCT00320385', 'guideline:NCCN', '1', 'trastuzumab + lapatinib', 'trastuzumab + lapatinib', 'trastuzumab + lapatinib', '曲妥珠单抗 + 拉帕替尼', 'trastuzumab + lapatinib|曲妥珠单抗 + 拉帕替尼', '4', 'breast cancer', 'breast cancer', '乳腺癌(HER2阳性)', '[NA;NA;HER2(+)]', 'sensitivity', 'EVI_001807', 'ERBB2:CNV:::gain', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'Phase III EGF104900 data demonstrated that lapatinib plus trastuzumab significantly improved progression-free survival (PFS) and clinical benefit rate versus lapatinib monotherapy, offering a chemotherapy-free option for patients with heavily pretreated human epidermal growth factor receptor 2 (HER2) -positive metastatic breast cancer (MBC). Final planned overall survival (OS) analysis from EGF104900 is reported here. In this updated final analysis of all patients randomly assigned with strata (n = 291), lapatinib plus trastuzumab continued to show superiority to lapatinib monotherapy in PFS (hazard ratio [HR], 0.74; 95% CI, 0.58 to 0.94; P = .011) and offered significant OS benefit (HR, 0.74; 95% CI, 0.57 to 0.97; P = .026). Improvements in absolute OS rates were 10% at 6 months and 15% at 12 months in the combination arm compared with the monotherapy arm. Multiple baseline factors, including Eastern Cooperative Oncology Group performance status of 0, nonvisceral disease, < three metastatic sites, and less time from initial diagnosis until random assignment, were associated with improved OS. Incidence of adverse events was consistent with previously reported rates. These data demonstrated a significant 4.5-month median OS advantage with the lapatinib and trastuzumab combination and support dual HER2 blockade in patients with heavily pretreated HER2-positive MBC.', '一项EGF104900 III期临床试验(NCT00320385)表明：与拉帕替尼单药相比，拉帕替尼联合曲妥珠单抗可显著改善无进展生存期(PFS)和临床获益率。本次研究纳入291例既往接受过以曲妥珠单抗为主的治疗并发生疾病进展的HER2阳性MBS患者，并按照1：1比例随机分配为拉帕替尼单药治疗组(n=145)和拉帕替尼与曲妥珠单抗联合治疗组(n=146)，主要终点为总生存率OS和无进展生存期PFS。结果显示：拉帕替尼联合曲妥珠单抗治疗组在PFS方面显著优于拉帕替尼单药，绝对OS率在6个月内提高了10%，在12个月内提高了15%。联合治疗组的美国东部肿瘤协作组评分为0，没有出现内脏疾病，转移部位少于3个，这些基线因素均与OS改善相关。不良事件的发生率与先前报道的发生率一致。这些数据表明，在经过预处理的HER2阳性的MBC患者中，拉帕替尼和曲妥珠单抗联合使用具有显着的中位OS优势并支持双重HER2阻断。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Gastric Cancer <4.2019>|Druglabel:trastuzumab_Revised:11/2018', 'NCT01041404', 'guideline:FDA', '1', 'trastuzumab + cisplatin + 5-fluorouracil', 'trastuzumab + cisplatin + 5-fluorouracil', 'trastuzumab + cisplatin + 5-fluorouracil', '曲妥珠单抗 + 顺铂 + 5-氟尿嘧啶', 'trastuzumab + cisplatin + 5-fluorouracil|曲妥珠单抗 + 顺铂 + 5-氟尿嘧啶', '4', 'gastroesophageal junction adenocarcinoma', 'gastroesophageal junction adenocarcinoma', '食管癌', '胃食管交界部腺癌', 'sensitivity', 'EVI_001808', 'ERBB2:CNV:.:.:widetype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. The safety and efficacy of Herceptin in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil) were studied in patients previously untreated for metastatic gastric or gastroesophageal junction adenocarcinoma. ToGA (Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomised controlled trial undertaken in 122 centres in 24 countries, 594 patients were randomized 1:1 to Herceptin in combination with cisplatin and a fluoropyrimidine (FC+H) or chemotherapy alone (FC). Randomization was stratified by extent of disease (metastatic vs. locally advanced), primary site (gastric vs. gastroesophageal junction), tumor measurability (yes vs. no), ECOG performance status (0,1 vs. 2), and fluoropyrimidine (capecitabine vs. 5-fluorouracil). All patients were either HER2 gene amplified (FISH+) or HER2 overexpressing (IHC 3+).  The main outcome measure of Study 7 was overall survival (OS), analyzed by the unstratified log-rank test. The final OS analysis based on 351 deaths was statistically significant (nominal significance level of 0.0193). An updated OS analysis was conducted at one year after the final analysis. The most common adverse events in both groups were nausea, vomiting, and neutropenia. Rates of overall grade 3 or 4 adverse events and cardiac adverse events did not differ between groups. Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer. ', 'FDA批准曲妥珠单抗与顺铂和卡培他滨或5-氟尿嘧啶联用，适用于治疗HER2过表达的转移性胃癌或胃食管交界部腺癌患者，且这些患者既往未接受过转移性疾病治疗。一项开放标签、国际化III期随机对照临床试验(NCT01041404)，在全球24个国家/地区的122个中心进行，用于评估曲妥珠单抗与顺铂联合氟嘧啶(卡培他滨或5-氟尿嘧啶)治疗转移性胃癌或胃食管交界部腺癌的安全性和有效性。共计纳入594例HER2阳性患者，随机按照1：1分为曲妥珠单抗联合化疗组(FC+H，n=298)和单独化疗组(FC，n=296)，主要研究重点为总生存期(OS)，其中FC+H治疗组中位随访时间为18.6个月(IQR 11-25)，单独化疗组为17.1个月(9-25)。FC+H和FC治疗组最终中位OS分别为13.5个月(95% CI：11.7, 15.7)和11.0个月(95% CI：9.4, 12.5)，两组中最常见的不良反应是恶心，呕吐和中性粒细胞减少症。总体3级或4级不良事件发生率和心脏不良事件发生率在各组间无差异。曲妥珠单抗联合化疗可被认为是HER2阳性的胃癌或胃食管交界部腺癌一种新的标准选择。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Gastric Cancer <4.2019>|Druglabel:trastuzumab_Revised:11/2018', 'NCT01041404', 'guideline:FDA', '1', 'trastuzumab + cisplatin + capecitabine', 'trastuzumab + cisplatin + capecitabine', 'trastuzumab + cisplatin + capecitabine', '曲妥珠单抗 + 顺铂 + 卡培他滨', 'trastuzumab + cisplatin + capecitabine|曲妥珠单抗 + 顺铂 + 卡培他滨', '4', 'gastroesophageal junction adenocarcinoma', 'gastroesophageal junction adenocarcinoma', '食管癌', '胃食管交界部腺癌', 'sensitivity', 'EVI_001809', 'ERBB2:CNV:.:.:widetype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. The safety and efficacy of Herceptin in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil) were studied in patients previously untreated for metastatic gastric or gastroesophageal junction adenocarcinoma. ToGA (Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomised controlled trial undertaken in 122 centres in 24 countries, 594 patients were randomized 1:1 to Herceptin in combination with cisplatin and a fluoropyrimidine (FC+H) or chemotherapy alone (FC). Randomization was stratified by extent of disease (metastatic vs. locally advanced), primary site (gastric vs. gastroesophageal junction), tumor measurability (yes vs. no), ECOG performance status (0,1 vs. 2), and fluoropyrimidine (capecitabine vs. 5-fluorouracil). All patients were either HER2 gene amplified (FISH+) or HER2 overexpressing (IHC 3+).  The main outcome measure of Study 7 was overall survival (OS), analyzed by the unstratified log-rank test. The final OS analysis based on 351 deaths was statistically significant (nominal significance level of 0.0193). An updated OS analysis was conducted at one year after the final analysis. The most common adverse events in both groups were nausea, vomiting, and neutropenia. Rates of overall grade 3 or 4 adverse events and cardiac adverse events did not differ between groups. Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer. ', 'FDA批准曲妥珠单抗与顺铂和卡培他滨或5-氟尿嘧啶联用，适用于治疗HER2过表达的转移性胃癌或胃食管交界部腺癌患者，且这些患者既往未接受过转移性疾病治疗。一项开放标签、国际化III期随机对照临床试验(NCT01041404)，在全球24个国家/地区的122个中心进行，用于评估曲妥珠单抗与顺铂联合氟嘧啶(卡培他滨或5-氟尿嘧啶)治疗转移性胃癌或胃食管交界部腺癌的安全性和有效性。共计纳入594例HER2阳性患者，随机按照1：1分为曲妥珠单抗联合化疗组(FC+H，n=298)和单独化疗组(FC，n=296)，主要研究重点为总生存期(OS)，其中FC+H治疗组中位随访时间为18.6个月(IQR 11-25)，单独化疗组为17.1个月(9-25)。FC+H和FC治疗组最终中位OS分别为13.5个月(95% CI：11.7, 15.7)和11.0个月(95% CI：9.4, 12.5)，两组中最常见的不良反应是恶心，呕吐和中性粒细胞减少症。总体3级或4级不良事件发生率和心脏不良事件发生率在各组间无差异。曲妥珠单抗联合化疗可被认为是HER2阳性的胃癌或胃食管交界部腺癌一种新的标准选择。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Gastric Cancer <4.2019>|Druglabel:trastuzumab_Revised:11/2018', 'NCT01041404', 'guideline:FDA', '1', 'trastuzumab + cisplatin + capecitabine', 'trastuzumab + cisplatin + capecitabine', 'trastuzumab + cisplatin + capecitabine', '曲妥珠单抗 + 顺铂 + 卡培他滨', 'trastuzumab + cisplatin + capecitabine|曲妥珠单抗 + 顺铂 + 卡培他滨', '4', 'gastric cancer', 'gastric cancer', '胃癌', '胃癌', 'sensitivity', 'EVI_001810', 'ERBB2:CNV:.:.:widetype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. The safety and efficacy of Herceptin in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil) were studied in patients previously untreated for metastatic gastric or gastroesophageal junction adenocarcinoma. ToGA (Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomised controlled trial undertaken in 122 centres in 24 countries, 594 patients were randomized 1:1 to Herceptin in combination with cisplatin and a fluoropyrimidine (FC+H) or chemotherapy alone (FC). Randomization was stratified by extent of disease (metastatic vs. locally advanced), primary site (gastric vs. gastroesophageal junction), tumor measurability (yes vs. no), ECOG performance status (0,1 vs. 2), and fluoropyrimidine (capecitabine vs. 5-fluorouracil). All patients were either HER2 gene amplified (FISH+) or HER2 overexpressing (IHC 3+).  The main outcome measure of Study 7 was overall survival (OS), analyzed by the unstratified log-rank test. The final OS analysis based on 351 deaths was statistically significant (nominal significance level of 0.0193). An updated OS analysis was conducted at one year after the final analysis. The most common adverse events in both groups were nausea, vomiting, and neutropenia. Rates of overall grade 3 or 4 adverse events and cardiac adverse events did not differ between groups. Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer. ', 'FDA批准曲妥珠单抗与顺铂和卡培他滨或5-氟尿嘧啶联用，适用于治疗HER2过表达的转移性胃癌或胃食管交界部腺癌患者，且这些患者既往未接受过转移性疾病治疗。一项开放标签、国际化III期随机对照临床试验(NCT01041404)，在全球24个国家/地区的122个中心进行，用于评估曲妥珠单抗与顺铂联合氟嘧啶(卡培他滨或5-氟尿嘧啶)治疗转移性胃癌或胃食管交界部腺癌的安全性和有效性。共计纳入594例HER2阳性患者，随机按照1：1分为曲妥珠单抗联合化疗组(FC+H，n=298)和单独化疗组(FC，n=296)，主要研究重点为总生存期(OS)，其中FC+H治疗组中位随访时间为18.6个月(IQR 11-25)，单独化疗组为17.1个月(9-25)。FC+H和FC治疗组最终中位OS分别为13.5个月(95% CI：11.7, 15.7)和11.0个月(95% CI：9.4, 12.5)，两组中最常见的不良反应是恶心，呕吐和中性粒细胞减少症。总体3级或4级不良事件发生率和心脏不良事件发生率在各组间无差异。曲妥珠单抗联合化疗可被认为是HER2阳性的胃癌或胃食管交界部腺癌一种新的标准选择。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Gastric Cancer <4.2019>|Druglabel:trastuzumab_Revised:11/2018', 'NCT01041404', 'guideline:FDA', '1', 'trastuzumab + cisplatin + 5-fluorouracil', 'trastuzumab + cisplatin + 5-fluorouracil', 'trastuzumab + cisplatin + 5-fluorouracil', '曲妥珠单抗 + 顺铂 + 5-氟尿嘧啶', 'trastuzumab + cisplatin + 5-fluorouracil|曲妥珠单抗 + 顺铂 + 5-氟尿嘧啶', '4', 'gastric cancer', 'gastric cancer', '胃癌', '胃癌', 'sensitivity', 'EVI_001811', 'ERBB2:CNV:.:.:widetype', 'ERBB2', 'CNV', 'CNV', '.', '.', 'gain', 'Herceptin is indicated, in combination with cisplatin and capecitabine or 5-fluorouracil, for the treatment of patients with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease. The safety and efficacy of Herceptin in combination with cisplatin and a fluoropyrimidine (capecitabine or 5-fluorouracil) were studied in patients previously untreated for metastatic gastric or gastroesophageal junction adenocarcinoma. ToGA (Trastuzumab for Gastric Cancer) was an open-label, international, phase 3, randomised controlled trial undertaken in 122 centres in 24 countries, 594 patients were randomized 1:1 to Herceptin in combination with cisplatin and a fluoropyrimidine (FC+H) or chemotherapy alone (FC). Randomization was stratified by extent of disease (metastatic vs. locally advanced), primary site (gastric vs. gastroesophageal junction), tumor measurability (yes vs. no), ECOG performance status (0,1 vs. 2), and fluoropyrimidine (capecitabine vs. 5-fluorouracil). All patients were either HER2 gene amplified (FISH+) or HER2 overexpressing (IHC 3+).  The main outcome measure of Study 7 was overall survival (OS), analyzed by the unstratified log-rank test. The final OS analysis based on 351 deaths was statistically significant (nominal significance level of 0.0193). An updated OS analysis was conducted at one year after the final analysis. The most common adverse events in both groups were nausea, vomiting, and neutropenia. Rates of overall grade 3 or 4 adverse events and cardiac adverse events did not differ between groups. Trastuzumab in combination with chemotherapy can be considered as a new standard option for patients with HER2-positive advanced gastric or gastro-oesophageal junction cancer. ', 'FDA批准曲妥珠单抗与顺铂和卡培他滨或5-氟尿嘧啶联用，适用于治疗HER2过表达的转移性胃癌或胃食管交界部腺癌患者，且这些患者既往未接受过转移性疾病治疗。一项开放标签、国际化III期随机对照临床试验(NCT01041404)，在全球24个国家/地区的122个中心进行，用于评估曲妥珠单抗与顺铂联合氟嘧啶(卡培他滨或5-氟尿嘧啶)治疗转移性胃癌或胃食管交界部腺癌的安全性和有效性。共计纳入594例HER2阳性患者，随机按照1：1分为曲妥珠单抗联合化疗组(FC+H，n=298)和单独化疗组(FC，n=296)，主要研究重点为总生存期(OS)，其中FC+H治疗组中位随访时间为18.6个月(IQR 11-25)，单独化疗组为17.1个月(9-25)。FC+H和FC治疗组最终中位OS分别为13.5个月(95% CI：11.7, 15.7)和11.0个月(95% CI：9.4, 12.5)，两组中最常见的不良反应是恶心，呕吐和中性粒细胞减少症。总体3级或4级不良事件发生率和心脏不良事件发生率在各组间无差异。曲妥珠单抗联合化疗可被认为是HER2阳性的胃癌或胃食管交界部腺癌一种新的标准选择。', 'S', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:21228335|PMID:20619739|PMID:18316791|PMID:20921465|PMID:24024839', '.', 'clinical study', '4', '.', '.', 'panitumumab', '帕尼单抗', 'panitumumab|帕尼单抗', '4', '.', 'Colorectal Cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_001812', 'KRAS:nonframeshift deletion:::ras_gof', 'KRAS', 'nonframeshift deletion', 'None_pos', '.', '.', 'ras_gof', '.', '在某些癌症中，由于EGFR基因的突变使其持续保持活化状态，导致癌细胞生长和分裂不受控制。抑制EGFR的药物通常有助于治疗此类癌症。但是，其中一些癌症的KRAS基因突变会产生异常的K-Ras蛋白，该蛋白位于EGFR信号下游。即使在没有来自EGFR信号的情况下，异常的RAS蛋白也始终处于活跃状态并可以刺激细胞生长。在此类癌症中，抑制EGFR或酪氨酸激酶的药物将无效。另外，KRAS的一个主要下游信号通路MEK/ERK通路对于细胞的存活也至关重要。一些临床试验表明，携带KRAS基因激活突变的肿瘤患者可能会从MEK类抑制剂的治疗中获益。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:21228335|PMID:20619739|PMID:18316791|PMID:20921465|PMID:24024839', '.', 'clinical study', '4', '.', '.', 'cetuximab', '西妥昔单抗', 'cetuximab|西妥昔单抗', '4', '.', 'Colorectal Cancer', '结直肠癌', '结直肠癌', 'resistance', 'EVI_001813', 'KRAS:nonframeshift deletion:::ras_gof', 'KRAS', 'nonframeshift deletion', 'None_pos', '.', '.', 'ras_gof', '.', '在某些癌症中，由于EGFR基因的突变使其持续保持活化状态，导致癌细胞生长和分裂不受控制。抑制EGFR的药物通常有助于治疗此类癌症。但是，其中一些癌症的KRAS基因突变会产生异常的K-Ras蛋白，该蛋白位于EGFR信号下游。即使在没有来自EGFR信号的情况下，异常的RAS蛋白也始终处于活跃状态并可以刺激细胞生长。在此类癌症中，抑制EGFR或酪氨酸激酶的药物将无效。另外，KRAS的一个主要下游信号通路MEK/ERK通路对于细胞的存活也至关重要。一些临床试验表明，携带KRAS基因激活突变的肿瘤患者可能会从MEK类抑制剂的治疗中获益。', 's', '可能耐药', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29236635|PMID:30867592|PMID:29247021|PMID:28783719', '.', 'clinical study', '4', '.', '.', 'cobimetinib', 'cobimetinib', 'cobimetinib|cobimetinib', '4', '.', 'All Solid Tumors', '非特定癌症', '非特定癌症', 'sensitivity', 'EVI_001814', 'KRAS:nonframeshift deletion:::ras_gof', 'KRAS', 'nonframeshift deletion', 'None_pos', '.', '.', 'ras_gof', '.', '在某些癌症中，由于EGFR基因的突变使其持续保持活化状态，导致癌细胞生长和分裂不受控制。抑制EGFR的药物通常有助于治疗此类癌症。但是，其中一些癌症的KRAS基因突变会产生异常的K-Ras蛋白，该蛋白位于EGFR信号下游。即使在没有来自EGFR信号的情况下，异常的RAS蛋白也始终处于活跃状态并可以刺激细胞生长。在此类癌症中，抑制EGFR或酪氨酸激酶的药物将无效。另外，KRAS的一个主要下游信号通路MEK/ERK通路对于细胞的存活也至关重要。一些临床试验表明，携带KRAS基因激活突变的肿瘤患者可能会从MEK类抑制剂的治疗中获益。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29236635|PMID:30867592|PMID:29247021|PMID:28783719', '.', 'clinical study', '4', '.', '.', 'binimetinib', 'binimetinib', 'binimetinib|binimetinib', '4', '.', 'All Solid Tumors', '非特定癌症', '非特定癌症', 'sensitivity', 'EVI_001815', 'KRAS:nonframeshift deletion:::ras_gof', 'KRAS', 'nonframeshift deletion', 'None_pos', '.', '.', 'ras_gof', '.', '在某些癌症中，由于EGFR基因的突变使其持续保持活化状态，导致癌细胞生长和分裂不受控制。抑制EGFR的药物通常有助于治疗此类癌症。但是，其中一些癌症的KRAS基因突变会产生异常的K-Ras蛋白，该蛋白位于EGFR信号下游。即使在没有来自EGFR信号的情况下，异常的RAS蛋白也始终处于活跃状态并可以刺激细胞生长。在此类癌症中，抑制EGFR或酪氨酸激酶的药物将无效。另外，KRAS的一个主要下游信号通路MEK/ERK通路对于细胞的存活也至关重要。一些临床试验表明，携带KRAS基因激活突变的肿瘤患者可能会从MEK类抑制剂的治疗中获益。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:29236635|PMID:30867592|PMID:29247021|PMID:28783719', '.', 'clinical study', '4', '.', '.', 'trametinib', '曲美替尼', 'trametinib|曲美替尼', '4', '.', 'All Solid Tumors', '非特定癌症', '非特定癌症', 'sensitivity', 'EVI_001816', 'KRAS:nonframeshift deletion:::ras_gof', 'KRAS', 'nonframeshift deletion', 'None_pos', '.', '.', 'ras_gof', '.', '在某些癌症中，由于EGFR基因的突变使其持续保持活化状态，导致癌细胞生长和分裂不受控制。抑制EGFR的药物通常有助于治疗此类癌症。但是，其中一些癌症的KRAS基因突变会产生异常的K-Ras蛋白，该蛋白位于EGFR信号下游。即使在没有来自EGFR信号的情况下，异常的RAS蛋白也始终处于活跃状态并可以刺激细胞生长。在此类癌症中，抑制EGFR或酪氨酸激酶的药物将无效。另外，KRAS的一个主要下游信号通路MEK/ERK通路对于细胞的存活也至关重要。一些临床试验表明，携带KRAS基因激活突变的肿瘤患者可能会从MEK类抑制剂的治疗中获益。', 's', '可能敏感', 'n');
INSERT INTO `main_ori` VALUES ('Druglabel:nimotuzumab_Revised: 01/2008', '.', 'guideline:NMPA', '1', 'nimotuzumab', 'nimotuzumab', 'nimotuzumab', '尼妥珠单抗', 'nimotuzumab|尼妥珠单抗', '4', 'nasopharyngeal squamous cell carcinoma', 'nasopharyngeal squamous cell carcinoma', '鼻咽癌', '鼻咽鳞状细胞癌', 'sensitivity', 'EVI_001817', 'EGFR:CNV:::gain', 'EGFR', 'CNV', 'CNV', '.', '.', 'gain', '.', '2008年1月，NMPA批准nimotuzumab(尼妥珠单抗)与放疗联合适用于治疗EGFR表达阳性的III/IV期鼻咽癌患者。此次获批基于一项随机、开放、多中心II期临床试验，共计137例EGFR中高表达的晚期鼻咽鳞状细胞癌(III/IVA-B期)患者入组，随机分为试验组(n=70)与对照组(n=67)，试验组70例患者全部接受尼妥珠单抗联合根治性放疗，对照组67例患者接受单纯根治性放疗，主要研究终点为完全缓解率和有效率。研究结果显示：130例可评估患者中，试验组与对照组肿瘤完全缓解率(CR)分别为90.63%和51.52%；治疗后第17周，肿瘤有效率(CR+PR)分别为100%和90.91%。主要不良反应为轻度发热(4.28%)，血压下降(2.86%)，恶心(1.43%)和皮疹(1.43%)。', 'A', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <3.2020>|PMID:31669155', 'NCT01970865', 'guideline:NCCN', '1', 'lorlatinib', 'lorlatinib', 'lorlatinib', '劳拉替尼', 'lorlatinib|劳拉替尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001818', 'ROS1:FUS:.:.-ROS1:.', 'ROS1', 'FUS', 'FUS', '.', '.-ROS1', '.', 'The NCCN NSCLC Panel also recommends lorlatinib (category 2A) as a subsequent therapy option for select patients with ROS1-positive NSCLC who have progressed after treatment with crizotinib, entrectinib, or ceritinib. A phase 1 to 2 trial assessed lorlatinib in patients with ROS1-positive metastatic NSCLC. Many patients (58% [40/69]) had previously received crizotinib; some patients were TKI naïve (30% [21/69]). Objective responses were achieved in 35% (14/40) of patients who had previously received crizotinib and 62% (13/21) of TKI-naïve patients. An intracranial response was observed in 50% (12/24) of patients who had previously received crizotinib and 64% (7/11) of TKI-naïve patients. Serious treatment-related adverse events occurred in 7% (5/69) of patients; no treatment-related deaths were reported.', 'NCCN专家小组推荐lorlatinib(2A)可作为ROS1阳性非小细胞肺癌(NSCLC)患者的后续治疗方案，这些患者曾接受过crizotinib, entrectinib或ceritinib治疗后发生疾病进展。一项开放标签、单臂1-2期临床试验(NCT01970865)，要求患者(年龄≥18)在组织学或细胞学上确认为ROS1阳性的NSCLC，有或没有中枢神经系统转移，接受lorlatinib治疗直至疾病进展或出现不可耐受毒性，或撤回同意书，或死亡。主要评价终点是由独立评审委员会确定的肿瘤总体缓解率或颅内缓解率。试验评估了69例ROS1阳性的NSCLC患者，其中21例(30%)未接受过ROS1-TKI治疗，40例(58%)仅接受过crizotinib治疗，8例曾接受过1种或1种以上非crizotinib的ROS1-TKI药物。中位随访时间为21.1个月(IQR 15.2-30.3)，其中13例(62%)未接受过ROS1-TKI治疗患者的中位无进展时间(mPFS)为21.0个月(95% CI: 4.2-31.9)，中位持续缓解时间(mDOR)为25.3个月(95% CI: 7.5-31.9)；14例(35%)仅接受过crizotinib治疗患者的DOR为13.8个月(95% CI: 9.7-NR)。7例(64%)未接受过ROS1-TKI治疗的患者和12例(50%；95% CI: 29-71)接受过crizotinib治疗的患者观察到颅内缓解。7%(5/69)的患者发生严重的治疗相关不良事件；没有报道与治疗相关的死亡事件。', 'F', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <3.2020>|PMID:27803005', 'NCT01823068', 'guideline:NCCN', '1', 'vandetanib', 'vandetanib', 'vandetanib', '凡德他尼', 'vandetanib|凡德他尼', '4', 'non-small cell lung cancer', 'non-small cell lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001819', 'RET:FUS::.-RET:', 'RET', 'FUS', 'FUS', '.', '.-RET', '.', 'The NCCN NSCLC Panel recommends vandetanib (category 2A) for RET fusions based on data from a phase 2 study in 18 patients who had received 2 or more previous chemotherapy regimens. The overall survival was 11.6 months and the PFS was 4.5 months. Partial remission (18%) was reported in 3 patients; stable disease was reported in another 8 patients. The disease control rate was 65%. Six (33%) patients died within 3 months of enrollment of the study due to rapid tumor progression. This study was a multi-center, open-label, phase II clinical trial. Patients were enrolled if they had metastatic or recurrent NSCLC with a RET rearrangement, which was confirmed by fluorescence in situ hybridization, had progressive disease against platinum-based doublet chemotherapy, and had a performance status of 0-2. The primary endpoint was the objective response rate.A total of 18 patients were enrolled in this study between July 2013 and October 2015. Patients were aged 35-71 years; three had a performance status of 2, and the majority were a heavily pretreated population (≥ two different previous chemotherapy regimens in 72% of the patients). Among the 17 evaluable patients, three had a partial response (objective response rate = 18%) and eight had a stable disease (disease control rate = 65%). Among these patients, the partial response or disease stabilization was durable for more than 6 months in eight patients. Vandetanib also showed a progression-free survival of 4.5 months, and an overall survival of 11.6 months during a median follow-up duration of 14 months. The safety profile was comparable with previous studies of vandetanib. Most vandetanib-related adverse events were mild with prevalent hypertension and rash (in >70% of patients). Grade 3 toxicity included hypertension (n = 3), QT prolongation (2), and elevation of aminotransferases (1), and as a consequence the dose was reduced in four patients. There were no adverse events associated with grade 4 or 5 toxicity. Vandetanib is moderately active in pretreated patients with advanced NSCLC-harboring RET rearrangements.', 'NCCN小组推荐vandetanib(2A)可用于RET融合的NSCLC患者，此推荐基于一项多中心、开放标签的II期临床试验(NCT01823068)结果，主要评估了vandetanib的有效性和安全性。2013年7月至2015年10月，共计入组18例经FISH法确认为RET重排的转移或复发的非小细胞肺癌患者，主要终点为客观缓解率(ORR)。在17例可评估患者中，3例部分缓解(ORR=18%)，8例疾病稳定(疾病控制率=65%)。这些患者中，有8例部分缓解或疾病稳定的患者持续时间超过6个月。此外，vandetanib治疗的中位随访时间为14个月，无进展生存期为4.5个月，总生存期为11.6个月。安全性与vandetanib之前的研究相当，常见不良事件为轻度的高血压和皮疹(发生率＞70%)。没有4级或5级毒性相关的不良事件。', 'F', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('NCCN Guideline: Non-Small Cell Lung Cancer (NSCLC) <3.2020>|PMID:27825636|PMID:23533264', 'NCT01639508', 'guideline:NCCN', '1', 'cabozantinib', 'cabozantinib', 'cabozantinib', '卡博替尼', 'cabozantinib|卡博替尼', '4', 'lung cancer', 'lung cancer', '肺癌', '非小细胞肺癌', 'sensitivity', 'EVI_001820', 'RET:FUS:.:.-RET:.', 'RET', 'FUS', 'FUS', '.', '.-RET', '.', 'The recommendation for cabozantinib for RET fusions is based on data from a phase II study in 26 patients. The overall response rate was 28% (95% CI, 12%–49%). Many patients (19 [73%]) needed dose reductions because of adverse events. The most common grade 3 adverse events included lipase elevation (4 patients [15%]), increased ALT (2 [8%]), decreased platelet count (2 [8%]), and hypophosphatemia (2 [8%]).', 'NCCN小组推荐cabozantinib用于RET重排的肺癌患者，此次推荐基于一项开放标签、单中心、单臂II期临床试验(NCT01639508)，主要用于评估cabozantinib在RET重排的肺癌患者中的活性。2012年7月13日至2016年4月30日，共计入组26例RET重排的肺癌患者，主要融合类型为KIF5B-RET(16例；62%)，主要评估指标是根据实体瘤反应评估标准(RECIST 1.1)确定的总体反应(OR)。在25例可评估患者中，7例(28%；95%CI: 12-49)出现部分缓解。最常见的3级不良事件包括脂肪酶升高(4例[15%])，ALT升高(2例[8%])，血小板计数下降(2例[8%])和低磷血症(2例[8%])。19例(73%)患者由于药物相关的不良事件，需要减少剂量。', 'F', '敏感', 'n');
INSERT INTO `main_ori` VALUES ('PMID:21606412', 'NCT00215605', 'clinical trial - phase1', '4', 'cabozantinib', 'cabozantinib', 'cabozantinib', '卡博替尼', 'cabozantinib|卡博替尼', '4', 'thyroid cancer', 'thyroid cancer', '甲状腺癌', 'na', 'sensitivity', 'EVI_001821', 'MET:CNV:.:.:gain', 'MET', 'CNV', 'CNV', '.', '.', 'gain', '.', 'test', 'A', '可能敏感', 'o');

SET FOREIGN_KEY_CHECKS = 1;
